From a31907aa1f1af57ff96d45aa0bf060af5f584462 Mon Sep 17 00:00:00 2001 From: Andrew Charlwood Date: Fri, 6 Feb 2026 00:33:29 +0000 Subject: [PATCH] feat: complete drug-aware indication matching and cleanup app_v2 - Remove app_v2.py (consolidated into pathways_app.py), fix __init__ import - Add DimSearchTerm.csv, drug_indication_clusters.csv, drug_snomed_mapping_enriched.csv as reference data for SNOMED-based indication matching - Add snomed_indication_mapping_query.sql (source for embedded cluster mapping) - Update DESIGN_SYSTEM.md, RALPH_PROMPT.md, ralph.ps1, uv.lock --- .claude/settings.local.json | 4 +- DESIGN_SYSTEM.md | 297 +- RALPH_PROMPT.md | 159 +- data/DimSearchTerm.csv | 166 + data/drug_indication_clusters.csv | 145 + data/drug_snomed_mapping_enriched.csv | 39784 ++++++++++++++++++++++++ pathways_app/__init__.py | 4 +- pathways_app/app_v2.py | 1988 -- ralph.ps1 | 67 +- snomed_indication_mapping_query.sql | 186 + uv.lock | 1408 +- 11 files changed, 41902 insertions(+), 2306 deletions(-) create mode 100644 data/DimSearchTerm.csv create mode 100644 data/drug_indication_clusters.csv create mode 100644 data/drug_snomed_mapping_enriched.csv delete mode 100644 pathways_app/app_v2.py create mode 100644 snomed_indication_mapping_query.sql diff --git a/.claude/settings.local.json b/.claude/settings.local.json index 7bda541..2d89e6a 100644 --- a/.claude/settings.local.json +++ b/.claude/settings.local.json @@ -5,7 +5,9 @@ "Bash(wc:*)", "WebFetch(domain:flet.dev)", "WebFetch(domain:github.com)", - "WebFetch(domain:docs.flet.dev)" + "WebFetch(domain:docs.flet.dev)", + "Bash(python -c:*)", + "Bash(Remove-Item -Path \"C:\\\\Users\\\\charlwoodand\\\\Ralph local\\\\Tasks\\\\UI Redesign\\\\logs\\\\*\" -Force)" ] } } diff --git a/DESIGN_SYSTEM.md b/DESIGN_SYSTEM.md index 2186858..c21d921 100644 --- a/DESIGN_SYSTEM.md +++ b/DESIGN_SYSTEM.md @@ -1,189 +1,194 @@ -# Design System - HCD Analysis v2 +# Design System - HCD Analysis v2.1 (SaaS Redesign) -This document defines the visual design language for the UI redesign. All components should reference these tokens for consistency. +This document defines the visual design language for the UI redesign. The goal is a **modern SaaS aesthetic** - think Stripe, Linear, Vercel - while staying thematically aligned with the blue color palette. + +**Design Philosophy**: +- The chart is the hero; everything else supports it +- Minimal chrome, maximum data visibility +- Clean, confident, spacious - not clinical or governmental +- Every pixel of vertical space matters ## Color Palette -### Primary Blues (NHS-inspired, modernized) +### Primary Blues (kept from original, used sparingly) | Name | Hex | Usage | |------|-----|-------| -| Heritage Blue | `#003087` | Deep headers, authoritative accents | -| Primary Blue | `#0066CC` | Main actions, links, focus states | -| Vibrant Blue | `#1E88E5` | Highlights, hover states, chart primary | -| Sky Blue | `#4FC3F7` | Accents, progress bars, secondary elements | -| Pale Blue | `#E3F2FD` | Subtle backgrounds, card tints | +| Heritage Blue | `#003087` | Top bar background, strong accents | +| Primary Blue | `#0066CC` | Interactive elements, links, focus | +| Vibrant Blue | `#1E88E5` | Hover states, active elements | +| Sky Blue | `#4FC3F7` | Subtle accents, progress indicators | +| Pale Blue | `#E3F2FD` | Selected states, subtle backgrounds | -### Neutrals (warm-tinted for clinical warmth) +### Neutrals (refined for modern feel) | Name | Hex | Usage | |------|-----|-------| -| Slate 900 | `#1E293B` | Primary text | +| Slate 900 | `#0F172A` | Primary text (slightly darker) | | Slate 700 | `#334155` | Secondary text | | Slate 500 | `#64748B` | Muted text, placeholders | | Slate 300 | `#CBD5E1` | Borders, dividers | -| Slate 100 | `#F1F5F9` | Card backgrounds, hover states | -| White | `#FFFFFF` | Page background | +| Slate 100 | `#F8FAFC` | Backgrounds (slightly lighter) | +| White | `#FFFFFF` | Card/modal backgrounds | ### Semantic Colors | Name | Hex | Usage | |------|-----|-------| -| Success | `#059669` | Positive states, confirmations | -| Warning | `#D97706` | Caution states, alerts | -| Error | `#DC2626` | Error states, destructive actions | -| Info | `#0284C7` | Informational (matches primary family) | - -### Chart Palette -``` -Primary series: #003087, #0066CC, #1E88E5, #4FC3F7, #90CAF9 -Categorical: #0066CC, #059669, #D97706, #8B5CF6, #EC4899 -``` +| Success | `#10B981` | Positive (modern green) | +| Warning | `#F59E0B` | Caution | +| Error | `#EF4444` | Errors | +| Info | `#3B82F6` | Informational | ## Typography **Font Family:** Inter (primary), system-ui (fallback) -| Style | Size | Weight | Tracking | Line Height | Usage | -|-------|------|--------|----------|-------------|-------| -| Display | 32px | 700 | -0.02em | 1.2 | Page titles | -| Heading 1 | 24px | 600 | -0.01em | 1.3 | Section headers | -| Heading 2 | 20px | 600 | normal | 1.4 | Card titles | -| Heading 3 | 16px | 600 | normal | 1.4 | Subsections | -| Body | 14px | 400 | normal | 1.5 | Default text | -| Body Small | 13px | 400 | normal | 1.5 | Secondary info | -| Caption | 12px | 500 | normal | 1.4 | Labels, metadata | -| Mono | 13px | 400 | normal | 1.5 | Data values, codes (JetBrains Mono) | +| Style | Size | Weight | Usage | +|-------|------|--------|-------| +| Display | 28px | 600 | Page titles (reduced from 32px) | +| Heading 1 | 18px | 600 | Section headers (reduced from 24px) | +| Heading 2 | 16px | 600 | Card titles (reduced from 20px) | +| Heading 3 | 14px | 600 | Subsections | +| Body | 14px | 400 | Default text | +| Body Small | 13px | 400 | Secondary info | +| Caption | 11px | 500 | Labels, metadata (reduced from 12px) | +| Mono | 13px | 500 | Data values (JetBrains Mono) | -## Spacing Scale +## Spacing Scale (Tighter) | Token | Value | Usage | |-------|-------|-------| -| xs | 4px | Tight internal padding | -| sm | 8px | Between related elements | -| md | 12px | Standard gaps | -| lg | 16px | Section padding | -| xl | 24px | Card padding | -| 2xl | 32px | Major section gaps | -| 3xl | 48px | Page margins | +| xs | 4px | Tight gaps | +| sm | 6px | Between related elements (was 8px) | +| md | 8px | Standard gaps (was 12px) | +| lg | 12px | Section padding (was 16px) | +| xl | 16px | Card padding (was 24px) | +| 2xl | 24px | Major gaps (was 32px) | +| 3xl | 32px | Page margins (was 48px) | -## Border Radius +## Layout Specifications -| Token | Value | Usage | -|-------|-------|-------| -| sm | 4px | Small elements, inputs | -| md | 8px | Buttons, small cards | -| lg | 12px | Cards, modals | -| xl | 16px | Large containers | -| full | 9999px | Pills, avatars | +### Page Structure (Target) +``` +┌─────────────────────────────────────────────────────────────────┐ +│ Logo │ Tabs │ Freshness │ 48px +├─────────────────────────────────────────────────────────────────┤ +│ [Initiated▾] [LastSeen▾] │ [Drugs▾] [Ind▾] [Dir▾] │ KPI badges │ 48px +├─────────────────────────────────────────────────────────────────┤ +│ │ +│ I C I C L E C H A R T │ flex +│ (full viewport width) │ +│ │ +└─────────────────────────────────────────────────────────────────┘ +``` + +### Top Bar +- **Height**: 48px (reduced from 64px) +- **Background**: Heritage Blue +- **Logo**: 28px height (reduced from 36px) +- **Tabs**: Small pills, 28px height + +### Filter Strip +- **Height**: 48px (single row) +- **Layout**: Horizontal flex, all filters inline +- **Dropdown triggers**: 32px height, 8px padding +- **No section header** - labels are in dropdown triggers +- **Background**: Slate 100 or transparent + +### KPI Section (Options) + +**Option A: Inline badges** (preferred - zero extra height) +``` +Filters row: [Initiated▾] [LastSeen▾] | [Drugs▾] ... | 12,345 patients • £45.2M • 89 drugs +``` + +**Option B: Compact strip** (48px max) +``` +┌─────┬─────┬─────┬─────┐ +│12.3K│£45M │ 89 │ 7 │ 28px value +│pts │cost │drugs│trust│ 14px label +└─────┴─────┴─────┴─────┘ +``` + +### Chart Container +- **Width**: Full viewport minus 32px (16px padding each side) +- **Height**: Fill remaining space (min 500px) +- **No max-width constraint** +- **Margins**: Minimal (t:40, l:8, r:8, b:24) + +## Component Specifications + +### Compact Dropdown Trigger +- Height: 32px +- Padding: 8px 12px +- Border: 1px Slate 300 +- Border radius: 6px +- Font: 13px +- Chevron: 14px icon + +### Compact KPI Badge +- Padding: 4px 12px +- Border radius: 16px (pill) +- Background: Slate 100 +- Value: 14px mono, weight 600 +- Label: 11px, Slate 500 + +### Searchable Dropdown Panel +- Max height: 200px (items area) +- Item padding: 6px 8px +- Search input height: 28px +- Width: 240px min ## Shadows | Token | Value | Usage | |-------|-------|-------| -| sm | `0 1px 2px rgba(0,0,0,0.05)` | Subtle elevation | -| md | `0 1px 3px rgba(0,0,0,0.08)` | Cards at rest | -| lg | `0 4px 6px rgba(0,0,0,0.1)` | Cards on hover, dropdowns | -| xl | `0 10px 15px rgba(0,0,0,0.1)` | Modals, popovers | +| sm | `0 1px 2px rgba(0,0,0,0.04)` | Subtle (lighter) | +| md | `0 1px 3px rgba(0,0,0,0.06)` | Cards at rest | +| lg | `0 4px 8px rgba(0,0,0,0.08)` | Dropdowns, hover | -## Component Specifications +## Border Radius -### Cards -- Background: White -- Border: 1px Slate 300 (optional, or use shadow only) -- Border radius: lg (12px) -- Padding: xl (24px) -- Shadow: md at rest, lg on hover -- Hover: translateY(-2px) transition - -### Buttons -**Primary:** -- Background: Primary Blue -- Text: White -- Border radius: md (8px) -- Padding: 10px 20px -- Hover: Vibrant Blue background, slight scale (1.02) - -**Secondary:** -- Background: White -- Border: 1px Primary Blue -- Text: Primary Blue -- Hover: Pale Blue background - -**Ghost:** -- Background: transparent -- Text: Primary Blue -- Hover: Pale Blue background - -### Form Controls -- Height: 40px (inputs, selects) -- Border: 1px Slate 300 -- Border radius: md (8px) -- Focus: 2px Primary Blue ring -- Placeholder: Slate 500 - -### Data Cards (KPIs) -- Large mono number: 32-48px, Slate 900 -- Label: Caption size, Slate 500 -- Background: White or Pale Blue tint -- Optional trend indicator or sparkline - -## Layout - -### Page Structure -``` -┌─────────────────────────────────────────────────────────────────┐ -│ Logo + App Name [Chart Tabs] Data Freshness │ ← Top Bar (64px height) -├─────────────────────────────────────────────────────────────────┤ -│ │ -│ ┌─ Filters ─────────────────────────────────────────────────┐ │ ← Filter Section -│ │ Date ranges, dropdowns, filter controls │ │ -│ └───────────────────────────────────────────────────────────┘ │ -│ │ -│ ┌─ KPIs ────────────────────────────────────────────────────┐ │ ← KPI Row -│ │ [ Metric 1 ] [ Metric 2 ] [ Metric 3 ] [ Metric 4 ] │ │ -│ └───────────────────────────────────────────────────────────┘ │ -│ │ -│ ┌─ Chart ───────────────────────────────────────────────────┐ │ ← Main Chart (fills remaining) -│ │ │ │ -│ │ [ Interactive Visualization ] │ │ -│ │ │ │ -│ └───────────────────────────────────────────────────────────┘ │ -│ │ -└─────────────────────────────────────────────────────────────────┘ -``` - -### Responsive Breakpoints -- Mobile: < 640px -- Tablet: 640px - 1024px -- Desktop: > 1024px +| Token | Value | Usage | +|-------|-------|-------| +| sm | 4px | Small elements | +| md | 6px | Inputs, buttons | +| lg | 8px | Cards | +| full | 9999px | Pills, badges | ## Transitions -| Property | Duration | Easing | -|----------|----------|--------| -| Color, background | 150ms | ease-out | -| Transform | 200ms | ease-out | -| Shadow | 200ms | ease-out | -| Opacity | 200ms | ease-in-out | +All transitions: 150ms ease-out (faster than before) -## Reflex Implementation Notes +## Implementation Notes -### Using Design Tokens -Create a `styles.py` module with these values as Python constants. Import throughout the app: +### Key Changes from v2.0 +1. **Vertical space reduction**: ~210px saved (364px → ~156px overhead) +2. **Full-width chart**: Remove PAGE_MAX_WIDTH for chart +3. **Inline KPIs**: Either badges in filter row or minimal strip +4. **Smaller fonts**: Headlines and captions reduced +5. **Tighter spacing**: All spacing tokens reduced by ~25% -```python -# Example structure -class Colors: - PRIMARY = "#0066CC" - PRIMARY_DARK = "#003087" - # etc. +### CSS Patterns +```css +/* Full-height chart container */ +.chart-container { + height: calc(100vh - 96px); /* viewport minus top bar + filter strip */ + min-height: 500px; + width: calc(100vw - 32px); + margin: 0 16px; +} -class Spacing: - XS = "4px" - SM = "8px" - # etc. +/* Filter strip */ +.filter-strip { + display: flex; + align-items: center; + height: 48px; + gap: 12px; + padding: 0 16px; +} ``` -### rx.theme Configuration -Configure Reflex's theme provider with the color palette for consistent component styling. - -### Custom CSS -For styles not achievable via Reflex props, use `rx.style` or a custom CSS file. +### Reflex Implementation +- Use `height="calc(100vh - 96px)"` for chart container +- Use `width="100%"` with `padding_x="16px"` for full-width +- Use `flex="1"` to let chart grow +- Keep `min_height="500px"` as fallback diff --git a/RALPH_PROMPT.md b/RALPH_PROMPT.md index b6539c3..c366505 100644 --- a/RALPH_PROMPT.md +++ b/RALPH_PROMPT.md @@ -1,6 +1,8 @@ -# Ralph Wiggum Loop - Reflex UI Redesign +# Ralph Wiggum Loop - Drug-Aware Indication Matching -You are operating inside an automated loop building a Reflex frontend application. Each iteration you receive fresh context — you have NO memory of previous iterations. Your only memory is the filesystem. +You are operating inside an automated loop extending a pathway analysis application with drug-aware indication matching. Each iteration you receive fresh context — you have NO memory of previous iterations. Your only memory is the filesystem. + +**Current Focus**: Update indication charts so that patient indications are matched **per drug**, not just per patient. Each drug must be validated against the patient's GP diagnoses AND the drug-to-indication mapping from DimSearchTerm.csv. ## First Actions Every Iteration @@ -9,7 +11,7 @@ Read these files in this order before doing anything else: 1. `progress.txt` — What previous iterations accomplished, what's blocked, and what to do next. The most recent entry is most important. 2. `IMPLEMENTATION_PLAN.md` — Task list with status markers, project overview, and completion criteria. 3. `guardrails.md` — Known failure patterns to avoid. You MUST read and follow these. -4. `DESIGN_SYSTEM.md` — Color palette, typography, spacing, and component specifications. +4. `CLAUDE.md` — Project architecture and code patterns. Then run `git log --oneline -5` to see recent commits. @@ -18,48 +20,109 @@ Then run `git log --oneline -5` to see recent commits. Narrate your work as you go. Your output is the only visibility the operator has into what's happening. For every significant action, explain what you're doing and why: - **Reading files**: "Reading progress.txt to check what the last iteration accomplished..." -- **Creating components**: "Creating the top_bar() component with logo, title, and chart tabs..." -- **Debugging**: "Reflex compilation failed with TypeError. Checking the error — looks like rx.foreach issue..." -- **Testing**: "Running reflex compile to verify the component renders..." -- **Making decisions**: "The design system specifies Primary Blue #0066CC for buttons. Using that." -- **Committing**: "Committing styles.py — design token module complete." +- **Creating code**: "Adding assign_drug_indications() function to diagnosis_lookup.py..." +- **Debugging**: "Drug matching returned 0 results for ADALIMUMAB. Checking DimSearchTerm lookup..." +- **Testing**: "Running import check to verify the new function is accessible..." +- **Making decisions**: "The guardrails say to use substring matching for drug fragments." +- **Committing**: "Committing drug-indication matching logic." Do NOT just output a summary at the end. Narrate throughout. Think of this as a live log of your reasoning. ## Task Selection -Pick the highest-priority task that is READY to work on: +You have flexibility to choose which task to work on. Use your judgement, but document your reasoning. 1. Read ALL tasks in IMPLEMENTATION_PLAN.md — understand the full picture 2. Skip any marked `[x]` (complete) or `[B]` (blocked) -3. Check progress.txt for guidance — if the previous iteration recommended a specific next task, prefer that unless it's blocked -4. If no guidance exists, pick the first `[ ]` (ready) task in the first incomplete phase -5. Mark your chosen task `[~]` (in progress) in IMPLEMENTATION_PLAN.md +3. Check progress.txt for guidance — the previous iteration may have recommendations +4. **Choose a task** based on: + - Dependencies (some tasks require others to be done first) + - Logical flow (query changes before matching logic, matching before pipeline integration) + - Your assessment of what would be most valuable to tackle next + - Previous iteration's recommendations (consider but don't blindly follow) +5. **Document your reasoning**: Before starting work, briefly explain WHY you chose this task over others +6. Mark your chosen task `[~]` (in progress) in IMPLEMENTATION_PLAN.md If your chosen task turns out to be blocked during work: - Mark it `[B]` with a reason in IMPLEMENTATION_PLAN.md - Document the blocker in progress.txt -- Move to the next ready task within this same iteration +- Move to a different ready task within this same iteration ## Development Work on ONE task per iteration. Build incrementally and verify as you go. +### Key Concepts + +**Drug-Indication Matching Flow:** +1. Get patient's GP-matched Search_Terms from Snowflake (ALL matches, not just most recent, with code_frequency) + - Only count GP codes from MIN(Intervention Date) onwards (the HCD data window) +2. Load DimSearchTerm.csv to get which drugs belong to which Search_Terms +3. For each patient-drug pair: intersection of (Search_Terms listing this drug) AND (patient's GP matches) + - If multiple matches: pick highest code_frequency (most GP coding = most likely indication) +4. Modify UPID to include matched indication: `{UPID}|{search_term}` +5. Drugs sharing the same indication for the same patient → same modified UPID → same pathway +6. Drugs under different indications → different modified UPIDs → separate pathways + +**DimSearchTerm.csv:** +- `Search_Term`: Clinical condition (e.g., "rheumatoid arthritis") +- `CleanedDrugName`: Pipe-separated drug fragments (e.g., "ADALIMUMAB|GOLIMUMAB|...") +- `PrimaryDirectorate`: The directorate for this condition +- Drug matching: check if any fragment is a substring of the HCD drug name (case-insensitive) + +**Modified UPID Format:** +- Original: `RMV12345` (Provider Code[:3] + PersonKey) +- Modified: `RMV12345|rheumatoid arthritis` +- Fallback: `RMV12345|RHEUMATOLOGY (no GP dx)` +- The existing pathway analyzer treats UPID as an opaque identifier — this works transparently + ### Code Patterns -- **Use design tokens**: Import from `pathways_app/styles.py` — never hardcode colors/spacing -- **Reflex Vars in rx.foreach**: Use `.to(int)` for comparisons, `.to_string()` for text interpolation -- **Component functions**: Each component should be a function returning `rx.Component` -- **State class**: All reactive state goes in the `AppState` class -- **Computed properties**: Use `@rx.var` decorator for derived values +- **Snowflake queries**: Use parameterized queries, embed the cluster CTE from CLUSTER_MAPPING_SQL +- **GP record matching**: Return ALL matches per patient (not just most recent) +- **Drug mapping**: Load from `data/DimSearchTerm.csv`, match drug name fragments +- **Pathway pipeline**: Use existing functions — modified UPIDs flow through naturally +- **Reflex state**: No changes expected — indication charts already work, just with better matching + +### Key Data Structures + +**GP Matches (from Snowflake) — updated to return ALL matches with frequency:** +```python +# Multiple rows per patient (one per matched Search_Term) +# code_frequency = COUNT of matching SNOMED codes (used as tiebreaker) +# Only counts codes from MIN(Intervention Date) onwards +DataFrame with: PatientPseudonym, Search_Term, code_frequency +``` + +**Drug-to-Indication Mapping (from DimSearchTerm.csv):** +```python +# search_term → list of drug fragments +{"rheumatoid arthritis": ["ABATACEPT", "ADALIMUMAB", "ANAKINRA", ...]} +``` + +**Modified HCD Data:** +```python +# Original UPID replaced with indication-aware UPID +df["UPID"] = "RMV12345|rheumatoid arthritis" # for matched drugs +df["UPID"] = "RMV12345|RHEUMATOLOGY (no GP dx)" # for unmatched drugs +``` + +**Indication DataFrame:** +```python +# Maps modified UPID → Search_Term (for pathway hierarchy level 2) +indication_df = pd.DataFrame({ + 'Directory': ['rheumatoid arthritis', 'asthma', 'CARDIOLOGY (no GP dx)'] +}, index=['RMV12345|rheumatoid arthritis', 'RMV12345|asthma', 'RMV67890|CARDIOLOGY (no GP dx)']) +``` ### Verification Steps After writing code, ALWAYS verify: -1. **Syntax check**: `python -m py_compile pathways_app/app_v2.py` -2. **Import check**: `python -c "from pathways_app.app_v2 import app"` -3. **Reflex compile**: Run `reflex run` briefly to check for compilation errors +1. **Syntax check**: `python -m py_compile ` +2. **Import check**: `python -c "from module import function"` +3. **For database changes**: Test with query against pathways.db +4. **For Reflex changes**: `python -m reflex compile` If any step fails, fix the issue before proceeding. @@ -69,18 +132,19 @@ Every task MUST pass validation before being marked complete: ### Tier 1: Code Validation (MANDATORY) - Code compiles without Python syntax errors -- Reflex compiles the app without errors +- Imports work without errors - No TypeErrors, ImportErrors, or AttributeErrors -### Tier 2: Visual Validation (MANDATORY for UI tasks) -- Component renders in the browser -- Styling matches DESIGN_SYSTEM.md specifications -- Responsive behavior works (if applicable) +### Tier 2: Data Validation (for data/pipeline tasks) +- Queries return expected row counts +- Data structures have correct columns/types +- Drug-indication matching produces valid results +- Modified UPIDs have correct format -### Tier 3: Functional Validation (MANDATORY for state/logic tasks) -- State changes trigger expected UI updates -- Computed properties return correct values -- Filters produce expected data transformations +### Tier 3: Functional Validation (for UI/integration tasks) +- Reflex compiles the app without errors +- State changes trigger expected behavior +- Both chart types render correctly ### Validation Failure @@ -97,8 +161,7 @@ Before marking ANY task `[x]`, ALL of these must be true: 1. Code is saved to the appropriate file(s) 2. Tier 1 code validation passed 3. Tier 2/3 validation passed (as applicable) -4. Design tokens used — no hardcoded colors, fonts, or spacing -5. All changes committed to git with a descriptive message +4. All changes committed to git with a descriptive message These are non-negotiable. A task that "feels done" but hasn't passed all gates is NOT done. @@ -109,18 +172,21 @@ After completing your work (whether the task succeeded, failed, or was blocked), ``` ## Iteration [N] — [YYYY-MM-DD] ### Task: [which task you worked on] +### Why this task: +- [Brief explanation of why you chose this task over others] +- [What dependencies or logical flow led to this choice] ### Status: COMPLETE | BLOCKED | IN PROGRESS ### What was done: - [Specific actions taken] ### Validation results: -- Tier 1 (Code): [syntax check, import check, reflex compile] -- Tier 2 (Visual): [what was checked visually, or N/A] -- Tier 3 (Functional): [what logic was tested, or N/A] +- Tier 1 (Code): [syntax check, import check] +- Tier 2 (Data): [query results, row counts] +- Tier 3 (Functional): [reflex compile, UI check] ### Files changed: - [list of files created/modified] ### Committed: [git hash] "[commit message]" ### Patterns discovered: -- [Any reusable learnings — Reflex quirks, component patterns] +- [Any reusable learnings — query patterns, matching logic quirks] ### Next iteration should: - [Explicit guidance for what the next fresh instance should do first] - [Note any context that would be lost without writing it here] @@ -132,8 +198,8 @@ If you discover a failure pattern that future iterations should avoid, add it to ## Commit Changes -1. Stage changed files (styles.py, app_v2.py, etc.) -2. Use a descriptive commit message referencing the task (e.g., "feat: create design tokens module") +1. Stage changed files +2. Use a descriptive commit message referencing the task (e.g., "feat: add drug-indication matching function (Task 2.1)") 3. Commit after your task is validated and complete — one commit per logical unit of work 4. If you updated progress.txt with a blocked status, commit that too @@ -141,7 +207,7 @@ If you discover a failure pattern that future iterations should avoid, add it to If ALL tasks in IMPLEMENTATION_PLAN.md are marked `[x]`: -1. Run `reflex run` and verify the app works end-to-end +1. Run `reflex compile` to verify app compiles 2. Verify all completion criteria at the bottom of IMPLEMENTATION_PLAN.md are satisfied 3. Only then output the completion signal on its own line: @@ -156,10 +222,15 @@ DO NOT paraphrase, vary, or conditionally output this string. ## Rules - Complete ONE task per iteration, then update progress and stop -- ALWAYS read progress.txt, guardrails.md, and DESIGN_SYSTEM.md before starting work -- **Use design tokens** — never hardcode hex colors, pixel values, or font names -- **Reflex Var safety** — use `.to()` methods when working with Vars from rx.foreach or computed properties +- ALWAYS read progress.txt, guardrails.md before starting work +- **Match drugs to indications** — not just patients to indications +- **Use DimSearchTerm.csv** for drug-to-Search_Term mapping +- **Return ALL GP matches** — not just most recent (remove QUALIFY ROW_NUMBER = 1) +- **Modified UPID format**: `{UPID}|{search_term}` — pipe delimiter is safe +- **Use PseudoNHSNoLinked** — NOT PersonKey for GP record matching +- **Substring matching** for drug fragments from DimSearchTerm.csv - Keep commits atomic and well-described - If stuck on the same issue for more than 2 attempts within one iteration, document it in progress.txt and move to the next ready task -- When in doubt, check the existing `pathways_app.py` for patterns that work -- The goal is a working, beautiful app — correctness and visual quality matter equally +- When in doubt, check existing code for patterns that work +- **Pipeline before UI** — processing logic before Reflex changes +- **Don't change directory charts** — only indication chart matching changes diff --git a/data/DimSearchTerm.csv b/data/DimSearchTerm.csv new file mode 100644 index 0000000..2b42913 --- /dev/null +++ b/data/DimSearchTerm.csv @@ -0,0 +1,166 @@ +Search_Term,CleanedDrugName,PrimaryDirectorate +acute coronary syndrome,ABCIXIMAB|CLOPIDOGREL|PRASUGREL|RIVAROXABAN|TICAGRELOR,CARDIOLOGY +acute lymphoblastic leukaemia,BLINATUMOMAB|DASATINIB|INOTUZUMAB|PEGASPARGASE|PONATINIB|TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY +acute myeloid leukaemia,AZACITIDINE|DECITABINE|GEMTUZUMAB|GILTERITINIB|GLASDEGIB|LIPOSOMAL|MIDOSTAURIN|ORAL|VENETOCLAX,CLINICAL HAEMATOLOGY +acute promyelocytic leukaemia,ARSENIC|GEMTUZUMAB,CLINICAL HAEMATOLOGY +allergic asthma,OMALIZUMAB,THORACIC MEDICINE +allergic rhinitis,SQ,ENT +alzheimer's disease,DONEPEZIL,NEUROLOGY +amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY +anaemia,ERYTHROPOIESIS-STIMULATING|ERYTHROPOIETIN,CLINICAL HAEMATOLOGY +anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY +ankylosing spondylitis,ADALIMUMAB|GOLIMUMAB|SECUKINUMAB|UPADACITINIB,RHEUMATOLOGY +apixaban,ANDEXANET,CARDIOLOGY +aplastic anaemia,ELTROMBOPAG,CLINICAL HAEMATOLOGY +arthritis,ETANERCEPT,RHEUMATOLOGY +asthma,BENRALIZUMAB|DUPILUMAB|INHALED|MEPOLIZUMAB|OMALIZUMAB|RESLIZUMAB,THORACIC MEDICINE +atopic dermatitis,ABROCITINIB|ALCLOMETASONE|BARICITINIB|CRISABOROLE|DUPILUMAB|PIMECROLIMUS,DERMATOLOGY +atrial fibrillation,APIXABAN|DABIGATRAN|DRONEDARONE|EDOXABAN|RIVAROXABAN|VERNAKALANT,CARDIOLOGY +attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH +attention-deficit hyperactivity disorder,METHYLPHENIDATE,MENTAL HEALTH +axial spondyloarthritis,ADALIMUMAB|GOLIMUMAB|IXEKIZUMAB|SECUKINUMAB|UPADACITINIB,RHEUMATOLOGY +basal cell carcinoma,VISMODEGIB,DERMATOLOGY +bipolar disorder,LOXAPINE|OLANZAPINE,MENTAL HEALTH +bladder,MIRABEGRON,MEDICAL ONCOLOGY +brca,OLAPARIB,MEDICAL ONCOLOGY +breast cancer,ABEMACICLIB|ALPELISIB|ANASTROZOLE|ATEZOLIZUMAB|BEVACIZUMAB|CAPECITABINE|DENOSUMAB|DOCETAXEL|ERIBULIN|EVEROLIMUS|FULVESTRANT|GEMCITABINE|INTRABEAM|LAPATINIB|NERATINIB|OLAPARIB|PACLITAXEL|PALBOCICLI|PALBOCICLIB|PEMBROLIZUMAB|PERTUZUMAB|RIBOCICLIB|SACITUZUMAB|TRASTUZUMAB|TUCATINIB|VINORELBINE,MEDICAL ONCOLOGY +cardiomyopathy,TAFAMIDIS,CARDIOLOGY +cardiovascular disease,ATORVASTATIN,CARDIOLOGY +cervical cancer,TOPOTECAN,MEDICAL ONCOLOGY +cholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY +choroidal neovascularisation,AFLIBERCEPT|RANIBIZUMAB,OPHTHALMOLOGY +chronic kidney disease,DAPAGLIFLOZIN|IMLIFIDASE|ROXADUSTAT,NEPHROLOGY +chronic liver disease,AVATROMBOPAG|LUSUTROMBOPAG,GASTROENTEROLOGY +chronic lymphocytic leukaemia,ACALABRUTINIB|BENDAMUSTINE|DUVELISIB|IBRUTINIB|IDELALISIB|OBINUTUZUMAB|OFATUMUMAB|RITUXIMAB|VENETOCLAX,CLINICAL HAEMATOLOGY +chronic myeloid leukaemia,ASCIMINIB|BOSUTINIB|STANDARD-DOSE|DASATINIB|DASITINIB|NILOTINIB|PONATINIB,CLINICAL HAEMATOLOGY +chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE +colon cancer,CAPECITABINE,MEDICAL ONCOLOGY +colorectal cancer,BEVACIZUMAB|CAPECITABINE|IRINOTECAN,MEDICAL ONCOLOGY +constipation,LUBIPROSTONE|METHYLNALTREXONE|NALDEMEDINE|NALOXEGOL|PRUCALOPRIDE,GASTROENTEROLOGY +covid-19,NIRMATRELVIR,INFECTIOUS DISEASES +crohn's disease,INFLIXIMAB|VEDOLIZUMAB,GASTROENTEROLOGY +cutaneous t-cell lymphoma,BRENTUXIMAB|CHLORMETHINE,CLINICAL HAEMATOLOGY +cystic fibrosis,COLISTIMETHATE|LUMACAFTOR|MANNITOL,THORACIC MEDICINE +cytomegalovirus,LETERMOVIR|MARIBAVIR,INFECTIOUS DISEASES +deep vein thrombosis,APIXABAN|DABIGATRAN|EDOXABAN|RIVAROXABAN,VASCULAR SURGERY +depression,ESKETAMINE,MENTAL HEALTH +diabetes,ERTUGLIFLOZIN|INHALED|AFLIBERCEPT|BROLUCIZUMAB|DEXAMETHASONE|FARICIMAB|FLUOCINOLONE|RANIBIZUMAB,DIABETIC MEDICINE +diabetes,ERTUGLIFLOZIN|INHALED|AFLIBERCEPT|BROLUCIZUMAB|DEXAMETHASONE|FARICIMAB|FLUOCINOLONE|RANIBIZUMAB,OPHTHALMOLOGY +diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY +diffuse large b-cell lymphoma,AXICABTAGENE|POLATUZUMAB|TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY +dravet syndrome,CANNABIDIOL|FENFLURAMINE,NEUROLOGY +drug misuse,BUPRENORPHINE|NALTREXONE,MENTAL HEALTH +dry eye,CICLOSPORIN,OPHTHALMOLOGY +dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY +endometrial cancer,DOSTARLIMAB,MEDICAL ONCOLOGY +epilepsy,CENOBAMATE|GABAPENTIN|RETIGABINE,NEUROLOGY +fallopian tube,BEVACIZUMAB|NIRAPARIB|OLAPARIB|RUCAPARIB,MEDICAL ONCOLOGY +follicular lymphoma,DUVELISIB|IDELALISIB|LENALIDOMIDE|OBINUTUZUMAB|RITUXIMAB|TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY +gastric cancer,CAPECITABINE|RAMUCIRUMAB|TRASTUZUMAB|TRIFLURIDINE,MEDICAL ONCOLOGY +gastro-oesophageal junction,NIVOLUMAB|PEMBROLIZUMAB,MEDICAL ONCOLOGY +giant cell arteritis,TOCILIZUMAB,RHEUMATOLOGY +glioma,CARMUSTINE,MEDICAL ONCOLOGY +gout,CANAKINUMAB|FEBUXOSTAT|LESINURAD,RHEUMATOLOGY +graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY +granulomatosis with polyangiitis,AVACOPAN|MEPOLIZUMAB,RHEUMATOLOGY +growth hormone deficiency,SOMATROPIN,ENDOCRINOLOGY +hand eczema,ALITRETINOIN,DERMATOLOGY +heart failure,DAPAGLIFLOZIN|EMPAGLIFLOZIN|IVABRADINE|SACUBITRIL|VERICIGUAT,CARDIOLOGY +hepatitis b,ADEFOVIR,GASTROENTEROLOGY +hepatitis c,BOCEPREVIR|DACLATASVIR|ELBASVIR|GLECAPREVIR|INTERFERON|LEDIPASVIR|OMBITASVIR|PEGINTERFERON|PEGYLATED|SIMEPREVIR|SOFOSBUVIR|TELAPREVIR,GASTROENTEROLOGY +hepatocellular carcinoma,ATEZOLIZUMAB|CABOZANTINIB|LENVATINIB|RAMUCIRUMAB|REGORAFENIB|SELECTIVE|SORAFENIB,MEDICAL ONCOLOGY +hiv,CABOTEGRAVIR,INFECTIOUS DISEASES +hodgkin lymphoma,BRENTUXIMAB|NIVOLUMAB|PEMBROLIZUMAB,CLINICAL HAEMATOLOGY +hormone receptor,ABEMACICLIB,MEDICAL ONCOLOGY +hypercholesterolaemia,EZETIMIBE,CARDIOLOGY +hyperparathyroidism,CINACALCET|ETELCALCETIDE,ENDOCRINOLOGY +immune thrombocytopenia,AVATROMBOPAG|FOSTAMATINIB,CLINICAL HAEMATOLOGY +influenza,AMANTADINE|ZANAMIVIR|BALOXAVIR,INFECTIOUS DISEASES +insomnia,ZALEPLON,NEUROLOGY +irritable bowel syndrome,ELUXADOLINE,GASTROENTEROLOGY +ischaemic stroke,ALTEPLASE,STROKE MEDICINE +juvenile idiopathic arthritis,ABATECEPT|CANAKINUMAB|TOCILIZUMAB|TOFACITINIB,RHEUMATOLOGY +kidney transplant,BASILIXIMAB,NEPHROLOGY +leukaemia,FLUDARABINE|IMATINIB,CLINICAL HAEMATOLOGY +lung cancer,ATEZOLIZUMAB|DURVALUMAB|GEFITINIB|ORAL|NINTEDANIB,MEDICAL ONCOLOGY +lymphoma,BENDAMUSTINE|CRIZOTINIB|PIXANTRONE|RITUXIMAB,CLINICAL HAEMATOLOGY +macular degeneration,AFLIBERCEPT|BROLUCIZUMAB|FARICIMAB|RANIBIZUMAB,OPHTHALMOLOGY +macular oedema,AFLIBERCEPT|RANIBIZUMAB,OPHTHALMOLOGY +major depressive episodes,AGOMELATINE|VORTIOXETINE,MENTAL HEALTH +malignant melanoma,VEMURAFENIB,MEDICAL ONCOLOGY +malignant pleural mesothelioma,NIVOLUMAB|PEMETREXED,MEDICAL ONCOLOGY +manic episode,ARIPIPRAZOLE,MENTAL HEALTH +mantle cell lymphoma,AUTOLOGOUS|BORTEZOMIB|IBRUTINIB|LENALIDOMIDE|TEMSIROLIMUS,CLINICAL HAEMATOLOGY +melanoma,COBIMETINIB|DABRAFENIB|ENCORAFENIB|IPILIMUMAB|NIVOLUMAB|PEMBROLIZUMAB|TALIMOGENE|TRAMETINIB,MEDICAL ONCOLOGY +merkel cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY +migraine,BOTULINUM|EPTINEZUMAB|ERENUMAB|FREMANEZUMAB|GALCANEZUMAB,NEUROLOGY +motor neurone disease,RILUZOLE,NEUROLOGY +multiple myeloma,BORTEZOMIB|THALIDOMIDE|CARFILZOMIB|DARATUMUMAB|DENOSUMAB|ELOTUZUMAB|ISATUXIMAB|IXAZOMIB|LENALIDOMIDE|PANOBINOSTAT|POMALIDOMIDE|SELINEXOR|TECLISTAMAB,CLINICAL HAEMATOLOGY +multiple sclerosis,ALEMTUZUMAB|BETA|CLADRIBINE|DACLIZUMAB|DIMETHYL|DIROXIMEL|FINGOLIMOD|INTERFERON|NATALIZUMAB|OCRELIZUMAB|OZANIMOD|PEGINTERFERON|PONESIMOD|SIPONIMOD|TERIFLUNOMIDE,NEUROLOGY +myelodysplastic,LENALIDOMIDE|LUSPATERCEPT,CLINICAL HAEMATOLOGY +myelofibrosis,FEDRATINIB|RUXOLITINIB,CLINICAL HAEMATOLOGY +myocardial infarction,ALTEPLASE|BIVALIRUDIN|TICAGRELOR,CARDIOLOGY +myotonia,MEXILETINE,NEUROLOGY +narcolepsy,SOLRIAMFETOL,NEUROLOGY +neuroendocrine tumour,EVEROLIMUS|LUTETIUM,MEDICAL ONCOLOGY +non-small cell lung cancer,ATEZOLIZMAB|DOCETAXEL|ERLOTINIB|PEMETREXED,MEDICAL ONCOLOGY +non-small-cell lung cancer,AFATINIB|ALECTINIB|AMIVANTAMAB|ATEZOLIZUMAB|BEVACIZUMAB|BRIGATINIB|CEMIPLIMAB|CERITINIB|CRIZOTINIB|DABRAFENIB|DACOMITINIB|DURVALUMAB|ENTRECTINIB|ERLOTINIB|GEFITINIB|LORLATINIB|MOBOCERTINIB|NECITUMUMAB|NIVOLUMAB|OSIMERTINIB|PACLITAXEL|PEMBROLIZUMAB|PEMETREXED|PRALSETINIB|RAMUCIRUMAB|SELPERCATINIB|SOTORASIB|TEPOTINIB,MEDICAL ONCOLOGY +obesity,LIRAGLUTIDE|NALTREXONE|ORLISTAT|SEMAGLUTIDE|SIBUTRAMINE,ENDOCRINOLOGY +oesophageal cancer,NIVOLUMAB,MEDICAL ONCOLOGY +osteoarthritis,CELECOXIB,RHEUMATOLOGY +osteoporosis,ALENDRONATE|DENOSUMAB|ORAL|ROMOSOZUMAB,RHEUMATOLOGY +osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY +ovarian cancer,BEVACIZUMAB|PACLITAXEL|PEGYLATED|TOPOTECAN|TRABECTEDIN,MEDICAL ONCOLOGY +overweight,RIMONABANT,ENDOCRINOLOGY +pancreatic cancer,GEMCITABINE|OLAPARIB|PACLITAXEL|PEGYLATED,MEDICAL ONCOLOGY +paroxysmal nocturnal haemoglobinuria,PEGCETACOPLAN|RAVULIZUMAB,CLINICAL HAEMATOLOGY +peripheral arterial disease,NAFTIDROFYRYL,VASCULAR SURGERY +plaque psoriasis,ADALIMUMAB|APREMILAST|BIMEKIZUMAB|BRODALUMAB|CERTOLIZUMAB|GUSELKUMAB|INFLIXIMAB|IXEKIZUMAB|RISANKIZUMAB|SECUKINUMAB|TILDRAKIZUAMB|USTEKINUMAB,DERMATOLOGY +polycystic kidney disease,TOLVAPTAN,NEPHROLOGY +polycythaemia vera,RUXOLITINIB,CLINICAL HAEMATOLOGY +pregnancy,ROUTINE,OBSTETRICS +primary biliary cholangitis,OBETICHOLIC,GASTROENTEROLOGY +primary hypercholesterolaemia,ALIROCUMAB|EVOLOCUMAB,CARDIOLOGY +prostate cancer,ABIRATERONE|APALUTAMIDE|CABAZITAXEL|DAROLUTAMIDE|DEGARELIX|DENOSUMAB|DOCETAXEL|ENZALUTAMIDE|OLAPARIB|PADELIPORFIN|RADIUM-|RADIUM|SIPULEUCEL-T,MEDICAL ONCOLOGY +psoriasis,EFALUZIMAB,DERMATOLOGY +psoriatic arthritis,ABATACEPT|ADALIMUMAB|APREMILAST|CERTOLIZUMAB|ETANERCEPT|GOLIMUMAB|GUSELKUMAB|IXEKIZUMAB|RISANKIZUMAB|TOFACITINIB|UPADACITINIB|USTEKINUMAB,RHEUMATOLOGY +pulmonary embolism,APIXABAN|DABIGATRAN|EDOXABAN|RIVAROXABAN,THORACIC MEDICINE +pulmonary fibrosis,NINTEDANIB|PIRFENIDONE,THORACIC MEDICINE +relapsing multiple sclerosis,OFATUMUMAB,NEUROLOGY +renal cell carcinoma,AVELUMAB|AXITINIB|BEVACIZUMAB|CABOZANTINIB|EVEROLIMUS|LENVATINIB|NIVOLUMAB|PAZOPANIB|PEMBROLIZUMAB|SUNITINIB|TIVOZANIB,MEDICAL ONCOLOGY +renal transplantation,BASILIXIMAB|INDUCTION,NEPHROLOGY +retinal vein occlusion,AFLIBERCEPT|DEXAMETHASONE|RANIBIZUMAB,OPHTHALMOLOGY +rheumatoid arthritis,ABATACEPT|ADALIMUMAB|ANAKINRA|BARICITINIB|CELECOXIB|CERTOLIZUMAB|ETANERCEPT|FILGOTINIB|GOLIMUMAB|RITUXIMAB|SARILUMAB|TOCILIZUMAB|TOFACITINIB|UPADACITINIB,RHEUMATOLOGY +rivaroxaban,ANDEXANET,CARDIOLOGY +schizophrenia,AMISULPRIDE|ARIPIPRAZOLE|LOXAPINE,MENTAL HEALTH +seizures,CANNABIDIOL,NEUROLOGY +sepsis,DROTRECOGIN,INFECTIOUS DISEASES +severe persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE +short bowel syndrome,TEDUGLUTIDE,GASTROENTEROLOGY +sickle cell disease,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY +sleep apnoea,PITOLISANT|SOLRIAMFETOL,THORACIC MEDICINE +smoking cessation,NICOTINE|VARENICLINE,THORACIC MEDICINE +soft tissue sarcoma,INTRAVENOUS|NBTXR-|OLARATUMAB,MEDICAL ONCOLOGY +spinal muscular atrophy,NUSINERSEN|RISDIPLAM,NEUROLOGY +squamous cell,CETUXIMAB,MEDICAL ONCOLOGY +squamous cell carcinoma,CEMIPLIMAB|NIVOLUMAB|PEMBROLIZUMAB,MEDICAL ONCOLOGY +stem cell transplant,MELPHALAN|TREOSULFAN,CLINICAL HAEMATOLOGY +stroke,APIXABAN|DABIGATRAN|EDOXABAN|RIVAROXABAN,STROKE MEDICINE +systemic lupus erythematosus,ANIFROLUMAB|ETANERCEPT,RHEUMATOLOGY +systemic mastocytosis,MIDOSTAURIN,CLINICAL HAEMATOLOGY +thrombocytopenic purpura,ELTROMBOPAG|ROMIPLOSTIM,CLINICAL HAEMATOLOGY +thrombotic thrombocytopenic purpura,CAPLACIZUMAB,CLINICAL HAEMATOLOGY +thyroid cancer,CABOZANTINIB|LENVATINIB|SELPERCATINIB|VANDETANIB,MEDICAL ONCOLOGY +tophaceous gout,PEGLOTICASE,RHEUMATOLOGY +transitional cell carcinoma,VINFLUNINE,MEDICAL ONCOLOGY +tuberous sclerosis,CANNABIDIOL,NEUROLOGY +type 1 diabetes,CONTINUOUS|DAPAGLIFLOZIN|INSULIN|SOTAGLIFLOZIN,DIABETIC MEDICINE +type 2 diabetes,CANAGLIFLOZIN|CONTINUOUS|DAPAGLIFLOZIN|EMPAGLIFLOZIN|ERTUGLIFLOZIN|EXENATIDE|FINERENONE|INSULIN|LIRAGLUTIDE|PIOGLITAZONE|ROSIGLITAZONE,DIABETIC MEDICINE +ulcerative colitis,ADALIMUMAB|INFLIXIMAB|FILGOTINIB|OZANIMOD|TOFACITINIB|UPADACITINIB|USTEKINUMAB|VEDOLIZUMAB,GASTROENTEROLOGY +urothelial carcinoma,ATEZOLIZUMAB|PEMBROLIZUMAB,MEDICAL ONCOLOGY +urticaria,OMALIZUMAB,DERMATOLOGY +uterine fibroids,RELUGOLIX,GYNAECOLOGY +uveitis,ADALIMUMAB|FLUOCINOLONE,OPHTHALMOLOGY +vascular disease,MODIFIED-RELEASE|CLOPIDOGREL,VASCULAR SURGERY +vasculitis,RITUXIMAB,RHEUMATOLOGY +venous thromboembolism,APIXABAN|DABIGATRAN|RIVAROXABAN,CLINICAL HAEMATOLOGY diff --git a/data/drug_indication_clusters.csv b/data/drug_indication_clusters.csv new file mode 100644 index 0000000..853bd29 --- /dev/null +++ b/data/drug_indication_clusters.csv @@ -0,0 +1,145 @@ +Drug,Indication,Cluster_ID,Cluster_Description,NICE_TA_Reference +ABATACEPT,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA195/TA280/TA375 +ABATACEPT,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA195/TA280/TA375 +ABATACEPT,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA568 +ACALABRUTINIB,Chronic lymphocytic leukaemia,CLL_COD,Chronic lymphocytic leukaemia,TA689 +ADALIMUMAB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA130/TA195/TA375 +ADALIMUMAB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA130/TA195/TA375 +ADALIMUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA146/TA455 +ADALIMUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA146/TA455 +ADALIMUMAB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA125/TA199 +ADALIMUMAB,Crohn's disease,CROHNS_COD,Crohn's disease codes,TA187 +ADALIMUMAB,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,TA329 +ADALIMUMAB,Ankylosing spondylitis,ANKSPON_COD,Ankylosing spondylitis codes,TA143/TA383 +AFLIBERCEPT,Diabetic macular oedema,DM_COD,Diabetes mellitus codes,TA346 +AFLIBERCEPT,Diabetic macular oedema,DMTYPE2AUDIT_COD,Type 2 diabetes codes,TA346 +ALIROCUMAB,Hypercholesterolaemia,HYPERCHOL_COD,Hypercholesterolaemia codes,TA393 +APREMILAST,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA419 +APREMILAST,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA419 +APREMILAST,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA433 +ATEZOLIZUMAB,Cancer (various),CANCER_COD,Cancer codes (various),TA492/TA520/TA525 +BARICITINIB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA466 +BARICITINIB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA466 +BARICITINIB,Atopic dermatitis,ECZEMA_COD,Atopic dermatitis/eczema codes,TA681 +BEVACIZUMAB,Cancer (various),CANCER_COD,Cancer codes (various),TA584/TA666 +BIMEKIZUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA723 +BIMEKIZUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA723 +BOTULINUM A TOXIN,Spasticity (various),SPASTICITY_COD,Spasticity and movement disorder codes,No specific TA +BRODALUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA511 +BRODALUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA511 +CERTOLIZUMAB PEGOL,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA375/TA415 +CERTOLIZUMAB PEGOL,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA375/TA415 +CERTOLIZUMAB PEGOL,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA574 +CERTOLIZUMAB PEGOL,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA445 +CERTOLIZUMAB PEGOL,Ankylosing spondylitis,ANKSPON_COD,Ankylosing spondylitis codes,TA383 +DENOSUMAB,Osteoporosis,OSTEO_COD,Osteoporosis codes,TA204 +DENOSUMAB,Bone metastases,CANCER_COD,Cancer codes (bone metastases),TA265 +DEXAMETHASONE,Diabetic macular oedema,DM_COD,Diabetes mellitus codes,TA349/TA824 +DEXAMETHASONE,Diabetic macular oedema,DMTYPE2AUDIT_COD,Type 2 diabetes codes,TA349/TA824 +DEXAMETHASONE,Multiple myeloma,MM_COD,Multiple myeloma codes,TA311/TA380 +DEXAMETHASONE,Uveitis,UVEITIS_COD,Uveitis codes,TA460 +DIMETHYL FUMARATE,Multiple sclerosis,MS_COD,Multiple sclerosis codes,TA320 +DIMETHYL FUMARATE,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA475 +DOCETAXEL,Cancer (various),CANCER_COD,Cancer codes (breast/lung/prostate),TA006/TA030/TA101 +DUPILUMAB,Atopic dermatitis,ECZEMA_COD,Atopic dermatitis/eczema codes,TA534 +DUPILUMAB,Asthma,ASTHMA_COD,Asthma codes,TA751 +ERENUMAB,Migraine,MIGRAINE_COD,Migraine codes,TA682 +ETANERCEPT,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA036/TA130/TA195 +ETANERCEPT,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA036/TA130/TA195 +ETANERCEPT,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA103 +ETANERCEPT,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA103 +ETANERCEPT,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA104/TA199 +ETANERCEPT,Ankylosing spondylitis,ANKSPON_COD,Ankylosing spondylitis codes,TA143/TA383 +EVOLOCUMAB,Hypercholesterolaemia,HYPERCHOL_COD,Hypercholesterolaemia codes,TA394 +FARICIMAB,Diabetic macular oedema,DM_COD,Diabetes mellitus codes,TA799 +FARICIMAB,Diabetic macular oedema,DMTYPE2AUDIT_COD,Type 2 diabetes codes,TA799 +FILGOTINIB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA676 +FILGOTINIB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA676 +FILGOTINIB,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,TA792 +FLUOCINOLONE,Atopic dermatitis,ECZEMA_COD,Atopic dermatitis/eczema codes,TA081 +FLUOCINOLONE,Diabetic macular oedema,DM_COD,Diabetes mellitus codes,TA301 +FLUOCINOLONE,Uveitis,UVEITIS_COD,Uveitis codes,TA590 +FLUOCINOLONE ACETONIDE,Atopic dermatitis,ECZEMA_COD,Atopic dermatitis/eczema codes,TA081 +FLUOCINOLONE ACETONIDE,Diabetic macular oedema,DM_COD,Diabetes mellitus codes,TA301 +FLUOCINOLONE ACETONIDE,Uveitis,UVEITIS_COD,Uveitis codes,TA590 +FREMANEZUMAB,Migraine,MIGRAINE_COD,Migraine codes,TA631/TA764 +GALCANEZUMAB,Migraine,MIGRAINE_COD,Migraine codes,TA659 +GOLIMUMAB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA225/TA375 +GOLIMUMAB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA225/TA375 +GOLIMUMAB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA220 +GOLIMUMAB,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,TA329 +GOLIMUMAB,Ankylosing spondylitis,ANKSPON_COD,Ankylosing spondylitis codes,TA233/TA383 +GUSELKUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA521 +GUSELKUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA521 +GUSELKUMAB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA711/TA815 +IDARUCIZUMAB,Anticoagulant reversal,ANTICOAG_COD,Anticoagulation-related codes,No specific TA +IMATINIB,Chronic myeloid leukaemia,CML_COD,Chronic myeloid leukaemia codes,TA050/TA070/TA251 +IMATINIB,Gastrointestinal stromal tumours,GIST_COD,Gastrointestinal stromal tumour codes,TA086/TA326 +IMMUNOGLOBULIN,Immunodeficiency (various),IMMUNODEF_COD,Primary/secondary immunodeficiency codes,TA481/TA482 +INFLIXIMAB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA036/TA130/TA195 +INFLIXIMAB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA036/TA130/TA195 +INFLIXIMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA134 +INFLIXIMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA134 +INFLIXIMAB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA104/TA199 +INFLIXIMAB,Crohn's disease,CROHNS_COD,Crohn's disease codes,TA040/TA187 +INFLIXIMAB,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,TA163/TA329 +INFLIXIMAB,Ankylosing spondylitis,ANKSPON_COD,Ankylosing spondylitis codes,TA383 +IXEKIZUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA442 +IXEKIZUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA442 +IXEKIZUMAB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA537 +IXEKIZUMAB,Ankylosing spondylitis,ANKSPON_COD,Ankylosing spondylitis codes,TA718 +LUCENTIS,Diabetic macular oedema,DM_COD,Diabetes mellitus codes,Biosimilar of ranibizumab +LUCENTIS,Diabetic macular oedema,DMTYPE2AUDIT_COD,Type 2 diabetes codes,Biosimilar of ranibizumab +OBINUTUZUMAB,Chronic lymphocytic leukaemia,CLL_COD,Chronic lymphocytic leukaemia codes,TA343/TA663 +OBINUTUZUMAB,Follicular lymphoma,FL_COD,Follicular lymphoma codes,TA472/TA513/TA629 +OCTREOTIDE,Neuroendocrine tumours,NET_COD,Neuroendocrine tumour codes,No specific TA +OMALIZUMAB,Asthma,ASTHMA_COD,Asthma codes,TA133/TA278 +OMALIZUMAB,Chronic urticaria,URTICARIA_COD,Urticaria codes,TA339 +RANIBIZUMAB,Diabetic macular oedema,DM_COD,Diabetes mellitus codes,TA274 +RANIBIZUMAB,Diabetic macular oedema,DMTYPE2AUDIT_COD,Type 2 diabetes codes,TA274 +REMICADE,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,Brand name for infliximab +REMICADE,Crohn's disease,CROHNS_COD,Crohn's disease codes,Brand name for infliximab +REMICADE,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,Brand name for infliximab +REMICADE,Psoriasis,PSORIASIS_COD,Psoriasis codes,Brand name for infliximab +RILUZOLE,Motor neurone disease,MND_COD,Motor neurone disease codes,TA020 +RISANKIZUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA596 +RISANKIZUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA596 +RISANKIZUMAB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA803 +RITUXIMAB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA126/TA195 +RITUXIMAB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA126/TA195 +RITUXIMAB,Non-Hodgkin's lymphoma,NHL_COD,Non-Hodgkin's lymphoma codes,TA037/TA065/TA110 +RITUXIMAB,Chronic lymphocytic leukaemia,CLL_COD,Chronic lymphocytic leukaemia codes,TA174/TA193/TA359 +RITUXIMAB,ANCA-associated vasculitis,VASCULITIS_COD,Vasculitis codes,TA308 +RIXATHON,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,Biosimilar of rituximab +RIXATHON,Non-Hodgkin's lymphoma,NHL_COD,Non-Hodgkin's lymphoma codes,Biosimilar of rituximab +SACITUZUMAB,Triple-negative breast cancer,BREASTCA_COD,Breast cancer codes,TA819 +SARILUMAB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA485 +SARILUMAB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA485 +SECUKINUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA350/TA734 +SECUKINUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA350/TA734 +SECUKINUMAB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA445 +SECUKINUMAB,Ankylosing spondylitis,ANKSPON_COD,Ankylosing spondylitis codes,TA407/TA719 +TERIPARATIDE,Osteoporosis,OSTEO_COD,Osteoporosis codes,TA087/TA161 +TILDRAKIZUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,No TA match found +TILDRAKIZUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),No TA match found +TOCILIZUMAB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA198/TA247/TA375 +TOCILIZUMAB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA198/TA247/TA375 +TOCILIZUMAB,Juvenile idiopathic arthritis,JIA_COD,Juvenile idiopathic arthritis codes,TA238/TA373 +TOCILIZUMAB,Giant cell arteritis,GCA_COD,Giant cell arteritis codes,TA518 +TOFACITINIB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA480 +TOFACITINIB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA480 +TOFACITINIB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA543 +TOFACITINIB,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,TA547 +UPADACITINIB,Rheumatoid arthritis,RARTH_COD,Rheumatoid arthritis diagnosis codes,TA665/TA744 +UPADACITINIB,Rheumatoid arthritis,C19RARTH_COD,Rheumatoid arthritis disorders (broader),TA665/TA744 +UPADACITINIB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA768 +UPADACITINIB,Atopic dermatitis,ECZEMA_COD,Atopic dermatitis/eczema codes,TA814 +UPADACITINIB,Ankylosing spondylitis,ANKSPON_COD,Ankylosing spondylitis codes,TA829 +UPADACITINIB,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,TA856 +USTEKINUMAB,Psoriasis,PSORIASIS_COD,Psoriasis codes,TA180/TA455 +USTEKINUMAB,Psoriasis,CUST_CMMS_PSORIASIS,Psoriasis (Cambridge Multimorbidity),TA180/TA455 +USTEKINUMAB,Psoriatic arthritis,PSORIASIS_COD,Psoriasis codes (for psoriatic arthritis),TA340 +USTEKINUMAB,Crohn's disease,CROHNS_COD,Crohn's disease codes,TA456 +USTEKINUMAB,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,TA633 +VEDOLIZUMAB,Ulcerative colitis,ULCCOLITIS_COD,Ulcerative colitis codes,TA342 +VEDOLIZUMAB,Crohn's disease,CROHNS_COD,Crohn's disease codes,TA352 diff --git a/data/drug_snomed_mapping_enriched.csv b/data/drug_snomed_mapping_enriched.csv new file mode 100644 index 0000000..046d691 --- /dev/null +++ b/data/drug_snomed_mapping_enriched.csv @@ -0,0 +1,39784 @@ +Drug,Indication,TA_ID,Search_Term,SNOMEDCode,SNOMEDDescription,CleanedDrugName,PrimaryDirectorate,AllDirectorates +ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,156370009,Psoriatic arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ABATECEPT,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +ABATECEPT,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +ABCIXIMAB,Acute coronary syndromes,TA047,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY +ABCIXIMAB (INTRAVENOUS),Acute coronary syndromes,TA012,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,134405005,Suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,160287004,FH: Breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,268547008,Screening for breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,429740004,Family history of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,706970001,TNBC - Triple-negative breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,94361000000105,Breast cancer detected by national screening programme,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,838351000000107,Education about risk of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,874291000000100,QCancer breast cancer risk,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,1035841000000108,Lymphoedema following breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,134405005,Suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,160287004,FH: Breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,268547008,Screening for breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,429740004,Family history of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,706970001,TNBC - Triple-negative breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,94361000000105,Breast cancer detected by national screening programme,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,838351000000107,Education about risk of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,874291000000100,QCancer breast cancer risk,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,1035841000000108,Lymphoedema following breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,134405005,Suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,160287004,FH: Breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,hormone receptor,237521008,Hypothyroidism due to thyroid stimulating hormone receptor blocking antibody,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,268547008,Screening for breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,hormone receptor,417742002,Hormone receptor positive tumour,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,429740004,Family history of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,hormone receptor,438628005,Hormone receptor negative tumour,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,706970001,TNBC - Triple-negative breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,94361000000105,Breast cancer detected by national screening programme,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,hormone receptor,310871000000100,Tumour hormone receptor status,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,838351000000107,Education about risk of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,874291000000100,QCancer breast cancer risk,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,1035841000000108,Lymphoedema following breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,134405005,Suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,160287004,FH: Breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,268547008,Screening for breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,429740004,Family history of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,706970001,TNBC - Triple-negative breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,94361000000105,Breast cancer detected by national screening programme,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,838351000000107,Education about risk of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,874291000000100,QCancer breast cancer risk,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,1035841000000108,Lymphoedema following breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,315268008,Suspected prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,428262008,H/O: prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,698470001,Advice given about prostate cancer screening,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,712837004,Active surveillance of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,720007002,Prostate cancer care review,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,31011000119107,Prostate cancer screening declined,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,874211000000109,QCancer prostate cancer risk,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,878401000000104,No FH of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,315268008,Suspected prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,428262008,H/O: prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,698470001,Advice given about prostate cancer screening,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,712837004,Active surveillance of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,720007002,Prostate cancer care review,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,31011000119107,Prostate cancer screening declined,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,874211000000109,QCancer prostate cancer risk,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,878401000000104,No FH of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,315268008,Suspected prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,428262008,H/O: prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,698470001,Advice given about prostate cancer screening,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,712837004,Active surveillance of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,720007002,Prostate cancer care review,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,31011000119107,Prostate cancer screening declined,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,874211000000109,QCancer prostate cancer risk,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,878401000000104,No FH of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238543002,Discoid atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238545009,Follicular atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,axial spondyloarthritis,723116002,Axial spondyloarthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,4927003,Acute anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,11226001,Fuchs uveitis syndrome,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,43363007,Posterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,75614007,Panuveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,89114005,Infectious anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,95707009,Phacotoxic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,267619000,Non-infectious anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,312922007,Uveitis related cystoid macular oedema,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,314029000,Tuberculous uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,314030005,Post-traumatic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,314033007,Secondary open-angle glaucoma with uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,314493000,Postoperative uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,370506009,Keratouveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,398155003,Chronic anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,410494003,Phacoantigenic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,410692006,Anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,342151000119100,Acute anterior uveitis of left eye,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +ADALIMUMAB,Plaque psoriasis,TA146,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ADALIMUMAB,Plaque psoriasis,TA146,plaque psoriasis,402307000,Chronic large plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ADALIMUMAB,Plaque psoriasis,TA146,plaque psoriasis,402310007,Chronic stable plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ADALIMUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ADALIMUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402307000,Chronic large plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ADALIMUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402310007,Chronic stable plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,156370009,Psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,156370009,Psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ADALIMUMAB,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +ADALIMUMAB,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,64766004,UC - ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,160383003,FH: Ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,275129008,Family history of ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,275549008,History of ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,445243001,Left sided ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,16584000,Administration of vaccine product containing only Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,17627009,Hepatitis B e antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,22290004,Hepatitis B virus surface antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,47758006,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,61977001,Chronic viral hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,76795007,Acute hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,81665004,Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,82409003,Hepatitis B core antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,82645009,Hepatitis B virus surface antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,116800003,Hepatitis B Virus immune globulin administration,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,122450004,Hepatitis B virus antibody,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,161638000,Hepatitis B Occupational risk,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,165806002,Hepatitis B surface antigen positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,165807006,Hepatitis Be antigen present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,165808001,Hepatitis B non-immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170370000,First hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170371001,Administration of second dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170372008,Third hepatitis B immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170373003,Hepatitis B booster vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170374009,Fourth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170375005,Administration of fifth dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170436000,Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170542003,Requires course of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,171122006,Hepatitis B screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,171123001,Hepatitis B screening required,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,186626002,Acute hepatitis B with delta-agent (coinfection) without hepatic coma,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,192723002,Post hepatitis B vaccination encephalitis,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,235871004,Hepatitis B carrier,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,268504008,Anti-hepatitis B immunoglobulin given,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,271511000,Hepatitis B immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,278969009,Hepatitis B status,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,293110008,Adverse reaction to component of vaccine product containing Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,294637001,Hepatitis B immunoglobulin allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,294646007,Hepatitis B vaccine allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,303233001,Antigen of Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,313234004,Hepatitis B antibody present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,406010001,Hepatitis B surface antigen not detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,408778004,Hepatitis B vaccination declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,416923003,Sixth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,425569004,Hepatitis B immunization recommended,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,426519003,History of two doses hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,426980004,History of one dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,427390007,History of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,429203008,History of three hepatitis B vaccinations,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,429721005,History of hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,698604002,Hepatitis B outbreak education,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,699037006,Hepatitis B vaccination contraindicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,707287001,Hepatitis B vaccination not indicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,736687002,Hepatitis B core antibody detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,736693005,Hepatitis B core antibody negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,736699009,Requires hepatitis B booster,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,198041000000109,Hepatitis B vaccination refused,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,201591000000101,Advice on hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,202271000000108,Hepatitis B screening declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,204681000000104,Hepatitis B screening counselling,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,221021000000103,Hepatitis B treatment drugs Band 1,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,356121000000100,Hepatitis B screening positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,362851000000109,Hepatitis B screening negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835791000000107,Hepatitis B vaccination invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835811000000108,Hepatitis B vaccination invitation first letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835831000000100,Hepatitis B vaccination invitation second letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835851000000107,Hepatitis B vaccination invitation third letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835871000000103,Hepatitis B vaccination verbal invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,839711000000101,Hepatitis B vaccination not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,846421000000105,Hepatitis B screening not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,865061000000108,First hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,865081000000104,Second hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,865101000000105,Third hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,865121000000101,Fourth hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,991971000000109,Hepatitis B immunity test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,991981000000106,Hepatitis B core antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,991991000000108,Hepatitis B e antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,995941000000101,Anti HBc (hepatitis B core) IgG level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1008441000000106,Hepatitis B deoxyribonucleic acid detection assay,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1008791000000106,HBsAg (hepatitis B surface antigen) antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1009271000000109,Hepatitis B screening test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1014201000000102,Hepatitis B surface antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1014211000000100,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1014231000000108,Hepatitis B core antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1014241000000104,Hepatitis B e antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1028341000000105,Hepatitis B antigen screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1037211000000101,First hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1037231000000109,Second hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1060591000000103,Hepatitis B resolved,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1091701000000105,At risk of hepatitis B infection,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1107691000000105,Hepatitis B screening offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,16584000,Administration of vaccine product containing only Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,17627009,Hepatitis B e antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,22290004,Hepatitis B virus surface antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,47758006,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,61977001,Chronic viral hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,76795007,Acute hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,81665004,Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,82409003,Hepatitis B core antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,82645009,Hepatitis B virus surface antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,116800003,Hepatitis B Virus immune globulin administration,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,122450004,Hepatitis B virus antibody,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,161638000,Hepatitis B Occupational risk,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,165806002,Hepatitis B surface antigen positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,165807006,Hepatitis Be antigen present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,165808001,Hepatitis B non-immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170370000,First hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170371001,Administration of second dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170372008,Third hepatitis B immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170373003,Hepatitis B booster vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170374009,Fourth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170375005,Administration of fifth dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170436000,Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170542003,Requires course of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,171122006,Hepatitis B screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,171123001,Hepatitis B screening required,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,186626002,Acute hepatitis B with delta-agent (coinfection) without hepatic coma,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,192723002,Post hepatitis B vaccination encephalitis,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,235871004,Hepatitis B carrier,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,268504008,Anti-hepatitis B immunoglobulin given,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,271511000,Hepatitis B immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,278969009,Hepatitis B status,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,293110008,Adverse reaction to component of vaccine product containing Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,294637001,Hepatitis B immunoglobulin allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,294646007,Hepatitis B vaccine allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,303233001,Antigen of Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,313234004,Hepatitis B antibody present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,406010001,Hepatitis B surface antigen not detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,408778004,Hepatitis B vaccination declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,416923003,Sixth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,425569004,Hepatitis B immunization recommended,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,426519003,History of two doses hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,426980004,History of one dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,427390007,History of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,429203008,History of three hepatitis B vaccinations,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,429721005,History of hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,698604002,Hepatitis B outbreak education,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,699037006,Hepatitis B vaccination contraindicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,707287001,Hepatitis B vaccination not indicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,736687002,Hepatitis B core antibody detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,736693005,Hepatitis B core antibody negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,736699009,Requires hepatitis B booster,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,198041000000109,Hepatitis B vaccination refused,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,201591000000101,Advice on hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,202271000000108,Hepatitis B screening declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,204681000000104,Hepatitis B screening counselling,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,221021000000103,Hepatitis B treatment drugs Band 1,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,356121000000100,Hepatitis B screening positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,362851000000109,Hepatitis B screening negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835791000000107,Hepatitis B vaccination invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835811000000108,Hepatitis B vaccination invitation first letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835831000000100,Hepatitis B vaccination invitation second letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835851000000107,Hepatitis B vaccination invitation third letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835871000000103,Hepatitis B vaccination verbal invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,839711000000101,Hepatitis B vaccination not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,846421000000105,Hepatitis B screening not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,865061000000108,First hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,865081000000104,Second hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,865101000000105,Third hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,865121000000101,Fourth hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,991971000000109,Hepatitis B immunity test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,991981000000106,Hepatitis B core antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,991991000000108,Hepatitis B e antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,995941000000101,Anti HBc (hepatitis B core) IgG level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1008441000000106,Hepatitis B deoxyribonucleic acid detection assay,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1008791000000106,HBsAg (hepatitis B surface antigen) antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1009271000000109,Hepatitis B screening test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1014201000000102,Hepatitis B surface antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1014211000000100,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1014231000000108,Hepatitis B core antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1014241000000104,Hepatitis B e antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1028341000000105,Hepatitis B antigen screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1037211000000101,First hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1037231000000109,Second hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1060591000000103,Hepatitis B resolved,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1091701000000105,At risk of hepatitis B infection,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1107691000000105,Hepatitis B screening offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,162573006,Suspected lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,254637007,Non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,275981009,Lung cancer screening,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,429011007,Family history of lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,877691000000107,No FH of lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,162573006,Suspected lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,254637007,Non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,275981009,Lung cancer screening,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,429011007,Family history of lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,877691000000107,No FH of lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AFLIBERCEPT,Choroidal neovascularisation,TA486,choroidal neovascularisation,733124000,Myopic choroidal neovascularisation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Choroidal neovascularisation,TA486,choroidal neovascularisation,380621000000102,Subfoveal choroidal neovascularisation drugs Band 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,37231002,Macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,232039004,Central retinal vein occlusion with macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,232045007,Macular oedema due to hemispheric retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312911008,CSME - clinically significant macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312912001,Macular oedema due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312920004,Postoperative cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312921000,Autosomal dominant cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312922007,Uveitis related cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,769218003,Macular oedema of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,895021000000102,Macular oedema drugs Band 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,37231002,Macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,232039004,Central retinal vein occlusion with macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,232045007,Macular oedema due to hemispheric retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312911008,CSME - clinically significant macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312912001,Macular oedema due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312920004,Postoperative cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312921000,Autosomal dominant cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312922007,Uveitis related cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,769218003,Macular oedema of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,895021000000102,Macular oedema drugs Band 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,193384000,Senile macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,267718000,Age-related macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,312898002,Myopic macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,1296526000,Disciform macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,191610000,"Recurrent major depressive episodes, mild",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH +AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,191611001,"Recurrent major depressive episodes, moderate",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH +AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,191613003,"Recurrent major depressive episodes, severe, with psychosis",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH +AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,268621008,Recurrent major depressive episodes,AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH +AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,755331000000108,"Recurrent major depressive episodes, severe, with psychosis, psychosis in remission",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH +AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,764611000000100,"Recurrent major depressive episodes, severe",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH +AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,764691000000109,"Recurrent major depressive episodes, in partial remission",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH +ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,162573006,Suspected lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,275981009,Lung cancer screening,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,429011007,Family history of lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,162573006,Suspected lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,275981009,Lung cancer screening,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,429011007,Family history of lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,24700007,Multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,160337009,Family history of multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,192926004,Brain stem multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,192928003,Generalised multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,428700003,Primary progressive multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,438511000,Benign multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,700409000,Suspected multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,198491000000106,Multiple sclerosis review,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,515931000000104,Multiple sclerosis review declined,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ALIROCUMAB,Treating primary hypercholesterolaemia and mixed dyslipidaemia,TA393,primary hypercholesterolaemia,238076009,Primary hypercholesterolaemia,ALIROCUMAB,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +ALITRETINOIN,Severe chronic hand eczema,TA177,hand eczema,238556009,Psoriasiform hand eczema,ALITRETINOIN,DERMATOLOGY,DERMATOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,134405005,Suspected breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,160287004,FH: Breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,268547008,Screening for breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,429740004,Family history of breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,706970001,TNBC - Triple-negative breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,94361000000105,Breast cancer detected by national screening programme,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,838351000000107,Education about risk of breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,874291000000100,QCancer breast cancer risk,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,1035841000000108,Lymphoedema following breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,134405005,Suspected breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,160287004,FH: Breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,268547008,Screening for breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,429740004,Family history of breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,706970001,TNBC - Triple-negative breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,94361000000105,Breast cancer detected by national screening programme,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,838351000000107,Education about risk of breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,874291000000100,QCancer breast cancer risk,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,1035841000000108,Lymphoedema following breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ALTEPLASE,Ischaemic stroke (acute),TA122,ischaemic stroke,422504002,Ischaemic stroke,ALTEPLASE,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +ALTEPLASE,Ischaemic stroke (acute),TA264,ischaemic stroke,422504002,Ischaemic stroke,ALTEPLASE,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +ALTEPLASE,Ischaemic stroke (acute),TA122,ischaemic stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,ALTEPLASE,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +ALTEPLASE,Ischaemic stroke (acute),TA264,ischaemic stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,ALTEPLASE,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,1755008,Healed myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,22298006,MI - myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,52035003,Acute anteroapical myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,54329005,Acute anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,57054005,Acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,65547006,Acute inferolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,66189004,Postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,70211005,Acute anterolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,79009004,Acute myocardial infarction of septum,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,129574000,Postoperative myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194809007,Acute myocardial infarction of atrium,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194821006,Aborted myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194856005,Subsequent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233838001,Acute posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233839009,Old anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233840006,Old inferior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233841005,Old lateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233842003,Old posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233843008,Silent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233885007,Pericarditis following myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,266897007,Family history of myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,304914007,Acute Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,308065005,History of myocardial infarction in last year,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,314207007,Non-Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,394710008,First myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,399211009,Previous myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (prevention),TA067,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,6142004,Influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,24662006,Influenza caused by Influenza B virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,41269000,Influenzal bronchopneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,44470000,Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,46233009,Influenza virus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,51593004,Haemophilus parainfluenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,64917006,Pneumonia due to parainfluenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,70036007,Haemophilus influenzae pneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,74644004,Influenza with encephalopathy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,89117003,Parainfluenza virus type 4,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,91428005,Haemophilus influenzae infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,95891005,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,120753009,Influenza A virus antibody,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,120843002,Influenza B virus Ab,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,120975003,Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,127787002,Haemophilus influenzae type b immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,170343007,First Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,170345000,Third Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,171272004,No consent - influenza immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,171282003,Influenza immunization advised at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,171290003,Influenza vaccination consent given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,171291004,No consent for Haemophilus influenzae type b immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,185900003,Has influenza vaccination at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,185901004,Has influenza vaccination at surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,185902006,Has influenza vaccination at hospital,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,185903001,Needs influenza immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,192721000,Post influenza vaccination encephalitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,194946005,Acute myocarditis - influenzal,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,195726000,Acute parainfluenza virus bronchitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,195878008,Pneumonia and influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,195923003,Influenza with laryngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,195924009,Influenza with pharyngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,195929004,Influenza with gastrointestinal tract involvement,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,195931008,Influenza like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,266393000,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,268561003,Influenza immunization advised in surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,275983007,Influenza immunisation advised,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,291749008,Influenza vaccine poisoning,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,293112000,Influenza split virion vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,293113005,Influenza surface antigen vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,294647003,Allergy to influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,294648008,Allergy to influenza split virion vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,294649000,Allergy to influenza surface antigen vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,294664000,Haemophilus influenzae type b vaccine allergy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,308532005,Influenza vaccination status,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,309789002,Encephalitis caused by Influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,315640000,Influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,315641001,Influenza vaccination invitation letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,390796006,Influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,396425006,FLU - Influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,407479009,Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,407480007,Influenza B virus(B/Lee/40),ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,407489008,Human parainfluenza virus 1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,407491000,Parainfluenza virus type 2,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,407493002,Human parainfluenza virus 3,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,407498006,Human parainfluenza viruses,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,407573008,Influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,414496007,Influenza vaccination telephone invite,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,416928007,Has influenza vaccination at work,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,441043003,Influenza A virus subtype H1 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,441049004,Influenza A virus subtype H3 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,441343005,Influenza A virus subtype H5 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,441344004,Human parainfluenza virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,441345003,Influenza B virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,442438000,Influenza caused by Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,442696006,Influenza A (H1N1) swine flu,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,444426005,Swine influenza contact,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,473169009,History of influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,698353005,Requires influenza virus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,709410003,Hib (Haemophilus influenzae type b) infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,711330007,Influenza A virus subtype H1N1 detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,711334003,Influenza A virus H1N1 subtype not detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,736818002,Influenza vaccination requested,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,737041000,Influenza immunisation telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,787016008,Administration of influenza vaccine via nasal route,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,73701000119109,Vaccination for influenza given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,135221000119101,Influenza A H1N1 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,199331000000106,Did not attend influenza vaccination appointment,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,200481000000107,Influenza vaccination invitation first letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,200491000000109,Influenza vaccination invitation second letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,200501000000103,Influenza vaccination invitation third letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,201391000000106,Booster influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,202301000000106,First pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,202311000000108,Second pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,380271000000101,Consent given for pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,380381000000108,Pandemic influenza vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,380631000000100,Pandemic influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,380801000000105,Pandemic influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,506751000000104,Possible influenza A virus H1N1 subtype,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,516101000000103,No response to influenza vaccination invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,540151000000108,Pneumonia or influenza NOS,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,761311000000109,Influenza vaccination verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,777791000000102,Influenza vaccination invitation first text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,822851000000102,Seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,822931000000100,Seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,822951000000107,Seasonal influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,822971000000103,Seasonal influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,822991000000104,Consent given for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,844941000000103,Influenza vaccination invitation email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,844961000000102,Influenza vaccination invitation first email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,844981000000106,Influenza vaccination invitation second email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,845001000000101,Influenza vaccination invitation third email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,860151000000103,Influenza vaccination first verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,860171000000107,Influenza vaccination second verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,860211000000105,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,860291000000101,Influenza vaccination third verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,868241000000109,Administration of intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,868491000000103,No consent for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,871521000000104,First intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,871541000000106,Second intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,871751000000104,Administration of first intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,871781000000105,Administration of second intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,873681000000101,Provision of information about seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,913961000000102,Education about influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,932221000000103,At risk of influenza related complication,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,935351000000106,Long term indication for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,955641000000103,Influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,996211000000100,Influenza (A and B) serology,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,996761000000106,Haemophilus influenzae B IgG level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1001341000000106,Influenza A antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1001351000000109,Influenza B antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1005101000000108,Parainfluenza virus antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1005111000000105,Parainfluenza type 3 antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1008771000000107,Haemophilus influenzae B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1014261000000103,Influenza A antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1014271000000105,Influenza B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1020381000000100,Parainfluenza virus antigen assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1033051000000101,Influenza due to zoonotic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1033071000000105,Influenza due to pandemic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1033091000000109,Influenza due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1095821000000105,Influenza vaccination first telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1095831000000107,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1095841000000103,Influenza vaccination third telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1239861000000100,Seasonal influenza vaccination given in school,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA058,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMANTADINE,Influenza (treatment),TA168,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMISULPRIDE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,162573006,Suspected lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,254637007,Non-small cell lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,275981009,Lung cancer screening,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,429011007,Family history of lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,877691000000107,No FH of lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,134405005,Suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,160287004,FH: Breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,268547008,Screening for breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,429740004,Family history of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,706970001,TNBC - Triple-negative breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,94361000000105,Breast cancer detected by national screening programme,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,838351000000107,Education about risk of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,874291000000100,QCancer breast cancer risk,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANASTROZOLE,Breast cancer (early),TA112,breast cancer,1035841000000108,Lymphoedema following breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985211000000107,Apixaban adverse reaction,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985211000000107,Apixaban adverse reaction,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985231000000104,Rivaroxaban adverse reaction,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985231000000104,Rivaroxaban adverse reaction,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985251000000106,Allergy to rivaroxaban,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985251000000106,Allergy to rivaroxaban,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985311000000102,Rivaroxaban declined,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985311000000102,Rivaroxaban declined,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985331000000105,Apixaban not tolerated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985331000000105,Apixaban not tolerated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985351000000103,Rivaroxaban not tolerated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985351000000103,Rivaroxaban not tolerated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985631000000101,Apixaban contraindicated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985631000000101,Apixaban contraindicated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985661000000106,Rivaroxaban contraindicated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985661000000106,Rivaroxaban contraindicated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,4676006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class II",ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,36402006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class IV",ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,73286009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class I",ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,76521009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class III",ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,95644001,Cerebral systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,196138005,Lung disease with systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,201436003,Drug-induced systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,230307005,Chorea due to systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,239887007,Systemic lupus erythematosus with organ/system involvement,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,239889005,Bullous systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,239890001,Systemic lupus erythematosus with multisystem involvement,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,273863009,Systemic lupus erythematosus disease activity index,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,307755009,Renal tubulo-interstitial disorder due to systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,309762007,Systemic lupus erythematosus with pericarditis,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,315268008,Suspected prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,428262008,H/O: prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,698470001,Advice given about prostate cancer screening,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,712837004,Active surveillance of prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,720007002,Prostate cancer care review,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,31011000119107,Prostate cancer screening declined,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,874211000000109,QCancer prostate cancer risk,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,878401000000104,No FH of prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,315268008,Suspected prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,428262008,H/O: prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,698470001,Advice given about prostate cancer screening,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,712837004,Active surveillance of prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,720007002,Prostate cancer care review,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,31011000119107,Prostate cancer screening declined,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,874211000000109,QCancer prostate cancer risk,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,878401000000104,No FH of prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,2517002,Stroke rehabilitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,25133001,Completed stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,28690004,Stroke test,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,39925003,"MELAS - mitochondrial encephalopathy, lactic acidosis and stroke-like episodes",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,44922000,Bounding pulse with rapid upstroke and descent,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,49436004,Atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,90096001,Stroke volume,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,134377004,Atrial fibrillation monitoring,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,135875009,Stroke prevention,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,135877001,Stroke risk,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,160252004,No family history of cardiovascular accident or stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,160271002,No family history of stroke and/or transient ischaemic attack,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,170600009,Stroke monitoring,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,195080001,Atrial fibrillation and flutter,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,195163003,Stroke due to intracerebral haemorrhage,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,195212005,Brainstem stroke syndrome,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,195213000,Cerebellar stroke syndrome,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,212937007,Heat stroke and sunstroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230690007,Stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230694003,Total anterior cerebral circulation stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230695002,Partial anterior cerebral circulation stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230696001,Posterior cerebral circulation stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230700009,Pure sensory stroke due to and following lacunar infarction,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230713003,Stroke of uncertain pathology,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230714009,Anterior circulation stroke of uncertain pathology,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230715005,Posterior circulation stroke of uncertain pathology,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230739000,Spinal cord stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,275434003,Stroke in the puerperium,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,276898003,Left ventricular stroke work index,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,277286006,Chronic central post-stroke pain,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,277381004,Stroke index,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,282825002,Intermittent atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,297250002,No family history of stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,299403002,Stroke test positive,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,299404008,Stroke test negative,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,300996004,Controlled atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,306802002,Referral to stroke service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,306803007,Admission to stroke unit,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,306808003,Discharge from stroke service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,306810001,Seen by stroke service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,308067002,History of stroke in last year,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,309966001,Stroke unit,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,310137004,Stroke service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,312442005,History of atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,371040005,Thrombotic stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,371041009,Embolic stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,412773009,Referral to stroke clinic,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,413119003,Stroke group member,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,413124000,Stroke/transient ischaemic attack referral,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,415628004,Stroke/transient ischaemic attack monitoring first letter,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,415629007,Stroke/transient ischemic attack monitoring second letter,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,415630002,Stroke/transient ischaemic attack monitoring status,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,415631003,Stroke/transient ischemic attack monitoring third letter,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,417059002,Stroke/transient ischemic attack monitoring verbal invitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,417506008,Hemorrhagic stroke monitoring,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,417540008,Stroke/transient ischaemic attack monitoring invitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,422504002,Ischaemic stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,440028005,Permanent atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,440059007,Persistent atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,450743008,NIHSS (National Institutes of Health stroke scale) score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,704154001,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR (international normalised ratio), elderly over 65, and drugs and/or alcohol concomitantly) score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,704180000,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,707514001,Stroke impact scale version 3.0 score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,719008003,At increased risk of atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,722929005,Perinatal arterial ischemic stroke of fetus and/or neonate,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,724424009,Cerebral ischemic stroke due to small artery occlusion,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,736712009,PASS (Postural Assessment Scale for Stroke Patients) score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,788884002,Cerebral ischemic stroke due to subarachnoid hemorrhage,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,88601000000107,DNA (did not attend) stroke clinic,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,112901000000108,Referral to multidisciplinary stroke function improvement service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,140921000119102,Ischemic stroke without coma,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,143471000000105,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation using preferred method of communication,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,196371000000102,Atrial fibrillation resolved,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,201501000000108,Seen in stroke clinic,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,231231000000107,Delivery of rehabilitation for stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,248411000000105,Atrial fibrillation annual review,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,519751000000106,Stroke 6 month review,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,521411000000106,Did not attend stroke review,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,685631000000102,Stroke and cerebrovascular accident unspecified,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,713771000000100,Stroke/transient ischaemic attack monitoring administration,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,716021000000109,Excepted from stroke quality indicators - informed dissent,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,716331000000108,Exception reporting - stroke quality indicators,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,716581000000101,Excepted from stroke quality indicators - patient unsuitable,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,717241000000108,Stroke/transient ischaemic attack monitoring telephone invitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,769211000000103,Suspected stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,810991000000109,Stroke self-management plan review,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,812041000000104,Stroke self-management plan agreed,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,816401000000105,Atrial fibrillation excluded,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,816561000000108,Stroke initial post discharge review,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,842441000000104,Provision of written information about stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,870631000000105,QStroke 10 year risk of stroke calculator,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1062151000000103,Stroke TOM (Therapy Outcome Measure) activity score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1062171000000107,Stroke TOM (Therapy Outcome Measure) impairment score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1062181000000109,Stroke TOM (Therapy Outcome Measure) participation score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1062191000000106,Stroke TOM (Therapy Outcome Measure) wellbeing score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1066831000000104,Atrial fibrillation detected,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1078001000000105,Haemorrhagic stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1085311000000106,QStroke risk calculator score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,APIXABAN,CARDIOLOGY,CARDIOLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1110981000000104,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,16371781000119100,Cerebellar stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,443749004,Venous thromboembolism risk assessment,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,699035003,At low risk of venous thromboembolism,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,711293008,At moderate risk of venous thromboembolism,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,711328005,At high risk of venous thromboembolism,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,787331000000107,Venous thromboembolism prevention management,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,844041000000102,Education about risk of venous thromboembolism,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,14534009,Deep vein thrombosis of splenic vein,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,49956009,Antenatal DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,56272000,Puerperal DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,59282003,Pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,128053003,Deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,134399007,Deep vein thrombosis of leg related to air travel,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,161508001,History of DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,200232006,Antenatal deep vein thrombosis - delivered,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,200233001,Antenatal deep vein thrombosis with antenatal complication,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,200238005,Postnatal deep vein thrombosis with postnatal complication,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,200284000,Obstetric pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,200286003,Obstetric air pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,213220000,Postoperative deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,225999004,At increased risk of DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,233217004,Operation for pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,233936003,Acute massive pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,233937007,Subacute massive pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,234044007,Ileofemoral deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,401186003,Deep vein thrombosis screening,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,413459009,Advised risk of deep vein thrombosis in air travel,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,413956008,Deep vein thrombosis of leg related to intravenous drug use,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,429053008,Wells deep vein thrombosis clinical probability score,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,430801003,Family history of pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,432805000,Suspected deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,438773007,Recurrent pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,443210003,Deep vein thrombosis of peroneal vein,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,710167004,Recurrent DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,198301000000109,FH: deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,323631000000102,DVT (deep vein thrombosis) prevention,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,492161000000109,Deep vein thrombosis enhanced services administration,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,503421000000105,Deep vein thrombosis enhanced services administration stage 1 service level,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,503451000000100,Deep vein thrombosis enhanced services administration stage 2 service level,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,503481000000106,Deep vein thrombosis enhanced services administration stage 3 service level,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,513251000000101,Low probability of deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,513271000000105,Moderate probability of deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,513291000000109,High probability of deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,869611000000104,On deep vein thrombosis care pathway,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,872221000000109,No history of deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,978421000000101,Unprovoked deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,978441000000108,Provoked deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +APREMILAST,Moderate to severe plaque psoriasis,TA368,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),APREMILAST,DERMATOLOGY,DERMATOLOGY +APREMILAST,Moderate to severe plaque psoriasis,TA368,plaque psoriasis,402307000,Chronic large plaque psoriasis,APREMILAST,DERMATOLOGY,DERMATOLOGY +APREMILAST,Moderate to severe plaque psoriasis,TA368,plaque psoriasis,402310007,Chronic stable plaque psoriasis,APREMILAST,DERMATOLOGY,DERMATOLOGY +APREMILAST,Treating moderate to severe plaque psoriasis,TA419,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),APREMILAST,DERMATOLOGY,DERMATOLOGY +APREMILAST,Treating moderate to severe plaque psoriasis,TA419,plaque psoriasis,402307000,Chronic large plaque psoriasis,APREMILAST,DERMATOLOGY,DERMATOLOGY +APREMILAST,Treating moderate to severe plaque psoriasis,TA419,plaque psoriasis,402310007,Chronic stable plaque psoriasis,APREMILAST,DERMATOLOGY,DERMATOLOGY +APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,156370009,Psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,156370009,Psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191583000,"Single manic episode, mild",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191584006,"Single manic episode, moderate",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191586008,"Single manic episode, severe, with psychosis",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191592002,"Recurrent manic episodes, mild",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191595000,"Recurrent manic episodes, severe, with psychosis",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191597008,"Recurrent manic episodes, in full remission",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,4926007,Schizophrenia in remission,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,12939007,Chronic disorganized schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,31373002,Hebephrenic schizophrenia in remission,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,31658008,Chronic paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,35252006,Disorganised schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,39610001,Undifferentiated schizophrenia in remission,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,58214004,Schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,63181006,"Paranoid schizophrenia, in remission",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,64905009,Paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,79866005,Subchronic paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,83746006,Chronic schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,111484002,Undifferentiated schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,160328009,Family history of schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,161103001,Schizophrenia association member,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,161468000,History of schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191527001,Simple schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191559008,Latent schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191565008,Latent schizophrenia in remission,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191567000,Schizoaffective schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191570001,Chronic schizoaffective schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,247804008,Prodromal schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,274952002,Borderline schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,444180005,History of schizophrenia in child of subject,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,285521000000103,Schizophrenia resolved,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH +ARSENIC TRIOXIDE,Acute promyelocytic leukaemia,TA526,acute promyelocytic leukaemia,28950004,Acute promyelocytic leukaemia with,ARSENIC,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ARSENIC TRIOXIDE,Acute promyelocytic leukaemia,TA526,acute promyelocytic leukaemia,110004001,Acute promyelocytic leukaemia (clinical),ARSENIC,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ASCIMINIB,Chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors,TA813,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,ASCIMINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +"ATEZOLIZMAB WITH BEVACIZUMAB, PACLITAXEL AND CARBOPLATIN",First-line treatment of metastatic non-squamous non-small cell lung cancer,TA584,non-small cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"ATEZOLIZMAB WITH BEVACIZUMAB, PACLITAXEL AND CARBOPLATIN",First-line treatment of metastatic non-squamous non-small cell lung cancer,TA584,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"ATEZOLIZMAB WITH BEVACIZUMAB, PACLITAXEL AND CARBOPLATIN",First-line treatment of metastatic non-squamous non-small cell lung cancer,TA584,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"ATEZOLIZMAB WITH BEVACIZUMAB, PACLITAXEL AND CARBOPLATIN",First-line treatment of metastatic non-squamous non-small cell lung cancer,TA584,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA525,urothelial carcinoma,12400006,Papillary urothelial carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA525,urothelial carcinoma,27090000,Urothelial carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA525,urothelial carcinoma,1259709004,Primary micropapillary urothelial carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH BEVACIZUMAB,Advanced or unresectable hepatocellular carcinoma,TA666,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH BEVACIZUMAB,Advanced or unresectable hepatocellular carcinoma,TA666,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH BEVACIZUMAB,Advanced or unresectable hepatocellular carcinoma,TA666,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,134405005,Suspected breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,160287004,FH: Breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,268547008,Screening for breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,429740004,Family history of breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,706970001,TNBC - Triple-negative breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,94361000000105,Breast cancer detected by national screening programme,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,838351000000107,Education about risk of breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,874291000000100,QCancer breast cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,1035841000000108,Lymphoedema following breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,7461003,"Attention deficit hyperactivity disorder, hyperactive impulsive type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,31177006,"Attention deficit hyperactivity disorder, combined type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702536007,Stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702538008,Drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,703314001,Non-stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516401000000106,Attention deficit hyperactivity disorder monitoring invitation first letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516891000000101,Attention deficit hyperactivity disorder monitoring invitation second letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516911000000103,Attention deficit hyperactivity disorder monitoring invitation third letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,710071000000106,Attention deficit hyperactivity disorder annual review,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886371000000105,On drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886391000000109,On stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886411000000109,On non-stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1863681000000108,Attention deficit hyperactivity disorder suspected,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1914891000000100,Diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2427101000000103,Signposting to attention deficit hyperactivity disorder resource,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2437121000000109,Referral for diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +AUTOLOGOUS ANTI-CD19-TRANSDUCED CD3+ CELLS,Relapsed or refractory mantle cell lymphoma,TA677,mantle cell lymphoma,74654000,Mantle cell lymphoma,AUTOLOGOUS,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +AUTOLOGOUS ANTI-CD19-TRANSDUCED CD3+ CELLS,Relapsed or refractory mantle cell lymphoma,TA677,mantle cell lymphoma,443487006,Mantle cell lymphoma,AUTOLOGOUS,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +AVACOPAN,Severe active granulomatosis with polyangiitis or microscopic polyangiitis,TA825,granulomatosis with polyangiitis,82275008,EGPA - eosinophilic granulomatosis with polyangiitis,AVACOPAN,RHEUMATOLOGY,RHEUMATOLOGY|THORACIC MEDICINE|NEPHROLOGY +AVACOPAN,Severe active granulomatosis with polyangiitis or microscopic polyangiitis,TA825,granulomatosis with polyangiitis,239935007,Limited granulomatosis with polyangiitis,AVACOPAN,RHEUMATOLOGY,RHEUMATOLOGY|THORACIC MEDICINE|NEPHROLOGY +AVATROMBOPAG,Primary chronic immune thrombocytopenia,TA853,immune thrombocytopenia,2897005,ITP - immune thrombocytopenia,AVATROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +AVATROMBOPAG,Primary chronic immune thrombocytopenia,TA853,immune thrombocytopenia,128091003,Primary ITP (immune thrombocytopenia),AVATROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +AVATROMBOPAG,Primary chronic immune thrombocytopenia,TA853,immune thrombocytopenia,240305000,NAIT - neonatal alloimmune thrombocytopenia,AVATROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +AVATROMBOPAG,Severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure,TA626,chronic liver disease,197279005,Cirrhosis and chronic liver disease,AVATROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY +AVATROMBOPAG,Severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure,TA626,chronic liver disease,197324004,Liver abscess and sequelae of chronic liver disease,AVATROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY +AVATROMBOPAG,Severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure,TA626,chronic liver disease,328383001,Chronic liver disease,AVATROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY +AVELUMAB,Untreated metastatic Merkel cell carcinoma,TA691,merkel cell carcinoma,133871000119103,Merkel cell carcinoma of upper limb,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +AVELUMAB (FIRST-LINE),Metastatic Merkel cell carcinoma,TA517,merkel cell carcinoma,133871000119103,Merkel cell carcinoma of upper limb,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +AVELUMAB (SECOND-LINE AND BEYOND TREATMENT),Metastatic Merkel cell carcinoma,TA517,merkel cell carcinoma,133871000119103,Merkel cell carcinoma of upper limb,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,733608000,Papillary renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AXICABTAGENE CILOLEUCEL,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,TA559,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,AXICABTAGENE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +AXICABTAGENE CILOLEUCEL,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,TA872,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,AXICABTAGENE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +AXICABTAGENE CILOLEUCEL,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,TA559,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,AXICABTAGENE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +AXICABTAGENE CILOLEUCEL,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,TA872,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,AXICABTAGENE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,733608000,Papillary renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +AZACITIDINE,"Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia",TA218,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",AZACITIDINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +AZACITIDINE,Treating acute myeloid leukaemia with more than 30% bone marrow blasts,TA399,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",AZACITIDINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,6142004,Influenza,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,24662006,Influenza caused by Influenza B virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,41269000,Influenzal bronchopneumonia,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,44470000,Haemophilus influenzae,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,46233009,Influenza virus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,51593004,Haemophilus parainfluenzae,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,64917006,Pneumonia due to parainfluenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,70036007,Haemophilus influenzae pneumonia,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,74644004,Influenza with encephalopathy,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,89117003,Parainfluenza virus type 4,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,91428005,Haemophilus influenzae infection,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,95891005,Influenza-like illness,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,120753009,Influenza A virus antibody,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,120843002,Influenza B virus Ab,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,120975003,Haemophilus influenzae type b antigen,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,127787002,Haemophilus influenzae type b immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170343007,First Haemophilus influenzae type b vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170345000,Third Haemophilus influenzae type b vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,171272004,No consent - influenza immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,171282003,Influenza immunization advised at home,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,171290003,Influenza vaccination consent given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,171291004,No consent for Haemophilus influenzae type b immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,185900003,Has influenza vaccination at home,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,185901004,Has influenza vaccination at surgery,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,185902006,Has influenza vaccination at hospital,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,185903001,Needs influenza immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,192721000,Post influenza vaccination encephalitis,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,194946005,Acute myocarditis - influenzal,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195726000,Acute parainfluenza virus bronchitis,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195878008,Pneumonia and influenza,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195923003,Influenza with laryngitis,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195924009,Influenza with pharyngitis,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195929004,Influenza with gastrointestinal tract involvement,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195931008,Influenza like illness,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,266393000,Influenza-like illness,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,268561003,Influenza immunization advised in surgery,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,275983007,Influenza immunisation advised,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,291749008,Influenza vaccine poisoning,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,293112000,Influenza split virion vaccine adverse reaction,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,293113005,Influenza surface antigen vaccine adverse reaction,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,294647003,Allergy to influenza vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,294648008,Allergy to influenza split virion vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,294649000,Allergy to influenza surface antigen vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,294664000,Haemophilus influenzae type b vaccine allergy,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,308532005,Influenza vaccination status,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,309789002,Encephalitis caused by Influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,315640000,Influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,315641001,Influenza vaccination invitation letter sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,390796006,Influenza vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,396425006,FLU - Influenza vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407479009,Influenza A virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407480007,Influenza B virus(B/Lee/40),BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407489008,Human parainfluenza virus 1,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407491000,Parainfluenza virus type 2,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407493002,Human parainfluenza virus 3,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407498006,Human parainfluenza viruses,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407573008,Influenza vaccination not indicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,414496007,Influenza vaccination telephone invite,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,416928007,Has influenza vaccination at work,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441043003,Influenza A virus subtype H1 present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441049004,Influenza A virus subtype H3 present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441343005,Influenza A virus subtype H5 present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441344004,Human parainfluenza virus present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441345003,Influenza B virus present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,442438000,Influenza caused by Influenza A virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,442696006,Influenza A (H1N1) swine flu,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,444426005,Swine influenza contact,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,473169009,History of influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,698353005,Requires influenza virus vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,709410003,Hib (Haemophilus influenzae type b) infection,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,711330007,Influenza A virus subtype H1N1 detected,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,711334003,Influenza A virus H1N1 subtype not detected,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,736818002,Influenza vaccination requested,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,737041000,Influenza immunisation telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,787016008,Administration of influenza vaccine via nasal route,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,73701000119109,Vaccination for influenza given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,135221000119101,Influenza A H1N1 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,199331000000106,Did not attend influenza vaccination appointment,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,200481000000107,Influenza vaccination invitation first letter sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,200491000000109,Influenza vaccination invitation second letter sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,200501000000103,Influenza vaccination invitation third letter sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,201391000000106,Booster influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,202301000000106,First pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,202311000000108,Second pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380271000000101,Consent given for pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380381000000108,Pandemic influenza vaccination refused,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380631000000100,Pandemic influenza vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380801000000105,Pandemic influenza vaccination not indicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,506751000000104,Possible influenza A virus H1N1 subtype,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,516101000000103,No response to influenza vaccination invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,540151000000108,Pneumonia or influenza NOS,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,761311000000109,Influenza vaccination verbal invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,777791000000102,Influenza vaccination invitation first text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822851000000102,Seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822931000000100,Seasonal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822951000000107,Seasonal influenza vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822971000000103,Seasonal influenza vaccination not indicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822991000000104,Consent given for seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,844941000000103,Influenza vaccination invitation email,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,844961000000102,Influenza vaccination invitation first email,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,844981000000106,Influenza vaccination invitation second email,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,845001000000101,Influenza vaccination invitation third email,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,860151000000103,Influenza vaccination first verbal invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,860171000000107,Influenza vaccination second verbal invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,860211000000105,Influenza vaccination second telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,860291000000101,Influenza vaccination third verbal invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,868241000000109,Administration of intranasal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,868491000000103,No consent for seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,871521000000104,First intranasal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,871541000000106,Second intranasal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,871751000000104,Administration of first intranasal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,871781000000105,Administration of second intranasal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,873681000000101,Provision of information about seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,913961000000102,Education about influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,932221000000103,At risk of influenza related complication,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,935351000000106,Long term indication for seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955641000000103,Influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,996211000000100,Influenza (A and B) serology,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,996761000000106,Haemophilus influenzae B IgG level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1001341000000106,Influenza A antigen level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1001351000000109,Influenza B antigen level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1005101000000108,Parainfluenza virus antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1005111000000105,Parainfluenza type 3 antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008771000000107,Haemophilus influenzae B antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1014261000000103,Influenza A antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1014271000000105,Influenza B antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1020381000000100,Parainfluenza virus antigen assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1033051000000101,Influenza due to zoonotic influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1033071000000105,Influenza due to pandemic influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1033091000000109,Influenza due to seasonal influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1095821000000105,Influenza vaccination first telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1095831000000107,Influenza vaccination second telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1095841000000103,Influenza vaccination third telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1239861000000100,Seasonal influenza vaccination given in school,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238543002,Discoid atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238545009,Follicular atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238546005,Pruriginous atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,584621000000108,Atopic dermatitis NOS,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,161567008,History of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,161567008,History of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,161567008,History of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BASILIXIMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,4676006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class II",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,36402006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class IV",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,73286009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class I",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,76521009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class III",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,95644001,Cerebral systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,196138005,Lung disease with systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,201436003,Drug-induced systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,230307005,Chorea due to systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,239887007,Systemic lupus erythematosus with organ/system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,239889005,Bullous systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,239890001,Systemic lupus erythematosus with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,273863009,Systemic lupus erythematosus disease activity index,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,307755009,Renal tubulo-interstitial disorder due to systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,309762007,Systemic lupus erythematosus with pericarditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,4676006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class II",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,36402006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class IV",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,73286009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class I",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,76521009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class III",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,95644001,Cerebral systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,196138005,Lung disease with systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,201436003,Drug-induced systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,230307005,Chorea due to systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,239887007,Systemic lupus erythematosus with organ/system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,239889005,Bullous systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,239890001,Systemic lupus erythematosus with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,273863009,Systemic lupus erythematosus disease activity index,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,307755009,Renal tubulo-interstitial disorder due to systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,309762007,Systemic lupus erythematosus with pericarditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,835009,Angioimmunoblastic lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1929004,"Malignant lymphoma, diffuse",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,19340000,Plasmacytic lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,20776008,Adenolymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,21964009,Lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,21983002,Struma lymphomatosa,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,28054005,Cutaneous lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,28175004,Gastric pseudolymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,30440004,Lymphoma stage I,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,31047003,Lymphomatoid papulosis,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,55150002,"Malignant lymphoma, nodular",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,56944001,Lymphoma stage III,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,66445009,Lymphoma stage IV,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,74654000,Mantle cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,76422004,Lymphoma stage II,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93198004,Malignant lymphoma of spleen,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,95193005,Nodular lymphoma of spleen,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,106252000,Staging classification for lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109962001,Nonfollicular lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109969005,Diffuse large B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109975001,T-zone lymphoma (clinical),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109976000,Lymphoepithelioid lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109978004,T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109979007,B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109988003,True histiocytic lymphoma (clinical),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,115244002,Malignant lymphoma - category,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118599009,"Lymphoma, Hodgkins",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118600007,Malignant lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118601006,Non-Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118617000,Burkitt lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128803008,Marginal zone lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128929007,Non-Hodgkin lymphoma - category,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128930002,Hodgkin lymphoma - category,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,189958005,"Lymphomatous tumour, benign",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,189962004,"Malignant lymphoma, stem cell type",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,232075002,Lymphoma of retina,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,236513009,Lymphoma of kidney,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,239297008,Lymphomatoid granulomatosis of lung,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,239940004,Lymphomatoid granulomatosis,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,254372002,Ann Arbor lymphoma staging system,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,255102004,Intravascular lymphomatosis,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,258279002,Lymphoma staging symptom status values,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,269476000,Nodular lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,274905008,Mantle zone lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,276811008,Gastric lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,276815004,Lymphoma of intestine,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,276836002,Primary cerebral lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277570003,Lymphoma with spill,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277615007,Low grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277616008,Diffuse low grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277617004,High grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277618009,Nodular malignant lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277623009,Monocytoid B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277626001,Diffuse high grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277627005,Nodular high grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277637000,Large cell anaplastic lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277641001,Follicular malignant lymphoma - large cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277642008,Low grade T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277643003,High grade T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277654008,Enteropathy-type T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277664004,Malignant lymphoma of testis,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,278051002,Malignant lymphoma of thyroid gland,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,278052009,Malignant lymphoma of breast,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,302841002,Malignant lymphoma - small cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,308121000,Follicular lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314922006,B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314923001,Low grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314925008,High grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314926009,T-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,315264005,Suspected lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,400001003,Primary cutaneous lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,404140004,SALT type B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,420788006,Vitreoretinal lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,426071002,Hodgkin lymphoma in remission,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,427141003,Malignant lymphoma in remission,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,428046009,History of non-Hodgkins lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,433450000,Family history of non-Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,443487006,Mantle cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,445406001,Hepatosplenic T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,447100004,Marginal zone lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,448211002,Adenolymphoma of parotid gland,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,449074003,Lymphoma of small intestine,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,449220000,Diffuse follicle center lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,721555001,Follicular lymphoma of small intestine,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,724648008,Plasmablastic lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,762690000,Classical Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1148851002,Follicular lymphoma grade IIIa,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847481000000109,Follicular lymphoma grade 1,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847631000000107,Follicular lymphoma grade 2,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847651000000100,Follicular lymphoma grade 3,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847691000000108,Follicular lymphoma grade 3a,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847701000000108,Follicular lymphoma grade 3b,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847741000000106,Diffuse large B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BENDAMUSTINE (1ST LINE),Chronic lymphocytic leukaemia (Binet stage B or C),TA216,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +BENDAMUSTINE (1ST LINE),Chronic lymphocytic leukaemia (Binet stage B or C),TA216,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +BENDAMUSTINE (1ST LINE),Chronic lymphocytic leukaemia (Binet stage B or C),TA216,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +BENDAMUSTINE (1ST LINE),Chronic lymphocytic leukaemia (Binet stage B or C),TA216,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,12428000,Intrinsic asthma without status asthmaticus,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,31387002,Exercise-induced asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,34015007,Flour asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,56018004,Asthmatic breathing,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,56968009,Asthma caused by wood dust,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,57607007,Industrial asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,63088003,Allergic asthma without status asthmaticus,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,71892000,Cardiac asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,93432008,Drug-induced asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,160377001,Family history of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,161105008,Asthma society member,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,161527007,History of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,162660004,Asthma resolved,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170631002,Asthma disturbing sleep,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170632009,Asthma causing night waking,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170633004,Asthma disturbs sleep weekly,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170634005,Asthma disturbs sleep frequently,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170635006,Asthma not disturbing sleep,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170636007,Asthma never disturbs sleep,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170637003,Asthma limiting activities,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170638008,Asthma not limiting activities,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170642006,Asthma severity,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170647000,Asthma prophylactic medication used,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170655007,Asthma restricts exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170656008,Asthma sometimes restricts exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170657004,Asthma severely restricts exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170658009,Asthma never restricts exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,171231001,Asthma screening,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182724005,Further asthma - drug prevention,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182726007,Asthma control step 0,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182727003,Asthma control step 1,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182728008,Asthma control step 2,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182729000,Asthma control step 3,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182730005,Asthma control step 4,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182731009,Asthma control step 5,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,183099005,Asthma leaflet given,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,183478001,Emergency hospital admission for asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185242005,Seen in asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185728001,Attends asthma monitoring,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185730004,Asthma monitor offer default,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185731000,Asthma monitoring call first letter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185732007,Asthma monitoring call second letter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185734008,Asthma monitoring call third letter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185735009,Asthma monitoring call verbal invite,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185736005,Asthma monitoring call telephone invite,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185737001,Asthma monitoring deleted,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185940009,Patient in asthma study,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195949008,Chronic asthmatic bronchitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195967001,Asthmatic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195973000,Late-onset asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195977004,Mixed asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195983001,Exercise induced asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,219036002,Adverse reaction to antiasthmatic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,225057002,Brittle asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,233678006,Childhood asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,233679003,Late-onset asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,233683003,Hay fever with asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,233691007,Eosinophilic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,266361008,Non-allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,266396008,Extrinsic asthma - atopy (& pollen),BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,266397004,Intrinsic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,266398009,Asthma attack,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,270442000,Asthma monitoring check done,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,275908000,Asthma monitoring,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,281239006,Asthma attack,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,302220000,Asthma control steps,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,304527002,Acute asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,308500005,Asthma monitoring call,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,308501009,Asthma monitoring status,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,312453004,Asthma - currently active,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,312454005,Asthma - currently dormant,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,366874008,Number of asthma exacerbations in past year,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370204008,Asthma causes daytime symptoms most days,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370206005,Asthma limits walking on the flat,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370207001,Asthma limits walking up hills or stairs,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370208006,Asthma never causes daytime symptoms,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370218001,Mild asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370219009,Moderate asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370220003,Occasional asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370221004,Severe asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370225008,Asthma treatment compliance unsatisfactory,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370226009,Asthma treatment compliance satisfactory,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,373899003,Asthma daytime symptoms,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,389145006,Allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390798007,Asthma finding,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390872009,Change in asthma management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390877003,Step up change in asthma management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390878008,Step down change in asthma management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390921001,Absent from work or school due to asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390940007,Asthma monitoring due,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,394700004,Asthma annual review,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,394701000,Asthma follow-up,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,394720003,Asthma medication review,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,394967008,Suspected asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,395022009,Nocturnal asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,400987003,Asthma trigger,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401135008,Health education - asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401182001,Asthma monitoring by nurse,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401183006,Asthma monitoring by doctor,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401193004,Asthma confirmed,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,405944004,Asthmatic bronchitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,406162001,Asthma care,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,407674008,Aspirin-induced asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,409663006,Cough variant asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,415265005,Referral to asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,424643009,Allergic atopic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,425969006,Acute intermittent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,426656000,Severe persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,426979002,Mild persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,427295004,Moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,427603009,Intermittent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,427679007,Mild intermittent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,443117005,Asthma control test score,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,445427006,Seasonal asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,445531003,ACQ - Asthma control questionnaire,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,473391009,Asthma never causes night symptoms,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,698509001,Under care of asthma specialist nurse,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,699191007,Did not attend asthma review,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,702823004,Asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,704008007,No family history of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707445000,Acute mild persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707446004,Acute exacerbation of moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707447008,Exacerbation of severe persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707511009,Uncomplicated mild persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707512002,Uncomplicated moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707513007,Uncomplicated severe persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707979007,Acute severe exacerbation of severe persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707981009,Acute severe exacerbation of mild persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708038006,Acute exacerbation of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708090002,Acute severe exacerbation of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708093000,Acute exacerbation of allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708094006,Acute exacerbation of intrinsic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708095007,Acute severe exacerbation of extrinsic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708358003,Emergency asthma admission since last encounter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708373002,Emergency asthma patient visit since last encounter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,711442001,Recent asthma management,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,715191006,Telehealth asthma monitoring,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,734346005,Use of asthma symptom diary,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,734904007,Life threatening acute exacerbation of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,734905008,Moderate acute exacerbation of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,736056000,Asthma clinical management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,762521001,Acute allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,763077003,Asthma Control Questionnaire score,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,763221007,Asthma monitoring declined,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,782520007,Exacerbation of allergic asthma due to infection,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,782559003,Asthma never causes night symptoms,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401000119107,Asthma with irreversible airway obstruction,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,641000119106,Intermittent asthma well controlled,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1741000119102,Intermittent asthma uncontrolled,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,72301000119103,Asthma in pregnancy,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,89581000000109,DNA (did not attend) asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,143901000000108,Registration for access to online asthma self-management application,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,143931000000102,Declined to register for access to online asthma self-management application,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,176711000000100,Does not have asthma management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,198971000000102,Asthma outreach clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201031000000108,Asthma trigger - respiratory infection,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201041000000104,Asthma trigger - seasonal,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201051000000101,Asthma trigger - animal,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201191000000108,Asthma trigger - cold air,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201201000000105,Asthma trigger - damp,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201211000000107,Asthma trigger - emotion,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340891000000106,Asthma trigger - airborne dust,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340901000000107,Asthma trigger - exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340911000000109,Asthma trigger - pollen,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340921000000103,Asthma trigger - tobacco smoke,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340931000000101,Asthma trigger - warm air,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,527171000000103,Patient has a written asthma personal action plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,527191000000104,Health education - asthma self management,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,527211000000100,Health education - structured asthma discussion,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,527231000000108,Health education - structured patient focused asthma discussion,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,713701000000108,Asthma monitoring administration,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,713711000000105,Asthma clinic administration,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,715801000000103,Exception reporting - asthma quality indicators,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,771941000000102,Asthma causes symptoms most nights,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,772051000000106,Asthma limits activities most days,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,791401000000104,Seen in school asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,810901000000102,Asthma self-management plan review,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,811921000000103,Asthma self-management plan agreed,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,815631000000106,Asthma trigger - wind,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,818161000000104,Asthma trigger - perfume,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,867171000000106,No asthma trigger identified by subject,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,892301000000100,Asthma management plan declined,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,905301000000103,Childhood Asthma Control Test score,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,928451000000107,Asthma monitoring invitation short message service text message,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,928511000000107,Asthma monitoring invitation email,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,928651000000105,Review of patient at risk of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,928691000000102,At risk of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,959901000000107,Asthma action plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,966011000000109,At risk of severe asthma exacerbation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,966031000000101,Severe asthma exacerbation risk assessment,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10674991000119104,Intermittent allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10675431000119106,Severe persistent allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10675871000119106,Mild persistent allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10676031000119106,Mild persistent allergic asthma controlled,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,24700007,Multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,160337009,Family history of multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,192926004,Brain stem multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,192928003,Generalised multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,428700003,Primary progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,438511000,Benign multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,700409000,Suspected multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,198491000000106,Multiple sclerosis review,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,515931000000104,Multiple sclerosis review declined,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,162573006,Suspected lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,254637007,Non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,275981009,Lung cancer screening,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,429011007,Family history of lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,877691000000107,No FH of lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB,First recurrence of platinum-sensitive advanced ovarian cancer,TA560,ovarian cancer,423274005,Ovarian cancer stage 4,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,First recurrence of platinum-sensitive advanced ovarian cancer,TA560,ovarian cancer,762997004,Suspected ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,First recurrence of platinum-sensitive advanced ovarian cancer,TA560,ovarian cancer,758821000000106,No family history of ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,First recurrence of platinum-sensitive advanced ovarian cancer,TA560,ovarian cancer,848891000000105,QCancer ovarian cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,8100009,Structure of infundibulum of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,9361007,Downward displacement of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,22611009,Endometriosis of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,25344002,Fimbriectomy of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,32587001,Rupture of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,32987009,Both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,41393008,Excision of cyst of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,42618007,Atresia of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,44793005,Excision of lesion of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,46536000,Inflammation of ovary and fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,46946009,Torsion of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,49558004,Fallopian tube tuberculosis,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,56900004,Infarction of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,78328007,Aspiration of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,78517009,Dilation of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,79586000,Fallopian tube pregnancy,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,85029000,Congenital anomaly of fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,88157006,Inflammation of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,92100009,Benign neoplasm of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,92591008,Carcinoma in situ of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,118869008,Procedure on fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,120062000,Fallopian tube reconstruction,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,128134005,Fallopian tube disorder,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176936004,Open occlusion of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176937008,Open ligation of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176948001,Open ligation of right fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176949009,Open ligation of left fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176965005,Drainage of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176975008,Exploration of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198305004,Prolapse of ovary and fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,236927008,Removal of clip from fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,236938008,Laparoscopy of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,245482004,Entire left cornu of Fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,262931005,Transection of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,265071006,Open clipping of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,265076001,Open clipping of left fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,271414005,Fallopian tube prosthesis operation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,271415006,Removal of products of conception from fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,274977001,Unilateral occlusion of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,280504001,Fallopian tube stenosis,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,283958000,Hematoma of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,287664005,Ligation of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,287931008,Fallopian tube cornual resection,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,287943009,Insufflation of fallopian tube using saline,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,287944003,Insufflation of fallopian tube using gas,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,288032001,Transection of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,288033006,Unilateral ligation of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,288034000,Unilateral fallopian tube division,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,289832005,Fallopian tube present,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,289833000,Fallopian tube absent,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,300020002,Diathermy of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,302954008,Congenital cyst of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,307264000,Remaining fallopian tube removed,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,309290005,Fallopian tube biopsy specimen,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,310808000,Fallopian tube clip,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,387615001,Removal of gestational sac from fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,392250009,Operation on fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,398319002,Abscess of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,427543006,Recanalisation of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,719447009,Ectopic fallopian tube tissue,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,561491000000108,Fallopian tube operations NOS,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,134405005,Suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,160287004,FH: Breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,268547008,Screening for breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,429740004,Family history of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,431330007,Family history of breast cancer 1 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,431331006,Family history of breast cancer 2 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,706970001,TNBC - Triple-negative breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,94361000000105,Breast cancer detected by national screening programme,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,276341000000100,Fast track referral for suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,838351000000107,Education about risk of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,874291000000100,QCancer breast cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,1035841000000108,Lymphoedema following breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,162573006,Suspected lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,254637007,Non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,275981009,Lung cancer screening,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,429011007,Family history of lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,877691000000107,No FH of lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,722731000000100,Colorectal cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,848861000000104,QCancer colorectal cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,134405005,Suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,160287004,FH: Breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,268547008,Screening for breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,429740004,Family history of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,431330007,Family history of breast cancer 1 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,431331006,Family history of breast cancer 2 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,706970001,TNBC - Triple-negative breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,94361000000105,Breast cancer detected by national screening programme,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,276341000000100,Fast track referral for suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,838351000000107,Education about risk of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,874291000000100,QCancer breast cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,1035841000000108,Lymphoedema following breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,134405005,Suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,160287004,FH: Breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,268547008,Screening for breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,429740004,Family history of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,431330007,Family history of breast cancer 1 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,431331006,Family history of breast cancer 2 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,706970001,TNBC - Triple-negative breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,94361000000105,Breast cancer detected by national screening programme,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,276341000000100,Fast track referral for suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,838351000000107,Education about risk of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,874291000000100,QCancer breast cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,1035841000000108,Lymphoedema following breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN,First recurrence of platinum-sensitive advanced ovarian cancer,TA285,ovarian cancer,423274005,Ovarian cancer stage 4,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN,First recurrence of platinum-sensitive advanced ovarian cancer,TA285,ovarian cancer,762997004,Suspected ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN,First recurrence of platinum-sensitive advanced ovarian cancer,TA285,ovarian cancer,758821000000106,No family history of ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN,First recurrence of platinum-sensitive advanced ovarian cancer,TA285,ovarian cancer,848891000000105,QCancer ovarian cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN,Advanced ovarian cancer (1st line),TA284,ovarian cancer,423274005,Ovarian cancer stage 4,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN,Advanced ovarian cancer (1st line),TA284,ovarian cancer,762997004,Suspected ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN,Advanced ovarian cancer (1st line),TA284,ovarian cancer,758821000000106,No family history of ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN,Advanced ovarian cancer (1st line),TA284,ovarian cancer,848891000000105,QCancer ovarian cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +BIMEKIZUMAB,Moderate to severe plaque psoriasis,TA723,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),BIMEKIZUMAB,DERMATOLOGY,DERMATOLOGY +BIMEKIZUMAB,Moderate to severe plaque psoriasis,TA723,plaque psoriasis,402307000,Chronic large plaque psoriasis,BIMEKIZUMAB,DERMATOLOGY,DERMATOLOGY +BIMEKIZUMAB,Moderate to severe plaque psoriasis,TA723,plaque psoriasis,402310007,Chronic stable plaque psoriasis,BIMEKIZUMAB,DERMATOLOGY,DERMATOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,1755008,Healed myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,22298006,MI - myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,52035003,Acute anteroapical myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,54329005,Acute anterior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,57054005,Acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,65547006,Acute inferolateral myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,66189004,Postmyocardial infarction syndrome,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,70211005,Acute anterolateral myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,79009004,Acute myocardial infarction of septum,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,129574000,Postoperative myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194809007,Acute myocardial infarction of atrium,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194821006,Aborted myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194856005,Subsequent myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233838001,Acute posterior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233839009,Old anterior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233840006,Old inferior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233841005,Old lateral myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233842003,Old posterior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233843008,Silent myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233885007,Pericarditis following myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,266897007,Family history of myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,304914007,Acute Q wave myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,308065005,History of myocardial infarction in last year,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,314207007,Non-Q wave myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,394710008,First myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,399211009,Previous myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY +BLINATUMOMAB,Acute lymphoblastic leukaemia in remission with minimal residual disease activity,TA589,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +BLINATUMOMAB,Acute lymphoblastic leukaemia in remission with minimal residual disease activity,TA589,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +BLINATUMOMAB,Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia,TA450,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +BLINATUMOMAB,Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia,TA450,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +BLINATUMOMAB,Previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia,TA686,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +BLINATUMOMAB,Previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia,TA686,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,62944002,Hepatitis C virus,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,62944002,Hepatitis C virus,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,72165005,Hepatitis C virus antibody,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,72165005,Hepatitis C virus antibody,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,170489004,Viral hepatitis carrier,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,170489004,Viral hepatitis carrier,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,197344005,Hepatitis caused by adenovirus,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,197344005,Hepatitis caused by adenovirus,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,235872006,Hepatitis C carrier,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,235872006,Hepatitis C carrier,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278973007,Hepatitis C status,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278973007,Hepatitis C status,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278974001,Hepatitis C immune,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278974001,Hepatitis C immune,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278975000,Hepatitis C non-immune,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278975000,Hepatitis C non-immune,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,314706002,Hepatitis C antibody detected,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,314706002,Hepatitis C antibody detected,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,314707006,Hepatitis C antibody test negative,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,314707006,Hepatitis C antibody test negative,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,413107006,Hepatitis C screening,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,413107006,Hepatitis C screening,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,773113008,Acute hepatitis caused by infection,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,773113008,Acute hepatitis caused by infection,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,12891000175105,Hepatitis C screening declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,12891000175105,Hepatitis C screening declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,200371000000104,Hepatitis C contact,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,200371000000104,Hepatitis C contact,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,201451000000105,Hepatitis C immunisation declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,201451000000105,Hepatitis C immunisation declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,202281000000105,Hepatitis C screening declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,202281000000105,Hepatitis C screening declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,204671000000101,Hepatitis C screening counselling,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,204671000000101,Hepatitis C screening counselling,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,304821000000107,Hepatitis C screening not offered,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,304821000000107,Hepatitis C screening not offered,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,362491000000104,Hepatitis C screening negative,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,362491000000104,Hepatitis C screening negative,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,362751000000101,Hepatitis C screening positive,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,362751000000101,Hepatitis C screening positive,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,761381000000102,Hepatitis C resolved,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,761381000000102,Hepatitis C resolved,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,824841000000105,Hepatitis C genotype 1,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,824841000000105,Hepatitis C genotype 1,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,824871000000104,Hepatitis C genotype 3,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,824871000000104,Hepatitis C genotype 3,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,829731000000106,On hepatitis C treatment plan,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,829731000000106,On hepatitis C treatment plan,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,992751000000109,Hepatitis C viral load,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,992751000000109,Hepatitis C viral load,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,992771000000100,Hepatitis C virus genotype,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,992771000000100,Hepatitis C virus genotype,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,996031000000104,Hepatitis C IgG level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,996031000000104,Hepatitis C IgG level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,998771000000103,Hepatitis C antibody level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,998771000000103,Hepatitis C antibody level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1001331000000102,Hepatitis C antigen level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1001331000000102,Hepatitis C antigen level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1008931000000108,Hepatitis C antibody test,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1008931000000108,Hepatitis C antibody test,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1107671000000106,Hepatitis C screening offered,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1107671000000106,Hepatitis C screening offered,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +BORTEZOMIB,Multiple myeloma,TA129,multiple myeloma,230586003,Neuropathy due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB,Multiple myeloma,TA129,multiple myeloma,413587002,Smoldering multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB,Multiple myeloma,TA129,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB,Multiple myeloma after second or subsequent relapse,TA453,multiple myeloma,230586003,Neuropathy due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB,Multiple myeloma after second or subsequent relapse,TA453,multiple myeloma,413587002,Smoldering multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB,Multiple myeloma after second or subsequent relapse,TA453,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB,Previously untreated mantle cell lymphoma,TA370,mantle cell lymphoma,74654000,Mantle cell lymphoma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB,Previously untreated mantle cell lymphoma,TA370,mantle cell lymphoma,443487006,Mantle cell lymphoma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,230586003,Neuropathy due to multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,413587002,Smoldering multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BORTEZOMIB IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE, OR WITH DEXAMETHASONE AND THALIDOMIDE",For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,TA311,multiple myeloma,230586003,Neuropathy due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE, OR WITH DEXAMETHASONE AND THALIDOMIDE",For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,TA311,multiple myeloma,413587002,Smoldering multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE, OR WITH DEXAMETHASONE AND THALIDOMIDE",For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,TA311,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BOSUTINIB,Chronic myeloid leukaemia,TA576,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,BOSUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +BOSUTINIB,Previously treated chronic myeloid leukaemia,TA299,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,BOSUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +BOSUTINIB,Previously treated chronic myeloid leukaemia,TA401,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,BOSUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,4473006,Classical migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,23186000,Menstrual migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,37796009,Migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,56097005,Migraine without aura,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,59292006,Hemiplegic migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,75879005,Decapitated migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,79267007,Retinal migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,83351003,Basilar artery migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,95655001,Ocular migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,95656000,Familial hemiplegic migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,160342001,Family history of migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,161481007,History of migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,162040008,Abdominal migraine - symptom,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,193030005,Migraine variants,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,193039006,Complex migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,230462002,Migraine with typical aura,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,230464001,Sporadic hemiplegic migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,230465000,Migraine aura without headache,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,230468003,Migraine with ischaemic complication,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,232284007,Vestibular migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,394707001,No history of migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,408381007,Migraine prophylaxis,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,427419006,Chronic migraine,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,608837004,History of migraine with aura,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,124171000119105,Chronic intractable migraine without aura,BOTULINUM,NEUROLOGY,NEUROLOGY +BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,781381000000100,Migraine induced by oestrogen contraceptive,BOTULINUM,NEUROLOGY,NEUROLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,CD30-positive cutaneous T-cell lymphoma,TA577,cutaneous t-cell lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|DERMATOLOGY +BRENTUXIMAB VEDOTIN,Relapsed or refractory systemic anaplastic large cell lymphoma,TA478,anaplastic large cell lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Relapsed or refractory systemic anaplastic large cell lymphoma,TA478,anaplastic large cell lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN IN COMBINATION,Untreated systemic anaplastic large cell lymphoma,TA641,anaplastic large cell lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRENTUXIMAB VEDOTIN IN COMBINATION,Untreated systemic anaplastic large cell lymphoma,TA641,anaplastic large cell lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,162573006,Suspected lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,254637007,Non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,275981009,Lung cancer screening,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,429011007,Family history of lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,877691000000107,No FH of lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,162573006,Suspected lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,254637007,Non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,275981009,Lung cancer screening,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,429011007,Family history of lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,877691000000107,No FH of lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +BRODALUMAB,Moderate to severe plaque psoriasis,TA511,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),BRODALUMAB,DERMATOLOGY,DERMATOLOGY +BRODALUMAB,Moderate to severe plaque psoriasis,TA511,plaque psoriasis,402307000,Chronic large plaque psoriasis,BRODALUMAB,DERMATOLOGY,DERMATOLOGY +BRODALUMAB,Moderate to severe plaque psoriasis,TA511,plaque psoriasis,402310007,Chronic stable plaque psoriasis,BRODALUMAB,DERMATOLOGY,DERMATOLOGY +BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,193384000,Senile macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,267718000,Age-related macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,312898002,Myopic macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,1296526000,Disciform macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,169941005,Maternal drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228366006,Drug misuse history,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228371004,Long-term drug misuser,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228372006,Poly-drug misuser,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228390007,Frequency of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228411009,Time since stopped drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228413007,Age at starting drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,371435006,History of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,439213009,Paternal drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,442080007,Drug misuse by mother,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,700187009,Seen in drug misuse clinic,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712542001,Abstinent from drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712543006,Abstinent from drug misuse in normal environment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712544000,Abstinent from drug misuse in protected environment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712545004,Abstinent from drug misuse on maintenance replacement,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712546003,Abstinent from drug misuse when receiving blocking therapy,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,713070003,Drug misuser in household,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,744857009,Under care of drug misuse service,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,176811000000105,Drug misuse enhanced services administration,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,176831000000102,Drug misuse enhanced service completed,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,362451000000107,Drug misuse assessment declined,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,372511000000103,Shared care drug misuse treatment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,372541000000102,Drug misuse treatment in primary care,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,383871000000108,Health problem secondary to drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,503771000000102,SMR25a drug misuse initial assessment form,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,503801000000104,SMR25b drug misuse follow up assessment form,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,505091000000102,Declined consent for notification of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,507041000000101,Name of pharmacy attended due to drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,869161000000106,Drug misuse clinic administration,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,1364721000000101,Date stopped drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,390900001,Smoking cessation milestones,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,395700008,Referral to smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,401068004,Seen by smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,401160008,Smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,710081004,Smoking cessation therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,713700008,Smoking cessation drug therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,765001003,Monitoring of smoking cessation therapy refused,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,771155005,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,1290027009,Consultation for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,25261000000107,Did not attend smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,200221000000105,Smoking cessation advice provided by community pharmacist,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,201931000000109,Attends practice smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,201941000000100,Attends smoking cessation clinic not at practice,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,374361000000100,Smoking cessation enhanced services administration,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,374391000000106,Smoking cessation enhanced services administration monitoring template completed,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,506491000000102,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,527151000000107,Smoking cessation advice declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,712971000000108,Practice based smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,720401000000103,Smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,750821000000109,Consent given for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,750851000000104,Consent given for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,751101000000101,Declined consent for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,751661000000106,Declined consent for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,755721000000107,Consent given for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,755741000000100,Declined consent for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,767641000000109,Referral for smoking cessation service offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,768971000000109,Lost to smoking cessation follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,822591000000108,Smoking cessation drug therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,850331000000104,Smoking cessation 12 week follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,871641000000105,Referral to smoking cessation service declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,871661000000106,Referral to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,966971000000103,Varenicline smoking cessation therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,966991000000104,Varenicline smoking cessation therapy offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,1084381000000100,Signposting to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,1087441000000106,Smoking cessation programme declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +BUPROPION,Smoking cessation,TA039,smoking cessation,2140191000000108,Referral to Community Pharmacy Smoking Cessation Service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,315268008,Suspected prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,428262008,H/O: prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,698470001,Advice given about prostate cancer screening,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,712837004,Active surveillance of prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,720007002,Prostate cancer care review,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,31011000119107,Prostate cancer screening declined,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,874211000000109,QCancer prostate cancer risk,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,878401000000104,No FH of prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,315268008,Suspected prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,428262008,H/O: prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,698470001,Advice given about prostate cancer screening,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,712837004,Active surveillance of prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,720007002,Prostate cancer care review,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,31011000119107,Prostate cancer screening declined,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,874211000000109,QCancer prostate cancer risk,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,878401000000104,No FH of prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,48943007,Archivist,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,48943007,Archivist,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,161855003,Complaining of shivering,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,201272008,Hives,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,201272008,Hives,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,248456009,Shivering or rigors,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1287783000,HIV-PrEP - Human immunodeficiency virus pre-exposure prophylaxis,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1287783000,HIV-PrEP - Human immunodeficiency virus pre-exposure prophylaxis,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,200901000000108,HIV (human immunodeficiency virus) screening counselling,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,200901000000108,HIV (human immunodeficiency virus) screening counselling,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,768801000000109,HIV (human immunodeficiency virus) test not appropriate,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,928531000000104,Ministry of Defence Personal Medical Record F MED 4 closed and archived,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,928531000000104,Ministry of Defence Personal Medical Record F MED 4 closed and archived,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,970551000000107,Main spoken language Dhivehi,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,970551000000107,Main spoken language Dhivehi,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,992781000000103,HIV (human immunodeficiency virus) screening test,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,992781000000103,HIV (human immunodeficiency virus) screening test,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,998701000000106,HIV (human immunodeficiency virus) viral load,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,998701000000106,HIV (human immunodeficiency virus) viral load,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,998711000000108,HIV (human immunodeficiency virus) p24 antigen level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,998711000000108,HIV (human immunodeficiency virus) p24 antigen level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008351000000102,HIV (human immunodeficiency virus) 1 ribonucleic acid detection assay,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008351000000102,HIV (human immunodeficiency virus) 1 ribonucleic acid detection assay,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008801000000105,HIV1 (human immunodeficiency virus 1) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008801000000105,HIV1 (human immunodeficiency virus 1) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008811000000107,HIV2 (human immunodeficiency virus 2) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008811000000107,HIV2 (human immunodeficiency virus 2) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1014121000000102,HIV (human immunodeficiency virus) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1014121000000102,HIV (human immunodeficiency virus) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1014171000000103,HIV (human immunodeficiency virus) antibody/antigen (Duo),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1014171000000103,HIV (human immunodeficiency virus) antibody/antigen (Duo),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1020841000000100,HIV (human immunodeficiency virus) serology,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1020841000000100,HIV (human immunodeficiency virus) serology,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1027831000000105,HIV - Human immunodeficiency virus test,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086581000000100,Daily HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis) commenced,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086581000000100,Daily HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis) commenced,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086591000000103,Intermittent HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis) commenced,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086591000000103,Intermittent HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis) commenced,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086721000000106,Daily HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086721000000106,Daily HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086731000000108,Event-based HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086731000000108,Event-based HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086751000000101,HIV (human immunodeficiency virus) test declined,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOTEGRAVIR WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086751000000101,HIV (human immunodeficiency virus) test declined,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES +CABOZANTINIB,Medullary thyroid cancer,TA516,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Medullary thyroid cancer,TA516,thyroid cancer,363478007,Malignant tumour of thyroid gland,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA582,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA849,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA582,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA849,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA582,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA849,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,733608000,Papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,733608000,Papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,9386003,Gouty neuritis,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,14763005,Gouty tophus of pinna,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,24595009,Idiopathic gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,27277001,Tophus of heart co-occurrent and due to gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,43193009,Gouty iritis,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,48440001,Gouty arthropathy,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,67148009,Arthritis of great toe due to gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,90560007,Gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,160308005,Family history: Gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,161451004,History of gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170730005,Gout monitoring,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170731009,Initial gout assessment,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170732002,Follow-up gout assessment,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170733007,Joints gout affected,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170735000,Date gout treatment started,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170736004,Date of last gout attack,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170737008,Gout associated problem,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170738003,Gout drug side effect,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170739006,Gout treatment changed,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170740008,Date gout treatment stopped,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,171190009,Gout screening,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,190828008,Gouty arthropathy,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,190829000,Gouty nephropathy,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,190842000,Chronic tophaceous gout of hand,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,200983001,Parapsoriasis en gouttes,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201663006,Articular gout of shoulder region,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201666003,Gouty arthritis of hand,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201667007,Gouty arthritis of pelvic region and thigh,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201669005,Gouty arthritis of ankle and/or foot,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201670006,Articular gout of multiple joints,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,230312006,Aicardi Goutieres syndrome,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,239843003,Secondary gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,239844009,Gout secondary to renal impairment,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,239845005,Gout secondary to drug,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,239848007,Gouty bursitis,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,243859006,Gout monitoring status,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,268142006,Pseudogout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,281362006,Gouty tophus of bursa,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,281363001,Tophus of tendon co-occurrent and due to gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,281364007,Gouty tophus of olecranon bursa,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,281365008,Gouty tophus of prepatellar bursa,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,292671009,Drug for the treatment of gout adverse reaction,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,402469004,Gouty tophus,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,428839004,Articular gout of toe,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,770924008,Gout attack,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,427211000000108,[V]Screening for gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,924311000000106,Acute exacerbation of gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Gouty arthritis attacks,TA281,gout,1033961000000104,Gouty tophi of toe,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CANAKINUMAB,Systemic juvenile idiopathic arthritis,TA302,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +CANAKINUMAB,Systemic juvenile idiopathic arthritis,TA302,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +CANNABIDIOL,Treating seizures caused by tuberous sclerosis complex,TA873,tuberous sclerosis,36025004,Fibrous skin tumor of tuberous sclerosis,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CANNABIDIOL,Treating seizures caused by tuberous sclerosis complex,TA873,tuberous sclerosis,417001009,Family history of tuberous sclerosis,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CANNABIDIOL WITH CLOBAZAM,Seizures associated with Dravet syndrome,TA614,dravet syndrome,230437002,Dravet Syndrome,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,407618000,1 to 12 seizures a year,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,407620002,1 to 7 seizures a week,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,407622005,Many seizures a day,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,699688008,Genetic epilepsy with febrile seizures plus,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,134405005,Suspected breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,160287004,FH: Breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,268547008,Screening for breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,429740004,Family history of breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,431330007,Family history of breast cancer 1 gene mutation,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,431331006,Family history of breast cancer 2 gene mutation,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,706970001,TNBC - Triple-negative breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,94361000000105,Breast cancer detected by national screening programme,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,276341000000100,Fast track referral for suspected breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,838351000000107,Education about risk of breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,874291000000100,QCancer breast cancer risk,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,1035841000000108,Lymphoedema following breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,722731000000100,Colorectal cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,848861000000104,QCancer colorectal cancer risk,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CAPECITABINE (1ST LINE),Inoperable advanced gastric cancer,TA191,gastric cancer,276809004,Early gastric cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +CAPECITABINE (1ST LINE),Inoperable advanced gastric cancer,TA191,gastric cancer,276810009,Late gastric cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +CAPECITABINE (ADJUVANT),Colon cancer,TA100,colon cancer,275978004,Screening for colon cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CAPECITABINE (ADJUVANT),Colon cancer,TA100,colon cancer,315058005,Hereditary nonpolyposis colon cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,134405005,Suspected breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,160287004,FH: Breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,268547008,Screening for breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,429740004,Family history of breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,431330007,Family history of breast cancer 1 gene mutation,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,431331006,Family history of breast cancer 2 gene mutation,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,706970001,TNBC - Triple-negative breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,94361000000105,Breast cancer detected by national screening programme,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,276341000000100,Fast track referral for suspected breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,838351000000107,Education about risk of breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,874291000000100,QCancer breast cancer risk,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,1035841000000108,Lymphoedema following breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +CAPLACIZUMAB,Acute acquired thrombotic thrombocytopenic purpura,TA667,thrombotic thrombocytopenic purpura,78129009,TTP - thrombotic thrombocytopenic purpura,CAPLACIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +CARFILZOMIB FOR PREVIOUSLY TREATED MULTIPLE MYELOMA,Previously treated multiple myeloma,TA657,multiple myeloma,230586003,Neuropathy due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB FOR PREVIOUSLY TREATED MULTIPLE MYELOMA,Previously treated multiple myeloma,TA657,multiple myeloma,413587002,Smoldering multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB FOR PREVIOUSLY TREATED MULTIPLE MYELOMA,Previously treated multiple myeloma,TA657,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE,Previously treated multiple myeloma,TA457,multiple myeloma,230586003,Neuropathy due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE,Previously treated multiple myeloma,TA457,multiple myeloma,413587002,Smoldering multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE,Previously treated multiple myeloma,TA457,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB WITH DARATUMUMAB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA841,multiple myeloma,230586003,Neuropathy due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB WITH DARATUMUMAB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA841,multiple myeloma,413587002,Smoldering multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB WITH DARATUMUMAB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA841,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB WITH DEXAMETHASONE AND LENALIDOMIDE,Previously treated multiple myeloma,TA695,multiple myeloma,230586003,Neuropathy due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB WITH DEXAMETHASONE AND LENALIDOMIDE,Previously treated multiple myeloma,TA695,multiple myeloma,413587002,Smoldering multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARFILZOMIB WITH DEXAMETHASONE AND LENALIDOMIDE,Previously treated multiple myeloma,TA695,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,803009,Paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,3102004,"Oligodendroglioma, anaplastic",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,9903002,"Paraganglioma, malignant",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,26138003,Gliomatosis cerebri,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,31794002,Sympathetic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,32037004,Jugular paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,72787006,Gangliocytic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,73348003,Oligodendroglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,74532006,"Glioma, malignant",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,89880005,Ganglioglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,107694002,"Paraganglioma, benign",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,115222007,Paraganglioma AND/OR glomus tumor,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,115240006,Glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,253029009,Gangliocytic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,253031000,Tympanic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,254940005,Oligodendroglioma of brain,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,254947008,Glioma of spinal cord,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,254976006,Optic nerve glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,276826005,Malignant glioma of brain,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,276827001,Malignant glioma of spinal cord,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,302833002,Paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,307649006,Microglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,307829004,Excision of nasal glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,443565000,Oligodendroglioma - category,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,443936004,Oligodendroglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,22193007,Osteoarthritis of joint of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,33952002,Localised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,37895003,Osteoarthritis of first carpometacarpal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,82300000,Osteoarthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,160414002,Family history: Osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,161568003,History of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201819000,Generalised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201852006,"Localised, secondary osteoarthritis of the hand",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201889009,"Osteoarthritis NOS, of the upper arm",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201890000,Wrist osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201891001,Thumb osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201893003,Knee osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201894009,"Osteoarthritis NOS, of ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,202655008,Osteoarthritis of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239863005,Osteoarthritis of spinal facet joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239866002,Osteoarthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239868001,Osteoarthritis of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239874001,Osteoarthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239878003,Osteoarthritis of toe joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267889007,Generalized osteoarthritis of the hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,268054009,Osteoarthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313257005,"Localized, primary osteoarthritis of the wrist",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313258000,"Localised, primary osteoarthritis of toe",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313259008,"Localized, primary osteoarthritis of elbow",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,373623009,Osteoarthritis of glenohumeral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,394991004,Flare of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,443524000,Secondary osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,450521003,Osteoarthritis of patellofemoral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,700324005,Osteoarthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1162304008,Oligoarticular osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343601009,OA (osteoarthritis) of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343603007,Osteoarthritis of thoracic spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343604001,Cervical osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343605000,Osteoarthritis of lumbar spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323301000119109,Osteoarthritis of left knee joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323311000119107,Osteoarthritis of right hip joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666451000000100,"Osteoarthritis NOS, other specified site",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,850791000000102,Osteoarthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,402815007,Squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,402815007,Squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,162573006,Suspected lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,275981009,Lung cancer screening,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,429011007,Family history of lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,6204001,Juvenile myoclonic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,16873003,Musicogenic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,19598007,Generalized epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,36803009,IGE - idiopathic generalized epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,38281008,Self-limited neonatal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,50866000,CAE - childhood absence epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,65120008,Generalised convulsive epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,71831005,Secondary generalised epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,79745005,Sensory-induced epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,84757009,Epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,95208000,Photic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,160341008,Family history of epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,161480008,History of epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,162658001,Epilepsy resolved,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170702005,Epilepsy monitoring,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170703000,Initial epilepsy assessment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170704006,Follow-up epilepsy assessment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170706008,Epilepsy associated problems,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170709001,Epilepsy drug side effect,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170710006,Epilepsy treatment changed,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170711005,Epilepsy treatment started,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170712003,Epilepsy treatment stopped,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,192979009,Generalized non-convulsive epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,192990004,Myoclonic epilepsy in infancy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,192999003,Partial epilepsy with impairment of consciousness,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193000002,Temporal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193002005,Psychosensory epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193007004,Focal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193008009,Somatosensory epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193009001,Partial epilepsy with autonomic symptoms,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193011005,Unilateral epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193021002,Running epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230381009,Localization-related epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230382002,Benign frontal epilepsy of childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230384001,Benign atypical partial epilepsy in childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230386004,Benign occipital epilepsy of childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230388003,Late onset occipital epilepsy of childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230390002,Localisation-related symptomatic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230393000,Lateral temporal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230394006,Frontal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230403005,Parietal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230404004,Occipital lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230408001,Localisation-related cryptogenic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230412007,Myoclonic epilepsy of early childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230413002,JAE - juvenile absence epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230415009,Cryptogenic generalised epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230422001,Epilepsy with myoclonic absence,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230428002,Idiopathic myoclonic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230430000,Symptomatic myoclonic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230438007,Aphasia co-occurrent with epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230440002,Secondary reading epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230441003,Drug-induced epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230444006,Catamenial epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230450001,Eating epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230452009,Toothbrushing epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230454005,Bathing epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,243857008,Epilepsy monitoring status,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,267581004,Progressive myoclonic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,278510009,Localisation-related idiopathic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,307356008,Motor epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,314827004,Epilepsy control good,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,314828009,Epilepsy control poor,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,352818000,Grand mal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,361123003,Psychomotor epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,361268000,Alcohol-induced epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,401062003,Epilepsy medication review,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,401178003,Epilepsy care arrangement,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,407616001,Epilepsy severity,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,407623000,Emergency epilepsy treatment since last appointment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,407625007,Suspected epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,407627004,Epilepsy confirmed,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,413101007,Stress-induced epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,414113005,Epilepsy leaflet given,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,414860000,No epilepsy drug side effects,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,416090009,Epilepsy monitoring verbal invite,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,417568007,Epilepsy monitoring call,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,429279006,Seen in epilepsy clinic,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,719425009,Sudden unexpected death in epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,1260117009,Combined focal and generalized epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,1260407007,Genetic generalised epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,88491000000102,Epilepsy limits activities,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,93141000000105,Epilepsy restricts employment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,93151000000108,Epilepsy prevents employment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,93211000000101,Epilepsy does not limit activities,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,108211000000104,Epilepsy impairs education,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,109121000000109,Epilepsy society member,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,116401000119105,Recurrent complex partial epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,202061000000107,Epilepsy monitoring call first letter,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,202071000000100,Epilepsy monitoring call second letter,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,202081000000103,Epilepsy monitoring call third letter,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,509341000000107,Petit-mal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,711501000000104,Epilepsy screening invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,715091000000100,Epilepsy screening administration,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,715791000000102,Epilepsy screening second invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,716011000000103,Epilepsy screening first invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,716811000000106,Epilepsy screening third invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,809381000000103,Referral for epilepsy review,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,809551000000103,Referral to epilepsy clinic,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,810161000000101,Epilepsy monitoring in secondary care,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,811411000000104,Under care of epilepsy specialist nurse,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,840261000000103,Epilepsy management plan given,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,850201000000104,Epilepsy annual review,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,865371000000104,No history of epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,876461000000101,No FH of epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,892181000000107,Referral to epilepsy service,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,162573006,Suspected lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,275981009,Lung cancer screening,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,429011007,Family history of lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,162573006,Suspected lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,275981009,Lung cancer screening,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,429011007,Family history of lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,axial spondyloarthritis,723116002,Axial spondyloarthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +CERTOLIZUMAB PEGOL,Moderate to severe plaque psoriasis,TA574,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),CERTOLIZUMAB,DERMATOLOGY,DERMATOLOGY +CERTOLIZUMAB PEGOL,Moderate to severe plaque psoriasis,TA574,plaque psoriasis,402307000,Chronic large plaque psoriasis,CERTOLIZUMAB,DERMATOLOGY,DERMATOLOGY +CERTOLIZUMAB PEGOL,Moderate to severe plaque psoriasis,TA574,plaque psoriasis,402310007,Chronic stable plaque psoriasis,CERTOLIZUMAB,DERMATOLOGY,DERMATOLOGY +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,156370009,Psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,10288008,Squamous cell carcinoma - spindle cell,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,12478003,Microinvasive squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,18048008,"Squamous cell carcinoma, keratinising",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,28899001,Squamous cell epithelioma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,37304002,Mixed basal-squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,39056008,Papillary squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,59529006,Squamous cell carcinoma in situ,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,64204000,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,65692009,Polypoid squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,85956000,Pseudoglandular squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,89906000,Verrucous SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,90121000,"Inverted papilloma, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,107692003,Mixed squamous cell and glandular papilloma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,118286007,Squamous cell neoplasm,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,231825000,Squamous cell papilloma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,231830001,Squamous cell carcinoma in situ of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,231831002,Squamous cell carcinoma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,252994001,Benign squamous cell tumour,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254620000,Squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254634000,Squamous cell carcinoma of lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254652000,Clear cell squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254654004,Acantholytic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254661000,Squamous cell papilloma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254886006,Squamous cell carcinoma of cervix,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,255003007,Squamous cell carcinoma of conjunctiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,255071008,Squamous cell carcinoma of lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,255111004,Squamous cell carcinoma of urinary bladder,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276804009,Squamous cell carcinoma of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276860003,Squamous cell carcinoma of scrotum,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276878008,Squamous cell hyperplasia of vulva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276952000,Squamous cell carcinoma of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276953005,Squamous cell carcinoma of gingiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276954004,Squamous cell carcinoma of floor of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276962007,Squamous cell carcinoma of palate,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,285307007,Squamous cell carcinoma of skin of upper lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,285308002,Squamous cell carcinoma of skin of lower lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,285309005,Squamous cell carcinoma of skin of cheek,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,300987004,Disseminated squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,307502000,Squamous cell carcinoma of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,400066006,Intraepithelial squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,400155002,Squamous cell carcinoma - category,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,402815007,Squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,402816008,Squamous cell carcinoma of anogenital area,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,403901001,Acantholytic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,403904009,Verrucous squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,403906006,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,405822008,"Cancer of the larynx, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,408649007,Squamous cell carcinoma of pharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,422599000,Squamous cell carcinoma of back,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,423700001,Squamous cell carcinoma of auricle,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,700193001,Family history of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,700399008,Cervical smear - borderline change in squamous cells,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707388009,Primary squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707429002,Overlapping squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707576008,Primary squamous cell carcinoma of subglottis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707581004,Primary papillary squamous cell carcinoma of oropharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707662004,Primary basaloid squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,716659002,Squamous cell carcinoma of head and neck,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,719052006,Recurrent SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,721618006,Primary squamous cell carcinoma of upper third of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722530005,Primary squamous cell carcinoma of adenoid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722542000,Primary squamous cell carcinoma of anal canal,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722672002,Primary squamous cell carcinoma of root of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722673007,Primary squamous cell carcinoma of lingual tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722674001,Primary squamous cell carcinoma of parotid gland,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,723182009,Primary squamous cell carcinoma of nasal cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,723265000,Primary squamous cell carcinoma of anus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,733343005,Primary squamous cell carcinoma of oral cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,1254755004,Metastatic basosquamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,1255632004,Spindle cell squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,78461000119105,Metastatic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,91271000119101,Metastatic squamous cell carcinoma of bone,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,105041000119109,Metastatic squamous cell carcinoma to lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,470781000000106,[M]Papillary &/or squamous cell neoplasms,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,688851000119108,Primary squamous cell carcinoma of glans penis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,878441000000101,No FH of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,1014611000000103,Squamous cell carcinoma antigen level,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,1082071000119102,Primary squamous cell carcinoma of left ear,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,12240991000119102,Squamous cell carcinoma of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,10288008,Squamous cell carcinoma - spindle cell,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,12478003,Microinvasive squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,18048008,"Squamous cell carcinoma, keratinising",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,28899001,Squamous cell epithelioma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,37304002,Mixed basal-squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,39056008,Papillary squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,59529006,Squamous cell carcinoma in situ,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,64204000,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,65692009,Polypoid squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,85956000,Pseudoglandular squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,89906000,Verrucous SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,90121000,"Inverted papilloma, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,107692003,Mixed squamous cell and glandular papilloma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,118286007,Squamous cell neoplasm,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,231825000,Squamous cell papilloma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,231830001,Squamous cell carcinoma in situ of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,231831002,Squamous cell carcinoma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,252994001,Benign squamous cell tumour,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254620000,Squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254634000,Squamous cell carcinoma of lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254652000,Clear cell squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254654004,Acantholytic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254661000,Squamous cell papilloma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254886006,Squamous cell carcinoma of cervix,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,255003007,Squamous cell carcinoma of conjunctiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,255071008,Squamous cell carcinoma of lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,255111004,Squamous cell carcinoma of urinary bladder,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276804009,Squamous cell carcinoma of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276860003,Squamous cell carcinoma of scrotum,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276878008,Squamous cell hyperplasia of vulva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276952000,Squamous cell carcinoma of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276953005,Squamous cell carcinoma of gingiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276954004,Squamous cell carcinoma of floor of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276962007,Squamous cell carcinoma of palate,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,285307007,Squamous cell carcinoma of skin of upper lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,285308002,Squamous cell carcinoma of skin of lower lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,285309005,Squamous cell carcinoma of skin of cheek,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,300987004,Disseminated squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,307502000,Squamous cell carcinoma of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,400066006,Intraepithelial squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,400155002,Squamous cell carcinoma - category,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,402815007,Squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,402816008,Squamous cell carcinoma of anogenital area,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,403901001,Acantholytic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,403904009,Verrucous squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,403906006,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,405822008,"Cancer of the larynx, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,408649007,Squamous cell carcinoma of pharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,422599000,Squamous cell carcinoma of back,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,423700001,Squamous cell carcinoma of auricle,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,700193001,Family history of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,700399008,Cervical smear - borderline change in squamous cells,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707388009,Primary squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707429002,Overlapping squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707576008,Primary squamous cell carcinoma of subglottis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707581004,Primary papillary squamous cell carcinoma of oropharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707662004,Primary basaloid squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,716659002,Squamous cell carcinoma of head and neck,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,719052006,Recurrent SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,721618006,Primary squamous cell carcinoma of upper third of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722530005,Primary squamous cell carcinoma of adenoid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722542000,Primary squamous cell carcinoma of anal canal,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722672002,Primary squamous cell carcinoma of root of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722673007,Primary squamous cell carcinoma of lingual tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722674001,Primary squamous cell carcinoma of parotid gland,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,723182009,Primary squamous cell carcinoma of nasal cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,723265000,Primary squamous cell carcinoma of anus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,733343005,Primary squamous cell carcinoma of oral cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,1254755004,Metastatic basosquamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,1255632004,Spindle cell squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,78461000119105,Metastatic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,91271000119101,Metastatic squamous cell carcinoma of bone,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,105041000119109,Metastatic squamous cell carcinoma to lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,470781000000106,[M]Papillary &/or squamous cell neoplasms,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,688851000119108,Primary squamous cell carcinoma of glans penis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,878441000000101,No FH of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,1014611000000103,Squamous cell carcinoma antigen level,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,1082071000119102,Primary squamous cell carcinoma of left ear,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB,Recurrent and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,12240991000119102,Squamous cell carcinoma of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,722731000000100,Colorectal cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,848861000000104,QCancer colorectal cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,10288008,Squamous cell carcinoma - spindle cell,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,12478003,Microinvasive squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,18048008,"Squamous cell carcinoma, keratinising",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,28899001,Squamous cell epithelioma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,37304002,Mixed basal-squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,39056008,Papillary squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,59529006,Squamous cell carcinoma in situ,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,64204000,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,65692009,Polypoid squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,85956000,Pseudoglandular squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,89906000,Verrucous SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,90121000,"Inverted papilloma, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,107692003,Mixed squamous cell and glandular papilloma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,118286007,Squamous cell neoplasm,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,231825000,Squamous cell papilloma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,231830001,Squamous cell carcinoma in situ of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,231831002,Squamous cell carcinoma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,252994001,Benign squamous cell tumour,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254620000,Squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254634000,Squamous cell carcinoma of lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254652000,Clear cell squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254654004,Acantholytic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254661000,Squamous cell papilloma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254886006,Squamous cell carcinoma of cervix,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,255003007,Squamous cell carcinoma of conjunctiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,255071008,Squamous cell carcinoma of lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,255111004,Squamous cell carcinoma of urinary bladder,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276804009,Squamous cell carcinoma of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276860003,Squamous cell carcinoma of scrotum,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276878008,Squamous cell hyperplasia of vulva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276952000,Squamous cell carcinoma of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276953005,Squamous cell carcinoma of gingiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276954004,Squamous cell carcinoma of floor of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276962007,Squamous cell carcinoma of palate,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,285307007,Squamous cell carcinoma of skin of upper lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,285308002,Squamous cell carcinoma of skin of lower lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,285309005,Squamous cell carcinoma of skin of cheek,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,300987004,Disseminated squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,307502000,Squamous cell carcinoma of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,400066006,Intraepithelial squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,400155002,Squamous cell carcinoma - category,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,402815007,Squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,402816008,Squamous cell carcinoma of anogenital area,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,403901001,Acantholytic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,403904009,Verrucous squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,403906006,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,405822008,"Cancer of the larynx, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,408649007,Squamous cell carcinoma of pharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,422599000,Squamous cell carcinoma of back,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,423700001,Squamous cell carcinoma of auricle,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,700193001,Family history of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,700399008,Cervical smear - borderline change in squamous cells,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707388009,Primary squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707429002,Overlapping squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707576008,Primary squamous cell carcinoma of subglottis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707581004,Primary papillary squamous cell carcinoma of oropharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707662004,Primary basaloid squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,716659002,Squamous cell carcinoma of head and neck,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,719052006,Recurrent SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,721618006,Primary squamous cell carcinoma of upper third of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722530005,Primary squamous cell carcinoma of adenoid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722542000,Primary squamous cell carcinoma of anal canal,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722672002,Primary squamous cell carcinoma of root of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722673007,Primary squamous cell carcinoma of lingual tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722674001,Primary squamous cell carcinoma of parotid gland,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,723182009,Primary squamous cell carcinoma of nasal cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,723265000,Primary squamous cell carcinoma of anus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,733343005,Primary squamous cell carcinoma of oral cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,1254755004,Metastatic basosquamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,1255632004,Spindle cell squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,78461000119105,Metastatic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,91271000119101,Metastatic squamous cell carcinoma of bone,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,105041000119109,Metastatic squamous cell carcinoma to lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,470781000000106,[M]Papillary &/or squamous cell neoplasms,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,688851000119108,Primary squamous cell carcinoma of glans penis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,878441000000101,No FH of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,1014611000000103,Squamous cell carcinoma antigen level,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,1082071000119102,Primary squamous cell carcinoma of left ear,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,12240991000119102,Squamous cell carcinoma of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +CHLORMETHINE GEL,Mycosis fungoides-type cutaneous T-cell lymphoma,TA720,cutaneous t-cell lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,CHLORMETHINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|DERMATOLOGY +CICLOSPORIN,Treating dry eye disease that has not improved despite treatment with artificial tears,TA369,dry eye,162290004,Dry eyes,CICLOSPORIN,OPHTHALMOLOGY,OPHTHALMOLOGY +CICLOSPORIN,Treating dry eye disease that has not improved despite treatment with artificial tears,TA369,dry eye,164742009,Dry eye test,CICLOSPORIN,OPHTHALMOLOGY,OPHTHALMOLOGY +CICLOSPORIN,Treating dry eye disease that has not improved despite treatment with artificial tears,TA369,dry eye,340951000119104,Left dry eye syndrome,CICLOSPORIN,OPHTHALMOLOGY,OPHTHALMOLOGY +CILOSTAZOL,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822611000000100,Exception reporting - peripheral arterial disease quality indicators,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CILOSTAZOL,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822641000000104,Excepted from peripheral arterial disease quality indicators - patient unsuitable,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CILOSTAZOL,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822671000000105,Excepted from peripheral arterial disease quality indicators - informed dissent,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CILOSTAZOL,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,968121000000103,Peripheral arterial disease screening,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,36348003,Primary hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY +CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,66999008,Hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY +CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,78200003,Tertiary hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY +CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,91478007,Secondary hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY +CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,203471008,Brown tumour of hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY +CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,237653008,Familial hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,24700007,Multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,160337009,Family history of multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,192926004,Brain stem multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,192928003,Generalised multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,428700003,Primary progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,438511000,Benign multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,700409000,Suspected multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,198491000000106,Multiple sclerosis review,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,515931000000104,Multiple sclerosis review declined,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,24700007,Multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,160337009,Family history of multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,192926004,Brain stem multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,192928003,Generalised multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,428700003,Primary progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,438511000,Benign multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,700409000,Suspected multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,198491000000106,Multiple sclerosis review,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,515931000000104,Multiple sclerosis review declined,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION +CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CLOPIDOGREL,Acute coronary syndromes,TA080,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,CLOPIDOGREL,CARDIOLOGY,CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,62914000,Cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,72092001,Arteriosclerotic vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,123799005,Hypertension due to renovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,127014009,Diabetic peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,134379001,Peripheral vascular disease monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,160270001,No family history of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,161499004,H/O: cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,171405001,Examination for suspected cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,195239002,Late effects of cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,198057005,Male genital organ vascular diseases,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,230738008,Asymptomatic cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,233845001,Coronary microvascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,266320008,Peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,266894000,Family history of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,266995000,History of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,275509000,Infective vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,302909007,Diffuse cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,308064009,History of cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,308071004,History of peripheral vascular disease procedure,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,395048001,Cardiovascular disease monitoring not required,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,400047006,PVD - peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,413988000,Did not attend peripheral vascular disease clinic,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,417206009,Cardiovascular disease monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,417287002,Cardiovascular disease interim monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,417322008,Cardiovascular disease annual review,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,429284000,Cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,429785003,Cardiovascular disease health education,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,438370008,Vascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,440401008,Vascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,441829007,Assessment for risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,443929000,Small vessel cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,473109007,History of peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,205001000000100,Suspected cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,302881000000102,Cardiovascular disease annual review declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375421000000101,Vascular disease risk assessment invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375511000000106,Vascular disease risk assessment first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375541000000107,Vascular disease risk assessment second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375571000000101,Vascular disease risk assessment third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,492581000000108,Cardiovascular disease high risk review declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,492611000000102,Cardiovascular disease high risk review,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,646351000000103,Peripheral vascular disease NOS,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,810681000000101,Coronary microvascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,837461000000101,High risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,845171000000108,At risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,858191000000103,FH: peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,865391000000100,No peripheral vascular disease symptoms,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,990301000000105,Cardiovascular disease risk assessment done,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA090,vascular disease,16434071000119108,At increased risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +CLOPIDOGREL,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,915007,Malignant melanoma in junctional naevus,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,1556006,Clark melanoma level 4,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,2092003,Malignant melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,2142002,Nodular melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,16974005,"Acral lentiginous melanoma, malignant",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,21119008,Benign melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,21165006,Clark melanoma level 3,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,37138001,Epithelioid cell melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,39896009,"Malignant melanoma, regressing",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,44474009,Lentigo maligna melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,50542000,Clark melanoma level 2,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,50813003,Spitz melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,51757004,"Desmoplastic melanoma, amelanotic",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,55320002,Superficial spreading melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,68827007,Spindle cell melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,70594002,Amelanotic melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,77986002,Melanoma in situ,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93209006,Malignant melanoma of perianal skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93214005,Malignant melanoma of skin of back,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93217003,Malignant melanoma of skin of cheek,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93220006,Malignant melanoma of skin of ear,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93221005,Malignant melanoma of skin of elbow,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93223008,Malignant melanoma of eyebrow,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93225001,Malignant melanoma of skin of face,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93227009,Malignant melanoma of skin of foot,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93228004,Malignant melanoma of skin of forearm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93642000,Malignant melanoma of skin of neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93643005,Malignant melanoma of external surface of nose,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93646002,Malignant melanoma of skin of scalp,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93647006,Malignant melanoma of skin of shoulder,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93651008,Malignant melanoma of skin of trunk,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93653006,Malignant melanoma of skin of upper limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93654000,Malignant melanoma of skin of wrist,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93655004,MM (malignant melanoma) of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,106243009,Breslow depth staging for melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109266006,Melanoma in situ of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109270003,Melanoma in situ of face,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109272006,Melanoma in situ of lip,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109276009,Melanoma in situ of scalp,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109278005,Melanoma in situ of ear,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109282007,Melanoma in situ of neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109284008,Melanoma in situ of trunk,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109290007,Melanoma in situ of upper limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109294003,Melanoma in situ of lower limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,127330008,Melanoma in situ by body site (clinical),COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,161432005,History of malignant melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,177281002,Excision of melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188030005,Malignant melanoma of lip,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188033007,Malignant melanoma of auricle (ear),COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188034001,Malignant melanoma of external auditory meatus,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188038003,Malignant melanoma of chin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188040008,Malignant melanoma of forehead,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188042000,Malignant melanoma of temple,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188044004,Malignant melanoma of scalp and/or neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188045003,Malignant melanoma of scalp,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188046002,Malignant melanoma of neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188049009,Malignant melanoma of axilla,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188050009,Malignant melanoma of breast,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188051008,Malignant melanoma of buttock,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188052001,Malignant melanoma of groin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188054000,Malignant melanoma of perineum,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188055004,Malignant melanoma of umbilicus,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188060000,Malignant melanoma of shoulder,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188061001,Malignant melanoma of upper arm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188062008,Malignant melanoma of forearm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188063003,Malignant melanoma of hand,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188064009,Malignant melanoma of finger,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188065005,Malignant melanoma of thumb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188067002,Malignant melanoma of lower limb and hip,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188068007,Malignant melanoma of hip,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188069004,Malignant melanoma of thigh,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188070003,Malignant melanoma of knee,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188071004,Malignant melanoma of popliteal fossa area,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188072006,Malignant melanoma of lower leg,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188073001,Malignant melanoma of ankle,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188074007,Malignant melanoma of heel,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188075008,Malignant melanoma of foot,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188076009,Malignant melanoma of toe,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188077000,Malignant melanoma of great toe,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,189758001,Melanoma in situ,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,231834005,Malignant melanoma of eyelid,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254731001,Nodular melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254732008,Acral lentiginous melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254896002,Malignant melanoma of vulva,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,255004001,Malignant melanoma of conjunctiva,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,255012009,Malignant melanoma of iris,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,255015006,Malignant melanoma of ciliary body,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,255021005,Malignant melanoma of choroid,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,269578002,Malignant melanoma of head and neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,269579005,Malignant melanoma of trunk,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,269580008,Malignant melanoma of upper limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,269581007,Malignant melanoma of lower limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,274087000,MM (malignant melanoma) of eye,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,276751004,Amelanotic melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,276821000,Malignant melanoma of anus,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,276822007,Malignant melanoma of rectum,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,302837001,Lentigo maligna melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,310498001,Malignant melanoma of back,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,312941005,Melanoma associated retinopathy,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,313248004,Malignant melanoma of chest wall,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,314976006,Local recurrence of malignant melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,314987003,Metastasis from malignant melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,315036008,Melanoma in situ of back of hand,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,315230006,Melanoma in situ of back,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,372158004,"Malignant melanoma, metastatic",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,427858005,Family history of malignant melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,443493003,Metastatic malignant melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,449636007,Malignant melanoma of skin of lower leg,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,449637003,Malignant melanoma of skin of upper arm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,698040004,Malignant melanoma of nasal cavity,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,1197324006,Metastatic malignant melanoma to skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,351961000119109,Malignant melanoma of skin of right arm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,352211000119108,Malignant melanoma of skin of left ear,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,546881000000105,Malignant melanoma of skin NOS,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956331000000107,Malignant melanoma stage IA,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956351000000100,Malignant melanoma stage IB,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956371000000109,Malignant melanoma stage IIA,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956391000000108,Malignant melanoma stage IIB,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956451000000107,Malignant melanoma stage IIIB,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956471000000103,Malignant melanoma stage IIIC,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956511000000107,Malignant melanoma stage IV M1a,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956551000000106,Malignant melanoma stage IV M1c,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,1080941000119109,Malignant melanoma of left choroid,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,1080981000119104,Malignant melanoma of right choroid,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,86555001,Cystic fibrosis of the lung,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,160309002,Family history of cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,171191008,Cystic fibrosis screening,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,235978006,Cystic fibrosis of pancreas,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,427022004,Liver disease due to cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428273001,Cystic fibrosis not suspected,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428301001,Suspected cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428841003,Cystic fibrosis screening declined,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,441520002,Carrier of cystic fibrosis gene mutation,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,698529000,Seen in cystic fibrosis clinic,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,302651000000109,Cystic fibrosis carrier comment,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,302771000000109,Cystic fibrosis not screened for or screening incomplete,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,384341000000107,Cystic fibrosis repeat screening with further sample required,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,384401000000104,Cystic fibrosis not suspected and other disorders follow up required,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,515611000000104,Cystic fibrosis monitoring,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,515631000000107,Cystic fibrosis annual review,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,526071000000104,Arthropathy in cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,526091000000100,Cystic fibrosis with distal intestinal obstruction syndrome,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,776981000000103,Cirrhosis associated with cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,859041000000103,Exacerbation of cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947031000000109,"Cystic fibrosis screening declined, no history of being screened",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947041000000100,"Cystic fibrosis screening declined, screened in UK (as reported by parents) with no evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947061000000104,"Cystic fibrosis screening declined, screened outside UK with evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947081000000108,"Cystic fibrosis screening declined, screened outside UK with no evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947101000000102,"Cystic fibrosis screening, too young for reliable screening",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947121000000106,"Cystic fibrosis screening,sample taken too soon after blood transfusion (less than 72 hours)",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947141000000104,"Cystic fibrosis screening, insufficient sample",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947161000000103,"Cystic fibrosis screening, unsuitable sample (blood quality): incorrect blood application",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947181000000107,"Cystic fibrosis screening, unsuitable sample (blood quality): compressed/damaged",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947201000000106,"Cystic fibrosis screening, unsuitable sample: day 0 and day 5 on same card",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947221000000102,"Cystic fibrosis screening, unsuitable sample: possible faecal contamination",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947241000000109,"Cystic fibrosis screening, unsuitable sample: NHS number missing/not accurately recorded",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947281000000101,"Cystic fibrosis screening, unsuitable sample: date of sample missing/not accurately recorded",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947301000000100,"Cystic fibrosis screening, unsuitable sample: date of birth not accurately matched",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947321000000109,"Cystic fibrosis screening, unsuitable sample: expired card used",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947341000000102,"Cystic fibrosis screening, unsuitable sample: more than 14 days in transit, too old for analysis",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947361000000101,"Cystic fibrosis screening, unsuitable sample: damaged in transit",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947381000000105,"Cystic fibrosis screening, inconclusive result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947401000000105,"Cystic fibrosis not screened for or screening incomplete: more than 8 weeks, too old for screening",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947491000000103,"Cystic fibrosis not screened for or screening incomplete, moved out of area",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947511000000106,"Cystic fibrosis not screened for or screening incomplete, not contactable, reasonable efforts made",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947551000000105,"Cystic fibrosis not screened for or screening incomplete, not required, previous valid result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,1015871000000108,Cystic fibrosis screening test,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,1028351000000108,Cystic fibrosis screening,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238543002,Discoid atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238545009,Follicular atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238546005,Pruriginous atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,584621000000108,Atopic dermatitis NOS,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,193370005,Proliferative retinopathy due to sickle cell disease,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,416180004,Sickle cell disease without crisis,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,442186003,Screening for sickle cell disease,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,473131004,Suspected sickle cell disease,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,473132006,Sickle cell disease not suspected,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,991891000000102,Sickle cell disease screening test,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,1027811000000102,Sickle cell disease screening,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,162573006,Suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,275981009,Lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,429011007,Family history of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,835009,Angioimmunoblastic lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1929004,"Malignant lymphoma, diffuse",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,19340000,Plasmacytic lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,20776008,Adenolymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,21964009,Lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,21983002,Struma lymphomatosa,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,28054005,Cutaneous lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,28175004,Gastric pseudolymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,30440004,Lymphoma stage I,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,31047003,Lymphomatoid papulosis,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,55150002,"Malignant lymphoma, nodular",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,56944001,Lymphoma stage III,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,66445009,Lymphoma stage IV,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,74654000,Mantle cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,76422004,Lymphoma stage II,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93198004,Malignant lymphoma of spleen,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,95193005,Nodular lymphoma of spleen,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,106252000,Staging classification for lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109962001,Nonfollicular lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109969005,Diffuse large B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109975001,T-zone lymphoma (clinical),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109976000,Lymphoepithelioid lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109978004,T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109979007,B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109988003,True histiocytic lymphoma (clinical),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,115244002,Malignant lymphoma - category,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118599009,"Lymphoma, Hodgkins",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118600007,Malignant lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118601006,Non-Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118617000,Burkitt lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128803008,Marginal zone lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128929007,Non-Hodgkin lymphoma - category,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128930002,Hodgkin lymphoma - category,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,162573006,Suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,189958005,"Lymphomatous tumour, benign",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,189962004,"Malignant lymphoma, stem cell type",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,232075002,Lymphoma of retina,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,236513009,Lymphoma of kidney,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,239297008,Lymphomatoid granulomatosis of lung,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,239940004,Lymphomatoid granulomatosis,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,254372002,Ann Arbor lymphoma staging system,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,255102004,Intravascular lymphomatosis,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,258279002,Lymphoma staging symptom status values,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,269476000,Nodular lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,274905008,Mantle zone lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,275981009,Lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,276811008,Gastric lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,276815004,Lymphoma of intestine,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,276836002,Primary cerebral lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277570003,Lymphoma with spill,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277615007,Low grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277616008,Diffuse low grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277617004,High grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277618009,Nodular malignant lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277623009,Monocytoid B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277626001,Diffuse high grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277627005,Nodular high grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277637000,Large cell anaplastic lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277641001,Follicular malignant lymphoma - large cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277642008,Low grade T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277643003,High grade T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277654008,Enteropathy-type T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277664004,Malignant lymphoma of testis,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,278051002,Malignant lymphoma of thyroid gland,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,278052009,Malignant lymphoma of breast,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,302841002,Malignant lymphoma - small cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,308121000,Follicular lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314922006,B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314923001,Low grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314925008,High grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314926009,T-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,315264005,Suspected lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,400001003,Primary cutaneous lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,404140004,SALT type B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,420788006,Vitreoretinal lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,426071002,Hodgkin lymphoma in remission,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,427141003,Malignant lymphoma in remission,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,428046009,History of non-Hodgkins lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,429011007,Family history of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,433450000,Family history of non-Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,443487006,Mantle cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,445406001,Hepatosplenic T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,447100004,Marginal zone lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,448211002,Adenolymphoma of parotid gland,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,449074003,Lymphoma of small intestine,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,449220000,Diffuse follicle center lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,721555001,Follicular lymphoma of small intestine,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,724648008,Plasmablastic lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,762690000,Classical Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1148851002,Follicular lymphoma grade IIIa,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847481000000109,Follicular lymphoma grade 1,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847631000000107,Follicular lymphoma grade 2,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847651000000100,Follicular lymphoma grade 3,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847691000000108,Follicular lymphoma grade 3a,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847701000000108,Follicular lymphoma grade 3b,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847741000000106,Diffuse large B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,162573006,Suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,275981009,Lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,429011007,Family history of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,162573006,Suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,275981009,Lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,429011007,Family history of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,2517002,Stroke rehabilitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,25133001,Completed stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,28690004,Stroke test,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,39925003,"MELAS - mitochondrial encephalopathy, lactic acidosis and stroke-like episodes",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,44922000,Bounding pulse with rapid upstroke and descent,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,49436004,Atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,90096001,Stroke volume,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,134377004,Atrial fibrillation monitoring,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,135875009,Stroke prevention,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,135877001,Stroke risk,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,160252004,No family history of cardiovascular accident or stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,160271002,No family history of stroke and/or transient ischaemic attack,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,170600009,Stroke monitoring,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,195080001,Atrial fibrillation and flutter,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,195163003,Stroke due to intracerebral haemorrhage,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,195212005,Brainstem stroke syndrome,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,195213000,Cerebellar stroke syndrome,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,212937007,Heat stroke and sunstroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230690007,Stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230694003,Total anterior cerebral circulation stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230695002,Partial anterior cerebral circulation stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230696001,Posterior cerebral circulation stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230700009,Pure sensory stroke due to and following lacunar infarction,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230713003,Stroke of uncertain pathology,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230714009,Anterior circulation stroke of uncertain pathology,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230715005,Posterior circulation stroke of uncertain pathology,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230739000,Spinal cord stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,275434003,Stroke in the puerperium,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,276898003,Left ventricular stroke work index,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,277286006,Chronic central post-stroke pain,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,277381004,Stroke index,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,282825002,Intermittent atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,297250002,No family history of stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,299403002,Stroke test positive,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,299404008,Stroke test negative,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,300996004,Controlled atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,306802002,Referral to stroke service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,306803007,Admission to stroke unit,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,306808003,Discharge from stroke service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,306810001,Seen by stroke service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,308067002,History of stroke in last year,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,309966001,Stroke unit,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,310137004,Stroke service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,312442005,History of atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,371040005,Thrombotic stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,371041009,Embolic stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,412773009,Referral to stroke clinic,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,413119003,Stroke group member,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,413124000,Stroke/transient ischaemic attack referral,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,415628004,Stroke/transient ischaemic attack monitoring first letter,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,415629007,Stroke/transient ischemic attack monitoring second letter,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,415630002,Stroke/transient ischaemic attack monitoring status,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,415631003,Stroke/transient ischemic attack monitoring third letter,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,417059002,Stroke/transient ischemic attack monitoring verbal invitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,417506008,Hemorrhagic stroke monitoring,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,417540008,Stroke/transient ischaemic attack monitoring invitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,422504002,Ischaemic stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,440028005,Permanent atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,440059007,Persistent atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,450743008,NIHSS (National Institutes of Health stroke scale) score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,704154001,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR (international normalised ratio), elderly over 65, and drugs and/or alcohol concomitantly) score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,704180000,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,707514001,Stroke impact scale version 3.0 score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,719008003,At increased risk of atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,722929005,Perinatal arterial ischemic stroke of fetus and/or neonate,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,724424009,Cerebral ischemic stroke due to small artery occlusion,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,736712009,PASS (Postural Assessment Scale for Stroke Patients) score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,788884002,Cerebral ischemic stroke due to subarachnoid hemorrhage,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,88601000000107,DNA (did not attend) stroke clinic,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,112901000000108,Referral to multidisciplinary stroke function improvement service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,140921000119102,Ischemic stroke without coma,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,143471000000105,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation using preferred method of communication,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,196371000000102,Atrial fibrillation resolved,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,201501000000108,Seen in stroke clinic,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,231231000000107,Delivery of rehabilitation for stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,248411000000105,Atrial fibrillation annual review,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,519751000000106,Stroke 6 month review,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,521411000000106,Did not attend stroke review,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,685631000000102,Stroke and cerebrovascular accident unspecified,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,713771000000100,Stroke/transient ischaemic attack monitoring administration,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,716021000000109,Excepted from stroke quality indicators - informed dissent,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,716331000000108,Exception reporting - stroke quality indicators,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,716581000000101,Excepted from stroke quality indicators - patient unsuitable,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,717241000000108,Stroke/transient ischaemic attack monitoring telephone invitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,769211000000103,Suspected stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,810991000000109,Stroke self-management plan review,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,812041000000104,Stroke self-management plan agreed,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,816401000000105,Atrial fibrillation excluded,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,816561000000108,Stroke initial post discharge review,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,842441000000104,Provision of written information about stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,870631000000105,QStroke 10 year risk of stroke calculator,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1062151000000103,Stroke TOM (Therapy Outcome Measure) activity score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1062171000000107,Stroke TOM (Therapy Outcome Measure) impairment score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1062181000000109,Stroke TOM (Therapy Outcome Measure) participation score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1062191000000106,Stroke TOM (Therapy Outcome Measure) wellbeing score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1066831000000104,Atrial fibrillation detected,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1078001000000105,Haemorrhagic stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1085311000000106,QStroke risk calculator score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1110981000000104,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,16371781000119100,Cerebellar stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,443749004,Venous thromboembolism risk assessment,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,699035003,At low risk of venous thromboembolism,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,711293008,At moderate risk of venous thromboembolism,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,711328005,At high risk of venous thromboembolism,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,787331000000107,Venous thromboembolism prevention management,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,844041000000102,Education about risk of venous thromboembolism,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,14534009,Deep vein thrombosis of splenic vein,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,49956009,Antenatal DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,56272000,Puerperal DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,59282003,Pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,128053003,Deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,134399007,Deep vein thrombosis of leg related to air travel,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,161508001,History of DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,200232006,Antenatal deep vein thrombosis - delivered,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,200233001,Antenatal deep vein thrombosis with antenatal complication,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,200238005,Postnatal deep vein thrombosis with postnatal complication,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,200284000,Obstetric pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,200286003,Obstetric air pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,213220000,Postoperative deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,225999004,At increased risk of DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,233217004,Operation for pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,233936003,Acute massive pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,233937007,Subacute massive pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,234044007,Ileofemoral deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,401186003,Deep vein thrombosis screening,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,413459009,Advised risk of deep vein thrombosis in air travel,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,413956008,Deep vein thrombosis of leg related to intravenous drug use,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,429053008,Wells deep vein thrombosis clinical probability score,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,430801003,Family history of pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,432805000,Suspected deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,438773007,Recurrent pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,443210003,Deep vein thrombosis of peroneal vein,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,710167004,Recurrent DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,198301000000109,FH: deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,323631000000102,DVT (deep vein thrombosis) prevention,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,492161000000109,Deep vein thrombosis enhanced services administration,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,503421000000105,Deep vein thrombosis enhanced services administration stage 1 service level,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,503451000000100,Deep vein thrombosis enhanced services administration stage 2 service level,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,503481000000106,Deep vein thrombosis enhanced services administration stage 3 service level,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,513251000000101,Low probability of deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,513271000000105,Moderate probability of deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,513291000000109,High probability of deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,869611000000104,On deep vein thrombosis care pathway,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,872221000000109,No history of deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,978421000000101,Unprovoked deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,978441000000108,Provoked deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,162573006,Suspected lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,254637007,Non-small cell lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,275981009,Lung cancer screening,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,429011007,Family history of lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,877691000000107,No FH of lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,915007,Malignant melanoma in junctional naevus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,1556006,Clark melanoma level 4,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,2092003,Malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,2142002,Nodular melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,16974005,"Acral lentiginous melanoma, malignant",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,21119008,Benign melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,21165006,Clark melanoma level 3,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,37138001,Epithelioid cell melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,39896009,"Malignant melanoma, regressing",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,44474009,Lentigo maligna melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,50542000,Clark melanoma level 2,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,50813003,Spitz melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,51757004,"Desmoplastic melanoma, amelanotic",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,55320002,Superficial spreading melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,68827007,Spindle cell melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,70594002,Amelanotic melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,77986002,Melanoma in situ,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93209006,Malignant melanoma of perianal skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93214005,Malignant melanoma of skin of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93217003,Malignant melanoma of skin of cheek,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93220006,Malignant melanoma of skin of ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93221005,Malignant melanoma of skin of elbow,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93223008,Malignant melanoma of eyebrow,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93225001,Malignant melanoma of skin of face,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93227009,Malignant melanoma of skin of foot,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93228004,Malignant melanoma of skin of forearm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93642000,Malignant melanoma of skin of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93643005,Malignant melanoma of external surface of nose,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93646002,Malignant melanoma of skin of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93647006,Malignant melanoma of skin of shoulder,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93651008,Malignant melanoma of skin of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93653006,Malignant melanoma of skin of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93654000,Malignant melanoma of skin of wrist,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93655004,MM (malignant melanoma) of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,106243009,Breslow depth staging for melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109266006,Melanoma in situ of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109270003,Melanoma in situ of face,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109272006,Melanoma in situ of lip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109276009,Melanoma in situ of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109278005,Melanoma in situ of ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109282007,Melanoma in situ of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109284008,Melanoma in situ of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109290007,Melanoma in situ of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109294003,Melanoma in situ of lower limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,127330008,Melanoma in situ by body site (clinical),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,161432005,History of malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,177281002,Excision of melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188030005,Malignant melanoma of lip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188033007,Malignant melanoma of auricle (ear),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188034001,Malignant melanoma of external auditory meatus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188038003,Malignant melanoma of chin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188040008,Malignant melanoma of forehead,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188042000,Malignant melanoma of temple,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188044004,Malignant melanoma of scalp and/or neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188045003,Malignant melanoma of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188046002,Malignant melanoma of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188049009,Malignant melanoma of axilla,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188050009,Malignant melanoma of breast,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188051008,Malignant melanoma of buttock,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188052001,Malignant melanoma of groin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188054000,Malignant melanoma of perineum,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188055004,Malignant melanoma of umbilicus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188060000,Malignant melanoma of shoulder,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188061001,Malignant melanoma of upper arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188062008,Malignant melanoma of forearm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188063003,Malignant melanoma of hand,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188064009,Malignant melanoma of finger,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188065005,Malignant melanoma of thumb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188067002,Malignant melanoma of lower limb and hip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188068007,Malignant melanoma of hip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188069004,Malignant melanoma of thigh,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188070003,Malignant melanoma of knee,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188071004,Malignant melanoma of popliteal fossa area,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188072006,Malignant melanoma of lower leg,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188073001,Malignant melanoma of ankle,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188074007,Malignant melanoma of heel,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188075008,Malignant melanoma of foot,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188076009,Malignant melanoma of toe,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188077000,Malignant melanoma of great toe,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,189758001,Melanoma in situ,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,231834005,Malignant melanoma of eyelid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254731001,Nodular melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254732008,Acral lentiginous melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254896002,Malignant melanoma of vulva,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,255004001,Malignant melanoma of conjunctiva,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,255012009,Malignant melanoma of iris,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,255015006,Malignant melanoma of ciliary body,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,255021005,Malignant melanoma of choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,269578002,Malignant melanoma of head and neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,269579005,Malignant melanoma of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,269580008,Malignant melanoma of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,269581007,Malignant melanoma of lower limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,274087000,MM (malignant melanoma) of eye,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,276751004,Amelanotic melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,276821000,Malignant melanoma of anus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,276822007,Malignant melanoma of rectum,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,302837001,Lentigo maligna melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,310498001,Malignant melanoma of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,312941005,Melanoma associated retinopathy,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,313248004,Malignant melanoma of chest wall,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,314976006,Local recurrence of malignant melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,314987003,Metastasis from malignant melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,315036008,Melanoma in situ of back of hand,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,315230006,Melanoma in situ of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,372158004,"Malignant melanoma, metastatic",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,427858005,Family history of malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,443493003,Metastatic malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,449636007,Malignant melanoma of skin of lower leg,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,449637003,Malignant melanoma of skin of upper arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,698040004,Malignant melanoma of nasal cavity,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,1197324006,Metastatic malignant melanoma to skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,351961000119109,Malignant melanoma of skin of right arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,352211000119108,Malignant melanoma of skin of left ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,546881000000105,Malignant melanoma of skin NOS,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956331000000107,Malignant melanoma stage IA,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956351000000100,Malignant melanoma stage IB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956371000000109,Malignant melanoma stage IIA,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956391000000108,Malignant melanoma stage IIB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956451000000107,Malignant melanoma stage IIIB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956471000000103,Malignant melanoma stage IIIC,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956511000000107,Malignant melanoma stage IV M1a,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956551000000106,Malignant melanoma stage IV M1c,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,1080941000119109,Malignant melanoma of left choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,1080981000119104,Malignant melanoma of right choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,915007,Malignant melanoma in junctional naevus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,1556006,Clark melanoma level 4,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,2092003,Malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,2142002,Nodular melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,16974005,"Acral lentiginous melanoma, malignant",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,21119008,Benign melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,21165006,Clark melanoma level 3,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,37138001,Epithelioid cell melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,39896009,"Malignant melanoma, regressing",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,44474009,Lentigo maligna melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,50542000,Clark melanoma level 2,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,50813003,Spitz melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,51757004,"Desmoplastic melanoma, amelanotic",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,55320002,Superficial spreading melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,68827007,Spindle cell melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,70594002,Amelanotic melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,77986002,Melanoma in situ,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93209006,Malignant melanoma of perianal skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93214005,Malignant melanoma of skin of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93217003,Malignant melanoma of skin of cheek,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93220006,Malignant melanoma of skin of ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93221005,Malignant melanoma of skin of elbow,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93223008,Malignant melanoma of eyebrow,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93225001,Malignant melanoma of skin of face,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93227009,Malignant melanoma of skin of foot,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93228004,Malignant melanoma of skin of forearm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93642000,Malignant melanoma of skin of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93643005,Malignant melanoma of external surface of nose,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93646002,Malignant melanoma of skin of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93647006,Malignant melanoma of skin of shoulder,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93651008,Malignant melanoma of skin of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93653006,Malignant melanoma of skin of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93654000,Malignant melanoma of skin of wrist,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93655004,MM (malignant melanoma) of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,106243009,Breslow depth staging for melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109266006,Melanoma in situ of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109270003,Melanoma in situ of face,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109272006,Melanoma in situ of lip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109276009,Melanoma in situ of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109278005,Melanoma in situ of ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109282007,Melanoma in situ of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109284008,Melanoma in situ of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109290007,Melanoma in situ of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109294003,Melanoma in situ of lower limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,127330008,Melanoma in situ by body site (clinical),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,161432005,History of malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,177281002,Excision of melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188030005,Malignant melanoma of lip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188033007,Malignant melanoma of auricle (ear),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188034001,Malignant melanoma of external auditory meatus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188038003,Malignant melanoma of chin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188040008,Malignant melanoma of forehead,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188042000,Malignant melanoma of temple,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188044004,Malignant melanoma of scalp and/or neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188045003,Malignant melanoma of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188046002,Malignant melanoma of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188049009,Malignant melanoma of axilla,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188050009,Malignant melanoma of breast,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188051008,Malignant melanoma of buttock,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188052001,Malignant melanoma of groin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188054000,Malignant melanoma of perineum,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188055004,Malignant melanoma of umbilicus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188060000,Malignant melanoma of shoulder,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188061001,Malignant melanoma of upper arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188062008,Malignant melanoma of forearm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188063003,Malignant melanoma of hand,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188064009,Malignant melanoma of finger,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188065005,Malignant melanoma of thumb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188067002,Malignant melanoma of lower limb and hip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188068007,Malignant melanoma of hip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188069004,Malignant melanoma of thigh,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188070003,Malignant melanoma of knee,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188071004,Malignant melanoma of popliteal fossa area,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188072006,Malignant melanoma of lower leg,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188073001,Malignant melanoma of ankle,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188074007,Malignant melanoma of heel,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188075008,Malignant melanoma of foot,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188076009,Malignant melanoma of toe,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188077000,Malignant melanoma of great toe,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,189758001,Melanoma in situ,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,231834005,Malignant melanoma of eyelid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254731001,Nodular melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254732008,Acral lentiginous melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254896002,Malignant melanoma of vulva,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,255004001,Malignant melanoma of conjunctiva,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,255012009,Malignant melanoma of iris,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,255015006,Malignant melanoma of ciliary body,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,255021005,Malignant melanoma of choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,269578002,Malignant melanoma of head and neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,269579005,Malignant melanoma of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,269580008,Malignant melanoma of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,269581007,Malignant melanoma of lower limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,274087000,MM (malignant melanoma) of eye,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,276751004,Amelanotic melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,276821000,Malignant melanoma of anus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,276822007,Malignant melanoma of rectum,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,302837001,Lentigo maligna melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,310498001,Malignant melanoma of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,312941005,Melanoma associated retinopathy,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,313248004,Malignant melanoma of chest wall,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,314976006,Local recurrence of malignant melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,314987003,Metastasis from malignant melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,315036008,Melanoma in situ of back of hand,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,315230006,Melanoma in situ of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,372158004,"Malignant melanoma, metastatic",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,427858005,Family history of malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,443493003,Metastatic malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,449636007,Malignant melanoma of skin of lower leg,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,449637003,Malignant melanoma of skin of upper arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,698040004,Malignant melanoma of nasal cavity,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,1197324006,Metastatic malignant melanoma to skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,351961000119109,Malignant melanoma of skin of right arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,352211000119108,Malignant melanoma of skin of left ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,546881000000105,Malignant melanoma of skin NOS,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956331000000107,Malignant melanoma stage IA,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956351000000100,Malignant melanoma stage IB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956371000000109,Malignant melanoma stage IIA,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956391000000108,Malignant melanoma stage IIB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956451000000107,Malignant melanoma stage IIIB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956471000000103,Malignant melanoma stage IIIC,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956511000000107,Malignant melanoma stage IV M1a,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956551000000106,Malignant melanoma stage IV M1c,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,1080941000119109,Malignant melanoma of left choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,1080981000119104,Malignant melanoma of right choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,24700007,Multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,160337009,Family history of multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,192926004,Brain stem multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,192928003,Generalised multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,428700003,Primary progressive multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,438511000,Benign multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,700409000,Suspected multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,198491000000106,Multiple sclerosis review,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,515931000000104,Multiple sclerosis review declined,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +DACLIZUMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +DACLIZUMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +DACLIZUMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,162573006,Suspected lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,254637007,Non-small cell lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,275981009,Lung cancer screening,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,429011007,Family history of lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,877691000000107,No FH of lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,10335000,Chronic right-sided heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,10633002,Acute congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,48447003,Chronic heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,56675007,Acute heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,83291003,Right heart failure due to pulmonary hypertension,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,85232009,Left-sided heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,88805009,Chronic congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,111283005,Chronic left-sided heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,128404006,Right heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,134378009,Congestive heart failure monitoring,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,134440006,Referral to heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,161505003,History of heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,233924009,Heart failure as a complication of care,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,266308000,Right heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,309634009,History of heart failure in last year,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,314206003,Refractory heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,367363000,Right heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,390868005,Heart failure screen,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,390884006,Heart failure follow-up,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,390885007,Heart failure annual review,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,394887005,Suspected heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,394927007,Heart failure excluded,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,395105005,Heart failure confirmed,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,416683003,Emergency hospital admission for heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,416717003,Seen in heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,417146007,Referral to heart failure nurse,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,417359009,Seen by community heart failure nurse,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,423475008,Heart failure education,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,424404003,Decompensated chronic heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,426611007,Congestive heart failure due to valvular disease,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,429959009,Family history of heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,441530006,Chronic diastolic heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,473226007,Heart failure medication review,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,704095000,Referral to heart failure exercise programme,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,704096004,Referral to heart failure exercise programme not indicated,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,704097008,Referral to heart failure exercise program declined,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,735984001,Heart failure self management plan,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,1296659009,Acute on chronic heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,96311000119109,Exacerbation of congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,200171000000102,Referred by heart failure nurse specialist,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,202231000000106,Heart failure review completed,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,203791000000106,Referred to heart failure education group,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,247361000000100,Heart failure 6 month review,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,248571000000104,Did not attend heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,374231000000104,High risk of heart failure screening invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,521691000000100,Heart failure resolved,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,711461000000104,Heart failure monitoring invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,713791000000101,Heart failure monitoring administration,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,715951000000107,Exception reporting - heart failure quality indicators,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,716621000000101,Heart failure monitoring third letter,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,716971000000109,Heart failure monitoring first letter,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717191000000108,Heart failure monitoring second letter,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717501000000108,Heart failure monitoring verbal invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717531000000102,Heart failure monitoring telephone invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,763641000000102,Referral to heart failure education group declined,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,765661000000102,Discharge from heart failure nurse service,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,781051000000108,Has heart failure management plan,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,810971000000105,Heart failure self-management plan review,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,812001000000102,Heart failure self-management plan agreed,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,813991000000101,Education about deteriorating heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,835981000000108,Rehabilitation for heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,851071000000108,Heart failure initial assessment,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,851521000000102,Heart failure clinical pathway,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,871681000000102,Heart failure monitoring,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,872361000000105,Discussion about heart failure care plan,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,873881000000100,Referral to rapid access heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,915571000000102,On optimal heart failure therapy,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,961881000000101,Provision of information about heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,171234009,Chronic kidney disease screening,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,431855005,Chronic kidney disease stage 1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,431856006,Chronic kidney disease stage 2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,431857002,Chronic kidney disease stage 4,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,433144002,Chronic kidney disease stage 3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,433146000,Chronic kidney disease stage 5,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,472953006,H/O chronic kidney disease,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,698463001,At increased risk of chronic kidney disease,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,700378005,Chronic kidney disease stage 3A,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,700379002,Chronic kidney disease stage 3B,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,709044004,Chronic kidney disease,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,714152005,Chronic kidney disease 5d,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,248721000000108,Chronic kidney disease monitoring,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,249171000000102,Chronic kidney disease annual review,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,249311000000109,Predicted stage chronic kidney disease,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,298141000000107,Did not attend chronic kidney disease monitoring clinic,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324121000000109,CKD (chronic kidney disease stage) 1 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324151000000104,CKD (chronic kidney disease) stage 1 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324181000000105,CKD (chronic kidney disease) stage 2 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324211000000106,CKD (chronic kidney disease) stage 2 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324251000000105,CKD (chronic kidney disease) stage 3 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324281000000104,CKD (chronic kidney disease) stage 3 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324311000000101,CKD (chronic kidney disease) stage 3A with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324341000000100,CKD (chronic kidney disease) stage 3A without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324371000000106,CKD (chronic kidney disease) stage 3B with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324411000000105,CKD (chronic kidney disease) stage 3B without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324441000000106,CKD (chronic kidney disease) stage 4 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324471000000100,CKD (chronic kidney disease) stage 4 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324501000000107,CKD (chronic kidney disease) stage 5 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324541000000105,CKD (chronic kidney disease) stage 5 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,711421000000107,Chronic kidney disease monitoring invitation,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,713811000000100,Chronic kidney disease monitoring administration,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,716651000000106,Chronic kidney disease monitoring first letter,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,716881000000104,Excepted from chronic kidney disease quality indicators - informed dissent,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,716891000000102,Excepted from chronic kidney disease quality indicators - patient unsuitable,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717231000000104,Chronic kidney disease monitoring verbal invite,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717361000000100,Exception reporting - chronic kidney disease quality indicators,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717461000000108,Chronic kidney disease monitoring third letter,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717511000000105,Chronic kidney disease monitoring telephone invite,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717751000000104,Chronic kidney disease monitoring second letter,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,811021000000104,Chronic kidney disease self-management plan review,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,811941000000105,Chronic kidney disease self-management plan agreed,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,857971000000104,Estimated glomerular filtration rate using Chronic Kidney Disease Epidemiology Collaboration formula,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,903261000000109,Chronic kidney disease laboratory study,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,939211000000104,Chronic kidney disease resolved,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949401000000103,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949421000000107,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949481000000108,CKD G1A3 - chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949521000000108,CKD G2A1 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949561000000100,Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949621000000109,CKD G2A3 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949881000000106,CKD G3aA1 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949901000000109,CKD G3aA2 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949921000000100,Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950061000000103,Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950081000000107,CKD G3bA2 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950101000000101,CKD G3bA3 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950181000000106,CKD G4A1 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950211000000107,CKD G4A2 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950231000000104,CKD G4A3 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950251000000106,CKD G5A1 - chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950291000000103,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950311000000102,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,1011481000000105,Estimated glomerular filtration rate using creatinine Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,1011491000000107,Estimated glomerular filtration rate using cystatin C Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +DARATUMUMAB,Multiple myeloma,TA573,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB,Multiple myeloma,TA573,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB,Multiple myeloma,TA573,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB,Relapsed or refractory multiple myeloma,TA454,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB,Relapsed or refractory multiple myeloma,TA454,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB,Relapsed or refractory multiple myeloma,TA454,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB IN COMBINATION,Multiple myeloma when a stem cell transplant is suitable,TA763,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB IN COMBINATION,Multiple myeloma when a stem cell transplant is suitable,TA763,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB IN COMBINATION,Multiple myeloma when a stem cell transplant is suitable,TA763,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB MONOTHERAPY,Relapsed and refractory multiple myeloma,TA510,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB MONOTHERAPY,Relapsed and refractory multiple myeloma,TA510,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB MONOTHERAPY,Relapsed and refractory multiple myeloma,TA510,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB MONOTHERAPY FOR TREATING RELAPSED AND REFRACTORY MULTIPLE MYELOMA,Relapsed and refractory multiple myeloma,TA783,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB MONOTHERAPY FOR TREATING RELAPSED AND REFRACTORY MULTIPLE MYELOMA,Relapsed and refractory multiple myeloma,TA783,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB MONOTHERAPY FOR TREATING RELAPSED AND REFRACTORY MULTIPLE MYELOMA,Relapsed and refractory multiple myeloma,TA783,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"DARATUMUMAB WITH BORTEZOMIB, MELPHALAN AND PREDNISONE",Untreated multiple myeloma,TA771,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"DARATUMUMAB WITH BORTEZOMIB, MELPHALAN AND PREDNISONE",Untreated multiple myeloma,TA771,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"DARATUMUMAB WITH BORTEZOMIB, MELPHALAN AND PREDNISONE",Untreated multiple myeloma,TA771,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE,Untreated multiple myeloma,TA634,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE,Untreated multiple myeloma,TA634,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE,Untreated multiple myeloma,TA634,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA726,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA726,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DARATUMUMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA726,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,315268008,Suspected prostate cancer,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,428262008,H/O: prostate cancer,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,698470001,Advice given about prostate cancer screening,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,712837004,Active surveillance of prostate cancer,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,720007002,Prostate cancer care review,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,31011000119107,Prostate cancer screening declined,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,874211000000109,QCancer prostate cancer risk,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,878401000000104,No FH of prostate cancer,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DASATINIB,Philadelphia-chromosome-positive acute lymphoblastic leukaemia,TA714,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +DASATINIB,Philadelphia-chromosome-positive acute lymphoblastic leukaemia,TA714,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +DASATINIB,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia,TA251,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,STANDARD-DOSE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +DASATINIB,Untreated chronic myeloid leukaemia,TA426,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +DASITINIB,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,TA425,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +DECITABINE,Acute myeloid leukaemia,TA270,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",DECITABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DECITABINE,Untreated acute myeloid leukaemia,TA548,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",DECITABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,315268008,Suspected prostate cancer,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,428262008,H/O: prostate cancer,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,698470001,Advice given about prostate cancer screening,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,712837004,Active surveillance of prostate cancer,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,720007002,Prostate cancer care review,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,31011000119107,Prostate cancer screening declined,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,874211000000109,QCancer prostate cancer risk,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,878401000000104,No FH of prostate cancer,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,14651005,Drug-induced osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,18040001,Age-related osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,64859006,Osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,102447009,Postmenopausal osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,160313009,Family history of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203429007,Idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203433000,Postoophorectomy osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203435007,Localized osteoporosis - Lequesne,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203437004,Osteoporosis in endocrine disorders,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203438009,Osteoporosis of spine,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240157009,Secondary generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240158004,Regional migrating osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240159007,Transient osteoporosis of hip,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240162005,Secondary localized osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,268028001,Localised disuse osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,276661002,Primary osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,281387004,Regional osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,300004007,Screening for osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,309745002,Osteoporosis localized to spine,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,310251007,No family history: Osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,313423004,At increased risk of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,390833005,Osteoporosis caused by corticosteroid,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391003008,Osteoporosis monitoring administration,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391004002,Attends osteoporosis monitoring,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391006000,Osteoporosis monitoring default,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391007009,Osteoporosis monitoring first letter,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391008004,Osteoporosis monitoring second letter,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391012005,Osteoporosis monitoring deleted,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391013000,Osteoporosis monitoring check done,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391014006,Osteoporosis risk assessment done,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391015007,Osteoporosis risk assessment declined,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391016008,Osteoporosis risk assessment defaulted,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391017004,Osteoporosis monitoring,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391018009,Initial osteoporosis assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391019001,Follow-up osteoporosis assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391020007,Osteoporosis treatment started,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391021006,Osteoporosis treatment stopped,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391022004,Osteoporosis treatment changed,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391023009,Osteoporosis - no treatment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391024003,Osteoporosis - dietary advice,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391025002,Osteoporosis - dietary assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391026001,Osteoporosis - exercise advice,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391027005,Osteoporosis - falls prevention,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391028000,Osteoporosis - treatment response,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391033001,Refer to osteoporosis specialist,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391037000,Seen in osteoporosis clinic,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,394936006,Health education - osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,412717001,Referral to osteoporosis clinic,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,473120007,History of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,763322002,Osteoporosis monitoring refused,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,278781000000105,Osteoporosis treatment not indicated,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,505141000000108,Osteoporosis enhanced services administration,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,711341000000106,Osteoporosis resolved,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,965871000000101,Osteoporosis medication compliance review,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,14651005,Drug-induced osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,18040001,Age-related osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,64859006,Osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,102447009,Postmenopausal osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,160313009,Family history of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203429007,Idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203433000,Postoophorectomy osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203435007,Localized osteoporosis - Lequesne,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203437004,Osteoporosis in endocrine disorders,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203438009,Osteoporosis of spine,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240157009,Secondary generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240158004,Regional migrating osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240159007,Transient osteoporosis of hip,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240162005,Secondary localized osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,268028001,Localised disuse osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,276661002,Primary osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,281387004,Regional osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,300004007,Screening for osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,309745002,Osteoporosis localized to spine,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,310251007,No family history: Osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,313423004,At increased risk of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,390833005,Osteoporosis caused by corticosteroid,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391003008,Osteoporosis monitoring administration,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391004002,Attends osteoporosis monitoring,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391006000,Osteoporosis monitoring default,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391007009,Osteoporosis monitoring first letter,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391008004,Osteoporosis monitoring second letter,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391012005,Osteoporosis monitoring deleted,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391013000,Osteoporosis monitoring check done,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391014006,Osteoporosis risk assessment done,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391015007,Osteoporosis risk assessment declined,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391016008,Osteoporosis risk assessment defaulted,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391017004,Osteoporosis monitoring,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391018009,Initial osteoporosis assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391019001,Follow-up osteoporosis assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391020007,Osteoporosis treatment started,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391021006,Osteoporosis treatment stopped,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391022004,Osteoporosis treatment changed,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391023009,Osteoporosis - no treatment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391024003,Osteoporosis - dietary advice,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391025002,Osteoporosis - dietary assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391026001,Osteoporosis - exercise advice,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391027005,Osteoporosis - falls prevention,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391028000,Osteoporosis - treatment response,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391033001,Refer to osteoporosis specialist,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391037000,Seen in osteoporosis clinic,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,394936006,Health education - osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,412717001,Referral to osteoporosis clinic,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,473120007,History of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,763322002,Osteoporosis monitoring refused,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,278781000000105,Osteoporosis treatment not indicated,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,505141000000108,Osteoporosis enhanced services administration,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,711341000000106,Osteoporosis resolved,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,965871000000101,Osteoporosis medication compliance review,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +DENOSUMAB,Preventing skeletal-related events in multiple myeloma,TA549,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DENOSUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DENOSUMAB,Preventing skeletal-related events in multiple myeloma,TA549,multiple myeloma,413587002,Smoldering multiple myeloma,DENOSUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DENOSUMAB,Preventing skeletal-related events in multiple myeloma,TA549,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DENOSUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,134405005,Suspected breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,160287004,FH: Breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,268547008,Screening for breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,429740004,Family history of breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,706970001,TNBC - Triple-negative breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,94361000000105,Breast cancer detected by national screening programme,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,838351000000107,Education about risk of breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,874291000000100,QCancer breast cancer risk,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,1035841000000108,Lymphoedema following breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,315268008,Suspected prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,428262008,H/O: prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,698470001,Advice given about prostate cancer screening,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,712837004,Active surveillance of prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,720007002,Prostate cancer care review,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,31011000119107,Prostate cancer screening declined,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,874211000000109,QCancer prostate cancer risk,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,878401000000104,No FH of prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,315268008,Suspected prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,428262008,H/O: prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,698470001,Advice given about prostate cancer screening,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,712837004,Active surveillance of prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,720007002,Prostate cancer care review,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,31011000119107,Prostate cancer screening declined,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,874211000000109,QCancer prostate cancer risk,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,878401000000104,No FH of prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema caused following central retinal vein occlusion,TA229,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema caused following central retinal vein occlusion,TA229,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema caused following central retinal vein occlusion,TA229,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema following branch retinal vein occlusion,TA229,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema following branch retinal vein occlusion,TA229,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema following branch retinal vein occlusion,TA229,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,4927003,Acute anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,11226001,Fuchs uveitis syndrome,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,43363007,Posterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,75614007,Panuveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,89114005,Infectious anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,95707009,Phacotoxic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,267619000,Non-infectious anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,312922007,Uveitis related cystoid macular oedema,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,314029000,Tuberculous uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,314030005,Post-traumatic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,314033007,Secondary open-angle glaucoma with uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,314493000,Postoperative uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,370506009,Keratouveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,398155003,Chronic anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,410494003,Phacoantigenic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,410692006,Anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,342151000119100,Acute anterior uveitis of left eye,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,7461003,"Attention deficit hyperactivity disorder, hyperactive impulsive type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,31177006,"Attention deficit hyperactivity disorder, combined type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702536007,Stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702538008,Drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,703314001,Non-stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516401000000106,Attention deficit hyperactivity disorder monitoring invitation first letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516891000000101,Attention deficit hyperactivity disorder monitoring invitation second letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516911000000103,Attention deficit hyperactivity disorder monitoring invitation third letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,710071000000106,Attention deficit hyperactivity disorder annual review,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886371000000105,On drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886391000000109,On stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886411000000109,On non-stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1863681000000108,Attention deficit hyperactivity disorder suspected,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1914891000000100,Diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2427101000000103,Signposting to attention deficit hyperactivity disorder resource,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2437121000000109,Referral for diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,24700007,Multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,160337009,Family history of multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,192926004,Brain stem multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,192928003,Generalised multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,428700003,Primary progressive multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,438511000,Benign multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,700409000,Suspected multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,198491000000106,Multiple sclerosis review,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,515931000000104,Multiple sclerosis review declined,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,24700007,Multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,160337009,Family history of multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,192926004,Brain stem multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,192928003,Generalised multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,428700003,Primary progressive multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,438511000,Benign multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,700409000,Suspected multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,198491000000106,Multiple sclerosis review,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,515931000000104,Multiple sclerosis review declined,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Advanced breast cancer,TA006,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,315268008,Suspected prostate cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,428262008,H/O: prostate cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,698470001,Advice given about prostate cancer screening,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,712837004,Active surveillance of prostate cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,720007002,Prostate cancer care review,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,31011000119107,Prostate cancer screening declined,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,874211000000109,QCancer prostate cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,878401000000104,No FH of prostate cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,254637007,Non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DOCETAXEL (2ND LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +DONEPEZIL,Alzheimer's disease,TA019,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease,TA111,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease,TA019,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease,TA111,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease,TA019,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease,TA111,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease,TA019,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease,TA111,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DONEPEZIL,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +DOSTARLIMAB,Previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,TA779,endometrial cancer,315267003,Suspected endometrial cancer,DOSTARLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +DOSTARLIMAB,Previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,TA779,endometrial cancer,874231000000101,QCancer endometrial cancer risk,DOSTARLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,49436004,Atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,134377004,Atrial fibrillation monitoring,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,195080001,Atrial fibrillation and flutter,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,282825002,Intermittent atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,300996004,Controlled atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,312442005,History of atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,440028005,Permanent atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,440059007,Persistent atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,719008003,At increased risk of atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,196371000000102,Atrial fibrillation resolved,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,248411000000105,Atrial fibrillation annual review,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,816401000000105,Atrial fibrillation excluded,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1066831000000104,Atrial fibrillation detected,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY +DROTRECOGIN,Sepsis (severe),TA084,sepsis,1089000,Intrauterine fetal sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,25042006,Tracheostomy sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,67465009,Spontaneous abortion with sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,76571007,Sepsis-associated hypotension,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,91302008,Sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,206376005,Sepsis of the newborn,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,206378006,Sepsis of newborn caused by Staphylococcus aureus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,206379003,Sepsis of newborn caused by Escherichia coli,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,206380000,Sepsis of newborn caused by anaerobes,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,233812001,Sepsis-associated lung injury,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,235657005,Sepsis-related gastritis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,238151006,Sepsis-associated organ dysfunction,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,275827007,Maintaining asepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,276229008,Sepsis-associated gastrointestinal haemorrhage,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,276669000,Bacterial sepsis of newborn,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,276678006,Umbilical sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,308887002,Postprocedural intra-abdominal sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,310669007,Sepsis due to enterococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,443980004,Neutropenic sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,447841007,Sepsis caused by Candida,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,447843005,Severe sepsis with acute organ dysfunction caused by anaerobic bacteria,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,447894003,Severe sepsis with acute organ dysfunction caused by Staphylococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,447899008,Sepsis caused by Escherichia coli,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,448417001,Sepsis caused by Staphylococcus aureus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,448418006,Severe sepsis with acute organ dysfunction caused by Streptococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,448419003,Severe sepsis with acute organ dysfunction caused by Group B streptococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,448421008,Severe sepsis with acute organ dysfunction caused by Pneumococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,448784003,Sepsis due to herpes simplex,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,448813005,Severe sepsis with acute organ dysfunction caused by Pseudomonas,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,449082003,Severe sepsis with acute organ dysfunction caused by Gram-negative bacteria,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,449083008,Severe sepsis with acute organ dysfunction caused by Salmonella,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,449335002,Listerial sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,449504009,Severe sepsis with acute organ dysfunction caused by Group A streptococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,449505005,Severe sepsis with acute organ dysfunction caused by coagulase negative Staphylococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,609485004,Induced termination of pregnancy complicated by sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,698819004,Postoperative sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,721104000,Sepsis due to urinary tract infection,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,870441004,Screening for sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,870588003,Sepsis due to disease caused by severe acute respiratory syndrome coronavirus 2,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,750511000000101,Biliary sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,859701000000104,Suspected sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,944061000000108,Neonatal sepsis due to Streptococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,944071000000101,Neonatal sepsis due to Staphylococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DROTRECOGIN,Sepsis (severe),TA084,sepsis,957431000000102,Red flag sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,12428000,Intrinsic asthma without status asthmaticus,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,31387002,Exercise-induced asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,34015007,Flour asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,56018004,Asthmatic breathing,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,56968009,Asthma caused by wood dust,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,57607007,Industrial asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,63088003,Allergic asthma without status asthmaticus,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,71892000,Cardiac asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,93432008,Drug-induced asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,160377001,Family history of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,161105008,Asthma society member,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,161527007,History of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,162660004,Asthma resolved,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170631002,Asthma disturbing sleep,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170632009,Asthma causing night waking,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170633004,Asthma disturbs sleep weekly,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170634005,Asthma disturbs sleep frequently,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170635006,Asthma not disturbing sleep,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170636007,Asthma never disturbs sleep,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170637003,Asthma limiting activities,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170638008,Asthma not limiting activities,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170642006,Asthma severity,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170647000,Asthma prophylactic medication used,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170655007,Asthma restricts exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170656008,Asthma sometimes restricts exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170657004,Asthma severely restricts exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170658009,Asthma never restricts exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,171231001,Asthma screening,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182724005,Further asthma - drug prevention,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182726007,Asthma control step 0,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182727003,Asthma control step 1,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182728008,Asthma control step 2,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182729000,Asthma control step 3,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182730005,Asthma control step 4,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182731009,Asthma control step 5,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,183099005,Asthma leaflet given,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,183478001,Emergency hospital admission for asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185242005,Seen in asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185728001,Attends asthma monitoring,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185730004,Asthma monitor offer default,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185731000,Asthma monitoring call first letter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185732007,Asthma monitoring call second letter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185734008,Asthma monitoring call third letter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185735009,Asthma monitoring call verbal invite,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185736005,Asthma monitoring call telephone invite,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185737001,Asthma monitoring deleted,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185940009,Patient in asthma study,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195949008,Chronic asthmatic bronchitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195967001,Asthmatic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195973000,Late-onset asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195977004,Mixed asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195983001,Exercise induced asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,219036002,Adverse reaction to antiasthmatic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,225057002,Brittle asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,233678006,Childhood asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,233679003,Late-onset asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,233683003,Hay fever with asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,233691007,Eosinophilic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,266361008,Non-allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,266396008,Extrinsic asthma - atopy (& pollen),DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,266397004,Intrinsic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,266398009,Asthma attack,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,270442000,Asthma monitoring check done,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,275908000,Asthma monitoring,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,281239006,Asthma attack,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,302220000,Asthma control steps,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,304527002,Acute asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,308500005,Asthma monitoring call,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,308501009,Asthma monitoring status,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,312453004,Asthma - currently active,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,312454005,Asthma - currently dormant,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,366874008,Number of asthma exacerbations in past year,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370204008,Asthma causes daytime symptoms most days,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370206005,Asthma limits walking on the flat,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370207001,Asthma limits walking up hills or stairs,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370208006,Asthma never causes daytime symptoms,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370218001,Mild asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370219009,Moderate asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370220003,Occasional asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370221004,Severe asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370225008,Asthma treatment compliance unsatisfactory,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370226009,Asthma treatment compliance satisfactory,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,373899003,Asthma daytime symptoms,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,389145006,Allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390798007,Asthma finding,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390872009,Change in asthma management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390877003,Step up change in asthma management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390878008,Step down change in asthma management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390921001,Absent from work or school due to asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390940007,Asthma monitoring due,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,394700004,Asthma annual review,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,394701000,Asthma follow-up,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,394720003,Asthma medication review,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,394967008,Suspected asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,395022009,Nocturnal asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,400987003,Asthma trigger,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401135008,Health education - asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401182001,Asthma monitoring by nurse,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401183006,Asthma monitoring by doctor,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401193004,Asthma confirmed,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,405944004,Asthmatic bronchitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,406162001,Asthma care,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,407674008,Aspirin-induced asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,409663006,Cough variant asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,415265005,Referral to asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,424643009,Allergic atopic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,425969006,Acute intermittent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,426656000,Severe persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,426979002,Mild persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,427295004,Moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,427603009,Intermittent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,427679007,Mild intermittent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,443117005,Asthma control test score,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,445427006,Seasonal asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,445531003,ACQ - Asthma control questionnaire,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,473391009,Asthma never causes night symptoms,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,698509001,Under care of asthma specialist nurse,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,699191007,Did not attend asthma review,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,702823004,Asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,704008007,No family history of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707445000,Acute mild persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707446004,Acute exacerbation of moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707447008,Exacerbation of severe persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707511009,Uncomplicated mild persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707512002,Uncomplicated moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707513007,Uncomplicated severe persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707979007,Acute severe exacerbation of severe persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707981009,Acute severe exacerbation of mild persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708038006,Acute exacerbation of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708090002,Acute severe exacerbation of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708093000,Acute exacerbation of allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708094006,Acute exacerbation of intrinsic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708095007,Acute severe exacerbation of extrinsic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708358003,Emergency asthma admission since last encounter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708373002,Emergency asthma patient visit since last encounter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,711442001,Recent asthma management,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,715191006,Telehealth asthma monitoring,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,734346005,Use of asthma symptom diary,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,734904007,Life threatening acute exacerbation of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,734905008,Moderate acute exacerbation of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,736056000,Asthma clinical management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,762521001,Acute allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,763077003,Asthma Control Questionnaire score,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,763221007,Asthma monitoring declined,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,782520007,Exacerbation of allergic asthma due to infection,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,782559003,Asthma never causes night symptoms,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401000119107,Asthma with irreversible airway obstruction,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,641000119106,Intermittent asthma well controlled,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1741000119102,Intermittent asthma uncontrolled,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,72301000119103,Asthma in pregnancy,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,89581000000109,DNA (did not attend) asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,143901000000108,Registration for access to online asthma self-management application,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,143931000000102,Declined to register for access to online asthma self-management application,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,176711000000100,Does not have asthma management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,198971000000102,Asthma outreach clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201031000000108,Asthma trigger - respiratory infection,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201041000000104,Asthma trigger - seasonal,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201051000000101,Asthma trigger - animal,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201191000000108,Asthma trigger - cold air,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201201000000105,Asthma trigger - damp,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201211000000107,Asthma trigger - emotion,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340891000000106,Asthma trigger - airborne dust,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340901000000107,Asthma trigger - exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340911000000109,Asthma trigger - pollen,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340921000000103,Asthma trigger - tobacco smoke,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340931000000101,Asthma trigger - warm air,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,527171000000103,Patient has a written asthma personal action plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,527191000000104,Health education - asthma self management,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,527211000000100,Health education - structured asthma discussion,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,527231000000108,Health education - structured patient focused asthma discussion,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,713701000000108,Asthma monitoring administration,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,713711000000105,Asthma clinic administration,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,715801000000103,Exception reporting - asthma quality indicators,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,771941000000102,Asthma causes symptoms most nights,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,772051000000106,Asthma limits activities most days,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,791401000000104,Seen in school asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,810901000000102,Asthma self-management plan review,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,811921000000103,Asthma self-management plan agreed,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,815631000000106,Asthma trigger - wind,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,818161000000104,Asthma trigger - perfume,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,867171000000106,No asthma trigger identified by subject,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,892301000000100,Asthma management plan declined,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,905301000000103,Childhood Asthma Control Test score,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,928451000000107,Asthma monitoring invitation short message service text message,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,928511000000107,Asthma monitoring invitation email,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,928651000000105,Review of patient at risk of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,928691000000102,At risk of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,959901000000107,Asthma action plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,966011000000109,At risk of severe asthma exacerbation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,966031000000101,Severe asthma exacerbation risk assessment,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10674991000119104,Intermittent allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10675431000119106,Severe persistent allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10675871000119106,Mild persistent allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10676031000119106,Mild persistent allergic asthma controlled,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238543002,Discoid atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238545009,Follicular atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238546005,Pruriginous atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,584621000000108,Atopic dermatitis NOS,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,162573006,Suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,254637007,Non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,275981009,Lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,429011007,Family history of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,877691000000107,No FH of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,162573006,Suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,254637007,Non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,275981009,Lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,429011007,Family history of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,877691000000107,No FH of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,162573006,Suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,254637007,Non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,275981009,Lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,429011007,Family history of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,723301009,Squamous non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1259727001,Primary non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,276491000000101,Fast track referral for suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,848881000000108,QCancer lung cancer risk,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,877691000000107,No FH of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1771781000000107,Did not attend lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,109962001,Nonfollicular lymphoma,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,308121000,Follicular lymphoma,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,721555001,Follicular lymphoma of small intestine,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +DUVELISIB,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,TA811,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +DUVELISIB,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,TA811,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +DUVELISIB,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,TA811,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +DUVELISIB,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,TA811,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,2517002,Stroke rehabilitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,25133001,Completed stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,28690004,Stroke test,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,39925003,"MELAS - mitochondrial encephalopathy, lactic acidosis and stroke-like episodes",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,44922000,Bounding pulse with rapid upstroke and descent,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,49436004,Atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,90096001,Stroke volume,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,134377004,Atrial fibrillation monitoring,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,135875009,Stroke prevention,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,135877001,Stroke risk,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,160252004,No family history of cardiovascular accident or stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,160271002,No family history of stroke and/or transient ischaemic attack,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,170600009,Stroke monitoring,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,195080001,Atrial fibrillation and flutter,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,195163003,Stroke due to intracerebral haemorrhage,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,195212005,Brainstem stroke syndrome,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,195213000,Cerebellar stroke syndrome,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,212937007,Heat stroke and sunstroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230690007,Stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230694003,Total anterior cerebral circulation stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230695002,Partial anterior cerebral circulation stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230696001,Posterior cerebral circulation stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230700009,Pure sensory stroke due to and following lacunar infarction,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230713003,Stroke of uncertain pathology,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230714009,Anterior circulation stroke of uncertain pathology,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230715005,Posterior circulation stroke of uncertain pathology,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230739000,Spinal cord stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,275434003,Stroke in the puerperium,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,276898003,Left ventricular stroke work index,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,277286006,Chronic central post-stroke pain,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,277381004,Stroke index,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,282825002,Intermittent atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,297250002,No family history of stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,299403002,Stroke test positive,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,299404008,Stroke test negative,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,300996004,Controlled atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,306802002,Referral to stroke service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,306803007,Admission to stroke unit,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,306808003,Discharge from stroke service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,306810001,Seen by stroke service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,308067002,History of stroke in last year,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,309966001,Stroke unit,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,310137004,Stroke service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,312442005,History of atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,371040005,Thrombotic stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,371041009,Embolic stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,412773009,Referral to stroke clinic,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,413119003,Stroke group member,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,413124000,Stroke/transient ischaemic attack referral,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,415628004,Stroke/transient ischaemic attack monitoring first letter,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,415629007,Stroke/transient ischemic attack monitoring second letter,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,415630002,Stroke/transient ischaemic attack monitoring status,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,415631003,Stroke/transient ischemic attack monitoring third letter,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,417059002,Stroke/transient ischemic attack monitoring verbal invitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,417506008,Hemorrhagic stroke monitoring,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,417540008,Stroke/transient ischaemic attack monitoring invitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,422504002,Ischaemic stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,440028005,Permanent atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,440059007,Persistent atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,450743008,NIHSS (National Institutes of Health stroke scale) score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,704154001,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR (international normalised ratio), elderly over 65, and drugs and/or alcohol concomitantly) score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,704180000,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,707514001,Stroke impact scale version 3.0 score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,719008003,At increased risk of atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,722929005,Perinatal arterial ischemic stroke of fetus and/or neonate,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,724424009,Cerebral ischemic stroke due to small artery occlusion,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,736712009,PASS (Postural Assessment Scale for Stroke Patients) score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,788884002,Cerebral ischemic stroke due to subarachnoid hemorrhage,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,88601000000107,DNA (did not attend) stroke clinic,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,112901000000108,Referral to multidisciplinary stroke function improvement service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,140921000119102,Ischemic stroke without coma,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,143471000000105,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation using preferred method of communication,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,196371000000102,Atrial fibrillation resolved,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,201501000000108,Seen in stroke clinic,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,231231000000107,Delivery of rehabilitation for stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,248411000000105,Atrial fibrillation annual review,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,519751000000106,Stroke 6 month review,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,521411000000106,Did not attend stroke review,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,685631000000102,Stroke and cerebrovascular accident unspecified,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,713771000000100,Stroke/transient ischaemic attack monitoring administration,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,716021000000109,Excepted from stroke quality indicators - informed dissent,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,716331000000108,Exception reporting - stroke quality indicators,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,716581000000101,Excepted from stroke quality indicators - patient unsuitable,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,717241000000108,Stroke/transient ischaemic attack monitoring telephone invitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,769211000000103,Suspected stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,810991000000109,Stroke self-management plan review,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,812041000000104,Stroke self-management plan agreed,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,816401000000105,Atrial fibrillation excluded,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,816561000000108,Stroke initial post discharge review,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,842441000000104,Provision of written information about stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,870631000000105,QStroke 10 year risk of stroke calculator,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1062151000000103,Stroke TOM (Therapy Outcome Measure) activity score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1062171000000107,Stroke TOM (Therapy Outcome Measure) impairment score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1062181000000109,Stroke TOM (Therapy Outcome Measure) participation score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1062191000000106,Stroke TOM (Therapy Outcome Measure) wellbeing score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1066831000000104,Atrial fibrillation detected,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1078001000000105,Haemorrhagic stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1085311000000106,QStroke risk calculator score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,EDOXABAN,CARDIOLOGY,CARDIOLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1110981000000104,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,16371781000119100,Cerebellar stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,14534009,Deep vein thrombosis of splenic vein,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,49956009,Antenatal DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,56272000,Puerperal DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,59282003,Pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,128053003,Deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,134399007,Deep vein thrombosis of leg related to air travel,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,161508001,History of DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,200232006,Antenatal deep vein thrombosis - delivered,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,200233001,Antenatal deep vein thrombosis with antenatal complication,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,200238005,Postnatal deep vein thrombosis with postnatal complication,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,200284000,Obstetric pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,200286003,Obstetric air pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,213220000,Postoperative deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,225999004,At increased risk of DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,233217004,Operation for pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,233936003,Acute massive pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,233937007,Subacute massive pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,234044007,Ileofemoral deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,401186003,Deep vein thrombosis screening,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,413459009,Advised risk of deep vein thrombosis in air travel,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,413956008,Deep vein thrombosis of leg related to intravenous drug use,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,429053008,Wells deep vein thrombosis clinical probability score,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,430801003,Family history of pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,432805000,Suspected deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,438773007,Recurrent pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,443210003,Deep vein thrombosis of peroneal vein,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,710167004,Recurrent DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,198301000000109,FH: deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,323631000000102,DVT (deep vein thrombosis) prevention,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,492161000000109,Deep vein thrombosis enhanced services administration,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,503421000000105,Deep vein thrombosis enhanced services administration stage 1 service level,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,503451000000100,Deep vein thrombosis enhanced services administration stage 2 service level,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,503481000000106,Deep vein thrombosis enhanced services administration stage 3 service level,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,513251000000101,Low probability of deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,513271000000105,Moderate probability of deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,513291000000109,High probability of deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,869611000000104,On deep vein thrombosis care pathway,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,872221000000109,No history of deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,978421000000101,Unprovoked deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,978441000000108,Provoked deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,9014002,Psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,16341002,Parapsoriasis lichenoides,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,25847004,Sebopsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,37042000,Guttate psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,38360005,Acute generalized pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,81271001,Localised pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,88233000,Parapsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,160408009,Family history: Psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,161562002,History of psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200962007,Psoriasis annularis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200963002,Psoriasis circinata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200964008,Psoriasis diffusa,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200965009,Discoid psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200966005,Psoriasis geographica,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200967001,Psoriasis gyrata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200968006,Psoriasis inveterata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200969003,Ostraceous psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200970002,Psoriasis palmaris,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200971003,Psoriasis plantaris,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200972005,Psoriasis punctata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200973000,Pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200974006,Psoriasis universalis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200977004,Exfoliative psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200982006,Parapsoriasis herpetiformis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200983001,Parapsoriasis en gouttes,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200984007,Parapsoriasis papulata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,200985008,Parapsoriasis varioliformis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238600001,Inverse psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238601002,Unstable psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238602009,Eczematous psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238603004,Eczematised psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238608008,Psoriasis of scalp,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238609000,Kobner psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238612002,Acute generalized pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238614001,Pustular psoriasis in children,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,238617008,Circinate and annular pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,239803008,Juvenile psoriatic arthritis with psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,267851002,Parapsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,402307000,Chronic large plaque psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,402310007,Chronic stable plaque psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,430543001,Family history of psoriasis with psoriatic arthritis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,845091000000108,Education for psoriasis care,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,866311000000102,PASI - psoriasis area and severity index,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,866341000000101,PASI (psoriasis area and severity index) score,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +EFALUZIMAB,Psoriasis,TA103,psoriasis,1853821000000104,Psoriasis Epidemiology Screening Tool total score,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,62944002,Hepatitis C virus,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,62944002,Hepatitis C virus,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,72165005,Hepatitis C virus antibody,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,72165005,Hepatitis C virus antibody,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,170489004,Viral hepatitis carrier,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,170489004,Viral hepatitis carrier,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,197344005,Hepatitis caused by adenovirus,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,197344005,Hepatitis caused by adenovirus,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,235872006,Hepatitis C carrier,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,235872006,Hepatitis C carrier,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278973007,Hepatitis C status,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278973007,Hepatitis C status,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278974001,Hepatitis C immune,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278974001,Hepatitis C immune,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278975000,Hepatitis C non-immune,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278975000,Hepatitis C non-immune,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,314706002,Hepatitis C antibody detected,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,314706002,Hepatitis C antibody detected,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,314707006,Hepatitis C antibody test negative,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,314707006,Hepatitis C antibody test negative,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,413107006,Hepatitis C screening,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,413107006,Hepatitis C screening,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,773113008,Acute hepatitis caused by infection,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,773113008,Acute hepatitis caused by infection,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,12891000175105,Hepatitis C screening declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,12891000175105,Hepatitis C screening declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,200371000000104,Hepatitis C contact,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,200371000000104,Hepatitis C contact,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,201451000000105,Hepatitis C immunisation declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,201451000000105,Hepatitis C immunisation declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,202281000000105,Hepatitis C screening declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,202281000000105,Hepatitis C screening declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,204671000000101,Hepatitis C screening counselling,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,204671000000101,Hepatitis C screening counselling,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,304821000000107,Hepatitis C screening not offered,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,304821000000107,Hepatitis C screening not offered,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,362491000000104,Hepatitis C screening negative,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,362491000000104,Hepatitis C screening negative,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,362751000000101,Hepatitis C screening positive,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,362751000000101,Hepatitis C screening positive,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,761381000000102,Hepatitis C resolved,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,761381000000102,Hepatitis C resolved,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,824841000000105,Hepatitis C genotype 1,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,824841000000105,Hepatitis C genotype 1,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,824871000000104,Hepatitis C genotype 3,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,824871000000104,Hepatitis C genotype 3,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,829731000000106,On hepatitis C treatment plan,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,829731000000106,On hepatitis C treatment plan,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,992751000000109,Hepatitis C viral load,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,992751000000109,Hepatitis C viral load,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,992771000000100,Hepatitis C virus genotype,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,992771000000100,Hepatitis C virus genotype,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,996031000000104,Hepatitis C IgG level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,996031000000104,Hepatitis C IgG level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,998771000000103,Hepatitis C antibody level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,998771000000103,Hepatitis C antibody level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1001331000000102,Hepatitis C antigen level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1001331000000102,Hepatitis C antigen level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1008931000000108,Hepatitis C antibody test,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1008931000000108,Hepatitis C antibody test,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1107671000000106,Hepatitis C screening offered,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1107671000000106,Hepatitis C screening offered,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +ELOTUZUMAB,Previously treated multiple myeloma,TA434,multiple myeloma,230586003,Neuropathy due to multiple myeloma,ELOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +ELOTUZUMAB,Previously treated multiple myeloma,TA434,multiple myeloma,413587002,Smoldering multiple myeloma,ELOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +ELOTUZUMAB,Previously treated multiple myeloma,TA434,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ELOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA205,thrombocytopenic purpura,78129009,TTP - thrombotic thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA293,thrombocytopenic purpura,78129009,TTP - thrombotic thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA205,thrombocytopenic purpura,234493006,Non-thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA293,thrombocytopenic purpura,234493006,Non-thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA205,thrombocytopenic purpura,234494000,Primary non-thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA293,thrombocytopenic purpura,234494000,Primary non-thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA205,thrombocytopenic purpura,302873008,Thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA293,thrombocytopenic purpura,302873008,Thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELTROMBOPAG,Treating severe aplastic anaemia refractory to immunosuppressive therapy,TA382,aplastic anaemia,191256002,Idiopathic aplastic anaemia,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,197125005,Irritable bowel syndrome with diarrhea,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY +ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,440544005,Irritable bowel syndrome characterized by alternating bowel habit,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY +ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,70871000119100,H/O irritable bowel syndrome,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY +ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,817511000000108,Management of irritable bowel syndrome,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY +ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,1083671000000108,Irritable Bowel Syndrome - Symptom Severity Scale score,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,10335000,Chronic right-sided heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,10633002,Acute congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,48447003,Chronic heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,56675007,Acute heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,83291003,Right heart failure due to pulmonary hypertension,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,85232009,Left-sided heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,88805009,Chronic congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,111283005,Chronic left-sided heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,128404006,Right heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,134378009,Congestive heart failure monitoring,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,134440006,Referral to heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,161505003,History of heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,233924009,Heart failure as a complication of care,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,266308000,Right heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,309634009,History of heart failure in last year,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,314206003,Refractory heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,367363000,Right heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,390868005,Heart failure screen,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,390884006,Heart failure follow-up,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,390885007,Heart failure annual review,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,394887005,Suspected heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,394927007,Heart failure excluded,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,395105005,Heart failure confirmed,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,416683003,Emergency hospital admission for heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,416717003,Seen in heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,417146007,Referral to heart failure nurse,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,417359009,Seen by community heart failure nurse,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,423475008,Heart failure education,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,424404003,Decompensated chronic heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,426611007,Congestive heart failure due to valvular disease,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,429959009,Family history of heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,441530006,Chronic diastolic heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,473226007,Heart failure medication review,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,704095000,Referral to heart failure exercise programme,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,704096004,Referral to heart failure exercise programme not indicated,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,704097008,Referral to heart failure exercise program declined,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,735984001,Heart failure self management plan,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,1296659009,Acute on chronic heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,96311000119109,Exacerbation of congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,200171000000102,Referred by heart failure nurse specialist,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,202231000000106,Heart failure review completed,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,203791000000106,Referred to heart failure education group,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,247361000000100,Heart failure 6 month review,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,248571000000104,Did not attend heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,374231000000104,High risk of heart failure screening invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,521691000000100,Heart failure resolved,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,711461000000104,Heart failure monitoring invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,713791000000101,Heart failure monitoring administration,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,715951000000107,Exception reporting - heart failure quality indicators,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,716621000000101,Heart failure monitoring third letter,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,716971000000109,Heart failure monitoring first letter,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717191000000108,Heart failure monitoring second letter,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717501000000108,Heart failure monitoring verbal invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717531000000102,Heart failure monitoring telephone invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,763641000000102,Referral to heart failure education group declined,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,765661000000102,Discharge from heart failure nurse service,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,781051000000108,Has heart failure management plan,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,810971000000105,Heart failure self-management plan review,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,812001000000102,Heart failure self-management plan agreed,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,813991000000101,Education about deteriorating heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,835981000000108,Rehabilitation for heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,851071000000108,Heart failure initial assessment,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,851521000000102,Heart failure clinical pathway,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,871681000000102,Heart failure monitoring,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,872361000000105,Discussion about heart failure care plan,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,873881000000100,Referral to rapid access heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,915571000000102,On optimal heart failure therapy,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,961881000000101,Provision of information about heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,915007,Malignant melanoma in junctional naevus,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,1556006,Clark melanoma level 4,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,2092003,Malignant melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,2142002,Nodular melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,16974005,"Acral lentiginous melanoma, malignant",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,21119008,Benign melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,21165006,Clark melanoma level 3,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,37138001,Epithelioid cell melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,39896009,"Malignant melanoma, regressing",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,44474009,Lentigo maligna melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,50542000,Clark melanoma level 2,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,50813003,Spitz melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,51757004,"Desmoplastic melanoma, amelanotic",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,55320002,Superficial spreading melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,68827007,Spindle cell melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,70594002,Amelanotic melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,77986002,Melanoma in situ,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93209006,Malignant melanoma of perianal skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93214005,Malignant melanoma of skin of back,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93217003,Malignant melanoma of skin of cheek,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93220006,Malignant melanoma of skin of ear,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93221005,Malignant melanoma of skin of elbow,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93223008,Malignant melanoma of eyebrow,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93225001,Malignant melanoma of skin of face,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93227009,Malignant melanoma of skin of foot,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93228004,Malignant melanoma of skin of forearm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93642000,Malignant melanoma of skin of neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93643005,Malignant melanoma of external surface of nose,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93646002,Malignant melanoma of skin of scalp,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93647006,Malignant melanoma of skin of shoulder,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93651008,Malignant melanoma of skin of trunk,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93653006,Malignant melanoma of skin of upper limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93654000,Malignant melanoma of skin of wrist,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93655004,MM (malignant melanoma) of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,106243009,Breslow depth staging for melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109266006,Melanoma in situ of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109270003,Melanoma in situ of face,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109272006,Melanoma in situ of lip,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109276009,Melanoma in situ of scalp,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109278005,Melanoma in situ of ear,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109282007,Melanoma in situ of neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109284008,Melanoma in situ of trunk,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109290007,Melanoma in situ of upper limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109294003,Melanoma in situ of lower limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,127330008,Melanoma in situ by body site (clinical),ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,161432005,History of malignant melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,177281002,Excision of melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188030005,Malignant melanoma of lip,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188033007,Malignant melanoma of auricle (ear),ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188034001,Malignant melanoma of external auditory meatus,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188038003,Malignant melanoma of chin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188040008,Malignant melanoma of forehead,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188042000,Malignant melanoma of temple,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188044004,Malignant melanoma of scalp and/or neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188045003,Malignant melanoma of scalp,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188046002,Malignant melanoma of neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188049009,Malignant melanoma of axilla,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188050009,Malignant melanoma of breast,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188051008,Malignant melanoma of buttock,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188052001,Malignant melanoma of groin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188054000,Malignant melanoma of perineum,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188055004,Malignant melanoma of umbilicus,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188060000,Malignant melanoma of shoulder,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188061001,Malignant melanoma of upper arm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188062008,Malignant melanoma of forearm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188063003,Malignant melanoma of hand,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188064009,Malignant melanoma of finger,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188065005,Malignant melanoma of thumb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188067002,Malignant melanoma of lower limb and hip,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188068007,Malignant melanoma of hip,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188069004,Malignant melanoma of thigh,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188070003,Malignant melanoma of knee,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188071004,Malignant melanoma of popliteal fossa area,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188072006,Malignant melanoma of lower leg,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188073001,Malignant melanoma of ankle,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188074007,Malignant melanoma of heel,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188075008,Malignant melanoma of foot,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188076009,Malignant melanoma of toe,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188077000,Malignant melanoma of great toe,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,189758001,Melanoma in situ,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,231834005,Malignant melanoma of eyelid,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254731001,Nodular melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254732008,Acral lentiginous melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254896002,Malignant melanoma of vulva,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,255004001,Malignant melanoma of conjunctiva,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,255012009,Malignant melanoma of iris,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,255015006,Malignant melanoma of ciliary body,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,255021005,Malignant melanoma of choroid,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,269578002,Malignant melanoma of head and neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,269579005,Malignant melanoma of trunk,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,269580008,Malignant melanoma of upper limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,269581007,Malignant melanoma of lower limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,274087000,MM (malignant melanoma) of eye,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,276751004,Amelanotic melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,276821000,Malignant melanoma of anus,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,276822007,Malignant melanoma of rectum,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,302837001,Lentigo maligna melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,310498001,Malignant melanoma of back,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,312941005,Melanoma associated retinopathy,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,313248004,Malignant melanoma of chest wall,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,314976006,Local recurrence of malignant melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,314987003,Metastasis from malignant melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,315036008,Melanoma in situ of back of hand,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,315230006,Melanoma in situ of back,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,372158004,"Malignant melanoma, metastatic",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,427858005,Family history of malignant melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,443493003,Metastatic malignant melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,449636007,Malignant melanoma of skin of lower leg,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,449637003,Malignant melanoma of skin of upper arm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,698040004,Malignant melanoma of nasal cavity,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,1197324006,Metastatic malignant melanoma to skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,351961000119109,Malignant melanoma of skin of right arm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,352211000119108,Malignant melanoma of skin of left ear,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,546881000000105,Malignant melanoma of skin NOS,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956331000000107,Malignant melanoma stage IA,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956351000000100,Malignant melanoma stage IB,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956371000000109,Malignant melanoma stage IIA,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956391000000108,Malignant melanoma stage IIB,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956451000000107,Malignant melanoma stage IIIB,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956471000000103,Malignant melanoma stage IIIC,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956511000000107,Malignant melanoma stage IV M1a,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956551000000106,Malignant melanoma stage IV M1c,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,1080941000119109,Malignant melanoma of left choroid,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,1080981000119104,Malignant melanoma of right choroid,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,162573006,Suspected lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,275981009,Lung cancer screening,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,429011007,Family history of lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,315268008,Suspected prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,428262008,H/O: prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,698470001,Advice given about prostate cancer screening,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,712837004,Active surveillance of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,720007002,Prostate cancer care review,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,31011000119107,Prostate cancer screening declined,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,874211000000109,QCancer prostate cancer risk,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,878401000000104,No FH of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,315268008,Suspected prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,428262008,H/O: prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,698470001,Advice given about prostate cancer screening,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,712837004,Active surveillance of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,720007002,Prostate cancer care review,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,31011000119107,Prostate cancer screening declined,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,874211000000109,QCancer prostate cancer risk,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,878401000000104,No FH of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,315268008,Suspected prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,428262008,H/O: prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,698470001,Advice given about prostate cancer screening,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,712837004,Active surveillance of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,720007002,Prostate cancer care review,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,31011000119107,Prostate cancer screening declined,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,874211000000109,QCancer prostate cancer risk,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,878401000000104,No FH of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,315268008,Suspected prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,428262008,H/O: prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,698470001,Advice given about prostate cancer screening,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,712837004,Active surveillance of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,720007002,Prostate cancer care review,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,31011000119107,Prostate cancer screening declined,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,874211000000109,QCancer prostate cancer risk,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,878401000000104,No FH of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EPTIFIBATIDE (INTRAVENOUS),Acute coronary syndromes,TA012,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY +EPTIFIBITIDE,Acute coronary syndromes,TA047,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,4473006,Classical migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,23186000,Menstrual migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,37796009,Migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,56097005,Migraine without aura,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,59292006,Hemiplegic migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,75879005,Decapitated migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,79267007,Retinal migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,83351003,Basilar artery migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,95655001,Ocular migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,95656000,Familial hemiplegic migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,160342001,Family history of migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,161481007,History of migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,162040008,Abdominal migraine - symptom,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,193030005,Migraine variants,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,193039006,Complex migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,230462002,Migraine with typical aura,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,230464001,Sporadic hemiplegic migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,230465000,Migraine aura without headache,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,230468003,Migraine with ischaemic complication,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,232284007,Vestibular migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,394707001,No history of migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,408381007,Migraine prophylaxis,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,427419006,Chronic migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,608837004,History of migraine with aura,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,124171000119105,Chronic intractable migraine without aura,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +EPTINEZUMAB,Preventing migraine,TA871,migraine,781381000000100,Migraine induced by oestrogen contraceptive,EPTINEZUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,4473006,Classical migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,23186000,Menstrual migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,37796009,Migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,56097005,Migraine without aura,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,59292006,Hemiplegic migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,75879005,Decapitated migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,79267007,Retinal migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,83351003,Basilar artery migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,95655001,Ocular migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,95656000,Familial hemiplegic migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,160342001,Family history of migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,161481007,History of migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,162040008,Abdominal migraine - symptom,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,193030005,Migraine variants,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,193039006,Complex migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,230462002,Migraine with typical aura,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,230464001,Sporadic hemiplegic migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,230465000,Migraine aura without headache,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,230468003,Migraine with ischaemic complication,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,232284007,Vestibular migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,394707001,No history of migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,408381007,Migraine prophylaxis,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,427419006,Chronic migraine,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,608837004,History of migraine with aura,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,124171000119105,Chronic intractable migraine without aura,ERENUMAB,NEUROLOGY,NEUROLOGY +ERENUMAB,Migraine,TA682,migraine,781381000000100,Migraine induced by oestrogen contraceptive,ERENUMAB,NEUROLOGY,NEUROLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,134405005,Suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,160287004,FH: Breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,268547008,Screening for breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,429740004,Family history of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,706970001,TNBC - Triple-negative breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,94361000000105,Breast cancer detected by national screening programme,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,838351000000107,Education about risk of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,874291000000100,QCancer breast cancer risk,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,1035841000000108,Lymphoedema following breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,134405005,Suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,160287004,FH: Breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,268547008,Screening for breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,429740004,Family history of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,706970001,TNBC - Triple-negative breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,94361000000105,Breast cancer detected by national screening programme,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,838351000000107,Education about risk of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,874291000000100,QCancer breast cancer risk,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,1035841000000108,Lymphoedema following breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,134405005,Suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,160287004,FH: Breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,268547008,Screening for breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,429740004,Family history of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,706970001,TNBC - Triple-negative breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,94361000000105,Breast cancer detected by national screening programme,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,838351000000107,Education about risk of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,874291000000100,QCancer breast cancer risk,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,1035841000000108,Lymphoedema following breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE),Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,TA258,non-small cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE),Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,TA258,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE),Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,TA258,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (1ST LINE),Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,TA258,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,2751001,Fibrocalculous pancreatic diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,4855003,Retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,5368009,Drug-induced diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,6143009,Diabetes mellitus education,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,8801005,Secondary diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,9414007,Latent diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,11530004,Brittle diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,11687002,GDM - gestational diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,15771004,Diabetes insipidus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,21584002,Maternal diabetes syndrome,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,25093002,Disorder of eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,43959009,Cataract of eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,44054006,T2DM - diabetes mellitus type 2,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,46635009,T1DM - type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,48951005,Bullous disease due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,49455004,Polyneuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,49817004,Neonatal diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,61165007,Adiuretin-resistant diabetes insipidus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,73211009,Diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,74627003,Complication due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,111552007,Diabetes mellitus without complication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,127012008,Lipodystrophic diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,127013003,Disorder of kidney due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,160274005,No family history of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,160303001,Family history of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,160402005,Family history: Diabetes in pregnancy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,161445009,History of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,161641009,At increased risk of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170745003,Diet controlled diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170752001,Has seen dietitian - diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170753006,Understands diet - diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170774007,Diabetes: practice program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170775008,Diabetes: shared care program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,171183004,Diabetes mellitus screening,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185753003,Attends diabetes monitoring,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185754009,Diabetes monitoring declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185755005,Diabetes monitoring default,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185756006,Diabetes monitoring first letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185757002,Diabetes monitoring second letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185758007,Diabetes monitoring third letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185759004,Diabetes monitoring verbal invite,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185760009,Diabetes monitoring telephone invite,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185761008,Diabetes monitoring deleted,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190323008,Non-insulin dependent diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190349003,Diabetes mellitus with neuropathy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190354007,Diabetes with gangrene,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190372001,Insulin-dependent diabetes maturity onset,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190389009,Type 2 diabetes mellitus with ulcer,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190411003,Multiple complications due to malnutrition related diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190416008,Steroid-induced diabetes mellitus without complication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190447002,Steroid-induced diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190484000,Diabetes insipidus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193489006,Iritis due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199230006,Pre-existing type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230572002,Neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230577008,Mononeuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,232020009,Disorder of macula due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237599002,Insulin treated type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237601000,Secondary endocrine diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237619009,Maternally-inherited diabetes and hearing loss,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237632004,Hypoglycemic event due to diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,238982009,Dermopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,267471001,Diabetes + eye manifestation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,268519009,Diabetes mellitus uncontrolled,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,270445003,Diabetes monitoring check done,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,273411009,Diabetes clinic satisfaction questionnaire,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,273412002,Diabetes treatment satisfaction questionnaire,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,273413007,Diabetes wellbeing questionnaire,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,284350006,Diabetes mellitus diet education,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,290002008,Unstable type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,303059007,Postpancreatectomy diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,304752002,Perceived control of insulin-dependent diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,308505000,Diabetes monitoring call,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309417009,Diabetes dietitian,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309426007,Glomerulopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309593006,Education score - diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309596003,Retinal abnormality - non-diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309598002,Foot abnormality - non-diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309635005,History of admission in last year for diabetes foot problem,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,310425007,Diabetes monitoring invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312856000,Referral to diabetes nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312888008,Attending diabetes clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312912001,Macular oedema due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,313435000,Insulin-dependent diabetes without complication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,313436004,Type II diabetes mellitus without complication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314537004,Optic papillopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,315051004,Diabetes resolved,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,315216001,Diabetes mellitus excluded,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,371087003,Ulcer of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,385805005,Health education - diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,394725008,Diabetes medication review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,395123002,Urine screening test for diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,405749004,Newly diagnosed diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,408290003,Diabetes key contact,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,408392008,Under care of diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,413180006,Pan retinal photocoagulation for diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,413597006,Attended diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,414229005,Family/carer attended diabetes structured education program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,414230000,Family/carer referral to diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,415269004,Referral to diabetes preconception counselling clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,415270003,Referral to diabetes structured education program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,415744000,Transition of diabetes care options discussed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,416554009,Seen in community diabetes specialist clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,416855002,Family history of diabetes mellitus in first degree relative,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,417467000,Discharged from care of diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,419100001,Infection of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420422005,Ketoacidosis due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420868002,Disorder due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422014003,Disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422183001,Skin ulcer due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422275004,Gangrene due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,428274007,Dietary advice for type II diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,429094000,Dietary advice for type 1 diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,430678008,Family history of diabetes mellitus type 1,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,430679000,Family history of diabetes mellitus type 2,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,439051004,Dietary advice for gestational diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,444094009,History of diabetes mellitus in child of subject,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,472969004,H/O diabetes mellitus type 2,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,472970003,H/O diabetes mellitus type 1,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,473127005,Suspected diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,609561005,MODY - maturity onset diabetes of young,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,698610002,Education about self management of diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,699826006,Lifestyle education regarding risk of diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,700414001,Education about diabetes and driving,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,703040004,Agreeing on diabetes care plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,703136005,Diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,703137001,Type 1 diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,703138006,Type 2 diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,704408003,Invitation for diabetes screening,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,714628002,Prediabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,715159005,Referral to diabetes service,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,715759002,Provision of written information about diabetes and hypertension,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,715879000,Provision of written information about diabetes and high cholesterol,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,720685006,Seen by diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,720724003,Has diabetes identity card,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,724136006,Mastopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,735199000,History of diabetes related lower limb amputation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,735985000,Diabetes self management plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,736284000,Diabetes clinical management plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,762489000,Acute complication due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,763782001,Provision of patient held diabetes record declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769244003,Disorder of right macula due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769245002,Disorder of left macula due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,878859007,Self management of diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,897238003,Diabetes management using closed-loop delivery system,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1258872006,Family referred to diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1258873001,Caregiver referred to diabetes structured education program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1268646002,Gestational diabetes mellitus screening,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1296758008,Diabetes insipidus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,113131000000107,Informed consent for diabetes national audit,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,113141000000103,Informed dissent for diabetes national audit,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,143911000000105,Registration for access to online diabetes self-management application,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,279291000000109,Diabetes type 1 review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,279321000000104,Diabetes type II review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,279521000000108,Referral to community diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306591000000103,Diabetes structured education programme declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306861000000107,Did not attend diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306931000000106,Did not complete diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,334711000000100,Referral to diabetes special interest general practitioner,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,335621000000101,Maternally inherited diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,344061000000104,Referral to children's diabetes nurse specialist,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,385041000000108,Diabetes mellitus with multiple complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,385051000000106,Pre-existing diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,494961000000102,Discharged from diabetes shared care programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,512561000000108,Unsuitable for diabetes year of care programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,512581000000104,Declined consent for diabetes year of care programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713671000000109,Diabetes monitoring administration,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713691000000108,Diabetes clinic administration,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,715111000000105,Diabetes screening administration,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,716911000000104,Exception reporting - diabetes quality indicators,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,754461000000105,Referral to type I diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,755491000000100,Diabetes structured education programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,764921000000102,Gestational diabetes information leaflet given,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,771571000000102,H/O: secondary diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,787061000000100,Diabetes care plan declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,810961000000103,Diabetes self-management plan review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,811391000000104,Referral to community diabetes service,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,811981000000102,Diabetes self-management plan agreed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816711000000104,Gestational diabetes mellitus annual review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,819301000000105,Diabetes monitoring injection site check declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,819331000000104,Diabetes monitoring injection site not checked,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,828901000000109,Endocrinology and diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,829521000000104,Provision of diabetes clinical summary,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,837491000000107,High risk of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,841221000000102,Referral to community diabetes clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,850581000000106,High risk of diabetes mellitus annual review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,851501000000106,Diabetes clinical pathway,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,851991000000108,Diabetes quality of life questionnaire score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,857921000000103,Provision of written information about diabetes and driving,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,858301000000107,Pre-diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,863501000000102,QDiabetes risk calculator,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,863521000000106,QDiabetes risk calculator score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,885931000000100,Diabetes structured education programme not available,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,887861000000105,Diabetes Year of Care annual review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,923461000000103,Lifestyle education for diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,927821000000100,Discharge from secondary care diabetes service,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,961931000000109,Diabetes education care plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1024941000000100,NHS Diabetes Prevention Programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025601000000108,Leicester Diabetes Risk Score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1083111000000108,Diabetes monitoring invitation email,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1092721000000109,Signposting to Diabetes UK,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1103691000000102,Diabetes structured education programme offered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1108731000000100,Referral to online diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1362341000000103,Diabetes care plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,12275391000119108,Diabetes screening declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,2694001,Leucoerythroblastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,4854004,Acquired haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,5315003,HNSHA (hereditary nonspherocytic haemolytic anaemia) due to increased adenosine deaminase activity,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,28975000,Congenital aplastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,30575002,Fanconi anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,41841004,Sideroblastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,45828008,"Anaemia in mother complicating pregnancy, childbirth AND/OR puerperium",ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,48983004,X-linked sideroblastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,49708008,Anaemia of chronic renal failure,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,52951008,CDA - congenital dyserythropoietic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,53743006,Anaemia following foetal blood loss,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,55907008,Idiopathic acquired aplastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,55995005,Congenital spherocytic haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,56921004,Perinatal jaundice due to hereditary haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,61261009,Haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,63565007,Congenital anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,74703006,PK (pyruvate kinase) deficiency haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,81711008,Haemolytic anaemia caused by drugs,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,83414005,Macrocytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,85649008,Folate deficiency anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,87522002,Chlorotic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,90414007,Chronic acquired pure red cell anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,161457000,History of anaemia vitamin B12 deficient,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,161458005,History of haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,164139008,On examination - anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,171201007,Anaemia screening,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,189509003,"Refractory anaemia without sideroblasts, so stated",ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191125001,Deficiency anaemiasm (& [asiderotic] or [sideropenic]),ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191127009,Iron deficiency anaemia due to blood loss,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191142007,Vitamin B12 deficiency anaemia due to malabsorption with proteinuria,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191147001,Anaemia: [folate-deficiency or megaloblastic due to dietary causes] or [goat's milk],ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191150003,Folate deficiency anaemia due to liver disorders,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191154007,Combined B12 and folate deficiency anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191210005,Primary cold-type haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191217008,Mechanical haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191218003,Toxic haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191248000,Aplastic anaemia caused by toxic cause,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191251007,Transient hypoplastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191256002,Idiopathic aplastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191277004,Normocytic anaemia due to unspecified cause,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,199244000,Anaemia during pregnancy - baby delivered,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,206434001,Late anaemia of newborn due to isoimmunisation,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234339009,Macrocytosis - no anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234340006,Iron deficiency without anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234347009,Anaemia of systemic disease,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234349007,Microcytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234360003,Vegan anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234402007,Chronic non-spherocytic haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,266888008,Family history: Anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,267513007,Deficiency anaemias,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,267553005,Microcytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,267554004,Deficiency anaemias excl. iron,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,271737000,Anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,275538002,History of anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,276578004,Physiological anaemia of infancy,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,300980002,Normocytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,307726001,Anaemia in ovarian carcinoma,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,309742004,Drug-induced autoimmune haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,310647000,Anaemia secondary to renal failure,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,413533008,Anaemia due to chronic blood loss,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,413603009,Autoimmune haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,417425009,Sickle cell anaemia with crisis,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,441482006,History of sickle cell anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,221241000000101,Hypoplastic haemolytic and renal anaemia drugs Band 2,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,389601000000102,[X]Anaemia in other chronic diseases classified elsewhere,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,421261000000104,"[X]Vitamin B12, folic acid and other anti-megaloblastic anaemia preparations causing adverse effects in therapeutic use",ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,579711000000100,Other specified megaloblastic anaemia NEC,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,668381000000100,Anaemia unspecified,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,820601000000103,Refractory anaemia with multilineage dysplasia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,866381000000109,Recurrent anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,2694001,Leucoerythroblastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,4854004,Acquired haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,5315003,HNSHA (hereditary nonspherocytic haemolytic anaemia) due to increased adenosine deaminase activity,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,28975000,Congenital aplastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,30575002,Fanconi anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,41841004,Sideroblastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,45828008,"Anaemia in mother complicating pregnancy, childbirth AND/OR puerperium",ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,48983004,X-linked sideroblastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,49708008,Anaemia of chronic renal failure,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,52951008,CDA - congenital dyserythropoietic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,53743006,Anaemia following foetal blood loss,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,55907008,Idiopathic acquired aplastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,55995005,Congenital spherocytic haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,56921004,Perinatal jaundice due to hereditary haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,61261009,Haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,63565007,Congenital anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,74703006,PK (pyruvate kinase) deficiency haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,81711008,Haemolytic anaemia caused by drugs,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,83414005,Macrocytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,85649008,Folate deficiency anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,87522002,Chlorotic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,90414007,Chronic acquired pure red cell anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,161457000,History of anaemia vitamin B12 deficient,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,161458005,History of haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,164139008,On examination - anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,171201007,Anaemia screening,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,189509003,"Refractory anaemia without sideroblasts, so stated",ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191125001,Deficiency anaemiasm (& [asiderotic] or [sideropenic]),ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191127009,Iron deficiency anaemia due to blood loss,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191142007,Vitamin B12 deficiency anaemia due to malabsorption with proteinuria,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191147001,Anaemia: [folate-deficiency or megaloblastic due to dietary causes] or [goat's milk],ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191150003,Folate deficiency anaemia due to liver disorders,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191154007,Combined B12 and folate deficiency anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191210005,Primary cold-type haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191217008,Mechanical haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191218003,Toxic haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191248000,Aplastic anaemia caused by toxic cause,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191251007,Transient hypoplastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191256002,Idiopathic aplastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191277004,Normocytic anaemia due to unspecified cause,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,199244000,Anaemia during pregnancy - baby delivered,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,206434001,Late anaemia of newborn due to isoimmunisation,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234339009,Macrocytosis - no anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234340006,Iron deficiency without anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234347009,Anaemia of systemic disease,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234349007,Microcytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234360003,Vegan anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234402007,Chronic non-spherocytic haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,266888008,Family history: Anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,267513007,Deficiency anaemias,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,267553005,Microcytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,267554004,Deficiency anaemias excl. iron,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,271737000,Anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,275538002,History of anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,276578004,Physiological anaemia of infancy,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,300980002,Normocytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,307726001,Anaemia in ovarian carcinoma,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,309742004,Drug-induced autoimmune haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,310647000,Anaemia secondary to renal failure,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,413533008,Anaemia due to chronic blood loss,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,413603009,Autoimmune haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,417425009,Sickle cell anaemia with crisis,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,441482006,History of sickle cell anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,221241000000101,Hypoplastic haemolytic and renal anaemia drugs Band 2,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,389601000000102,[X]Anaemia in other chronic diseases classified elsewhere,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,421261000000104,"[X]Vitamin B12, folic acid and other anti-megaloblastic anaemia preparations causing adverse effects in therapeutic use",ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,579711000000100,Other specified megaloblastic anaemia NEC,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,668381000000100,Anaemia unspecified,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,820601000000103,Refractory anaemia with multilineage dysplasia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,866381000000109,Recurrent anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,832007,Moderate major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,15639000,"Moderate major depression, single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,18818009,Moderate recurrent major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,19527009,"Major depression, single episode, in full remission",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,26141007,ST segment depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,28475009,Severe recurrent major depression with psychotic features,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,33135002,Recurrent major depression in partial remission,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,36474008,Severe recurrent major depression without psychotic features,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,36923009,"Major depression, single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,39540007,Congenital depression in skull,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,40379007,Mild recurrent major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,46244001,Recurrent major depression in complete remission,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,58703003,Postpartum depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,70747007,"Major depression single episode, in partial remission",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,73867007,Psychotic depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,75084000,Severe major depression without psychotic features,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,76441001,"Severe major depression, single episode, without psychotic features",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,79298009,"Mild major depression, single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,82218004,Postoperative depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,83458005,Agitated depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,87227007,Cerebral depression in newborn,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,87414006,Reactive depression (situational),ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,87512008,Mild major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,160329001,Family history of depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,160403000,Family history: Puerperal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,161104007,Manic-depression association member,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,171207006,Depression screening,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191455000,Presenile dementia with depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191459006,Senile dementia with depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191466007,Arteriosclerotic dementia with depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191599006,Endogenous depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191616006,Recurrent depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191627008,"Bipolar affective disorder, current episode depression",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191676002,Psychotic reactive depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191740008,Neurotic depression reactive type,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,192079006,Postviral depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,192080009,Chronic depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,231485007,Post-schizophrenic depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,231499006,Endogenous depression first episode,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,231500002,Masked depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,231504006,Anxiety depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,233928007,Myocardial depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,237350002,Severe postnatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,247802007,Depression worse later in day,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,251245007,PR depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,255339005,Depression - motion,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,263923006,Vasodepression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,268753005,Depression - postnatal,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273306008,Beck depression inventory,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273333007,Brief depression rating scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273362008,Child depression scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273402009,Depression anxiety scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273403004,Depression self rating scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273441006,EPDS - Edinburgh postnatal depression scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273481004,Geriatric depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273503001,HAMD - Hamilton rating scale for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273524006,Hospital anxiety and depression scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,274948002,Endogenous depression - recurrent,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,300706003,Endogenous depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,310495003,[X]Mild depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,310496002,Moderate depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,310497006,Severe depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,395072006,Postnatal depression counseling,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,401174001,Depression management program,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,401319005,Hospital Anxiety and Depression scale: anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,401320004,Hospital Anxiety and Depression scale: depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413169006,On depression register,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413170007,Removed from depression register,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413972000,Depression annual review,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413973005,Depression interim review,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413974004,Depression medication review,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,416619008,Depression anxiety stress scales anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,416954004,Depression anxiety stress scales depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,425402008,GDS - Geriatric depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,444949001,GDS (geriatric depression scale) 4 item score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,445064009,GDS (geriatric depression scale) original long form score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,445676008,Assessment using GDS (geriatric depression scale) short form,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,446053003,BDI (Beck depression inventory) score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,446087008,Montgomery-Asberg depression rating scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,449413009,Decline in Edinburgh postnatal depression scale score at 8 months,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,450320001,EPDS (Edinburgh postnatal depression scale) score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,450714000,Severe major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,473126001,Suspected depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,698569004,Postnatal depression not discussed,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,700143000,No history of depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,715252007,Depression screening using Patient Health Questionnaire Nine Item score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718316006,BASDEC (Brief Assessment Schedule Depression Cards) score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718366000,Beck Depression Inventory II score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718655001,Revised Children's Anxiety and Depression Scale Major Depressive Disorder score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718656000,RCADS (Revised Children's Anxiety and Depression Scale) generalized anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718657009,RCADS (Revised Children's Anxiety and Depression Scale) Obsessive Compulsive Disorder subscale score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718658004,RCADS (Revised Children's Anxiety and Depression Scale) Panic Disorder subscale score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718660002,Revised Children's Anxiety and Depression Scale social phobia score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718661003,Revised Children's Anxiety and Depression Scale total anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718662005,Revised Children's Anxiety and Depression Scale total anxiety and depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718666008,Revised Children's Anxiety and Depression Scale Parent Version generalized anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718668009,RCADS (Revised Children's Anxiety and Depression Scale) Parent Version Panic Disorder subscale score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718669001,RCADS (Revised Children's Anxiety and Depression Scale) Parent Version separation anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718670000,Revised Children's Anxiety and Depression Scale Parent Version social phobia score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718671001,RCADS (Revised Children's Anxiety and Depression Scale) Parent Version total anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718672008,RCADS (Revised Children's Anxiety and Depression Scale) Parent Version total anxiety and depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718738005,Revised Children's Anxiety and Depression Scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,720453001,Moderately severe major depression single episode,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,720834000,Depression screening declined,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,761880008,HAM-D (Hamilton Rating Scale for Depression) score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,763265004,Montgomery-Asberg Depression Rating Scale score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,765176007,Psychosis and severe depression co-occurrent and due to bipolar affective disorder,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,788120007,Antenatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,870191006,Follow up for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1153570009,Treatment resistant depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,251000119105,"Severe major depression, single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,281000119103,Severe recurrent major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,10211000132109,Perinatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,104851000119103,Postpartum major depression in remission,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,112001000119100,Positive screening for depression on Patient Health Questionnaire 9,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,112011000119102,Negative screening for depression on Patient Health Questionnaire 9,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,143391000000100,QOF (Quality and Outcomes Framework) depression quality indicator-related care invitation using preferred method of communication,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,149631000000108,Digital cognitive behavioural therapy for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,166291000000108,Depression enhanced services administration,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,166481000000107,Depression enhanced service completed,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,196381000000100,Depression resolved,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,199111000000100,Referral for guided self-help for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,200971000000100,Depression screening using questions,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,206341000000108,Discussion about maternal wellbeing - postnatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,248641000000109,BASDEC - Brief Assessment Schedule Depression Cards,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,286711000000107,Counseling for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,311611000000104,History of postnatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,361761000000106,On full dose long term treatment for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,713831000000108,Depression monitoring administration,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,715831000000109,Excepted from depression quality indicators - informed dissent,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,716421000000103,Depression monitoring telephone invitation,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,716681000000100,Depression monitoring second letter,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,716831000000103,Excepted from depression quality indicators - patient unsuitable,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,716961000000102,Depression monitoring third letter,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,717211000000107,Depression monitoring first letter,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,717261000000109,Depression monitoring verbal invitation,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,792491000000100,Assessment using Whooley depression screen,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,803351000000106,Whooley depression screen score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,814191000000100,Referral to postnatal depression group,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,821611000000108,EQ-5D-5L (EuroQol five dimension five level) anxiety depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,883491000000106,Did not attend depression review,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,933441000000101,Referral for guided self-help for depression declined,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,987331000000104,Current View Provisional Problem Description item 9 score - depression/low mood,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,988671000000106,HADS (Hospital Anxiety and Depression Scale) declined,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1038261000000100,Maternal postnatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1057351000000106,Signposting to depression self-help group,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1083051000000106,Depression monitoring invitation email,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1083071000000102,Depression monitoring invitation SMS (short message service) text message,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1086661000000108,"Reactive depression, prolonged single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1089511000000100,Recurrent depression with current severe episode and psychotic features,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1110911000000106,QOF (Quality and Outcomes Framework) depression quality indicator-related care invitation,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364401000000101,RCADS-P (Revised Children's Anxiety and Depression Scale Parent Version) Major Depression T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364411000000104,Revised Children's Anxiety and Depression Scale Parent Version Generalized Anxiety T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364421000000105,Revised Children's Anxiety and Depression Scale Parent Version Obsessive-Compulsive T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364431000000107,Revised Children's Anxiety and Depression Scale Parent Version Panic Disorder T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364441000000103,RCADS-P (Revised Children's Anxiety and Depression Scale Parent Version) Separation Anxiety T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364451000000100,RCADS-P (Revised Children's Anxiety and Depression Scale Parent Version) Social Phobia T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364461000000102,RCADS (Revised Children's Anxiety and Depression Scale) Major Depression T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364481000000106,RCADS (Revised Children's Anxiety and Depression Scale) Obsessive-Compulsive T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364491000000108,Revised Children's Anxiety and Depression Scale Panic Disorder T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364501000000102,Revised Children's Anxiety and Depression Scale Separation Anxiety T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364511000000100,Revised Children's Anxiety and Depression Scale Social Phobia T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1854961000000104,Revised Children's Anxiety and Depression Scale-25 Parent Version Total Depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1976801000000106,Revised Children's Anxiety and Depression Scale Total Anxiety and Depression T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,602001,Epidemic polyarthritis and exanthema,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,3723001,Inflammatory arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,9350004,Arthritis due to inflammatory bowel disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,9467007,Meningococcal arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,11939005,Acute arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,14175009,Arthritis due to rheumatic fever,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,16935003,Allergic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,19431000,Infective arthritis caused by Rubella virus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,19514005,Arthritis mutilans,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,20358003,Septic arthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,22193007,Osteoarthritis of joint of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,28880005,Rheumatoid arthritis with carditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,33937009,Arthritis in Lyme disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,33952002,Localised osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,34934005,Septic arthritis of multiple sites,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,35908007,Chronic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,36678001,Septic arthritis of shoulder region,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,37895003,Osteoarthritis of first carpometacarpal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,39838007,Ochronotic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,48245008,Bacterial arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,50921008,Periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,51646002,Streptococcal arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,61112000,Septic arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,61126009,Infective arthritis of multiple sites,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,65323003,Senile arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,67148009,Arthritis of great toe due to gout,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,67224007,Reactive arthritis triad,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,71299003,Salmonella arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,74391003,Pauciarticular onset juvenile chronic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,75822003,Acute juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,77888002,Menopausal arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,80813006,Haemophilic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,82300000,Osteoarthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,84172003,Spondarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,111242007,Periarthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,156370009,Psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,160413008,Family history: Rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,160414002,Family history: Osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,161567008,History of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,161568003,History of osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,171238007,Arthritis screening,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,171239004,Rheum arthritis screening test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,190920002,Hyperuricemia without signs of inflammatory arthritis and tophaceous disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,193250002,Myopathy due to rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201466005,Staphylococcal arthritis and polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201467001,Pneumococcal arthritis and polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201500003,Reactive arthritis of joint of hand due to and following dysentery,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201504007,Reactive arthritis of joint of multiple sites due to and following dysentery,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201558003,Reactive arthritis of glenohumeral joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201559006,Reactive arthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201560001,Reactive arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201561002,Reactive arthritis of joint of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201564005,Reactive arthritis of metacarpophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201567003,Reactive arthritis of joint of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201568008,Reactive arthritis of sacroiliac joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201569000,Reactive arthritis of joint of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201571000,Reactive arthritis of joint of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201572007,Reactive arthritis of subtalar joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201573002,Reactive arthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201575009,Reactive arthritis of first metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201576005,Reactive arthritis of lesser metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201577001,Reactive arthritis of interphalangeal joint of toe,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201666003,Gouty arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201667007,Gouty arthritis of pelvic region and thigh,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201669005,Gouty arthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201752004,"Arthritis associated with other disease, knee",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201764007,Rheumatoid arthritis of cervical spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201766009,Rheumatoid arthritis of shoulder,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201769002,Rheumatoid arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201771002,Rheumatoid arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201775006,Rheumatoid arthritis of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201777003,Rheumatoid arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201779000,Rheumatoid arthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201780002,Rheumatoid arthritis of subtalar joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201791009,Flare of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201805000,Juvenile arthritis in Crohn disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201819000,Generalised osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201852006,"Localised, secondary osteoarthritis of the hand",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201889009,"Osteoarthritis NOS, of the upper arm",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201890000,Wrist osteoarthritis NOS,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201891001,Thumb osteoarthritis NOS,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201893003,Knee osteoarthritis NOS,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201894009,"Osteoarthritis NOS, of ankle and foot",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201964002,Allergic arthritis of the shoulder region,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201967009,Allergic arthritis of the hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201970008,Allergic arthritis of the ankle and foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201972000,Allergic arthritis of multiple sites,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201977006,Climacteric arthritis of the shoulder region,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201980007,Climacteric arthritis of the hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201983009,Climacteric arthritis of the ankle and foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201985002,Climacteric arthritis of multiple sites,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,202031002,Generalised arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,202033004,Unspecified monoarthritis (& [coxitis]),ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,202046009,Arthritis secondary to malignancy,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,202655008,Osteoarthritis of spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,236690002,Urethritis due to reactive arthritis triad,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,236744002,Circinate balanitis co-occurrent with reactive arthritis triad,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,237876008,Arthritis secondary to amyloidosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239777004,Septic arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239778009,Septic arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239779001,Septic arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239780003,Infective arthritis caused by virus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239783001,Arthritis occurring after infection,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239785008,Reactive arthritis due to and following dysentery,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239787000,Post-tuberculous reactive arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239791005,Seropositive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239792003,Seronegative rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239796000,Juvenile arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239797009,Early onset pauciarticular chronic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239799007,Early onset polyarticular juvenile chronic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239802003,Juvenile psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239807009,Juvenile reactive arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239808004,Juvenile reactive arthritis triad,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239809007,Juvenile arthritis of inflammatory bowel disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239814006,Seronegative arthritis secondary to inflammatory bowel disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239819001,Undifferentiated oligoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239820007,Undifferentiated monoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239821006,Secondary inflammatory arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239828000,Basic calcium phosphate arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239831004,Calcific periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239834007,Pyrophosphate arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239835008,Idiopathic pyrophosphate arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239836009,Secondary pyrophosphate arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239842008,Monosodium urate arthritis and periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239849004,Intra-articular steroid-induced arthritis and periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239851000,Cholesterol-related arthritis and periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239863005,Osteoarthritis of spinal facet joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239866002,Osteoarthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239868001,Osteoarthritis of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239874001,Osteoarthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239878003,Osteoarthritis of toe joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267878000,Septic arthritis of upper arm,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267879008,Pyogenic arthritis of the forearm,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267880006,Septic arthritis of the pelvic region and thigh,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267881005,Septic arthritis of lower leg,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267882003,Septic arthritis of the ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267889007,Generalized osteoarthritis of the hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,268054009,Osteoarthritis of multiple joints,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,274135002,Arthritis/arthrosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,275134007,Family history: Arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,275554004,History of arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,275902004,Rheumatoid arthritis monitoring,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,275920008,Arthritis monitoring,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,276653007,Parvovirus arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,287006005,Rheumatoid arthritis of multiple joints,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,287007001,Rheumatoid arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,300028009,Drainage of septic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,308143008,Seropositive erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,313257005,"Localized, primary osteoarthritis of the wrist",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,313258000,"Localised, primary osteoarthritis of toe",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,313259008,"Localized, primary osteoarthritis of elbow",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,361198004,Arthritis secondary to sarcoidosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,371081002,Arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,372939007,Pyogenic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,372941008,Septic arthritis of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,373623009,Osteoarthritis of glenohumeral joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,394991004,Flare of osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,396234004,Septic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,399112009,Seronegative arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,399114005,Duplay's periarthritis syndrome,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,399923009,Rheumatoid arthritis with arteritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,400054000,Rheumatoid arthritis with vasculitis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410502007,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410793008,Chronic arthritis of juvenile onset,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410795001,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410797009,"Juvenile chronic arthritis, polyarticular seronegative",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,416956002,Undifferentiated inflammatory polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,417180005,Undifferentiated inflammatory arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,417373000,Inflammatory polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,422565003,Post-infective polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,423515003,Post-infective arthritis of joint of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,429192004,Rheumatoid arthritis of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,429459001,Arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,431956005,Suspected inflammatory arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,439656005,Arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,443524000,Secondary osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,446478005,AIMS (arthritis impact measurement scale) score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,448394006,Arthritis of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,450521003,Osteoarthritis of patellofemoral joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,698475006,Monoarthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,699462004,Monoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,700324005,Osteoarthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,723116002,Axial spondyloarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,724606001,Peripheral spondyloarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,735599007,Rheumatoid arthritis with erosion of joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1162304008,Oligoarticular osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1303835007,Arthritis of shoulder region joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1343601009,OA (osteoarthritis) of spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1343603007,Osteoarthritis of thoracic spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1343604001,Cervical osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1343605000,Osteoarthritis of lumbar spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1771000119109,Arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,6011000119108,Transient arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,143441000119108,Rheumatoid arthritis in remission,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,323301000119109,Osteoarthritis of left knee joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,323311000119107,Osteoarthritis of right hip joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,666451000000100,"Osteoarthritis NOS, other specified site",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,847261000000104,Rheumatoid arthritis annual review,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,850791000000102,Osteoarthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1016811000000108,Rheumatoid arthritis screening test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1029271000000101,Rheumatoid arthritis latex test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1073781000119104,Rheumatoid arthritis of right foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1073791000119101,Rheumatoid arthritis of right hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1074801000119103,Arthritis of carpometacarpal joint of left thumb,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1074881000119106,Arthritis of left ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,12236561000119100,Arthritis of finger of left hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,12236601000119100,Arthritis of finger of right hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Plaque psoriasis in children and young people,TA455,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402307000,Chronic large plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402310007,Chronic stable plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,9014002,Psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,16341002,Parapsoriasis lichenoides,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,25847004,Sebopsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,37042000,Guttate psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,38360005,Acute generalized pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,81271001,Localised pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,88233000,Parapsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,160408009,Family history: Psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,161562002,History of psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200962007,Psoriasis annularis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200963002,Psoriasis circinata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200964008,Psoriasis diffusa,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200965009,Discoid psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200966005,Psoriasis geographica,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200967001,Psoriasis gyrata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200968006,Psoriasis inveterata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200969003,Ostraceous psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200970002,Psoriasis palmaris,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200971003,Psoriasis plantaris,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200972005,Psoriasis punctata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200973000,Pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200974006,Psoriasis universalis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200977004,Exfoliative psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200982006,Parapsoriasis herpetiformis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200983001,Parapsoriasis en gouttes,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200984007,Parapsoriasis papulata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,200985008,Parapsoriasis varioliformis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238600001,Inverse psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238601002,Unstable psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238602009,Eczematous psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238603004,Eczematised psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238608008,Psoriasis of scalp,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238609000,Kobner psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238612002,Acute generalized pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238614001,Pustular psoriasis in children,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,238617008,Circinate and annular pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,239803008,Juvenile psoriatic arthritis with psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,267851002,Parapsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,402307000,Chronic large plaque psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,402310007,Chronic stable plaque psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,430543001,Family history of psoriasis with psoriatic arthritis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,845091000000108,Education for psoriasis care,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,866311000000102,PASI - psoriasis area and severity index,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,866341000000101,PASI (psoriasis area and severity index) score,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriasis,TA103,psoriasis,1853821000000104,Psoriasis Epidemiology Screening Tool total score,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,156370009,Psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,156370009,Psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +ETANERCEPT,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +ETANERCEPT,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,36348003,Primary hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY +ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,66999008,Hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY +ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,78200003,Tertiary hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY +ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,91478007,Secondary hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY +ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,203471008,Brown tumour of hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY +ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,237653008,Familial hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,22193007,Osteoarthritis of joint of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,33952002,Localised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,37895003,Osteoarthritis of first carpometacarpal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,82300000,Osteoarthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,160414002,Family history: Osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,161568003,History of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201819000,Generalised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201852006,"Localised, secondary osteoarthritis of the hand",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201889009,"Osteoarthritis NOS, of the upper arm",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201890000,Wrist osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201891001,Thumb osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201893003,Knee osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201894009,"Osteoarthritis NOS, of ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,202655008,Osteoarthritis of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239863005,Osteoarthritis of spinal facet joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239866002,Osteoarthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239868001,Osteoarthritis of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239874001,Osteoarthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239878003,Osteoarthritis of toe joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267889007,Generalized osteoarthritis of the hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,268054009,Osteoarthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313257005,"Localized, primary osteoarthritis of the wrist",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313258000,"Localised, primary osteoarthritis of toe",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313259008,"Localized, primary osteoarthritis of elbow",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,373623009,Osteoarthritis of glenohumeral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,394991004,Flare of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,443524000,Secondary osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,450521003,Osteoarthritis of patellofemoral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,700324005,Osteoarthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1162304008,Oligoarticular osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343601009,OA (osteoarthritis) of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343603007,Osteoarthritis of thoracic spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343604001,Cervical osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343605000,Osteoarthritis of lumbar spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323301000119109,Osteoarthritis of left knee joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323311000119107,Osteoarthritis of right hip joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666451000000100,"Osteoarthritis NOS, other specified site",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,850791000000102,Osteoarthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,733608000,Papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,733608000,Papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,48554007,Enterochromaffin cell neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,60346004,Non-functioning pancreatic neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,707594002,Bronchial neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,1287573002,Well-differentiated neuroendocrine tumour of bronchus,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,1290068000,Well-differentiated neuroendocrine tumour of rectum,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,134405005,Suspected breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,160287004,FH: Breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,268547008,Screening for breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,429740004,Family history of breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,431330007,Family history of breast cancer 1 gene mutation,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,431331006,Family history of breast cancer 2 gene mutation,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,706970001,TNBC - Triple-negative breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,94361000000105,Breast cancer detected by national screening programme,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,276341000000100,Fast track referral for suspected breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,838351000000107,Education about risk of breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,874291000000100,QCancer breast cancer risk,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,1035841000000108,Lymphoedema following breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,134405005,Suspected breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,160287004,FH: Breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,268547008,Screening for breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,429740004,Family history of breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,431330007,Family history of breast cancer 1 gene mutation,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,431331006,Family history of breast cancer 2 gene mutation,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,706970001,TNBC - Triple-negative breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,94361000000105,Breast cancer detected by national screening programme,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,276341000000100,Fast track referral for suspected breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,838351000000107,Education about risk of breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,874291000000100,QCancer breast cancer risk,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,1035841000000108,Lymphoedema following breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EVOLOCUMAB,Treating primary hypercholesterolaemia and mixed dyslipidaemia,TA394,primary hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EVOLOCUMAB,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,134405005,Suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,160287004,FH: Breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,268547008,Screening for breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,429740004,Family history of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,706970001,TNBC - Triple-negative breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,94361000000105,Breast cancer detected by national screening programme,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,838351000000107,Education about risk of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,874291000000100,QCancer breast cancer risk,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +EXEMESTANE,Breast cancer (early),TA112,breast cancer,1035841000000108,Lymphoedema following breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,13644009,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,160314003,Family history: Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238079002,Familial hypercholesterolaemia - heterozygous,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238081000,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B-100,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,267432004,Pure hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,267500001,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,398036000,Familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,403831006,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,767133009,Compound heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,149601000000102,Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,149611000000100,Simon Broome diagnostic criteria for familial hypercholesterolaemia result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,163841000237109,Familial hypercholesterolaemia comprehensive genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,163851000237107,Familial hypercholesterolaemia targeted genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,204931000237105,Genetic variant causing familial hypercholesterolaemia not detected,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,513831000000107,Possible heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,519851000000103,Assessment using Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,804641000000101,Dietary surveillance in hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,858671000000107,No FH of hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,867261000000106,Probable familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,872541000000104,Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia score,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,925211000000100,Familial hypercholesterolaemia targeted genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,925221000000106,Familial hypercholesterolaemia comprehensive genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1326181000000100,Assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1326191000000103,Referral for assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1363961000000109,H/O secondary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1365251000000103,Referral for assessment for familial hypercholesterolaemia refused,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,13644009,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,160314003,Family history: Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238079002,Familial hypercholesterolaemia - heterozygous,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238081000,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B-100,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,267432004,Pure hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,267500001,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,398036000,Familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,403831006,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,767133009,Compound heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,149601000000102,Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,149611000000100,Simon Broome diagnostic criteria for familial hypercholesterolaemia result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,163841000237109,Familial hypercholesterolaemia comprehensive genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,163851000237107,Familial hypercholesterolaemia targeted genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,204931000237105,Genetic variant causing familial hypercholesterolaemia not detected,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,513831000000107,Possible heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,519851000000103,Assessment using Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,804641000000101,Dietary surveillance in hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,858671000000107,No FH of hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,867261000000106,Probable familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,872541000000104,Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia score,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,925211000000100,Familial hypercholesterolaemia targeted genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,925221000000106,Familial hypercholesterolaemia comprehensive genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1326181000000100,Assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1326191000000103,Referral for assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1363961000000109,H/O secondary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1365251000000103,Referral for assessment for familial hypercholesterolaemia refused,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,13644009,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,160314003,Family history: Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238079002,Familial hypercholesterolaemia - heterozygous,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238081000,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B-100,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,267432004,Pure hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,267500001,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,398036000,Familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,403831006,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,767133009,Compound heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,149601000000102,Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,149611000000100,Simon Broome diagnostic criteria for familial hypercholesterolaemia result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,163841000237109,Familial hypercholesterolaemia comprehensive genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,163851000237107,Familial hypercholesterolaemia targeted genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,204931000237105,Genetic variant causing familial hypercholesterolaemia not detected,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,513831000000107,Possible heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,519851000000103,Assessment using Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,804641000000101,Dietary surveillance in hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,858671000000107,No FH of hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,867261000000106,Probable familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,872541000000104,Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia score,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,925211000000100,Familial hypercholesterolaemia targeted genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,925221000000106,Familial hypercholesterolaemia comprehensive genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1326181000000100,Assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1326191000000103,Referral for assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1363961000000109,H/O secondary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1365251000000103,Referral for assessment for familial hypercholesterolaemia refused,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,13644009,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,160314003,Family history: Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238079002,Familial hypercholesterolaemia - heterozygous,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238081000,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B-100,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,267432004,Pure hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,267500001,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,398036000,Familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,403831006,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,767133009,Compound heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,149601000000102,Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,149611000000100,Simon Broome diagnostic criteria for familial hypercholesterolaemia result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,163841000237109,Familial hypercholesterolaemia comprehensive genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,163851000237107,Familial hypercholesterolaemia targeted genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,204931000237105,Genetic variant causing familial hypercholesterolaemia not detected,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,513831000000107,Possible heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,519851000000103,Assessment using Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,804641000000101,Dietary surveillance in hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,858671000000107,No FH of hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,867261000000106,Probable familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,872541000000104,Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia score,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,925211000000100,Familial hypercholesterolaemia targeted genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,925221000000106,Familial hypercholesterolaemia comprehensive genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1326181000000100,Assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1326191000000103,Referral for assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1363961000000109,H/O secondary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1365251000000103,Referral for assessment for familial hypercholesterolaemia refused,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY +FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,193384000,Senile macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,267718000,Age-related macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,312898002,Myopic macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,1296526000,Disciform macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,9386003,Gouty neuritis,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,14763005,Gouty tophus of pinna,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,24595009,Idiopathic gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,27277001,Tophus of heart co-occurrent and due to gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,43193009,Gouty iritis,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,48440001,Gouty arthropathy,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,67148009,Arthritis of great toe due to gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,90560007,Gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,160308005,Family history: Gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,161451004,History of gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170730005,Gout monitoring,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170731009,Initial gout assessment,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170732002,Follow-up gout assessment,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170733007,Joints gout affected,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170735000,Date gout treatment started,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170736004,Date of last gout attack,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170737008,Gout associated problem,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170738003,Gout drug side effect,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170739006,Gout treatment changed,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170740008,Date gout treatment stopped,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,171190009,Gout screening,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,190828008,Gouty arthropathy,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,190829000,Gouty nephropathy,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,190842000,Chronic tophaceous gout of hand,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,200983001,Parapsoriasis en gouttes,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201663006,Articular gout of shoulder region,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201666003,Gouty arthritis of hand,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201667007,Gouty arthritis of pelvic region and thigh,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201669005,Gouty arthritis of ankle and/or foot,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201670006,Articular gout of multiple joints,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,230312006,Aicardi Goutieres syndrome,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,239843003,Secondary gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,239844009,Gout secondary to renal impairment,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,239845005,Gout secondary to drug,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,239848007,Gouty bursitis,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,243859006,Gout monitoring status,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,268142006,Pseudogout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,281362006,Gouty tophus of bursa,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,281363001,Tophus of tendon co-occurrent and due to gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,281364007,Gouty tophus of olecranon bursa,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,281365008,Gouty tophus of prepatellar bursa,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,292671009,Drug for the treatment of gout adverse reaction,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,402469004,Gouty tophus,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,428839004,Articular gout of toe,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,770924008,Gout attack,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,427211000000108,[V]Screening for gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,924311000000106,Acute exacerbation of gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,1033961000000104,Gouty tophi of toe,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY +FEDRATINIB,Disease-related splenomegaly or symptoms in myelofibrosis,TA756,myelofibrosis,80570006,Acute panmyelosis with myelofibrosis,FEDRATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +FENFLURAMINE,Treating seizures associated with Dravet syndrome,TA808,dravet syndrome,230437002,Dravet Syndrome,FENFLURAMINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,64766004,UC - ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,160383003,FH: Ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,275129008,Family history of ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,275549008,History of ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,445243001,Left sided ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,161567008,History of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,161567008,History of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,161567008,History of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,161567008,History of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,24700007,Multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,160337009,Family history of multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,192926004,Brain stem multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,192928003,Generalised multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,428700003,Primary progressive multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,438511000,Benign multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,700409000,Suspected multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,198491000000106,Multiple sclerosis review,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,515931000000104,Multiple sclerosis review declined,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,17788007,Acute non-lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,22197008,Burkitt cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,24072005,Blast cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,28950004,Acute promyelocytic leukaemia with,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,32280000,Lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,37810007,Monocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,69077002,Acute basophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,87163000,Leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,91857003,Acute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,91861009,"Acute myeloid leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,92811003,Chronic leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,92812005,"Chronic leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,92817004,Chronic myeloid leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,93142004,Leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,110002002,Mast cell leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,110006004,Prolymphocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128831004,Chronic myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128922003,"Plasma cell leukaemia, morphology",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128931003,Leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128933000,Chronic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128935007,Lymphoid leukaemia (category),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,160292002,Family history: leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,161436008,History of leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188726003,Subacute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188732008,Myeloid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188733003,Chronic eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188734009,Chronic neutrophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188768003,Myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,190055003,Eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277568007,Hairy cell leukaemia variant,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277569004,Large granular lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277602003,Acute megakaryoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,315262009,Suspected leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,413440007,Acute lymphoblastic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,634651000000103,Other specified leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,17788007,Acute non-lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,22197008,Burkitt cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,24072005,Blast cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,28950004,Acute promyelocytic leukaemia with,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,32280000,Lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,37810007,Monocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,69077002,Acute basophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,87163000,Leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,91857003,Acute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,91861009,"Acute myeloid leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92811003,Chronic leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92812005,"Chronic leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92817004,Chronic myeloid leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,93142004,Leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110002002,Mast cell leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110006004,Prolymphocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128831004,Chronic myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128922003,"Plasma cell leukaemia, morphology",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128931003,Leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128933000,Chronic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128935007,Lymphoid leukaemia (category),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,160292002,Family history: leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,161436008,History of leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188726003,Subacute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188732008,Myeloid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188733003,Chronic eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188734009,Chronic neutrophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188768003,Myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,190055003,Eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277568007,Hairy cell leukaemia variant,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277569004,Large granular lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277602003,Acute megakaryoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,315262009,Suspected leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,413440007,Acute lymphoblastic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,634651000000103,Other specified leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,17788007,Acute non-lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,22197008,Burkitt cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,24072005,Blast cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,28950004,Acute promyelocytic leukaemia with,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,32280000,Lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,37810007,Monocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,69077002,Acute basophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,87163000,Leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,91857003,Acute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,91861009,"Acute myeloid leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92811003,Chronic leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92812005,"Chronic leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92817004,Chronic myeloid leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,93142004,Leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110002002,Mast cell leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110006004,Prolymphocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128831004,Chronic myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128922003,"Plasma cell leukaemia, morphology",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128931003,Leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128933000,Chronic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128935007,Lymphoid leukaemia (category),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,160292002,Family history: leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,161436008,History of leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188726003,Subacute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188732008,Myeloid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188733003,Chronic eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188734009,Chronic neutrophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188768003,Myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,190055003,Eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277568007,Hairy cell leukaemia variant,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277569004,Large granular lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277602003,Acute megakaryoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,315262009,Suspected leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,413440007,Acute lymphoblastic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,634651000000103,Other specified leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,4927003,Acute anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,11226001,Fuchs uveitis syndrome,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,43363007,Posterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,75614007,Panuveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,89114005,Infectious anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,95707009,Phacotoxic uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,267619000,Non-infectious anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,312922007,Uveitis related cystoid macular oedema,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,314029000,Tuberculous uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,314030005,Post-traumatic uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,314033007,Secondary open-angle glaucoma with uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,314493000,Postoperative uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,370506009,Keratouveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,398155003,Chronic anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,410494003,Phacoantigenic uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,410692006,Anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,342151000119100,Acute anterior uveitis of left eye,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY +FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA759,immune thrombocytopenia,2897005,ITP - immune thrombocytopenia,FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA835,immune thrombocytopenia,2897005,ITP - immune thrombocytopenia,FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA759,immune thrombocytopenia,128091003,Primary ITP (immune thrombocytopenia),FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA835,immune thrombocytopenia,128091003,Primary ITP (immune thrombocytopenia),FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA759,immune thrombocytopenia,240305000,NAIT - neonatal alloimmune thrombocytopenia,FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA835,immune thrombocytopenia,240305000,NAIT - neonatal alloimmune thrombocytopenia,FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,4473006,Classical migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,23186000,Menstrual migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,37796009,Migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,56097005,Migraine without aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,59292006,Hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,75879005,Decapitated migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,79267007,Retinal migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,83351003,Basilar artery migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,95655001,Ocular migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,95656000,Familial hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,160342001,Family history of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,161481007,History of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,162040008,Abdominal migraine - symptom,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,193030005,Migraine variants,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,193039006,Complex migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,230462002,Migraine with typical aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,230464001,Sporadic hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,230465000,Migraine aura without headache,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,230468003,Migraine with ischaemic complication,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,232284007,Vestibular migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,394707001,No history of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,408381007,Migraine prophylaxis,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,427419006,Chronic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,608837004,History of migraine with aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,124171000119105,Chronic intractable migraine without aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Preventing migraine,TA764,migraine,781381000000100,Migraine induced by oestrogen contraceptive,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,4473006,Classical migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,23186000,Menstrual migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,37796009,Migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,56097005,Migraine without aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,59292006,Hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,75879005,Decapitated migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,79267007,Retinal migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,83351003,Basilar artery migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,95655001,Ocular migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,95656000,Familial hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,160342001,Family history of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,161481007,History of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,162040008,Abdominal migraine - symptom,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,193030005,Migraine variants,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,193039006,Complex migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,230462002,Migraine with typical aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,230464001,Sporadic hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,230465000,Migraine aura without headache,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,230468003,Migraine with ischaemic complication,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,232284007,Vestibular migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,394707001,No history of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,408381007,Migraine prophylaxis,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,427419006,Chronic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,608837004,History of migraine with aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,124171000119105,Chronic intractable migraine without aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,781381000000100,Migraine induced by oestrogen contraceptive,FREMANEZUMAB,NEUROLOGY,NEUROLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,134405005,Suspected breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,160287004,FH: Breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,268547008,Screening for breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,429740004,Family history of breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,431330007,Family history of breast cancer 1 gene mutation,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,431331006,Family history of breast cancer 2 gene mutation,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,706970001,TNBC - Triple-negative breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,94361000000105,Breast cancer detected by national screening programme,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,276341000000100,Fast track referral for suspected breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,838351000000107,Education about risk of breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,874291000000100,QCancer breast cancer risk,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,1035841000000108,Lymphoedema following breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,134405005,Suspected breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,160287004,FH: Breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,268547008,Screening for breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,429740004,Family history of breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,431330007,Family history of breast cancer 1 gene mutation,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,431331006,Family history of breast cancer 2 gene mutation,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,706970001,TNBC - Triple-negative breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,94361000000105,Breast cancer detected by national screening programme,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,276341000000100,Fast track referral for suspected breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,838351000000107,Education about risk of breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,874291000000100,QCancer breast cancer risk,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,1035841000000108,Lymphoedema following breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GABAPENTIN,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +GALANTAMINE,Alzheimer's disease,TA019,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease,TA111,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease,TA019,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease,TA111,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease,TA019,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease,TA111,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease,TA019,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease,TA111,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALANTAMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +GALCANEZUMAB,Preventing migraine,TA659,migraine,4473006,Classical migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,23186000,Menstrual migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,37796009,Migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,56097005,Migraine without aura,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,59292006,Hemiplegic migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,75879005,Decapitated migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,79267007,Retinal migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,83351003,Basilar artery migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,95655001,Ocular migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,95656000,Familial hemiplegic migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,160342001,Family history of migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,161481007,History of migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,162040008,Abdominal migraine - symptom,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,193030005,Migraine variants,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,193039006,Complex migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,230462002,Migraine with typical aura,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,230464001,Sporadic hemiplegic migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,230465000,Migraine aura without headache,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,230468003,Migraine with ischaemic complication,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,232284007,Vestibular migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,394707001,No history of migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,408381007,Migraine prophylaxis,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,427419006,Chronic migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,608837004,History of migraine with aura,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,124171000119105,Chronic intractable migraine without aura,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GALCANEZUMAB,Preventing migraine,TA659,migraine,781381000000100,Migraine induced by oestrogen contraceptive,GALCANEZUMAB,NEUROLOGY,NEUROLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,162573006,Suspected lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,254637007,Non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,275981009,Lung cancer screening,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,429011007,Family history of lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,877691000000107,No FH of lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,162573006,Suspected lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,254637007,Non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,275981009,Lung cancer screening,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,429011007,Family history of lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,723301009,Squamous non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1259727001,Primary non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,276491000000101,Fast track referral for suspected lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,848881000000108,QCancer lung cancer risk,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,877691000000107,No FH of lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1771781000000107,Did not attend lung cancer screening,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,134405005,Suspected breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,160287004,FH: Breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,268547008,Screening for breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,429740004,Family history of breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,431330007,Family history of breast cancer 1 gene mutation,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,431331006,Family history of breast cancer 2 gene mutation,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,706970001,TNBC - Triple-negative breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,94361000000105,Breast cancer detected by national screening programme,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,276341000000100,Fast track referral for suspected breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,838351000000107,Education about risk of breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,874291000000100,QCancer breast cancer risk,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE,Breast cancer,TA116,breast cancer,1035841000000108,Lymphoedema following breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +GEMCITABINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,254637007,Non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEMCITABINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEMCITABINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEMCITABINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +GEMCITABINE (1ST LINE),Pancreatic cancer,TA025,pancreatic cancer,429000004,Family history of pancreatic cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +GEMCITABINE (1ST LINE),Pancreatic cancer,TA025,pancreatic cancer,247591000000101,Suspected pancreatic cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +GEMCITABINE (1ST LINE),Pancreatic cancer,TA025,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +GEMCITABINE (2ND LINE),Pancreatic cancer,TA025,pancreatic cancer,429000004,Family history of pancreatic cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +GEMCITABINE (2ND LINE),Pancreatic cancer,TA025,pancreatic cancer,247591000000101,Suspected pancreatic cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +GEMCITABINE (2ND LINE),Pancreatic cancer,TA025,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +GEMCITABINE IN COMBINATION WITH CARBOPLATIN,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +GEMCITABINE IN COMBINATION WITH CARBOPLATIN,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +GEMCITABINE IN COMBINATION WITH CARBOPLATIN,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +GEMCITABINE IN COMBINATION WITH CARBOPLATIN,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +GEMTUZUMAB OZOGAMICIN WITH DAUNORUBICIN AND CYTARABINE,Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above,TA545,acute promyelocytic leukaemia,28950004,Acute promyelocytic leukaemia with,GEMTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +GEMTUZUMAB OZOGAMICIN WITH DAUNORUBICIN AND CYTARABINE,Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above,TA545,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",GEMTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +GEMTUZUMAB OZOGAMICIN WITH DAUNORUBICIN AND CYTARABINE,Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above,TA545,acute promyelocytic leukaemia,110004001,Acute promyelocytic leukaemia (clinical),GEMTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +GILTERITINIB,Relapsed or refractory acute myeloid leukaemia,TA642,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",GILTERITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +GLASDEGIB,Untreated acute myeloid leukaemia,TA646,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",GLASDEGIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,24700007,Multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,24700007,Multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,160337009,Family history of multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,160337009,Family history of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,192926004,Brain stem multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,192926004,Brain stem multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,192928003,Generalised multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,192928003,Generalised multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,428700003,Primary progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,428700003,Primary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,438511000,Benign multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,438511000,Benign multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,700409000,Suspected multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,700409000,Suspected multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,198491000000106,Multiple sclerosis review,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,198491000000106,Multiple sclerosis review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,515931000000104,Multiple sclerosis review declined,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,515931000000104,Multiple sclerosis review declined,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION +GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,62944002,Hepatitis C virus,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,62944002,Hepatitis C virus,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,72165005,Hepatitis C virus antibody,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,72165005,Hepatitis C virus antibody,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,170489004,Viral hepatitis carrier,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,170489004,Viral hepatitis carrier,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,197344005,Hepatitis caused by adenovirus,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,197344005,Hepatitis caused by adenovirus,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,235872006,Hepatitis C carrier,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,235872006,Hepatitis C carrier,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278973007,Hepatitis C status,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278973007,Hepatitis C status,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278974001,Hepatitis C immune,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278974001,Hepatitis C immune,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278975000,Hepatitis C non-immune,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278975000,Hepatitis C non-immune,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,314706002,Hepatitis C antibody detected,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,314706002,Hepatitis C antibody detected,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,314707006,Hepatitis C antibody test negative,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,314707006,Hepatitis C antibody test negative,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,413107006,Hepatitis C screening,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,413107006,Hepatitis C screening,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,773113008,Acute hepatitis caused by infection,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,773113008,Acute hepatitis caused by infection,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,12891000175105,Hepatitis C screening declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,12891000175105,Hepatitis C screening declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,200371000000104,Hepatitis C contact,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,200371000000104,Hepatitis C contact,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,201451000000105,Hepatitis C immunisation declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,201451000000105,Hepatitis C immunisation declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,202281000000105,Hepatitis C screening declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,202281000000105,Hepatitis C screening declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,204671000000101,Hepatitis C screening counselling,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,204671000000101,Hepatitis C screening counselling,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,304821000000107,Hepatitis C screening not offered,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,304821000000107,Hepatitis C screening not offered,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,362491000000104,Hepatitis C screening negative,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,362491000000104,Hepatitis C screening negative,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,362751000000101,Hepatitis C screening positive,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,362751000000101,Hepatitis C screening positive,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,761381000000102,Hepatitis C resolved,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,761381000000102,Hepatitis C resolved,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,824841000000105,Hepatitis C genotype 1,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,824841000000105,Hepatitis C genotype 1,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,824871000000104,Hepatitis C genotype 3,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,824871000000104,Hepatitis C genotype 3,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,829731000000106,On hepatitis C treatment plan,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,829731000000106,On hepatitis C treatment plan,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,992751000000109,Hepatitis C viral load,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,992751000000109,Hepatitis C viral load,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,992771000000100,Hepatitis C virus genotype,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,992771000000100,Hepatitis C virus genotype,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,996031000000104,Hepatitis C IgG level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,996031000000104,Hepatitis C IgG level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,998771000000103,Hepatitis C antibody level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,998771000000103,Hepatitis C antibody level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1001331000000102,Hepatitis C antigen level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1001331000000102,Hepatitis C antigen level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1008931000000108,Hepatitis C antibody test,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1008931000000108,Hepatitis C antibody test,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1107671000000106,Hepatitis C screening offered,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1107671000000106,Hepatitis C screening offered,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,161567008,History of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB,Non-radiographic axial spondyloarthritis,TA497,axial spondyloarthritis,723116002,Axial spondyloarthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,156370009,Psoriatic arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,161567008,History of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,161567008,History of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,156370009,Psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,156370009,Psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +GUSELKUMAB,Moderate to severe plaque psoriasis,TA521,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),GUSELKUMAB,DERMATOLOGY,DERMATOLOGY +GUSELKUMAB,Moderate to severe plaque psoriasis,TA521,plaque psoriasis,402307000,Chronic large plaque psoriasis,GUSELKUMAB,DERMATOLOGY,DERMATOLOGY +GUSELKUMAB,Moderate to severe plaque psoriasis,TA521,plaque psoriasis,402310007,Chronic stable plaque psoriasis,GUSELKUMAB,DERMATOLOGY,DERMATOLOGY +HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HIGH-DOSE IMATINIB,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,TA425,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +IBRUTINIB,Relapsed or refractory mantle cell lymphoma,TA502,mantle cell lymphoma,74654000,Mantle cell lymphoma,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IBRUTINIB,Relapsed or refractory mantle cell lymphoma,TA502,mantle cell lymphoma,443487006,Mantle cell lymphoma,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IBRUTINIB,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,TA452,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,TA452,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,TA452,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,TA452,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB ALONE,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,TA429,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB ALONE,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,TA429,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB ALONE,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,TA429,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB ALONE,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,TA429,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH BENDAMUSTINE AND RITUXIMAB,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy,TA437,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH BENDAMUSTINE AND RITUXIMAB,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy,TA437,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH BENDAMUSTINE AND RITUXIMAB,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy,TA437,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH BENDAMUSTINE AND RITUXIMAB,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy,TA437,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma,TA702,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma,TA702,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma,TA702,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma,TA702,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH RITUXIMAB,Untreated chronic lymphocytic leukaemia,TA703,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH RITUXIMAB,Untreated chronic lymphocytic leukaemia,TA703,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH RITUXIMAB,Untreated chronic lymphocytic leukaemia,TA703,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IBRUTINIB WITH RITUXIMAB,Untreated chronic lymphocytic leukaemia,TA703,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,109962001,Nonfollicular lymphoma,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,308121000,Follicular lymphoma,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,721555001,Follicular lymphoma of small intestine,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,109962001,Nonfollicular lymphoma,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,308121000,Follicular lymphoma,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,721555001,Follicular lymphoma of small intestine,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IDELALISIB IN COMBINATION WITH RITUXIMAB,Treating chronic lymphocytic leukaemia,TA359,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IDELALISIB IN COMBINATION WITH RITUXIMAB,Treating chronic lymphocytic leukaemia,TA359,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IDELALISIB IN COMBINATION WITH RITUXIMAB,Treating chronic lymphocytic leukaemia,TA359,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IDELALISIB IN COMBINATION WITH RITUXIMAB,Treating chronic lymphocytic leukaemia,TA359,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IDELALISIB WITH OFATUMUMAB,Chronic lymphocytic leukaemia,TA469,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IDELALISIB WITH OFATUMUMAB,Chronic lymphocytic leukaemia,TA469,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IDELALISIB WITH OFATUMUMAB,Chronic lymphocytic leukaemia,TA469,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IDELALISIB WITH OFATUMUMAB,Chronic lymphocytic leukaemia,TA469,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,17788007,Acute non-lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,17788007,Acute non-lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,22197008,Burkitt cell leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,22197008,Burkitt cell leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,24072005,Blast cell leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,24072005,Blast cell leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,28950004,Acute promyelocytic leukaemia with,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,28950004,Acute promyelocytic leukaemia with,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,32280000,Lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,32280000,Lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,37810007,Monocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,37810007,Monocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,69077002,Acute basophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,69077002,Acute basophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,87163000,Leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,87163000,Leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,91857003,Acute lymphoid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,91857003,Acute lymphoid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,91861009,"Acute myeloid leukaemia, disease",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,91861009,"Acute myeloid leukaemia, disease",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,92811003,Chronic leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,92811003,Chronic leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,92812005,"Chronic leukaemia, disease",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,92812005,"Chronic leukaemia, disease",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,92817004,Chronic myeloid leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,92817004,Chronic myeloid leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,93142004,Leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,93142004,Leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,110002002,Mast cell leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,110002002,Mast cell leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,110006004,Prolymphocytic leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,110006004,Prolymphocytic leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,128831004,Chronic myelomonocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,128831004,Chronic myelomonocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,128922003,"Plasma cell leukaemia, morphology",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,128922003,"Plasma cell leukaemia, morphology",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,128931003,Leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,128931003,Leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,128933000,Chronic leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,128933000,Chronic leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,128935007,Lymphoid leukaemia (category),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,128935007,Lymphoid leukaemia (category),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,160292002,Family history: leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,160292002,Family history: leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,161436008,History of leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,161436008,History of leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,188726003,Subacute lymphoid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,188726003,Subacute lymphoid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,188732008,Myeloid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,188732008,Myeloid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,188733003,Chronic eosinophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,188733003,Chronic eosinophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,188734009,Chronic neutrophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,188734009,Chronic neutrophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,188768003,Myelomonocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,188768003,Myelomonocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,190055003,Eosinophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,190055003,Eosinophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,277568007,Hairy cell leukaemia variant,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,277568007,Hairy cell leukaemia variant,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,277569004,Large granular lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,277569004,Large granular lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,277602003,Acute megakaryoblastic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,277602003,Acute megakaryoblastic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,315262009,Suspected leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,315262009,Suspected leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,413440007,Acute lymphoblastic leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,413440007,Acute lymphoblastic leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,634651000000103,Other specified leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,634651000000103,Other specified leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA050,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Leukaemia (CML),TA070,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IMATINIB,Untreated chronic myeloid leukaemia,TA426,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,171234009,Chronic kidney disease screening,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,431855005,Chronic kidney disease stage 1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,431856006,Chronic kidney disease stage 2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,431857002,Chronic kidney disease stage 4,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,433144002,Chronic kidney disease stage 3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,433146000,Chronic kidney disease stage 5,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,472953006,H/O chronic kidney disease,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,698463001,At increased risk of chronic kidney disease,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,700378005,Chronic kidney disease stage 3A,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,700379002,Chronic kidney disease stage 3B,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,709044004,Chronic kidney disease,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,714152005,Chronic kidney disease 5d,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,248721000000108,Chronic kidney disease monitoring,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,249171000000102,Chronic kidney disease annual review,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,249311000000109,Predicted stage chronic kidney disease,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,298141000000107,Did not attend chronic kidney disease monitoring clinic,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324121000000109,CKD (chronic kidney disease stage) 1 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324151000000104,CKD (chronic kidney disease) stage 1 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324181000000105,CKD (chronic kidney disease) stage 2 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324211000000106,CKD (chronic kidney disease) stage 2 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324251000000105,CKD (chronic kidney disease) stage 3 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324281000000104,CKD (chronic kidney disease) stage 3 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324311000000101,CKD (chronic kidney disease) stage 3A with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324341000000100,CKD (chronic kidney disease) stage 3A without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324371000000106,CKD (chronic kidney disease) stage 3B with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324411000000105,CKD (chronic kidney disease) stage 3B without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324441000000106,CKD (chronic kidney disease) stage 4 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324471000000100,CKD (chronic kidney disease) stage 4 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324501000000107,CKD (chronic kidney disease) stage 5 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324541000000105,CKD (chronic kidney disease) stage 5 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,711421000000107,Chronic kidney disease monitoring invitation,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,713811000000100,Chronic kidney disease monitoring administration,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,716651000000106,Chronic kidney disease monitoring first letter,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,716881000000104,Excepted from chronic kidney disease quality indicators - informed dissent,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,716891000000102,Excepted from chronic kidney disease quality indicators - patient unsuitable,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717231000000104,Chronic kidney disease monitoring verbal invite,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717361000000100,Exception reporting - chronic kidney disease quality indicators,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717461000000108,Chronic kidney disease monitoring third letter,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717511000000105,Chronic kidney disease monitoring telephone invite,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717751000000104,Chronic kidney disease monitoring second letter,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,811021000000104,Chronic kidney disease self-management plan review,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,811941000000105,Chronic kidney disease self-management plan agreed,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,857971000000104,Estimated glomerular filtration rate using Chronic Kidney Disease Epidemiology Collaboration formula,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,903261000000109,Chronic kidney disease laboratory study,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,939211000000104,Chronic kidney disease resolved,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949401000000103,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949421000000107,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949481000000108,CKD G1A3 - chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949521000000108,CKD G2A1 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949561000000100,Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949621000000109,CKD G2A3 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949881000000106,CKD G3aA1 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949901000000109,CKD G3aA2 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949921000000100,Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950061000000103,Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950081000000107,CKD G3bA2 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950101000000101,CKD G3bA3 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950181000000106,CKD G4A1 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950211000000107,CKD G4A2 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950231000000104,CKD G4A3 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950251000000106,CKD G5A1 - chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950291000000103,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950311000000102,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,1011481000000105,Estimated glomerular filtration rate using creatinine Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,1011491000000107,Estimated glomerular filtration rate using cystatin C Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +INDUCTION THERAPY (BASILIXIMAB),Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +INDUCTION THERAPY (BASILIXIMAB),Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +INDUCTION THERAPY (BASILIXIMAB),Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +INDUCTION THERAPY (DACLIZUMAB),Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +INDUCTION THERAPY (DACLIZUMAB),Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +INDUCTION THERAPY (DACLIZUMAB),Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +INFLIXIMAB,Active fistulising Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Active fistulising Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Active fistulising Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Active fistulising Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Crohn's disease (active severe),TA040,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Crohn's disease (active severe),TA040,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Crohn's disease (active severe),TA040,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Crohn's disease (active severe),TA040,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Crohn's disease (fistulising),TA040,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Crohn's disease (fistulising),TA040,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Crohn's disease (fistulising),TA040,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Crohn's disease (fistulising),TA040,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,156370009,Psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,156370009,Psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +INFLIXIMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Severe active Crohn's disease (children aged 6 - 17 years),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Severe active Crohn's disease (children aged 6 - 17 years),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Severe active Crohn's disease (children aged 6 - 17 years),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Severe active Crohn's disease (children aged 6 - 17 years),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY +INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (2ND LINE),Plaque psoriasis,TA134,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),INFLIXIMAB,DERMATOLOGY,DERMATOLOGY +INFLIXIMAB (2ND LINE),Plaque psoriasis,TA134,plaque psoriasis,402307000,Chronic large plaque psoriasis,INFLIXIMAB,DERMATOLOGY,DERMATOLOGY +INFLIXIMAB (2ND LINE),Plaque psoriasis,TA134,plaque psoriasis,402310007,Chronic stable plaque psoriasis,INFLIXIMAB,DERMATOLOGY,DERMATOLOGY +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,12428000,Intrinsic asthma without status asthmaticus,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,31387002,Exercise-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,34015007,Flour asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,56018004,Asthmatic breathing,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,56968009,Asthma caused by wood dust,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,57607007,Industrial asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,63088003,Allergic asthma without status asthmaticus,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,71892000,Cardiac asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,93432008,Drug-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,160377001,Family history of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,161105008,Asthma society member,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,161527007,History of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,162660004,Asthma resolved,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170631002,Asthma disturbing sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170632009,Asthma causing night waking,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170633004,Asthma disturbs sleep weekly,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170634005,Asthma disturbs sleep frequently,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170635006,Asthma not disturbing sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170636007,Asthma never disturbs sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170637003,Asthma limiting activities,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170638008,Asthma not limiting activities,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170642006,Asthma severity,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170647000,Asthma prophylactic medication used,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170655007,Asthma restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170656008,Asthma sometimes restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170657004,Asthma severely restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170658009,Asthma never restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,171231001,Asthma screening,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182724005,Further asthma - drug prevention,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182726007,Asthma control step 0,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182727003,Asthma control step 1,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182728008,Asthma control step 2,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182729000,Asthma control step 3,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182730005,Asthma control step 4,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182731009,Asthma control step 5,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,183099005,Asthma leaflet given,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,183478001,Emergency hospital admission for asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185242005,Seen in asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185728001,Attends asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185730004,Asthma monitor offer default,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185731000,Asthma monitoring call first letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185732007,Asthma monitoring call second letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185734008,Asthma monitoring call third letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185735009,Asthma monitoring call verbal invite,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185736005,Asthma monitoring call telephone invite,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185737001,Asthma monitoring deleted,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185940009,Patient in asthma study,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195949008,Chronic asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195967001,Asthmatic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195973000,Late-onset asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195977004,Mixed asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195983001,Exercise induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,219036002,Adverse reaction to antiasthmatic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,225057002,Brittle asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,233678006,Childhood asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,233679003,Late-onset asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,233683003,Hay fever with asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,233691007,Eosinophilic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,266361008,Non-allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,266396008,Extrinsic asthma - atopy (& pollen),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,266397004,Intrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,266398009,Asthma attack,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,270442000,Asthma monitoring check done,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,275908000,Asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,281239006,Asthma attack,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,302220000,Asthma control steps,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,304527002,Acute asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,308500005,Asthma monitoring call,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,308501009,Asthma monitoring status,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,312453004,Asthma - currently active,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,312454005,Asthma - currently dormant,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,366874008,Number of asthma exacerbations in past year,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370204008,Asthma causes daytime symptoms most days,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370206005,Asthma limits walking on the flat,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370207001,Asthma limits walking up hills or stairs,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370208006,Asthma never causes daytime symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370218001,Mild asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370219009,Moderate asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370220003,Occasional asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370221004,Severe asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370225008,Asthma treatment compliance unsatisfactory,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370226009,Asthma treatment compliance satisfactory,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,373899003,Asthma daytime symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,389145006,Allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390798007,Asthma finding,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390872009,Change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390877003,Step up change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390878008,Step down change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390921001,Absent from work or school due to asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390940007,Asthma monitoring due,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,394700004,Asthma annual review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,394701000,Asthma follow-up,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,394720003,Asthma medication review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,394967008,Suspected asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,395022009,Nocturnal asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,400987003,Asthma trigger,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401135008,Health education - asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401182001,Asthma monitoring by nurse,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401183006,Asthma monitoring by doctor,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401193004,Asthma confirmed,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,405944004,Asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,406162001,Asthma care,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,407674008,Aspirin-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,409663006,Cough variant asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,415265005,Referral to asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,424643009,Allergic atopic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,425969006,Acute intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,426656000,Severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,426979002,Mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,427295004,Moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,427603009,Intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,427679007,Mild intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,443117005,Asthma control test score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,445427006,Seasonal asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,445531003,ACQ - Asthma control questionnaire,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,473391009,Asthma never causes night symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,698509001,Under care of asthma specialist nurse,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,699191007,Did not attend asthma review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,702823004,Asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,704008007,No family history of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707445000,Acute mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707446004,Acute exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707447008,Exacerbation of severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707511009,Uncomplicated mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707512002,Uncomplicated moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707513007,Uncomplicated severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707979007,Acute severe exacerbation of severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707981009,Acute severe exacerbation of mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708038006,Acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708090002,Acute severe exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708093000,Acute exacerbation of allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708094006,Acute exacerbation of intrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708095007,Acute severe exacerbation of extrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708358003,Emergency asthma admission since last encounter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708373002,Emergency asthma patient visit since last encounter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,711442001,Recent asthma management,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,715191006,Telehealth asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,734346005,Use of asthma symptom diary,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,734904007,Life threatening acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,734905008,Moderate acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,736056000,Asthma clinical management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,762521001,Acute allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,763077003,Asthma Control Questionnaire score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,763221007,Asthma monitoring declined,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,782520007,Exacerbation of allergic asthma due to infection,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,782559003,Asthma never causes night symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401000119107,Asthma with irreversible airway obstruction,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,641000119106,Intermittent asthma well controlled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1741000119102,Intermittent asthma uncontrolled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,72301000119103,Asthma in pregnancy,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,89581000000109,DNA (did not attend) asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,143901000000108,Registration for access to online asthma self-management application,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,143931000000102,Declined to register for access to online asthma self-management application,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,176711000000100,Does not have asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,198971000000102,Asthma outreach clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201031000000108,Asthma trigger - respiratory infection,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201041000000104,Asthma trigger - seasonal,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201051000000101,Asthma trigger - animal,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201191000000108,Asthma trigger - cold air,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201201000000105,Asthma trigger - damp,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201211000000107,Asthma trigger - emotion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340891000000106,Asthma trigger - airborne dust,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340901000000107,Asthma trigger - exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340911000000109,Asthma trigger - pollen,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340921000000103,Asthma trigger - tobacco smoke,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340931000000101,Asthma trigger - warm air,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,527171000000103,Patient has a written asthma personal action plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,527191000000104,Health education - asthma self management,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,527211000000100,Health education - structured asthma discussion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,527231000000108,Health education - structured patient focused asthma discussion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,713701000000108,Asthma monitoring administration,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,713711000000105,Asthma clinic administration,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,715801000000103,Exception reporting - asthma quality indicators,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,771941000000102,Asthma causes symptoms most nights,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,772051000000106,Asthma limits activities most days,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,791401000000104,Seen in school asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,810901000000102,Asthma self-management plan review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,811921000000103,Asthma self-management plan agreed,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,815631000000106,Asthma trigger - wind,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,818161000000104,Asthma trigger - perfume,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,867171000000106,No asthma trigger identified by subject,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,892301000000100,Asthma management plan declined,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,905301000000103,Childhood Asthma Control Test score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,928451000000107,Asthma monitoring invitation short message service text message,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,928511000000107,Asthma monitoring invitation email,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,928651000000105,Review of patient at risk of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,928691000000102,At risk of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,959901000000107,Asthma action plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,966011000000109,At risk of severe asthma exacerbation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,966031000000101,Severe asthma exacerbation risk assessment,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10674991000119104,Intermittent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10675431000119106,Severe persistent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10675871000119106,Mild persistent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10676031000119106,Mild persistent allergic asthma controlled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,12428000,Intrinsic asthma without status asthmaticus,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,31387002,Exercise-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,34015007,Flour asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,56018004,Asthmatic breathing,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,56968009,Asthma caused by wood dust,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,57607007,Industrial asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,63088003,Allergic asthma without status asthmaticus,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,71892000,Cardiac asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,93432008,Drug-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,160377001,Family history of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,161105008,Asthma society member,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,161527007,History of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,162660004,Asthma resolved,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170631002,Asthma disturbing sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170632009,Asthma causing night waking,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170633004,Asthma disturbs sleep weekly,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170634005,Asthma disturbs sleep frequently,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170635006,Asthma not disturbing sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170636007,Asthma never disturbs sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170637003,Asthma limiting activities,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170638008,Asthma not limiting activities,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170642006,Asthma severity,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170647000,Asthma prophylactic medication used,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170655007,Asthma restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170656008,Asthma sometimes restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170657004,Asthma severely restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170658009,Asthma never restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,171231001,Asthma screening,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182724005,Further asthma - drug prevention,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182726007,Asthma control step 0,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182727003,Asthma control step 1,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182728008,Asthma control step 2,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182729000,Asthma control step 3,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182730005,Asthma control step 4,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182731009,Asthma control step 5,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,183099005,Asthma leaflet given,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,183478001,Emergency hospital admission for asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185242005,Seen in asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185728001,Attends asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185730004,Asthma monitor offer default,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185731000,Asthma monitoring call first letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185732007,Asthma monitoring call second letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185734008,Asthma monitoring call third letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185735009,Asthma monitoring call verbal invite,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185736005,Asthma monitoring call telephone invite,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185737001,Asthma monitoring deleted,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185940009,Patient in asthma study,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195949008,Chronic asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195967001,Asthmatic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195973000,Late-onset asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195977004,Mixed asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195983001,Exercise induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,219036002,Adverse reaction to antiasthmatic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,225057002,Brittle asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,233678006,Childhood asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,233679003,Late-onset asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,233683003,Hay fever with asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,233691007,Eosinophilic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,266361008,Non-allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,266396008,Extrinsic asthma - atopy (& pollen),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,266397004,Intrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,266398009,Asthma attack,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,270442000,Asthma monitoring check done,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,275908000,Asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,281239006,Asthma attack,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,302220000,Asthma control steps,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,304527002,Acute asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,308500005,Asthma monitoring call,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,308501009,Asthma monitoring status,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,312453004,Asthma - currently active,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,312454005,Asthma - currently dormant,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,366874008,Number of asthma exacerbations in past year,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370204008,Asthma causes daytime symptoms most days,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370206005,Asthma limits walking on the flat,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370207001,Asthma limits walking up hills or stairs,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370208006,Asthma never causes daytime symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370218001,Mild asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370219009,Moderate asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370220003,Occasional asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370221004,Severe asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370225008,Asthma treatment compliance unsatisfactory,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370226009,Asthma treatment compliance satisfactory,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,373899003,Asthma daytime symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,389145006,Allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390798007,Asthma finding,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390872009,Change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390877003,Step up change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390878008,Step down change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390921001,Absent from work or school due to asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390940007,Asthma monitoring due,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,394700004,Asthma annual review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,394701000,Asthma follow-up,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,394720003,Asthma medication review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,394967008,Suspected asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,395022009,Nocturnal asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,400987003,Asthma trigger,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401135008,Health education - asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401182001,Asthma monitoring by nurse,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401183006,Asthma monitoring by doctor,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401193004,Asthma confirmed,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,405944004,Asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,406162001,Asthma care,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,407674008,Aspirin-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,409663006,Cough variant asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,415265005,Referral to asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,424643009,Allergic atopic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,425969006,Acute intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,426656000,Severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,426979002,Mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,427295004,Moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,427603009,Intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,427679007,Mild intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,443117005,Asthma control test score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,445427006,Seasonal asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,445531003,ACQ - Asthma control questionnaire,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,473391009,Asthma never causes night symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,698509001,Under care of asthma specialist nurse,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,699191007,Did not attend asthma review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,702823004,Asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,704008007,No family history of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707445000,Acute mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707446004,Acute exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707447008,Exacerbation of severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707511009,Uncomplicated mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707512002,Uncomplicated moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707513007,Uncomplicated severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707979007,Acute severe exacerbation of severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707981009,Acute severe exacerbation of mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708038006,Acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708090002,Acute severe exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708093000,Acute exacerbation of allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708094006,Acute exacerbation of intrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708095007,Acute severe exacerbation of extrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708358003,Emergency asthma admission since last encounter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708373002,Emergency asthma patient visit since last encounter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,711442001,Recent asthma management,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,715191006,Telehealth asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,734346005,Use of asthma symptom diary,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,734904007,Life threatening acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,734905008,Moderate acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,736056000,Asthma clinical management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,762521001,Acute allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,763077003,Asthma Control Questionnaire score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,763221007,Asthma monitoring declined,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,782520007,Exacerbation of allergic asthma due to infection,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,782559003,Asthma never causes night symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401000119107,Asthma with irreversible airway obstruction,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,641000119106,Intermittent asthma well controlled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1741000119102,Intermittent asthma uncontrolled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,72301000119103,Asthma in pregnancy,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,89581000000109,DNA (did not attend) asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,143901000000108,Registration for access to online asthma self-management application,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,143931000000102,Declined to register for access to online asthma self-management application,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,176711000000100,Does not have asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,198971000000102,Asthma outreach clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201031000000108,Asthma trigger - respiratory infection,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201041000000104,Asthma trigger - seasonal,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201051000000101,Asthma trigger - animal,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201191000000108,Asthma trigger - cold air,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201201000000105,Asthma trigger - damp,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201211000000107,Asthma trigger - emotion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340891000000106,Asthma trigger - airborne dust,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340901000000107,Asthma trigger - exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340911000000109,Asthma trigger - pollen,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340921000000103,Asthma trigger - tobacco smoke,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340931000000101,Asthma trigger - warm air,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,527171000000103,Patient has a written asthma personal action plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,527191000000104,Health education - asthma self management,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,527211000000100,Health education - structured asthma discussion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,527231000000108,Health education - structured patient focused asthma discussion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,713701000000108,Asthma monitoring administration,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,713711000000105,Asthma clinic administration,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,715801000000103,Exception reporting - asthma quality indicators,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,771941000000102,Asthma causes symptoms most nights,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,772051000000106,Asthma limits activities most days,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,791401000000104,Seen in school asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,810901000000102,Asthma self-management plan review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,811921000000103,Asthma self-management plan agreed,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,815631000000106,Asthma trigger - wind,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,818161000000104,Asthma trigger - perfume,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,867171000000106,No asthma trigger identified by subject,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,892301000000100,Asthma management plan declined,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,905301000000103,Childhood Asthma Control Test score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,928451000000107,Asthma monitoring invitation short message service text message,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,928511000000107,Asthma monitoring invitation email,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,928651000000105,Review of patient at risk of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,928691000000102,At risk of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,959901000000107,Asthma action plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,966011000000109,At risk of severe asthma exacerbation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,966031000000101,Severe asthma exacerbation risk assessment,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10674991000119104,Intermittent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10675431000119106,Severe persistent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10675871000119106,Mild persistent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10676031000119106,Mild persistent allergic asthma controlled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,2751001,Fibrocalculous pancreatic diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,4855003,Retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,5368009,Drug-induced diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,6143009,Diabetes mellitus education,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,8801005,Secondary diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,9414007,Latent diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,11530004,Brittle diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,11687002,GDM - gestational diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,15771004,Diabetes insipidus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,21584002,Maternal diabetes syndrome,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,25093002,Disorder of eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,43959009,Cataract of eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,44054006,T2DM - diabetes mellitus type 2,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,46635009,T1DM - type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,48951005,Bullous disease due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,49455004,Polyneuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,49817004,Neonatal diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,61165007,Adiuretin-resistant diabetes insipidus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,73211009,Diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,74627003,Complication due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,111552007,Diabetes mellitus without complication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,127012008,Lipodystrophic diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,127013003,Disorder of kidney due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,160274005,No family history of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,160303001,Family history of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,160402005,Family history: Diabetes in pregnancy,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,161445009,History of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,161641009,At increased risk of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170745003,Diet controlled diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170752001,Has seen dietitian - diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170753006,Understands diet - diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170774007,Diabetes: practice program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170775008,Diabetes: shared care program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,171183004,Diabetes mellitus screening,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185753003,Attends diabetes monitoring,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185754009,Diabetes monitoring declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185755005,Diabetes monitoring default,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185756006,Diabetes monitoring first letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185757002,Diabetes monitoring second letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185758007,Diabetes monitoring third letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185759004,Diabetes monitoring verbal invite,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185760009,Diabetes monitoring telephone invite,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185761008,Diabetes monitoring deleted,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190323008,Non-insulin dependent diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190349003,Diabetes mellitus with neuropathy,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190354007,Diabetes with gangrene,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190372001,Insulin-dependent diabetes maturity onset,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190389009,Type 2 diabetes mellitus with ulcer,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190411003,Multiple complications due to malnutrition related diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190416008,Steroid-induced diabetes mellitus without complication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190447002,Steroid-induced diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190484000,Diabetes insipidus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193489006,Iritis due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199230006,Pre-existing type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230572002,Neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230577008,Mononeuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,232020009,Disorder of macula due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237599002,Insulin treated type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237601000,Secondary endocrine diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237619009,Maternally-inherited diabetes and hearing loss,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237632004,Hypoglycemic event due to diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,238982009,Dermopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,267471001,Diabetes + eye manifestation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,268519009,Diabetes mellitus uncontrolled,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,270445003,Diabetes monitoring check done,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,273411009,Diabetes clinic satisfaction questionnaire,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,273412002,Diabetes treatment satisfaction questionnaire,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,273413007,Diabetes wellbeing questionnaire,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,284350006,Diabetes mellitus diet education,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,290002008,Unstable type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,303059007,Postpancreatectomy diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,304752002,Perceived control of insulin-dependent diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,308505000,Diabetes monitoring call,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309417009,Diabetes dietitian,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309426007,Glomerulopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309593006,Education score - diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309596003,Retinal abnormality - non-diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309598002,Foot abnormality - non-diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309635005,History of admission in last year for diabetes foot problem,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,310425007,Diabetes monitoring invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312856000,Referral to diabetes nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312888008,Attending diabetes clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312912001,Macular oedema due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,313435000,Insulin-dependent diabetes without complication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,313436004,Type II diabetes mellitus without complication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314537004,Optic papillopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,315051004,Diabetes resolved,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,315216001,Diabetes mellitus excluded,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,371087003,Ulcer of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,385805005,Health education - diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,394725008,Diabetes medication review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,395123002,Urine screening test for diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,405749004,Newly diagnosed diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,408290003,Diabetes key contact,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,408392008,Under care of diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,413180006,Pan retinal photocoagulation for diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,413597006,Attended diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,414229005,Family/carer attended diabetes structured education program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,414230000,Family/carer referral to diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,415269004,Referral to diabetes preconception counselling clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,415270003,Referral to diabetes structured education program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,415744000,Transition of diabetes care options discussed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,416554009,Seen in community diabetes specialist clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,416855002,Family history of diabetes mellitus in first degree relative,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,417467000,Discharged from care of diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,419100001,Infection of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420422005,Ketoacidosis due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420868002,Disorder due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422014003,Disorder due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422183001,Skin ulcer due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422275004,Gangrene due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,428274007,Dietary advice for type II diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,429094000,Dietary advice for type 1 diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,430678008,Family history of diabetes mellitus type 1,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,430679000,Family history of diabetes mellitus type 2,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,439051004,Dietary advice for gestational diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,444094009,History of diabetes mellitus in child of subject,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,472969004,H/O diabetes mellitus type 2,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,472970003,H/O diabetes mellitus type 1,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,473127005,Suspected diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,609561005,MODY - maturity onset diabetes of young,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,698610002,Education about self management of diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,699826006,Lifestyle education regarding risk of diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,700414001,Education about diabetes and driving,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,703040004,Agreeing on diabetes care plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,703136005,Diabetes mellitus in remission,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,703137001,Type 1 diabetes mellitus in remission,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,703138006,Type 2 diabetes mellitus in remission,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,704408003,Invitation for diabetes screening,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,714628002,Prediabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,715159005,Referral to diabetes service,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,715759002,Provision of written information about diabetes and hypertension,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,715879000,Provision of written information about diabetes and high cholesterol,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,720685006,Seen by diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,720724003,Has diabetes identity card,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,724136006,Mastopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,735199000,History of diabetes related lower limb amputation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,735985000,Diabetes self management plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,736284000,Diabetes clinical management plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,762489000,Acute complication due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,763782001,Provision of patient held diabetes record declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769244003,Disorder of right macula due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769245002,Disorder of left macula due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,878859007,Self management of diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,897238003,Diabetes management using closed-loop delivery system,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1258872006,Family referred to diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1258873001,Caregiver referred to diabetes structured education program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1268646002,Gestational diabetes mellitus screening,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1296758008,Diabetes insipidus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,113131000000107,Informed consent for diabetes national audit,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,113141000000103,Informed dissent for diabetes national audit,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,143911000000105,Registration for access to online diabetes self-management application,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,279291000000109,Diabetes type 1 review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,279321000000104,Diabetes type II review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,279521000000108,Referral to community diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306591000000103,Diabetes structured education programme declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306861000000107,Did not attend diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306931000000106,Did not complete diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,334711000000100,Referral to diabetes special interest general practitioner,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,335621000000101,Maternally inherited diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,344061000000104,Referral to children's diabetes nurse specialist,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,385041000000108,Diabetes mellitus with multiple complications,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,385051000000106,Pre-existing diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,494961000000102,Discharged from diabetes shared care programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,512561000000108,Unsuitable for diabetes year of care programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,512581000000104,Declined consent for diabetes year of care programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713671000000109,Diabetes monitoring administration,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713691000000108,Diabetes clinic administration,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,715111000000105,Diabetes screening administration,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,716911000000104,Exception reporting - diabetes quality indicators,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,754461000000105,Referral to type I diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,755491000000100,Diabetes structured education programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,764921000000102,Gestational diabetes information leaflet given,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,771571000000102,H/O: secondary diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,787061000000100,Diabetes care plan declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,810961000000103,Diabetes self-management plan review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,811391000000104,Referral to community diabetes service,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,811981000000102,Diabetes self-management plan agreed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816711000000104,Gestational diabetes mellitus annual review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,819301000000105,Diabetes monitoring injection site check declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,819331000000104,Diabetes monitoring injection site not checked,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,828901000000109,Endocrinology and diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,829521000000104,Provision of diabetes clinical summary,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,837491000000107,High risk of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,841221000000102,Referral to community diabetes clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,850581000000106,High risk of diabetes mellitus annual review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,851501000000106,Diabetes clinical pathway,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,851991000000108,Diabetes quality of life questionnaire score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,857921000000103,Provision of written information about diabetes and driving,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,858301000000107,Pre-diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,863501000000102,QDiabetes risk calculator,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,863521000000106,QDiabetes risk calculator score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,885931000000100,Diabetes structured education programme not available,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,887861000000105,Diabetes Year of Care annual review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,923461000000103,Lifestyle education for diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,927821000000100,Discharge from secondary care diabetes service,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,961931000000109,Diabetes education care plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1024941000000100,NHS Diabetes Prevention Programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025601000000108,Leicester Diabetes Risk Score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1083111000000108,Diabetes monitoring invitation email,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1092721000000109,Signposting to Diabetes UK,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1103691000000102,Diabetes structured education programme offered,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1108731000000100,Referral to online diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1362341000000103,Diabetes care plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,12275391000119108,Diabetes screening declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INOSITOL NICOTINATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822611000000100,Exception reporting - peripheral arterial disease quality indicators,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +INOSITOL NICOTINATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822641000000104,Excepted from peripheral arterial disease quality indicators - patient unsuitable,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +INOSITOL NICOTINATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822671000000105,Excepted from peripheral arterial disease quality indicators - informed dissent,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +INOSITOL NICOTINATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,968121000000103,Peripheral arterial disease screening,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +INOTUZUMAB,Relapsed or refractory B-cell acute lymphoblastic leukaemia,TA541,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,INOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +INOTUZUMAB,Relapsed or refractory B-cell acute lymphoblastic leukaemia,TA541,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,INOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,62944002,Hepatitis C virus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,62944002,Hepatitis C virus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,72165005,Hepatitis C virus antibody,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,72165005,Hepatitis C virus antibody,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,170489004,Viral hepatitis carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,170489004,Viral hepatitis carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,197344005,Hepatitis caused by adenovirus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,197344005,Hepatitis caused by adenovirus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,235872006,Hepatitis C carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,235872006,Hepatitis C carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278973007,Hepatitis C status,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278973007,Hepatitis C status,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278974001,Hepatitis C immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278974001,Hepatitis C immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278975000,Hepatitis C non-immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278975000,Hepatitis C non-immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,314706002,Hepatitis C antibody detected,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,314706002,Hepatitis C antibody detected,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,314707006,Hepatitis C antibody test negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,314707006,Hepatitis C antibody test negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,413107006,Hepatitis C screening,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,413107006,Hepatitis C screening,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,773113008,Acute hepatitis caused by infection,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,773113008,Acute hepatitis caused by infection,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,12891000175105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,12891000175105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,200371000000104,Hepatitis C contact,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,200371000000104,Hepatitis C contact,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,201451000000105,Hepatitis C immunisation declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,201451000000105,Hepatitis C immunisation declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,202281000000105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,202281000000105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,204671000000101,Hepatitis C screening counselling,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,204671000000101,Hepatitis C screening counselling,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,304821000000107,Hepatitis C screening not offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,304821000000107,Hepatitis C screening not offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,362491000000104,Hepatitis C screening negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,362491000000104,Hepatitis C screening negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,362751000000101,Hepatitis C screening positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,362751000000101,Hepatitis C screening positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,761381000000102,Hepatitis C resolved,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,761381000000102,Hepatitis C resolved,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,824841000000105,Hepatitis C genotype 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,824841000000105,Hepatitis C genotype 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,824871000000104,Hepatitis C genotype 3,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,824871000000104,Hepatitis C genotype 3,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,829731000000106,On hepatitis C treatment plan,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,829731000000106,On hepatitis C treatment plan,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,992751000000109,Hepatitis C viral load,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,992751000000109,Hepatitis C viral load,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,992771000000100,Hepatitis C virus genotype,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,992771000000100,Hepatitis C virus genotype,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,996031000000104,Hepatitis C IgG level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,996031000000104,Hepatitis C IgG level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,998771000000103,Hepatitis C antibody level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,998771000000103,Hepatitis C antibody level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1001331000000102,Hepatitis C antigen level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1001331000000102,Hepatitis C antigen level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1008931000000108,Hepatitis C antibody test,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1008931000000108,Hepatitis C antibody test,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1107671000000106,Hepatitis C screening offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1107671000000106,Hepatitis C screening offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,24700007,Multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,160337009,Family history of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,192926004,Brain stem multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,192928003,Generalised multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,428700003,Primary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,438511000,Benign multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,700409000,Suspected multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,198491000000106,Multiple sclerosis review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,515931000000104,Multiple sclerosis review declined,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,24700007,Multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,160337009,Family history of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,192926004,Brain stem multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,192928003,Generalised multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,428700003,Primary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,438511000,Benign multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,700409000,Suspected multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,198491000000106,Multiple sclerosis review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,515931000000104,Multiple sclerosis review declined,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,24700007,Multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,160337009,Family history of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,192926004,Brain stem multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,192928003,Generalised multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,428700003,Primary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,438511000,Benign multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,700409000,Suspected multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,198491000000106,Multiple sclerosis review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,515931000000104,Multiple sclerosis review declined,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,134405005,Suspected breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,160287004,FH: Breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,268547008,Screening for breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,429740004,Family history of breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,431330007,Family history of breast cancer 1 gene mutation,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,431331006,Family history of breast cancer 2 gene mutation,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,706970001,TNBC - Triple-negative breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,94361000000105,Breast cancer detected by national screening programme,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,276341000000100,Fast track referral for suspected breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,838351000000107,Education about risk of breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,874291000000100,QCancer breast cancer risk,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,1035841000000108,Lymphoedema following breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,14651005,Drug-induced osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,18040001,Age-related osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,64859006,Osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,102447009,Postmenopausal osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,160313009,Family history of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203429007,Idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203433000,Postoophorectomy osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203435007,Localized osteoporosis - Lequesne,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203437004,Osteoporosis in endocrine disorders,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203438009,Osteoporosis of spine,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240157009,Secondary generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240158004,Regional migrating osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240159007,Transient osteoporosis of hip,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240162005,Secondary localized osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,268028001,Localised disuse osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,276661002,Primary osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,281387004,Regional osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,300004007,Screening for osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,309745002,Osteoporosis localized to spine,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,310251007,No family history: Osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,313423004,At increased risk of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391003008,Osteoporosis monitoring administration,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391004002,Attends osteoporosis monitoring,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391006000,Osteoporosis monitoring default,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391007009,Osteoporosis monitoring first letter,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391008004,Osteoporosis monitoring second letter,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391012005,Osteoporosis monitoring deleted,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391013000,Osteoporosis monitoring check done,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391014006,Osteoporosis risk assessment done,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391015007,Osteoporosis risk assessment declined,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391017004,Osteoporosis monitoring,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391018009,Initial osteoporosis assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391019001,Follow-up osteoporosis assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391020007,Osteoporosis treatment started,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391021006,Osteoporosis treatment stopped,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391022004,Osteoporosis treatment changed,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391023009,Osteoporosis - no treatment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391024003,Osteoporosis - dietary advice,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391025002,Osteoporosis - dietary assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391026001,Osteoporosis - exercise advice,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391027005,Osteoporosis - falls prevention,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391028000,Osteoporosis - treatment response,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391033001,Refer to osteoporosis specialist,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391037000,Seen in osteoporosis clinic,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,394936006,Health education - osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,412717001,Referral to osteoporosis clinic,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,473120007,History of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,763322002,Osteoporosis monitoring refused,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,711341000000106,Osteoporosis resolved,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,965871000000101,Osteoporosis medication compliance review,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,162573006,Suspected lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,254637007,Non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,275981009,Lung cancer screening,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,429011007,Family history of lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,723301009,Squamous non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1259727001,Primary non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,276491000000101,Fast track referral for suspected lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,848881000000108,QCancer lung cancer risk,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,877691000000107,No FH of lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1771781000000107,Did not attend lung cancer screening,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +INTRAVENOUS TRABECTEDIN,Advanced soft tissue sarcoma,TA185,soft tissue sarcoma,2424003,Soft tissue sarcoma,INTRAVENOUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,915007,Malignant melanoma in junctional naevus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,1556006,Clark melanoma level 4,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,2092003,Malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,2142002,Nodular melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,16974005,"Acral lentiginous melanoma, malignant",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,21119008,Benign melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,21165006,Clark melanoma level 3,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,37138001,Epithelioid cell melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,39896009,"Malignant melanoma, regressing",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,44474009,Lentigo maligna melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,50542000,Clark melanoma level 2,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,50813003,Spitz melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,51757004,"Desmoplastic melanoma, amelanotic",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,55320002,Superficial spreading melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,68827007,Spindle cell melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,70594002,Amelanotic melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,77986002,Melanoma in situ,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93209006,Malignant melanoma of perianal skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93214005,Malignant melanoma of skin of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93217003,Malignant melanoma of skin of cheek,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93220006,Malignant melanoma of skin of ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93221005,Malignant melanoma of skin of elbow,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93223008,Malignant melanoma of eyebrow,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93225001,Malignant melanoma of skin of face,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93227009,Malignant melanoma of skin of foot,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93228004,Malignant melanoma of skin of forearm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93642000,Malignant melanoma of skin of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93643005,Malignant melanoma of external surface of nose,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93646002,Malignant melanoma of skin of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93647006,Malignant melanoma of skin of shoulder,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93651008,Malignant melanoma of skin of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93653006,Malignant melanoma of skin of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93654000,Malignant melanoma of skin of wrist,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93655004,MM (malignant melanoma) of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,106243009,Breslow depth staging for melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109266006,Melanoma in situ of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109270003,Melanoma in situ of face,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109272006,Melanoma in situ of lip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109276009,Melanoma in situ of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109278005,Melanoma in situ of ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109282007,Melanoma in situ of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109284008,Melanoma in situ of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109290007,Melanoma in situ of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109294003,Melanoma in situ of lower limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,127330008,Melanoma in situ by body site (clinical),IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,161432005,History of malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,177281002,Excision of melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188030005,Malignant melanoma of lip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188033007,Malignant melanoma of auricle (ear),IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188034001,Malignant melanoma of external auditory meatus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188038003,Malignant melanoma of chin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188040008,Malignant melanoma of forehead,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188042000,Malignant melanoma of temple,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188044004,Malignant melanoma of scalp and/or neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188045003,Malignant melanoma of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188046002,Malignant melanoma of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188049009,Malignant melanoma of axilla,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188050009,Malignant melanoma of breast,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188051008,Malignant melanoma of buttock,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188052001,Malignant melanoma of groin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188054000,Malignant melanoma of perineum,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188055004,Malignant melanoma of umbilicus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188060000,Malignant melanoma of shoulder,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188061001,Malignant melanoma of upper arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188062008,Malignant melanoma of forearm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188063003,Malignant melanoma of hand,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188064009,Malignant melanoma of finger,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188065005,Malignant melanoma of thumb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188067002,Malignant melanoma of lower limb and hip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188068007,Malignant melanoma of hip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188069004,Malignant melanoma of thigh,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188070003,Malignant melanoma of knee,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188071004,Malignant melanoma of popliteal fossa area,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188072006,Malignant melanoma of lower leg,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188073001,Malignant melanoma of ankle,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188074007,Malignant melanoma of heel,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188075008,Malignant melanoma of foot,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188076009,Malignant melanoma of toe,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188077000,Malignant melanoma of great toe,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,189758001,Melanoma in situ,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,231834005,Malignant melanoma of eyelid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254731001,Nodular melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254732008,Acral lentiginous melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254896002,Malignant melanoma of vulva,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,255004001,Malignant melanoma of conjunctiva,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,255012009,Malignant melanoma of iris,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,255015006,Malignant melanoma of ciliary body,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,255021005,Malignant melanoma of choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,269578002,Malignant melanoma of head and neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,269579005,Malignant melanoma of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,269580008,Malignant melanoma of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,269581007,Malignant melanoma of lower limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,274087000,MM (malignant melanoma) of eye,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,276751004,Amelanotic melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,276821000,Malignant melanoma of anus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,276822007,Malignant melanoma of rectum,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,302837001,Lentigo maligna melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,310498001,Malignant melanoma of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,312941005,Melanoma associated retinopathy,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,313248004,Malignant melanoma of chest wall,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,314976006,Local recurrence of malignant melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,314987003,Metastasis from malignant melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,315036008,Melanoma in situ of back of hand,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,315230006,Melanoma in situ of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,372158004,"Malignant melanoma, metastatic",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,427858005,Family history of malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,443493003,Metastatic malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,449636007,Malignant melanoma of skin of lower leg,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,449637003,Malignant melanoma of skin of upper arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,698040004,Malignant melanoma of nasal cavity,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,1197324006,Metastatic malignant melanoma to skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,351961000119109,Malignant melanoma of skin of right arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,352211000119108,Malignant melanoma of skin of left ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,546881000000105,Malignant melanoma of skin NOS,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956331000000107,Malignant melanoma stage IA,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956351000000100,Malignant melanoma stage IB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956371000000109,Malignant melanoma stage IIA,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956391000000108,Malignant melanoma stage IIB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956451000000107,Malignant melanoma stage IIIB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956471000000103,Malignant melanoma stage IIIC,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956511000000107,Malignant melanoma stage IV M1a,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956551000000106,Malignant melanoma stage IV M1c,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,1080941000119109,Malignant melanoma of left choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,1080981000119104,Malignant melanoma of right choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,915007,Malignant melanoma in junctional naevus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,1556006,Clark melanoma level 4,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,2092003,Malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,2142002,Nodular melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,16974005,"Acral lentiginous melanoma, malignant",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,21119008,Benign melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,21165006,Clark melanoma level 3,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,37138001,Epithelioid cell melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,39896009,"Malignant melanoma, regressing",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,44474009,Lentigo maligna melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,50542000,Clark melanoma level 2,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,50813003,Spitz melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,51757004,"Desmoplastic melanoma, amelanotic",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,55320002,Superficial spreading melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,68827007,Spindle cell melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,70594002,Amelanotic melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,77986002,Melanoma in situ,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93209006,Malignant melanoma of perianal skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93214005,Malignant melanoma of skin of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93217003,Malignant melanoma of skin of cheek,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93220006,Malignant melanoma of skin of ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93221005,Malignant melanoma of skin of elbow,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93223008,Malignant melanoma of eyebrow,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93225001,Malignant melanoma of skin of face,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93227009,Malignant melanoma of skin of foot,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93228004,Malignant melanoma of skin of forearm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93642000,Malignant melanoma of skin of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93643005,Malignant melanoma of external surface of nose,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93646002,Malignant melanoma of skin of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93647006,Malignant melanoma of skin of shoulder,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93651008,Malignant melanoma of skin of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93653006,Malignant melanoma of skin of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93654000,Malignant melanoma of skin of wrist,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93655004,MM (malignant melanoma) of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,106243009,Breslow depth staging for melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109266006,Melanoma in situ of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109270003,Melanoma in situ of face,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109272006,Melanoma in situ of lip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109276009,Melanoma in situ of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109278005,Melanoma in situ of ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109282007,Melanoma in situ of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109284008,Melanoma in situ of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109290007,Melanoma in situ of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109294003,Melanoma in situ of lower limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,127330008,Melanoma in situ by body site (clinical),IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,161432005,History of malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,177281002,Excision of melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188030005,Malignant melanoma of lip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188033007,Malignant melanoma of auricle (ear),IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188034001,Malignant melanoma of external auditory meatus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188038003,Malignant melanoma of chin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188040008,Malignant melanoma of forehead,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188042000,Malignant melanoma of temple,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188044004,Malignant melanoma of scalp and/or neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188045003,Malignant melanoma of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188046002,Malignant melanoma of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188049009,Malignant melanoma of axilla,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188050009,Malignant melanoma of breast,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188051008,Malignant melanoma of buttock,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188052001,Malignant melanoma of groin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188054000,Malignant melanoma of perineum,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188055004,Malignant melanoma of umbilicus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188060000,Malignant melanoma of shoulder,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188061001,Malignant melanoma of upper arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188062008,Malignant melanoma of forearm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188063003,Malignant melanoma of hand,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188064009,Malignant melanoma of finger,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188065005,Malignant melanoma of thumb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188067002,Malignant melanoma of lower limb and hip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188068007,Malignant melanoma of hip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188069004,Malignant melanoma of thigh,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188070003,Malignant melanoma of knee,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188071004,Malignant melanoma of popliteal fossa area,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188072006,Malignant melanoma of lower leg,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188073001,Malignant melanoma of ankle,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188074007,Malignant melanoma of heel,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188075008,Malignant melanoma of foot,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188076009,Malignant melanoma of toe,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188077000,Malignant melanoma of great toe,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,189758001,Melanoma in situ,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,231834005,Malignant melanoma of eyelid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254731001,Nodular melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254732008,Acral lentiginous melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254896002,Malignant melanoma of vulva,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,255004001,Malignant melanoma of conjunctiva,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,255012009,Malignant melanoma of iris,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,255015006,Malignant melanoma of ciliary body,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,255021005,Malignant melanoma of choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,269578002,Malignant melanoma of head and neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,269579005,Malignant melanoma of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,269580008,Malignant melanoma of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,269581007,Malignant melanoma of lower limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,274087000,MM (malignant melanoma) of eye,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,276751004,Amelanotic melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,276821000,Malignant melanoma of anus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,276822007,Malignant melanoma of rectum,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,302837001,Lentigo maligna melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,310498001,Malignant melanoma of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,312941005,Melanoma associated retinopathy,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,313248004,Malignant melanoma of chest wall,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,314976006,Local recurrence of malignant melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,314987003,Metastasis from malignant melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,315036008,Melanoma in situ of back of hand,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,315230006,Melanoma in situ of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,372158004,"Malignant melanoma, metastatic",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,427858005,Family history of malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,443493003,Metastatic malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,449636007,Malignant melanoma of skin of lower leg,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,449637003,Malignant melanoma of skin of upper arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,698040004,Malignant melanoma of nasal cavity,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,1197324006,Metastatic malignant melanoma to skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,351961000119109,Malignant melanoma of skin of right arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,352211000119108,Malignant melanoma of skin of left ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,546881000000105,Malignant melanoma of skin NOS,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956331000000107,Malignant melanoma stage IA,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956351000000100,Malignant melanoma stage IB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956371000000109,Malignant melanoma stage IIA,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956391000000108,Malignant melanoma stage IIB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956451000000107,Malignant melanoma stage IIIB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956471000000103,Malignant melanoma stage IIIC,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956511000000107,Malignant melanoma stage IV M1a,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956551000000106,Malignant melanoma stage IV M1c,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,1080941000119109,Malignant melanoma of left choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,1080981000119104,Malignant melanoma of right choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +ISATUXIMAB WITH CARFILZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA727,multiple myeloma,230586003,Neuropathy due to multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +ISATUXIMAB WITH CARFILZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA727,multiple myeloma,413587002,Smoldering multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +ISATUXIMAB WITH CARFILZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA727,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +ISATUXIMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed and refractory multiple myeloma,TA658,multiple myeloma,230586003,Neuropathy due to multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +ISATUXIMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed and refractory multiple myeloma,TA658,multiple myeloma,413587002,Smoldering multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +ISATUXIMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed and refractory multiple myeloma,TA658,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,10335000,Chronic right-sided heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,10633002,Acute congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,48447003,Chronic heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,56675007,Acute heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,83291003,Right heart failure due to pulmonary hypertension,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,85232009,Left-sided heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,88805009,Chronic congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,111283005,Chronic left-sided heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,128404006,Right heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,134378009,Congestive heart failure monitoring,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,134440006,Referral to heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,161505003,History of heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,233924009,Heart failure as a complication of care,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,266308000,Right heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,309634009,History of heart failure in last year,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,314206003,Refractory heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,367363000,Right heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,390868005,Heart failure screen,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,390884006,Heart failure follow-up,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,390885007,Heart failure annual review,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,394887005,Suspected heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,394927007,Heart failure excluded,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,395105005,Heart failure confirmed,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,416683003,Emergency hospital admission for heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,416717003,Seen in heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,417146007,Referral to heart failure nurse,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,417359009,Seen by community heart failure nurse,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,423475008,Heart failure education,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,424404003,Decompensated chronic heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,426611007,Congestive heart failure due to valvular disease,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,429959009,Family history of heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,441530006,Chronic diastolic heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,473226007,Heart failure medication review,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,704095000,Referral to heart failure exercise programme,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,704096004,Referral to heart failure exercise programme not indicated,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,704097008,Referral to heart failure exercise program declined,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,735984001,Heart failure self management plan,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,1296659009,Acute on chronic heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,96311000119109,Exacerbation of congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,200171000000102,Referred by heart failure nurse specialist,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,202231000000106,Heart failure review completed,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,203791000000106,Referred to heart failure education group,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,247361000000100,Heart failure 6 month review,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,248571000000104,Did not attend heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,374231000000104,High risk of heart failure screening invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,521691000000100,Heart failure resolved,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,711461000000104,Heart failure monitoring invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,713791000000101,Heart failure monitoring administration,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,715951000000107,Exception reporting - heart failure quality indicators,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,716621000000101,Heart failure monitoring third letter,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,716971000000109,Heart failure monitoring first letter,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,717191000000108,Heart failure monitoring second letter,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,717501000000108,Heart failure monitoring verbal invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,717531000000102,Heart failure monitoring telephone invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,763641000000102,Referral to heart failure education group declined,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,765661000000102,Discharge from heart failure nurse service,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,781051000000108,Has heart failure management plan,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,810971000000105,Heart failure self-management plan review,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,812001000000102,Heart failure self-management plan agreed,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,813991000000101,Education about deteriorating heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,835981000000108,Rehabilitation for heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,851071000000108,Heart failure initial assessment,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,851521000000102,Heart failure clinical pathway,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,871681000000102,Heart failure monitoring,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,872361000000105,Discussion about heart failure care plan,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,873881000000100,Referral to rapid access heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,915571000000102,On optimal heart failure therapy,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,961881000000101,Provision of information about heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IVABRADINE,Chronic heart failure,TA267,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY +IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA505,multiple myeloma,230586003,Neuropathy due to multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA870,multiple myeloma,230586003,Neuropathy due to multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA505,multiple myeloma,413587002,Smoldering multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA870,multiple myeloma,413587002,Smoldering multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA505,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA870,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +IXEKIZUMAB,Axial spondyloarthritis,TA718,axial spondyloarthritis,723116002,Axial spondyloarthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY +IXEKIZUMAB,Moderate to severe plaque psoriasis,TA442,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),IXEKIZUMAB,DERMATOLOGY,DERMATOLOGY +IXEKIZUMAB,Moderate to severe plaque psoriasis,TA442,plaque psoriasis,402307000,Chronic large plaque psoriasis,IXEKIZUMAB,DERMATOLOGY,DERMATOLOGY +IXEKIZUMAB,Moderate to severe plaque psoriasis,TA442,plaque psoriasis,402310007,Chronic stable plaque psoriasis,IXEKIZUMAB,DERMATOLOGY,DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,156370009,Psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,156370009,Psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,156370009,Psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,3696007,Non ulcer dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,191972002,Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,192434000,[X]Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,196752002,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,249511005,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,299969005,Dyspepsia caused by drug,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,416202003,Under care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,417691002,Discharged from care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,203661000000105,Undiagnosed dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,248131000000106,Referral to dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,134405005,Suspected breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,160287004,FH: Breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,268547008,Screening for breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,429740004,Family history of breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,431330007,Family history of breast cancer 1 gene mutation,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,431331006,Family history of breast cancer 2 gene mutation,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,706970001,TNBC - Triple-negative breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,94361000000105,Breast cancer detected by national screening programme,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,276341000000100,Fast track referral for suspected breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,838351000000107,Education about risk of breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,874291000000100,QCancer breast cancer risk,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,1035841000000108,Lymphoedema following breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,62944002,Hepatitis C virus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,62944002,Hepatitis C virus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,72165005,Hepatitis C virus antibody,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,72165005,Hepatitis C virus antibody,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,170489004,Viral hepatitis carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,170489004,Viral hepatitis carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,197344005,Hepatitis caused by adenovirus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,197344005,Hepatitis caused by adenovirus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,235872006,Hepatitis C carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,235872006,Hepatitis C carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278973007,Hepatitis C status,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278973007,Hepatitis C status,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278974001,Hepatitis C immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278974001,Hepatitis C immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278975000,Hepatitis C non-immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278975000,Hepatitis C non-immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,314706002,Hepatitis C antibody detected,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,314706002,Hepatitis C antibody detected,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,314707006,Hepatitis C antibody test negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,314707006,Hepatitis C antibody test negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,413107006,Hepatitis C screening,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,413107006,Hepatitis C screening,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,773113008,Acute hepatitis caused by infection,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,773113008,Acute hepatitis caused by infection,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,12891000175105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,12891000175105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,200371000000104,Hepatitis C contact,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,200371000000104,Hepatitis C contact,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,201451000000105,Hepatitis C immunisation declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,201451000000105,Hepatitis C immunisation declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,202281000000105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,202281000000105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,204671000000101,Hepatitis C screening counselling,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,204671000000101,Hepatitis C screening counselling,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,304821000000107,Hepatitis C screening not offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,304821000000107,Hepatitis C screening not offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,362491000000104,Hepatitis C screening negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,362491000000104,Hepatitis C screening negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,362751000000101,Hepatitis C screening positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,362751000000101,Hepatitis C screening positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,761381000000102,Hepatitis C resolved,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,761381000000102,Hepatitis C resolved,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,824841000000105,Hepatitis C genotype 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,824841000000105,Hepatitis C genotype 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,824871000000104,Hepatitis C genotype 3,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,824871000000104,Hepatitis C genotype 3,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,829731000000106,On hepatitis C treatment plan,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,829731000000106,On hepatitis C treatment plan,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,992751000000109,Hepatitis C viral load,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,992751000000109,Hepatitis C viral load,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,992771000000100,Hepatitis C virus genotype,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,992771000000100,Hepatitis C virus genotype,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,996031000000104,Hepatitis C IgG level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,996031000000104,Hepatitis C IgG level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,998771000000103,Hepatitis C antibody level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,998771000000103,Hepatitis C antibody level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1001331000000102,Hepatitis C antigen level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1001331000000102,Hepatitis C antigen level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1008931000000108,Hepatitis C antibody test,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1008931000000108,Hepatitis C antibody test,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1107671000000106,Hepatitis C screening offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1107671000000106,Hepatitis C screening offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,62944002,Hepatitis C virus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,62944002,Hepatitis C virus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,72165005,Hepatitis C virus antibody,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,72165005,Hepatitis C virus antibody,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,170489004,Viral hepatitis carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,170489004,Viral hepatitis carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,197344005,Hepatitis caused by adenovirus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,197344005,Hepatitis caused by adenovirus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,235872006,Hepatitis C carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,235872006,Hepatitis C carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278973007,Hepatitis C status,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278973007,Hepatitis C status,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278974001,Hepatitis C immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278974001,Hepatitis C immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278975000,Hepatitis C non-immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278975000,Hepatitis C non-immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,314706002,Hepatitis C antibody detected,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,314706002,Hepatitis C antibody detected,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,314707006,Hepatitis C antibody test negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,314707006,Hepatitis C antibody test negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,413107006,Hepatitis C screening,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,413107006,Hepatitis C screening,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,773113008,Acute hepatitis caused by infection,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,773113008,Acute hepatitis caused by infection,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,12891000175105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,12891000175105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,200371000000104,Hepatitis C contact,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,200371000000104,Hepatitis C contact,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,201451000000105,Hepatitis C immunisation declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,201451000000105,Hepatitis C immunisation declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,202281000000105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,202281000000105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,204671000000101,Hepatitis C screening counselling,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,204671000000101,Hepatitis C screening counselling,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,304821000000107,Hepatitis C screening not offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,304821000000107,Hepatitis C screening not offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,362491000000104,Hepatitis C screening negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,362491000000104,Hepatitis C screening negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,362751000000101,Hepatitis C screening positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,362751000000101,Hepatitis C screening positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,761381000000102,Hepatitis C resolved,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,761381000000102,Hepatitis C resolved,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,824841000000105,Hepatitis C genotype 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,824841000000105,Hepatitis C genotype 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,824871000000104,Hepatitis C genotype 3,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,824871000000104,Hepatitis C genotype 3,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,829731000000106,On hepatitis C treatment plan,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,829731000000106,On hepatitis C treatment plan,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,992751000000109,Hepatitis C viral load,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,992751000000109,Hepatitis C viral load,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,992771000000100,Hepatitis C virus genotype,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,992771000000100,Hepatitis C virus genotype,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,996031000000104,Hepatitis C IgG level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,996031000000104,Hepatitis C IgG level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,998771000000103,Hepatitis C antibody level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,998771000000103,Hepatitis C antibody level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1001331000000102,Hepatitis C antigen level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1001331000000102,Hepatitis C antigen level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1008931000000108,Hepatitis C antibody test,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1008931000000108,Hepatitis C antibody test,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1107671000000106,Hepatitis C screening offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1107671000000106,Hepatitis C screening offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +LENALIDOMIDE,Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,TA680,multiple myeloma,230586003,Neuropathy due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE,Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,TA680,multiple myeloma,413587002,Smoldering multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE,Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,TA680,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE,Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,TA322,myelodysplastic,109998009,MDS-RS-SLD - myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +LENALIDOMIDE,Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,TA322,myelodysplastic,398623004,Myelodysplastic syndrome with excess blasts,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +LENALIDOMIDE,Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,TA322,myelodysplastic,447596005,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +LENALIDOMIDE,Relapsed or refractory mantle cell lymphoma,TA774,mantle cell lymphoma,74654000,Mantle cell lymphoma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE,Relapsed or refractory mantle cell lymphoma,TA774,mantle cell lymphoma,443487006,Mantle cell lymphoma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Untreated multiple myeloma,TA603,multiple myeloma,230586003,Neuropathy due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Untreated multiple myeloma,TA603,multiple myeloma,413587002,Smoldering multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Untreated multiple myeloma,TA603,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH DEXAMETHASONE,Multiple myeloma in adults who have hade at least one prior therapy,TA586,multiple myeloma,230586003,Neuropathy due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH DEXAMETHASONE,Multiple myeloma in adults who have hade at least one prior therapy,TA586,multiple myeloma,413587002,Smoldering multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH DEXAMETHASONE,Multiple myeloma in adults who have hade at least one prior therapy,TA586,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH DEXAMETHASONE,Previously untreated multiple myeloma who are not eligible for transplant,TA587,multiple myeloma,230586003,Neuropathy due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH DEXAMETHASONE,Previously untreated multiple myeloma who are not eligible for transplant,TA587,multiple myeloma,413587002,Smoldering multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH DEXAMETHASONE,Previously untreated multiple myeloma who are not eligible for transplant,TA587,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,109962001,Nonfollicular lymphoma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,308121000,Follicular lymphoma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,721555001,Follicular lymphoma of small intestine,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LENVATINIB,Thyroid cancer,TA535,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +LENVATINIB,Thyroid cancer,TA535,thyroid cancer,363478007,Malignant tumour of thyroid gland,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advance hepatocellular carcinoma,TA551,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advance hepatocellular carcinoma,TA551,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advance hepatocellular carcinoma,TA551,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,733608000,Papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,733608000,Papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,733608000,Papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,9386003,Gouty neuritis,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,14763005,Gouty tophus of pinna,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,24595009,Idiopathic gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,27277001,Tophus of heart co-occurrent and due to gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,43193009,Gouty iritis,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,48440001,Gouty arthropathy,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,67148009,Arthritis of great toe due to gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,90560007,Gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,160308005,Family history: Gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,161451004,History of gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170730005,Gout monitoring,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170731009,Initial gout assessment,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170732002,Follow-up gout assessment,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170733007,Joints gout affected,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170735000,Date gout treatment started,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170736004,Date of last gout attack,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170737008,Gout associated problem,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170738003,Gout drug side effect,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170739006,Gout treatment changed,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170740008,Date gout treatment stopped,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,171190009,Gout screening,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,190828008,Gouty arthropathy,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,190829000,Gouty nephropathy,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,190842000,Chronic tophaceous gout of hand,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,200983001,Parapsoriasis en gouttes,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201663006,Articular gout of shoulder region,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201666003,Gouty arthritis of hand,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201667007,Gouty arthritis of pelvic region and thigh,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201669005,Gouty arthritis of ankle and/or foot,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201670006,Articular gout of multiple joints,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,230312006,Aicardi Goutieres syndrome,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,239843003,Secondary gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,239844009,Gout secondary to renal impairment,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,239845005,Gout secondary to drug,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,239848007,Gouty bursitis,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,243859006,Gout monitoring status,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,268142006,Pseudogout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,281362006,Gouty tophus of bursa,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,281363001,Tophus of tendon co-occurrent and due to gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,281364007,Gouty tophus of olecranon bursa,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,281365008,Gouty tophus of prepatellar bursa,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,292671009,Drug for the treatment of gout adverse reaction,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,402469004,Gouty tophus,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,428839004,Articular gout of toe,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,770924008,Gout attack,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,427211000000108,[V]Screening for gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,924311000000106,Acute exacerbation of gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,1033961000000104,Gouty tophi of toe,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,28944009,Cytomegalovirus disease,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,59527008,Congenital cytomegalovirus infection,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,75469003,"Toxoplasmosis, other infections, rubella, cytomegalovirus, and herpes simplex virus antibody panel measurement",LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,120941004,Cytomegalovirus immunoglobulin,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,243579005,Human cytomegalovirus,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,252410004,Cytomegalovirus antibody screening,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,260207001,Early antigen of Cytomegalovirus,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,271500008,Intravenous injection of anticytomegalovirus immunoglobulin,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,304289003,Cytomegalovirus status,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,407444007,Genus Cytomegalovirus,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,445459004,Cytomegalovirus antibody detected in serum,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,64681000237105,CMV (cytomegalovirus) IgG antibody in serum qualitative result,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,791021000000102,Cytomegalovirus IgM antibody positive,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,791071000000103,Cytomegalovirus IgM antibody negative,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,995431000000104,CMV (cytomegalovirus) antibody level,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,998791000000104,Cytomegalovirus antigen test,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1008531000000101,Cytomegalovirus DNA (deoxyribonucleic acid) detection assay,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1008731000000105,CMV (cytomegalovirus) IgM antibody level,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1008741000000101,CMV (cytomegalovirus) IgG antibody level,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1014131000000100,Cytomegalovirus early antigen level,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1018601000000108,Cytomegalovirus IgG avidity test,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1030491000000105,Cytomegalovirus nucleic acid detection assay,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1031441000000108,Cytomegalovirus latex test,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +LETROZOLE,Breast cancer (early),TA112,breast cancer,134405005,Suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,160287004,FH: Breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,268547008,Screening for breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,429740004,Family history of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,706970001,TNBC - Triple-negative breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,94361000000105,Breast cancer detected by national screening programme,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,838351000000107,Education about risk of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,874291000000100,QCancer breast cancer risk,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LETROZOLE,Breast cancer (early),TA112,breast cancer,1035841000000108,Lymphoedema following breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +LIPOSOMAL CYTARABINE–DAUNORUBICIN,Untreated acute myeloid leukaemia,TA552,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",LIPOSOMAL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,44772007,Maternal obesity without hypertension,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,82793005,Hypothalamic obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,160311006,Family history: Obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,161453001,History of obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,162864005,Body mass index 30+ - obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170793009,Obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170794003,Initial obesity assessment,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170795002,Follow-up obesity assessment,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170797005,Has seen dietician - obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170798000,Treatment of obesity changed,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170799008,Treatment of obesity started,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170800007,Treatment of obesity stopped,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170807005,Reason for obesity therapy - occupational,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185741002,Attends obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185743004,Obesity monitoring default,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185744005,Obesity monitoring first letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185745006,Obesity monitoring second letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185746007,Obesity monitoring third letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185747003,Obesity monitoring verbal invite,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185748008,Obesity monitoring telephone invite,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185749000,Obesity monitoring deleted,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185750000,Obesity monitoring check done,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,190965006,Drug-induced obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,190966007,Obesity hypoventilation syndrome,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,235240002,Procedure using anti-obesity gastric balloon,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,238132000,Upper body obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,238133005,Gynecoid obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,238134004,Generalized obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,238136002,Morbid obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,243862009,Obesity monitoring status,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,247824007,Fear of obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,267511009,Hyperalimentation incl.obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,268522006,Obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,268551005,Obesity screening,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,270486005,Localized obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,276792008,Pulmonary hypertension with extreme obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,277831002,Anxiety about obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,284352003,Obesity diet education,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,294493008,Lifelong obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,296526005,Adult-onset obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,308504001,Obesity monitoring call,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,310428009,Obesity monitoring invitation,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,415530009,Obesity due to excess calories,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,444862003,Childhood obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,703316004,Lymphoedema associated with obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,715279006,Telehealth obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,763085007,Obesity monitoring declined,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,198181000000102,Obesity resolved,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,640791000000105,Obesity and other hyperalimentation,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,713951000000106,Obesity monitoring administration,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,713971000000102,Obesity clinic administration,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,753691000000104,Exception reporting - obesity quality indicators,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,822741000000107,Anti-obesity drug therapy,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,894961000000105,Referral to multidisciplinary obesity clinic,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,898011000000103,Obesity multidisciplinary case review,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,914801000000107,Anti-obesity drug therapy commenced,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,914821000000103,Obesity medication stopped,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386191000000105,National Health Service obesity medication pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386231000000101,NHS obesity medication pathway started,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386241000000105,National Health Service obesity medication pathway declined,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386251000000108,Review of anti-obesity drug therapy,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,44772007,Maternal obesity without hypertension,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,82793005,Hypothalamic obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,160311006,Family history: Obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,161453001,History of obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,162864005,Body mass index 30+ - obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170793009,Obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170794003,Initial obesity assessment,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170795002,Follow-up obesity assessment,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170797005,Has seen dietician - obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170798000,Treatment of obesity changed,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170799008,Treatment of obesity started,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170800007,Treatment of obesity stopped,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170807005,Reason for obesity therapy - occupational,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185741002,Attends obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185743004,Obesity monitoring default,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185744005,Obesity monitoring first letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185745006,Obesity monitoring second letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185746007,Obesity monitoring third letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185747003,Obesity monitoring verbal invite,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185748008,Obesity monitoring telephone invite,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185749000,Obesity monitoring deleted,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185750000,Obesity monitoring check done,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,190965006,Drug-induced obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,190966007,Obesity hypoventilation syndrome,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,235240002,Procedure using anti-obesity gastric balloon,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,238132000,Upper body obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,238133005,Gynecoid obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,238134004,Generalized obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,238136002,Morbid obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,243862009,Obesity monitoring status,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,247824007,Fear of obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,267511009,Hyperalimentation incl.obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,268522006,Obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,268551005,Obesity screening,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,270486005,Localized obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,276792008,Pulmonary hypertension with extreme obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,277831002,Anxiety about obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,284352003,Obesity diet education,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,294493008,Lifelong obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,296526005,Adult-onset obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,308504001,Obesity monitoring call,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,310428009,Obesity monitoring invitation,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,415530009,Obesity due to excess calories,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,444862003,Childhood obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,703316004,Lymphoedema associated with obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,715279006,Telehealth obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,763085007,Obesity monitoring declined,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,198181000000102,Obesity resolved,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,640791000000105,Obesity and other hyperalimentation,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,713951000000106,Obesity monitoring administration,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,713971000000102,Obesity clinic administration,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,753691000000104,Exception reporting - obesity quality indicators,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,822741000000107,Anti-obesity drug therapy,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,894961000000105,Referral to multidisciplinary obesity clinic,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,898011000000103,Obesity multidisciplinary case review,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,914801000000107,Anti-obesity drug therapy commenced,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,914821000000103,Obesity medication stopped,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386191000000105,National Health Service obesity medication pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386231000000101,NHS obesity medication pathway started,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386241000000105,National Health Service obesity medication pathway declined,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386251000000108,Review of anti-obesity drug therapy,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,162573006,Suspected lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,254637007,Non-small cell lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,275981009,Lung cancer screening,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,429011007,Family history of lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,877691000000107,No FH of lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,4441000,Severe bipolar disorder with psychotic features,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,4926007,Schizophrenia in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,5703000,Bipolar disorder in partial remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,12939007,Chronic disorganized schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,13313007,Mild bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,31373002,Hebephrenic schizophrenia in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,31658008,Chronic paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,35252006,Disorganised schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,39610001,Undifferentiated schizophrenia in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,41836007,Bipolar disorder in full remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,53049002,Severe bipolar disorder without psychotic features,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,58214004,Schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,63181006,"Paranoid schizophrenia, in remission",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,64905009,Paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,79584002,Moderate bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,79866005,Subchronic paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,83746006,Chronic schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,85248005,Bipolar disorder in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,111484002,Undifferentiated schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,160328009,Family history of schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,160331005,Family history of bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,161103001,Schizophrenia association member,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,161468000,History of schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191527001,Simple schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191559008,Latent schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191565008,Latent schizophrenia in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191567000,Schizoaffective schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191570001,Chronic schizoaffective schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,231444002,Organic bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,247804008,Prodromal schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,274952002,Borderline schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,444180005,History of schizophrenia in child of subject,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,767632000,"Bipolar disorder, most recent episode manic",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,285521000000103,Schizophrenia resolved,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,1365951000000107,Family intervention for psychosis and bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,21782001,Drug-induced constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,31499008,Chronic constipation with overflow,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,35298007,Colonic constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,82934008,Chronic idiopathic constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,129691005,At increased risk for constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,191973007,Psychogenic constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,197118003,Functional constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,197119006,Acute constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,197120000,Chronic constipation without overflow,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,236069009,Chronic constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,236070005,Simple constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,249517009,Constipation alternates with diarrhea,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,266524003,(Functional constipation) or (impacted feces),LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,440630006,Constipation predominant irritable bowel syndrome,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,443307007,Dietary education for constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,448880001,Cleveland Clinic constipation score,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,847591000000107,Constipation in children clinical pathway,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,1325741000000102,Constipation care indicated,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,86555001,Cystic fibrosis of the lung,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,160309002,Family history of cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,171191008,Cystic fibrosis screening,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,235978006,Cystic fibrosis of pancreas,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,427022004,Liver disease due to cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,428273001,Cystic fibrosis not suspected,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,428301001,Suspected cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,428841003,Cystic fibrosis screening declined,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,441520002,Carrier of cystic fibrosis gene mutation,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,698529000,Seen in cystic fibrosis clinic,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,302651000000109,Cystic fibrosis carrier comment,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,302771000000109,Cystic fibrosis not screened for or screening incomplete,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,384341000000107,Cystic fibrosis repeat screening with further sample required,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,384401000000104,Cystic fibrosis not suspected and other disorders follow up required,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,515611000000104,Cystic fibrosis monitoring,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,515631000000107,Cystic fibrosis annual review,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,526071000000104,Arthropathy in cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,526091000000100,Cystic fibrosis with distal intestinal obstruction syndrome,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,776981000000103,Cirrhosis associated with cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,859041000000103,Exacerbation of cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947031000000109,"Cystic fibrosis screening declined, no history of being screened",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947041000000100,"Cystic fibrosis screening declined, screened in UK (as reported by parents) with no evidence of result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947061000000104,"Cystic fibrosis screening declined, screened outside UK with evidence of result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947081000000108,"Cystic fibrosis screening declined, screened outside UK with no evidence of result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947101000000102,"Cystic fibrosis screening, too young for reliable screening",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947121000000106,"Cystic fibrosis screening,sample taken too soon after blood transfusion (less than 72 hours)",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947141000000104,"Cystic fibrosis screening, insufficient sample",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947161000000103,"Cystic fibrosis screening, unsuitable sample (blood quality): incorrect blood application",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947181000000107,"Cystic fibrosis screening, unsuitable sample (blood quality): compressed/damaged",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947201000000106,"Cystic fibrosis screening, unsuitable sample: day 0 and day 5 on same card",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947221000000102,"Cystic fibrosis screening, unsuitable sample: possible faecal contamination",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947241000000109,"Cystic fibrosis screening, unsuitable sample: NHS number missing/not accurately recorded",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947281000000101,"Cystic fibrosis screening, unsuitable sample: date of sample missing/not accurately recorded",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947301000000100,"Cystic fibrosis screening, unsuitable sample: date of birth not accurately matched",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947321000000109,"Cystic fibrosis screening, unsuitable sample: expired card used",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947341000000102,"Cystic fibrosis screening, unsuitable sample: more than 14 days in transit, too old for analysis",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947361000000101,"Cystic fibrosis screening, unsuitable sample: damaged in transit",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947381000000105,"Cystic fibrosis screening, inconclusive result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947401000000105,"Cystic fibrosis not screened for or screening incomplete: more than 8 weeks, too old for screening",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947491000000103,"Cystic fibrosis not screened for or screening incomplete, moved out of area",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947511000000106,"Cystic fibrosis not screened for or screening incomplete, not contactable, reasonable efforts made",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947551000000105,"Cystic fibrosis not screened for or screening incomplete, not required, previous valid result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,1015871000000108,Cystic fibrosis screening test,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,1028351000000108,Cystic fibrosis screening,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +LUSPATERCEPT,Anaemia caused by myelodysplastic syndromes,TA844,myelodysplastic,109998009,MDS-RS-SLD - myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia,LUSPATERCEPT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +LUSPATERCEPT,Anaemia caused by myelodysplastic syndromes,TA844,myelodysplastic,398623004,Myelodysplastic syndrome with excess blasts,LUSPATERCEPT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +LUSPATERCEPT,Anaemia caused by myelodysplastic syndromes,TA844,myelodysplastic,447596005,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",LUSPATERCEPT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +LUSUTROMBOPAG,Trombocytopenia in people with chronic liver disease needing a planned invasive procedure,TA617,chronic liver disease,197279005,Cirrhosis and chronic liver disease,LUSUTROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY +LUSUTROMBOPAG,Trombocytopenia in people with chronic liver disease needing a planned invasive procedure,TA617,chronic liver disease,197324004,Liver abscess and sequelae of chronic liver disease,LUSUTROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY +LUSUTROMBOPAG,Trombocytopenia in people with chronic liver disease needing a planned invasive procedure,TA617,chronic liver disease,328383001,Chronic liver disease,LUSUTROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY +LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,48554007,Enterochromaffin cell neuroendocrine tumour,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,60346004,Non-functioning pancreatic neuroendocrine tumour,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,707594002,Bronchial neuroendocrine tumour,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,1287573002,Well-differentiated neuroendocrine tumour of bronchus,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,1290068000,Well-differentiated neuroendocrine tumour of rectum,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,86555001,Cystic fibrosis of the lung,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,160309002,Family history of cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,171191008,Cystic fibrosis screening,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,235978006,Cystic fibrosis of pancreas,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,427022004,Liver disease due to cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,428273001,Cystic fibrosis not suspected,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,428301001,Suspected cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,428841003,Cystic fibrosis screening declined,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,441520002,Carrier of cystic fibrosis gene mutation,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,698529000,Seen in cystic fibrosis clinic,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,302651000000109,Cystic fibrosis carrier comment,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,302771000000109,Cystic fibrosis not screened for or screening incomplete,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,384341000000107,Cystic fibrosis repeat screening with further sample required,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,384401000000104,Cystic fibrosis not suspected and other disorders follow up required,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,515611000000104,Cystic fibrosis monitoring,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,515631000000107,Cystic fibrosis annual review,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,526071000000104,Arthropathy in cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,526091000000100,Cystic fibrosis with distal intestinal obstruction syndrome,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,776981000000103,Cirrhosis associated with cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,859041000000103,Exacerbation of cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947031000000109,"Cystic fibrosis screening declined, no history of being screened",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947041000000100,"Cystic fibrosis screening declined, screened in UK (as reported by parents) with no evidence of result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947061000000104,"Cystic fibrosis screening declined, screened outside UK with evidence of result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947081000000108,"Cystic fibrosis screening declined, screened outside UK with no evidence of result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947101000000102,"Cystic fibrosis screening, too young for reliable screening",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947121000000106,"Cystic fibrosis screening,sample taken too soon after blood transfusion (less than 72 hours)",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947141000000104,"Cystic fibrosis screening, insufficient sample",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947161000000103,"Cystic fibrosis screening, unsuitable sample (blood quality): incorrect blood application",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947181000000107,"Cystic fibrosis screening, unsuitable sample (blood quality): compressed/damaged",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947201000000106,"Cystic fibrosis screening, unsuitable sample: day 0 and day 5 on same card",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947221000000102,"Cystic fibrosis screening, unsuitable sample: possible faecal contamination",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947241000000109,"Cystic fibrosis screening, unsuitable sample: NHS number missing/not accurately recorded",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947281000000101,"Cystic fibrosis screening, unsuitable sample: date of sample missing/not accurately recorded",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947301000000100,"Cystic fibrosis screening, unsuitable sample: date of birth not accurately matched",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947321000000109,"Cystic fibrosis screening, unsuitable sample: expired card used",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947341000000102,"Cystic fibrosis screening, unsuitable sample: more than 14 days in transit, too old for analysis",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947361000000101,"Cystic fibrosis screening, unsuitable sample: damaged in transit",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947381000000105,"Cystic fibrosis screening, inconclusive result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947401000000105,"Cystic fibrosis not screened for or screening incomplete: more than 8 weeks, too old for screening",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947491000000103,"Cystic fibrosis not screened for or screening incomplete, moved out of area",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947511000000106,"Cystic fibrosis not screened for or screening incomplete, not contactable, reasonable efforts made",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947551000000105,"Cystic fibrosis not screened for or screening incomplete, not required, previous valid result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,1015871000000108,Cystic fibrosis screening test,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,1028351000000108,Cystic fibrosis screening,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,28944009,Cytomegalovirus disease,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,59527008,Congenital cytomegalovirus infection,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,75469003,"Toxoplasmosis, other infections, rubella, cytomegalovirus, and herpes simplex virus antibody panel measurement",MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,120941004,Cytomegalovirus immunoglobulin,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,243579005,Human cytomegalovirus,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,252410004,Cytomegalovirus antibody screening,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,260207001,Early antigen of Cytomegalovirus,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,271500008,Intravenous injection of anticytomegalovirus immunoglobulin,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,304289003,Cytomegalovirus status,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,407444007,Genus Cytomegalovirus,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,445459004,Cytomegalovirus antibody detected in serum,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,64681000237105,CMV (cytomegalovirus) IgG antibody in serum qualitative result,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,791021000000102,Cytomegalovirus IgM antibody positive,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,791071000000103,Cytomegalovirus IgM antibody negative,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,995431000000104,CMV (cytomegalovirus) antibody level,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,998791000000104,Cytomegalovirus antigen test,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1008531000000101,Cytomegalovirus DNA (deoxyribonucleic acid) detection assay,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1008731000000105,CMV (cytomegalovirus) IgM antibody level,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1008741000000101,CMV (cytomegalovirus) IgG antibody level,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1014131000000100,Cytomegalovirus early antigen level,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1018601000000108,Cytomegalovirus IgG avidity test,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1030491000000105,Cytomegalovirus nucleic acid detection assay,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1031441000000108,Cytomegalovirus latex test,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,22193007,Osteoarthritis of joint of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,33952002,Localised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,37895003,Osteoarthritis of first carpometacarpal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,82300000,Osteoarthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,160414002,Family history: Osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,161568003,History of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201819000,Generalised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201852006,"Localised, secondary osteoarthritis of the hand",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201889009,"Osteoarthritis NOS, of the upper arm",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201890000,Wrist osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201891001,Thumb osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201893003,Knee osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201894009,"Osteoarthritis NOS, of ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,202655008,Osteoarthritis of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239863005,Osteoarthritis of spinal facet joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239866002,Osteoarthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239868001,Osteoarthritis of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239874001,Osteoarthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239878003,Osteoarthritis of toe joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267889007,Generalized osteoarthritis of the hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,268054009,Osteoarthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313257005,"Localized, primary osteoarthritis of the wrist",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313258000,"Localised, primary osteoarthritis of toe",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313259008,"Localized, primary osteoarthritis of elbow",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,373623009,Osteoarthritis of glenohumeral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,394991004,Flare of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,443524000,Secondary osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,450521003,Osteoarthritis of patellofemoral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,700324005,Osteoarthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1162304008,Oligoarticular osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343601009,OA (osteoarthritis) of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343603007,Osteoarthritis of thoracic spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343604001,Cervical osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343605000,Osteoarthritis of lumbar spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323301000119109,Osteoarthritis of left knee joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323311000119107,Osteoarthritis of right hip joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666451000000100,"Osteoarthritis NOS, other specified site",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,850791000000102,Osteoarthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,234336002,Haemopoietic stem cell transplant,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,397554006,Limbal stem cell transplantation,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,425843001,Allogeneic peripheral blood stem cell transplant,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,425983008,Autologous peripheral blood stem cell transplant,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,284681000000100,Syngeneic peripheral blood stem cell transplant,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +MEMANTINE,Alzheimer's disease,TA111,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease,TA111,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease,TA111,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease,TA111,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease (moderate),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease (moderate),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease (moderate),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease (moderate),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease (severe),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease (severe),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease (severe),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEMANTINE,Alzheimer's disease (severe),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +MEPOLIZUMAB,Eosinophilic granulomatosis with polyangiitis,TA845,granulomatosis with polyangiitis,82275008,EGPA - eosinophilic granulomatosis with polyangiitis,MEPOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|THORACIC MEDICINE|NEPHROLOGY +MEPOLIZUMAB,Eosinophilic granulomatosis with polyangiitis,TA845,granulomatosis with polyangiitis,239935007,Limited granulomatosis with polyangiitis,MEPOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|THORACIC MEDICINE|NEPHROLOGY +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,12428000,Intrinsic asthma without status asthmaticus,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,31387002,Exercise-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,34015007,Flour asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,56018004,Asthmatic breathing,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,56968009,Asthma caused by wood dust,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,57607007,Industrial asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,63088003,Allergic asthma without status asthmaticus,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,71892000,Cardiac asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,93432008,Drug-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,160377001,Family history of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,161105008,Asthma society member,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,161527007,History of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,162660004,Asthma resolved,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170631002,Asthma disturbing sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170632009,Asthma causing night waking,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170633004,Asthma disturbs sleep weekly,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170634005,Asthma disturbs sleep frequently,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170635006,Asthma not disturbing sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170636007,Asthma never disturbs sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170637003,Asthma limiting activities,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170638008,Asthma not limiting activities,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170642006,Asthma severity,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170647000,Asthma prophylactic medication used,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170655007,Asthma restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170656008,Asthma sometimes restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170657004,Asthma severely restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170658009,Asthma never restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,171231001,Asthma screening,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182724005,Further asthma - drug prevention,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182726007,Asthma control step 0,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182727003,Asthma control step 1,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182728008,Asthma control step 2,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182729000,Asthma control step 3,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182730005,Asthma control step 4,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182731009,Asthma control step 5,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,183099005,Asthma leaflet given,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,183478001,Emergency hospital admission for asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185242005,Seen in asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185728001,Attends asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185730004,Asthma monitor offer default,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185731000,Asthma monitoring call first letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185732007,Asthma monitoring call second letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185734008,Asthma monitoring call third letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185735009,Asthma monitoring call verbal invite,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185736005,Asthma monitoring call telephone invite,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185737001,Asthma monitoring deleted,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185940009,Patient in asthma study,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195949008,Chronic asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195967001,Asthmatic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195973000,Late-onset asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195977004,Mixed asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195983001,Exercise induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,219036002,Adverse reaction to antiasthmatic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,225057002,Brittle asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,233678006,Childhood asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,233679003,Late-onset asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,233683003,Hay fever with asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,233691007,Eosinophilic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,266361008,Non-allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,266396008,Extrinsic asthma - atopy (& pollen),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,266397004,Intrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,266398009,Asthma attack,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,270442000,Asthma monitoring check done,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,275908000,Asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,281239006,Asthma attack,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,302220000,Asthma control steps,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,304527002,Acute asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,308500005,Asthma monitoring call,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,308501009,Asthma monitoring status,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,312453004,Asthma - currently active,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,312454005,Asthma - currently dormant,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,366874008,Number of asthma exacerbations in past year,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370204008,Asthma causes daytime symptoms most days,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370206005,Asthma limits walking on the flat,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370207001,Asthma limits walking up hills or stairs,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370208006,Asthma never causes daytime symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370218001,Mild asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370219009,Moderate asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370220003,Occasional asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370221004,Severe asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370225008,Asthma treatment compliance unsatisfactory,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370226009,Asthma treatment compliance satisfactory,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,373899003,Asthma daytime symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,389145006,Allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390798007,Asthma finding,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390872009,Change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390877003,Step up change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390878008,Step down change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390921001,Absent from work or school due to asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390940007,Asthma monitoring due,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,394700004,Asthma annual review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,394701000,Asthma follow-up,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,394720003,Asthma medication review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,394967008,Suspected asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,395022009,Nocturnal asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,400987003,Asthma trigger,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401135008,Health education - asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401182001,Asthma monitoring by nurse,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401183006,Asthma monitoring by doctor,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401193004,Asthma confirmed,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,405944004,Asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,406162001,Asthma care,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,407674008,Aspirin-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,409663006,Cough variant asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,415265005,Referral to asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,424643009,Allergic atopic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,425969006,Acute intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,426656000,Severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,426979002,Mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,427295004,Moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,427603009,Intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,427679007,Mild intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,443117005,Asthma control test score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,445427006,Seasonal asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,445531003,ACQ - Asthma control questionnaire,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,473391009,Asthma never causes night symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,698509001,Under care of asthma specialist nurse,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,699191007,Did not attend asthma review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,702823004,Asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,704008007,No family history of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707445000,Acute mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707446004,Acute exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707447008,Exacerbation of severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707511009,Uncomplicated mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707512002,Uncomplicated moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707513007,Uncomplicated severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707979007,Acute severe exacerbation of severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707981009,Acute severe exacerbation of mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708038006,Acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708090002,Acute severe exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708093000,Acute exacerbation of allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708094006,Acute exacerbation of intrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708095007,Acute severe exacerbation of extrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708358003,Emergency asthma admission since last encounter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708373002,Emergency asthma patient visit since last encounter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,711442001,Recent asthma management,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,715191006,Telehealth asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,734346005,Use of asthma symptom diary,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,734904007,Life threatening acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,734905008,Moderate acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,736056000,Asthma clinical management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,762521001,Acute allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,763077003,Asthma Control Questionnaire score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,763221007,Asthma monitoring declined,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,782520007,Exacerbation of allergic asthma due to infection,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,782559003,Asthma never causes night symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401000119107,Asthma with irreversible airway obstruction,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,641000119106,Intermittent asthma well controlled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1741000119102,Intermittent asthma uncontrolled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,72301000119103,Asthma in pregnancy,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,89581000000109,DNA (did not attend) asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,143901000000108,Registration for access to online asthma self-management application,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,143931000000102,Declined to register for access to online asthma self-management application,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,176711000000100,Does not have asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,198971000000102,Asthma outreach clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201031000000108,Asthma trigger - respiratory infection,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201041000000104,Asthma trigger - seasonal,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201051000000101,Asthma trigger - animal,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201191000000108,Asthma trigger - cold air,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201201000000105,Asthma trigger - damp,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201211000000107,Asthma trigger - emotion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340891000000106,Asthma trigger - airborne dust,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340901000000107,Asthma trigger - exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340911000000109,Asthma trigger - pollen,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340921000000103,Asthma trigger - tobacco smoke,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340931000000101,Asthma trigger - warm air,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,527171000000103,Patient has a written asthma personal action plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,527191000000104,Health education - asthma self management,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,527211000000100,Health education - structured asthma discussion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,527231000000108,Health education - structured patient focused asthma discussion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,713701000000108,Asthma monitoring administration,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,713711000000105,Asthma clinic administration,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,715801000000103,Exception reporting - asthma quality indicators,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,771941000000102,Asthma causes symptoms most nights,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,772051000000106,Asthma limits activities most days,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,791401000000104,Seen in school asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,810901000000102,Asthma self-management plan review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,811921000000103,Asthma self-management plan agreed,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,815631000000106,Asthma trigger - wind,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,818161000000104,Asthma trigger - perfume,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,867171000000106,No asthma trigger identified by subject,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,892301000000100,Asthma management plan declined,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,905301000000103,Childhood Asthma Control Test score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,928451000000107,Asthma monitoring invitation short message service text message,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,928511000000107,Asthma monitoring invitation email,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,928651000000105,Review of patient at risk of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,928691000000102,At risk of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,959901000000107,Asthma action plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,966011000000109,At risk of severe asthma exacerbation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,966031000000101,Severe asthma exacerbation risk assessment,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10674991000119104,Intermittent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10675431000119106,Severe persistent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10675871000119106,Mild persistent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10676031000119106,Mild persistent allergic asthma controlled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,12428000,Intrinsic asthma without status asthmaticus,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,31387002,Exercise-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,34015007,Flour asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,56018004,Asthmatic breathing,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,56968009,Asthma caused by wood dust,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,57607007,Industrial asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,63088003,Allergic asthma without status asthmaticus,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,71892000,Cardiac asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,93432008,Drug-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,160377001,Family history of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,161105008,Asthma society member,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,161527007,History of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,162660004,Asthma resolved,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170631002,Asthma disturbing sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170632009,Asthma causing night waking,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170633004,Asthma disturbs sleep weekly,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170634005,Asthma disturbs sleep frequently,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170635006,Asthma not disturbing sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170636007,Asthma never disturbs sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170637003,Asthma limiting activities,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170638008,Asthma not limiting activities,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170642006,Asthma severity,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170647000,Asthma prophylactic medication used,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170655007,Asthma restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170656008,Asthma sometimes restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170657004,Asthma severely restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170658009,Asthma never restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,171231001,Asthma screening,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182724005,Further asthma - drug prevention,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182726007,Asthma control step 0,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182727003,Asthma control step 1,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182728008,Asthma control step 2,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182729000,Asthma control step 3,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182730005,Asthma control step 4,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182731009,Asthma control step 5,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,183099005,Asthma leaflet given,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,183478001,Emergency hospital admission for asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185242005,Seen in asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185728001,Attends asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185730004,Asthma monitor offer default,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185731000,Asthma monitoring call first letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185732007,Asthma monitoring call second letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185734008,Asthma monitoring call third letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185735009,Asthma monitoring call verbal invite,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185736005,Asthma monitoring call telephone invite,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185737001,Asthma monitoring deleted,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185940009,Patient in asthma study,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195949008,Chronic asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195967001,Asthmatic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195973000,Late-onset asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195977004,Mixed asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195983001,Exercise induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,219036002,Adverse reaction to antiasthmatic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,225057002,Brittle asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,233678006,Childhood asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,233679003,Late-onset asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,233683003,Hay fever with asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,233691007,Eosinophilic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,266361008,Non-allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,266396008,Extrinsic asthma - atopy (& pollen),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,266397004,Intrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,266398009,Asthma attack,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,270442000,Asthma monitoring check done,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,275908000,Asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,281239006,Asthma attack,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,302220000,Asthma control steps,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,304527002,Acute asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,308500005,Asthma monitoring call,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,308501009,Asthma monitoring status,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,312453004,Asthma - currently active,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,312454005,Asthma - currently dormant,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,366874008,Number of asthma exacerbations in past year,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370204008,Asthma causes daytime symptoms most days,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370206005,Asthma limits walking on the flat,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370207001,Asthma limits walking up hills or stairs,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370208006,Asthma never causes daytime symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370218001,Mild asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370219009,Moderate asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370220003,Occasional asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370221004,Severe asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370225008,Asthma treatment compliance unsatisfactory,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370226009,Asthma treatment compliance satisfactory,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,373899003,Asthma daytime symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,389145006,Allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390798007,Asthma finding,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390872009,Change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390877003,Step up change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390878008,Step down change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390921001,Absent from work or school due to asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390940007,Asthma monitoring due,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,394700004,Asthma annual review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,394701000,Asthma follow-up,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,394720003,Asthma medication review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,394967008,Suspected asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,395022009,Nocturnal asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,400987003,Asthma trigger,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401135008,Health education - asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401182001,Asthma monitoring by nurse,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401183006,Asthma monitoring by doctor,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401193004,Asthma confirmed,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,405944004,Asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,406162001,Asthma care,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,407674008,Aspirin-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,409663006,Cough variant asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,415265005,Referral to asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,424643009,Allergic atopic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,425969006,Acute intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,426656000,Severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,426979002,Mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,427295004,Moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,427603009,Intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,427679007,Mild intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,443117005,Asthma control test score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,445427006,Seasonal asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,445531003,ACQ - Asthma control questionnaire,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,473391009,Asthma never causes night symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,698509001,Under care of asthma specialist nurse,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,699191007,Did not attend asthma review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,702823004,Asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,704008007,No family history of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707445000,Acute mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707446004,Acute exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707447008,Exacerbation of severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707511009,Uncomplicated mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707512002,Uncomplicated moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707513007,Uncomplicated severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707979007,Acute severe exacerbation of severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707981009,Acute severe exacerbation of mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708038006,Acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708090002,Acute severe exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708093000,Acute exacerbation of allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708094006,Acute exacerbation of intrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708095007,Acute severe exacerbation of extrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708358003,Emergency asthma admission since last encounter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708373002,Emergency asthma patient visit since last encounter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,711442001,Recent asthma management,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,715191006,Telehealth asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,734346005,Use of asthma symptom diary,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,734904007,Life threatening acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,734905008,Moderate acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,736056000,Asthma clinical management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,762521001,Acute allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,763077003,Asthma Control Questionnaire score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,763221007,Asthma monitoring declined,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,782520007,Exacerbation of allergic asthma due to infection,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,782559003,Asthma never causes night symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401000119107,Asthma with irreversible airway obstruction,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,641000119106,Intermittent asthma well controlled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1741000119102,Intermittent asthma uncontrolled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,72301000119103,Asthma in pregnancy,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,89581000000109,DNA (did not attend) asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,143901000000108,Registration for access to online asthma self-management application,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,143931000000102,Declined to register for access to online asthma self-management application,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,176711000000100,Does not have asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,198971000000102,Asthma outreach clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201031000000108,Asthma trigger - respiratory infection,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201041000000104,Asthma trigger - seasonal,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201051000000101,Asthma trigger - animal,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201191000000108,Asthma trigger - cold air,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201201000000105,Asthma trigger - damp,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201211000000107,Asthma trigger - emotion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340891000000106,Asthma trigger - airborne dust,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340901000000107,Asthma trigger - exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340911000000109,Asthma trigger - pollen,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340921000000103,Asthma trigger - tobacco smoke,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340931000000101,Asthma trigger - warm air,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,527171000000103,Patient has a written asthma personal action plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,527191000000104,Health education - asthma self management,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,527211000000100,Health education - structured asthma discussion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,527231000000108,Health education - structured patient focused asthma discussion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,713701000000108,Asthma monitoring administration,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,713711000000105,Asthma clinic administration,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,715801000000103,Exception reporting - asthma quality indicators,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,771941000000102,Asthma causes symptoms most nights,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,772051000000106,Asthma limits activities most days,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,791401000000104,Seen in school asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,810901000000102,Asthma self-management plan review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,811921000000103,Asthma self-management plan agreed,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,815631000000106,Asthma trigger - wind,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,818161000000104,Asthma trigger - perfume,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,867171000000106,No asthma trigger identified by subject,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,892301000000100,Asthma management plan declined,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,905301000000103,Childhood Asthma Control Test score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,928451000000107,Asthma monitoring invitation short message service text message,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,928511000000107,Asthma monitoring invitation email,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,928651000000105,Review of patient at risk of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,928691000000102,At risk of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,959901000000107,Asthma action plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,966011000000109,At risk of severe asthma exacerbation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,966031000000101,Severe asthma exacerbation risk assessment,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10674991000119104,Intermittent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10675431000119106,Severe persistent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10675871000119106,Mild persistent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10676031000119106,Mild persistent allergic asthma controlled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,169941005,Maternal drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228366006,Drug misuse history,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228371004,Long-term drug misuser,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228372006,Poly-drug misuser,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228390007,Frequency of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228411009,Time since stopped drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228413007,Age at starting drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,371435006,History of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,439213009,Paternal drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,442080007,Drug misuse by mother,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,700187009,Seen in drug misuse clinic,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712542001,Abstinent from drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712543006,Abstinent from drug misuse in normal environment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712544000,Abstinent from drug misuse in protected environment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712545004,Abstinent from drug misuse on maintenance replacement,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712546003,Abstinent from drug misuse when receiving blocking therapy,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,713070003,Drug misuser in household,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,744857009,Under care of drug misuse service,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,176811000000105,Drug misuse enhanced services administration,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,176831000000102,Drug misuse enhanced service completed,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,362451000000107,Drug misuse assessment declined,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,372511000000103,Shared care drug misuse treatment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,372541000000102,Drug misuse treatment in primary care,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,383871000000108,Health problem secondary to drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,503771000000102,SMR25a drug misuse initial assessment form,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,503801000000104,SMR25b drug misuse follow up assessment form,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,505091000000102,Declined consent for notification of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,507041000000101,Name of pharmacy attended due to drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,869161000000106,Drug misuse clinic administration,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,1364721000000101,Date stopped drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,21782001,Drug-induced constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,31499008,Chronic constipation with overflow,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,35298007,Colonic constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,82934008,Chronic idiopathic constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,129691005,At increased risk for constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,191973007,Psychogenic constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,197118003,Functional constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,197119006,Acute constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,197120000,Chronic constipation without overflow,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,236069009,Chronic constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,236070005,Simple constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,249517009,Constipation alternates with diarrhea,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,266524003,(Functional constipation) or (impacted feces),METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,440630006,Constipation predominant irritable bowel syndrome,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,443307007,Dietary education for constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,448880001,Cleveland Clinic constipation score,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,847591000000107,Constipation in children clinical pathway,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,1325741000000102,Constipation care indicated,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,7461003,"Attention deficit hyperactivity disorder, hyperactive impulsive type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,31177006,"Attention deficit hyperactivity disorder, combined type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702536007,Stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702538008,Drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,703314001,Non-stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516401000000106,Attention deficit hyperactivity disorder monitoring invitation first letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516891000000101,Attention deficit hyperactivity disorder monitoring invitation second letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516911000000103,Attention deficit hyperactivity disorder monitoring invitation third letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,710071000000106,Attention deficit hyperactivity disorder annual review,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886371000000105,On drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886391000000109,On stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886411000000109,On non-stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1863681000000108,Attention deficit hyperactivity disorder suspected,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1914891000000100,Diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2427101000000103,Signposting to attention deficit hyperactivity disorder resource,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2437121000000109,Referral for diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +METHYLPHENIDATE,Attention-Deficit Hyperactivity Disorder,TA013,attention-deficit hyperactivity disorder,769390009,World Health Organization Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale,METHYLPHENIDATE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS +MEXILETINE,Myotonia in non-dystrophic myotonic disorders,TA748,myotonia,63135006,Amyotonia congenita,MEXILETINE,NEUROLOGY,NEUROLOGY +MIDOSTAURIN,Advanced systemic mastocytosis,TA728,systemic mastocytosis,50150000,Malignant systemic mastocytosis,MIDOSTAURIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CLINICAL IMMUNOLOGY +MIDOSTAURIN,Advanced systemic mastocytosis,TA728,systemic mastocytosis,70910003,Indolent systemic mastocytosis,MIDOSTAURIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CLINICAL IMMUNOLOGY +MIDOSTAURIN,Untreated acute myeloid leukaemia,TA523,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",MIDOSTAURIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,12302002,Round cell osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY +MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,12690005,Fibroblastic osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY +MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,21708004,Osteosarcoma - morphology,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY +MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,33681003,Osteosarcoma in Paget disease of bone,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY +MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,76312009,Chondroblastic osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY +MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,128918008,Parosteal osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY +MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,307576001,Osteosarcoma of bone,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY +MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,735680008,Primary osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,6744007,Painful urinary bladder spasm,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,13516000,Adhesions of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,14329006,Dilation of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,19744006,Operation on gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,22421007,Congenital absence of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,31911002,Radiography of kidney-ureter-bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,36503003,Biopsy of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,39621005,Gallbladder disease,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,42111002,Urinary bladder function,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,43748006,Removal of urinary bladder catheter,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,44817001,Extracorporeal shockwave lithotripsy of bladder calculus,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,68666001,Fistula of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,76875008,Hypertrophy of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,79184009,Trabeculation of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,89310008,Contracted bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,89837001,Bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,91992005,Benign neoplasm of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,92599005,Carcinoma in situ of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,94754000,Neoplasm of uncertain behaviour of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,94850000,Neoplasm of uncertain behavior of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,95586000,Telangiectasia of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,111372003,Gallbladder gangrene,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,126854002,Neoplasm of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,126885006,Neoplasm of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,126886007,Tumor of trigone of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,161537002,H/O: gallbladder dis.,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,163361001,On examination - bladder not palpable,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,168053004,On examination - bladder calculus,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,168854009,Contrast radiography of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,169010007,Fluoroscopy - gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,169250003,Ultrasound scan of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,170214001,Child examination: bladder control,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,174520006,Exploration of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,174525001,Percutaneous drainage of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,174526000,Percutaneous fragmentation of gallbladder stone,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176116001,Enlargement &/or replacement of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176146003,Open biopsy of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176166007,Transurethral transection of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176167003,Balloon distension of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176182008,Diagnostic cystoscopy and biopsy of bladder lesion using rigid instrument,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176184009,Rigid check cystoscopy and biopsy of bladder lesion,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176188007,Check cystoscopy and biopsy of bladder lesion using flexible instrument,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176201006,Instillation of therapeutic substance into bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176220008,Abdominal operations to support outlet of female bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176234008,Open resection of female urinary bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176246007,Transurethral excision of female urinary bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176247003,Endoscopic myotomy of female bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,181423002,Structure of outlet of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,183228000,Bladder control,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,188239000,Malignant tumour of trigone of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,189459005,Transitional cell papilloma of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,197859007,Stenosis of bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,199205008,Infections of bladder in pregnancy,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,204999002,Atresia of neck of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,205022009,Congenital hernia of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,211648000,Foreign body in urinary bladder and urethra,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,213268006,Accidental bladder perforation during operation,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,235523007,Fine needle aspiration of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,236238000,Transurethral extraction of bladder calculus without disintegration,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,236242002,Fixed suspension procedure of urinary bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,236631000,Leukoplakia of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,236671005,Necrosis of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,237330001,Obstetric injury of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,249297006,Spasm of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,249569004,Gallbladder finding,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,249586005,Urinary bladder palpable,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,252006009,Finding of sensation of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,252010007,Functional urinary bladder capacity,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,252011006,Maximum anaesthetic urinary bladder capacity,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,252904009,Bladder neck electric conductance test,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,254339002,Tumor-node-metastasis (TNM) urinary bladder tumour staging,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,254929002,Tumour of vault of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,258493006,Urinary bladder calculus specimen,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,262805007,Injury of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,265566009,Enlargement or replacement of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,266535008,Gallbladder disease,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,267590006,Cauda equina syndrome with cord bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,274037007,Transurethral excision of papilloma of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,274360007,Surgical biopsy of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,275075003,Replacement of artificial urinary bladder neck sphincter in female,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,275550008,History of gallbladder disease,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,275819003,Bladder control - child,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,279412007,Entire muscularis of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,281386008,Entire posterior wall of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,281700003,Benign papilloma of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,285640005,Metastasis to bladder of unknown primary,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,288011009,Transurethral electroresection of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,288014001,Reconstruction of sphincter of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300341002,Gallbladder absent,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300344005,Gallbladder enlarged,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300355005,Gallbladder normal,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300455006,Large urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300457003,Lesion of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,303088008,Incompetence of neck of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,303409005,Structure of urinary bladder and outflow,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,309248004,Urinary bladder polyp,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,309272009,Urinary bladder tissue specimen,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,309509003,Transurethral endoscopic lithotripsy of bladder calculus,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,314962005,Local recurrence of malignant neoplasm of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,314995004,Metastasis from malignant tumour of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,361259002,Cystoscopy and cauterization of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,366279009,Finding of urinary bladder control,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,370984003,Removal of calculus from bladder by incision,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,371005009,Removal of calculus of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,372140005,Carcinoma of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,373721004,Urinary bladder emptying,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,384629005,Transurethral destruction of bladder lesion,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,388229009,Transurethral external sphincterotomy of male urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,398064005,Neurogenic urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,399326009,Bladder cancer,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,762619000,Screening for malignant neoplasm of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,784285002,Tenesmus of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,285081000000106,High intensity focused ultrasound of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,500851000000105,[D]Bladder filling defect,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,571631000000102,Other gallbladder disorders NOS,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,597971000000106,Other gallbladder disorders,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,655301000000105,Bladder disorders NOS,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,661941000000101,Other disorders of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,795311000000108,Diagnostic endoscopic examination of bladder and biopsy of lesion of prostate,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,162573006,Suspected lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,254637007,Non-small cell lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,275981009,Lung cancer screening,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,429011007,Family history of lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,877691000000107,No FH of lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,62914000,Cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,72092001,Arteriosclerotic vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,123799005,Hypertension due to renovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,127014009,Diabetic peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,134379001,Peripheral vascular disease monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,160270001,No family history of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,161499004,H/O: cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,171405001,Examination for suspected cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,195239002,Late effects of cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,198057005,Male genital organ vascular diseases,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,230738008,Asymptomatic cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,233845001,Coronary microvascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,266320008,Peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,266894000,Family history of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,266995000,History of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,275509000,Infective vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,302909007,Diffuse cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,308064009,History of cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,308071004,History of peripheral vascular disease procedure,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,395048001,Cardiovascular disease monitoring not required,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,400047006,PVD - peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,413988000,Did not attend peripheral vascular disease clinic,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,417206009,Cardiovascular disease monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,417287002,Cardiovascular disease interim monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,417322008,Cardiovascular disease annual review,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,429284000,Cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,429785003,Cardiovascular disease health education,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,438370008,Vascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,440401008,Vascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,441829007,Assessment for risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,443929000,Small vessel cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,473109007,History of peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,205001000000100,Suspected cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,302881000000102,Cardiovascular disease annual review declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375421000000101,Vascular disease risk assessment invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375511000000106,Vascular disease risk assessment first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375541000000107,Vascular disease risk assessment second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375571000000101,Vascular disease risk assessment third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,492581000000108,Cardiovascular disease high risk review declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,492611000000102,Cardiovascular disease high risk review,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,646351000000103,Peripheral vascular disease NOS,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,810681000000101,Coronary microvascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,837461000000101,High risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,845171000000108,At risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,858191000000103,FH: peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,865391000000100,No peripheral vascular disease symptoms,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,990301000000105,Cardiovascular disease risk assessment done,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,16434071000119108,At increased risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (children),TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (children),TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (children),TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM (MPS),Renal transplantation (children),TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM (MPS),Renal transplantation (children),TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +MYCOPHENOLATE SODIUM (MPS),Renal transplantation (children),TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +NAFTIDROFYRYL OXALATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822611000000100,Exception reporting - peripheral arterial disease quality indicators,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +NAFTIDROFYRYL OXALATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822641000000104,Excepted from peripheral arterial disease quality indicators - patient unsuitable,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +NAFTIDROFYRYL OXALATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822671000000105,Excepted from peripheral arterial disease quality indicators - informed dissent,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +NAFTIDROFYRYL OXALATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,968121000000103,Peripheral arterial disease screening,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,21782001,Drug-induced constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,31499008,Chronic constipation with overflow,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,35298007,Colonic constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,82934008,Chronic idiopathic constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,129691005,At increased risk for constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,191973007,Psychogenic constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,197118003,Functional constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,197119006,Acute constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,197120000,Chronic constipation without overflow,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,236069009,Chronic constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,236070005,Simple constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,249517009,Constipation alternates with diarrhea,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,266524003,(Functional constipation) or (impacted feces),NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,440630006,Constipation predominant irritable bowel syndrome,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,443307007,Dietary education for constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,448880001,Cleveland Clinic constipation score,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,847591000000107,Constipation in children clinical pathway,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,1325741000000102,Constipation care indicated,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,21782001,Drug-induced constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,31499008,Chronic constipation with overflow,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,35298007,Colonic constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,82934008,Chronic idiopathic constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,129691005,At increased risk for constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,191973007,Psychogenic constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,197118003,Functional constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,197119006,Acute constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,197120000,Chronic constipation without overflow,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,236069009,Chronic constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,236070005,Simple constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,249517009,Constipation alternates with diarrhea,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,266524003,(Functional constipation) or (impacted feces),NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,440630006,Constipation predominant irritable bowel syndrome,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,443307007,Dietary education for constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,448880001,Cleveland Clinic constipation score,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,847591000000107,Constipation in children clinical pathway,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALOXEGOL,Opioid‑induced constipation,TA345,constipation,1325741000000102,Constipation care indicated,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,169941005,Maternal drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,228366006,Drug misuse history,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,228371004,Long-term drug misuser,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,228372006,Poly-drug misuser,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,228390007,Frequency of drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,228411009,Time since stopped drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,228413007,Age at starting drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,371435006,History of drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,439213009,Paternal drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,442080007,Drug misuse by mother,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,700187009,Seen in drug misuse clinic,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,712542001,Abstinent from drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,712543006,Abstinent from drug misuse in normal environment,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,712544000,Abstinent from drug misuse in protected environment,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,712545004,Abstinent from drug misuse on maintenance replacement,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,712546003,Abstinent from drug misuse when receiving blocking therapy,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,713070003,Drug misuser in household,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,744857009,Under care of drug misuse service,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,176811000000105,Drug misuse enhanced services administration,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,176831000000102,Drug misuse enhanced service completed,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,362451000000107,Drug misuse assessment declined,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,372511000000103,Shared care drug misuse treatment,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,372541000000102,Drug misuse treatment in primary care,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,383871000000108,Health problem secondary to drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,503771000000102,SMR25a drug misuse initial assessment form,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,503801000000104,SMR25b drug misuse follow up assessment form,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,505091000000102,Declined consent for notification of drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,507041000000101,Name of pharmacy attended due to drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,869161000000106,Drug misuse clinic administration,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE,Drug misuse,TA115,drug misuse,1364721000000101,Date stopped drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,44772007,Maternal obesity without hypertension,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,82793005,Hypothalamic obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,160311006,Family history: Obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,161453001,History of obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,162864005,Body mass index 30+ - obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170793009,Obesity monitoring,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170794003,Initial obesity assessment,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170795002,Follow-up obesity assessment,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170797005,Has seen dietician - obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170798000,Treatment of obesity changed,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170799008,Treatment of obesity started,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170800007,Treatment of obesity stopped,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170807005,Reason for obesity therapy - occupational,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185741002,Attends obesity monitoring,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185743004,Obesity monitoring default,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185744005,Obesity monitoring first letter,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185745006,Obesity monitoring second letter,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185746007,Obesity monitoring third letter,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185747003,Obesity monitoring verbal invite,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185748008,Obesity monitoring telephone invite,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185749000,Obesity monitoring deleted,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185750000,Obesity monitoring check done,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,190965006,Drug-induced obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,190966007,Obesity hypoventilation syndrome,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,235240002,Procedure using anti-obesity gastric balloon,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,238132000,Upper body obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,238133005,Gynecoid obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,238134004,Generalized obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,238136002,Morbid obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,243862009,Obesity monitoring status,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,247824007,Fear of obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,267511009,Hyperalimentation incl.obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,268522006,Obesity monitoring,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,268551005,Obesity screening,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,270486005,Localized obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,276792008,Pulmonary hypertension with extreme obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,277831002,Anxiety about obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,284352003,Obesity diet education,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,294493008,Lifelong obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,296526005,Adult-onset obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,308504001,Obesity monitoring call,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,310428009,Obesity monitoring invitation,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,415530009,Obesity due to excess calories,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,444862003,Childhood obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,703316004,Lymphoedema associated with obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,715279006,Telehealth obesity monitoring,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,763085007,Obesity monitoring declined,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,198181000000102,Obesity resolved,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,640791000000105,Obesity and other hyperalimentation,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,713951000000106,Obesity monitoring administration,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,713971000000102,Obesity clinic administration,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,753691000000104,Exception reporting - obesity quality indicators,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,822741000000107,Anti-obesity drug therapy,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,894961000000105,Referral to multidisciplinary obesity clinic,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,898011000000103,Obesity multidisciplinary case review,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,914801000000107,Anti-obesity drug therapy commenced,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,914821000000103,Obesity medication stopped,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386191000000105,National Health Service obesity medication pathway,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386231000000101,NHS obesity medication pathway started,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386241000000105,National Health Service obesity medication pathway declined,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386251000000108,Review of anti-obesity drug therapy,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,24700007,Multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,160337009,Family history of multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,192926004,Brain stem multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,192928003,Generalised multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,428700003,Primary progressive multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,438511000,Benign multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,700409000,Suspected multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,198491000000106,Multiple sclerosis review,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,515931000000104,Multiple sclerosis review declined,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +NBTXR-3,Advanced soft tissue sarcoma,TA745,soft tissue sarcoma,2424003,Soft tissue sarcoma,NBTXR-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,162573006,Suspected lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,275981009,Lung cancer screening,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,429011007,Family history of lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,134405005,Suspected breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,160287004,FH: Breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,268547008,Screening for breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,429740004,Family history of breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,431330007,Family history of breast cancer 1 gene mutation,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,431331006,Family history of breast cancer 2 gene mutation,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,706970001,TNBC - Triple-negative breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,94361000000105,Breast cancer detected by national screening programme,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,276341000000100,Fast track referral for suspected breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,838351000000107,Education about risk of breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,874291000000100,QCancer breast cancer risk,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,1035841000000108,Lymphoedema following breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,390900001,Smoking cessation milestones,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,395700008,Referral to smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,401068004,Seen by smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,401160008,Smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,710081004,Smoking cessation therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,713700008,Smoking cessation drug therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,765001003,Monitoring of smoking cessation therapy refused,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,771155005,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,1290027009,Consultation for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,25261000000107,Did not attend smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,200221000000105,Smoking cessation advice provided by community pharmacist,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,201931000000109,Attends practice smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,201941000000100,Attends smoking cessation clinic not at practice,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,374361000000100,Smoking cessation enhanced services administration,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,374391000000106,Smoking cessation enhanced services administration monitoring template completed,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,506491000000102,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,527151000000107,Smoking cessation advice declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,712971000000108,Practice based smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,720401000000103,Smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,750821000000109,Consent given for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,750851000000104,Consent given for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,751101000000101,Declined consent for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,751661000000106,Declined consent for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,755721000000107,Consent given for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,755741000000100,Declined consent for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,767641000000109,Referral for smoking cessation service offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,768971000000109,Lost to smoking cessation follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,822591000000108,Smoking cessation drug therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,850331000000104,Smoking cessation 12 week follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,871641000000105,Referral to smoking cessation service declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,871661000000106,Referral to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,966971000000103,Varenicline smoking cessation therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,966991000000104,Varenicline smoking cessation therapy offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,1084381000000100,Signposting to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,1087441000000106,Smoking cessation programme declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,2140191000000108,Referral to Community Pharmacy Smoking Cessation Service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,390900001,Smoking cessation milestones,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,395700008,Referral to smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,401068004,Seen by smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,401160008,Smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,710081004,Smoking cessation therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,713700008,Smoking cessation drug therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,765001003,Monitoring of smoking cessation therapy refused,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,771155005,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,1290027009,Consultation for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,25261000000107,Did not attend smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,200221000000105,Smoking cessation advice provided by community pharmacist,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,201931000000109,Attends practice smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,201941000000100,Attends smoking cessation clinic not at practice,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,374361000000100,Smoking cessation enhanced services administration,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,374391000000106,Smoking cessation enhanced services administration monitoring template completed,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,506491000000102,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,527151000000107,Smoking cessation advice declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,712971000000108,Practice based smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,720401000000103,Smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,750821000000109,Consent given for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,750851000000104,Consent given for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,751101000000101,Declined consent for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,751661000000106,Declined consent for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,755721000000107,Consent given for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,755741000000100,Declined consent for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,767641000000109,Referral for smoking cessation service offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,768971000000109,Lost to smoking cessation follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,822591000000108,Smoking cessation drug therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,850331000000104,Smoking cessation 12 week follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,871641000000105,Referral to smoking cessation service declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,871661000000106,Referral to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,966971000000103,Varenicline smoking cessation therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,966991000000104,Varenicline smoking cessation therapy offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,1084381000000100,Signposting to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,1087441000000106,Smoking cessation programme declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,2140191000000108,Referral to Community Pharmacy Smoking Cessation Service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +NILOTINIB,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,TA425,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +NILOTINIB,Treatment of chronic or accelerated phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults whose CML is resistant to treatment with standard-dose imatinib or who have imatinib intolerance,TA241,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,NILOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +NILOTINIB,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia,TA251,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,STANDARD-DOSE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +NILOTINIB,Untreated chronic myeloid leukaemia,TA426,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,90610005,Interstitial pulmonary fibrosis of prematurity,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,196028003,Chronic pulmonary fibrosis caused by chemical fumes,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,196125002,Diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,233724002,Chemical-induced diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,233725001,Drug-induced diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,233726000,Localised pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,233770009,Pulmonary fibrosis due to sarcoidosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,266368002,Post-inflammatory pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,700250006,IPF - idiopathic pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,90610005,Interstitial pulmonary fibrosis of prematurity,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,196028003,Chronic pulmonary fibrosis caused by chemical fumes,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,196125002,Diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,233724002,Chemical-induced diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,233725001,Drug-induced diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,233726000,Localised pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,233770009,Pulmonary fibrosis due to sarcoidosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,266368002,Post-inflammatory pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,700250006,IPF - idiopathic pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,162573006,Suspected lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,254637007,Non-small cell lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,275981009,Lung cancer screening,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,429011007,Family history of lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,723301009,Squamous non-small cell lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1259727001,Primary non-small cell lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,276491000000101,Fast track referral for suspected lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,848881000000108,QCancer lung cancer risk,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,877691000000107,No FH of lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1771781000000107,Did not attend lung cancer screening,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,8100009,Structure of infundibulum of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,9361007,Downward displacement of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,22611009,Endometriosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,25344002,Fimbriectomy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,32587001,Rupture of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,32987009,Both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,41393008,Excision of cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,42618007,Atresia of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,44793005,Excision of lesion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,46536000,Inflammation of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,46946009,Torsion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,49558004,Fallopian tube tuberculosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,56900004,Infarction of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,78328007,Aspiration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,78517009,Dilation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,79586000,Fallopian tube pregnancy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,85029000,Congenital anomaly of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,88157006,Inflammation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,92100009,Benign neoplasm of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,92591008,Carcinoma in situ of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,118869008,Procedure on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,120062000,Fallopian tube reconstruction,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,128134005,Fallopian tube disorder,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176936004,Open occlusion of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176937008,Open ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176948001,Open ligation of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176949009,Open ligation of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176965005,Drainage of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176975008,Exploration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198305004,Prolapse of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,236927008,Removal of clip from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,236938008,Laparoscopy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,245482004,Entire left cornu of Fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,262931005,Transection of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,265071006,Open clipping of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,265076001,Open clipping of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,271414005,Fallopian tube prosthesis operation,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,271415006,Removal of products of conception from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,274977001,Unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,280504001,Fallopian tube stenosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,283958000,Hematoma of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,287664005,Ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,287931008,Fallopian tube cornual resection,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,287943009,Insufflation of fallopian tube using saline,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,287944003,Insufflation of fallopian tube using gas,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,288032001,Transection of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,288033006,Unilateral ligation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,288034000,Unilateral fallopian tube division,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,289832005,Fallopian tube present,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,289833000,Fallopian tube absent,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,300020002,Diathermy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,302954008,Congenital cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,307264000,Remaining fallopian tube removed,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,309290005,Fallopian tube biopsy specimen,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,310808000,Fallopian tube clip,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,387615001,Removal of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,392250009,Operation on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,398319002,Abscess of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,427543006,Recanalisation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,719447009,Ectopic fallopian tube tissue,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,561491000000108,Fallopian tube operations NOS,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,8100009,Structure of infundibulum of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,9361007,Downward displacement of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,22611009,Endometriosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,25344002,Fimbriectomy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,32587001,Rupture of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,32987009,Both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,41393008,Excision of cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,42618007,Atresia of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,44793005,Excision of lesion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,46536000,Inflammation of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,46946009,Torsion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,49558004,Fallopian tube tuberculosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,56900004,Infarction of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,78328007,Aspiration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,78517009,Dilation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,79586000,Fallopian tube pregnancy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,85029000,Congenital anomaly of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,88157006,Inflammation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,92100009,Benign neoplasm of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,92591008,Carcinoma in situ of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,118869008,Procedure on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,120062000,Fallopian tube reconstruction,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,128134005,Fallopian tube disorder,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176936004,Open occlusion of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176937008,Open ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176948001,Open ligation of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176949009,Open ligation of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176965005,Drainage of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176975008,Exploration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198305004,Prolapse of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,236927008,Removal of clip from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,236938008,Laparoscopy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,245482004,Entire left cornu of Fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,262931005,Transection of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,265071006,Open clipping of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,265076001,Open clipping of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,271414005,Fallopian tube prosthesis operation,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,271415006,Removal of products of conception from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,274977001,Unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,280504001,Fallopian tube stenosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,283958000,Hematoma of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,287664005,Ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,287931008,Fallopian tube cornual resection,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,287943009,Insufflation of fallopian tube using saline,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,287944003,Insufflation of fallopian tube using gas,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,288032001,Transection of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,288033006,Unilateral ligation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,288034000,Unilateral fallopian tube division,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,289832005,Fallopian tube present,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,289833000,Fallopian tube absent,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,300020002,Diathermy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,302954008,Congenital cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,307264000,Remaining fallopian tube removed,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,309290005,Fallopian tube biopsy specimen,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,310808000,Fallopian tube clip,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,387615001,Removal of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,392250009,Operation on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,398319002,Abscess of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,427543006,Recanalisation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,719447009,Ectopic fallopian tube tissue,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,561491000000108,Fallopian tube operations NOS,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,8100009,Structure of infundibulum of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,9361007,Downward displacement of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,22611009,Endometriosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,25344002,Fimbriectomy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,32587001,Rupture of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,32987009,Both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,41393008,Excision of cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,42618007,Atresia of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,44793005,Excision of lesion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,46536000,Inflammation of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,46946009,Torsion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,49558004,Fallopian tube tuberculosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,56900004,Infarction of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,78328007,Aspiration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,78517009,Dilation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,79586000,Fallopian tube pregnancy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,85029000,Congenital anomaly of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,88157006,Inflammation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,92100009,Benign neoplasm of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,92591008,Carcinoma in situ of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,118869008,Procedure on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,120062000,Fallopian tube reconstruction,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,128134005,Fallopian tube disorder,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176936004,Open occlusion of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176937008,Open ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176948001,Open ligation of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176949009,Open ligation of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176965005,Drainage of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176975008,Exploration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198305004,Prolapse of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,236927008,Removal of clip from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,236938008,Laparoscopy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,245482004,Entire left cornu of Fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,262931005,Transection of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,265071006,Open clipping of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,265076001,Open clipping of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,271414005,Fallopian tube prosthesis operation,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,271415006,Removal of products of conception from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,274977001,Unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,280504001,Fallopian tube stenosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,283958000,Hematoma of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,287664005,Ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,287931008,Fallopian tube cornual resection,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,287943009,Insufflation of fallopian tube using saline,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,287944003,Insufflation of fallopian tube using gas,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,288032001,Transection of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,288033006,Unilateral ligation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,288034000,Unilateral fallopian tube division,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,289832005,Fallopian tube present,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,289833000,Fallopian tube absent,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,300020002,Diathermy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,302954008,Congenital cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,307264000,Remaining fallopian tube removed,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,309290005,Fallopian tube biopsy specimen,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,310808000,Fallopian tube clip,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,387615001,Removal of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,392250009,Operation on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,398319002,Abscess of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,427543006,Recanalisation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,719447009,Ectopic fallopian tube tissue,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,561491000000108,Fallopian tube operations NOS,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,28531000087107,COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,28531000087107,COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,28531000087107,COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,28531000087107,COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300721000000109,COVID-19 confirmed by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300721000000109,COVID-19 confirmed by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300721000000109,COVID-19 confirmed by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300721000000109,COVID-19 confirmed by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325031000000108,Referral to long term effects of COVID-19 assessment clinic,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325031000000108,Referral to long term effects of COVID-19 assessment clinic,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325031000000108,Referral to long term effects of COVID-19 assessment clinic,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325031000000108,Referral to long term effects of COVID-19 assessment clinic,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325151000000100,PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325151000000100,PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325151000000100,PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325151000000100,PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,42985911000001104,Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna Biotech Distributor UK Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,42985911000001104,Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna Biotech Distributor UK Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,42985911000001104,Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna Biotech Distributor UK Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,42985911000001104,Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna Biotech Distributor UK Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,915007,Malignant melanoma in junctional naevus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,1556006,Clark melanoma level 4,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,2092003,Malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,2142002,Nodular melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,16974005,"Acral lentiginous melanoma, malignant",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,21119008,Benign melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,21165006,Clark melanoma level 3,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,37138001,Epithelioid cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,39896009,"Malignant melanoma, regressing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,44474009,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,50542000,Clark melanoma level 2,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,50813003,Spitz melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,51757004,"Desmoplastic melanoma, amelanotic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,55320002,Superficial spreading melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,68827007,Spindle cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,70594002,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,77986002,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93209006,Malignant melanoma of perianal skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93214005,Malignant melanoma of skin of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93217003,Malignant melanoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93220006,Malignant melanoma of skin of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93221005,Malignant melanoma of skin of elbow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93223008,Malignant melanoma of eyebrow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93225001,Malignant melanoma of skin of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93227009,Malignant melanoma of skin of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93228004,Malignant melanoma of skin of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93642000,Malignant melanoma of skin of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93643005,Malignant melanoma of external surface of nose,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93646002,Malignant melanoma of skin of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93647006,Malignant melanoma of skin of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93651008,Malignant melanoma of skin of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93653006,Malignant melanoma of skin of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93654000,Malignant melanoma of skin of wrist,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93655004,MM (malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,106243009,Breslow depth staging for melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109266006,Melanoma in situ of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109270003,Melanoma in situ of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109272006,Melanoma in situ of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109276009,Melanoma in situ of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109278005,Melanoma in situ of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109282007,Melanoma in situ of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109284008,Melanoma in situ of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109290007,Melanoma in situ of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109294003,Melanoma in situ of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,127330008,Melanoma in situ by body site (clinical),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,161432005,History of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,177281002,Excision of melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188030005,Malignant melanoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188033007,Malignant melanoma of auricle (ear),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188034001,Malignant melanoma of external auditory meatus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188038003,Malignant melanoma of chin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188040008,Malignant melanoma of forehead,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188042000,Malignant melanoma of temple,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188044004,Malignant melanoma of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188045003,Malignant melanoma of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188046002,Malignant melanoma of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188049009,Malignant melanoma of axilla,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188050009,Malignant melanoma of breast,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188051008,Malignant melanoma of buttock,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188052001,Malignant melanoma of groin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188054000,Malignant melanoma of perineum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188055004,Malignant melanoma of umbilicus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188060000,Malignant melanoma of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188061001,Malignant melanoma of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188062008,Malignant melanoma of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188063003,Malignant melanoma of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188064009,Malignant melanoma of finger,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188065005,Malignant melanoma of thumb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188067002,Malignant melanoma of lower limb and hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188068007,Malignant melanoma of hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188069004,Malignant melanoma of thigh,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188070003,Malignant melanoma of knee,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188071004,Malignant melanoma of popliteal fossa area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188072006,Malignant melanoma of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188073001,Malignant melanoma of ankle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188074007,Malignant melanoma of heel,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188075008,Malignant melanoma of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188076009,Malignant melanoma of toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188077000,Malignant melanoma of great toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,189758001,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,231834005,Malignant melanoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254731001,Nodular melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254732008,Acral lentiginous melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254896002,Malignant melanoma of vulva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,255004001,Malignant melanoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,255012009,Malignant melanoma of iris,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,255015006,Malignant melanoma of ciliary body,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,255021005,Malignant melanoma of choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,269578002,Malignant melanoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,269579005,Malignant melanoma of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,269580008,Malignant melanoma of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,269581007,Malignant melanoma of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,274087000,MM (malignant melanoma) of eye,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,276751004,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,276821000,Malignant melanoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,276822007,Malignant melanoma of rectum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,302837001,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,310498001,Malignant melanoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,312941005,Melanoma associated retinopathy,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,313248004,Malignant melanoma of chest wall,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,314976006,Local recurrence of malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,314987003,Metastasis from malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,315036008,Melanoma in situ of back of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,315230006,Melanoma in situ of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,372158004,"Malignant melanoma, metastatic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,427858005,Family history of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,443493003,Metastatic malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,449636007,Malignant melanoma of skin of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,449637003,Malignant melanoma of skin of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,698040004,Malignant melanoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,1197324006,Metastatic malignant melanoma to skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,351961000119109,Malignant melanoma of skin of right arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,352211000119108,Malignant melanoma of skin of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,546881000000105,Malignant melanoma of skin NOS,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956331000000107,Malignant melanoma stage IA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956351000000100,Malignant melanoma stage IB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956371000000109,Malignant melanoma stage IIA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956391000000108,Malignant melanoma stage IIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956451000000107,Malignant melanoma stage IIIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956471000000103,Malignant melanoma stage IIIC,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956511000000107,Malignant melanoma stage IV M1a,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956551000000106,Malignant melanoma stage IV M1c,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,1080941000119109,Malignant melanoma of left choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,1080981000119104,Malignant melanoma of right choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,915007,Malignant melanoma in junctional naevus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,1556006,Clark melanoma level 4,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,2092003,Malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,2142002,Nodular melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,16974005,"Acral lentiginous melanoma, malignant",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,21119008,Benign melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,21165006,Clark melanoma level 3,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,37138001,Epithelioid cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,39896009,"Malignant melanoma, regressing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,44474009,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,50542000,Clark melanoma level 2,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,50813003,Spitz melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,51757004,"Desmoplastic melanoma, amelanotic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,55320002,Superficial spreading melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,68827007,Spindle cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,70594002,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,77986002,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93209006,Malignant melanoma of perianal skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93214005,Malignant melanoma of skin of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93217003,Malignant melanoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93220006,Malignant melanoma of skin of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93221005,Malignant melanoma of skin of elbow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93223008,Malignant melanoma of eyebrow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93225001,Malignant melanoma of skin of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93227009,Malignant melanoma of skin of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93228004,Malignant melanoma of skin of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93642000,Malignant melanoma of skin of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93643005,Malignant melanoma of external surface of nose,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93646002,Malignant melanoma of skin of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93647006,Malignant melanoma of skin of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93651008,Malignant melanoma of skin of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93653006,Malignant melanoma of skin of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93654000,Malignant melanoma of skin of wrist,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93655004,MM (malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,106243009,Breslow depth staging for melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109266006,Melanoma in situ of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109270003,Melanoma in situ of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109272006,Melanoma in situ of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109276009,Melanoma in situ of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109278005,Melanoma in situ of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109282007,Melanoma in situ of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109284008,Melanoma in situ of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109290007,Melanoma in situ of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109294003,Melanoma in situ of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,127330008,Melanoma in situ by body site (clinical),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,161432005,History of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,177281002,Excision of melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188030005,Malignant melanoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188033007,Malignant melanoma of auricle (ear),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188034001,Malignant melanoma of external auditory meatus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188038003,Malignant melanoma of chin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188040008,Malignant melanoma of forehead,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188042000,Malignant melanoma of temple,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188044004,Malignant melanoma of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188045003,Malignant melanoma of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188046002,Malignant melanoma of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188049009,Malignant melanoma of axilla,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188050009,Malignant melanoma of breast,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188051008,Malignant melanoma of buttock,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188052001,Malignant melanoma of groin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188054000,Malignant melanoma of perineum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188055004,Malignant melanoma of umbilicus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188060000,Malignant melanoma of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188061001,Malignant melanoma of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188062008,Malignant melanoma of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188063003,Malignant melanoma of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188064009,Malignant melanoma of finger,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188065005,Malignant melanoma of thumb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188067002,Malignant melanoma of lower limb and hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188068007,Malignant melanoma of hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188069004,Malignant melanoma of thigh,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188070003,Malignant melanoma of knee,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188071004,Malignant melanoma of popliteal fossa area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188072006,Malignant melanoma of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188073001,Malignant melanoma of ankle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188074007,Malignant melanoma of heel,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188075008,Malignant melanoma of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188076009,Malignant melanoma of toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188077000,Malignant melanoma of great toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,189758001,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,231834005,Malignant melanoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254731001,Nodular melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254732008,Acral lentiginous melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254896002,Malignant melanoma of vulva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,255004001,Malignant melanoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,255012009,Malignant melanoma of iris,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,255015006,Malignant melanoma of ciliary body,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,255021005,Malignant melanoma of choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,269578002,Malignant melanoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,269579005,Malignant melanoma of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,269580008,Malignant melanoma of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,269581007,Malignant melanoma of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,274087000,MM (malignant melanoma) of eye,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,276751004,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,276821000,Malignant melanoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,276822007,Malignant melanoma of rectum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,302837001,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,310498001,Malignant melanoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,312941005,Melanoma associated retinopathy,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,313248004,Malignant melanoma of chest wall,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,314976006,Local recurrence of malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,314987003,Metastasis from malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,315036008,Melanoma in situ of back of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,315230006,Melanoma in situ of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,372158004,"Malignant melanoma, metastatic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,427858005,Family history of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,443493003,Metastatic malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,449636007,Malignant melanoma of skin of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,449637003,Malignant melanoma of skin of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,698040004,Malignant melanoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,1197324006,Metastatic malignant melanoma to skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,351961000119109,Malignant melanoma of skin of right arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,352211000119108,Malignant melanoma of skin of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,546881000000105,Malignant melanoma of skin NOS,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956331000000107,Malignant melanoma stage IA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956351000000100,Malignant melanoma stage IB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956371000000109,Malignant melanoma stage IIA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956391000000108,Malignant melanoma stage IIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956451000000107,Malignant melanoma stage IIIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956471000000103,Malignant melanoma stage IIIC,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956511000000107,Malignant melanoma stage IV M1a,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956551000000106,Malignant melanoma stage IV M1c,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,1080941000119109,Malignant melanoma of left choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,1080981000119104,Malignant melanoma of right choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,915007,Malignant melanoma in junctional naevus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,1556006,Clark melanoma level 4,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,2092003,Malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,2142002,Nodular melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,16974005,"Acral lentiginous melanoma, malignant",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,21119008,Benign melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,21165006,Clark melanoma level 3,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,37138001,Epithelioid cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,39896009,"Malignant melanoma, regressing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,44474009,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,50542000,Clark melanoma level 2,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,50813003,Spitz melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,51757004,"Desmoplastic melanoma, amelanotic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,55320002,Superficial spreading melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,68827007,Spindle cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,70594002,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,77986002,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93209006,Malignant melanoma of perianal skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93214005,Malignant melanoma of skin of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93217003,Malignant melanoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93220006,Malignant melanoma of skin of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93221005,Malignant melanoma of skin of elbow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93223008,Malignant melanoma of eyebrow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93225001,Malignant melanoma of skin of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93227009,Malignant melanoma of skin of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93228004,Malignant melanoma of skin of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93642000,Malignant melanoma of skin of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93643005,Malignant melanoma of external surface of nose,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93646002,Malignant melanoma of skin of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93647006,Malignant melanoma of skin of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93651008,Malignant melanoma of skin of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93653006,Malignant melanoma of skin of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93654000,Malignant melanoma of skin of wrist,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93655004,MM (malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,106243009,Breslow depth staging for melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109266006,Melanoma in situ of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109270003,Melanoma in situ of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109272006,Melanoma in situ of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109276009,Melanoma in situ of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109278005,Melanoma in situ of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109282007,Melanoma in situ of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109284008,Melanoma in situ of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109290007,Melanoma in situ of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109294003,Melanoma in situ of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,127330008,Melanoma in situ by body site (clinical),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,161432005,History of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,177281002,Excision of melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188030005,Malignant melanoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188033007,Malignant melanoma of auricle (ear),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188034001,Malignant melanoma of external auditory meatus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188038003,Malignant melanoma of chin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188040008,Malignant melanoma of forehead,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188042000,Malignant melanoma of temple,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188044004,Malignant melanoma of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188045003,Malignant melanoma of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188046002,Malignant melanoma of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188049009,Malignant melanoma of axilla,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188050009,Malignant melanoma of breast,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188051008,Malignant melanoma of buttock,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188052001,Malignant melanoma of groin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188054000,Malignant melanoma of perineum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188055004,Malignant melanoma of umbilicus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188060000,Malignant melanoma of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188061001,Malignant melanoma of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188062008,Malignant melanoma of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188063003,Malignant melanoma of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188064009,Malignant melanoma of finger,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188065005,Malignant melanoma of thumb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188067002,Malignant melanoma of lower limb and hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188068007,Malignant melanoma of hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188069004,Malignant melanoma of thigh,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188070003,Malignant melanoma of knee,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188071004,Malignant melanoma of popliteal fossa area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188072006,Malignant melanoma of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188073001,Malignant melanoma of ankle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188074007,Malignant melanoma of heel,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188075008,Malignant melanoma of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188076009,Malignant melanoma of toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188077000,Malignant melanoma of great toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,189758001,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,231834005,Malignant melanoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254731001,Nodular melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254732008,Acral lentiginous melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254896002,Malignant melanoma of vulva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,255004001,Malignant melanoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,255012009,Malignant melanoma of iris,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,255015006,Malignant melanoma of ciliary body,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,255021005,Malignant melanoma of choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,269578002,Malignant melanoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,269579005,Malignant melanoma of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,269580008,Malignant melanoma of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,269581007,Malignant melanoma of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,274087000,MM (malignant melanoma) of eye,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,276751004,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,276821000,Malignant melanoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,276822007,Malignant melanoma of rectum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,302837001,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,310498001,Malignant melanoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,312941005,Melanoma associated retinopathy,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,313248004,Malignant melanoma of chest wall,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,314976006,Local recurrence of malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,314987003,Metastasis from malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,315036008,Melanoma in situ of back of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,315230006,Melanoma in situ of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,372158004,"Malignant melanoma, metastatic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,427858005,Family history of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,443493003,Metastatic malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,449636007,Malignant melanoma of skin of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,449637003,Malignant melanoma of skin of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,698040004,Malignant melanoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,1197324006,Metastatic malignant melanoma to skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,351961000119109,Malignant melanoma of skin of right arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,352211000119108,Malignant melanoma of skin of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,546881000000105,Malignant melanoma of skin NOS,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956331000000107,Malignant melanoma stage IA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956351000000100,Malignant melanoma stage IB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956371000000109,Malignant melanoma stage IIA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956391000000108,Malignant melanoma stage IIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956451000000107,Malignant melanoma stage IIIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956471000000103,Malignant melanoma stage IIIC,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956511000000107,Malignant melanoma stage IV M1a,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956551000000106,Malignant melanoma stage IV M1c,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,1080941000119109,Malignant melanoma of left choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,1080981000119104,Malignant melanoma of right choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,733608000,Papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB,Previously treated unresectable advanced or recurrent oesophageal cancer,TA707,oesophageal cancer,848871000000106,QCancer gastro-oesophageal cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,402815007,Squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +NIVOLUMAB,Resected oesophageal or gastro-oesophageal junction cancer,TA746,gastro-oesophageal junction,427421001,Fibreoptic endoscopic endoluminal plication of gastro-oesophageal junction,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,402815007,Squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,915007,Malignant melanoma in junctional naevus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,1556006,Clark melanoma level 4,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,2092003,Malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,2142002,Nodular melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,16974005,"Acral lentiginous melanoma, malignant",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,21119008,Benign melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,21165006,Clark melanoma level 3,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,37138001,Epithelioid cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,39896009,"Malignant melanoma, regressing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,44474009,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,50542000,Clark melanoma level 2,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,50813003,Spitz melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,51757004,"Desmoplastic melanoma, amelanotic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,55320002,Superficial spreading melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,68827007,Spindle cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,70594002,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,77986002,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93209006,Malignant melanoma of perianal skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93214005,Malignant melanoma of skin of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93217003,Malignant melanoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93220006,Malignant melanoma of skin of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93221005,Malignant melanoma of skin of elbow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93223008,Malignant melanoma of eyebrow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93225001,Malignant melanoma of skin of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93227009,Malignant melanoma of skin of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93228004,Malignant melanoma of skin of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93642000,Malignant melanoma of skin of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93643005,Malignant melanoma of external surface of nose,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93646002,Malignant melanoma of skin of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93647006,Malignant melanoma of skin of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93651008,Malignant melanoma of skin of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93653006,Malignant melanoma of skin of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93654000,Malignant melanoma of skin of wrist,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93655004,MM (malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,106243009,Breslow depth staging for melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109266006,Melanoma in situ of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109270003,Melanoma in situ of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109272006,Melanoma in situ of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109276009,Melanoma in situ of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109278005,Melanoma in situ of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109282007,Melanoma in situ of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109284008,Melanoma in situ of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109290007,Melanoma in situ of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109294003,Melanoma in situ of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,127330008,Melanoma in situ by body site (clinical),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,161432005,History of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,177281002,Excision of melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188030005,Malignant melanoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188033007,Malignant melanoma of auricle (ear),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188034001,Malignant melanoma of external auditory meatus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188038003,Malignant melanoma of chin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188040008,Malignant melanoma of forehead,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188042000,Malignant melanoma of temple,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188044004,Malignant melanoma of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188045003,Malignant melanoma of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188046002,Malignant melanoma of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188049009,Malignant melanoma of axilla,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188050009,Malignant melanoma of breast,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188051008,Malignant melanoma of buttock,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188052001,Malignant melanoma of groin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188054000,Malignant melanoma of perineum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188055004,Malignant melanoma of umbilicus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188060000,Malignant melanoma of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188061001,Malignant melanoma of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188062008,Malignant melanoma of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188063003,Malignant melanoma of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188064009,Malignant melanoma of finger,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188065005,Malignant melanoma of thumb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188067002,Malignant melanoma of lower limb and hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188068007,Malignant melanoma of hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188069004,Malignant melanoma of thigh,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188070003,Malignant melanoma of knee,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188071004,Malignant melanoma of popliteal fossa area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188072006,Malignant melanoma of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188073001,Malignant melanoma of ankle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188074007,Malignant melanoma of heel,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188075008,Malignant melanoma of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188076009,Malignant melanoma of toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188077000,Malignant melanoma of great toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,189758001,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,231834005,Malignant melanoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254731001,Nodular melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254732008,Acral lentiginous melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254896002,Malignant melanoma of vulva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,255004001,Malignant melanoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,255012009,Malignant melanoma of iris,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,255015006,Malignant melanoma of ciliary body,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,255021005,Malignant melanoma of choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,269578002,Malignant melanoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,269579005,Malignant melanoma of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,269580008,Malignant melanoma of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,269581007,Malignant melanoma of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,274087000,MM (malignant melanoma) of eye,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,276751004,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,276821000,Malignant melanoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,276822007,Malignant melanoma of rectum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,302837001,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,310498001,Malignant melanoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,312941005,Melanoma associated retinopathy,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,313248004,Malignant melanoma of chest wall,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,314976006,Local recurrence of malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,314987003,Metastasis from malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,315036008,Melanoma in situ of back of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,315230006,Melanoma in situ of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,372158004,"Malignant melanoma, metastatic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,427858005,Family history of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,443493003,Metastatic malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,449636007,Malignant melanoma of skin of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,449637003,Malignant melanoma of skin of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,698040004,Malignant melanoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,1197324006,Metastatic malignant melanoma to skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,351961000119109,Malignant melanoma of skin of right arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,352211000119108,Malignant melanoma of skin of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,546881000000105,Malignant melanoma of skin NOS,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956331000000107,Malignant melanoma stage IA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956351000000100,Malignant melanoma stage IB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956371000000109,Malignant melanoma stage IIA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956391000000108,Malignant melanoma stage IIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956451000000107,Malignant melanoma stage IIIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956471000000103,Malignant melanoma stage IIIC,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956511000000107,Malignant melanoma stage IV M1a,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956551000000106,Malignant melanoma stage IV M1c,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,1080941000119109,Malignant melanoma of left choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,1080981000119104,Malignant melanoma of right choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,733608000,Papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,402815007,Squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,733608000,Papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,733608000,Papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB,Untreated unresectable malignant pleural mesothelioma,TA818,malignant pleural mesothelioma,254645002,Malignant pleural mesothelioma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +NIVOLUMAB WITH PLATINUM- AND FLUOROPYRIMIDINE-BASED CHEMOTHERAPY,"Untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma",TA857,gastro-oesophageal junction,427421001,Fibreoptic endoscopic endoluminal plication of gastro-oesophageal junction,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,5262007,Progressive spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,54280009,Familial spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,64383006,Infantile spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,85505000,Generalized spinal muscular atrophy of late onset,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,128212001,Late infantile spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,230247001,Distal spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,230252006,Oculopharyngeal spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OBETICHOLIC ACID,Primary biliary cholangitis,TA443,primary biliary cholangitis,31712002,Primary biliary cholangitis,OBETICHOLIC,GASTROENTEROLOGY,GASTROENTEROLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,109962001,Nonfollicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,308121000,Follicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,721555001,Follicular lymphoma of small intestine,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA343,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA343,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA343,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA343,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,109962001,Nonfollicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,308121000,Follicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,721555001,Follicular lymphoma of small intestine,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,109962001,Nonfollicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,308121000,Follicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,721555001,Follicular lymphoma of small intestine,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,24700007,Multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,160337009,Family history of multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,192926004,Brain stem multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,192928003,Generalised multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,428700003,Primary progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,438511000,Benign multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,700409000,Suspected multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,198491000000106,Multiple sclerosis review,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,515931000000104,Multiple sclerosis review declined,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,24700007,Multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,160337009,Family history of multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,192926004,Brain stem multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,192928003,Generalised multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,428700003,Primary progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,438511000,Benign multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,700409000,Suspected multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,198491000000106,Multiple sclerosis review,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,515931000000104,Multiple sclerosis review declined,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OFATUMUMAB,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,TA202,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,TA202,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,TA202,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,TA202,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB FOR TREATING RELAPSING MULTIPLE SCLEROSIS,Relapsing multiple sclerosis,TA699,relapsing multiple sclerosis,230372003,Acute relapsing multiple sclerosis,OFATUMUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OFATUMUMAB FOR TREATING RELAPSING MULTIPLE SCLEROSIS,Relapsing multiple sclerosis,TA699,relapsing multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,OFATUMUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION +OFATUMUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA344,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA344,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA344,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA344,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB WITH CHEMOTHERAPY,Chronic lymphocytic leukaemia,TA470,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB WITH CHEMOTHERAPY,Chronic lymphocytic leukaemia,TA470,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB WITH CHEMOTHERAPY,Chronic lymphocytic leukaemia,TA470,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OFATUMUMAB WITH CHEMOTHERAPY,Chronic lymphocytic leukaemia,TA470,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,4441000,Severe bipolar disorder with psychotic features,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,5703000,Bipolar disorder in partial remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,13313007,Mild bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,41836007,Bipolar disorder in full remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,53049002,Severe bipolar disorder without psychotic features,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,79584002,Moderate bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,85248005,Bipolar disorder in remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,160331005,Family history of bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,231444002,Organic bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,767632000,"Bipolar disorder, most recent episode manic",OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,1365951000000107,Family intervention for psychosis and bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLANZAPINE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,134405005,Suspected breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,160287004,FH: Breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,268547008,Screening for breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,412734009,BRCA1 gene mutation detected,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,412736006,BRCA1 gene mutation not detected,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,412738007,BRCA2 gene mutation detected,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,412739004,BRCA2 gene mutation not detected,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,429740004,Family history of breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,431330007,Family history of breast cancer 1 gene mutation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,431331006,Family history of breast cancer 2 gene mutation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,706970001,TNBC - Triple-negative breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,31881000119108,Family history of BRCA gene mutation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,94361000000105,Breast cancer detected by national screening programme,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,276341000000100,Fast track referral for suspected breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,838351000000107,Education about risk of breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,874291000000100,QCancer breast cancer risk,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,1035841000000108,Lymphoedema following breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +OLAPARIB,Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy,TA750,pancreatic cancer,429000004,Family history of pancreatic cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +OLAPARIB,Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy,TA750,pancreatic cancer,247591000000101,Suspected pancreatic cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +OLAPARIB,Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy,TA750,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,315268008,Suspected prostate cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,428262008,H/O: prostate cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,698470001,Advice given about prostate cancer screening,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,712837004,Active surveillance of prostate cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,720007002,Prostate cancer care review,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,31011000119107,Prostate cancer screening declined,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,874211000000109,QCancer prostate cancer risk,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,878401000000104,No FH of prostate cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +OLARATUMAB IN COMBINATION WITH DOXORUBICIN,Advanced soft tissue sarcoma,TA465,soft tissue sarcoma,2424003,Soft tissue sarcoma,OLARATUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|CLINICAL ONCOLOGY +OMALIZUMAB,Add-on treatment for severe persistent allergic asthma,TA278,severe persistent allergic asthma,10675431000119106,Severe persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,4244005,Urticaria neonatorum,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,10347006,Sunlight-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,14907004,Urticaria bullosa,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,40178009,Allergic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,42265009,Idiopathic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,51247001,Vibratory urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,62211002,Urticaria caused by heat,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,64305001,Urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,73098005,Cholinergic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,74774004,Cold-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,89322006,Allergic urticaria due to drug,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,89870006,Aquagenic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,123584008,Urticaria perstans,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,126485001,Urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,201260002,Drug induced urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,201261003,Urticaria caused by cold and heat,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,201268009,Urticaria geographica,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,201269001,Menstrual urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,213325008,Urticaria caused by serum,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,238688005,Cold reflex urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,238690006,Persisting cholinergic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,238693008,Reflex urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,238697009,Immune complex urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241956005,Venom-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241957001,Food-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241958006,Drug-aggravated angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241959003,Non-steroid anti-inflammatory drug-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241960008,Aspirin-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241962000,Chemical-aggravated angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241963005,Azo-dye-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241964004,Sodium benzoate-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241965003,Latex-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,252507009,Physical urticaria test,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,269433002,(Angioneurotic edema) or (urticaria),OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,277785006,Penicillin-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302161006,Acute idiopathic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302162004,Chronic spontaneous urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302163009,Idiopathic micropapular urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302165002,Idiopathic cold urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302167005,Cold urticaria with cryoglobulins,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302972002,Urticarial transfusion reaction,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,361200005,Familial febrile urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,373907006,Minimal urticarial dose,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,387788000,Delayed pressure urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402305008,Non-immunological contact urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402394004,Urticaria caused by salicylate,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402408009,Acute urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402413008,Arthus type urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402601007,Physical urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,230191000000108,Reverse passive transfer test for solar urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,230201000000105,Autologous serum skin test for urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,230211000000107,Physical challenge tests for urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,462821000000106,[X]Urticaria and erythema,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,12428000,Intrinsic asthma without status asthmaticus,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,31387002,Exercise-induced asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,34015007,Flour asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,56018004,Asthmatic breathing,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,56968009,Asthma caused by wood dust,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,57607007,Industrial asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,63088003,Allergic asthma without status asthmaticus,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,71892000,Cardiac asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,93432008,Drug-induced asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,160377001,Family history of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,161105008,Asthma society member,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,161527007,History of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,162660004,Asthma resolved,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170631002,Asthma disturbing sleep,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170632009,Asthma causing night waking,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170633004,Asthma disturbs sleep weekly,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170634005,Asthma disturbs sleep frequently,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170635006,Asthma not disturbing sleep,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170636007,Asthma never disturbs sleep,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170637003,Asthma limiting activities,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170638008,Asthma not limiting activities,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170642006,Asthma severity,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170647000,Asthma prophylactic medication used,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170655007,Asthma restricts exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170656008,Asthma sometimes restricts exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170657004,Asthma severely restricts exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170658009,Asthma never restricts exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,171231001,Asthma screening,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182724005,Further asthma - drug prevention,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182726007,Asthma control step 0,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182727003,Asthma control step 1,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182728008,Asthma control step 2,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182729000,Asthma control step 3,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182730005,Asthma control step 4,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182731009,Asthma control step 5,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,183099005,Asthma leaflet given,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,183478001,Emergency hospital admission for asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185242005,Seen in asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185728001,Attends asthma monitoring,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185730004,Asthma monitor offer default,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185731000,Asthma monitoring call first letter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185732007,Asthma monitoring call second letter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185734008,Asthma monitoring call third letter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185735009,Asthma monitoring call verbal invite,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185736005,Asthma monitoring call telephone invite,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185737001,Asthma monitoring deleted,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185940009,Patient in asthma study,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195949008,Chronic asthmatic bronchitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195967001,Asthmatic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195973000,Late-onset asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195977004,Mixed asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195983001,Exercise induced asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,219036002,Adverse reaction to antiasthmatic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,225057002,Brittle asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,233678006,Childhood asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,233679003,Late-onset asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,233683003,Hay fever with asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,233691007,Eosinophilic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,266361008,Non-allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,266396008,Extrinsic asthma - atopy (& pollen),OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,266397004,Intrinsic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,266398009,Asthma attack,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,270442000,Asthma monitoring check done,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,275908000,Asthma monitoring,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,281239006,Asthma attack,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,302220000,Asthma control steps,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,304527002,Acute asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,308500005,Asthma monitoring call,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,308501009,Asthma monitoring status,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,312453004,Asthma - currently active,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,312454005,Asthma - currently dormant,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,366874008,Number of asthma exacerbations in past year,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370204008,Asthma causes daytime symptoms most days,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370206005,Asthma limits walking on the flat,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370207001,Asthma limits walking up hills or stairs,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370208006,Asthma never causes daytime symptoms,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370218001,Mild asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370219009,Moderate asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370220003,Occasional asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370221004,Severe asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370225008,Asthma treatment compliance unsatisfactory,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370226009,Asthma treatment compliance satisfactory,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,373899003,Asthma daytime symptoms,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,389145006,Allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390798007,Asthma finding,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390872009,Change in asthma management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390877003,Step up change in asthma management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390878008,Step down change in asthma management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390921001,Absent from work or school due to asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390940007,Asthma monitoring due,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,394700004,Asthma annual review,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,394701000,Asthma follow-up,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,394720003,Asthma medication review,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,394967008,Suspected asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,395022009,Nocturnal asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,400987003,Asthma trigger,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401135008,Health education - asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401182001,Asthma monitoring by nurse,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401183006,Asthma monitoring by doctor,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401193004,Asthma confirmed,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,405944004,Asthmatic bronchitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,406162001,Asthma care,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,407674008,Aspirin-induced asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,409663006,Cough variant asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,415265005,Referral to asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,424643009,Allergic atopic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,425969006,Acute intermittent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,426656000,Severe persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,426979002,Mild persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,427295004,Moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,427603009,Intermittent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,427679007,Mild intermittent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,443117005,Asthma control test score,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,445427006,Seasonal asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,445531003,ACQ - Asthma control questionnaire,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,473391009,Asthma never causes night symptoms,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,698509001,Under care of asthma specialist nurse,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,699191007,Did not attend asthma review,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,702823004,Asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,704008007,No family history of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707445000,Acute mild persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707446004,Acute exacerbation of moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707447008,Exacerbation of severe persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707511009,Uncomplicated mild persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707512002,Uncomplicated moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707513007,Uncomplicated severe persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707979007,Acute severe exacerbation of severe persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707981009,Acute severe exacerbation of mild persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708038006,Acute exacerbation of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708090002,Acute severe exacerbation of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708093000,Acute exacerbation of allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708094006,Acute exacerbation of intrinsic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708095007,Acute severe exacerbation of extrinsic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708358003,Emergency asthma admission since last encounter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708373002,Emergency asthma patient visit since last encounter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,711442001,Recent asthma management,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,715191006,Telehealth asthma monitoring,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,734346005,Use of asthma symptom diary,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,734904007,Life threatening acute exacerbation of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,734905008,Moderate acute exacerbation of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,736056000,Asthma clinical management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,762521001,Acute allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,763077003,Asthma Control Questionnaire score,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,763221007,Asthma monitoring declined,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,782520007,Exacerbation of allergic asthma due to infection,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,782559003,Asthma never causes night symptoms,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401000119107,Asthma with irreversible airway obstruction,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,641000119106,Intermittent asthma well controlled,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1741000119102,Intermittent asthma uncontrolled,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,72301000119103,Asthma in pregnancy,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,89581000000109,DNA (did not attend) asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,143901000000108,Registration for access to online asthma self-management application,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,143931000000102,Declined to register for access to online asthma self-management application,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,176711000000100,Does not have asthma management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,198971000000102,Asthma outreach clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201031000000108,Asthma trigger - respiratory infection,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201041000000104,Asthma trigger - seasonal,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201051000000101,Asthma trigger - animal,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201191000000108,Asthma trigger - cold air,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201201000000105,Asthma trigger - damp,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201211000000107,Asthma trigger - emotion,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340891000000106,Asthma trigger - airborne dust,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340901000000107,Asthma trigger - exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340911000000109,Asthma trigger - pollen,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340921000000103,Asthma trigger - tobacco smoke,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340931000000101,Asthma trigger - warm air,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,527171000000103,Patient has a written asthma personal action plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,527191000000104,Health education - asthma self management,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,527211000000100,Health education - structured asthma discussion,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,527231000000108,Health education - structured patient focused asthma discussion,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,713701000000108,Asthma monitoring administration,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,713711000000105,Asthma clinic administration,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,715801000000103,Exception reporting - asthma quality indicators,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,771941000000102,Asthma causes symptoms most nights,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,772051000000106,Asthma limits activities most days,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,791401000000104,Seen in school asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,810901000000102,Asthma self-management plan review,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,811921000000103,Asthma self-management plan agreed,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,815631000000106,Asthma trigger - wind,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,818161000000104,Asthma trigger - perfume,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,867171000000106,No asthma trigger identified by subject,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,892301000000100,Asthma management plan declined,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,905301000000103,Childhood Asthma Control Test score,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,928451000000107,Asthma monitoring invitation short message service text message,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,928511000000107,Asthma monitoring invitation email,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,928651000000105,Review of patient at risk of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,928691000000102,At risk of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,959901000000107,Asthma action plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,966011000000109,At risk of severe asthma exacerbation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,966031000000101,Severe asthma exacerbation risk assessment,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10674991000119104,Intermittent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10675431000119106,Severe persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10675871000119106,Mild persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10676031000119106,Mild persistent allergic asthma controlled,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,63088003,Allergic asthma without status asthmaticus,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,266361008,Non-allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,389145006,Allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,423889005,Non-immunoglobulin E mediated allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,708093000,Acute exacerbation of allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,762521001,Acute allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,782520007,Exacerbation of allergic asthma due to infection,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,10674991000119104,Intermittent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,10675431000119106,Severe persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,10675871000119106,Mild persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMALIZUMAB,"Treatment of severe +persistent allergic asthma in +children aged 6 to 11 years",TA201,allergic asthma,10676031000119106,Mild persistent allergic asthma controlled,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,62944002,Hepatitis C virus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,62944002,Hepatitis C virus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,72165005,Hepatitis C virus antibody,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,72165005,Hepatitis C virus antibody,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,170489004,Viral hepatitis carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,170489004,Viral hepatitis carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,197344005,Hepatitis caused by adenovirus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,197344005,Hepatitis caused by adenovirus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,235872006,Hepatitis C carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,235872006,Hepatitis C carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278973007,Hepatitis C status,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278973007,Hepatitis C status,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278974001,Hepatitis C immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278974001,Hepatitis C immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278975000,Hepatitis C non-immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278975000,Hepatitis C non-immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314706002,Hepatitis C antibody detected,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314706002,Hepatitis C antibody detected,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314707006,Hepatitis C antibody test negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314707006,Hepatitis C antibody test negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,413107006,Hepatitis C screening,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,413107006,Hepatitis C screening,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,773113008,Acute hepatitis caused by infection,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,773113008,Acute hepatitis caused by infection,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,12891000175105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,12891000175105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,200371000000104,Hepatitis C contact,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,200371000000104,Hepatitis C contact,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,201451000000105,Hepatitis C immunisation declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,201451000000105,Hepatitis C immunisation declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,202281000000105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,202281000000105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,204671000000101,Hepatitis C screening counselling,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,204671000000101,Hepatitis C screening counselling,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,304821000000107,Hepatitis C screening not offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,304821000000107,Hepatitis C screening not offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362491000000104,Hepatitis C screening negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362491000000104,Hepatitis C screening negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362751000000101,Hepatitis C screening positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362751000000101,Hepatitis C screening positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,761381000000102,Hepatitis C resolved,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,761381000000102,Hepatitis C resolved,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824841000000105,Hepatitis C genotype 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824841000000105,Hepatitis C genotype 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824871000000104,Hepatitis C genotype 3,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824871000000104,Hepatitis C genotype 3,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829731000000106,On hepatitis C treatment plan,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829731000000106,On hepatitis C treatment plan,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992751000000109,Hepatitis C viral load,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992751000000109,Hepatitis C viral load,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992771000000100,Hepatitis C virus genotype,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992771000000100,Hepatitis C virus genotype,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,996031000000104,Hepatitis C IgG level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,996031000000104,Hepatitis C IgG level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,998771000000103,Hepatitis C antibody level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,998771000000103,Hepatitis C antibody level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1001331000000102,Hepatitis C antigen level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1001331000000102,Hepatitis C antigen level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1008931000000108,Hepatitis C antibody test,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1008931000000108,Hepatitis C antibody test,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1107671000000106,Hepatitis C screening offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1107671000000106,Hepatitis C screening offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,62944002,Hepatitis C virus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,62944002,Hepatitis C virus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,72165005,Hepatitis C virus antibody,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,72165005,Hepatitis C virus antibody,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,170489004,Viral hepatitis carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,170489004,Viral hepatitis carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,197344005,Hepatitis caused by adenovirus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,197344005,Hepatitis caused by adenovirus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,235872006,Hepatitis C carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,235872006,Hepatitis C carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278973007,Hepatitis C status,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278973007,Hepatitis C status,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278974001,Hepatitis C immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278974001,Hepatitis C immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278975000,Hepatitis C non-immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278975000,Hepatitis C non-immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314706002,Hepatitis C antibody detected,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314706002,Hepatitis C antibody detected,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314707006,Hepatitis C antibody test negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314707006,Hepatitis C antibody test negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,413107006,Hepatitis C screening,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,413107006,Hepatitis C screening,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,773113008,Acute hepatitis caused by infection,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,773113008,Acute hepatitis caused by infection,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,12891000175105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,12891000175105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,200371000000104,Hepatitis C contact,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,200371000000104,Hepatitis C contact,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,201451000000105,Hepatitis C immunisation declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,201451000000105,Hepatitis C immunisation declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,202281000000105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,202281000000105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,204671000000101,Hepatitis C screening counselling,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,204671000000101,Hepatitis C screening counselling,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,304821000000107,Hepatitis C screening not offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,304821000000107,Hepatitis C screening not offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362491000000104,Hepatitis C screening negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362491000000104,Hepatitis C screening negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362751000000101,Hepatitis C screening positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362751000000101,Hepatitis C screening positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,761381000000102,Hepatitis C resolved,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,761381000000102,Hepatitis C resolved,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824841000000105,Hepatitis C genotype 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824841000000105,Hepatitis C genotype 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824871000000104,Hepatitis C genotype 3,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824871000000104,Hepatitis C genotype 3,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829731000000106,On hepatitis C treatment plan,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829731000000106,On hepatitis C treatment plan,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992751000000109,Hepatitis C viral load,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992751000000109,Hepatitis C viral load,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992771000000100,Hepatitis C virus genotype,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992771000000100,Hepatitis C virus genotype,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,996031000000104,Hepatitis C IgG level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,996031000000104,Hepatitis C IgG level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,998771000000103,Hepatitis C antibody level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,998771000000103,Hepatitis C antibody level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1001331000000102,Hepatitis C antigen level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1001331000000102,Hepatitis C antigen level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1008931000000108,Hepatitis C antibody test,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1008931000000108,Hepatitis C antibody test,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1107671000000106,Hepatitis C screening offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1107671000000106,Hepatitis C screening offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,3696007,Non ulcer dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,191972002,Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,192434000,[X]Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,196752002,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,249511005,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,299969005,Dyspepsia caused by drug,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,416202003,Under care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,417691002,Discharged from care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,203661000000105,Undiagnosed dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,248131000000106,Referral to dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +ORAL AZACITIDINE,Maintenance treatment of acute myeloid leukaemia after induction therapy,TA827,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",ORAL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,14651005,Drug-induced osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,18040001,Age-related osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,64859006,Osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,102447009,Postmenopausal osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,160313009,Family history of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203429007,Idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203433000,Postoophorectomy osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203435007,Localized osteoporosis - Lequesne,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203437004,Osteoporosis in endocrine disorders,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203438009,Osteoporosis of spine,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240157009,Secondary generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240158004,Regional migrating osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240159007,Transient osteoporosis of hip,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240162005,Secondary localized osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,268028001,Localised disuse osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,276661002,Primary osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,281387004,Regional osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,300004007,Screening for osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,309745002,Osteoporosis localized to spine,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,310251007,No family history: Osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,313423004,At increased risk of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391003008,Osteoporosis monitoring administration,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391004002,Attends osteoporosis monitoring,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391006000,Osteoporosis monitoring default,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391007009,Osteoporosis monitoring first letter,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391008004,Osteoporosis monitoring second letter,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391012005,Osteoporosis monitoring deleted,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391013000,Osteoporosis monitoring check done,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391014006,Osteoporosis risk assessment done,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391015007,Osteoporosis risk assessment declined,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391017004,Osteoporosis monitoring,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391018009,Initial osteoporosis assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391019001,Follow-up osteoporosis assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391020007,Osteoporosis treatment started,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391021006,Osteoporosis treatment stopped,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391022004,Osteoporosis treatment changed,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391023009,Osteoporosis - no treatment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391024003,Osteoporosis - dietary advice,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391025002,Osteoporosis - dietary assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391026001,Osteoporosis - exercise advice,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391027005,Osteoporosis - falls prevention,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391028000,Osteoporosis - treatment response,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391033001,Refer to osteoporosis specialist,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391037000,Seen in osteoporosis clinic,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,394936006,Health education - osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,412717001,Referral to osteoporosis clinic,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,473120007,History of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,763322002,Osteoporosis monitoring refused,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,711341000000106,Osteoporosis resolved,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,965871000000101,Osteoporosis medication compliance review,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,162573006,Suspected lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,254637007,Non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,275981009,Lung cancer screening,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,429011007,Family history of lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,723301009,Squamous non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1259727001,Primary non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,276491000000101,Fast track referral for suspected lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,848881000000108,QCancer lung cancer risk,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,877691000000107,No FH of lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1771781000000107,Did not attend lung cancer screening,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +ORLISTAT,Obesity,TA022,obesity,44772007,Maternal obesity without hypertension,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,82793005,Hypothalamic obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,160311006,Family history: Obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,161453001,History of obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,162864005,Body mass index 30+ - obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,170793009,Obesity monitoring,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,170794003,Initial obesity assessment,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,170795002,Follow-up obesity assessment,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,170797005,Has seen dietician - obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,170798000,Treatment of obesity changed,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,170799008,Treatment of obesity started,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,170800007,Treatment of obesity stopped,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,170807005,Reason for obesity therapy - occupational,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185741002,Attends obesity monitoring,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185743004,Obesity monitoring default,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185744005,Obesity monitoring first letter,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185745006,Obesity monitoring second letter,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185746007,Obesity monitoring third letter,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185747003,Obesity monitoring verbal invite,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185748008,Obesity monitoring telephone invite,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185749000,Obesity monitoring deleted,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,185750000,Obesity monitoring check done,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,190965006,Drug-induced obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,190966007,Obesity hypoventilation syndrome,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,235240002,Procedure using anti-obesity gastric balloon,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,238132000,Upper body obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,238133005,Gynecoid obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,238134004,Generalized obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,238136002,Morbid obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,243862009,Obesity monitoring status,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,247824007,Fear of obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,267511009,Hyperalimentation incl.obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,268522006,Obesity monitoring,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,268551005,Obesity screening,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,270486005,Localized obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,276792008,Pulmonary hypertension with extreme obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,277831002,Anxiety about obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,284352003,Obesity diet education,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,294493008,Lifelong obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,296526005,Adult-onset obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,308504001,Obesity monitoring call,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,310428009,Obesity monitoring invitation,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,415530009,Obesity due to excess calories,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,444862003,Childhood obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,703316004,Lymphoedema associated with obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,715279006,Telehealth obesity monitoring,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,763085007,Obesity monitoring declined,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,198181000000102,Obesity resolved,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,640791000000105,Obesity and other hyperalimentation,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,713951000000106,Obesity monitoring administration,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,713971000000102,Obesity clinic administration,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,753691000000104,Exception reporting - obesity quality indicators,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,822741000000107,Anti-obesity drug therapy,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,894961000000105,Referral to multidisciplinary obesity clinic,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,898011000000103,Obesity multidisciplinary case review,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,914801000000107,Anti-obesity drug therapy commenced,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,914821000000103,Obesity medication stopped,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,2386191000000105,National Health Service obesity medication pathway,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,2386231000000101,NHS obesity medication pathway started,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,2386241000000105,National Health Service obesity medication pathway declined,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,2386251000000108,Review of anti-obesity drug therapy,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +ORLISTAT,Obesity,TA022,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (prevention),TA067,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,6142004,Influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,24662006,Influenza caused by Influenza B virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,41269000,Influenzal bronchopneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,44470000,Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,46233009,Influenza virus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,51593004,Haemophilus parainfluenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,64917006,Pneumonia due to parainfluenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,70036007,Haemophilus influenzae pneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,74644004,Influenza with encephalopathy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,89117003,Parainfluenza virus type 4,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,91428005,Haemophilus influenzae infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,95891005,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,120753009,Influenza A virus antibody,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,120843002,Influenza B virus Ab,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,120975003,Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,127787002,Haemophilus influenzae type b immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,170343007,First Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,170345000,Third Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,171272004,No consent - influenza immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,171282003,Influenza immunization advised at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,171290003,Influenza vaccination consent given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,171291004,No consent for Haemophilus influenzae type b immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,185900003,Has influenza vaccination at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,185901004,Has influenza vaccination at surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,185902006,Has influenza vaccination at hospital,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,185903001,Needs influenza immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,192721000,Post influenza vaccination encephalitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,194946005,Acute myocarditis - influenzal,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,195726000,Acute parainfluenza virus bronchitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,195878008,Pneumonia and influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,195923003,Influenza with laryngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,195924009,Influenza with pharyngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,195929004,Influenza with gastrointestinal tract involvement,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,195931008,Influenza like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,266393000,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,268561003,Influenza immunization advised in surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,275983007,Influenza immunisation advised,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,291749008,Influenza vaccine poisoning,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,293112000,Influenza split virion vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,293113005,Influenza surface antigen vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,294647003,Allergy to influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,294648008,Allergy to influenza split virion vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,294649000,Allergy to influenza surface antigen vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,294664000,Haemophilus influenzae type b vaccine allergy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,308532005,Influenza vaccination status,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,309789002,Encephalitis caused by Influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,315640000,Influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,315641001,Influenza vaccination invitation letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,390796006,Influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,396425006,FLU - Influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,407479009,Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,407480007,Influenza B virus(B/Lee/40),ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,407489008,Human parainfluenza virus 1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,407491000,Parainfluenza virus type 2,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,407493002,Human parainfluenza virus 3,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,407498006,Human parainfluenza viruses,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,407573008,Influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,414496007,Influenza vaccination telephone invite,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,416928007,Has influenza vaccination at work,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,441043003,Influenza A virus subtype H1 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,441049004,Influenza A virus subtype H3 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,441343005,Influenza A virus subtype H5 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,441344004,Human parainfluenza virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,441345003,Influenza B virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,442438000,Influenza caused by Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,442696006,Influenza A (H1N1) swine flu,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,444426005,Swine influenza contact,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,473169009,History of influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,698353005,Requires influenza virus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,709410003,Hib (Haemophilus influenzae type b) infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,711330007,Influenza A virus subtype H1N1 detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,711334003,Influenza A virus H1N1 subtype not detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,736818002,Influenza vaccination requested,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,737041000,Influenza immunisation telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,787016008,Administration of influenza vaccine via nasal route,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,73701000119109,Vaccination for influenza given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,135221000119101,Influenza A H1N1 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,199331000000106,Did not attend influenza vaccination appointment,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,200481000000107,Influenza vaccination invitation first letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,200491000000109,Influenza vaccination invitation second letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,200501000000103,Influenza vaccination invitation third letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,201391000000106,Booster influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,202301000000106,First pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,202311000000108,Second pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,380271000000101,Consent given for pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,380381000000108,Pandemic influenza vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,380631000000100,Pandemic influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,380801000000105,Pandemic influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,506751000000104,Possible influenza A virus H1N1 subtype,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,516101000000103,No response to influenza vaccination invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,540151000000108,Pneumonia or influenza NOS,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,761311000000109,Influenza vaccination verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,777791000000102,Influenza vaccination invitation first text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,822851000000102,Seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,822931000000100,Seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,822951000000107,Seasonal influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,822971000000103,Seasonal influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,822991000000104,Consent given for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,844941000000103,Influenza vaccination invitation email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,844961000000102,Influenza vaccination invitation first email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,844981000000106,Influenza vaccination invitation second email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,845001000000101,Influenza vaccination invitation third email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,860151000000103,Influenza vaccination first verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,860171000000107,Influenza vaccination second verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,860211000000105,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,860291000000101,Influenza vaccination third verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,868241000000109,Administration of intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,868491000000103,No consent for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,871521000000104,First intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,871541000000106,Second intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,871751000000104,Administration of first intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,871781000000105,Administration of second intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,873681000000101,Provision of information about seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,913961000000102,Education about influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,932221000000103,At risk of influenza related complication,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,935351000000106,Long term indication for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,955641000000103,Influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,996211000000100,Influenza (A and B) serology,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,996761000000106,Haemophilus influenzae B IgG level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1001341000000106,Influenza A antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1001351000000109,Influenza B antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1005101000000108,Parainfluenza virus antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1005111000000105,Parainfluenza type 3 antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008771000000107,Haemophilus influenzae B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1014261000000103,Influenza A antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1014271000000105,Influenza B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1020381000000100,Parainfluenza virus antigen assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1033051000000101,Influenza due to zoonotic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1033071000000105,Influenza due to pandemic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1033091000000109,Influenza due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1095821000000105,Influenza vaccination first telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1095831000000107,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1095841000000103,Influenza vaccination third telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1239861000000100,Seasonal influenza vaccination given in school,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA058,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSELTAMIVIR,Influenza (treatment),TA168,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (ADJUVANT),Colon cancer,TA100,colon cancer,275978004,Screening for colon cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (ADJUVANT),Colon cancer,TA100,colon cancer,315058005,Hereditary nonpolyposis colon cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,64766004,UC - ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,160383003,FH: Ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,275129008,Family history of ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,275549008,History of ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,445243001,Left sided ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,24700007,Multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,160337009,Family history of multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,192926004,Brain stem multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,192928003,Generalised multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,428700003,Primary progressive multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,438511000,Benign multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,700409000,Suspected multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,198491000000106,Multiple sclerosis review,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,515931000000104,Multiple sclerosis review declined,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Advanced breast cancer,TA006,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,134405005,Suspected breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,160287004,FH: Breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,268547008,Screening for breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,429740004,Family history of breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,706970001,TNBC - Triple-negative breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,94361000000105,Breast cancer detected by national screening programme,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,838351000000107,Education about risk of breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,874291000000100,QCancer breast cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Breast cancer (early),TA108,breast cancer,1035841000000108,Lymphoedema following breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL,Ovarian cancer,TA003,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL,Ovarian cancer,TA003,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL,Ovarian cancer,TA003,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL,Ovarian cancer,TA003,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL,Ovarian cancer (advanced),TA091,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL,Ovarian cancer (advanced),TA091,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL,Ovarian cancer (advanced),TA091,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL,Ovarian cancer (advanced),TA091,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,254637007,Non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL (1ST LINE),Ovarian cancer,TA055,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL (1ST LINE),Ovarian cancer,TA055,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL (1ST LINE),Ovarian cancer,TA055,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL (1ST LINE),Ovarian cancer,TA055,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Ovarian cancer,TA055,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Ovarian cancer,TA055,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Ovarian cancer,TA055,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL (2ND LINE),Ovarian cancer,TA055,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES (NAB‑PACLITAXEL) WITH GEMCITABINE,Untreated metastatic pancreatic cancer,TA476,pancreatic cancer,429000004,Family history of pancreatic cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES (NAB‑PACLITAXEL) WITH GEMCITABINE,Untreated metastatic pancreatic cancer,TA476,pancreatic cancer,247591000000101,Suspected pancreatic cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES (NAB‑PACLITAXEL) WITH GEMCITABINE,Untreated metastatic pancreatic cancer,TA476,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,162573006,Suspected lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,275981009,Lung cancer screening,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,429011007,Family history of lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN‑BOUND NANOPARTICLES IN COMBINATION WITH GEMCITABINE,Previously untreated metastatic pancreatic cancer,TA360,pancreatic cancer,429000004,Family history of pancreatic cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN‑BOUND NANOPARTICLES IN COMBINATION WITH GEMCITABINE,Previously untreated metastatic pancreatic cancer,TA360,pancreatic cancer,247591000000101,Suspected pancreatic cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PACLITAXEL AS ALBUMIN‑BOUND NANOPARTICLES IN COMBINATION WITH GEMCITABINE,Previously untreated metastatic pancreatic cancer,TA360,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PACLITAXEL IN COMBINATION WITH A PLATINUM-BASED COMPOUND,Ovarian cancer (advanced),TA091,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL IN COMBINATION WITH A PLATINUM-BASED COMPOUND,Ovarian cancer (advanced),TA091,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL IN COMBINATION WITH A PLATINUM-BASED COMPOUND,Ovarian cancer (advanced),TA091,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL IN COMBINATION WITH A PLATINUM-BASED COMPOUND,Ovarian cancer (advanced),TA091,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL IN COMBINATION WITH PLATINUM OR AS MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL IN COMBINATION WITH PLATINUM OR AS MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL IN COMBINATION WITH PLATINUM OR AS MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PACLITAXEL IN COMBINATION WITH PLATINUM OR AS MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,315268008,Suspected prostate cancer,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,428262008,H/O: prostate cancer,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,698470001,Advice given about prostate cancer screening,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,712837004,Active surveillance of prostate cancer,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,720007002,Prostate cancer care review,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,31011000119107,Prostate cancer screening declined,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,874211000000109,QCancer prostate cancer risk,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,878401000000104,No FH of prostate cancer,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,134405005,Suspected breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,160287004,FH: Breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,268547008,Screening for breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,429740004,Family history of breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,706970001,TNBC - Triple-negative breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,94361000000105,Breast cancer detected by national screening programme,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,838351000000107,Education about risk of breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,874291000000100,QCancer breast cancer risk,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,1035841000000108,Lymphoedema following breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,134405005,Suspected breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,160287004,FH: Breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,268547008,Screening for breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,429740004,Family history of breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,706970001,TNBC - Triple-negative breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,94361000000105,Breast cancer detected by national screening programme,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,838351000000107,Education about risk of breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,874291000000100,QCancer breast cancer risk,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,1035841000000108,Lymphoedema following breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,134405005,Suspected breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,160287004,FH: Breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,268547008,Screening for breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,429740004,Family history of breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,706970001,TNBC - Triple-negative breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,94361000000105,Breast cancer detected by national screening programme,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,838351000000107,Education about risk of breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,874291000000100,QCancer breast cancer risk,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,1035841000000108,Lymphoedema following breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE,Treating multiple myeloma after at least 2 previous treatments,TA380,multiple myeloma,230586003,Neuropathy due to multiple myeloma,PANOBINOSTAT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE,Treating multiple myeloma after at least 2 previous treatments,TA380,multiple myeloma,413587002,Smoldering multiple myeloma,PANOBINOSTAT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE,Treating multiple myeloma after at least 2 previous treatments,TA380,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,PANOBINOSTAT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,3696007,Non ulcer dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,191972002,Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,192434000,[X]Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,196752002,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,249511005,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,299969005,Dyspepsia caused by drug,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,416202003,Under care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,417691002,Discharged from care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,203661000000105,Undiagnosed dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,248131000000106,Referral to dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,733608000,Papillary renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,193384000,Senile macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,267718000,Age-related macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,312898002,Myopic macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,1296526000,Disciform macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +"PEGASPARGASE, AS PART OF ANTINEOPLASTIC COMBINATION THERAPY",Treating acute lymphoblastic leukaemia,TA408,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,PEGASPARGASE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +"PEGASPARGASE, AS PART OF ANTINEOPLASTIC COMBINATION THERAPY",Treating acute lymphoblastic leukaemia,TA408,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,PEGASPARGASE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +PEGCETACOPLAN,Paroxysmal nocturnal haemoglobinuria,TA778,paroxysmal nocturnal haemoglobinuria,1006421000000103,PNH (paroxysmal nocturnal haemoglobinuria) screening test,PEGCETACOPLAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +PEGCETACOPLAN,Paroxysmal nocturnal haemoglobinuria,TA778,paroxysmal nocturnal haemoglobinuria,1013561000000103,Paroxysmal nocturnal haemoglobinuria cell marker analysis,PEGCETACOPLAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,16584000,Administration of vaccine product containing only Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,17627009,Hepatitis B e antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,22290004,Hepatitis B virus surface antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,47758006,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,61977001,Chronic viral hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,76795007,Acute hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,81665004,Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,82409003,Hepatitis B core antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,82645009,Hepatitis B virus surface antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,116800003,Hepatitis B Virus immune globulin administration,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,122450004,Hepatitis B virus antibody,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,161638000,Hepatitis B Occupational risk,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,165806002,Hepatitis B surface antigen positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,165807006,Hepatitis Be antigen present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,165808001,Hepatitis B non-immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170370000,First hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170371001,Administration of second dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170372008,Third hepatitis B immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170373003,Hepatitis B booster vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170374009,Fourth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170375005,Administration of fifth dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170436000,Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170542003,Requires course of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,171122006,Hepatitis B screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,171123001,Hepatitis B screening required,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,186626002,Acute hepatitis B with delta-agent (coinfection) without hepatic coma,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,192723002,Post hepatitis B vaccination encephalitis,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,235871004,Hepatitis B carrier,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,268504008,Anti-hepatitis B immunoglobulin given,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,271511000,Hepatitis B immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,278969009,Hepatitis B status,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,293110008,Adverse reaction to component of vaccine product containing Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,294637001,Hepatitis B immunoglobulin allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,294646007,Hepatitis B vaccine allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,303233001,Antigen of Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,313234004,Hepatitis B antibody present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,406010001,Hepatitis B surface antigen not detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,408778004,Hepatitis B vaccination declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,416923003,Sixth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,425569004,Hepatitis B immunization recommended,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,426519003,History of two doses hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,426980004,History of one dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,427390007,History of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,429203008,History of three hepatitis B vaccinations,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,429721005,History of hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,698604002,Hepatitis B outbreak education,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,699037006,Hepatitis B vaccination contraindicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,707287001,Hepatitis B vaccination not indicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,736687002,Hepatitis B core antibody detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,736693005,Hepatitis B core antibody negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,736699009,Requires hepatitis B booster,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,198041000000109,Hepatitis B vaccination refused,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,201591000000101,Advice on hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,202271000000108,Hepatitis B screening declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,204681000000104,Hepatitis B screening counselling,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,221021000000103,Hepatitis B treatment drugs Band 1,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,356121000000100,Hepatitis B screening positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,362851000000109,Hepatitis B screening negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835791000000107,Hepatitis B vaccination invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835811000000108,Hepatitis B vaccination invitation first letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835831000000100,Hepatitis B vaccination invitation second letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835851000000107,Hepatitis B vaccination invitation third letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835871000000103,Hepatitis B vaccination verbal invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,839711000000101,Hepatitis B vaccination not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,846421000000105,Hepatitis B screening not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,865061000000108,First hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,865081000000104,Second hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,865101000000105,Third hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,865121000000101,Fourth hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,991971000000109,Hepatitis B immunity test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,991981000000106,Hepatitis B core antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,991991000000108,Hepatitis B e antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,995941000000101,Anti HBc (hepatitis B core) IgG level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1008441000000106,Hepatitis B deoxyribonucleic acid detection assay,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1008791000000106,HBsAg (hepatitis B surface antigen) antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1009271000000109,Hepatitis B screening test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1014201000000102,Hepatitis B surface antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1014211000000100,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1014231000000108,Hepatitis B core antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1014241000000104,Hepatitis B e antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1028341000000105,Hepatitis B antigen screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1037211000000101,First hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1037231000000109,Second hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1060591000000103,Hepatitis B resolved,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1091701000000105,At risk of hepatitis B infection,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1107691000000105,Hepatitis B screening offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,24700007,Multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,160337009,Family history of multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,192926004,Brain stem multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,192928003,Generalised multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,428700003,Primary progressive multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,438511000,Benign multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,700409000,Suspected multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,198491000000106,Multiple sclerosis review,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,515931000000104,Multiple sclerosis review declined,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION +PEGLOTICASE,Severe debilitating chronic tophaceous gout,TA291,tophaceous gout,190842000,Chronic tophaceous gout of hand,PEGLOTICASE,RHEUMATOLOGY,RHEUMATOLOGY +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,62944002,Hepatitis C virus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,62944002,Hepatitis C virus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,72165005,Hepatitis C virus antibody,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,72165005,Hepatitis C virus antibody,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,170489004,Viral hepatitis carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,170489004,Viral hepatitis carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,235872006,Hepatitis C carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,235872006,Hepatitis C carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278973007,Hepatitis C status,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278973007,Hepatitis C status,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278974001,Hepatitis C immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278974001,Hepatitis C immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278975000,Hepatitis C non-immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278975000,Hepatitis C non-immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,314706002,Hepatitis C antibody detected,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,314706002,Hepatitis C antibody detected,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,314707006,Hepatitis C antibody test negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,314707006,Hepatitis C antibody test negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,413107006,Hepatitis C screening,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,413107006,Hepatitis C screening,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,773113008,Acute hepatitis caused by infection,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,773113008,Acute hepatitis caused by infection,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,12891000175105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,12891000175105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,200371000000104,Hepatitis C contact,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,200371000000104,Hepatitis C contact,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,202281000000105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,202281000000105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,362491000000104,Hepatitis C screening negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,362491000000104,Hepatitis C screening negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,362751000000101,Hepatitis C screening positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,362751000000101,Hepatitis C screening positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,761381000000102,Hepatitis C resolved,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,761381000000102,Hepatitis C resolved,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,992751000000109,Hepatitis C viral load,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,992751000000109,Hepatitis C viral load,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,996031000000104,Hepatitis C IgG level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,996031000000104,Hepatitis C IgG level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,998771000000103,Hepatitis C antibody level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,998771000000103,Hepatitis C antibody level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,62944002,Hepatitis C virus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,62944002,Hepatitis C virus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,72165005,Hepatitis C virus antibody,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,72165005,Hepatitis C virus antibody,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,170489004,Viral hepatitis carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,170489004,Viral hepatitis carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,235872006,Hepatitis C carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,235872006,Hepatitis C carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278973007,Hepatitis C status,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278973007,Hepatitis C status,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278974001,Hepatitis C immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278974001,Hepatitis C immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278975000,Hepatitis C non-immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278975000,Hepatitis C non-immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,314706002,Hepatitis C antibody detected,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,314706002,Hepatitis C antibody detected,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,314707006,Hepatitis C antibody test negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,314707006,Hepatitis C antibody test negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,413107006,Hepatitis C screening,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,413107006,Hepatitis C screening,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,773113008,Acute hepatitis caused by infection,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,773113008,Acute hepatitis caused by infection,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,12891000175105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,12891000175105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,200371000000104,Hepatitis C contact,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,200371000000104,Hepatitis C contact,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,202281000000105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,202281000000105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,362491000000104,Hepatitis C screening negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,362491000000104,Hepatitis C screening negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,362751000000101,Hepatitis C screening positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,362751000000101,Hepatitis C screening positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,761381000000102,Hepatitis C resolved,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,761381000000102,Hepatitis C resolved,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,992751000000109,Hepatitis C viral load,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,992751000000109,Hepatitis C viral load,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,996031000000104,Hepatitis C IgG level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,996031000000104,Hepatitis C IgG level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,998771000000103,Hepatitis C antibody level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,998771000000103,Hepatitis C antibody level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA045,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA091,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA045,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA091,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA045,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA091,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA045,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA091,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH) MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH) MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH) MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH) MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL IRINOTECAN IN COMBINATION WITH 5‑FLUOROURACIL AND LEUCOVORIN,Pancreatic cancer after gemcitabine,TA440,pancreatic cancer,429000004,Family history of pancreatic cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL IRINOTECAN IN COMBINATION WITH 5‑FLUOROURACIL AND LEUCOVORIN,Pancreatic cancer after gemcitabine,TA440,pancreatic cancer,247591000000101,Suspected pancreatic cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PEGYLATED LIPOSOMAL IRINOTECAN IN COMBINATION WITH 5‑FLUOROURACIL AND LEUCOVORIN,Pancreatic cancer after gemcitabine,TA440,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,733608000,Papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA519,urothelial carcinoma,12400006,Papillary urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA692,urothelial carcinoma,12400006,Papillary urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA519,urothelial carcinoma,27090000,Urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA692,urothelial carcinoma,27090000,Urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA519,urothelial carcinoma,1259709004,Primary micropapillary urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA692,urothelial carcinoma,1259709004,Primary micropapillary urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,134405005,Suspected breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,160287004,FH: Breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,268547008,Screening for breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,429740004,Family history of breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,706970001,TNBC - Triple-negative breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,94361000000105,Breast cancer detected by national screening programme,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,838351000000107,Education about risk of breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,874291000000100,QCancer breast cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,1035841000000108,Lymphoedema following breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,402815007,Squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,402815007,Squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,134405005,Suspected breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,160287004,FH: Breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,268547008,Screening for breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,429740004,Family history of breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,706970001,TNBC - Triple-negative breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,94361000000105,Breast cancer detected by national screening programme,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,838351000000107,Education about risk of breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,874291000000100,QCancer breast cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,1035841000000108,Lymphoedema following breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,733608000,Papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMBROLIZUMAB WITH PLATINUM- AND FLUOROPYRIMIDINE-BASED CHEMOTHERAPY,Untreated advanced oesophageal and gastro-oesophageal junction cancer,TA737,gastro-oesophageal junction,427421001,Fibreoptic endoscopic endoluminal plication of gastro-oesophageal junction,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,275981009,Lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,275981009,Lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (2ND LINE),Non-small cell lung cancer,TA124,non-small cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (2ND LINE),Non-small cell lung cancer,TA124,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (2ND LINE),Non-small cell lung cancer,TA124,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (2ND LINE),Non-small cell lung cancer,TA124,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,275981009,Lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED DISODIUM,Malignant pleural mesothelioma,TA135,malignant pleural mesothelioma,254645002,Malignant pleural mesothelioma,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,275981009,Lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,52178006,Hepatocholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,253017000,Hilar cholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,274902006,Hepatocholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,312104005,Cholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,721716004,Primary intrahepatic cholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +PENTOXIFYLLINE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822611000000100,Exception reporting - peripheral arterial disease quality indicators,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +PENTOXIFYLLINE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822641000000104,Excepted from peripheral arterial disease quality indicators - patient unsuitable,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +PENTOXIFYLLINE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822671000000105,Excepted from peripheral arterial disease quality indicators - informed dissent,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +PENTOXIFYLLINE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,968121000000103,Peripheral arterial disease screening,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,134405005,Suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,160287004,FH: Breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,268547008,Screening for breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,429740004,Family history of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,706970001,TNBC - Triple-negative breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,94361000000105,Breast cancer detected by national screening programme,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,838351000000107,Education about risk of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,874291000000100,QCancer breast cancer risk,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,1035841000000108,Lymphoedema following breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,134405005,Suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,160287004,FH: Breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,268547008,Screening for breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,429740004,Family history of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,706970001,TNBC - Triple-negative breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,94361000000105,Breast cancer detected by national screening programme,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,838351000000107,Education about risk of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,874291000000100,QCancer breast cancer risk,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,1035841000000108,Lymphoedema following breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,134405005,Suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,160287004,FH: Breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,268547008,Screening for breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,429740004,Family history of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,706970001,TNBC - Triple-negative breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,94361000000105,Breast cancer detected by national screening programme,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,838351000000107,Education about risk of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,874291000000100,QCancer breast cancer risk,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,1035841000000108,Lymphoedema following breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238543002,Discoid atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238545009,Follicular atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238546005,Pruriginous atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,584621000000108,Atopic dermatitis NOS,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,90610005,Interstitial pulmonary fibrosis of prematurity,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,90610005,Interstitial pulmonary fibrosis of prematurity,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,196028003,Chronic pulmonary fibrosis caused by chemical fumes,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,196028003,Chronic pulmonary fibrosis caused by chemical fumes,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,196125002,Diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,196125002,Diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,233724002,Chemical-induced diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,233724002,Chemical-induced diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,233725001,Drug-induced diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,233725001,Drug-induced diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,233726000,Localised pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,233726000,Localised pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,233770009,Pulmonary fibrosis due to sarcoidosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,233770009,Pulmonary fibrosis due to sarcoidosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,266368002,Post-inflammatory pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,266368002,Post-inflammatory pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,700250006,IPF - idiopathic pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,700250006,IPF - idiopathic pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE +PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,79280005,Hypersomnia with sleep apnoea,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT +PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,206750008,Sleep apnoea syndrome,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT +PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,230493001,Complex sleep apnoea,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT +PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,230494007,Alveolar sleep apnoea,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT +PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,232531007,Pharyngeal operation for obstructive sleep apnoea and snoring,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT +PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,361208003,Primary sleep apnoea of newborn,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT +PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,774068004,"AHDC1-related intellectual disability, obstructive sleep apnoea, mild dysmorphism syndrome",PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT +PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,502901000000102,[D]Sleep apnoea syndrome,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,835009,Angioimmunoblastic lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1929004,"Malignant lymphoma, diffuse",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,19340000,Plasmacytic lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,20776008,Adenolymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,21964009,Lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,21983002,Struma lymphomatosa,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,28054005,Cutaneous lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,28175004,Gastric pseudolymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,30440004,Lymphoma stage I,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,31047003,Lymphomatoid papulosis,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,55150002,"Malignant lymphoma, nodular",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,56944001,Lymphoma stage III,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,66445009,Lymphoma stage IV,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,74654000,Mantle cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,76422004,Lymphoma stage II,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93198004,Malignant lymphoma of spleen,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,95193005,Nodular lymphoma of spleen,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,106252000,Staging classification for lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109962001,Nonfollicular lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109969005,Diffuse large B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109975001,T-zone lymphoma (clinical),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109976000,Lymphoepithelioid lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109978004,T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109979007,B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109988003,True histiocytic lymphoma (clinical),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,115244002,Malignant lymphoma - category,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118599009,"Lymphoma, Hodgkins",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118600007,Malignant lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118601006,Non-Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118617000,Burkitt lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128803008,Marginal zone lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128929007,Non-Hodgkin lymphoma - category,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128930002,Hodgkin lymphoma - category,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,189958005,"Lymphomatous tumour, benign",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,189962004,"Malignant lymphoma, stem cell type",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,232075002,Lymphoma of retina,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,236513009,Lymphoma of kidney,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,239297008,Lymphomatoid granulomatosis of lung,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,239940004,Lymphomatoid granulomatosis,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,254372002,Ann Arbor lymphoma staging system,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,255102004,Intravascular lymphomatosis,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,258279002,Lymphoma staging symptom status values,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,269476000,Nodular lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,274905008,Mantle zone lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,276811008,Gastric lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,276815004,Lymphoma of intestine,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,276836002,Primary cerebral lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277570003,Lymphoma with spill,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277615007,Low grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277616008,Diffuse low grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277617004,High grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277618009,Nodular malignant lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277623009,Monocytoid B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277626001,Diffuse high grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277627005,Nodular high grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277637000,Large cell anaplastic lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277641001,Follicular malignant lymphoma - large cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277642008,Low grade T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277643003,High grade T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277654008,Enteropathy-type T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277664004,Malignant lymphoma of testis,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,278051002,Malignant lymphoma of thyroid gland,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,278052009,Malignant lymphoma of breast,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,302841002,Malignant lymphoma - small cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,308121000,Follicular lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314922006,B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314923001,Low grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314925008,High grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314926009,T-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,315264005,Suspected lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,400001003,Primary cutaneous lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,404140004,SALT type B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,420788006,Vitreoretinal lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,426071002,Hodgkin lymphoma in remission,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,427141003,Malignant lymphoma in remission,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,428046009,History of non-Hodgkins lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,433450000,Family history of non-Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,443487006,Mantle cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,445406001,Hepatosplenic T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,447100004,Marginal zone lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,448211002,Adenolymphoma of parotid gland,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,449074003,Lymphoma of small intestine,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,449220000,Diffuse follicle center lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,721555001,Follicular lymphoma of small intestine,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,724648008,Plasmablastic lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,762690000,Classical Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1148851002,Follicular lymphoma grade IIIa,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847481000000109,Follicular lymphoma grade 1,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847631000000107,Follicular lymphoma grade 2,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847651000000100,Follicular lymphoma grade 3,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847691000000108,Follicular lymphoma grade 3a,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847701000000108,Follicular lymphoma grade 3b,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847741000000106,Diffuse large B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PLDH IN COMBINATION WITH PLATINUM,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PLDH IN COMBINATION WITH PLATINUM,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PLDH IN COMBINATION WITH PLATINUM,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +PLDH IN COMBINATION WITH PLATINUM,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +POLATUZUMAB VEDOTIN IN COMBINATION,Untreated diffuse large B-cell lymphoma,TA874,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,POLATUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POLATUZUMAB VEDOTIN IN COMBINATION,Untreated diffuse large B-cell lymphoma,TA874,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,POLATUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POLATUZUMAB VEDOTIN WITH RITUXIMAB AND BENDAMUSTINE,Relapsed or refractory diffuse large B-cell lymphoma,TA649,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,POLATUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POLATUZUMAB VEDOTIN WITH RITUXIMAB AND BENDAMUSTINE,Relapsed or refractory diffuse large B-cell lymphoma,TA649,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,POLATUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POMALIDOMIDE IN COMBINATION WITH DEXAMETHASONE,Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib,TA338,multiple myeloma,230586003,Neuropathy due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POMALIDOMIDE IN COMBINATION WITH DEXAMETHASONE,Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib,TA338,multiple myeloma,413587002,Smoldering multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POMALIDOMIDE IN COMBINATION WITH DEXAMETHASONE,Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib,TA338,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA602,multiple myeloma,230586003,Neuropathy due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA602,multiple myeloma,413587002,Smoldering multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA602,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"POMALIDOMIDE, IN COMBINATION WITH LOW‑DOSE DEXAMETHASONE",Multiple myeloma previously treated with lenalidomide and bortezomib,TA427,multiple myeloma,230586003,Neuropathy due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"POMALIDOMIDE, IN COMBINATION WITH LOW‑DOSE DEXAMETHASONE",Multiple myeloma previously treated with lenalidomide and bortezomib,TA427,multiple myeloma,413587002,Smoldering multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +"POMALIDOMIDE, IN COMBINATION WITH LOW‑DOSE DEXAMETHASONE",Multiple myeloma previously treated with lenalidomide and bortezomib,TA427,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +PONATINIB,Chronic myeloid leukaemia and acute lymphoblastic leukaemia,TA451,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,PONATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +PONATINIB,Chronic myeloid leukaemia and acute lymphoblastic leukaemia,TA451,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,PONATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +PONATINIB,Chronic myeloid leukaemia and acute lymphoblastic leukaemia,TA451,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,PONATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,24700007,Multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,160337009,Family history of multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,192926004,Brain stem multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,192928003,Generalised multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,428700003,Primary progressive multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,438511000,Benign multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,700409000,Suspected multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,198491000000106,Multiple sclerosis review,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,515931000000104,Multiple sclerosis review declined,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,162573006,Suspected lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,275981009,Lung cancer screening,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,429011007,Family history of lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +PRASUGREL IN COMBINATION WITH ASPIRIN,Acute coronary syndromes,TA317,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,PRASUGREL,CARDIOLOGY,CARDIOLOGY +PRASUGREL IN COMBINATION WITH ASPIRIN,Atherothrombotic events in people with acute coronary syndromes (prevention),TA182,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,PRASUGREL,CARDIOLOGY,CARDIOLOGY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,21782001,Drug-induced constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,31499008,Chronic constipation with overflow,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,35298007,Colonic constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,82934008,Chronic idiopathic constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,129691005,At increased risk for constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,191973007,Psychogenic constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,197118003,Functional constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,197119006,Acute constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,197120000,Chronic constipation without overflow,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,236069009,Chronic constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,236070005,Simple constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,249517009,Constipation alternates with diarrhea,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,266524003,(Functional constipation) or (impacted feces),PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,440630006,Constipation predominant irritable bowel syndrome,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,443307007,Dietary education for constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,448880001,Cleveland Clinic constipation score,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,847591000000107,Constipation in children clinical pathway,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,1325741000000102,Constipation care indicated,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +QUETIAPINE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +QUETIAPINE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,3696007,Non ulcer dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,191972002,Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,192434000,[X]Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,196752002,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,249511005,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,299969005,Dyspepsia caused by drug,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,416202003,Under care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,417691002,Discharged from care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,203661000000105,Undiagnosed dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,248131000000106,Referral to dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,315268008,Suspected prostate cancer,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,428262008,H/O: prostate cancer,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,698470001,Advice given about prostate cancer screening,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,712837004,Active surveillance of prostate cancer,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,720007002,Prostate cancer care review,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,31011000119107,Prostate cancer screening declined,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,874211000000109,QCancer prostate cancer risk,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,878401000000104,No FH of prostate cancer,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,315268008,Suspected prostate cancer,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,428262008,H/O: prostate cancer,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,698470001,Advice given about prostate cancer screening,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,712837004,Active surveillance of prostate cancer,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,720007002,Prostate cancer care review,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,31011000119107,Prostate cancer screening declined,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,874211000000109,QCancer prostate cancer risk,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,878401000000104,No FH of prostate cancer,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +RAMUCIRUMAB,Unresectable hepatocellular carcinoma after sorafenib,TA609,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +RAMUCIRUMAB,Unresectable hepatocellular carcinoma after sorafenib,TA609,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +RAMUCIRUMAB,Unresectable hepatocellular carcinoma after sorafenib,TA609,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +RAMUCIRUMAB ALONE OR WITH PACLITAXEL,Treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy,TA378,gastric cancer,276809004,Early gastric cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +RAMUCIRUMAB ALONE OR WITH PACLITAXEL,Treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy,TA378,gastric cancer,276810009,Late gastric cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,162573006,Suspected lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,254637007,Non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,275981009,Lung cancer screening,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,429011007,Family history of lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,877691000000107,No FH of lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,162573006,Suspected lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,254637007,Non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,275981009,Lung cancer screening,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,429011007,Family history of lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,877691000000107,No FH of lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +RANIBIZUMAB,Choroidal neovascularisation associated with pathological myopia,TA298,choroidal neovascularisation,733124000,Myopic choroidal neovascularisation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Choroidal neovascularisation associated with pathological myopia,TA298,choroidal neovascularisation,380621000000102,Subfoveal choroidal neovascularisation drugs Band 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,37231002,Macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,232039004,Central retinal vein occlusion with macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,232045007,Macular oedema due to hemispheric retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312911008,CSME - clinically significant macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312912001,Macular oedema due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312920004,Postoperative cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312921000,Autosomal dominant cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312922007,Uveitis related cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,769218003,Macular oedema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,895021000000102,Macular oedema drugs Band 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,37231002,Macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,232039004,Central retinal vein occlusion with macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,232045007,Macular oedema due to hemispheric retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312911008,CSME - clinically significant macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312912001,Macular oedema due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312920004,Postoperative cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312921000,Autosomal dominant cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312922007,Uveitis related cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,769218003,Macular oedema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,895021000000102,Macular oedema drugs Band 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,193384000,Senile macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,267718000,Age-related macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,312898002,Myopic macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,1296526000,Disciform macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,134395001,Diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,312906006,Early PDR (proliferative diabetic retinopathy),RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,312907002,High risk PDR (proliferative diabetic retinopathy),RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,312908007,Inactive PDR (proliferative diabetic retinopathy),RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,390850007,On examination - no right diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,390853009,On examination - no left diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408384004,Diabetic retinopathy 12 month review,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408385003,Diabetic retinopathy 6 month review,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408396006,Diabetic retinopathy screening not indicated,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408409007,On examination - right eye background diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408410002,On examination - left eye background diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408411003,On examination - right eye preproliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408412005,On examination - left eye preproliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408413000,On examination - right eye proliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408414006,On examination - left eye proliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,413122001,Diabetic retinopathy screening declined,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,414894003,On examination - left eye stable treated proliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,414910007,On examination - right eye stable treated proliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,417677008,On examination - sight threatening diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,702850009,Diabetic retinopathy clinic,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,769181007,Preproliferative diabetic retinopathy of right eye,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,199301000000100,Did not attend diabetic retinopathy clinic,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,201141000000103,No diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,248161000000101,Referral for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,305401000000104,Information sharing consent status for national screening programme for diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,371781000000108,Eligible for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,371811000000106,Ineligible for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,371841000000107,Eligibility temporarily inactive for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,371871000000101,Eligibility permanently inactive for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,373031000000105,Diabetic retinopathy screening administrative status,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,373041000000101,Impaired vision due to diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374601000000107,Excluded from diabetic retinopathy screening as moved away,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374631000000101,Excluded from diabetic retinopathy screening as deceased,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374661000000106,Excluded from diabetic retinopathy screening as under care of ophthalmologist,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374691000000100,Excluded from diabetic retinopathy screening as blind,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374721000000109,Excluded from diabetic retinopathy screening as no longer diabetic,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374781000000105,Excluded from diabetic retinopathy screening as no current contact details,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374811000000108,Excluded from diabetic retinopathy screening as terminal illness,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374841000000109,Excluded from diabetic retinopathy screening as learning disability,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374871000000103,Excluded from diabetic retinopathy screening as physical disorder,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374901000000103,Excluded from diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,775841000000109,Diabetic retinopathy detected by national screening programme,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,839811000000106,Diabetic retinopathy screening declined,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,846721000000101,Education about diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,1103701000000102,Diabetic retinopathy screening offered,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE +RAVULIZUMAB,Paroxysmal nocturnal haemoglobinuria,TA698,paroxysmal nocturnal haemoglobinuria,1006421000000103,PNH (paroxysmal nocturnal haemoglobinuria) screening test,RAVULIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RAVULIZUMAB,Paroxysmal nocturnal haemoglobinuria,TA698,paroxysmal nocturnal haemoglobinuria,1013561000000103,Paroxysmal nocturnal haemoglobinuria cell marker analysis,RAVULIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA514,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA555,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA514,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA555,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA514,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA555,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +RELUGOLIX–ESTRADIOL–NORETHISTERONE ACETATE,Moderate to severe symptoms of uterine fibroids,TA832,uterine fibroids,237217000,"Uterine fibroids in pregnancy, childbirth and the puerperium",RELUGOLIX,GYNAECOLOGY,GYNAECOLOGY +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,12428000,Intrinsic asthma without status asthmaticus,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,31387002,Exercise-induced asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,34015007,Flour asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,56018004,Asthmatic breathing,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,56968009,Asthma caused by wood dust,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,57607007,Industrial asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,63088003,Allergic asthma without status asthmaticus,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,71892000,Cardiac asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,93432008,Drug-induced asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,160377001,Family history of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,161105008,Asthma society member,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,161527007,History of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,162660004,Asthma resolved,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170631002,Asthma disturbing sleep,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170632009,Asthma causing night waking,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170633004,Asthma disturbs sleep weekly,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170634005,Asthma disturbs sleep frequently,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170635006,Asthma not disturbing sleep,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170636007,Asthma never disturbs sleep,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170637003,Asthma limiting activities,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170638008,Asthma not limiting activities,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170642006,Asthma severity,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170647000,Asthma prophylactic medication used,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170655007,Asthma restricts exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170656008,Asthma sometimes restricts exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170657004,Asthma severely restricts exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170658009,Asthma never restricts exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,171231001,Asthma screening,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182724005,Further asthma - drug prevention,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182726007,Asthma control step 0,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182727003,Asthma control step 1,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182728008,Asthma control step 2,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182729000,Asthma control step 3,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182730005,Asthma control step 4,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182731009,Asthma control step 5,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,183099005,Asthma leaflet given,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,183478001,Emergency hospital admission for asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185242005,Seen in asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185728001,Attends asthma monitoring,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185730004,Asthma monitor offer default,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185731000,Asthma monitoring call first letter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185732007,Asthma monitoring call second letter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185734008,Asthma monitoring call third letter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185735009,Asthma monitoring call verbal invite,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185736005,Asthma monitoring call telephone invite,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185737001,Asthma monitoring deleted,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185940009,Patient in asthma study,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195949008,Chronic asthmatic bronchitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195967001,Asthmatic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195973000,Late-onset asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195977004,Mixed asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195983001,Exercise induced asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,219036002,Adverse reaction to antiasthmatic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,225057002,Brittle asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,233678006,Childhood asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,233679003,Late-onset asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,233683003,Hay fever with asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,233691007,Eosinophilic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,266361008,Non-allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,266396008,Extrinsic asthma - atopy (& pollen),RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,266397004,Intrinsic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,266398009,Asthma attack,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,270442000,Asthma monitoring check done,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,275908000,Asthma monitoring,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,281239006,Asthma attack,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,302220000,Asthma control steps,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,304527002,Acute asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,308500005,Asthma monitoring call,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,308501009,Asthma monitoring status,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,312453004,Asthma - currently active,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,312454005,Asthma - currently dormant,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,366874008,Number of asthma exacerbations in past year,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370204008,Asthma causes daytime symptoms most days,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370206005,Asthma limits walking on the flat,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370207001,Asthma limits walking up hills or stairs,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370208006,Asthma never causes daytime symptoms,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370218001,Mild asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370219009,Moderate asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370220003,Occasional asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370221004,Severe asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370225008,Asthma treatment compliance unsatisfactory,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370226009,Asthma treatment compliance satisfactory,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,373899003,Asthma daytime symptoms,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,389145006,Allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390798007,Asthma finding,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390872009,Change in asthma management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390877003,Step up change in asthma management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390878008,Step down change in asthma management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390921001,Absent from work or school due to asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390940007,Asthma monitoring due,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,394700004,Asthma annual review,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,394701000,Asthma follow-up,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,394720003,Asthma medication review,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,394967008,Suspected asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,395022009,Nocturnal asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,400987003,Asthma trigger,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401135008,Health education - asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401182001,Asthma monitoring by nurse,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401183006,Asthma monitoring by doctor,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401193004,Asthma confirmed,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,405944004,Asthmatic bronchitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,406162001,Asthma care,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,407674008,Aspirin-induced asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,409663006,Cough variant asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,415265005,Referral to asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,424643009,Allergic atopic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,425969006,Acute intermittent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,426656000,Severe persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,426979002,Mild persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,427295004,Moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,427603009,Intermittent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,427679007,Mild intermittent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,443117005,Asthma control test score,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,445427006,Seasonal asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,445531003,ACQ - Asthma control questionnaire,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,473391009,Asthma never causes night symptoms,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,698509001,Under care of asthma specialist nurse,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,699191007,Did not attend asthma review,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,702823004,Asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,704008007,No family history of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707445000,Acute mild persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707446004,Acute exacerbation of moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707447008,Exacerbation of severe persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707511009,Uncomplicated mild persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707512002,Uncomplicated moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707513007,Uncomplicated severe persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707979007,Acute severe exacerbation of severe persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707981009,Acute severe exacerbation of mild persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708038006,Acute exacerbation of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708090002,Acute severe exacerbation of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708093000,Acute exacerbation of allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708094006,Acute exacerbation of intrinsic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708095007,Acute severe exacerbation of extrinsic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708358003,Emergency asthma admission since last encounter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708373002,Emergency asthma patient visit since last encounter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,711442001,Recent asthma management,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,715191006,Telehealth asthma monitoring,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,734346005,Use of asthma symptom diary,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,734904007,Life threatening acute exacerbation of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,734905008,Moderate acute exacerbation of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,736056000,Asthma clinical management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,762521001,Acute allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,763077003,Asthma Control Questionnaire score,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,763221007,Asthma monitoring declined,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,782520007,Exacerbation of allergic asthma due to infection,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,782559003,Asthma never causes night symptoms,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401000119107,Asthma with irreversible airway obstruction,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,641000119106,Intermittent asthma well controlled,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1741000119102,Intermittent asthma uncontrolled,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,72301000119103,Asthma in pregnancy,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,89581000000109,DNA (did not attend) asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,143901000000108,Registration for access to online asthma self-management application,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,143931000000102,Declined to register for access to online asthma self-management application,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,176711000000100,Does not have asthma management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,198971000000102,Asthma outreach clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201031000000108,Asthma trigger - respiratory infection,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201041000000104,Asthma trigger - seasonal,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201051000000101,Asthma trigger - animal,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201191000000108,Asthma trigger - cold air,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201201000000105,Asthma trigger - damp,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201211000000107,Asthma trigger - emotion,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340891000000106,Asthma trigger - airborne dust,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340901000000107,Asthma trigger - exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340911000000109,Asthma trigger - pollen,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340921000000103,Asthma trigger - tobacco smoke,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340931000000101,Asthma trigger - warm air,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,527171000000103,Patient has a written asthma personal action plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,527191000000104,Health education - asthma self management,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,527211000000100,Health education - structured asthma discussion,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,527231000000108,Health education - structured patient focused asthma discussion,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,713701000000108,Asthma monitoring administration,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,713711000000105,Asthma clinic administration,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,715801000000103,Exception reporting - asthma quality indicators,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,771941000000102,Asthma causes symptoms most nights,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,772051000000106,Asthma limits activities most days,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,791401000000104,Seen in school asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,810901000000102,Asthma self-management plan review,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,811921000000103,Asthma self-management plan agreed,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,815631000000106,Asthma trigger - wind,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,818161000000104,Asthma trigger - perfume,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,867171000000106,No asthma trigger identified by subject,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,892301000000100,Asthma management plan declined,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,905301000000103,Childhood Asthma Control Test score,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,928451000000107,Asthma monitoring invitation short message service text message,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,928511000000107,Asthma monitoring invitation email,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,928651000000105,Review of patient at risk of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,928691000000102,At risk of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,959901000000107,Asthma action plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,966011000000109,At risk of severe asthma exacerbation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,966031000000101,Severe asthma exacerbation risk assessment,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10674991000119104,Intermittent allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10675431000119106,Severe persistent allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10675871000119106,Mild persistent allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10676031000119106,Mild persistent allergic asthma controlled,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,1755008,Healed myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,22298006,MI - myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,52035003,Acute anteroapical myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,54329005,Acute anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,57054005,Acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,65547006,Acute inferolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,66189004,Postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,70211005,Acute anterolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,79009004,Acute myocardial infarction of septum,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,129574000,Postoperative myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194809007,Acute myocardial infarction of atrium,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194821006,Aborted myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194856005,Subsequent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233838001,Acute posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233839009,Old anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233840006,Old inferior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233841005,Old lateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233842003,Old posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233843008,Silent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233885007,Pericarditis following myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,266897007,Family history of myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,304914007,Acute Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,308065005,History of myocardial infarction in last year,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,314207007,Non-Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,394710008,First myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,399211009,Previous myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETEPLASE,Myocardial infarction,TA052,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,6204001,Juvenile myoclonic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,16873003,Musicogenic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,19598007,Generalized epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,36803009,IGE - idiopathic generalized epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,38281008,Self-limited neonatal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,50866000,CAE - childhood absence epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,65120008,Generalised convulsive epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,71831005,Secondary generalised epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,79745005,Sensory-induced epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,84757009,Epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,95208000,Photic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,160341008,Family history of epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,161480008,History of epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,162658001,Epilepsy resolved,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170702005,Epilepsy monitoring,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170703000,Initial epilepsy assessment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170704006,Follow-up epilepsy assessment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170706008,Epilepsy associated problems,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170709001,Epilepsy drug side effect,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170710006,Epilepsy treatment changed,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170711005,Epilepsy treatment started,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170712003,Epilepsy treatment stopped,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,192979009,Generalized non-convulsive epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,192990004,Myoclonic epilepsy in infancy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,192999003,Partial epilepsy with impairment of consciousness,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193000002,Temporal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193002005,Psychosensory epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193007004,Focal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193008009,Somatosensory epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193009001,Partial epilepsy with autonomic symptoms,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193011005,Unilateral epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193021002,Running epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230381009,Localization-related epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230382002,Benign frontal epilepsy of childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230384001,Benign atypical partial epilepsy in childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230386004,Benign occipital epilepsy of childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230388003,Late onset occipital epilepsy of childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230390002,Localisation-related symptomatic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230393000,Lateral temporal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230394006,Frontal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230403005,Parietal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230404004,Occipital lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230408001,Localisation-related cryptogenic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230412007,Myoclonic epilepsy of early childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230413002,JAE - juvenile absence epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230415009,Cryptogenic generalised epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230422001,Epilepsy with myoclonic absence,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230428002,Idiopathic myoclonic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230430000,Symptomatic myoclonic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230438007,Aphasia co-occurrent with epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230440002,Secondary reading epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230441003,Drug-induced epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230444006,Catamenial epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230450001,Eating epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230452009,Toothbrushing epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230454005,Bathing epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,243857008,Epilepsy monitoring status,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,267581004,Progressive myoclonic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,278510009,Localisation-related idiopathic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,307356008,Motor epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,314827004,Epilepsy control good,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,314828009,Epilepsy control poor,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,352818000,Grand mal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,361123003,Psychomotor epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,361268000,Alcohol-induced epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,401062003,Epilepsy medication review,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,401178003,Epilepsy care arrangement,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,407616001,Epilepsy severity,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,407623000,Emergency epilepsy treatment since last appointment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,407625007,Suspected epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,407627004,Epilepsy confirmed,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,413101007,Stress-induced epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,414113005,Epilepsy leaflet given,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,414860000,No epilepsy drug side effects,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,416090009,Epilepsy monitoring verbal invite,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,417568007,Epilepsy monitoring call,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,429279006,Seen in epilepsy clinic,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,719425009,Sudden unexpected death in epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,1260117009,Combined focal and generalized epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,1260407007,Genetic generalised epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,88491000000102,Epilepsy limits activities,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,93141000000105,Epilepsy restricts employment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,93151000000108,Epilepsy prevents employment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,93211000000101,Epilepsy does not limit activities,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,108211000000104,Epilepsy impairs education,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,109121000000109,Epilepsy society member,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,116401000119105,Recurrent complex partial epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,202061000000107,Epilepsy monitoring call first letter,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,202071000000100,Epilepsy monitoring call second letter,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,202081000000103,Epilepsy monitoring call third letter,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,509341000000107,Petit-mal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,711501000000104,Epilepsy screening invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,715091000000100,Epilepsy screening administration,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,715791000000102,Epilepsy screening second invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,716011000000103,Epilepsy screening first invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,716811000000106,Epilepsy screening third invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,809381000000103,Referral for epilepsy review,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,809551000000103,Referral to epilepsy clinic,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,810161000000101,Epilepsy monitoring in secondary care,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,811411000000104,Under care of epilepsy specialist nurse,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,840261000000103,Epilepsy management plan given,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,850201000000104,Epilepsy annual review,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,865371000000104,No history of epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,876461000000101,No FH of epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,892181000000107,Referral to epilepsy service,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,62944002,Hepatitis C virus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,62944002,Hepatitis C virus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,72165005,Hepatitis C virus antibody,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,72165005,Hepatitis C virus antibody,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,170489004,Viral hepatitis carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,170489004,Viral hepatitis carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,197344005,Hepatitis caused by adenovirus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,197344005,Hepatitis caused by adenovirus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,235872006,Hepatitis C carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,235872006,Hepatitis C carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278973007,Hepatitis C status,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278973007,Hepatitis C status,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278974001,Hepatitis C immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278974001,Hepatitis C immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278975000,Hepatitis C non-immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278975000,Hepatitis C non-immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,314706002,Hepatitis C antibody detected,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,314706002,Hepatitis C antibody detected,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,314707006,Hepatitis C antibody test negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,314707006,Hepatitis C antibody test negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,413107006,Hepatitis C screening,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,413107006,Hepatitis C screening,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,773113008,Acute hepatitis caused by infection,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,773113008,Acute hepatitis caused by infection,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,12891000175105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,12891000175105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,200371000000104,Hepatitis C contact,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,200371000000104,Hepatitis C contact,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,201451000000105,Hepatitis C immunisation declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,201451000000105,Hepatitis C immunisation declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,202281000000105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,202281000000105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,204671000000101,Hepatitis C screening counselling,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,204671000000101,Hepatitis C screening counselling,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,304821000000107,Hepatitis C screening not offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,304821000000107,Hepatitis C screening not offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,362491000000104,Hepatitis C screening negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,362491000000104,Hepatitis C screening negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,362751000000101,Hepatitis C screening positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,362751000000101,Hepatitis C screening positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,761381000000102,Hepatitis C resolved,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,761381000000102,Hepatitis C resolved,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,824841000000105,Hepatitis C genotype 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,824841000000105,Hepatitis C genotype 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,824871000000104,Hepatitis C genotype 3,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,824871000000104,Hepatitis C genotype 3,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,829731000000106,On hepatitis C treatment plan,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,829731000000106,On hepatitis C treatment plan,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,992751000000109,Hepatitis C viral load,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,992751000000109,Hepatitis C viral load,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,992771000000100,Hepatitis C virus genotype,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,992771000000100,Hepatitis C virus genotype,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,996031000000104,Hepatitis C IgG level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,996031000000104,Hepatitis C IgG level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,998771000000103,Hepatitis C antibody level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,998771000000103,Hepatitis C antibody level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1001331000000102,Hepatitis C antigen level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1001331000000102,Hepatitis C antigen level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1008931000000108,Hepatitis C antibody test,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1008931000000108,Hepatitis C antibody test,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1107671000000106,Hepatitis C screening offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1107671000000106,Hepatitis C screening offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,134405005,Suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,160287004,FH: Breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,268547008,Screening for breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,429740004,Family history of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,431330007,Family history of breast cancer 1 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,431331006,Family history of breast cancer 2 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,706970001,TNBC - Triple-negative breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,94361000000105,Breast cancer detected by national screening programme,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,276341000000100,Fast track referral for suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,838351000000107,Education about risk of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,874291000000100,QCancer breast cancer risk,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,1035841000000108,Lymphoedema following breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,134405005,Suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,160287004,FH: Breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,268547008,Screening for breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,429740004,Family history of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,431330007,Family history of breast cancer 1 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,431331006,Family history of breast cancer 2 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,706970001,TNBC - Triple-negative breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,94361000000105,Breast cancer detected by national screening programme,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,276341000000100,Fast track referral for suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,838351000000107,Education about risk of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,874291000000100,QCancer breast cancer risk,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,1035841000000108,Lymphoedema following breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,134405005,Suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,160287004,FH: Breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,268547008,Screening for breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,429740004,Family history of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,431330007,Family history of breast cancer 1 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,431331006,Family history of breast cancer 2 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,706970001,TNBC - Triple-negative breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,94361000000105,Breast cancer detected by national screening programme,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,276341000000100,Fast track referral for suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,838351000000107,Education about risk of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,874291000000100,QCancer breast cancer risk,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,1035841000000108,Lymphoedema following breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +RILUZOLE,Motor neurone disease,TA020,motor neurone disease,160344000,Family history of motor neurone disease,RILUZOLE,NEUROLOGY,NEUROLOGY|REHABILITATION|PALLIATIVE CARE +RILUZOLE,Motor neurone disease,TA020,motor neurone disease,230257000,Paraneoplastic motor neurone disease,RILUZOLE,NEUROLOGY,NEUROLOGY|REHABILITATION|PALLIATIVE CARE +RILUZOLE,Motor neurone disease,TA020,motor neurone disease,230274000,Frontal lobe degeneration with motor neurone disease,RILUZOLE,NEUROLOGY,NEUROLOGY|REHABILITATION|PALLIATIVE CARE +RIMONABANT,Overweight and obese adults,TA144,overweight,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",RIMONABANT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE +RIMONABANT,Overweight and obese adults,TA144,overweight,755921000000105,"Risk to health associated with overweight and obesity, at high risk",RIMONABANT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE +RIMONABANT,Overweight and obese adults,TA144,overweight,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",RIMONABANT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE +RISANKIZUMAB,Moderate to severe plaque psoriasis,TA596,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),RISANKIZUMAB,DERMATOLOGY,DERMATOLOGY +RISANKIZUMAB,Moderate to severe plaque psoriasis,TA596,plaque psoriasis,402307000,Chronic large plaque psoriasis,RISANKIZUMAB,DERMATOLOGY,DERMATOLOGY +RISANKIZUMAB,Moderate to severe plaque psoriasis,TA596,plaque psoriasis,402310007,Chronic stable plaque psoriasis,RISANKIZUMAB,DERMATOLOGY,DERMATOLOGY +RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,156370009,Psoriatic arthritis,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,5262007,Progressive spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,54280009,Familial spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,64383006,Infantile spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,85505000,Generalized spinal muscular atrophy of late onset,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,128212001,Late infantile spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,230247001,Distal spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,230252006,Oculopharyngeal spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +RISPERIDONE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RISPERIDONE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,161567008,History of rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY (OTHER THAN FLUDARABINE AND CYCLOPHOSPHAMIDE),Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY (OTHER THAN FLUDARABINE AND CYCLOPHOSPHAMIDE),Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY (OTHER THAN FLUDARABINE AND CYCLOPHOSPHAMIDE),Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY (OTHER THAN FLUDARABINE AND CYCLOPHOSPHAMIDE),Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (1ST LINE),Chronic lymphocytic leukaemia,TA174,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (1ST LINE),Chronic lymphocytic leukaemia,TA174,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (1ST LINE),Chronic lymphocytic leukaemia,TA174,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (1ST LINE),Chronic lymphocytic leukaemia,TA174,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,228007,Lepromatous cutaneous vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,77628002,Retinal vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,235992000,Peritoneal vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,238787009,Secondary cutaneous vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239924002,Primary necrotising systemic vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239933000,Primary necrotising vasculitis with granulomata,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239944008,Vasculitis due to lupus erythematosus,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239945009,Anti-C1q vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239947001,Essential cryoglobulinemic vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,400054000,Rheumatoid arthritis with vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,407530004,Primary systemic vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,472974007,H/O vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,724599009,Small vessel vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,2517002,Stroke rehabilitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,25133001,Completed stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,28690004,Stroke test,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,39925003,"MELAS - mitochondrial encephalopathy, lactic acidosis and stroke-like episodes",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,44922000,Bounding pulse with rapid upstroke and descent,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,49436004,Atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,90096001,Stroke volume,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,134377004,Atrial fibrillation monitoring,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,135875009,Stroke prevention,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,135877001,Stroke risk,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,160252004,No family history of cardiovascular accident or stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,160271002,No family history of stroke and/or transient ischaemic attack,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,170600009,Stroke monitoring,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,195080001,Atrial fibrillation and flutter,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,195163003,Stroke due to intracerebral haemorrhage,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,195212005,Brainstem stroke syndrome,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,195213000,Cerebellar stroke syndrome,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,212937007,Heat stroke and sunstroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230690007,Stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230694003,Total anterior cerebral circulation stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230695002,Partial anterior cerebral circulation stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230696001,Posterior cerebral circulation stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230700009,Pure sensory stroke due to and following lacunar infarction,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230713003,Stroke of uncertain pathology,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230714009,Anterior circulation stroke of uncertain pathology,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230715005,Posterior circulation stroke of uncertain pathology,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230739000,Spinal cord stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,275434003,Stroke in the puerperium,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,276898003,Left ventricular stroke work index,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,277286006,Chronic central post-stroke pain,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,277381004,Stroke index,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,282825002,Intermittent atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,297250002,No family history of stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,299403002,Stroke test positive,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,299404008,Stroke test negative,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,300996004,Controlled atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,306802002,Referral to stroke service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,306803007,Admission to stroke unit,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,306808003,Discharge from stroke service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,306810001,Seen by stroke service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,308067002,History of stroke in last year,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,309966001,Stroke unit,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,310137004,Stroke service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,312442005,History of atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,371040005,Thrombotic stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,371041009,Embolic stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,412773009,Referral to stroke clinic,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,413119003,Stroke group member,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,413124000,Stroke/transient ischaemic attack referral,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,415628004,Stroke/transient ischaemic attack monitoring first letter,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,415629007,Stroke/transient ischemic attack monitoring second letter,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,415630002,Stroke/transient ischaemic attack monitoring status,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,415631003,Stroke/transient ischemic attack monitoring third letter,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,417059002,Stroke/transient ischemic attack monitoring verbal invitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,417506008,Hemorrhagic stroke monitoring,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,417540008,Stroke/transient ischaemic attack monitoring invitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,422504002,Ischaemic stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,440028005,Permanent atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,440059007,Persistent atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,450743008,NIHSS (National Institutes of Health stroke scale) score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,704154001,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR (international normalised ratio), elderly over 65, and drugs and/or alcohol concomitantly) score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,704180000,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,707514001,Stroke impact scale version 3.0 score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,719008003,At increased risk of atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,722929005,Perinatal arterial ischemic stroke of fetus and/or neonate,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,724424009,Cerebral ischemic stroke due to small artery occlusion,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,736712009,PASS (Postural Assessment Scale for Stroke Patients) score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,788884002,Cerebral ischemic stroke due to subarachnoid hemorrhage,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,88601000000107,DNA (did not attend) stroke clinic,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,112901000000108,Referral to multidisciplinary stroke function improvement service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,140921000119102,Ischemic stroke without coma,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,143471000000105,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation using preferred method of communication,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,196371000000102,Atrial fibrillation resolved,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,201501000000108,Seen in stroke clinic,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,231231000000107,Delivery of rehabilitation for stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,248411000000105,Atrial fibrillation annual review,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,519751000000106,Stroke 6 month review,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,521411000000106,Did not attend stroke review,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,685631000000102,Stroke and cerebrovascular accident unspecified,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,713771000000100,Stroke/transient ischaemic attack monitoring administration,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,716021000000109,Excepted from stroke quality indicators - informed dissent,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,716331000000108,Exception reporting - stroke quality indicators,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,716581000000101,Excepted from stroke quality indicators - patient unsuitable,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,717241000000108,Stroke/transient ischaemic attack monitoring telephone invitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,769211000000103,Suspected stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,810991000000109,Stroke self-management plan review,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,812041000000104,Stroke self-management plan agreed,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,816401000000105,Atrial fibrillation excluded,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,816561000000108,Stroke initial post discharge review,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,842441000000104,Provision of written information about stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,870631000000105,QStroke 10 year risk of stroke calculator,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1062151000000103,Stroke TOM (Therapy Outcome Measure) activity score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1062171000000107,Stroke TOM (Therapy Outcome Measure) impairment score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1062181000000109,Stroke TOM (Therapy Outcome Measure) participation score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1062191000000106,Stroke TOM (Therapy Outcome Measure) wellbeing score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1066831000000104,Atrial fibrillation detected,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1078001000000105,Haemorrhagic stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1085311000000106,QStroke risk calculator score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1110981000000104,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,16371781000119100,Cerebellar stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,59282003,Pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,200284000,Obstetric pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,200286003,Obstetric air pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,233217004,Operation for pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,233936003,Acute massive pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,233937007,Subacute massive pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,430801003,Family history of pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,438773007,Recurrent pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,443749004,Venous thromboembolism risk assessment,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,699035003,At low risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,711293008,At moderate risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,711328005,At high risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,787331000000107,Venous thromboembolism prevention management,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,844041000000102,Education about risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,14534009,Deep vein thrombosis of splenic vein,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,49956009,Antenatal DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,56272000,Puerperal DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,59282003,Pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,128053003,Deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,134399007,Deep vein thrombosis of leg related to air travel,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,161508001,History of DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,200232006,Antenatal deep vein thrombosis - delivered,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,200233001,Antenatal deep vein thrombosis with antenatal complication,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,200238005,Postnatal deep vein thrombosis with postnatal complication,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,200284000,Obstetric pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,200286003,Obstetric air pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,213220000,Postoperative deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,225999004,At increased risk of DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,233217004,Operation for pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,233936003,Acute massive pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,233937007,Subacute massive pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,234044007,Ileofemoral deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,401186003,Deep vein thrombosis screening,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,413459009,Advised risk of deep vein thrombosis in air travel,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,413956008,Deep vein thrombosis of leg related to intravenous drug use,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,429053008,Wells deep vein thrombosis clinical probability score,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,430801003,Family history of pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,432805000,Suspected deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,438773007,Recurrent pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,443210003,Deep vein thrombosis of peroneal vein,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,710167004,Recurrent DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,198301000000109,FH: deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,323631000000102,DVT (deep vein thrombosis) prevention,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,492161000000109,Deep vein thrombosis enhanced services administration,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,503421000000105,Deep vein thrombosis enhanced services administration stage 1 service level,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,503451000000100,Deep vein thrombosis enhanced services administration stage 2 service level,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,503481000000106,Deep vein thrombosis enhanced services administration stage 3 service level,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,513251000000101,Low probability of deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,513271000000105,Moderate probability of deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,513291000000109,High probability of deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,869611000000104,On deep vein thrombosis care pathway,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,872221000000109,No history of deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,978421000000101,Unprovoked deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,978441000000108,Provoked deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY +RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,443749004,Venous thromboembolism risk assessment,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,699035003,At low risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,711293008,At moderate risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,711328005,At high risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,787331000000107,Venous thromboembolism prevention management,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,844041000000102,Education about risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY +RIVAROXABAN IN COMBINATION WITH ASPIRIN PLUS CLOPIDOGREL OR ASPIRIN ALONE,Preventing adverse outcomes after acute management of acute coronary syndrome,TA335,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY +RIVASTIGMINE,Alzheimer's disease,TA019,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease,TA111,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease,TA019,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease,TA111,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease,TA019,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease,TA111,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease,TA019,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease,TA111,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +RIVASTIGMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,22193007,Osteoarthritis of joint of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,33952002,Localised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,37895003,Osteoarthritis of first carpometacarpal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,82300000,Osteoarthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,160414002,Family history: Osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,161568003,History of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201819000,Generalised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201852006,"Localised, secondary osteoarthritis of the hand",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201889009,"Osteoarthritis NOS, of the upper arm",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201890000,Wrist osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201891001,Thumb osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201893003,Knee osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201894009,"Osteoarthritis NOS, of ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,202655008,Osteoarthritis of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239863005,Osteoarthritis of spinal facet joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239866002,Osteoarthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239868001,Osteoarthritis of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239874001,Osteoarthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239878003,Osteoarthritis of toe joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267889007,Generalized osteoarthritis of the hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,268054009,Osteoarthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313257005,"Localized, primary osteoarthritis of the wrist",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313258000,"Localised, primary osteoarthritis of toe",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313259008,"Localized, primary osteoarthritis of elbow",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,373623009,Osteoarthritis of glenohumeral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,394991004,Flare of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,443524000,Secondary osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,450521003,Osteoarthritis of patellofemoral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,700324005,Osteoarthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1162304008,Oligoarticular osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343601009,OA (osteoarthritis) of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343603007,Osteoarthritis of thoracic spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343604001,Cervical osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343605000,Osteoarthritis of lumbar spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323301000119109,Osteoarthritis of left knee joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323311000119107,Osteoarthritis of right hip joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666451000000100,"Osteoarthritis NOS, other specified site",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,850791000000102,Osteoarthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,135836000,End stage chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,171230000,Chronic obstructive pulmonary disease screening,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,195951007,Acute exacerbation of COPD (chronic obstructive pulmonary disease),ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,196001008,COPD (chronic obstructive pulmonary disease) with acute lower respiratory infection,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,270473001,History of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,285381006,Acute infective exacerbation of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,297241004,Family history of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,313296004,Mild chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,313297008,Moderate chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,313299006,Severe chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,390891009,Chronic obstructive pulmonary disease monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,390941006,Chronic obstructive pulmonary disease monitoring due,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,394702007,Chronic obstructive pulmonary disease follow-up,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,394703002,Chronic obstructive pulmonary disease annual review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,395159008,Chronic obstructive pulmonary disease leaflet given,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,401184000,Chronic obstructive pulmonary disease monitoring by nurse,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,401185004,Chronic obstructive pulmonary disease monitoring by doctor,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,401200002,At increased risk of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,408501008,Emergency hospital admission for chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,408552005,No family history of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,413845009,Chronic obstructive pulmonary disease accident and emergency attendance since last visit,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,414087000,Emergency chronic obstructive pulmonary disease admission since last appointment,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,445192002,Clinical COPD (chronic obstructive pulmonary disease) questionnaire total score,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,445312005,CCQ - Clinical COPD (chronic obstructive pulmonary disease) questionnaire,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,446660005,CAT - COPD (chronic obstructive pulmonary disease) assessment test score,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,473202005,Optimization of medication for chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,704121003,Step up change in chronic obstructive pulmonary disease management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,704123000,Step down change in chronic obstructive pulmonary disease management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,716358000,Telehealth chronic obstructive pulmonary disease monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,723245007,Number of chronic obstructive pulmonary disease exacerbations in past year,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,736283006,Chronic obstructive pulmonary disease clinical management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,741056003,COPD (chronic obstructive pulmonary disease) education,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,57671000052108,CAT - COPD (chronic obstructive pulmonary disease) assessment test,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,110011000000107,DNA - Did not attend chronic obstructive pulmonary disease clinic,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,143371000000104,QOF (Quality and Outcomes Framework) chronic obstructive pulmonary disease quality indicator-related care invitation using preferred method of communication,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,198401000000104,COPD (chronic obstructive pulmonary disease) disturbs sleep,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,198411000000102,COPD (chronic obstructive pulmonary disease) does not disturb sleep,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,198901000000105,Multiple chronic obstructive pulmonary disease emergency hospital admissions,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,201341000000101,Chronic obstructive pulmonary disease monitoring status,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,204991000000107,Suspected chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,293991000000106,Very severe chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,371611000000107,Chronic obstructive pulmonary disease patient unsuitable for pulmonary rehabilitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,374591000000101,Chronic obstructive pulmonary disease enhanced services administration,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,375851000000108,Referred for chronic obstructive pulmonary disease structured smoking assessment,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,375911000000102,Chronic obstructive pulmonary disease structured smoking assessment declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,383611000000102,At risk of COPD (chronic obstructive pulmonary disease) exacerbation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,527361000000107,CAT - COPD (chronic obstructive pulmonary disease) assessment test,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,711431000000109,Chronic obstructive pulmonary disease monitoring invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,713731000000102,Chronic obstructive pulmonary disease monitoring administration,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,716241000000106,Chronic obstructive pulmonary disease monitoring first letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,716281000000103,Chronic obstructive pulmonary disease monitoring verbal invite,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,716901000000101,Chronic obstructive pulmonary disease monitoring telephone invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,717021000000106,Chronic obstructive pulmonary disease monitoring second letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,717521000000104,Chronic obstructive pulmonary disease monitoring third letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,718241000000107,Provision of chronic obstructive pulmonary disease rescue pack,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,753941000000104,Discussion about chronic obstructive pulmonary disease exacerbation plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,760601000000107,Chronic obstructive pulmonary disease 3 monthly review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,760621000000103,Chronic obstructive pulmonary disease 6 monthly review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,783631000000109,General practitioner out of hours service notified of chronic obstructive pulmonary disease care plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,789661000000102,Preferred place of care for next exacerbation of COPD (chronic obstructive pulmonary disease),ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,790301000000101,Referral to chronic obstructive pulmonary disease community nursing team,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,810951000000101,COPD (chronic obstructive pulmonary disease) self-management plan review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,811961000000106,Chronic obstructive pulmonary disease self-management plan agreed,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,820341000000109,COPD (chronic obstructive pulmonary disease) rescue pack not indicated,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,826111000000109,On chronic obstructive pulmonary disease supportive care pathway,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,827571000000106,Has chronic obstructive pulmonary disease care plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,847091000000104,Acute non-infective exacerbation of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,848431000000106,COPD (chronic obstructive pulmonary disease) care pathway,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,857661000000104,Seen in chronic obstructive pulmonary disease clinic,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,857791000000103,Chronic obstructive pulmonary disease rescue pack declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,857811000000102,Chronic obstructive pulmonary disease written self management plan declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,857821000000108,Chronic obstructive pulmonary disease self management plan not appropriate,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,892321000000109,Chronic obstructive pulmonary disease management plan declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,897311000000101,Shared care COPD (chronic obstructive pulmonary disease) monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,941201000000103,Chronic obstructive pulmonary disease resolved,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1065151000000105,Number of hospital admissions due to COPD (chronic obstructive pulmonary disease) in past year,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066231000000103,Chronic obstructive pulmonary disease monitoring email invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066281000000104,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066821000000101,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message first invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066841000000108,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message second invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066851000000106,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message third invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1108721000000102,Excepted from COPD (chronic obstructive pulmonary disease) quality indicators - service unavailable,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1110861000000102,QOF (Quality and Outcomes Framework) chronic obstructive pulmonary disease quality indicator-related care invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,135836000,End stage chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,171230000,Chronic obstructive pulmonary disease screening,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,195951007,Acute exacerbation of COPD (chronic obstructive pulmonary disease),ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,196001008,COPD (chronic obstructive pulmonary disease) with acute lower respiratory infection,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,270473001,History of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,285381006,Acute infective exacerbation of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,297241004,Family history of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,313296004,Mild chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,313297008,Moderate chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,313299006,Severe chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,390891009,Chronic obstructive pulmonary disease monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,390941006,Chronic obstructive pulmonary disease monitoring due,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,394702007,Chronic obstructive pulmonary disease follow-up,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,394703002,Chronic obstructive pulmonary disease annual review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,395159008,Chronic obstructive pulmonary disease leaflet given,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,401184000,Chronic obstructive pulmonary disease monitoring by nurse,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,401185004,Chronic obstructive pulmonary disease monitoring by doctor,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,401200002,At increased risk of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,408501008,Emergency hospital admission for chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,408552005,No family history of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,413845009,Chronic obstructive pulmonary disease accident and emergency attendance since last visit,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,414087000,Emergency chronic obstructive pulmonary disease admission since last appointment,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,445192002,Clinical COPD (chronic obstructive pulmonary disease) questionnaire total score,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,445312005,CCQ - Clinical COPD (chronic obstructive pulmonary disease) questionnaire,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,446660005,CAT - COPD (chronic obstructive pulmonary disease) assessment test score,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,473202005,Optimization of medication for chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,704121003,Step up change in chronic obstructive pulmonary disease management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,704123000,Step down change in chronic obstructive pulmonary disease management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,716358000,Telehealth chronic obstructive pulmonary disease monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,723245007,Number of chronic obstructive pulmonary disease exacerbations in past year,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,736283006,Chronic obstructive pulmonary disease clinical management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,741056003,COPD (chronic obstructive pulmonary disease) education,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,57671000052108,CAT - COPD (chronic obstructive pulmonary disease) assessment test,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,110011000000107,DNA - Did not attend chronic obstructive pulmonary disease clinic,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,143371000000104,QOF (Quality and Outcomes Framework) chronic obstructive pulmonary disease quality indicator-related care invitation using preferred method of communication,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,198401000000104,COPD (chronic obstructive pulmonary disease) disturbs sleep,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,198411000000102,COPD (chronic obstructive pulmonary disease) does not disturb sleep,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,198901000000105,Multiple chronic obstructive pulmonary disease emergency hospital admissions,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,201341000000101,Chronic obstructive pulmonary disease monitoring status,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,204991000000107,Suspected chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,293991000000106,Very severe chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,371611000000107,Chronic obstructive pulmonary disease patient unsuitable for pulmonary rehabilitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,374591000000101,Chronic obstructive pulmonary disease enhanced services administration,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,375851000000108,Referred for chronic obstructive pulmonary disease structured smoking assessment,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,375911000000102,Chronic obstructive pulmonary disease structured smoking assessment declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,383611000000102,At risk of COPD (chronic obstructive pulmonary disease) exacerbation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,527361000000107,CAT - COPD (chronic obstructive pulmonary disease) assessment test,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,711431000000109,Chronic obstructive pulmonary disease monitoring invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,713731000000102,Chronic obstructive pulmonary disease monitoring administration,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,716241000000106,Chronic obstructive pulmonary disease monitoring first letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,716281000000103,Chronic obstructive pulmonary disease monitoring verbal invite,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,716901000000101,Chronic obstructive pulmonary disease monitoring telephone invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,717021000000106,Chronic obstructive pulmonary disease monitoring second letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,717521000000104,Chronic obstructive pulmonary disease monitoring third letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,718241000000107,Provision of chronic obstructive pulmonary disease rescue pack,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,753941000000104,Discussion about chronic obstructive pulmonary disease exacerbation plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,760601000000107,Chronic obstructive pulmonary disease 3 monthly review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,760621000000103,Chronic obstructive pulmonary disease 6 monthly review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,783631000000109,General practitioner out of hours service notified of chronic obstructive pulmonary disease care plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,789661000000102,Preferred place of care for next exacerbation of COPD (chronic obstructive pulmonary disease),ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,790301000000101,Referral to chronic obstructive pulmonary disease community nursing team,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,810951000000101,COPD (chronic obstructive pulmonary disease) self-management plan review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,811961000000106,Chronic obstructive pulmonary disease self-management plan agreed,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,820341000000109,COPD (chronic obstructive pulmonary disease) rescue pack not indicated,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,826111000000109,On chronic obstructive pulmonary disease supportive care pathway,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,827571000000106,Has chronic obstructive pulmonary disease care plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,847091000000104,Acute non-infective exacerbation of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,848431000000106,COPD (chronic obstructive pulmonary disease) care pathway,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,857661000000104,Seen in chronic obstructive pulmonary disease clinic,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,857791000000103,Chronic obstructive pulmonary disease rescue pack declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,857811000000102,Chronic obstructive pulmonary disease written self management plan declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,857821000000108,Chronic obstructive pulmonary disease self management plan not appropriate,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,892321000000109,Chronic obstructive pulmonary disease management plan declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,897311000000101,Shared care COPD (chronic obstructive pulmonary disease) monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,941201000000103,Chronic obstructive pulmonary disease resolved,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1065151000000105,Number of hospital admissions due to COPD (chronic obstructive pulmonary disease) in past year,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066231000000103,Chronic obstructive pulmonary disease monitoring email invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066281000000104,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066821000000101,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message first invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066841000000108,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message second invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066851000000106,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message third invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1108721000000102,Excepted from COPD (chronic obstructive pulmonary disease) quality indicators - service unavailable,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1110861000000102,QOF (Quality and Outcomes Framework) chronic obstructive pulmonary disease quality indicator-related care invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE +ROMIPLOSTIM,Chronic immune (idiopathic) thrombocytopenic purpura,TA221,thrombocytopenic purpura,78129009,TTP - thrombotic thrombocytopenic purpura,ROMIPLOSTIM,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ROMIPLOSTIM,Chronic immune (idiopathic) thrombocytopenic purpura,TA221,thrombocytopenic purpura,234493006,Non-thrombocytopenic purpura,ROMIPLOSTIM,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ROMIPLOSTIM,Chronic immune (idiopathic) thrombocytopenic purpura,TA221,thrombocytopenic purpura,234494000,Primary non-thrombocytopenic purpura,ROMIPLOSTIM,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ROMIPLOSTIM,Chronic immune (idiopathic) thrombocytopenic purpura,TA221,thrombocytopenic purpura,302873008,Thrombocytopenic purpura,ROMIPLOSTIM,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,14651005,Drug-induced osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,18040001,Age-related osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,64859006,Osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,102447009,Postmenopausal osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,160313009,Family history of osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203429007,Idiopathic generalised osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203433000,Postoophorectomy osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203435007,Localized osteoporosis - Lequesne,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203437004,Osteoporosis in endocrine disorders,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203438009,Osteoporosis of spine,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240157009,Secondary generalised osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240158004,Regional migrating osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240159007,Transient osteoporosis of hip,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240162005,Secondary localized osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,268028001,Localised disuse osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,276661002,Primary osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,281387004,Regional osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,300004007,Screening for osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,309745002,Osteoporosis localized to spine,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,310251007,No family history: Osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,313423004,At increased risk of osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391003008,Osteoporosis monitoring administration,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391004002,Attends osteoporosis monitoring,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391006000,Osteoporosis monitoring default,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391007009,Osteoporosis monitoring first letter,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391008004,Osteoporosis monitoring second letter,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391012005,Osteoporosis monitoring deleted,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391013000,Osteoporosis monitoring check done,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391014006,Osteoporosis risk assessment done,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391015007,Osteoporosis risk assessment declined,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391017004,Osteoporosis monitoring,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391018009,Initial osteoporosis assessment,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391019001,Follow-up osteoporosis assessment,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391020007,Osteoporosis treatment started,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391021006,Osteoporosis treatment stopped,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391022004,Osteoporosis treatment changed,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391023009,Osteoporosis - no treatment,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391024003,Osteoporosis - dietary advice,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391025002,Osteoporosis - dietary assessment,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391026001,Osteoporosis - exercise advice,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391027005,Osteoporosis - falls prevention,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391028000,Osteoporosis - treatment response,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391033001,Refer to osteoporosis specialist,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391037000,Seen in osteoporosis clinic,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,394936006,Health education - osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,412717001,Referral to osteoporosis clinic,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,473120007,History of osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,763322002,Osteoporosis monitoring refused,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,711341000000106,Osteoporosis resolved,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,965871000000101,Osteoporosis medication compliance review,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,8619003,Cannot achieve a pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,9899009,Ovarian pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,15230009,Liver disorder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,15394000,Toxemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,16356006,Multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,16756008,Albuminuria in pregnancy without hypertension,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,17433009,Ruptured ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,17787002,Peripheral neuritis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,18302006,Incision of uterus for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,20956009,Phlebitis complicating pregnancy AND/OR puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,31563000,Asymptomatic bacteriuria in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,31601007,Combined pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,34500003,Legal termination of pregnancy without complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,34801009,Ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,38720006,Septuplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,40609001,"Infections of pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,43990006,Sextuplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,44782008,Molar pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,44795003,Rhesus isoimmunisation in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,45828008,"Anaemia in mother complicating pregnancy, childbirth AND/OR puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,46764007,Severe proteinuric hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,47200007,HRP - high risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,48194001,Pregnancy-induced hypertension,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,57630001,First trimester pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,57797005,Termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,58532003,Unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,59466002,Second trimester pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,60810003,Quadruplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,64254006,Triplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,65147003,Twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,65727000,Intrauterine pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,67313008,Fetal death due to termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,69532007,Mural pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,72892002,Normal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,74036000,Pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,77386006,Pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,79290002,Cervical pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,79586000,Fallopian tube pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,82661006,Abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,83074005,Accidental pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,84939004,"Rubella in mother complicating pregnancy, childbirth AND/OR puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,87605005,Cornual pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,88697005,Papular dermatitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,88895004,Fatigue during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,90325002,Vomiting of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,90968009,Post-term pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,95212006,Gingival disease due to pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,102955006,Pregnancy with contraceptive device,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,111208003,Mask of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,118185001,Pregnancy observations,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127365008,Second pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127366009,Third pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127367000,Fourth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127368005,Fifth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127369002,Sixth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127370001,Seventh pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127371002,Eighth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127372009,Ninth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127373004,Tenth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,135881001,Review of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,146799005,Possible pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,160401003,Family history: Raised blood pressure in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,160402005,Family history: Diabetes in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161009004,Pregnancy benefits (& maternity allowances),ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161742008,Past pregnancy outcome,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161743003,Past pregnancy history of stillbirth,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161744009,Past pregnancy history of miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161755009,No history of induced termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161763005,Past pregnancy history of ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161765003,Past pregnancy history of premature delivery,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161804005,Past pregnancy history of antepartum hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161805006,Past pregnancy history of caesarean section,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161806007,Past pregnancy history of eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161807003,Past pregnancy history of severe pre-eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161809000,Past pregnancy history of postpartum hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161810005,Past pregnancy history of prolonged labor,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161813007,Past pregnancy history of previous forceps delivery,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,166434005,Serum pregnancy test (B-human chorionic gonadotropin),ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,166435006,Serum pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,166436007,Serum pregnancy test equivocal,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,166437003,Serum pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167252002,Urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167253007,Urine pregnancy test requested,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167254001,Urine pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167255000,Urine pregnancy test equivocal,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167256004,Urine pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169488004,Pregnancy on intrauterine contraceptive device,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169566002,Pregnancy unplanned but wanted,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169567006,Pregnancy unplanned and unwanted,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169568001,Unplanned pregnancy unknown if child is wanted,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169569009,Questionable if pregnancy was planned,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169574001,Antenatal care of second pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169575000,Antenatal care of 3rd pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169587007,Antenatal care: precious pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169602005,Antenatal care: 10 years plus since last pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169611005,No antenatal care: subject unaware of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169676009,Rhesus screening - 1st pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169677000,Rhesus screening - Second pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169678005,Rhesus screening - third pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169681000,"Rhesus - random, non-pregnancy sample",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169826009,Single live birth from singleton pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171054004,Diet in pregnancy advice,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171055003,Pregnancy smoking education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171056002,Pregnancy exercise education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171057006,Pregnancy alcohol education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171058001,Drugs in pregnancy advice,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171059009,Pregnancy dental advice,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171063002,Pregnancy prescription exemption education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,173300003,Disorder of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,176928008,Excision of ectopic ovarian pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,176929000,Excision of ruptured ectopic tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,176964009,Fimbrial extraction of tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,182936009,Pregnancy prophylactic therapy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,182947002,Administration of prophylactic iron during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,182948007,Vitamin supplement in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,183606009,Referral for counselling for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,184005004,Requests pregnancy termination,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,191733007,Fear of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198609003,"Complication of pregnancy, childbirth and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198617006,Delivery of viable foetus in abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198620003,Ruptured tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198690009,Termination of pregnancy (& [named variants]),ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198820000,Endometritis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198824009,Salpingo-oophoritis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198830009,Intravascular hemolysis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198841006,Renal failure following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198849008,Shock following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198863002,"Readmission for retained products of conception, illegal termination of pregnancy",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198941007,"Hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198942000,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198944004,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198945003,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198946002,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - not delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198947006,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198949009,"Renal hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198953006,"Renal hypertension complicating pregnancy, childbirth and the puerperium - not delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198965005,Transient hypertension of pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198966006,Transient hypertension of pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198967002,Transient hypertension of pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198968007,Transient hypertension of pregnancy with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198992004,Eclampsia in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199008003,"Pre-existing secondary hypertension complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199015006,"Unspecified hypertension complicating pregnancy, childbirth and the puerperium - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199018008,"Unspecified hypertension complicating pregnancy, childbirth and the puerperium with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199063009,Post-term pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199101006,Asymptomatic bacteriuria in pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199104003,Genitourinary tract infections in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199106001,Genitourinary tract infection in pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199107005,Genitourinary tract infection in pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199108000,Genitourinary tract infection in pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199110003,Infections of kidney in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199112006,Infections of the genital tract in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199122000,Fatigue during pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199123005,Fatigue during pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199132007,Glycosuria during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199135009,Glycosuria during pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199136005,Glycosuria during pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199175001,"Maternal tuberculosis during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199187008,Maternal malaria during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199190002,"Maternal rubella in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199192005,Maternal rubella during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199194006,Maternal rubella during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199205008,Infections of bladder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199225007,Diabetes mellitus during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199235001,"Thyroid dysfunction during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199244000,Anaemia during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199246003,"Maternal anemia in pregnancy, before birth",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199248002,Iron deficiency anemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199257008,"Mental disorders during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199261002,Mental disorder during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199268008,Congenital cardiovascular disorder during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199293005,"Disease of the respiratory system complicating pregnancy, childbirth and/or the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199295003,"Disease of skin and subcutaneous tissue complicating pregnancy, childbirth and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199296002,"Endocrine, nutritional and metabolic disease complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199297006,"Disease of nervous system complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199307003,Continuing pregnancy after intrauterine death of one or more foetuses,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199308008,"Subluxation of symphysis pubis in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199312002,Finding related to risk factor in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199317008,Twin pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199318003,Twin pregnancy with antenatal problem,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199321001,Triplet pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199325005,Quadruplet pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199378009,Multiple pregnancy with malpresentation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199446000,"Pelvic soft tissue abnormality in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199447009,"Congenital abnormality of uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199461004,"Uterine scar from previous surgery in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199610002,Small-for-dates fetus in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199741009,Malnutrition in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199742002,Retained intrauterine contraceptive device in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200147006,Caesarean section - pregnancy at term,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200204002,Varicose veins of legs in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200207009,Varicose veins of legs in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200208004,Varicose veins of legs in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200217004,Varicose veins of perineum and vulva in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200219001,Vaginal varices in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200222004,Superficial thrombophlebitis in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200224003,Superficial thrombophlebitis in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200226001,Superficial thrombophlebitis in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200227005,Superficial thrombophlebitis in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200249004,Pregnancy and postpartum piles,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200251000,Haemorrhoids in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200254008,Haemorrhoids in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200259003,Cerebral venous thrombosis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200402001,"Retraction of nipple in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200411001,"Cracked nipple in pregnancy, the puerperium or lactation - delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200412008,"Cracked nipple in pregnancy, the puerperium or lactation - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200413003,"Cracked nipple in pregnancy, the puerperium or lactation with antenatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200414009,"Cracked nipple in pregnancy, the puerperium or lactation with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200416006,"Breast engorgement in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200418007,"Breast engorgement in pregnancy, the puerperium or lactation - delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200444007,Galactorrhoea in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200446009,Galactorrhea in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200447000,Galactorrhoea in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200448005,Galactorrhea in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200449002,Galactorrhoea in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,201134009,Alopecia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206001006,Foetal or neonatal effect of maternal problem unrelated to pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206035009,Fetal or neonatal effect of maternal complication of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206044005,Fetal or neonatal effect of tubal ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206046007,Foetal or neonatal effect of multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206048008,Fetal or neonatal effect of twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,225327004,Counseling prior to the termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,234058009,Varicose veins of genitalia in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,235003004,Gingival pregnancy tumour,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,235888006,RICP - recurrent intrahepatic cholestasis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,236931002,Methotrexate injection into tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237036002,"Recurrent pregnancy loss, not pregnant",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237155000,"Disorder of vulva in pregnancy, childbirth, and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237170004,"Vaginal abnormality in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237179003,"Septate vagina in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237186006,"Stenosis of cervix in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237191007,"Polyp of cervix in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237196002,"Rectocele in pregnancy, childbirth or the puerperium NOS",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237197006,"Cystocele in pregnancy, childbirth or the puerperium NOS",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237208000,"Rectocele in pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237209008,"Pendulous abdomen in pregnancy, childbirth and/or the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237210003,"Cystocele in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237217000,"Uterine fibroids in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237225003,"Double uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237228001,Pregnancy and drug dependence,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237233002,Concealed pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237234008,Undiagnosed pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237237001,Undiagnosed twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237238006,Pregnancy with uncertain dates,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237239003,Low risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237240001,Teenage pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237241002,Viable pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237242009,Non-viable pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237243004,Biochemical pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237244005,Single pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237253003,Viable foetus in abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237254009,Unruptured tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237279007,Transient hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237284001,Symptomatic disorders in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237285000,Pregnancy induced oedema,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237286004,Varicose veins of vulva in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237300009,Pregnancy with isoimmunization,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237625008,Hyperglycemic disorder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237627000,Pregnancy and type 2 diabetes mellitus,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237628005,Impaired glucose tolerance in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,238820002,Erythema multiforme of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,239101008,Pregnancy dermatosis,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,239102001,Pruritus of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,239103006,Prurigo of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,239104000,Pruritic folliculitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,240160002,Transient osteoporosis of hip in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,240284002,Multifetal pregnancy reduction,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,246435002,Number of babies current pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,248982007,"Pregnancy, childbirth and puerperium finding",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,248985009,Reported conception - pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,248987001,Date symptom of pregnancy first noted,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,248990007,Duration of pregnancy at time of previous miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,249122000,Postmature pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250421003,Pregnancy test finding,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250423000,Pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250424006,Pregnancy test weakly positive,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250425007,Pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250426008,Pregnancy test indeterminate,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,252113007,Number of miscarriages or induced terminations of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,252114001,Number of induced terminations of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,252160004,Standard pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,252161000,Sensitive pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,259636000,Pregnancy associated plasma protein A,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,266906006,Family history: Multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267013003,Past pregnancy outcome,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267015005,Past pregnancy history of full term delivery,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267193004,Incomplete legal termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267194005,Complete legal termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267204006,Genitourinary tract infection in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267206008,"Drug dependence during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267207004,"Congenital cardiovascular disorders during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267212003,"Congenital abnormality of uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267219007,"Tumor of uterine body in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267238003,"Congenital or acquired abnormality of vagina in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267280004,Venous complication of pregnancy and/or puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267282007,Varicose veins of perineum and vulva in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267283002,Superficial thrombophlebitis in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267291006,"Cracked nipple in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267306006,Toxemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267308007,Pregnancy vomiting,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267320004,Pregnancy with mental disorders,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267322007,Pregnancy with orthopaedic problem,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,271903000,History of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,272058002,Past pregnancy history of delivery procedure,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274116002,Herpes in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274117006,Pregnancy and infectious disease,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274119009,Rubella in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274120003,Thyroid disease in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274973002,Dilation and curettage for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275133001,Family history: Twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275412000,Cystitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275425008,Retained products of conception following spontaneous termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275568006,Past pregnancy history of normal delivery,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275569003,Past pregnancy history of delivery with no details,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275922000,Administration of prophylactic vitamin and iron in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,276367008,Wanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,276881003,Secondary abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,281307002,Uncertain viability of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,284075002,Spotting per vagina in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,288043009,Hysterectomy in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,288045002,Injection of substance into amniotic cavity for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289203002,Finding of pattern of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289205009,Finding of measures of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289208006,Observation of viability of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289209003,Pregnancy problem,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289908002,Pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,301801008,Finding of position of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,302253005,Delivered by cesarean section - pregnancy at term,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,302375005,Operative termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,305875008,Seen by pregnancy termination service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,307534009,UTI (urinary tract infection) in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,307632004,Non-proteinuric hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,308133005,Varicose veins of legs in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,308136002,Superficial thrombophlebitis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,308140006,Hemorrhoids in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,309737007,Abdominal pain in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,310062002,Pregnancy termination service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,310506006,Reason for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,310592002,Pregnancy prolonged - 41 weeks,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,310594001,Pregnancy prolonged - 42 weeks,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,312891008,Pregnancy-related examination,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,313107007,Pre-pregnancy folic acid education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,314041007,Abdominal pain in early pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,314204000,Early stage of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,363681007,Pregnancy with abortive outcome,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,370381000,Antenatal scan unable to confirm pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,370382007,Antenatal ultrasound confirms ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,370383002,Antenatal ultrasound confirms intrauterine pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,372046001,"Abnormal glucose tolerance test during pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,372048000,Pregnancy with abnormal glucose tolerance test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,372054004,Glucose tolerance test during pregnancy - baby not yet delivered outside reference range,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,372055003,Glucose tolerance test during pregnancy - baby delivered outside reference range,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,373901007,Legal termination of pregnancy complicated by genital-pelvic infection,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,386394001,Pregnancy termination care,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,386639001,Termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,391897002,STOP - suction termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,394684000,Diabetic pre-pregnancy education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,398254007,Toxaemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,412758008,Past pregnancy history of medical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,413179008,Patient advised to have pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,415262008,Referral for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,417044008,Molar pregnancy with hydatid mole,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,417577000,Refer to early pregnancy unit,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,424040008,Delusion of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,426997005,Traumatic injury during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,428566005,Pregnancy with gestation less than 20 weeks,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,439163006,Referral for medical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,439310005,Referral for surgical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,439733009,Education about toxoplasmosis precautions during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,444517009,Exposure to rubella in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,449345000,Smoker before confirmation of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,449368009,Stopped smoking during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,449369001,Stopped smoking before pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,459168005,Monochorionic diamniotic twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,472971004,Past pregnancy history of gestational diabetes mellitus,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,473180009,Discussion about diabetic ketoacidosis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609443003,Retained products of conception following induced termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609446006,Induced termination of pregnancy with complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609448007,Termination of pregnancy complicated by delayed and/or excessive hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609449004,Termination of pregnancy complicated by embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609450004,Termination of pregnancy complicated by genital-pelvic infection,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609452007,Termination of pregnancy complicated by renal failure,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609458006,Induced termination of pregnancy complicated by amniotic fluid embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609459003,Termination of pregnancy complicated by blood-clot embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609472002,Induced termination of pregnancy complicated by acute renal failure with oliguria,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609480009,Induced termination of pregnancy complicated by pulmonary embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609483006,Termination of pregnancy complicated by salpingitis,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609485004,Induced termination of pregnancy complicated by sepsis,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609486003,Induced termination of pregnancy complicated by septic embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609491002,Induced termination of pregnancy complicated by urinary tract infection,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609496007,Complication occurring during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609506003,Induced termination of pregnancy complicated by cardiac arrest,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609510000,Induced termination of pregnancy complicated by infectious disease,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609525000,Miscarriage of tubal ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,699950009,Anti-D isoimmunisation affecting pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,700145007,No history of ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,702738006,Supervision of high risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,702742009,Supervision of high risk pregnancy for social problem,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,702744005,Supervision of high risk pregnancy for primigravida age 15 years or younger,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,707998009,Assessment for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,709881001,Past pregnancy history of gestational hypertension,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,710973002,Prevention of unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,713575004,Binovular twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,713651007,Past pregnancy history of pregnancy with abortive outcome,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,716379000,Nonalcoholic fatty liver during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,725944002,Past pregnancy history of episiotomy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,726565008,Past pregnancy history of small for gestational age baby,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,733899004,Past pregnancy history of fetal growth restriction,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,735260000,Seen in early pregnancy assessment unit,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,769087009,Vomiting during third trimester of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1156031002,Varicosities in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1290209002,Past pregnancy history of recurrent miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1290210007,Past pregnancy history of multiple miscarriages,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,4121000000101,Pregnancy test result received,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,10231000132102,In-vitro fertilization pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,40801000119106,Gestational diabetes mellitus complicating pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,72301000119103,Asthma in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,105651000119100,Past pregnancy history of pre-eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,151901000119101,Psychosocial problems related to unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200851000000104,Pregnancy test kit given,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,228881000000102,Ultrasound monitoring of early pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,299451000000108,Checking possibility of pregnancy prior to radiation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,339361000000101,Pregnancy counselling,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,410801000000102,[V]Illegitimate pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,426871000000102,"[V]Pregnancy examination or test, pregnancy unconfirmed",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,516071000000107,Health in Pregnancy grant claim form issued,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,526961000000105,Pregnancy advice for patients with epilepsy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,527131000000100,Pregnancy advice for patients with epilepsy declined,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,579531000000104,Unspecified pregnancy vomiting,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,590851000000108,Risk factors in pregnancy NOS,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,695711000000100,Transient hypertension of pregnancy NOS,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,769411000000104,Self referral to termination of pregnancy service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,775821000000102,Referral to teenage pregnancy and parenting support service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,813791000000104,Discussion about ectopic pregnancy risk,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,816051000000102,Plasma PAPP-A MoM (pregnancy associated plasma protein A multiple of median) measurement,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,837291000000106,At risk of unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,858901000000108,Pregnancy of unknown location,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,865901000000108,Pertussis vaccination in pregnancy invitation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866141000000103,Pertussis vaccination in pregnancy invitation first letter,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866191000000108,Pertussis vaccination in pregnancy invitation second letter,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866251000000106,Pertussis vaccination in pregnancy invitation third letter,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866351000000103,Did not attend pertussis vaccination in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866641000000105,Whooping cough vaccination in pregnancy refused,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,889881000000105,Advice on risks of harm to mother from maternal medication during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,889901000000108,Advice on risks of harm to fetus from maternal medication during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,926811000000109,Education about thyroid disease in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,956951000000104,Pertussis vaccination in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,956971000000108,Pertussis vaccination in pregnancy given by other healthcare provider,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,957291000000102,Pertussis vaccination in pregnancy contraindicated,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,980681000000106,Readmission (NHS codes): [abortive pregnancy] or [RPOC],ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,996401000000103,Serum pregnancy associated plasma protein-A mean of median,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,997141000000107,Serum B-HCG (beta human chorionic gonadotrophin) pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,998051000000105,Pregnancy associated plasma protein A level,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1003161000000106,Urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1003171000000104,High sensitivity urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1097321000000106,Signposting to pregnancy counselling service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129761000000105,Pregnancy prevention programme,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129771000000103,Pregnancy prevention programme started,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129791000000104,Pregnancy prevention programme not needed,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129801000000100,Pregnancy prevention programme declined,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129811000000103,Pregnancy prevention programme declined caregiver,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129821000000109,Pregnancy prevention programme declined by parent,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129831000000106,Did not attend pregnancy prevention programme,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129841000000102,Pregnancy prevention programme discontinued,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1188251000000101,Signposting to teenage pregnancy and parenting support service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1382571000000100,Pregnancy status unknown,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1874001000000104,Concern related to pregnancy less than 20 weeks of gestation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1874011000000102,Concern related to pregnancy at or greater than 20 weeks of gestation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,2181271000000102,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form completed,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,16216731000119106,Past pregnancy history of intrauterine foetal death,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,8619003,Cannot achieve a pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,9899009,Ovarian pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,15230009,Liver disorder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,15394000,Toxemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,16356006,Multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,16756008,Albuminuria in pregnancy without hypertension,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,17433009,Ruptured ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,17787002,Peripheral neuritis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,18302006,Incision of uterus for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,20956009,Phlebitis complicating pregnancy AND/OR puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,31563000,Asymptomatic bacteriuria in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,31601007,Combined pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,34500003,Legal termination of pregnancy without complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,34801009,Ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,38720006,Septuplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,40609001,"Infections of pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,43990006,Sextuplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,44782008,Molar pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,44795003,Rhesus isoimmunisation in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,45828008,"Anaemia in mother complicating pregnancy, childbirth AND/OR puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,46764007,Severe proteinuric hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,47200007,HRP - high risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,48194001,Pregnancy-induced hypertension,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,57630001,First trimester pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,57797005,Termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,58532003,Unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,59466002,Second trimester pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,60810003,Quadruplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,64254006,Triplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,65147003,Twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,65727000,Intrauterine pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,67313008,Fetal death due to termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,69532007,Mural pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,72892002,Normal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,74036000,Pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,77386006,Pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,79290002,Cervical pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,79586000,Fallopian tube pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,82661006,Abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,83074005,Accidental pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,84939004,"Rubella in mother complicating pregnancy, childbirth AND/OR puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,87605005,Cornual pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,88697005,Papular dermatitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,88895004,Fatigue during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,90325002,Vomiting of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,90968009,Post-term pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,95212006,Gingival disease due to pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,102955006,Pregnancy with contraceptive device,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,111208003,Mask of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,118185001,Pregnancy observations,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127365008,Second pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127366009,Third pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127367000,Fourth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127368005,Fifth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127369002,Sixth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127370001,Seventh pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127371002,Eighth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127372009,Ninth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127373004,Tenth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,135881001,Review of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,146799005,Possible pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,160401003,Family history: Raised blood pressure in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,160402005,Family history: Diabetes in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161009004,Pregnancy benefits (& maternity allowances),ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161742008,Past pregnancy outcome,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161743003,Past pregnancy history of stillbirth,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161744009,Past pregnancy history of miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161755009,No history of induced termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161763005,Past pregnancy history of ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161765003,Past pregnancy history of premature delivery,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161804005,Past pregnancy history of antepartum hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161805006,Past pregnancy history of caesarean section,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161806007,Past pregnancy history of eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161807003,Past pregnancy history of severe pre-eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161809000,Past pregnancy history of postpartum hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161810005,Past pregnancy history of prolonged labor,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161813007,Past pregnancy history of previous forceps delivery,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,166434005,Serum pregnancy test (B-human chorionic gonadotropin),ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,166435006,Serum pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,166436007,Serum pregnancy test equivocal,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,166437003,Serum pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167252002,Urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167253007,Urine pregnancy test requested,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167254001,Urine pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167255000,Urine pregnancy test equivocal,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167256004,Urine pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169488004,Pregnancy on intrauterine contraceptive device,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169566002,Pregnancy unplanned but wanted,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169567006,Pregnancy unplanned and unwanted,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169568001,Unplanned pregnancy unknown if child is wanted,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169569009,Questionable if pregnancy was planned,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169574001,Antenatal care of second pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169575000,Antenatal care of 3rd pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169587007,Antenatal care: precious pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169602005,Antenatal care: 10 years plus since last pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169611005,No antenatal care: subject unaware of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169676009,Rhesus screening - 1st pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169677000,Rhesus screening - Second pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169678005,Rhesus screening - third pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169681000,"Rhesus - random, non-pregnancy sample",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169826009,Single live birth from singleton pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171054004,Diet in pregnancy advice,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171055003,Pregnancy smoking education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171056002,Pregnancy exercise education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171057006,Pregnancy alcohol education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171058001,Drugs in pregnancy advice,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171059009,Pregnancy dental advice,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171063002,Pregnancy prescription exemption education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,173300003,Disorder of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,176928008,Excision of ectopic ovarian pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,176929000,Excision of ruptured ectopic tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,176964009,Fimbrial extraction of tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,182936009,Pregnancy prophylactic therapy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,182947002,Administration of prophylactic iron during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,182948007,Vitamin supplement in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,183606009,Referral for counselling for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,184005004,Requests pregnancy termination,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,191733007,Fear of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198609003,"Complication of pregnancy, childbirth and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198617006,Delivery of viable foetus in abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198620003,Ruptured tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198690009,Termination of pregnancy (& [named variants]),ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198820000,Endometritis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198824009,Salpingo-oophoritis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198830009,Intravascular hemolysis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198841006,Renal failure following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198849008,Shock following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198863002,"Readmission for retained products of conception, illegal termination of pregnancy",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198941007,"Hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198942000,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198944004,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198945003,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198946002,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - not delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198947006,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198949009,"Renal hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198953006,"Renal hypertension complicating pregnancy, childbirth and the puerperium - not delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198965005,Transient hypertension of pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198966006,Transient hypertension of pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198967002,Transient hypertension of pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198968007,Transient hypertension of pregnancy with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198992004,Eclampsia in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199008003,"Pre-existing secondary hypertension complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199015006,"Unspecified hypertension complicating pregnancy, childbirth and the puerperium - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199018008,"Unspecified hypertension complicating pregnancy, childbirth and the puerperium with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199063009,Post-term pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199101006,Asymptomatic bacteriuria in pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199104003,Genitourinary tract infections in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199106001,Genitourinary tract infection in pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199107005,Genitourinary tract infection in pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199108000,Genitourinary tract infection in pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199110003,Infections of kidney in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199112006,Infections of the genital tract in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199122000,Fatigue during pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199123005,Fatigue during pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199132007,Glycosuria during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199135009,Glycosuria during pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199136005,Glycosuria during pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199175001,"Maternal tuberculosis during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199187008,Maternal malaria during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199190002,"Maternal rubella in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199192005,Maternal rubella during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199194006,Maternal rubella during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199205008,Infections of bladder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199225007,Diabetes mellitus during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199235001,"Thyroid dysfunction during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199244000,Anaemia during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199246003,"Maternal anemia in pregnancy, before birth",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199248002,Iron deficiency anemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199257008,"Mental disorders during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199261002,Mental disorder during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199268008,Congenital cardiovascular disorder during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199293005,"Disease of the respiratory system complicating pregnancy, childbirth and/or the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199295003,"Disease of skin and subcutaneous tissue complicating pregnancy, childbirth and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199296002,"Endocrine, nutritional and metabolic disease complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199297006,"Disease of nervous system complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199307003,Continuing pregnancy after intrauterine death of one or more foetuses,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199308008,"Subluxation of symphysis pubis in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199312002,Finding related to risk factor in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199317008,Twin pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199318003,Twin pregnancy with antenatal problem,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199321001,Triplet pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199325005,Quadruplet pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199378009,Multiple pregnancy with malpresentation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199446000,"Pelvic soft tissue abnormality in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199447009,"Congenital abnormality of uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199461004,"Uterine scar from previous surgery in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199610002,Small-for-dates fetus in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199741009,Malnutrition in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199742002,Retained intrauterine contraceptive device in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200147006,Caesarean section - pregnancy at term,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200204002,Varicose veins of legs in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200207009,Varicose veins of legs in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200208004,Varicose veins of legs in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200217004,Varicose veins of perineum and vulva in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200219001,Vaginal varices in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200222004,Superficial thrombophlebitis in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200224003,Superficial thrombophlebitis in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200226001,Superficial thrombophlebitis in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200227005,Superficial thrombophlebitis in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200249004,Pregnancy and postpartum piles,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200251000,Haemorrhoids in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200254008,Haemorrhoids in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200259003,Cerebral venous thrombosis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200402001,"Retraction of nipple in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200411001,"Cracked nipple in pregnancy, the puerperium or lactation - delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200412008,"Cracked nipple in pregnancy, the puerperium or lactation - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200413003,"Cracked nipple in pregnancy, the puerperium or lactation with antenatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200414009,"Cracked nipple in pregnancy, the puerperium or lactation with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200416006,"Breast engorgement in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200418007,"Breast engorgement in pregnancy, the puerperium or lactation - delivered",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200444007,Galactorrhoea in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200446009,Galactorrhea in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200447000,Galactorrhoea in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200448005,Galactorrhea in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200449002,Galactorrhoea in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,201134009,Alopecia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206001006,Foetal or neonatal effect of maternal problem unrelated to pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206035009,Fetal or neonatal effect of maternal complication of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206044005,Fetal or neonatal effect of tubal ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206046007,Foetal or neonatal effect of multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206048008,Fetal or neonatal effect of twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,225327004,Counseling prior to the termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,234058009,Varicose veins of genitalia in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,235003004,Gingival pregnancy tumour,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,235888006,RICP - recurrent intrahepatic cholestasis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,236931002,Methotrexate injection into tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237036002,"Recurrent pregnancy loss, not pregnant",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237155000,"Disorder of vulva in pregnancy, childbirth, and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237170004,"Vaginal abnormality in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237179003,"Septate vagina in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237186006,"Stenosis of cervix in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237191007,"Polyp of cervix in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237196002,"Rectocele in pregnancy, childbirth or the puerperium NOS",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237197006,"Cystocele in pregnancy, childbirth or the puerperium NOS",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237208000,"Rectocele in pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237209008,"Pendulous abdomen in pregnancy, childbirth and/or the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237210003,"Cystocele in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237217000,"Uterine fibroids in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237225003,"Double uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237228001,Pregnancy and drug dependence,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237233002,Concealed pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237234008,Undiagnosed pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237237001,Undiagnosed twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237238006,Pregnancy with uncertain dates,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237239003,Low risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237240001,Teenage pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237241002,Viable pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237242009,Non-viable pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237243004,Biochemical pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237244005,Single pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237253003,Viable foetus in abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237254009,Unruptured tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237279007,Transient hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237284001,Symptomatic disorders in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237285000,Pregnancy induced oedema,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237286004,Varicose veins of vulva in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237300009,Pregnancy with isoimmunization,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237625008,Hyperglycemic disorder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237627000,Pregnancy and type 2 diabetes mellitus,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237628005,Impaired glucose tolerance in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,238820002,Erythema multiforme of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,239101008,Pregnancy dermatosis,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,239102001,Pruritus of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,239103006,Prurigo of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,239104000,Pruritic folliculitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,240160002,Transient osteoporosis of hip in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,240284002,Multifetal pregnancy reduction,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,246435002,Number of babies current pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,248982007,"Pregnancy, childbirth and puerperium finding",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,248985009,Reported conception - pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,248987001,Date symptom of pregnancy first noted,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,248990007,Duration of pregnancy at time of previous miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,249122000,Postmature pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250421003,Pregnancy test finding,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250423000,Pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250424006,Pregnancy test weakly positive,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250425007,Pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250426008,Pregnancy test indeterminate,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,252113007,Number of miscarriages or induced terminations of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,252114001,Number of induced terminations of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,252160004,Standard pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,252161000,Sensitive pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,259636000,Pregnancy associated plasma protein A,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,266906006,Family history: Multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267013003,Past pregnancy outcome,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267015005,Past pregnancy history of full term delivery,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267193004,Incomplete legal termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267194005,Complete legal termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267204006,Genitourinary tract infection in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267206008,"Drug dependence during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267207004,"Congenital cardiovascular disorders during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267212003,"Congenital abnormality of uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267219007,"Tumor of uterine body in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267238003,"Congenital or acquired abnormality of vagina in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267280004,Venous complication of pregnancy and/or puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267282007,Varicose veins of perineum and vulva in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267283002,Superficial thrombophlebitis in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267291006,"Cracked nipple in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267306006,Toxemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267308007,Pregnancy vomiting,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267320004,Pregnancy with mental disorders,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267322007,Pregnancy with orthopaedic problem,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,271903000,History of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,272058002,Past pregnancy history of delivery procedure,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274116002,Herpes in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274117006,Pregnancy and infectious disease,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274119009,Rubella in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274120003,Thyroid disease in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274973002,Dilation and curettage for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275133001,Family history: Twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275412000,Cystitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275425008,Retained products of conception following spontaneous termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275568006,Past pregnancy history of normal delivery,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275569003,Past pregnancy history of delivery with no details,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275922000,Administration of prophylactic vitamin and iron in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,276367008,Wanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,276881003,Secondary abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,281307002,Uncertain viability of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,284075002,Spotting per vagina in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,288043009,Hysterectomy in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,288045002,Injection of substance into amniotic cavity for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289203002,Finding of pattern of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289205009,Finding of measures of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289208006,Observation of viability of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289209003,Pregnancy problem,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289908002,Pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,301801008,Finding of position of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,302253005,Delivered by cesarean section - pregnancy at term,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,302375005,Operative termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,305875008,Seen by pregnancy termination service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,307534009,UTI (urinary tract infection) in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,307632004,Non-proteinuric hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,308133005,Varicose veins of legs in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,308136002,Superficial thrombophlebitis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,308140006,Hemorrhoids in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,309737007,Abdominal pain in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,310062002,Pregnancy termination service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,310506006,Reason for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,310592002,Pregnancy prolonged - 41 weeks,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,310594001,Pregnancy prolonged - 42 weeks,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,312891008,Pregnancy-related examination,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,313107007,Pre-pregnancy folic acid education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,314041007,Abdominal pain in early pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,314204000,Early stage of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,363681007,Pregnancy with abortive outcome,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,370381000,Antenatal scan unable to confirm pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,370382007,Antenatal ultrasound confirms ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,370383002,Antenatal ultrasound confirms intrauterine pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,372046001,"Abnormal glucose tolerance test during pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,372048000,Pregnancy with abnormal glucose tolerance test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,372054004,Glucose tolerance test during pregnancy - baby not yet delivered outside reference range,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,372055003,Glucose tolerance test during pregnancy - baby delivered outside reference range,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,373901007,Legal termination of pregnancy complicated by genital-pelvic infection,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,386394001,Pregnancy termination care,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,386639001,Termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,391897002,STOP - suction termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,394684000,Diabetic pre-pregnancy education,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,398254007,Toxaemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,412758008,Past pregnancy history of medical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,413179008,Patient advised to have pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,415262008,Referral for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,417044008,Molar pregnancy with hydatid mole,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,417577000,Refer to early pregnancy unit,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,424040008,Delusion of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,426997005,Traumatic injury during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,428566005,Pregnancy with gestation less than 20 weeks,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,439163006,Referral for medical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,439310005,Referral for surgical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,439733009,Education about toxoplasmosis precautions during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,444517009,Exposure to rubella in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,449345000,Smoker before confirmation of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,449368009,Stopped smoking during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,449369001,Stopped smoking before pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,459168005,Monochorionic diamniotic twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,472971004,Past pregnancy history of gestational diabetes mellitus,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,473180009,Discussion about diabetic ketoacidosis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609443003,Retained products of conception following induced termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609446006,Induced termination of pregnancy with complication,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609448007,Termination of pregnancy complicated by delayed and/or excessive hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609449004,Termination of pregnancy complicated by embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609450004,Termination of pregnancy complicated by genital-pelvic infection,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609452007,Termination of pregnancy complicated by renal failure,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609458006,Induced termination of pregnancy complicated by amniotic fluid embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609459003,Termination of pregnancy complicated by blood-clot embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609472002,Induced termination of pregnancy complicated by acute renal failure with oliguria,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609480009,Induced termination of pregnancy complicated by pulmonary embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609483006,Termination of pregnancy complicated by salpingitis,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609485004,Induced termination of pregnancy complicated by sepsis,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609486003,Induced termination of pregnancy complicated by septic embolism,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609491002,Induced termination of pregnancy complicated by urinary tract infection,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609496007,Complication occurring during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609506003,Induced termination of pregnancy complicated by cardiac arrest,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609510000,Induced termination of pregnancy complicated by infectious disease,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609525000,Miscarriage of tubal ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,699950009,Anti-D isoimmunisation affecting pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,700145007,No history of ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,702738006,Supervision of high risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,702742009,Supervision of high risk pregnancy for social problem,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,702744005,Supervision of high risk pregnancy for primigravida age 15 years or younger,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,707998009,Assessment for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,709881001,Past pregnancy history of gestational hypertension,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,710973002,Prevention of unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,713575004,Binovular twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,713651007,Past pregnancy history of pregnancy with abortive outcome,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,716379000,Nonalcoholic fatty liver during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,725944002,Past pregnancy history of episiotomy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,726565008,Past pregnancy history of small for gestational age baby,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,733899004,Past pregnancy history of fetal growth restriction,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,735260000,Seen in early pregnancy assessment unit,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,769087009,Vomiting during third trimester of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1156031002,Varicosities in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1290209002,Past pregnancy history of recurrent miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1290210007,Past pregnancy history of multiple miscarriages,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,4121000000101,Pregnancy test result received,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,10231000132102,In-vitro fertilization pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,40801000119106,Gestational diabetes mellitus complicating pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,72301000119103,Asthma in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,105651000119100,Past pregnancy history of pre-eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,151901000119101,Psychosocial problems related to unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200851000000104,Pregnancy test kit given,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,228881000000102,Ultrasound monitoring of early pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,299451000000108,Checking possibility of pregnancy prior to radiation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,339361000000101,Pregnancy counselling,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,410801000000102,[V]Illegitimate pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,426871000000102,"[V]Pregnancy examination or test, pregnancy unconfirmed",ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,516071000000107,Health in Pregnancy grant claim form issued,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,526961000000105,Pregnancy advice for patients with epilepsy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,527131000000100,Pregnancy advice for patients with epilepsy declined,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,579531000000104,Unspecified pregnancy vomiting,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,590851000000108,Risk factors in pregnancy NOS,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,695711000000100,Transient hypertension of pregnancy NOS,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,769411000000104,Self referral to termination of pregnancy service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,775821000000102,Referral to teenage pregnancy and parenting support service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,813791000000104,Discussion about ectopic pregnancy risk,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,816051000000102,Plasma PAPP-A MoM (pregnancy associated plasma protein A multiple of median) measurement,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,837291000000106,At risk of unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,858901000000108,Pregnancy of unknown location,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,865901000000108,Pertussis vaccination in pregnancy invitation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866141000000103,Pertussis vaccination in pregnancy invitation first letter,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866191000000108,Pertussis vaccination in pregnancy invitation second letter,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866251000000106,Pertussis vaccination in pregnancy invitation third letter,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866351000000103,Did not attend pertussis vaccination in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866641000000105,Whooping cough vaccination in pregnancy refused,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,889881000000105,Advice on risks of harm to mother from maternal medication during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,889901000000108,Advice on risks of harm to fetus from maternal medication during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,926811000000109,Education about thyroid disease in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,956951000000104,Pertussis vaccination in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,956971000000108,Pertussis vaccination in pregnancy given by other healthcare provider,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,957291000000102,Pertussis vaccination in pregnancy contraindicated,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,980681000000106,Readmission (NHS codes): [abortive pregnancy] or [RPOC],ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,996401000000103,Serum pregnancy associated plasma protein-A mean of median,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,997141000000107,Serum B-HCG (beta human chorionic gonadotrophin) pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,998051000000105,Pregnancy associated plasma protein A level,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1003161000000106,Urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1003171000000104,High sensitivity urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1097321000000106,Signposting to pregnancy counselling service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129761000000105,Pregnancy prevention programme,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129771000000103,Pregnancy prevention programme started,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129791000000104,Pregnancy prevention programme not needed,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129801000000100,Pregnancy prevention programme declined,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129811000000103,Pregnancy prevention programme declined caregiver,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129821000000109,Pregnancy prevention programme declined by parent,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129831000000106,Did not attend pregnancy prevention programme,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129841000000102,Pregnancy prevention programme discontinued,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1188251000000101,Signposting to teenage pregnancy and parenting support service,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1382571000000100,Pregnancy status unknown,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1874001000000104,Concern related to pregnancy less than 20 weeks of gestation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1874011000000102,Concern related to pregnancy at or greater than 20 weeks of gestation,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,2181271000000102,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form completed,ROUTINE,OBSTETRICS,OBSTETRICS +ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,16216731000119106,Past pregnancy history of intrauterine foetal death,ROUTINE,OBSTETRICS,OBSTETRICS +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,171234009,Chronic kidney disease screening,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,431855005,Chronic kidney disease stage 1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,431856006,Chronic kidney disease stage 2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,431857002,Chronic kidney disease stage 4,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,433144002,Chronic kidney disease stage 3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,433146000,Chronic kidney disease stage 5,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,472953006,H/O chronic kidney disease,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,698463001,At increased risk of chronic kidney disease,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,700378005,Chronic kidney disease stage 3A,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,700379002,Chronic kidney disease stage 3B,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,709044004,Chronic kidney disease,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,714152005,Chronic kidney disease 5d,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,248721000000108,Chronic kidney disease monitoring,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,249171000000102,Chronic kidney disease annual review,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,249311000000109,Predicted stage chronic kidney disease,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,298141000000107,Did not attend chronic kidney disease monitoring clinic,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324121000000109,CKD (chronic kidney disease stage) 1 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324151000000104,CKD (chronic kidney disease) stage 1 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324181000000105,CKD (chronic kidney disease) stage 2 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324211000000106,CKD (chronic kidney disease) stage 2 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324251000000105,CKD (chronic kidney disease) stage 3 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324281000000104,CKD (chronic kidney disease) stage 3 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324311000000101,CKD (chronic kidney disease) stage 3A with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324341000000100,CKD (chronic kidney disease) stage 3A without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324371000000106,CKD (chronic kidney disease) stage 3B with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324411000000105,CKD (chronic kidney disease) stage 3B without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324441000000106,CKD (chronic kidney disease) stage 4 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324471000000100,CKD (chronic kidney disease) stage 4 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324501000000107,CKD (chronic kidney disease) stage 5 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324541000000105,CKD (chronic kidney disease) stage 5 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,711421000000107,Chronic kidney disease monitoring invitation,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,713811000000100,Chronic kidney disease monitoring administration,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,716651000000106,Chronic kidney disease monitoring first letter,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,716881000000104,Excepted from chronic kidney disease quality indicators - informed dissent,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,716891000000102,Excepted from chronic kidney disease quality indicators - patient unsuitable,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717231000000104,Chronic kidney disease monitoring verbal invite,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717361000000100,Exception reporting - chronic kidney disease quality indicators,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717461000000108,Chronic kidney disease monitoring third letter,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717511000000105,Chronic kidney disease monitoring telephone invite,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717751000000104,Chronic kidney disease monitoring second letter,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,811021000000104,Chronic kidney disease self-management plan review,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,811941000000105,Chronic kidney disease self-management plan agreed,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,857971000000104,Estimated glomerular filtration rate using Chronic Kidney Disease Epidemiology Collaboration formula,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,903261000000109,Chronic kidney disease laboratory study,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,939211000000104,Chronic kidney disease resolved,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949401000000103,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949421000000107,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949481000000108,CKD G1A3 - chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949521000000108,CKD G2A1 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949561000000100,Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949621000000109,CKD G2A3 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949881000000106,CKD G3aA1 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949901000000109,CKD G3aA2 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949921000000100,Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950061000000103,Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950081000000107,CKD G3bA2 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950101000000101,CKD G3bA3 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950181000000106,CKD G4A1 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950211000000107,CKD G4A2 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950231000000104,CKD G4A3 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950251000000106,CKD G5A1 - chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950291000000103,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950311000000102,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,1011481000000105,Estimated glomerular filtration rate using creatinine Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,1011491000000107,Estimated glomerular filtration rate using cystatin C Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,8100009,Structure of infundibulum of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,9361007,Downward displacement of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,22611009,Endometriosis of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,25344002,Fimbriectomy of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,32587001,Rupture of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,32987009,Both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,41393008,Excision of cyst of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,42618007,Atresia of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,44793005,Excision of lesion of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,46536000,Inflammation of ovary and fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,46946009,Torsion of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,49558004,Fallopian tube tuberculosis,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,56900004,Infarction of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,78328007,Aspiration of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,78517009,Dilation of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,79586000,Fallopian tube pregnancy,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,85029000,Congenital anomaly of fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,88157006,Inflammation of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,92100009,Benign neoplasm of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,92591008,Carcinoma in situ of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,118869008,Procedure on fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,120062000,Fallopian tube reconstruction,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,128134005,Fallopian tube disorder,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176936004,Open occlusion of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176937008,Open ligation of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176948001,Open ligation of right fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176949009,Open ligation of left fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176965005,Drainage of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176975008,Exploration of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198305004,Prolapse of ovary and fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,236927008,Removal of clip from fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,236938008,Laparoscopy of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,245482004,Entire left cornu of Fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,262931005,Transection of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,265071006,Open clipping of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,265076001,Open clipping of left fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,271414005,Fallopian tube prosthesis operation,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,271415006,Removal of products of conception from fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,274977001,Unilateral occlusion of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,280504001,Fallopian tube stenosis,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,283958000,Hematoma of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,287664005,Ligation of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,287931008,Fallopian tube cornual resection,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,287943009,Insufflation of fallopian tube using saline,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,287944003,Insufflation of fallopian tube using gas,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,288032001,Transection of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,288033006,Unilateral ligation of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,288034000,Unilateral fallopian tube division,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,289832005,Fallopian tube present,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,289833000,Fallopian tube absent,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,300020002,Diathermy of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,302954008,Congenital cyst of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,307264000,Remaining fallopian tube removed,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,309290005,Fallopian tube biopsy specimen,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,310808000,Fallopian tube clip,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,387615001,Removal of gestational sac from fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,392250009,Operation on fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,398319002,Abscess of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,427543006,Recanalisation of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,719447009,Ectopic fallopian tube tissue,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,561491000000108,Fallopian tube operations NOS,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +RUXOLITINIB,Acute graft versus host disease refractory to corticosteroids,TA839,graft versus host disease,234646005,Graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +RUXOLITINIB,Acute graft versus host disease refractory to corticosteroids,TA839,graft versus host disease,402356004,Chronic graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +RUXOLITINIB,Chronic graft versus host disease refractory to corticosteroids,TA840,graft versus host disease,234646005,Graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +RUXOLITINIB,Chronic graft versus host disease refractory to corticosteroids,TA840,graft versus host disease,402356004,Chronic graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +RUXOLITINIB,Disease-related splenomegaly or symptoms in adults with myelofibrosis,TA289,myelofibrosis,80570006,Acute panmyelosis with myelofibrosis,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RUXOLITINIB,Treating disease-related splenomegaly or symptoms in adults with myelofibrosis,TA386,myelofibrosis,80570006,Acute panmyelosis with myelofibrosis,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RUXOLITINIB,Treating polycythaemia vera,TA356,polycythaemia vera,1659461000000103,JAK2-positive PV (polycythaemia vera),RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +RUXOLITINIB,Treating polycythaemia vera,TA356,polycythaemia vera,1659471000000105,Janus kinase 2 negative polycythaemia vera,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,134405005,Suspected breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,160287004,FH: Breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,268547008,Screening for breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,429740004,Family history of breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,431330007,Family history of breast cancer 1 gene mutation,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,431331006,Family history of breast cancer 2 gene mutation,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,706970001,TNBC - Triple-negative breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,94361000000105,Breast cancer detected by national screening programme,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,276341000000100,Fast track referral for suspected breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,838351000000107,Education about risk of breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,874291000000100,QCancer breast cancer risk,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,1035841000000108,Lymphoedema following breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,10335000,Chronic right-sided heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,10633002,Acute congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,48447003,Chronic heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,56675007,Acute heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,83291003,Right heart failure due to pulmonary hypertension,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,85232009,Left-sided heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,88805009,Chronic congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,111283005,Chronic left-sided heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,128404006,Right heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,134378009,Congestive heart failure monitoring,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,134440006,Referral to heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,161505003,History of heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,233924009,Heart failure as a complication of care,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,266308000,Right heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,309634009,History of heart failure in last year,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,314206003,Refractory heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,367363000,Right heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,390868005,Heart failure screen,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,390884006,Heart failure follow-up,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,390885007,Heart failure annual review,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,394887005,Suspected heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,394927007,Heart failure excluded,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,395105005,Heart failure confirmed,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,416683003,Emergency hospital admission for heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,416717003,Seen in heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,417146007,Referral to heart failure nurse,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,417359009,Seen by community heart failure nurse,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,423475008,Heart failure education,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,424404003,Decompensated chronic heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,426611007,Congestive heart failure due to valvular disease,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,429959009,Family history of heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,441530006,Chronic diastolic heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,473226007,Heart failure medication review,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,704095000,Referral to heart failure exercise programme,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,704096004,Referral to heart failure exercise programme not indicated,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,704097008,Referral to heart failure exercise program declined,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,735984001,Heart failure self management plan,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,1296659009,Acute on chronic heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,96311000119109,Exacerbation of congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,200171000000102,Referred by heart failure nurse specialist,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,202231000000106,Heart failure review completed,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,203791000000106,Referred to heart failure education group,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,247361000000100,Heart failure 6 month review,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,248571000000104,Did not attend heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,374231000000104,High risk of heart failure screening invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,521691000000100,Heart failure resolved,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,711461000000104,Heart failure monitoring invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,713791000000101,Heart failure monitoring administration,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,715951000000107,Exception reporting - heart failure quality indicators,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,716621000000101,Heart failure monitoring third letter,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,716971000000109,Heart failure monitoring first letter,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717191000000108,Heart failure monitoring second letter,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717501000000108,Heart failure monitoring verbal invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717531000000102,Heart failure monitoring telephone invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,763641000000102,Referral to heart failure education group declined,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,765661000000102,Discharge from heart failure nurse service,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,781051000000108,Has heart failure management plan,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,810971000000105,Heart failure self-management plan review,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,812001000000102,Heart failure self-management plan agreed,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,813991000000101,Education about deteriorating heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,835981000000108,Rehabilitation for heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,851071000000108,Heart failure initial assessment,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,851521000000102,Heart failure clinical pathway,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,871681000000102,Heart failure monitoring,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,872361000000105,Discussion about heart failure care plan,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,873881000000100,Referral to rapid access heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,915571000000102,On optimal heart failure therapy,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,961881000000101,Provision of information about heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,161567008,History of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,161567008,History of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,161567008,History of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,161567008,History of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +SECUKINUMAB,Moderate to severe plaque psoriasis,TA350,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),SECUKINUMAB,DERMATOLOGY,DERMATOLOGY +SECUKINUMAB,Moderate to severe plaque psoriasis,TA350,plaque psoriasis,402307000,Chronic large plaque psoriasis,SECUKINUMAB,DERMATOLOGY,DERMATOLOGY +SECUKINUMAB,Moderate to severe plaque psoriasis,TA350,plaque psoriasis,402310007,Chronic stable plaque psoriasis,SECUKINUMAB,DERMATOLOGY,DERMATOLOGY +SECUKINUMAB,Moderate to severe plaque psoriasis in children and young people,TA734,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),SECUKINUMAB,DERMATOLOGY,DERMATOLOGY +SECUKINUMAB,Moderate to severe plaque psoriasis in children and young people,TA734,plaque psoriasis,402307000,Chronic large plaque psoriasis,SECUKINUMAB,DERMATOLOGY,DERMATOLOGY +SECUKINUMAB,Moderate to severe plaque psoriasis in children and young people,TA734,plaque psoriasis,402310007,Chronic stable plaque psoriasis,SECUKINUMAB,DERMATOLOGY,DERMATOLOGY +SECUKINUMAB,Non-radiographic axial spondyloarthritis,TA719,axial spondyloarthritis,723116002,Axial spondyloarthritis,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY +"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,156370009,Psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +SELECTIVE INTERNAL RADIATION THERAPY QUIREMSPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELECTIVE INTERNAL RADIATION THERAPY QUIREMSPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELECTIVE INTERNAL RADIATION THERAPY QUIREMSPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELECTIVE INTERNAL RADIATION THERAPY SIR-SPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELECTIVE INTERNAL RADIATION THERAPY SIR-SPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELECTIVE INTERNAL RADIATION THERAPY SIR-SPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELECTIVE INTERNAL RADIATION THERAPY THERASPHERE,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELECTIVE INTERNAL RADIATION THERAPY THERASPHERE,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELECTIVE INTERNAL RADIATION THERAPY THERASPHERE,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SELINEXOR WITH LOW-DOSE DEXAMETHASONE FOR TREATING REFRACTORY MULTIPLE MYELOMA,Refractory multiple myeloma,TA700,multiple myeloma,230586003,Neuropathy due to multiple myeloma,SELINEXOR,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +SELINEXOR WITH LOW-DOSE DEXAMETHASONE FOR TREATING REFRACTORY MULTIPLE MYELOMA,Refractory multiple myeloma,TA700,multiple myeloma,413587002,Smoldering multiple myeloma,SELINEXOR,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +SELINEXOR WITH LOW-DOSE DEXAMETHASONE FOR TREATING REFRACTORY MULTIPLE MYELOMA,Refractory multiple myeloma,TA700,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,SELINEXOR,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +SELPERCATINIB,Advanced thyroid cancer with RET alterations,TA742,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SELPERCATINIB,Advanced thyroid cancer with RET alterations,TA742,thyroid cancer,363478007,Malignant tumour of thyroid gland,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,162573006,Suspected lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,254637007,Non-small cell lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,275981009,Lung cancer screening,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,429011007,Family history of lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,877691000000107,No FH of lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,44772007,Maternal obesity without hypertension,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,82793005,Hypothalamic obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,160311006,Family history: Obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,161453001,History of obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,162864005,Body mass index 30+ - obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170793009,Obesity monitoring,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170794003,Initial obesity assessment,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170795002,Follow-up obesity assessment,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170797005,Has seen dietician - obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170798000,Treatment of obesity changed,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170799008,Treatment of obesity started,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170800007,Treatment of obesity stopped,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170807005,Reason for obesity therapy - occupational,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185741002,Attends obesity monitoring,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185743004,Obesity monitoring default,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185744005,Obesity monitoring first letter,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185745006,Obesity monitoring second letter,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185746007,Obesity monitoring third letter,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185747003,Obesity monitoring verbal invite,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185748008,Obesity monitoring telephone invite,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185749000,Obesity monitoring deleted,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185750000,Obesity monitoring check done,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,190965006,Drug-induced obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,190966007,Obesity hypoventilation syndrome,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,235240002,Procedure using anti-obesity gastric balloon,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,238132000,Upper body obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,238133005,Gynecoid obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,238134004,Generalized obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,238136002,Morbid obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,243862009,Obesity monitoring status,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,247824007,Fear of obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,267511009,Hyperalimentation incl.obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,268522006,Obesity monitoring,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,268551005,Obesity screening,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,270486005,Localized obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,276792008,Pulmonary hypertension with extreme obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,277831002,Anxiety about obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,284352003,Obesity diet education,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,294493008,Lifelong obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,296526005,Adult-onset obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,308504001,Obesity monitoring call,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,310428009,Obesity monitoring invitation,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,415530009,Obesity due to excess calories,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,444862003,Childhood obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,703316004,Lymphoedema associated with obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,715279006,Telehealth obesity monitoring,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,763085007,Obesity monitoring declined,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,198181000000102,Obesity resolved,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,640791000000105,Obesity and other hyperalimentation,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,713951000000106,Obesity monitoring administration,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,713971000000102,Obesity clinic administration,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,753691000000104,Exception reporting - obesity quality indicators,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,822741000000107,Anti-obesity drug therapy,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,894961000000105,Referral to multidisciplinary obesity clinic,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,898011000000103,Obesity multidisciplinary case review,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,914801000000107,Anti-obesity drug therapy commenced,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,914821000000103,Obesity medication stopped,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386191000000105,National Health Service obesity medication pathway,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386231000000101,NHS obesity medication pathway started,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386241000000105,National Health Service obesity medication pathway declined,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386251000000108,Review of anti-obesity drug therapy,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SERTINDOLE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SERTINDOLE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +SIBUTRAMINE,Obesity,TA031,obesity,44772007,Maternal obesity without hypertension,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,82793005,Hypothalamic obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,160311006,Family history: Obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,161453001,History of obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,162864005,Body mass index 30+ - obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,170793009,Obesity monitoring,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,170794003,Initial obesity assessment,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,170795002,Follow-up obesity assessment,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,170797005,Has seen dietician - obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,170798000,Treatment of obesity changed,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,170799008,Treatment of obesity started,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,170800007,Treatment of obesity stopped,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,170807005,Reason for obesity therapy - occupational,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185741002,Attends obesity monitoring,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185743004,Obesity monitoring default,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185744005,Obesity monitoring first letter,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185745006,Obesity monitoring second letter,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185746007,Obesity monitoring third letter,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185747003,Obesity monitoring verbal invite,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185748008,Obesity monitoring telephone invite,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185749000,Obesity monitoring deleted,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,185750000,Obesity monitoring check done,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,190965006,Drug-induced obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,190966007,Obesity hypoventilation syndrome,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,235240002,Procedure using anti-obesity gastric balloon,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,238132000,Upper body obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,238133005,Gynecoid obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,238134004,Generalized obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,238136002,Morbid obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,243862009,Obesity monitoring status,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,247824007,Fear of obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,267511009,Hyperalimentation incl.obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,268522006,Obesity monitoring,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,268551005,Obesity screening,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,270486005,Localized obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,276792008,Pulmonary hypertension with extreme obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,277831002,Anxiety about obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,284352003,Obesity diet education,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,294493008,Lifelong obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,296526005,Adult-onset obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,308504001,Obesity monitoring call,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,310428009,Obesity monitoring invitation,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,415530009,Obesity due to excess calories,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,444862003,Childhood obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,703316004,Lymphoedema associated with obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,715279006,Telehealth obesity monitoring,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,763085007,Obesity monitoring declined,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,198181000000102,Obesity resolved,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,640791000000105,Obesity and other hyperalimentation,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,713951000000106,Obesity monitoring administration,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,713971000000102,Obesity clinic administration,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,753691000000104,Exception reporting - obesity quality indicators,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,822741000000107,Anti-obesity drug therapy,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,894961000000105,Referral to multidisciplinary obesity clinic,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,898011000000103,Obesity multidisciplinary case review,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,914801000000107,Anti-obesity drug therapy commenced,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,914821000000103,Obesity medication stopped,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,2386191000000105,National Health Service obesity medication pathway,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,2386231000000101,NHS obesity medication pathway started,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,2386241000000105,National Health Service obesity medication pathway declined,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,2386251000000108,Review of anti-obesity drug therapy,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIBUTRAMINE,Obesity,TA031,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,62944002,Hepatitis C virus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,62944002,Hepatitis C virus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,72165005,Hepatitis C virus antibody,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,72165005,Hepatitis C virus antibody,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,170489004,Viral hepatitis carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,170489004,Viral hepatitis carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,197344005,Hepatitis caused by adenovirus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,197344005,Hepatitis caused by adenovirus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,235872006,Hepatitis C carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,235872006,Hepatitis C carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278973007,Hepatitis C status,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278973007,Hepatitis C status,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278974001,Hepatitis C immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278974001,Hepatitis C immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278975000,Hepatitis C non-immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278975000,Hepatitis C non-immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,314706002,Hepatitis C antibody detected,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,314706002,Hepatitis C antibody detected,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,314707006,Hepatitis C antibody test negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,314707006,Hepatitis C antibody test negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,413107006,Hepatitis C screening,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,413107006,Hepatitis C screening,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,773113008,Acute hepatitis caused by infection,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,773113008,Acute hepatitis caused by infection,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,12891000175105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,12891000175105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,200371000000104,Hepatitis C contact,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,200371000000104,Hepatitis C contact,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,201451000000105,Hepatitis C immunisation declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,201451000000105,Hepatitis C immunisation declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,202281000000105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,202281000000105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,204671000000101,Hepatitis C screening counselling,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,204671000000101,Hepatitis C screening counselling,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,304821000000107,Hepatitis C screening not offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,304821000000107,Hepatitis C screening not offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,362491000000104,Hepatitis C screening negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,362491000000104,Hepatitis C screening negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,362751000000101,Hepatitis C screening positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,362751000000101,Hepatitis C screening positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,761381000000102,Hepatitis C resolved,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,761381000000102,Hepatitis C resolved,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,824841000000105,Hepatitis C genotype 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,824841000000105,Hepatitis C genotype 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,824871000000104,Hepatitis C genotype 3,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,824871000000104,Hepatitis C genotype 3,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,829731000000106,On hepatitis C treatment plan,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,829731000000106,On hepatitis C treatment plan,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,992751000000109,Hepatitis C viral load,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,992751000000109,Hepatitis C viral load,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,992771000000100,Hepatitis C virus genotype,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,992771000000100,Hepatitis C virus genotype,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,996031000000104,Hepatitis C IgG level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,996031000000104,Hepatitis C IgG level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,998771000000103,Hepatitis C antibody level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,998771000000103,Hepatitis C antibody level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1001331000000102,Hepatitis C antigen level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1001331000000102,Hepatitis C antigen level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1008931000000108,Hepatitis C antibody test,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1008931000000108,Hepatitis C antibody test,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1107671000000106,Hepatitis C screening offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1107671000000106,Hepatitis C screening offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,62944002,Hepatitis C virus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,62944002,Hepatitis C virus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,72165005,Hepatitis C virus antibody,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,72165005,Hepatitis C virus antibody,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,170489004,Viral hepatitis carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,170489004,Viral hepatitis carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,197344005,Hepatitis caused by adenovirus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,197344005,Hepatitis caused by adenovirus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,235872006,Hepatitis C carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,235872006,Hepatitis C carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278973007,Hepatitis C status,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278973007,Hepatitis C status,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278974001,Hepatitis C immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278974001,Hepatitis C immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278975000,Hepatitis C non-immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278975000,Hepatitis C non-immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,314706002,Hepatitis C antibody detected,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,314706002,Hepatitis C antibody detected,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,314707006,Hepatitis C antibody test negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,314707006,Hepatitis C antibody test negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,413107006,Hepatitis C screening,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,413107006,Hepatitis C screening,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,773113008,Acute hepatitis caused by infection,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,773113008,Acute hepatitis caused by infection,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,12891000175105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,12891000175105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,200371000000104,Hepatitis C contact,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,200371000000104,Hepatitis C contact,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,201451000000105,Hepatitis C immunisation declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,201451000000105,Hepatitis C immunisation declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,202281000000105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,202281000000105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,204671000000101,Hepatitis C screening counselling,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,204671000000101,Hepatitis C screening counselling,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,304821000000107,Hepatitis C screening not offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,304821000000107,Hepatitis C screening not offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,362491000000104,Hepatitis C screening negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,362491000000104,Hepatitis C screening negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,362751000000101,Hepatitis C screening positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,362751000000101,Hepatitis C screening positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,761381000000102,Hepatitis C resolved,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,761381000000102,Hepatitis C resolved,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,824841000000105,Hepatitis C genotype 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,824841000000105,Hepatitis C genotype 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,824871000000104,Hepatitis C genotype 3,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,824871000000104,Hepatitis C genotype 3,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,829731000000106,On hepatitis C treatment plan,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,829731000000106,On hepatitis C treatment plan,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,992751000000109,Hepatitis C viral load,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,992751000000109,Hepatitis C viral load,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,992771000000100,Hepatitis C virus genotype,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,992771000000100,Hepatitis C virus genotype,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,996031000000104,Hepatitis C IgG level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,996031000000104,Hepatitis C IgG level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,998771000000103,Hepatitis C antibody level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,998771000000103,Hepatitis C antibody level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1001331000000102,Hepatitis C antigen level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1001331000000102,Hepatitis C antigen level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1008931000000108,Hepatitis C antibody test,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1008931000000108,Hepatitis C antibody test,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1107671000000106,Hepatitis C screening offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1107671000000106,Hepatitis C screening offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,24700007,Multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,160337009,Family history of multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,192926004,Brain stem multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,192928003,Generalised multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,428700003,Primary progressive multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,438511000,Benign multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,700409000,Suspected multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,198491000000106,Multiple sclerosis review,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,515931000000104,Multiple sclerosis review declined,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,315268008,Suspected prostate cancer,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,428262008,H/O: prostate cancer,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,698470001,Advice given about prostate cancer screening,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,712837004,Active surveillance of prostate cancer,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,720007002,Prostate cancer care review,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,31011000119107,Prostate cancer screening declined,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,874211000000109,QCancer prostate cancer risk,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,878401000000104,No FH of prostate cancer,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Renal transplantation (children),TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Renal transplantation (children),TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SIROLIMUS,Renal transplantation (children),TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +SOLRIAMFETOL,Excessive daytime sleepiness caused by narcolepsy,TA758,narcolepsy,193042000,Cataplexy and narcolepsy,SOLRIAMFETOL,NEUROLOGY,NEUROLOGY +SOLRIAMFETOL,Excessive daytime sleepiness caused by narcolepsy,TA758,narcolepsy,735676003,Narcolepsy type 1,SOLRIAMFETOL,NEUROLOGY,NEUROLOGY +SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,79280005,Hypersomnia with sleep apnoea,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT +SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,206750008,Sleep apnoea syndrome,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT +SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,230493001,Complex sleep apnoea,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT +SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,230494007,Alveolar sleep apnoea,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT +SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,232531007,Pharyngeal operation for obstructive sleep apnoea and snoring,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT +SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,361208003,Primary sleep apnoea of newborn,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT +SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,774068004,"AHDC1-related intellectual disability, obstructive sleep apnoea, mild dysmorphism syndrome",SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT +SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,502901000000102,[D]Sleep apnoea syndrome,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT +SOMATROPIN,Growth hormone deficiency (adults),TA064,growth hormone deficiency,2109003,Isolated growth hormone deficiency,SOMATROPIN,ENDOCRINOLOGY,ENDOCRINOLOGY|PAEDIATRICS +SOMATROPIN,Growth hormone deficiency (adults),TA064,growth hormone deficiency,234533006,Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinaemia,SOMATROPIN,ENDOCRINOLOGY,ENDOCRINOLOGY|PAEDIATRICS +SOMATROPIN,Growth hormone deficiency (children),TA042,growth hormone deficiency,2109003,Isolated growth hormone deficiency,SOMATROPIN,ENDOCRINOLOGY,ENDOCRINOLOGY|PAEDIATRICS +SOMATROPIN,Growth hormone deficiency (children),TA042,growth hormone deficiency,234533006,Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinaemia,SOMATROPIN,ENDOCRINOLOGY,ENDOCRINOLOGY|PAEDIATRICS +SORAFENIB,Advanced hepatocellular carcinoma,TA474,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SORAFENIB,Advanced hepatocellular carcinoma,TA474,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SORAFENIB,Advanced hepatocellular carcinoma,TA474,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SORAFENIB,Thyroid cancer,TA535,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SORAFENIB,Thyroid cancer,TA535,thyroid cancer,363478007,Malignant tumour of thyroid gland,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and metastatic hepatocellular carcinoma,TA189,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and metastatic hepatocellular carcinoma,TA189,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and metastatic hepatocellular carcinoma,TA189,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,162573006,Suspected lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,254637007,Non-small cell lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,275981009,Lung cancer screening,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,429011007,Family history of lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,877691000000107,No FH of lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,61582004,Allergic rhinitis due to allergen,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,93447004,Eosinophilic nonallergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,232345000,Non-infective non-allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,232353008,Perennial allergic rhinitis with seasonal variation,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,266386004,Perennial allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,446096008,Nonseasonal allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY +STANDARD-DOSE IMATINIB (400MG/DAY),Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia,TA251,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,STANDARD-DOSE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,1755008,Healed myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,22298006,MI - myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,52035003,Acute anteroapical myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,54329005,Acute anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,57054005,Acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,65547006,Acute inferolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,66189004,Postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,70211005,Acute anterolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,79009004,Acute myocardial infarction of septum,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,129574000,Postoperative myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194809007,Acute myocardial infarction of atrium,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194821006,Aborted myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194856005,Subsequent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233838001,Acute posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233839009,Old anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233840006,Old inferior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233841005,Old lateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233842003,Old posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233843008,Silent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233885007,Pericarditis following myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,266897007,Family history of myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,304914007,Acute Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,308065005,History of myocardial infarction in last year,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,314207007,Non-Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,394710008,First myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,399211009,Previous myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,48554007,Enterochromaffin cell neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,60346004,Non-functioning pancreatic neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,707594002,Bronchial neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,1287573002,Well-differentiated neuroendocrine tumour of bronchus,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,1290068000,Well-differentiated neuroendocrine tumour of rectum,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,733608000,Papillary renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238543002,Discoid atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238545009,Follicular atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238546005,Pruriginous atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,584621000000108,Atopic dermatitis NOS,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TACROLIMUS,Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +TACROLIMUS,Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +TACROLIMUS,Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +TACROLIMUS,Renal transplantation (children),TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +TACROLIMUS,Renal transplantation (children),TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +TACROLIMUS,Renal transplantation (children),TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,35728003,Primary familial cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,62377009,Peripartum cardiomyopathy in puerperium,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,72972005,Dilated cardiomyopathy secondary to drug,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,83521008,Dilated cardiomyopathy caused by alcohol,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,195030007,Cardiomyopathy in Friedreich ataxia,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,195031006,Cardiomyopathy in myotonic dystrophy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,195032004,Dystrophic cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,233873004,Hypertrophic cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,233875006,Post-myocarditic cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,281170005,Arrhythmogenic right ventricular cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,398754006,Restrictive cardiomyopathy with endomyocardial fibrosis,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,426300009,Tachycardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,426856002,Dilated cardiomyopathy of ischemic origin,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,441541008,Stress cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,1234750000,Dilated cardiomyopathy caused by alcohol,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,847041000000109,Amyloid cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,915007,Malignant melanoma in junctional naevus,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,1556006,Clark melanoma level 4,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,2092003,Malignant melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,2142002,Nodular melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,16974005,"Acral lentiginous melanoma, malignant",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,21119008,Benign melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,21165006,Clark melanoma level 3,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,37138001,Epithelioid cell melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,39896009,"Malignant melanoma, regressing",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,44474009,Lentigo maligna melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,50542000,Clark melanoma level 2,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,50813003,Spitz melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,51757004,"Desmoplastic melanoma, amelanotic",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,55320002,Superficial spreading melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,68827007,Spindle cell melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,70594002,Amelanotic melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,77986002,Melanoma in situ,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93209006,Malignant melanoma of perianal skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93214005,Malignant melanoma of skin of back,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93217003,Malignant melanoma of skin of cheek,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93220006,Malignant melanoma of skin of ear,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93221005,Malignant melanoma of skin of elbow,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93223008,Malignant melanoma of eyebrow,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93225001,Malignant melanoma of skin of face,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93227009,Malignant melanoma of skin of foot,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93228004,Malignant melanoma of skin of forearm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93642000,Malignant melanoma of skin of neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93643005,Malignant melanoma of external surface of nose,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93646002,Malignant melanoma of skin of scalp,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93647006,Malignant melanoma of skin of shoulder,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93651008,Malignant melanoma of skin of trunk,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93653006,Malignant melanoma of skin of upper limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93654000,Malignant melanoma of skin of wrist,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93655004,MM (malignant melanoma) of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,106243009,Breslow depth staging for melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109266006,Melanoma in situ of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109270003,Melanoma in situ of face,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109272006,Melanoma in situ of lip,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109276009,Melanoma in situ of scalp,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109278005,Melanoma in situ of ear,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109282007,Melanoma in situ of neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109284008,Melanoma in situ of trunk,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109290007,Melanoma in situ of upper limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109294003,Melanoma in situ of lower limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,127330008,Melanoma in situ by body site (clinical),TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,161432005,History of malignant melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,177281002,Excision of melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188030005,Malignant melanoma of lip,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188033007,Malignant melanoma of auricle (ear),TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188034001,Malignant melanoma of external auditory meatus,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188038003,Malignant melanoma of chin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188040008,Malignant melanoma of forehead,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188042000,Malignant melanoma of temple,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188044004,Malignant melanoma of scalp and/or neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188045003,Malignant melanoma of scalp,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188046002,Malignant melanoma of neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188049009,Malignant melanoma of axilla,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188050009,Malignant melanoma of breast,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188051008,Malignant melanoma of buttock,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188052001,Malignant melanoma of groin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188054000,Malignant melanoma of perineum,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188055004,Malignant melanoma of umbilicus,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188060000,Malignant melanoma of shoulder,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188061001,Malignant melanoma of upper arm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188062008,Malignant melanoma of forearm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188063003,Malignant melanoma of hand,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188064009,Malignant melanoma of finger,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188065005,Malignant melanoma of thumb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188067002,Malignant melanoma of lower limb and hip,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188068007,Malignant melanoma of hip,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188069004,Malignant melanoma of thigh,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188070003,Malignant melanoma of knee,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188071004,Malignant melanoma of popliteal fossa area,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188072006,Malignant melanoma of lower leg,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188073001,Malignant melanoma of ankle,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188074007,Malignant melanoma of heel,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188075008,Malignant melanoma of foot,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188076009,Malignant melanoma of toe,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188077000,Malignant melanoma of great toe,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,189758001,Melanoma in situ,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,231834005,Malignant melanoma of eyelid,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254731001,Nodular melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254732008,Acral lentiginous melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254896002,Malignant melanoma of vulva,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,255004001,Malignant melanoma of conjunctiva,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,255012009,Malignant melanoma of iris,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,255015006,Malignant melanoma of ciliary body,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,255021005,Malignant melanoma of choroid,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,269578002,Malignant melanoma of head and neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,269579005,Malignant melanoma of trunk,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,269580008,Malignant melanoma of upper limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,269581007,Malignant melanoma of lower limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,274087000,MM (malignant melanoma) of eye,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,276751004,Amelanotic melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,276821000,Malignant melanoma of anus,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,276822007,Malignant melanoma of rectum,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,302837001,Lentigo maligna melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,310498001,Malignant melanoma of back,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,312941005,Melanoma associated retinopathy,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,313248004,Malignant melanoma of chest wall,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,314976006,Local recurrence of malignant melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,314987003,Metastasis from malignant melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,315036008,Melanoma in situ of back of hand,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,315230006,Melanoma in situ of back,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,372158004,"Malignant melanoma, metastatic",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,427858005,Family history of malignant melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,443493003,Metastatic malignant melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,449636007,Malignant melanoma of skin of lower leg,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,449637003,Malignant melanoma of skin of upper arm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,698040004,Malignant melanoma of nasal cavity,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,1197324006,Metastatic malignant melanoma to skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,351961000119109,Malignant melanoma of skin of right arm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,352211000119108,Malignant melanoma of skin of left ear,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,546881000000105,Malignant melanoma of skin NOS,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956331000000107,Malignant melanoma stage IA,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956351000000100,Malignant melanoma stage IB,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956371000000109,Malignant melanoma stage IIA,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956391000000108,Malignant melanoma stage IIB,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956451000000107,Malignant melanoma stage IIIB,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956471000000103,Malignant melanoma stage IIIC,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956511000000107,Malignant melanoma stage IV M1a,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956551000000106,Malignant melanoma stage IV M1c,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,1080941000119109,Malignant melanoma of left choroid,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,1080981000119104,Malignant melanoma of right choroid,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TECLISTAMAB,Relapsed or refractory multiple myeloma after 3 or more therapies,TA869,multiple myeloma,230586003,Neuropathy due to multiple myeloma,TECLISTAMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TECLISTAMAB,Relapsed or refractory multiple myeloma after 3 or more therapies,TA869,multiple myeloma,413587002,Smoldering multiple myeloma,TECLISTAMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TECLISTAMAB,Relapsed or refractory multiple myeloma after 3 or more therapies,TA869,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,TECLISTAMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TEDUGLUTIDE,Short bowel syndrome,TA690,short bowel syndrome,235724004,Post-resection short bowel syndrome,TEDUGLUTIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TEDUGLUTIDE,Short bowel syndrome,TA804,short bowel syndrome,235724004,Post-resection short bowel syndrome,TEDUGLUTIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,722731000000100,Colorectal cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,848861000000104,QCancer colorectal cancer risk,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,62944002,Hepatitis C virus,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,62944002,Hepatitis C virus,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,72165005,Hepatitis C virus antibody,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,72165005,Hepatitis C virus antibody,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,170489004,Viral hepatitis carrier,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,170489004,Viral hepatitis carrier,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,197344005,Hepatitis caused by adenovirus,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,197344005,Hepatitis caused by adenovirus,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,235872006,Hepatitis C carrier,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,235872006,Hepatitis C carrier,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278973007,Hepatitis C status,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278973007,Hepatitis C status,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278974001,Hepatitis C immune,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278974001,Hepatitis C immune,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278975000,Hepatitis C non-immune,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278975000,Hepatitis C non-immune,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,314706002,Hepatitis C antibody detected,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,314706002,Hepatitis C antibody detected,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,314707006,Hepatitis C antibody test negative,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,314707006,Hepatitis C antibody test negative,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,413107006,Hepatitis C screening,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,413107006,Hepatitis C screening,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,773113008,Acute hepatitis caused by infection,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,773113008,Acute hepatitis caused by infection,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,12891000175105,Hepatitis C screening declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,12891000175105,Hepatitis C screening declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,200371000000104,Hepatitis C contact,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,200371000000104,Hepatitis C contact,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,201451000000105,Hepatitis C immunisation declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,201451000000105,Hepatitis C immunisation declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,202281000000105,Hepatitis C screening declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,202281000000105,Hepatitis C screening declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,204671000000101,Hepatitis C screening counselling,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,204671000000101,Hepatitis C screening counselling,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,304821000000107,Hepatitis C screening not offered,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,304821000000107,Hepatitis C screening not offered,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,362491000000104,Hepatitis C screening negative,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,362491000000104,Hepatitis C screening negative,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,362751000000101,Hepatitis C screening positive,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,362751000000101,Hepatitis C screening positive,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,761381000000102,Hepatitis C resolved,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,761381000000102,Hepatitis C resolved,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,824841000000105,Hepatitis C genotype 1,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,824841000000105,Hepatitis C genotype 1,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,824871000000104,Hepatitis C genotype 3,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,824871000000104,Hepatitis C genotype 3,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,829731000000106,On hepatitis C treatment plan,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,829731000000106,On hepatitis C treatment plan,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,992751000000109,Hepatitis C viral load,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,992751000000109,Hepatitis C viral load,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,992771000000100,Hepatitis C virus genotype,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,992771000000100,Hepatitis C virus genotype,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,996031000000104,Hepatitis C IgG level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,996031000000104,Hepatitis C IgG level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,998771000000103,Hepatitis C antibody level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,998771000000103,Hepatitis C antibody level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1001331000000102,Hepatitis C antigen level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1001331000000102,Hepatitis C antigen level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1008931000000108,Hepatitis C antibody test,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1008931000000108,Hepatitis C antibody test,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1107671000000106,Hepatitis C screening offered,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1107671000000106,Hepatitis C screening offered,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,803009,Paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,3102004,"Oligodendroglioma, anaplastic",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,9903002,"Paraganglioma, malignant",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,26138003,Gliomatosis cerebri,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,31794002,Sympathetic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,32037004,Jugular paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,72787006,Gangliocytic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,73348003,Oligodendroglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,74532006,"Glioma, malignant",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,89880005,Ganglioglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,107694002,"Paraganglioma, benign",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,115222007,Paraganglioma AND/OR glomus tumor,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,115240006,Glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,253029009,Gangliocytic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,253031000,Tympanic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,254940005,Oligodendroglioma of brain,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,254947008,Glioma of spinal cord,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,254976006,Optic nerve glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,276826005,Malignant glioma of brain,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,276827001,Malignant glioma of spinal cord,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,302833002,Paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,307649006,Microglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,307829004,Excision of nasal glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,443565000,Oligodendroglioma - category,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,443936004,Oligodendroglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY +TEMSIROLIMUS,Mantle cell lymphoma (relapsed),TA207,mantle cell lymphoma,74654000,Mantle cell lymphoma,TEMSIROLIMUS,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TEMSIROLIMUS,Mantle cell lymphoma (relapsed),TA207,mantle cell lymphoma,443487006,Mantle cell lymphoma,TEMSIROLIMUS,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,1755008,Healed myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,22298006,MI - myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,52035003,Acute anteroapical myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,54329005,Acute anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,57054005,Acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,65547006,Acute inferolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,66189004,Postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,70211005,Acute anterolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,79009004,Acute myocardial infarction of septum,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,129574000,Postoperative myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194809007,Acute myocardial infarction of atrium,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194821006,Aborted myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194856005,Subsequent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233838001,Acute posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233839009,Old anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233840006,Old inferior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233841005,Old lateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233842003,Old posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233843008,Silent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233885007,Pericarditis following myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,266897007,Family history of myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,304914007,Acute Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,308065005,History of myocardial infarction in last year,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,314207007,Non-Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,394710008,First myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,399211009,Previous myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,ALTEPLASE,CARDIOLOGY,CARDIOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,162573006,Suspected lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,254637007,Non-small cell lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,275981009,Lung cancer screening,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,429011007,Family history of lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,877691000000107,No FH of lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,24700007,Multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,160337009,Family history of multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,192926004,Brain stem multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,192928003,Generalised multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,428700003,Primary progressive multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,438511000,Benign multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,700409000,Suspected multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,198491000000106,Multiple sclerosis review,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,515931000000104,Multiple sclerosis review declined,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE +THALIDOMIDE IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,230586003,Neuropathy due to multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +THALIDOMIDE IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,413587002,Smoldering multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +THALIDOMIDE IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TIAGABINE,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TIAGABINE,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,1755008,Healed myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,22298006,MI - myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,52035003,Acute anteroapical myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,54329005,Acute anterior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,57054005,Acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,65547006,Acute inferolateral myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,66189004,Postmyocardial infarction syndrome,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,70211005,Acute anterolateral myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,79009004,Acute myocardial infarction of septum,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,129574000,Postoperative myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194809007,Acute myocardial infarction of atrium,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194821006,Aborted myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194856005,Subsequent myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233838001,Acute posterior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233839009,Old anterior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233840006,Old inferior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233841005,Old lateral myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233842003,Old posterior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233843008,Silent myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233885007,Pericarditis following myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,266897007,Family history of myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,304914007,Acute Q wave myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,308065005,History of myocardial infarction in last year,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,314207007,Non-Q wave myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,394710008,First myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,399211009,Previous myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TICAGRELOR IN COMBINATION WITH LOW-DOSE ASPIRIN,Treatment of acute coronary syndromes,TA236,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,TICAGRELOR,CARDIOLOGY,CARDIOLOGY +TILDRAKIZUAMB,Moderate to severe plaque psoriasis,TA575,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),TILDRAKIZUAMB,DERMATOLOGY,DERMATOLOGY +TILDRAKIZUAMB,Moderate to severe plaque psoriasis,TA575,plaque psoriasis,402307000,Chronic large plaque psoriasis,TILDRAKIZUAMB,DERMATOLOGY,DERMATOLOGY +TILDRAKIZUAMB,Moderate to severe plaque psoriasis,TA575,plaque psoriasis,402310007,Chronic stable plaque psoriasis,TILDRAKIZUAMB,DERMATOLOGY,DERMATOLOGY +TIROFIBAN,Acute coronary syndromes,TA047,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY +TIROFIBAN (INTRAVENOUS),Acute coronary syndromes,TA012,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,109962001,Nonfollicular lymphoma,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,308121000,Follicular lymphoma,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,721555001,Follicular lymphoma of small intestine,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years,TA554,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +TISAGENLECLEUCEL,Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years,TA554,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS +TISAGENLECLEUCEL,Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies,TA567,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TISAGENLECLEUCEL,Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies,TA567,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,733608000,Papillary renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,86555001,Cystic fibrosis of the lung,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,160309002,Family history of cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,171191008,Cystic fibrosis screening,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,235978006,Cystic fibrosis of pancreas,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,427022004,Liver disease due to cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428273001,Cystic fibrosis not suspected,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428301001,Suspected cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428841003,Cystic fibrosis screening declined,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,441520002,Carrier of cystic fibrosis gene mutation,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,698529000,Seen in cystic fibrosis clinic,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,302651000000109,Cystic fibrosis carrier comment,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,302771000000109,Cystic fibrosis not screened for or screening incomplete,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,384341000000107,Cystic fibrosis repeat screening with further sample required,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,384401000000104,Cystic fibrosis not suspected and other disorders follow up required,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,515611000000104,Cystic fibrosis monitoring,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,515631000000107,Cystic fibrosis annual review,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,526071000000104,Arthropathy in cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,526091000000100,Cystic fibrosis with distal intestinal obstruction syndrome,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,776981000000103,Cirrhosis associated with cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,859041000000103,Exacerbation of cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947031000000109,"Cystic fibrosis screening declined, no history of being screened",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947041000000100,"Cystic fibrosis screening declined, screened in UK (as reported by parents) with no evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947061000000104,"Cystic fibrosis screening declined, screened outside UK with evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947081000000108,"Cystic fibrosis screening declined, screened outside UK with no evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947101000000102,"Cystic fibrosis screening, too young for reliable screening",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947121000000106,"Cystic fibrosis screening,sample taken too soon after blood transfusion (less than 72 hours)",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947141000000104,"Cystic fibrosis screening, insufficient sample",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947161000000103,"Cystic fibrosis screening, unsuitable sample (blood quality): incorrect blood application",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947181000000107,"Cystic fibrosis screening, unsuitable sample (blood quality): compressed/damaged",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947201000000106,"Cystic fibrosis screening, unsuitable sample: day 0 and day 5 on same card",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947221000000102,"Cystic fibrosis screening, unsuitable sample: possible faecal contamination",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947241000000109,"Cystic fibrosis screening, unsuitable sample: NHS number missing/not accurately recorded",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947281000000101,"Cystic fibrosis screening, unsuitable sample: date of sample missing/not accurately recorded",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947301000000100,"Cystic fibrosis screening, unsuitable sample: date of birth not accurately matched",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947321000000109,"Cystic fibrosis screening, unsuitable sample: expired card used",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947341000000102,"Cystic fibrosis screening, unsuitable sample: more than 14 days in transit, too old for analysis",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947361000000101,"Cystic fibrosis screening, unsuitable sample: damaged in transit",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947381000000105,"Cystic fibrosis screening, inconclusive result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947401000000105,"Cystic fibrosis not screened for or screening incomplete: more than 8 weeks, too old for screening",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947491000000103,"Cystic fibrosis not screened for or screening incomplete, moved out of area",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947511000000106,"Cystic fibrosis not screened for or screening incomplete, not contactable, reasonable efforts made",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947551000000105,"Cystic fibrosis not screened for or screening incomplete, not required, previous valid result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,1015871000000108,Cystic fibrosis screening test,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,1028351000000108,Cystic fibrosis screening,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +TOCILIZUMAB,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +TOCILIZUMAB,Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease continues to respond to methotrexate or who have not been previously treated with methotrexate,TA238,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +TOCILIZUMAB,Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease continues to respond to methotrexate or who have not been previously treated with methotrexate,TA238,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +TOCILIZUMAB,"Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate",TA238,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +TOCILIZUMAB,"Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate",TA238,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOCILIZUMAB WHEN USED WITH A TAPERING COURSE OF GLUCOCORTICOIDS (AND WHEN USED ALONE AFTER GLUCOCORTICOIDS),Giant cell arteritis,TA518,giant cell arteritis,400130008,Temporal giant cell arteritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY +TOFACITINIB,Juvenile idiopathic arthritis,TA735,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +TOFACITINIB,Juvenile idiopathic arthritis,TA735,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS +TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,64766004,UC - ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,160383003,FH: Ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,275129008,Family history of ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,275549008,History of ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,445243001,Left sided ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,156370009,Psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,156370009,Psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +TOLVAPTAN,Treating autosomal dominant polycystic kidney disease,TA358,polycystic kidney disease,28770003,Infantile polycystic kidney disease,TOLVAPTAN,NEPHROLOGY,NEPHROLOGY +TOLVAPTAN,Treating autosomal dominant polycystic kidney disease,TA358,polycystic kidney disease,253878003,Autosomal dominant polycystic kidney disease type 1,TOLVAPTAN,NEPHROLOGY,NEPHROLOGY +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPIRAMATE,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +TOPOTECAN,Ovarian cancer (advanced),TA091,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN,Ovarian cancer (advanced),TA091,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN,Ovarian cancer (advanced),TA091,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN,Ovarian cancer (advanced),TA091,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN (2ND AND SUBSEQUENT LINES OF TREATMENT),Advanced ovarian cancer,TA028,ovarian cancer,423274005,Ovarian cancer stage 4,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN (2ND AND SUBSEQUENT LINES OF TREATMENT),Advanced ovarian cancer,TA028,ovarian cancer,762997004,Suspected ovarian cancer,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN (2ND AND SUBSEQUENT LINES OF TREATMENT),Advanced ovarian cancer,TA028,ovarian cancer,758821000000106,No family history of ovarian cancer,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN (2ND AND SUBSEQUENT LINES OF TREATMENT),Advanced ovarian cancer,TA028,ovarian cancer,848891000000105,QCancer ovarian cancer risk,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,315266007,Suspected cervical cancer,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,736595007,Cervical cancer screening refused,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,112241000119107,Cervical cancer Papanicolaou smear screening declined,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,874251000000108,QCancer cervical cancer risk,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,1104621000000103,Cervical cancer screening offered,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,1104671000000104,Cervical cancer screening not offered,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRABECTEDIN IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,Relapsed platinum-sensitive ovarian cancer in women,TA222,ovarian cancer,423274005,Ovarian cancer stage 4,TRABECTEDIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRABECTEDIN IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,Relapsed platinum-sensitive ovarian cancer in women,TA222,ovarian cancer,762997004,Suspected ovarian cancer,TRABECTEDIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRABECTEDIN IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,Relapsed platinum-sensitive ovarian cancer in women,TA222,ovarian cancer,758821000000106,No family history of ovarian cancer,TRABECTEDIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRABECTEDIN IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,Relapsed platinum-sensitive ovarian cancer in women,TA222,ovarian cancer,848891000000105,QCancer ovarian cancer risk,TRABECTEDIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRABECTEDIN IN COMBINATION WITH PLDH,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRABECTEDIN IN COMBINATION WITH PLDH,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRABECTEDIN IN COMBINATION WITH PLDH,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRABECTEDIN IN COMBINATION WITH PLDH,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY +TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238543002,Discoid atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238545009,Follicular atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,915007,Malignant melanoma in junctional naevus,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,1556006,Clark melanoma level 4,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,2092003,Malignant melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,2142002,Nodular melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,16974005,"Acral lentiginous melanoma, malignant",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,21119008,Benign melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,21165006,Clark melanoma level 3,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,37138001,Epithelioid cell melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,39896009,"Malignant melanoma, regressing",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,44474009,Lentigo maligna melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,50542000,Clark melanoma level 2,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,50813003,Spitz melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,51757004,"Desmoplastic melanoma, amelanotic",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,55320002,Superficial spreading melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,68827007,Spindle cell melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,70594002,Amelanotic melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,77986002,Melanoma in situ,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93209006,Malignant melanoma of perianal skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93214005,Malignant melanoma of skin of back,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93217003,Malignant melanoma of skin of cheek,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93220006,Malignant melanoma of skin of ear,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93221005,Malignant melanoma of skin of elbow,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93223008,Malignant melanoma of eyebrow,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93225001,Malignant melanoma of skin of face,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93227009,Malignant melanoma of skin of foot,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93228004,Malignant melanoma of skin of forearm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93642000,Malignant melanoma of skin of neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93643005,Malignant melanoma of external surface of nose,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93646002,Malignant melanoma of skin of scalp,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93647006,Malignant melanoma of skin of shoulder,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93651008,Malignant melanoma of skin of trunk,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93653006,Malignant melanoma of skin of upper limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93654000,Malignant melanoma of skin of wrist,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93655004,MM (malignant melanoma) of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,106243009,Breslow depth staging for melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109266006,Melanoma in situ of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109270003,Melanoma in situ of face,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109272006,Melanoma in situ of lip,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109276009,Melanoma in situ of scalp,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109278005,Melanoma in situ of ear,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109282007,Melanoma in situ of neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109284008,Melanoma in situ of trunk,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109290007,Melanoma in situ of upper limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109294003,Melanoma in situ of lower limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,127330008,Melanoma in situ by body site (clinical),TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,161432005,History of malignant melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,177281002,Excision of melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188030005,Malignant melanoma of lip,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188033007,Malignant melanoma of auricle (ear),TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188034001,Malignant melanoma of external auditory meatus,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188038003,Malignant melanoma of chin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188040008,Malignant melanoma of forehead,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188042000,Malignant melanoma of temple,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188044004,Malignant melanoma of scalp and/or neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188045003,Malignant melanoma of scalp,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188046002,Malignant melanoma of neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188049009,Malignant melanoma of axilla,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188050009,Malignant melanoma of breast,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188051008,Malignant melanoma of buttock,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188052001,Malignant melanoma of groin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188054000,Malignant melanoma of perineum,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188055004,Malignant melanoma of umbilicus,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188060000,Malignant melanoma of shoulder,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188061001,Malignant melanoma of upper arm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188062008,Malignant melanoma of forearm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188063003,Malignant melanoma of hand,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188064009,Malignant melanoma of finger,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188065005,Malignant melanoma of thumb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188067002,Malignant melanoma of lower limb and hip,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188068007,Malignant melanoma of hip,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188069004,Malignant melanoma of thigh,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188070003,Malignant melanoma of knee,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188071004,Malignant melanoma of popliteal fossa area,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188072006,Malignant melanoma of lower leg,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188073001,Malignant melanoma of ankle,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188074007,Malignant melanoma of heel,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188075008,Malignant melanoma of foot,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188076009,Malignant melanoma of toe,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188077000,Malignant melanoma of great toe,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,189758001,Melanoma in situ,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,231834005,Malignant melanoma of eyelid,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254731001,Nodular melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254732008,Acral lentiginous melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254896002,Malignant melanoma of vulva,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,255004001,Malignant melanoma of conjunctiva,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,255012009,Malignant melanoma of iris,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,255015006,Malignant melanoma of ciliary body,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,255021005,Malignant melanoma of choroid,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,269578002,Malignant melanoma of head and neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,269579005,Malignant melanoma of trunk,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,269580008,Malignant melanoma of upper limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,269581007,Malignant melanoma of lower limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,274087000,MM (malignant melanoma) of eye,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,276751004,Amelanotic melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,276821000,Malignant melanoma of anus,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,276822007,Malignant melanoma of rectum,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,302837001,Lentigo maligna melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,310498001,Malignant melanoma of back,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,312941005,Melanoma associated retinopathy,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,313248004,Malignant melanoma of chest wall,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,314976006,Local recurrence of malignant melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,314987003,Metastasis from malignant melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,315036008,Melanoma in situ of back of hand,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,315230006,Melanoma in situ of back,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,372158004,"Malignant melanoma, metastatic",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,427858005,Family history of malignant melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,443493003,Metastatic malignant melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,449636007,Malignant melanoma of skin of lower leg,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,449637003,Malignant melanoma of skin of upper arm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,698040004,Malignant melanoma of nasal cavity,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,1197324006,Metastatic malignant melanoma to skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,351961000119109,Malignant melanoma of skin of right arm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,352211000119108,Malignant melanoma of skin of left ear,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,546881000000105,Malignant melanoma of skin NOS,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956331000000107,Malignant melanoma stage IA,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956351000000100,Malignant melanoma stage IB,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956371000000109,Malignant melanoma stage IIA,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956391000000108,Malignant melanoma stage IIB,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956451000000107,Malignant melanoma stage IIIB,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956471000000103,Malignant melanoma stage IIIC,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956511000000107,Malignant melanoma stage IV M1a,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956551000000106,Malignant melanoma stage IV M1c,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,1080941000119109,Malignant melanoma of left choroid,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,1080981000119104,Malignant melanoma of right choroid,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,134405005,Suspected breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,160287004,FH: Breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,268547008,Screening for breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,429740004,Family history of breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,431330007,Family history of breast cancer 1 gene mutation,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,431331006,Family history of breast cancer 2 gene mutation,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,706970001,TNBC - Triple-negative breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,94361000000105,Breast cancer detected by national screening programme,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,276341000000100,Fast track referral for suspected breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,838351000000107,Education about risk of breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,874291000000100,QCancer breast cancer risk,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,1035841000000108,Lymphoedema following breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH CISPLATIN AND CAPECITABINE OR 5-FLUOROURACIL,"Gastric cancer (HER2-positive, metastatic)",TA208,gastric cancer,276809004,Early gastric cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH CISPLATIN AND CAPECITABINE OR 5-FLUOROURACIL,"Gastric cancer (HER2-positive, metastatic)",TA208,gastric cancer,276810009,Late gastric cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,234336002,Haemopoietic stem cell transplant,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,397554006,Limbal stem cell transplantation,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,425843001,Allogeneic peripheral blood stem cell transplant,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,425983008,Autologous peripheral blood stem cell transplant,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,284681000000100,Syngeneic peripheral blood stem cell transplant,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY +TRIFLURIDINE–TIPIRACIL,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies,TA669,gastric cancer,276809004,Early gastric cancer,TRIFLURIDINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +TRIFLURIDINE–TIPIRACIL,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies,TA669,gastric cancer,276810009,Late gastric cancer,TRIFLURIDINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +TRIFLURIDINE–TIPIRACIL,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments,TA852,gastric cancer,276809004,Early gastric cancer,TRIFLURIDINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +TRIFLURIDINE–TIPIRACIL,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments,TA852,gastric cancer,276810009,Late gastric cancer,TRIFLURIDINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,134405005,Suspected breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,160287004,FH: Breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,268547008,Screening for breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,429740004,Family history of breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,706970001,TNBC - Triple-negative breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,94361000000105,Breast cancer detected by national screening programme,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,838351000000107,Education about risk of breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,874291000000100,QCancer breast cancer risk,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,1035841000000108,Lymphoedema following breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active non-radiographic axial spondyloarthritis,TA861,axial spondyloarthritis,723116002,Axial spondyloarthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY +UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,156370009,Psoriatic arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238543002,Discoid atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238545009,Follicular atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY +UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,64766004,UC - ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,160383003,FH: Ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,275129008,Family history of ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,275549008,History of ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,445243001,Left sided ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE +USTEKINUMAB,Plaque psoriasis,TA180,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),USTEKINUMAB,DERMATOLOGY,DERMATOLOGY +USTEKINUMAB,Plaque psoriasis,TA180,plaque psoriasis,402307000,Chronic large plaque psoriasis,USTEKINUMAB,DERMATOLOGY,DERMATOLOGY +USTEKINUMAB,Plaque psoriasis,TA180,plaque psoriasis,402310007,Chronic stable plaque psoriasis,USTEKINUMAB,DERMATOLOGY,DERMATOLOGY +USTEKINUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +USTEKINUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402307000,Chronic large plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +USTEKINUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402310007,Chronic stable plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY +USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,64766004,UC - ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,160383003,FH: Ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,275129008,Family history of ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,275549008,History of ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,445243001,Left sided ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,156370009,Psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,156370009,Psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,4441000,Severe bipolar disorder with psychotic features,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,5703000,Bipolar disorder in partial remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,13313007,Mild bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,41836007,Bipolar disorder in full remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,53049002,Severe bipolar disorder without psychotic features,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,79584002,Moderate bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,85248005,Bipolar disorder in remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,160331005,Family history of bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,231444002,Organic bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,767632000,"Bipolar disorder, most recent episode manic",OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,1365951000000107,Family intervention for psychosis and bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH +VANDETANIB,Medullary thyroid cancer,TA550,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,VANDETANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +VANDETANIB,Medullary thyroid cancer,TA550,thyroid cancer,363478007,Malignant tumour of thyroid gland,VANDETANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY +VARENICLINE,Smoking cessation,TA123,smoking cessation,390900001,Smoking cessation milestones,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,395700008,Referral to smoking cessation advisor,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,401068004,Seen by smoking cessation advisor,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,401160008,Smoking cessation programme start date,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,710081004,Smoking cessation therapy,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,713700008,Smoking cessation drug therapy,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,765001003,Monitoring of smoking cessation therapy refused,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,771155005,Brief intervention for smoking cessation,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,1290027009,Consultation for smoking cessation,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,25261000000107,Did not attend smoking cessation clinic,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,200221000000105,Smoking cessation advice provided by community pharmacist,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,201931000000109,Attends practice smoking cessation clinic,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,201941000000100,Attends smoking cessation clinic not at practice,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,374361000000100,Smoking cessation enhanced services administration,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,374391000000106,Smoking cessation enhanced services administration monitoring template completed,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,506491000000102,Brief intervention for smoking cessation,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,527151000000107,Smoking cessation advice declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,712971000000108,Practice based smoking cessation programme start date,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,720401000000103,Smoking cessation,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,750821000000109,Consent given for follow-up evaluation after smoking cessation intervention,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,750851000000104,Consent given for smoking cessation data sharing,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,751101000000101,Declined consent for follow-up evaluation after smoking cessation intervention,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,751661000000106,Declined consent for smoking cessation data sharing,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,755721000000107,Consent given for follow-up by smoking cessation team,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,755741000000100,Declined consent for follow-up by smoking cessation team,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,767641000000109,Referral for smoking cessation service offered,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,768971000000109,Lost to smoking cessation follow-up,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,822591000000108,Smoking cessation drug therapy declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,850331000000104,Smoking cessation 12 week follow-up,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,871641000000105,Referral to smoking cessation service declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,871661000000106,Referral to smoking cessation service,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,966971000000103,Varenicline smoking cessation therapy declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,966991000000104,Varenicline smoking cessation therapy offered,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,1084381000000100,Signposting to smoking cessation service,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,1087441000000106,Smoking cessation programme declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VARENICLINE,Smoking cessation,TA123,smoking cessation,2140191000000108,Referral to Community Pharmacy Smoking Cessation Service,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE +VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,64766004,UC - ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,160383003,FH: Ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,275129008,Family history of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,275549008,History of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,445243001,Left sided ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,64766004,UC - ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,160383003,FH: Ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,275129008,Family history of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,275549008,History of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,445243001,Left sided ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Treating moderately to severely active Crohn's disease after prior therapy,TA352,crohn's disease,196578009,Oral Crohn's disease,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Treating moderately to severely active Crohn's disease after prior therapy,TA352,crohn's disease,196578009,Oral Crohn's disease,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Treating moderately to severely active Crohn's disease after prior therapy,TA352,crohn's disease,273364009,Crohn's Disease Activity Index,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +VEDOLIZUMAB,Treating moderately to severely active Crohn's disease after prior therapy,TA352,crohn's disease,273364009,Crohn's Disease Activity Index,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,915007,Malignant melanoma in junctional naevus,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,39896009,"Malignant melanoma, regressing",VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93209006,Malignant melanoma of perianal skin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93214005,Malignant melanoma of skin of back,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93217003,Malignant melanoma of skin of cheek,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93220006,Malignant melanoma of skin of ear,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93221005,Malignant melanoma of skin of elbow,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93228004,Malignant melanoma of skin of forearm,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93642000,Malignant melanoma of skin of neck,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93643005,Malignant melanoma of external surface of nose,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93654000,Malignant melanoma of skin of wrist,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188030005,Malignant melanoma of lip,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188034001,Malignant melanoma of external auditory meatus,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188038003,Malignant melanoma of chin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188042000,Malignant melanoma of temple,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188049009,Malignant melanoma of axilla,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188050009,Malignant melanoma of breast,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188054000,Malignant melanoma of perineum,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188062008,Malignant melanoma of forearm,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188069004,Malignant melanoma of thigh,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188070003,Malignant melanoma of knee,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188071004,Malignant melanoma of popliteal fossa area,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188072006,Malignant melanoma of lower leg,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188076009,Malignant melanoma of toe,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,231834005,Malignant melanoma of eyelid,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,255004001,Malignant melanoma of conjunctiva,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,255012009,Malignant melanoma of iris,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,255015006,Malignant melanoma of ciliary body,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,255021005,Malignant melanoma of choroid,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,269578002,Malignant melanoma of head and neck,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,314976006,Local recurrence of malignant melanoma of skin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,314987003,Metastasis from malignant melanoma of skin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,1197324006,Metastatic malignant melanoma to skin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956371000000109,Malignant melanoma stage IIA,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956391000000108,Malignant melanoma stage IIB,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956451000000107,Malignant melanoma stage IIIB,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956511000000107,Malignant melanoma stage IV M1a,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956551000000106,Malignant melanoma stage IV M1c,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY +VENETOCLAX,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,TA561,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,TA561,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,TA561,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,TA561,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Chronic lymphocytic leukaemia,TA487,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Chronic lymphocytic leukaemia,TA796,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Chronic lymphocytic leukaemia,TA487,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Chronic lymphocytic leukaemia,TA796,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Chronic lymphocytic leukaemia,TA487,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Chronic lymphocytic leukaemia,TA796,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Chronic lymphocytic leukaemia,TA487,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX,Chronic lymphocytic leukaemia,TA796,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX WITH AZACITIDINE,Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,TA765,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +VENETOCLAX WITH LOW DOSE CYTARABINE,Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,TA787,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY +VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,10335000,Chronic right-sided heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,10633002,Acute congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,48447003,Chronic heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,56675007,Acute heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,83291003,Right heart failure due to pulmonary hypertension,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,85232009,Left-sided heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,88805009,Chronic congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,111283005,Chronic left-sided heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,128404006,Right heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,134378009,Congestive heart failure monitoring,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,134440006,Referral to heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,161505003,History of heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,233924009,Heart failure as a complication of care,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,266308000,Right heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,309634009,History of heart failure in last year,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,314206003,Refractory heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,367363000,Right heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,390868005,Heart failure screen,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,390884006,Heart failure follow-up,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,390885007,Heart failure annual review,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,394887005,Suspected heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,394927007,Heart failure excluded,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,395105005,Heart failure confirmed,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,416683003,Emergency hospital admission for heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,416717003,Seen in heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,417146007,Referral to heart failure nurse,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,417359009,Seen by community heart failure nurse,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,423475008,Heart failure education,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,424404003,Decompensated chronic heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,426611007,Congestive heart failure due to valvular disease,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,429959009,Family history of heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,441530006,Chronic diastolic heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,473226007,Heart failure medication review,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,704095000,Referral to heart failure exercise programme,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,704096004,Referral to heart failure exercise programme not indicated,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,704097008,Referral to heart failure exercise program declined,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,735984001,Heart failure self management plan,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,1296659009,Acute on chronic heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,96311000119109,Exacerbation of congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,200171000000102,Referred by heart failure nurse specialist,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,202231000000106,Heart failure review completed,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,203791000000106,Referred to heart failure education group,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,247361000000100,Heart failure 6 month review,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,248571000000104,Did not attend heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,374231000000104,High risk of heart failure screening invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,521691000000100,Heart failure resolved,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,711461000000104,Heart failure monitoring invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,713791000000101,Heart failure monitoring administration,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,715951000000107,Exception reporting - heart failure quality indicators,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,716621000000101,Heart failure monitoring third letter,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,716971000000109,Heart failure monitoring first letter,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717191000000108,Heart failure monitoring second letter,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717501000000108,Heart failure monitoring verbal invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717531000000102,Heart failure monitoring telephone invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,763641000000102,Referral to heart failure education group declined,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,765661000000102,Discharge from heart failure nurse service,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,781051000000108,Has heart failure management plan,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,810971000000105,Heart failure self-management plan review,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,812001000000102,Heart failure self-management plan agreed,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,813991000000101,Education about deteriorating heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,835981000000108,Rehabilitation for heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,851071000000108,Heart failure initial assessment,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,851521000000102,Heart failure clinical pathway,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,871681000000102,Heart failure monitoring,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,872361000000105,Discussion about heart failure care plan,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,873881000000100,Referral to rapid access heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,915571000000102,On optimal heart failure therapy,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,961881000000101,Provision of information about heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,49436004,Atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,134377004,Atrial fibrillation monitoring,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,195080001,Atrial fibrillation and flutter,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,282825002,Intermittent atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,300996004,Controlled atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,312442005,History of atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,440028005,Permanent atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,440059007,Persistent atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,719008003,At increased risk of atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,196371000000102,Atrial fibrillation resolved,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,248411000000105,Atrial fibrillation annual review,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,816401000000105,Atrial fibrillation excluded,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1066831000000104,Atrial fibrillation detected,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VIGABATRIN,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,53530009,Transitional cell carcinoma in situ,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,255109008,TCC (transitional cell carcinoma) of urinary bladder,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,300988009,Transitional cell carcinoma of ureter,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,408642003,Transitional cell carcinoma of kidney,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,1259423003,Primary transitional cell carcinoma of ureter,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,1263659007,Secondary transitional cell carcinoma of renal pelvis,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,689801000119101,Primary transitional cell carcinoma of lateral wall of urinary bladder,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,754351000000100,Grade 1 (Stage pTa) papillary urothelial/transitional cell carcinoma,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,754361000000102,Grade 2 (Stage pTa) papillary urothelial/transitional cell carcinoma,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY +VINORELBINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,254637007,Non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +VINORELBINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +VINORELBINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +VINORELBINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,134405005,Suspected breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,160287004,FH: Breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,268547008,Screening for breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,429740004,Family history of breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,431330007,Family history of breast cancer 1 gene mutation,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,431331006,Family history of breast cancer 2 gene mutation,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,706970001,TNBC - Triple-negative breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,94361000000105,Breast cancer detected by national screening programme,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,276341000000100,Fast track referral for suspected breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,838351000000107,Education about risk of breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,874291000000100,QCancer breast cancer risk,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,1035841000000108,Lymphoedema following breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,134405005,Suspected breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,160287004,FH: Breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,268547008,Screening for breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,429740004,Family history of breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,431330007,Family history of breast cancer 1 gene mutation,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,431331006,Family history of breast cancer 2 gene mutation,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,706970001,TNBC - Triple-negative breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,94361000000105,Breast cancer detected by national screening programme,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,276341000000100,Fast track referral for suspected breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,838351000000107,Education about risk of breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,874291000000100,QCancer breast cancer risk,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,1035841000000108,Lymphoedema following breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,43369006,"Basal cell carcinoma, fibroepithelial",VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,56665009,"Infiltrating basal cell carcinoma, sclerosing",VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,128636006,"Basal cell carcinoma, nodular",VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,134152008,Basal cell carcinoma - morpheic,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,254710004,Basal cell carcinoma with eccrine differentiation,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,300025007,Excision of basal cell carcinoma,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,300026008,Cryotherapy of basal cell carcinoma,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,302821007,Basal cell carcinoma - sclerosing type,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,400071004,"Basal cell carcinoma, micronodular",VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,402818009,Basal cell carcinoma of nose,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,403914000,Multicentric basal cell carcinoma,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,428796002,Excision biopsy of basal cell carcinoma,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,716274007,Nodular basal cell carcinoma of skin,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY +VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,191610000,"Recurrent major depressive episodes, mild",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH +VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,191611001,"Recurrent major depressive episodes, moderate",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH +VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,191613003,"Recurrent major depressive episodes, severe, with psychosis",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH +VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,268621008,Recurrent major depressive episodes,VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH +VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,755331000000108,"Recurrent major depressive episodes, severe, with psychosis, psychosis in remission",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH +VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,764611000000100,"Recurrent major depressive episodes, severe",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH +VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,764691000000109,"Recurrent major depressive episodes, in partial remission",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,16573007,Wild-type transthyretin cardiac amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,17602002,Amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,23132008,Primary amyloidosis of light chain type,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,42295001,Familial neuropathic amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,45502001,Cerebrovascular amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,59017008,Conjunctival amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,193187004,Polyneuropathy due to amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,196135008,Pulmonary amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,197604006,Nephrotic syndrome in amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,201337008,Amyloidosis of skin,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,232459006,Laryngeal amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,234510005,Amyloidosis of spleen,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237865009,Primary amyloidosis of light chain type,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237868006,Nonneuropathic heredofamilial amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237869003,Localised hereditary amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237870002,Familial lichen amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237875007,Localized non-hereditary amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237876008,Arthritis secondary to amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237877004,Wild type ATTR amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,274945004,Amyloid A amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,281034005,Secondary amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,398229007,Corino de Andrade paramyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,718105008,Lichen amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,854071000000105,Amyloidosis of intestine,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY +ZALEPLON,Insomnia,TA077,insomnia,3972004,Idiopathic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,41975002,Insomnia with sleep apnea,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,162201008,Cannot sleep - insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,162204000,Terminal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,191994005,Non-organic sleep disorders (& [hypersomnia] or [insomnia]),ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,191997003,Persistent insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,192454004,Nonorganic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,193462001,Insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,198437004,Menopausal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,268652009,Transient insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,272025006,Complaining of insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,440313002,Education about stimulus control behaviour in insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,762989006,Insomnia Severity Index score,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,1107191000000102,Referral for dCBT (digital cognitive behaviour therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZALEPLON,Insomnia,TA077,insomnia,1109721000000108,Digital CBT (cognitive behavioural therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZANAMIVIR,Influenza,TA015,influenza,6142004,Influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,24662006,Influenza caused by Influenza B virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,41269000,Influenzal bronchopneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,44470000,Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,46233009,Influenza virus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,51593004,Haemophilus parainfluenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,64917006,Pneumonia due to parainfluenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,70036007,Haemophilus influenzae pneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,74644004,Influenza with encephalopathy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,89117003,Parainfluenza virus type 4,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,91428005,Haemophilus influenzae infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,95891005,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,120753009,Influenza A virus antibody,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,120843002,Influenza B virus Ab,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,120975003,Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,127787002,Haemophilus influenzae type b immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,170343007,First Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,170345000,Third Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,171272004,No consent - influenza immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,171282003,Influenza immunization advised at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,171290003,Influenza vaccination consent given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,171291004,No consent for Haemophilus influenzae type b immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,185900003,Has influenza vaccination at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,185901004,Has influenza vaccination at surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,185902006,Has influenza vaccination at hospital,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,185903001,Needs influenza immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,192721000,Post influenza vaccination encephalitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,194946005,Acute myocarditis - influenzal,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,195726000,Acute parainfluenza virus bronchitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,195878008,Pneumonia and influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,195923003,Influenza with laryngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,195924009,Influenza with pharyngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,195929004,Influenza with gastrointestinal tract involvement,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,195931008,Influenza like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,266393000,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,268561003,Influenza immunization advised in surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,275983007,Influenza immunisation advised,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,291749008,Influenza vaccine poisoning,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,293112000,Influenza split virion vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,293113005,Influenza surface antigen vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,294647003,Allergy to influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,294648008,Allergy to influenza split virion vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,294649000,Allergy to influenza surface antigen vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,294664000,Haemophilus influenzae type b vaccine allergy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,308532005,Influenza vaccination status,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,309789002,Encephalitis caused by Influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,315640000,Influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,315641001,Influenza vaccination invitation letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,390796006,Influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,396425006,FLU - Influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,407479009,Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,407480007,Influenza B virus(B/Lee/40),ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,407489008,Human parainfluenza virus 1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,407491000,Parainfluenza virus type 2,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,407493002,Human parainfluenza virus 3,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,407498006,Human parainfluenza viruses,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,407573008,Influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,414496007,Influenza vaccination telephone invite,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,416928007,Has influenza vaccination at work,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,441043003,Influenza A virus subtype H1 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,441049004,Influenza A virus subtype H3 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,441343005,Influenza A virus subtype H5 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,441344004,Human parainfluenza virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,441345003,Influenza B virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,442438000,Influenza caused by Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,442696006,Influenza A (H1N1) swine flu,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,444426005,Swine influenza contact,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,473169009,History of influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,698353005,Requires influenza virus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,709410003,Hib (Haemophilus influenzae type b) infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,711330007,Influenza A virus subtype H1N1 detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,711334003,Influenza A virus H1N1 subtype not detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,736818002,Influenza vaccination requested,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,737041000,Influenza immunisation telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,787016008,Administration of influenza vaccine via nasal route,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,73701000119109,Vaccination for influenza given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,135221000119101,Influenza A H1N1 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,199331000000106,Did not attend influenza vaccination appointment,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,200481000000107,Influenza vaccination invitation first letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,200491000000109,Influenza vaccination invitation second letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,200501000000103,Influenza vaccination invitation third letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,201391000000106,Booster influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,202301000000106,First pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,202311000000108,Second pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,380271000000101,Consent given for pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,380381000000108,Pandemic influenza vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,380631000000100,Pandemic influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,380801000000105,Pandemic influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,506751000000104,Possible influenza A virus H1N1 subtype,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,516101000000103,No response to influenza vaccination invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,540151000000108,Pneumonia or influenza NOS,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,761311000000109,Influenza vaccination verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,777791000000102,Influenza vaccination invitation first text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,822851000000102,Seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,822931000000100,Seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,822951000000107,Seasonal influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,822971000000103,Seasonal influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,822991000000104,Consent given for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,844941000000103,Influenza vaccination invitation email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,844961000000102,Influenza vaccination invitation first email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,844981000000106,Influenza vaccination invitation second email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,845001000000101,Influenza vaccination invitation third email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,860151000000103,Influenza vaccination first verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,860171000000107,Influenza vaccination second verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,860211000000105,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,860291000000101,Influenza vaccination third verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,868241000000109,Administration of intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,868491000000103,No consent for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,871521000000104,First intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,871541000000106,Second intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,871751000000104,Administration of first intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,871781000000105,Administration of second intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,873681000000101,Provision of information about seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,913961000000102,Education about influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,932221000000103,At risk of influenza related complication,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,935351000000106,Long term indication for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,955641000000103,Influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,996211000000100,Influenza (A and B) serology,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,996761000000106,Haemophilus influenzae B IgG level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1001341000000106,Influenza A antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1001351000000109,Influenza B antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1005101000000108,Parainfluenza virus antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1005111000000105,Parainfluenza type 3 antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1008771000000107,Haemophilus influenzae B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1014261000000103,Influenza A antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1014271000000105,Influenza B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1020381000000100,Parainfluenza virus antigen assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1033051000000101,Influenza due to zoonotic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1033071000000105,Influenza due to pandemic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1033091000000109,Influenza due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1095821000000105,Influenza vaccination first telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1095831000000107,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1095841000000103,Influenza vaccination third telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1239861000000100,Seasonal influenza vaccination given in school,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza,TA015,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,6142004,Influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,24662006,Influenza caused by Influenza B virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,41269000,Influenzal bronchopneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,44470000,Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,46233009,Influenza virus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,51593004,Haemophilus parainfluenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,64917006,Pneumonia due to parainfluenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,70036007,Haemophilus influenzae pneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,74644004,Influenza with encephalopathy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,89117003,Parainfluenza virus type 4,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,91428005,Haemophilus influenzae infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,95891005,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,120753009,Influenza A virus antibody,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,120843002,Influenza B virus Ab,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,120975003,Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,127787002,Haemophilus influenzae type b immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,170343007,First Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,170345000,Third Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,171272004,No consent - influenza immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,171282003,Influenza immunization advised at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,171290003,Influenza vaccination consent given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,171291004,No consent for Haemophilus influenzae type b immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,185900003,Has influenza vaccination at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,185901004,Has influenza vaccination at surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,185902006,Has influenza vaccination at hospital,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,185903001,Needs influenza immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,192721000,Post influenza vaccination encephalitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,194946005,Acute myocarditis - influenzal,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,195726000,Acute parainfluenza virus bronchitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,195878008,Pneumonia and influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,195923003,Influenza with laryngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,195924009,Influenza with pharyngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,195929004,Influenza with gastrointestinal tract involvement,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,195931008,Influenza like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,266393000,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,268561003,Influenza immunization advised in surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,275983007,Influenza immunisation advised,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,291749008,Influenza vaccine poisoning,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,293112000,Influenza split virion vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,293113005,Influenza surface antigen vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,294647003,Allergy to influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,294648008,Allergy to influenza split virion vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,294649000,Allergy to influenza surface antigen vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,294664000,Haemophilus influenzae type b vaccine allergy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,308532005,Influenza vaccination status,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,309789002,Encephalitis caused by Influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,315640000,Influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,315641001,Influenza vaccination invitation letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,390796006,Influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,396425006,FLU - Influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,407479009,Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,407480007,Influenza B virus(B/Lee/40),ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,407489008,Human parainfluenza virus 1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,407491000,Parainfluenza virus type 2,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,407493002,Human parainfluenza virus 3,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,407498006,Human parainfluenza viruses,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,407573008,Influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,414496007,Influenza vaccination telephone invite,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,416928007,Has influenza vaccination at work,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,441043003,Influenza A virus subtype H1 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,441049004,Influenza A virus subtype H3 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,441343005,Influenza A virus subtype H5 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,441344004,Human parainfluenza virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,441345003,Influenza B virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,442438000,Influenza caused by Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,442696006,Influenza A (H1N1) swine flu,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,444426005,Swine influenza contact,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,473169009,History of influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,698353005,Requires influenza virus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,709410003,Hib (Haemophilus influenzae type b) infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,711330007,Influenza A virus subtype H1N1 detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,711334003,Influenza A virus H1N1 subtype not detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,736818002,Influenza vaccination requested,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,737041000,Influenza immunisation telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,787016008,Administration of influenza vaccine via nasal route,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,73701000119109,Vaccination for influenza given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,135221000119101,Influenza A H1N1 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,199331000000106,Did not attend influenza vaccination appointment,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,200481000000107,Influenza vaccination invitation first letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,200491000000109,Influenza vaccination invitation second letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,200501000000103,Influenza vaccination invitation third letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,201391000000106,Booster influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,202301000000106,First pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,202311000000108,Second pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,380271000000101,Consent given for pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,380381000000108,Pandemic influenza vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,380631000000100,Pandemic influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,380801000000105,Pandemic influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,506751000000104,Possible influenza A virus H1N1 subtype,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,516101000000103,No response to influenza vaccination invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,540151000000108,Pneumonia or influenza NOS,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,761311000000109,Influenza vaccination verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,777791000000102,Influenza vaccination invitation first text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,822851000000102,Seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,822931000000100,Seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,822951000000107,Seasonal influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,822971000000103,Seasonal influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,822991000000104,Consent given for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,844941000000103,Influenza vaccination invitation email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,844961000000102,Influenza vaccination invitation first email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,844981000000106,Influenza vaccination invitation second email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,845001000000101,Influenza vaccination invitation third email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,860151000000103,Influenza vaccination first verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,860171000000107,Influenza vaccination second verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,860211000000105,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,860291000000101,Influenza vaccination third verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,868241000000109,Administration of intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,868491000000103,No consent for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,871521000000104,First intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,871541000000106,Second intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,871751000000104,Administration of first intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,871781000000105,Administration of second intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,873681000000101,Provision of information about seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,913961000000102,Education about influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,932221000000103,At risk of influenza related complication,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,935351000000106,Long term indication for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,955641000000103,Influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,996211000000100,Influenza (A and B) serology,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,996761000000106,Haemophilus influenzae B IgG level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1001341000000106,Influenza A antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1001351000000109,Influenza B antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1005101000000108,Parainfluenza virus antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1005111000000105,Parainfluenza type 3 antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1008771000000107,Haemophilus influenzae B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1014261000000103,Influenza A antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1014271000000105,Influenza B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1020381000000100,Parainfluenza virus antigen assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1033051000000101,Influenza due to zoonotic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1033071000000105,Influenza due to pandemic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1033091000000109,Influenza due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1095821000000105,Influenza vaccination first telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1095831000000107,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1095841000000103,Influenza vaccination third telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1239861000000100,Seasonal influenza vaccination given in school,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA058,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZANAMIVIR,Influenza (treatment),TA168,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE +ZOLPIDEM,Insomnia,TA077,insomnia,3972004,Idiopathic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,41975002,Insomnia with sleep apnea,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,162201008,Cannot sleep - insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,162204000,Terminal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,191994005,Non-organic sleep disorders (& [hypersomnia] or [insomnia]),ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,191997003,Persistent insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,192454004,Nonorganic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,193462001,Insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,198437004,Menopausal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,268652009,Transient insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,272025006,Complaining of insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,440313002,Education about stimulus control behaviour in insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,762989006,Insomnia Severity Index score,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,1107191000000102,Referral for dCBT (digital cognitive behaviour therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOLPIDEM,Insomnia,TA077,insomnia,1109721000000108,Digital CBT (cognitive behavioural therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,3972004,Idiopathic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,41975002,Insomnia with sleep apnea,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,162201008,Cannot sleep - insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,162204000,Terminal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,191994005,Non-organic sleep disorders (& [hypersomnia] or [insomnia]),ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,191997003,Persistent insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,192454004,Nonorganic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,193462001,Insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,198437004,Menopausal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,268652009,Transient insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,272025006,Complaining of insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,440313002,Education about stimulus control behaviour in insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,762989006,Insomnia Severity Index score,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,1107191000000102,Referral for dCBT (digital cognitive behaviour therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOPICLONE,Insomnia,TA077,insomnia,1109721000000108,Digital CBT (cognitive behavioural therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +ZOTEPINE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190389009,Type 2 diabetes mellitus with ulcer,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199230006,Pre-existing type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237599002,Insulin treated type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422014003,Disorder due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,703138006,Type 2 diabetes mellitus in remission,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,46635009,T1DM - type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,290002008,Unstable type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420868002,Disorder due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,429094000,Dietary advice for type 1 diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,703137001,Type 1 diabetes mellitus in remission,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,2751001,Fibrocalculous pancreatic diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,4855003,Retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,5368009,Drug-induced diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,6143009,Diabetes mellitus education,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,8801005,Secondary diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,9414007,Latent diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,11530004,Brittle diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,11687002,GDM - gestational diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,15771004,Diabetes insipidus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,21584002,Maternal diabetes syndrome,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,25093002,Disorder of eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,43959009,Cataract of eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,44054006,T2DM - diabetes mellitus type 2,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,48951005,Bullous disease due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,49455004,Polyneuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,49817004,Neonatal diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,61165007,Adiuretin-resistant diabetes insipidus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,73211009,Diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,74627003,Complication due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,111552007,Diabetes mellitus without complication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,127012008,Lipodystrophic diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,127013003,Disorder of kidney due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,160274005,No family history of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,160303001,Family history of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,160402005,Family history: Diabetes in pregnancy,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,161445009,History of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,161641009,At increased risk of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170745003,Diet controlled diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170752001,Has seen dietitian - diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170753006,Understands diet - diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170774007,Diabetes: practice program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170775008,Diabetes: shared care program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,171183004,Diabetes mellitus screening,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185753003,Attends diabetes monitoring,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185754009,Diabetes monitoring declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185755005,Diabetes monitoring default,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185756006,Diabetes monitoring first letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185757002,Diabetes monitoring second letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185758007,Diabetes monitoring third letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185759004,Diabetes monitoring verbal invite,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185760009,Diabetes monitoring telephone invite,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185761008,Diabetes monitoring deleted,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190323008,Non-insulin dependent diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190349003,Diabetes mellitus with neuropathy,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190354007,Diabetes with gangrene,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190372001,Insulin-dependent diabetes maturity onset,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190411003,Multiple complications due to malnutrition related diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190416008,Steroid-induced diabetes mellitus without complication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190447002,Steroid-induced diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190484000,Diabetes insipidus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193489006,Iritis due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230572002,Neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230577008,Mononeuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,232020009,Disorder of macula due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237601000,Secondary endocrine diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237619009,Maternally-inherited diabetes and hearing loss,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237632004,Hypoglycemic event due to diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,238982009,Dermopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,267471001,Diabetes + eye manifestation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,268519009,Diabetes mellitus uncontrolled,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,270445003,Diabetes monitoring check done,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,273411009,Diabetes clinic satisfaction questionnaire,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,273412002,Diabetes treatment satisfaction questionnaire,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,273413007,Diabetes wellbeing questionnaire,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,284350006,Diabetes mellitus diet education,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,303059007,Postpancreatectomy diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,304752002,Perceived control of insulin-dependent diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,308505000,Diabetes monitoring call,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309417009,Diabetes dietitian,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309426007,Glomerulopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309593006,Education score - diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309596003,Retinal abnormality - non-diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309598002,Foot abnormality - non-diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309635005,History of admission in last year for diabetes foot problem,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,310425007,Diabetes monitoring invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312856000,Referral to diabetes nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312888008,Attending diabetes clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312912001,Macular oedema due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,313435000,Insulin-dependent diabetes without complication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,313436004,Type II diabetes mellitus without complication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314537004,Optic papillopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,315051004,Diabetes resolved,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,315216001,Diabetes mellitus excluded,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,371087003,Ulcer of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,385805005,Health education - diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,394725008,Diabetes medication review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,395123002,Urine screening test for diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,405749004,Newly diagnosed diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,408290003,Diabetes key contact,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,408392008,Under care of diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,413180006,Pan retinal photocoagulation for diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,413597006,Attended diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,414229005,Family/carer attended diabetes structured education program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,414230000,Family/carer referral to diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,415269004,Referral to diabetes preconception counselling clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,415270003,Referral to diabetes structured education program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,415744000,Transition of diabetes care options discussed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,416554009,Seen in community diabetes specialist clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,416855002,Family history of diabetes mellitus in first degree relative,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,417467000,Discharged from care of diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,419100001,Infection of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420422005,Ketoacidosis due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422183001,Skin ulcer due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422275004,Gangrene due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,428274007,Dietary advice for type II diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,430678008,Family history of diabetes mellitus type 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,430679000,Family history of diabetes mellitus type 2,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,439051004,Dietary advice for gestational diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,444094009,History of diabetes mellitus in child of subject,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,472969004,H/O diabetes mellitus type 2,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,472970003,H/O diabetes mellitus type 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,473127005,Suspected diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,609561005,MODY - maturity onset diabetes of young,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,698610002,Education about self management of diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,699826006,Lifestyle education regarding risk of diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,700414001,Education about diabetes and driving,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,703040004,Agreeing on diabetes care plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,703136005,Diabetes mellitus in remission,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,704408003,Invitation for diabetes screening,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,714628002,Prediabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,715159005,Referral to diabetes service,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,715759002,Provision of written information about diabetes and hypertension,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,715879000,Provision of written information about diabetes and high cholesterol,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,720685006,Seen by diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,720724003,Has diabetes identity card,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,724136006,Mastopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,735199000,History of diabetes related lower limb amputation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,735985000,Diabetes self management plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,736284000,Diabetes clinical management plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,762489000,Acute complication due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,763782001,Provision of patient held diabetes record declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769244003,Disorder of right macula due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769245002,Disorder of left macula due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,878859007,Self management of diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,897238003,Diabetes management using closed-loop delivery system,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1258872006,Family referred to diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1258873001,Caregiver referred to diabetes structured education program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1268646002,Gestational diabetes mellitus screening,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1296758008,Diabetes insipidus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,113131000000107,Informed consent for diabetes national audit,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,113141000000103,Informed dissent for diabetes national audit,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,143911000000105,Registration for access to online diabetes self-management application,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,279291000000109,Diabetes type 1 review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,279321000000104,Diabetes type II review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,279521000000108,Referral to community diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306591000000103,Diabetes structured education programme declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306861000000107,Did not attend diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306931000000106,Did not complete diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,334711000000100,Referral to diabetes special interest general practitioner,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,335621000000101,Maternally inherited diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,344061000000104,Referral to children's diabetes nurse specialist,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,385041000000108,Diabetes mellitus with multiple complications,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,385051000000106,Pre-existing diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,494961000000102,Discharged from diabetes shared care programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,512561000000108,Unsuitable for diabetes year of care programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,512581000000104,Declined consent for diabetes year of care programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713671000000109,Diabetes monitoring administration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713691000000108,Diabetes clinic administration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,715111000000105,Diabetes screening administration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,716911000000104,Exception reporting - diabetes quality indicators,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,754461000000105,Referral to type I diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,755491000000100,Diabetes structured education programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,764921000000102,Gestational diabetes information leaflet given,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,771571000000102,H/O: secondary diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,787061000000100,Diabetes care plan declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,810961000000103,Diabetes self-management plan review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,811391000000104,Referral to community diabetes service,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,811981000000102,Diabetes self-management plan agreed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816711000000104,Gestational diabetes mellitus annual review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,819301000000105,Diabetes monitoring injection site check declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,819331000000104,Diabetes monitoring injection site not checked,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,828901000000109,Endocrinology and diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,829521000000104,Provision of diabetes clinical summary,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,837491000000107,High risk of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,841221000000102,Referral to community diabetes clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,850581000000106,High risk of diabetes mellitus annual review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,851501000000106,Diabetes clinical pathway,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,851991000000108,Diabetes quality of life questionnaire score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,857921000000103,Provision of written information about diabetes and driving,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,858301000000107,Pre-diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,863501000000102,QDiabetes risk calculator,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,863521000000106,QDiabetes risk calculator score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,885931000000100,Diabetes structured education programme not available,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,887861000000105,Diabetes Year of Care annual review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,923461000000103,Lifestyle education for diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,927821000000100,Discharge from secondary care diabetes service,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,961931000000109,Diabetes education care plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1024941000000100,NHS Diabetes Prevention Programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025601000000108,Leicester Diabetes Risk Score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1083111000000108,Diabetes monitoring invitation email,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1092721000000109,Signposting to Diabetes UK,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1103691000000102,Diabetes structured education programme offered,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1108731000000100,Referral to online diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1362341000000103,Diabetes care plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,12275391000119108,Diabetes screening declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190389009,Type 2 diabetes mellitus with ulcer,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199230006,Pre-existing type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237599002,Insulin treated type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422014003,Disorder due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,703138006,Type 2 diabetes mellitus in remission,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,46635009,T1DM - type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,290002008,Unstable type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420868002,Disorder due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,429094000,Dietary advice for type 1 diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,703137001,Type 1 diabetes mellitus in remission,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,2751001,Fibrocalculous pancreatic diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,4855003,Retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,5368009,Drug-induced diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,6143009,Diabetes mellitus education,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,8801005,Secondary diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,9414007,Latent diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,11530004,Brittle diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,11687002,GDM - gestational diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,15771004,Diabetes insipidus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,21584002,Maternal diabetes syndrome,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,25093002,Disorder of eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,43959009,Cataract of eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,44054006,T2DM - diabetes mellitus type 2,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,48951005,Bullous disease due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,49455004,Polyneuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,49817004,Neonatal diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,61165007,Adiuretin-resistant diabetes insipidus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,73211009,Diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,74627003,Complication due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,111552007,Diabetes mellitus without complication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,127012008,Lipodystrophic diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,127013003,Disorder of kidney due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,160274005,No family history of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,160303001,Family history of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,160402005,Family history: Diabetes in pregnancy,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,161445009,History of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,161641009,At increased risk of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170745003,Diet controlled diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170752001,Has seen dietitian - diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170753006,Understands diet - diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170774007,Diabetes: practice program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170775008,Diabetes: shared care program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,171183004,Diabetes mellitus screening,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185753003,Attends diabetes monitoring,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185754009,Diabetes monitoring declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185755005,Diabetes monitoring default,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185756006,Diabetes monitoring first letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185757002,Diabetes monitoring second letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185758007,Diabetes monitoring third letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185759004,Diabetes monitoring verbal invite,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185760009,Diabetes monitoring telephone invite,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185761008,Diabetes monitoring deleted,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190323008,Non-insulin dependent diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190349003,Diabetes mellitus with neuropathy,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190354007,Diabetes with gangrene,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190372001,Insulin-dependent diabetes maturity onset,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190411003,Multiple complications due to malnutrition related diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190416008,Steroid-induced diabetes mellitus without complication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190447002,Steroid-induced diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190484000,Diabetes insipidus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193489006,Iritis due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230572002,Neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230577008,Mononeuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,232020009,Disorder of macula due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237601000,Secondary endocrine diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237619009,Maternally-inherited diabetes and hearing loss,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237632004,Hypoglycemic event due to diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,238982009,Dermopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,267471001,Diabetes + eye manifestation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,268519009,Diabetes mellitus uncontrolled,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,270445003,Diabetes monitoring check done,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,273411009,Diabetes clinic satisfaction questionnaire,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,273412002,Diabetes treatment satisfaction questionnaire,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,273413007,Diabetes wellbeing questionnaire,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,284350006,Diabetes mellitus diet education,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,303059007,Postpancreatectomy diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,304752002,Perceived control of insulin-dependent diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,308505000,Diabetes monitoring call,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309417009,Diabetes dietitian,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309426007,Glomerulopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309593006,Education score - diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309596003,Retinal abnormality - non-diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309598002,Foot abnormality - non-diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309635005,History of admission in last year for diabetes foot problem,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,310425007,Diabetes monitoring invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312856000,Referral to diabetes nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312888008,Attending diabetes clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312912001,Macular oedema due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,313435000,Insulin-dependent diabetes without complication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,313436004,Type II diabetes mellitus without complication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314537004,Optic papillopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,315051004,Diabetes resolved,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,315216001,Diabetes mellitus excluded,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,371087003,Ulcer of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,385805005,Health education - diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,394725008,Diabetes medication review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,395123002,Urine screening test for diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,405749004,Newly diagnosed diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,408290003,Diabetes key contact,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,408392008,Under care of diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,413180006,Pan retinal photocoagulation for diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,413597006,Attended diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,414229005,Family/carer attended diabetes structured education program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,414230000,Family/carer referral to diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,415269004,Referral to diabetes preconception counselling clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,415270003,Referral to diabetes structured education program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,415744000,Transition of diabetes care options discussed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,416554009,Seen in community diabetes specialist clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,416855002,Family history of diabetes mellitus in first degree relative,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,417467000,Discharged from care of diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,419100001,Infection of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420422005,Ketoacidosis due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422183001,Skin ulcer due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422275004,Gangrene due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,428274007,Dietary advice for type II diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,430678008,Family history of diabetes mellitus type 1,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,430679000,Family history of diabetes mellitus type 2,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,439051004,Dietary advice for gestational diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,444094009,History of diabetes mellitus in child of subject,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,472969004,H/O diabetes mellitus type 2,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,472970003,H/O diabetes mellitus type 1,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,473127005,Suspected diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,609561005,MODY - maturity onset diabetes of young,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,698610002,Education about self management of diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,699826006,Lifestyle education regarding risk of diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,700414001,Education about diabetes and driving,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,703040004,Agreeing on diabetes care plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,703136005,Diabetes mellitus in remission,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,704408003,Invitation for diabetes screening,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,714628002,Prediabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,715159005,Referral to diabetes service,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,715759002,Provision of written information about diabetes and hypertension,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,715879000,Provision of written information about diabetes and high cholesterol,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,720685006,Seen by diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,720724003,Has diabetes identity card,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,724136006,Mastopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,735199000,History of diabetes related lower limb amputation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,735985000,Diabetes self management plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,736284000,Diabetes clinical management plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,762489000,Acute complication due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,763782001,Provision of patient held diabetes record declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769244003,Disorder of right macula due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769245002,Disorder of left macula due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,878859007,Self management of diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,897238003,Diabetes management using closed-loop delivery system,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1258872006,Family referred to diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1258873001,Caregiver referred to diabetes structured education program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1268646002,Gestational diabetes mellitus screening,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1296758008,Diabetes insipidus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,113131000000107,Informed consent for diabetes national audit,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,113141000000103,Informed dissent for diabetes national audit,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,143911000000105,Registration for access to online diabetes self-management application,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,279291000000109,Diabetes type 1 review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,279321000000104,Diabetes type II review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,279521000000108,Referral to community diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306591000000103,Diabetes structured education programme declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306861000000107,Did not attend diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306931000000106,Did not complete diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,334711000000100,Referral to diabetes special interest general practitioner,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,335621000000101,Maternally inherited diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,344061000000104,Referral to children's diabetes nurse specialist,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,385041000000108,Diabetes mellitus with multiple complications,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,385051000000106,Pre-existing diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,494961000000102,Discharged from diabetes shared care programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,512561000000108,Unsuitable for diabetes year of care programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,512581000000104,Declined consent for diabetes year of care programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713671000000109,Diabetes monitoring administration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713691000000108,Diabetes clinic administration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,715111000000105,Diabetes screening administration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,716911000000104,Exception reporting - diabetes quality indicators,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,754461000000105,Referral to type I diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,755491000000100,Diabetes structured education programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,764921000000102,Gestational diabetes information leaflet given,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,771571000000102,H/O: secondary diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,787061000000100,Diabetes care plan declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,810961000000103,Diabetes self-management plan review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,811391000000104,Referral to community diabetes service,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,811981000000102,Diabetes self-management plan agreed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816711000000104,Gestational diabetes mellitus annual review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,819301000000105,Diabetes monitoring injection site check declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,819331000000104,Diabetes monitoring injection site not checked,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,828901000000109,Endocrinology and diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,829521000000104,Provision of diabetes clinical summary,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,837491000000107,High risk of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,841221000000102,Referral to community diabetes clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,850581000000106,High risk of diabetes mellitus annual review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,851501000000106,Diabetes clinical pathway,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,851991000000108,Diabetes quality of life questionnaire score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,857921000000103,Provision of written information about diabetes and driving,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,858301000000107,Pre-diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,863501000000102,QDiabetes risk calculator,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,863521000000106,QDiabetes risk calculator score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,885931000000100,Diabetes structured education programme not available,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,887861000000105,Diabetes Year of Care annual review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,923461000000103,Lifestyle education for diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,927821000000100,Discharge from secondary care diabetes service,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,961931000000109,Diabetes education care plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1024941000000100,NHS Diabetes Prevention Programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025601000000108,Leicester Diabetes Risk Score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1083111000000108,Diabetes monitoring invitation email,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1092721000000109,Signposting to Diabetes UK,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1103691000000102,Diabetes structured education programme offered,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1108731000000100,Referral to online diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1362341000000103,Diabetes care plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,12275391000119108,Diabetes screening declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190389009,Type 2 diabetes mellitus with ulcer,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199230006,Pre-existing type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237599002,Insulin treated type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422014003,Disorder due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,703138006,Type 2 diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,46635009,T1DM - type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,290002008,Unstable type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420868002,Disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,429094000,Dietary advice for type 1 diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,703137001,Type 1 diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,2751001,Fibrocalculous pancreatic diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,4855003,Retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,5368009,Drug-induced diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,6143009,Diabetes mellitus education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,8801005,Secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,9414007,Latent diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,11530004,Brittle diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,11687002,GDM - gestational diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,15771004,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,21584002,Maternal diabetes syndrome,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,25093002,Disorder of eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,43959009,Cataract of eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,44054006,T2DM - diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,48951005,Bullous disease due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,49455004,Polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,49817004,Neonatal diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,61165007,Adiuretin-resistant diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,73211009,Diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,74627003,Complication due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,111552007,Diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,127012008,Lipodystrophic diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,127013003,Disorder of kidney due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,160274005,No family history of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,160303001,Family history of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,160402005,Family history: Diabetes in pregnancy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,161445009,History of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,161641009,At increased risk of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170745003,Diet controlled diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170752001,Has seen dietitian - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170753006,Understands diet - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170774007,Diabetes: practice program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170775008,Diabetes: shared care program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,171183004,Diabetes mellitus screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185753003,Attends diabetes monitoring,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185754009,Diabetes monitoring declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185755005,Diabetes monitoring default,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185756006,Diabetes monitoring first letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185757002,Diabetes monitoring second letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185758007,Diabetes monitoring third letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185759004,Diabetes monitoring verbal invite,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185760009,Diabetes monitoring telephone invite,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185761008,Diabetes monitoring deleted,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190323008,Non-insulin dependent diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190349003,Diabetes mellitus with neuropathy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190354007,Diabetes with gangrene,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190372001,Insulin-dependent diabetes maturity onset,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190411003,Multiple complications due to malnutrition related diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190416008,Steroid-induced diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190447002,Steroid-induced diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190484000,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193489006,Iritis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230572002,Neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230577008,Mononeuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,232020009,Disorder of macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237601000,Secondary endocrine diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237619009,Maternally-inherited diabetes and hearing loss,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237632004,Hypoglycemic event due to diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,238982009,Dermopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,267471001,Diabetes + eye manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,268519009,Diabetes mellitus uncontrolled,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,270445003,Diabetes monitoring check done,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,273411009,Diabetes clinic satisfaction questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,273412002,Diabetes treatment satisfaction questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,273413007,Diabetes wellbeing questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,284350006,Diabetes mellitus diet education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,303059007,Postpancreatectomy diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,304752002,Perceived control of insulin-dependent diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,308505000,Diabetes monitoring call,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309417009,Diabetes dietitian,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309426007,Glomerulopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309593006,Education score - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309596003,Retinal abnormality - non-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309598002,Foot abnormality - non-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309635005,History of admission in last year for diabetes foot problem,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,310425007,Diabetes monitoring invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312856000,Referral to diabetes nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312888008,Attending diabetes clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312912001,Macular oedema due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,313435000,Insulin-dependent diabetes without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,313436004,Type II diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314537004,Optic papillopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,315051004,Diabetes resolved,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,315216001,Diabetes mellitus excluded,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,371087003,Ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,385805005,Health education - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,394725008,Diabetes medication review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,395123002,Urine screening test for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,405749004,Newly diagnosed diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,408290003,Diabetes key contact,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,408392008,Under care of diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,413180006,Pan retinal photocoagulation for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,413597006,Attended diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,414229005,Family/carer attended diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,414230000,Family/carer referral to diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,415269004,Referral to diabetes preconception counselling clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,415270003,Referral to diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,415744000,Transition of diabetes care options discussed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,416554009,Seen in community diabetes specialist clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,416855002,Family history of diabetes mellitus in first degree relative,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,417467000,Discharged from care of diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,419100001,Infection of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420422005,Ketoacidosis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422183001,Skin ulcer due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422275004,Gangrene due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,428274007,Dietary advice for type II diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,430678008,Family history of diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,430679000,Family history of diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,439051004,Dietary advice for gestational diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,444094009,History of diabetes mellitus in child of subject,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,472969004,H/O diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,472970003,H/O diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,473127005,Suspected diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,609561005,MODY - maturity onset diabetes of young,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,698610002,Education about self management of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,699826006,Lifestyle education regarding risk of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,700414001,Education about diabetes and driving,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,703040004,Agreeing on diabetes care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,703136005,Diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,704408003,Invitation for diabetes screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,714628002,Prediabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,715159005,Referral to diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,715759002,Provision of written information about diabetes and hypertension,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,715879000,Provision of written information about diabetes and high cholesterol,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,720685006,Seen by diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,720724003,Has diabetes identity card,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,724136006,Mastopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,735199000,History of diabetes related lower limb amputation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,735985000,Diabetes self management plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,736284000,Diabetes clinical management plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,762489000,Acute complication due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,763782001,Provision of patient held diabetes record declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769244003,Disorder of right macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769245002,Disorder of left macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,878859007,Self management of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,897238003,Diabetes management using closed-loop delivery system,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1258872006,Family referred to diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1258873001,Caregiver referred to diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1268646002,Gestational diabetes mellitus screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1296758008,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,113131000000107,Informed consent for diabetes national audit,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,113141000000103,Informed dissent for diabetes national audit,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,143911000000105,Registration for access to online diabetes self-management application,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,279291000000109,Diabetes type 1 review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,279321000000104,Diabetes type II review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,279521000000108,Referral to community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306591000000103,Diabetes structured education programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306861000000107,Did not attend diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306931000000106,Did not complete diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,334711000000100,Referral to diabetes special interest general practitioner,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,335621000000101,Maternally inherited diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,344061000000104,Referral to children's diabetes nurse specialist,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,385041000000108,Diabetes mellitus with multiple complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,385051000000106,Pre-existing diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,494961000000102,Discharged from diabetes shared care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,512561000000108,Unsuitable for diabetes year of care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,512581000000104,Declined consent for diabetes year of care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713671000000109,Diabetes monitoring administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713691000000108,Diabetes clinic administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,715111000000105,Diabetes screening administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,716911000000104,Exception reporting - diabetes quality indicators,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,754461000000105,Referral to type I diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,755491000000100,Diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,764921000000102,Gestational diabetes information leaflet given,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,771571000000102,H/O: secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,787061000000100,Diabetes care plan declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,810961000000103,Diabetes self-management plan review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,811391000000104,Referral to community diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,811981000000102,Diabetes self-management plan agreed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816711000000104,Gestational diabetes mellitus annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,819301000000105,Diabetes monitoring injection site check declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,819331000000104,Diabetes monitoring injection site not checked,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,828901000000109,Endocrinology and diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,829521000000104,Provision of diabetes clinical summary,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,837491000000107,High risk of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,841221000000102,Referral to community diabetes clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,850581000000106,High risk of diabetes mellitus annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,851501000000106,Diabetes clinical pathway,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,851991000000108,Diabetes quality of life questionnaire score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,857921000000103,Provision of written information about diabetes and driving,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,858301000000107,Pre-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,863501000000102,QDiabetes risk calculator,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,863521000000106,QDiabetes risk calculator score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,885931000000100,Diabetes structured education programme not available,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,887861000000105,Diabetes Year of Care annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,923461000000103,Lifestyle education for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,927821000000100,Discharge from secondary care diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,961931000000109,Diabetes education care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1024941000000100,NHS Diabetes Prevention Programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025601000000108,Leicester Diabetes Risk Score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1083111000000108,Diabetes monitoring invitation email,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1092721000000109,Signposting to Diabetes UK,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1103691000000102,Diabetes structured education programme offered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1108731000000100,Referral to online diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1362341000000103,Diabetes care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,12275391000119108,Diabetes screening declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190389009,Type 2 diabetes mellitus with ulcer,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199230006,Pre-existing type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237599002,Insulin treated type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422014003,Disorder due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,703138006,Type 2 diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,46635009,T1DM - type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,290002008,Unstable type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420868002,Disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,429094000,Dietary advice for type 1 diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,703137001,Type 1 diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,2751001,Fibrocalculous pancreatic diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,4855003,Retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,5368009,Drug-induced diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,6143009,Diabetes mellitus education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,8801005,Secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,9414007,Latent diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,11530004,Brittle diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,11687002,GDM - gestational diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,15771004,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,21584002,Maternal diabetes syndrome,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,25093002,Disorder of eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,43959009,Cataract of eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,44054006,T2DM - diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,48951005,Bullous disease due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,49455004,Polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,49817004,Neonatal diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,61165007,Adiuretin-resistant diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,73211009,Diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,74627003,Complication due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,111552007,Diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,127012008,Lipodystrophic diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,127013003,Disorder of kidney due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,160274005,No family history of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,160303001,Family history of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,160402005,Family history: Diabetes in pregnancy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,161445009,History of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,161641009,At increased risk of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170745003,Diet controlled diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170752001,Has seen dietitian - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170753006,Understands diet - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170774007,Diabetes: practice program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170775008,Diabetes: shared care program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,171183004,Diabetes mellitus screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185753003,Attends diabetes monitoring,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185754009,Diabetes monitoring declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185755005,Diabetes monitoring default,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185756006,Diabetes monitoring first letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185757002,Diabetes monitoring second letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185758007,Diabetes monitoring third letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185759004,Diabetes monitoring verbal invite,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185760009,Diabetes monitoring telephone invite,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185761008,Diabetes monitoring deleted,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190323008,Non-insulin dependent diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190349003,Diabetes mellitus with neuropathy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190354007,Diabetes with gangrene,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190372001,Insulin-dependent diabetes maturity onset,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190411003,Multiple complications due to malnutrition related diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190416008,Steroid-induced diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190447002,Steroid-induced diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190484000,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193489006,Iritis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230572002,Neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230577008,Mononeuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,232020009,Disorder of macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237601000,Secondary endocrine diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237619009,Maternally-inherited diabetes and hearing loss,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237632004,Hypoglycemic event due to diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,238982009,Dermopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,267471001,Diabetes + eye manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,268519009,Diabetes mellitus uncontrolled,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,270445003,Diabetes monitoring check done,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,273411009,Diabetes clinic satisfaction questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,273412002,Diabetes treatment satisfaction questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,273413007,Diabetes wellbeing questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,284350006,Diabetes mellitus diet education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,303059007,Postpancreatectomy diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,304752002,Perceived control of insulin-dependent diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,308505000,Diabetes monitoring call,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309417009,Diabetes dietitian,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309426007,Glomerulopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309593006,Education score - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309596003,Retinal abnormality - non-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309598002,Foot abnormality - non-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309635005,History of admission in last year for diabetes foot problem,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,310425007,Diabetes monitoring invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312856000,Referral to diabetes nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312888008,Attending diabetes clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312912001,Macular oedema due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,313435000,Insulin-dependent diabetes without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,313436004,Type II diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314537004,Optic papillopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,315051004,Diabetes resolved,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,315216001,Diabetes mellitus excluded,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,371087003,Ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,385805005,Health education - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,394725008,Diabetes medication review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,395123002,Urine screening test for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,405749004,Newly diagnosed diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,408290003,Diabetes key contact,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,408392008,Under care of diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,413180006,Pan retinal photocoagulation for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,413597006,Attended diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,414229005,Family/carer attended diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,414230000,Family/carer referral to diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,415269004,Referral to diabetes preconception counselling clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,415270003,Referral to diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,415744000,Transition of diabetes care options discussed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,416554009,Seen in community diabetes specialist clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,416855002,Family history of diabetes mellitus in first degree relative,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,417467000,Discharged from care of diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,419100001,Infection of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420422005,Ketoacidosis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422183001,Skin ulcer due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422275004,Gangrene due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,428274007,Dietary advice for type II diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,430678008,Family history of diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,430679000,Family history of diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,439051004,Dietary advice for gestational diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,444094009,History of diabetes mellitus in child of subject,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,472969004,H/O diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,472970003,H/O diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,473127005,Suspected diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,609561005,MODY - maturity onset diabetes of young,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,698610002,Education about self management of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,699826006,Lifestyle education regarding risk of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,700414001,Education about diabetes and driving,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,703040004,Agreeing on diabetes care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,703136005,Diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,704408003,Invitation for diabetes screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,714628002,Prediabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,715159005,Referral to diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,715759002,Provision of written information about diabetes and hypertension,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,715879000,Provision of written information about diabetes and high cholesterol,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,720685006,Seen by diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,720724003,Has diabetes identity card,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,724136006,Mastopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,735199000,History of diabetes related lower limb amputation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,735985000,Diabetes self management plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,736284000,Diabetes clinical management plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,762489000,Acute complication due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,763782001,Provision of patient held diabetes record declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769244003,Disorder of right macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769245002,Disorder of left macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,878859007,Self management of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,897238003,Diabetes management using closed-loop delivery system,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1258872006,Family referred to diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1258873001,Caregiver referred to diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1268646002,Gestational diabetes mellitus screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1296758008,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,113131000000107,Informed consent for diabetes national audit,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,113141000000103,Informed dissent for diabetes national audit,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,143911000000105,Registration for access to online diabetes self-management application,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,279291000000109,Diabetes type 1 review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,279321000000104,Diabetes type II review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,279521000000108,Referral to community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306591000000103,Diabetes structured education programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306861000000107,Did not attend diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306931000000106,Did not complete diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,334711000000100,Referral to diabetes special interest general practitioner,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,335621000000101,Maternally inherited diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,344061000000104,Referral to children's diabetes nurse specialist,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,385041000000108,Diabetes mellitus with multiple complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,385051000000106,Pre-existing diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,494961000000102,Discharged from diabetes shared care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,512561000000108,Unsuitable for diabetes year of care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,512581000000104,Declined consent for diabetes year of care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713671000000109,Diabetes monitoring administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713691000000108,Diabetes clinic administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,715111000000105,Diabetes screening administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,716911000000104,Exception reporting - diabetes quality indicators,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,754461000000105,Referral to type I diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,755491000000100,Diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,764921000000102,Gestational diabetes information leaflet given,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,771571000000102,H/O: secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,787061000000100,Diabetes care plan declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,810961000000103,Diabetes self-management plan review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,811391000000104,Referral to community diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,811981000000102,Diabetes self-management plan agreed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816711000000104,Gestational diabetes mellitus annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,819301000000105,Diabetes monitoring injection site check declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,819331000000104,Diabetes monitoring injection site not checked,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,828901000000109,Endocrinology and diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,829521000000104,Provision of diabetes clinical summary,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,837491000000107,High risk of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,841221000000102,Referral to community diabetes clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,850581000000106,High risk of diabetes mellitus annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,851501000000106,Diabetes clinical pathway,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,851991000000108,Diabetes quality of life questionnaire score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,857921000000103,Provision of written information about diabetes and driving,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,858301000000107,Pre-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,863501000000102,QDiabetes risk calculator,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,863521000000106,QDiabetes risk calculator score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,885931000000100,Diabetes structured education programme not available,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,887861000000105,Diabetes Year of Care annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,923461000000103,Lifestyle education for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,927821000000100,Discharge from secondary care diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,961931000000109,Diabetes education care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1024941000000100,NHS Diabetes Prevention Programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025601000000108,Leicester Diabetes Risk Score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1083111000000108,Diabetes monitoring invitation email,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1092721000000109,Signposting to Diabetes UK,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1103691000000102,Diabetes structured education programme offered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1108731000000100,Referral to online diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1362341000000103,Diabetes care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,12275391000119108,Diabetes screening declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190389009,Type 2 diabetes mellitus with ulcer,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,199230006,Pre-existing type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237599002,Insulin treated type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422014003,Disorder due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,703138006,Type 2 diabetes mellitus in remission,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,46635009,T1DM - type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,290002008,Unstable type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420868002,Disorder due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,429094000,Dietary advice for type 1 diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,703137001,Type 1 diabetes mellitus in remission,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,2751001,Fibrocalculous pancreatic diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,4855003,Retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,5368009,Drug-induced diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,6143009,Diabetes mellitus education,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,8801005,Secondary diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,9414007,Latent diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,11530004,Brittle diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,11687002,GDM - gestational diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,15771004,Diabetes insipidus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,21584002,Maternal diabetes syndrome,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,25093002,Disorder of eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,43959009,Cataract of eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,44054006,T2DM - diabetes mellitus type 2,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,48951005,Bullous disease due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,49455004,Polyneuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,49817004,Neonatal diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,61165007,Adiuretin-resistant diabetes insipidus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,73211009,Diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,74627003,Complication due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,111552007,Diabetes mellitus without complication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,127012008,Lipodystrophic diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,127013003,Disorder of kidney due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,160274005,No family history of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,160303001,Family history of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,160402005,Family history: Diabetes in pregnancy,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,161445009,History of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,161641009,At increased risk of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,170745003,Diet controlled diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,170752001,Has seen dietitian - diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,170753006,Understands diet - diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,170774007,Diabetes: practice program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,170775008,Diabetes: shared care program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,171183004,Diabetes mellitus screening,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185753003,Attends diabetes monitoring,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185754009,Diabetes monitoring declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185755005,Diabetes monitoring default,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185756006,Diabetes monitoring first letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185757002,Diabetes monitoring second letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185758007,Diabetes monitoring third letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185759004,Diabetes monitoring verbal invite,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185760009,Diabetes monitoring telephone invite,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,185761008,Diabetes monitoring deleted,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190323008,Non-insulin dependent diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190349003,Diabetes mellitus with neuropathy,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190354007,Diabetes with gangrene,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190372001,Insulin-dependent diabetes maturity onset,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190411003,Multiple complications due to malnutrition related diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190416008,Steroid-induced diabetes mellitus without complication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190447002,Steroid-induced diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,190484000,Diabetes insipidus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,193489006,Iritis due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,230572002,Neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,230577008,Mononeuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,232020009,Disorder of macula due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237601000,Secondary endocrine diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237619009,Maternally-inherited diabetes and hearing loss,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237632004,Hypoglycemic event due to diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,238982009,Dermopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,267471001,Diabetes + eye manifestation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,268519009,Diabetes mellitus uncontrolled,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,270445003,Diabetes monitoring check done,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,273411009,Diabetes clinic satisfaction questionnaire,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,273412002,Diabetes treatment satisfaction questionnaire,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,273413007,Diabetes wellbeing questionnaire,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,284350006,Diabetes mellitus diet education,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,303059007,Postpancreatectomy diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,304752002,Perceived control of insulin-dependent diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,308505000,Diabetes monitoring call,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,309417009,Diabetes dietitian,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,309426007,Glomerulopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,309593006,Education score - diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,309596003,Retinal abnormality - non-diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,309598002,Foot abnormality - non-diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,309635005,History of admission in last year for diabetes foot problem,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,310425007,Diabetes monitoring invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,312856000,Referral to diabetes nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,312888008,Attending diabetes clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,312912001,Macular oedema due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,313435000,Insulin-dependent diabetes without complication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,313436004,Type II diabetes mellitus without complication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314537004,Optic papillopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,315051004,Diabetes resolved,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,315216001,Diabetes mellitus excluded,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,371087003,Ulcer of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,385805005,Health education - diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,394725008,Diabetes medication review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,395123002,Urine screening test for diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,405749004,Newly diagnosed diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,408290003,Diabetes key contact,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,408392008,Under care of diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,413180006,Pan retinal photocoagulation for diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,413597006,Attended diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,414229005,Family/carer attended diabetes structured education program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,414230000,Family/carer referral to diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,415269004,Referral to diabetes preconception counselling clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,415270003,Referral to diabetes structured education program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,415744000,Transition of diabetes care options discussed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,416554009,Seen in community diabetes specialist clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,416855002,Family history of diabetes mellitus in first degree relative,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,417467000,Discharged from care of diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,419100001,Infection of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420422005,Ketoacidosis due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422183001,Skin ulcer due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,422275004,Gangrene due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,428274007,Dietary advice for type II diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,430678008,Family history of diabetes mellitus type 1,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,430679000,Family history of diabetes mellitus type 2,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,439051004,Dietary advice for gestational diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,444094009,History of diabetes mellitus in child of subject,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,472969004,H/O diabetes mellitus type 2,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,472970003,H/O diabetes mellitus type 1,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,473127005,Suspected diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,609561005,MODY - maturity onset diabetes of young,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,698610002,Education about self management of diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,699826006,Lifestyle education regarding risk of diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,700414001,Education about diabetes and driving,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,703040004,Agreeing on diabetes care plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,703136005,Diabetes mellitus in remission,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,704408003,Invitation for diabetes screening,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,714628002,Prediabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,715159005,Referral to diabetes service,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,715759002,Provision of written information about diabetes and hypertension,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,715879000,Provision of written information about diabetes and high cholesterol,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,720685006,Seen by diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,720724003,Has diabetes identity card,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,724136006,Mastopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,735199000,History of diabetes related lower limb amputation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,735985000,Diabetes self management plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,736284000,Diabetes clinical management plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,762489000,Acute complication due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,763782001,Provision of patient held diabetes record declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,769244003,Disorder of right macula due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,769245002,Disorder of left macula due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,878859007,Self management of diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,897238003,Diabetes management using closed-loop delivery system,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1258872006,Family referred to diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1258873001,Caregiver referred to diabetes structured education program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1268646002,Gestational diabetes mellitus screening,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1296758008,Diabetes insipidus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,113131000000107,Informed consent for diabetes national audit,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,113141000000103,Informed dissent for diabetes national audit,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,143911000000105,Registration for access to online diabetes self-management application,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,279291000000109,Diabetes type 1 review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,279321000000104,Diabetes type II review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,279521000000108,Referral to community diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306591000000103,Diabetes structured education programme declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306861000000107,Did not attend diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306931000000106,Did not complete diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,334711000000100,Referral to diabetes special interest general practitioner,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,335621000000101,Maternally inherited diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,344061000000104,Referral to children's diabetes nurse specialist,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,385041000000108,Diabetes mellitus with multiple complications,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,385051000000106,Pre-existing diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,494961000000102,Discharged from diabetes shared care programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,512561000000108,Unsuitable for diabetes year of care programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,512581000000104,Declined consent for diabetes year of care programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,713671000000109,Diabetes monitoring administration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,713691000000108,Diabetes clinic administration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,715111000000105,Diabetes screening administration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,716911000000104,Exception reporting - diabetes quality indicators,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,754461000000105,Referral to type I diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,755491000000100,Diabetes structured education programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,764921000000102,Gestational diabetes information leaflet given,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,771571000000102,H/O: secondary diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,787061000000100,Diabetes care plan declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,810961000000103,Diabetes self-management plan review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,811391000000104,Referral to community diabetes service,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,811981000000102,Diabetes self-management plan agreed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,816711000000104,Gestational diabetes mellitus annual review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,819301000000105,Diabetes monitoring injection site check declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,819331000000104,Diabetes monitoring injection site not checked,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,828901000000109,Endocrinology and diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,829521000000104,Provision of diabetes clinical summary,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,837491000000107,High risk of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,841221000000102,Referral to community diabetes clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,850581000000106,High risk of diabetes mellitus annual review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,851501000000106,Diabetes clinical pathway,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,851991000000108,Diabetes quality of life questionnaire score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,857921000000103,Provision of written information about diabetes and driving,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,858301000000107,Pre-diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,863501000000102,QDiabetes risk calculator,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,863521000000106,QDiabetes risk calculator score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,885931000000100,Diabetes structured education programme not available,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,887861000000105,Diabetes Year of Care annual review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,923461000000103,Lifestyle education for diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,927821000000100,Discharge from secondary care diabetes service,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,961931000000109,Diabetes education care plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1024941000000100,NHS Diabetes Prevention Programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025601000000108,Leicester Diabetes Risk Score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1083111000000108,Diabetes monitoring invitation email,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1092721000000109,Signposting to Diabetes UK,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1103691000000102,Diabetes structured education programme offered,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1108731000000100,Referral to online diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,1362341000000103,Diabetes care plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FARICIMAB,Diabetic macular oedema,TA799,diabetes,12275391000119108,Diabetes screening declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190389009,Type 2 diabetes mellitus with ulcer,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199230006,Pre-existing type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237599002,Insulin treated type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422014003,Disorder due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,703138006,Type 2 diabetes mellitus in remission,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,46635009,T1DM - type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,290002008,Unstable type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420868002,Disorder due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,429094000,Dietary advice for type 1 diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,703137001,Type 1 diabetes mellitus in remission,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,2751001,Fibrocalculous pancreatic diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,4855003,Retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,5368009,Drug-induced diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,6143009,Diabetes mellitus education,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,8801005,Secondary diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,9414007,Latent diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,11530004,Brittle diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,11687002,GDM - gestational diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,15771004,Diabetes insipidus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,21584002,Maternal diabetes syndrome,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,25093002,Disorder of eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,43959009,Cataract of eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,44054006,T2DM - diabetes mellitus type 2,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,48951005,Bullous disease due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,49455004,Polyneuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,49817004,Neonatal diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,61165007,Adiuretin-resistant diabetes insipidus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,73211009,Diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,74627003,Complication due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,111552007,Diabetes mellitus without complication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,127012008,Lipodystrophic diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,127013003,Disorder of kidney due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,160274005,No family history of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,160303001,Family history of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,160402005,Family history: Diabetes in pregnancy,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,161445009,History of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,161641009,At increased risk of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170745003,Diet controlled diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170752001,Has seen dietitian - diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170753006,Understands diet - diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170774007,Diabetes: practice program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170775008,Diabetes: shared care program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,171183004,Diabetes mellitus screening,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185753003,Attends diabetes monitoring,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185754009,Diabetes monitoring declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185755005,Diabetes monitoring default,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185756006,Diabetes monitoring first letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185757002,Diabetes monitoring second letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185758007,Diabetes monitoring third letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185759004,Diabetes monitoring verbal invite,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185760009,Diabetes monitoring telephone invite,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185761008,Diabetes monitoring deleted,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190323008,Non-insulin dependent diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190349003,Diabetes mellitus with neuropathy,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190354007,Diabetes with gangrene,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190372001,Insulin-dependent diabetes maturity onset,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190411003,Multiple complications due to malnutrition related diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190416008,Steroid-induced diabetes mellitus without complication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190447002,Steroid-induced diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190484000,Diabetes insipidus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193489006,Iritis due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230572002,Neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230577008,Mononeuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,232020009,Disorder of macula due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237601000,Secondary endocrine diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237619009,Maternally-inherited diabetes and hearing loss,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237632004,Hypoglycemic event due to diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,238982009,Dermopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,267471001,Diabetes + eye manifestation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,268519009,Diabetes mellitus uncontrolled,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,270445003,Diabetes monitoring check done,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,273411009,Diabetes clinic satisfaction questionnaire,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,273412002,Diabetes treatment satisfaction questionnaire,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,273413007,Diabetes wellbeing questionnaire,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,284350006,Diabetes mellitus diet education,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,303059007,Postpancreatectomy diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,304752002,Perceived control of insulin-dependent diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,308505000,Diabetes monitoring call,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309417009,Diabetes dietitian,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309426007,Glomerulopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309593006,Education score - diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309596003,Retinal abnormality - non-diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309598002,Foot abnormality - non-diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309635005,History of admission in last year for diabetes foot problem,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,310425007,Diabetes monitoring invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312856000,Referral to diabetes nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312888008,Attending diabetes clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312912001,Macular oedema due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,313435000,Insulin-dependent diabetes without complication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,313436004,Type II diabetes mellitus without complication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314537004,Optic papillopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,315051004,Diabetes resolved,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,315216001,Diabetes mellitus excluded,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,371087003,Ulcer of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,385805005,Health education - diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,394725008,Diabetes medication review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,395123002,Urine screening test for diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,405749004,Newly diagnosed diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,408290003,Diabetes key contact,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,408392008,Under care of diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,413180006,Pan retinal photocoagulation for diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,413597006,Attended diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,414229005,Family/carer attended diabetes structured education program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,414230000,Family/carer referral to diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,415269004,Referral to diabetes preconception counselling clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,415270003,Referral to diabetes structured education program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,415744000,Transition of diabetes care options discussed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,416554009,Seen in community diabetes specialist clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,416855002,Family history of diabetes mellitus in first degree relative,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,417467000,Discharged from care of diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,419100001,Infection of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420422005,Ketoacidosis due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422183001,Skin ulcer due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422275004,Gangrene due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,428274007,Dietary advice for type II diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,430678008,Family history of diabetes mellitus type 1,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,430679000,Family history of diabetes mellitus type 2,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,439051004,Dietary advice for gestational diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,444094009,History of diabetes mellitus in child of subject,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,472969004,H/O diabetes mellitus type 2,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,472970003,H/O diabetes mellitus type 1,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,473127005,Suspected diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,609561005,MODY - maturity onset diabetes of young,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,698610002,Education about self management of diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,699826006,Lifestyle education regarding risk of diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,700414001,Education about diabetes and driving,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,703040004,Agreeing on diabetes care plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,703136005,Diabetes mellitus in remission,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,704408003,Invitation for diabetes screening,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,714628002,Prediabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,715159005,Referral to diabetes service,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,715759002,Provision of written information about diabetes and hypertension,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,715879000,Provision of written information about diabetes and high cholesterol,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,720685006,Seen by diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,720724003,Has diabetes identity card,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,724136006,Mastopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,735199000,History of diabetes related lower limb amputation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,735985000,Diabetes self management plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,736284000,Diabetes clinical management plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,762489000,Acute complication due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,763782001,Provision of patient held diabetes record declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769244003,Disorder of right macula due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769245002,Disorder of left macula due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,878859007,Self management of diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,897238003,Diabetes management using closed-loop delivery system,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1258872006,Family referred to diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1258873001,Caregiver referred to diabetes structured education program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1268646002,Gestational diabetes mellitus screening,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1296758008,Diabetes insipidus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,113131000000107,Informed consent for diabetes national audit,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,113141000000103,Informed dissent for diabetes national audit,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,143911000000105,Registration for access to online diabetes self-management application,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,279291000000109,Diabetes type 1 review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,279321000000104,Diabetes type II review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,279521000000108,Referral to community diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306591000000103,Diabetes structured education programme declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306861000000107,Did not attend diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306931000000106,Did not complete diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,334711000000100,Referral to diabetes special interest general practitioner,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,335621000000101,Maternally inherited diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,344061000000104,Referral to children's diabetes nurse specialist,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,385041000000108,Diabetes mellitus with multiple complications,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,385051000000106,Pre-existing diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,494961000000102,Discharged from diabetes shared care programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,512561000000108,Unsuitable for diabetes year of care programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,512581000000104,Declined consent for diabetes year of care programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713671000000109,Diabetes monitoring administration,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713691000000108,Diabetes clinic administration,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,715111000000105,Diabetes screening administration,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,716911000000104,Exception reporting - diabetes quality indicators,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,754461000000105,Referral to type I diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,755491000000100,Diabetes structured education programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,764921000000102,Gestational diabetes information leaflet given,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,771571000000102,H/O: secondary diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,787061000000100,Diabetes care plan declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,810961000000103,Diabetes self-management plan review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,811391000000104,Referral to community diabetes service,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,811981000000102,Diabetes self-management plan agreed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816711000000104,Gestational diabetes mellitus annual review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,819301000000105,Diabetes monitoring injection site check declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,819331000000104,Diabetes monitoring injection site not checked,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,828901000000109,Endocrinology and diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,829521000000104,Provision of diabetes clinical summary,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,837491000000107,High risk of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,841221000000102,Referral to community diabetes clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,850581000000106,High risk of diabetes mellitus annual review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,851501000000106,Diabetes clinical pathway,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,851991000000108,Diabetes quality of life questionnaire score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,857921000000103,Provision of written information about diabetes and driving,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,858301000000107,Pre-diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,863501000000102,QDiabetes risk calculator,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,863521000000106,QDiabetes risk calculator score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,885931000000100,Diabetes structured education programme not available,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,887861000000105,Diabetes Year of Care annual review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,923461000000103,Lifestyle education for diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,927821000000100,Discharge from secondary care diabetes service,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,961931000000109,Diabetes education care plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1024941000000100,NHS Diabetes Prevention Programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025601000000108,Leicester Diabetes Risk Score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1083111000000108,Diabetes monitoring invitation email,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1092721000000109,Signposting to Diabetes UK,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1103691000000102,Diabetes structured education programme offered,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1108731000000100,Referral to online diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1362341000000103,Diabetes care plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,12275391000119108,Diabetes screening declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190389009,Type 2 diabetes mellitus with ulcer,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199230006,Pre-existing type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237599002,Insulin treated type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422014003,Disorder due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,703138006,Type 2 diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,46635009,T1DM - type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,290002008,Unstable type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420868002,Disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,429094000,Dietary advice for type 1 diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,703137001,Type 1 diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,2751001,Fibrocalculous pancreatic diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,4855003,Retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,5368009,Drug-induced diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,6143009,Diabetes mellitus education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,8801005,Secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,9414007,Latent diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,11530004,Brittle diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,11687002,GDM - gestational diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,15771004,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,21584002,Maternal diabetes syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,25093002,Disorder of eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,43959009,Cataract of eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,44054006,T2DM - diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,48951005,Bullous disease due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,49455004,Polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,49817004,Neonatal diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,61165007,Adiuretin-resistant diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,73211009,Diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,74627003,Complication due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,111552007,Diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,127012008,Lipodystrophic diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,127013003,Disorder of kidney due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,160274005,No family history of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,160303001,Family history of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,160402005,Family history: Diabetes in pregnancy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,161445009,History of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,161641009,At increased risk of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170745003,Diet controlled diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170752001,Has seen dietitian - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170753006,Understands diet - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170774007,Diabetes: practice program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170775008,Diabetes: shared care program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,171183004,Diabetes mellitus screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185753003,Attends diabetes monitoring,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185754009,Diabetes monitoring declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185755005,Diabetes monitoring default,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185756006,Diabetes monitoring first letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185757002,Diabetes monitoring second letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185758007,Diabetes monitoring third letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185759004,Diabetes monitoring verbal invite,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185760009,Diabetes monitoring telephone invite,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185761008,Diabetes monitoring deleted,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190323008,Non-insulin dependent diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190349003,Diabetes mellitus with neuropathy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190354007,Diabetes with gangrene,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190372001,Insulin-dependent diabetes maturity onset,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190411003,Multiple complications due to malnutrition related diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190416008,Steroid-induced diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190447002,Steroid-induced diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190484000,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193489006,Iritis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230572002,Neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230577008,Mononeuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,232020009,Disorder of macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237601000,Secondary endocrine diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237619009,Maternally-inherited diabetes and hearing loss,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237632004,Hypoglycemic event due to diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,238982009,Dermopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,267471001,Diabetes + eye manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,268519009,Diabetes mellitus uncontrolled,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,270445003,Diabetes monitoring check done,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,273411009,Diabetes clinic satisfaction questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,273412002,Diabetes treatment satisfaction questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,273413007,Diabetes wellbeing questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,284350006,Diabetes mellitus diet education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,303059007,Postpancreatectomy diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,304752002,Perceived control of insulin-dependent diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,308505000,Diabetes monitoring call,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309417009,Diabetes dietitian,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309426007,Glomerulopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309593006,Education score - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309596003,Retinal abnormality - non-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309598002,Foot abnormality - non-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309635005,History of admission in last year for diabetes foot problem,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,310425007,Diabetes monitoring invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312856000,Referral to diabetes nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312888008,Attending diabetes clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312912001,Macular oedema due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,313435000,Insulin-dependent diabetes without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,313436004,Type II diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314537004,Optic papillopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,315051004,Diabetes resolved,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,315216001,Diabetes mellitus excluded,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,371087003,Ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,385805005,Health education - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,394725008,Diabetes medication review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,395123002,Urine screening test for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,405749004,Newly diagnosed diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,408290003,Diabetes key contact,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,408392008,Under care of diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,413180006,Pan retinal photocoagulation for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,413597006,Attended diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,414229005,Family/carer attended diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,414230000,Family/carer referral to diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,415269004,Referral to diabetes preconception counselling clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,415270003,Referral to diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,415744000,Transition of diabetes care options discussed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,416554009,Seen in community diabetes specialist clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,416855002,Family history of diabetes mellitus in first degree relative,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,417467000,Discharged from care of diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,419100001,Infection of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420422005,Ketoacidosis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422183001,Skin ulcer due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422275004,Gangrene due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,428274007,Dietary advice for type II diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,430678008,Family history of diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,430679000,Family history of diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,439051004,Dietary advice for gestational diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,444094009,History of diabetes mellitus in child of subject,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,472969004,H/O diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,472970003,H/O diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,473127005,Suspected diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,609561005,MODY - maturity onset diabetes of young,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,698610002,Education about self management of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,699826006,Lifestyle education regarding risk of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,700414001,Education about diabetes and driving,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,703040004,Agreeing on diabetes care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,703136005,Diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,704408003,Invitation for diabetes screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,714628002,Prediabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,715159005,Referral to diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,715759002,Provision of written information about diabetes and hypertension,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,715879000,Provision of written information about diabetes and high cholesterol,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,720685006,Seen by diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,720724003,Has diabetes identity card,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,724136006,Mastopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,735199000,History of diabetes related lower limb amputation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,735985000,Diabetes self management plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,736284000,Diabetes clinical management plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,762489000,Acute complication due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,763782001,Provision of patient held diabetes record declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769244003,Disorder of right macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769245002,Disorder of left macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,878859007,Self management of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,897238003,Diabetes management using closed-loop delivery system,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1258872006,Family referred to diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1258873001,Caregiver referred to diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1268646002,Gestational diabetes mellitus screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1296758008,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,113131000000107,Informed consent for diabetes national audit,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,113141000000103,Informed dissent for diabetes national audit,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,143911000000105,Registration for access to online diabetes self-management application,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,279291000000109,Diabetes type 1 review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,279321000000104,Diabetes type II review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,279521000000108,Referral to community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306591000000103,Diabetes structured education programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306861000000107,Did not attend diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306931000000106,Did not complete diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,334711000000100,Referral to diabetes special interest general practitioner,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,335621000000101,Maternally inherited diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,344061000000104,Referral to children's diabetes nurse specialist,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,385041000000108,Diabetes mellitus with multiple complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,385051000000106,Pre-existing diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,494961000000102,Discharged from diabetes shared care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,512561000000108,Unsuitable for diabetes year of care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,512581000000104,Declined consent for diabetes year of care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713671000000109,Diabetes monitoring administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713691000000108,Diabetes clinic administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,715111000000105,Diabetes screening administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,716911000000104,Exception reporting - diabetes quality indicators,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,754461000000105,Referral to type I diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,755491000000100,Diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,764921000000102,Gestational diabetes information leaflet given,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,771571000000102,H/O: secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,787061000000100,Diabetes care plan declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,810961000000103,Diabetes self-management plan review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,811391000000104,Referral to community diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,811981000000102,Diabetes self-management plan agreed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816711000000104,Gestational diabetes mellitus annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,819301000000105,Diabetes monitoring injection site check declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,819331000000104,Diabetes monitoring injection site not checked,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,828901000000109,Endocrinology and diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,829521000000104,Provision of diabetes clinical summary,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,837491000000107,High risk of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,841221000000102,Referral to community diabetes clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,850581000000106,High risk of diabetes mellitus annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,851501000000106,Diabetes clinical pathway,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,851991000000108,Diabetes quality of life questionnaire score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,857921000000103,Provision of written information about diabetes and driving,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,858301000000107,Pre-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,863501000000102,QDiabetes risk calculator,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,863521000000106,QDiabetes risk calculator score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,885931000000100,Diabetes structured education programme not available,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,887861000000105,Diabetes Year of Care annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,923461000000103,Lifestyle education for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,927821000000100,Discharge from secondary care diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,961931000000109,Diabetes education care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1024941000000100,NHS Diabetes Prevention Programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025601000000108,Leicester Diabetes Risk Score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1083111000000108,Diabetes monitoring invitation email,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1092721000000109,Signposting to Diabetes UK,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1103691000000102,Diabetes structured education programme offered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1108731000000100,Referral to online diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1362341000000103,Diabetes care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,12275391000119108,Diabetes screening declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190389009,Type 2 diabetes mellitus with ulcer,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199230006,Pre-existing type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237599002,Insulin treated type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422014003,Disorder due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,703138006,Type 2 diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,46635009,T1DM - type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,290002008,Unstable type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420868002,Disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,429094000,Dietary advice for type 1 diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,703137001,Type 1 diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,2751001,Fibrocalculous pancreatic diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,4855003,Retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,5368009,Drug-induced diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,6143009,Diabetes mellitus education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,8801005,Secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,9414007,Latent diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,11530004,Brittle diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,11687002,GDM - gestational diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,15771004,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,21584002,Maternal diabetes syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,25093002,Disorder of eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,43959009,Cataract of eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,44054006,T2DM - diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,48951005,Bullous disease due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,49455004,Polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,49817004,Neonatal diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,61165007,Adiuretin-resistant diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,73211009,Diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,74627003,Complication due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,111552007,Diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,127012008,Lipodystrophic diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,127013003,Disorder of kidney due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,160274005,No family history of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,160303001,Family history of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,160402005,Family history: Diabetes in pregnancy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,161445009,History of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,161641009,At increased risk of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170745003,Diet controlled diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170752001,Has seen dietitian - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170753006,Understands diet - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170774007,Diabetes: practice program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170775008,Diabetes: shared care program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,171183004,Diabetes mellitus screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185753003,Attends diabetes monitoring,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185754009,Diabetes monitoring declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185755005,Diabetes monitoring default,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185756006,Diabetes monitoring first letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185757002,Diabetes monitoring second letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185758007,Diabetes monitoring third letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185759004,Diabetes monitoring verbal invite,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185760009,Diabetes monitoring telephone invite,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185761008,Diabetes monitoring deleted,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190323008,Non-insulin dependent diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190349003,Diabetes mellitus with neuropathy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190354007,Diabetes with gangrene,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190372001,Insulin-dependent diabetes maturity onset,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190411003,Multiple complications due to malnutrition related diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190416008,Steroid-induced diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190447002,Steroid-induced diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190484000,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193489006,Iritis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230572002,Neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230577008,Mononeuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,232020009,Disorder of macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237601000,Secondary endocrine diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237619009,Maternally-inherited diabetes and hearing loss,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237632004,Hypoglycemic event due to diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,238982009,Dermopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,267471001,Diabetes + eye manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,268519009,Diabetes mellitus uncontrolled,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,270445003,Diabetes monitoring check done,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,273411009,Diabetes clinic satisfaction questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,273412002,Diabetes treatment satisfaction questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,273413007,Diabetes wellbeing questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,284350006,Diabetes mellitus diet education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,303059007,Postpancreatectomy diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,304752002,Perceived control of insulin-dependent diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,308505000,Diabetes monitoring call,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309417009,Diabetes dietitian,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309426007,Glomerulopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309593006,Education score - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309596003,Retinal abnormality - non-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309598002,Foot abnormality - non-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309635005,History of admission in last year for diabetes foot problem,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,310425007,Diabetes monitoring invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312856000,Referral to diabetes nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312888008,Attending diabetes clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312912001,Macular oedema due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,313435000,Insulin-dependent diabetes without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,313436004,Type II diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314537004,Optic papillopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,315051004,Diabetes resolved,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,315216001,Diabetes mellitus excluded,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,371087003,Ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,385805005,Health education - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,394725008,Diabetes medication review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,395123002,Urine screening test for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,405749004,Newly diagnosed diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,408290003,Diabetes key contact,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,408392008,Under care of diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,413180006,Pan retinal photocoagulation for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,413597006,Attended diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,414229005,Family/carer attended diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,414230000,Family/carer referral to diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,415269004,Referral to diabetes preconception counselling clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,415270003,Referral to diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,415744000,Transition of diabetes care options discussed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,416554009,Seen in community diabetes specialist clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,416855002,Family history of diabetes mellitus in first degree relative,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,417467000,Discharged from care of diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,419100001,Infection of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420422005,Ketoacidosis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422183001,Skin ulcer due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422275004,Gangrene due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,428274007,Dietary advice for type II diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,430678008,Family history of diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,430679000,Family history of diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,439051004,Dietary advice for gestational diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,444094009,History of diabetes mellitus in child of subject,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,472969004,H/O diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,472970003,H/O diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,473127005,Suspected diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,609561005,MODY - maturity onset diabetes of young,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,698610002,Education about self management of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,699826006,Lifestyle education regarding risk of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,700414001,Education about diabetes and driving,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,703040004,Agreeing on diabetes care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,703136005,Diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,704408003,Invitation for diabetes screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,714628002,Prediabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,715159005,Referral to diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,715759002,Provision of written information about diabetes and hypertension,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,715879000,Provision of written information about diabetes and high cholesterol,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,720685006,Seen by diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,720724003,Has diabetes identity card,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,724136006,Mastopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,735199000,History of diabetes related lower limb amputation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,735985000,Diabetes self management plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,736284000,Diabetes clinical management plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,762489000,Acute complication due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,763782001,Provision of patient held diabetes record declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769244003,Disorder of right macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769245002,Disorder of left macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,878859007,Self management of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,897238003,Diabetes management using closed-loop delivery system,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1258872006,Family referred to diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1258873001,Caregiver referred to diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1268646002,Gestational diabetes mellitus screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1296758008,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,113131000000107,Informed consent for diabetes national audit,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,113141000000103,Informed dissent for diabetes national audit,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,143911000000105,Registration for access to online diabetes self-management application,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,279291000000109,Diabetes type 1 review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,279321000000104,Diabetes type II review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,279521000000108,Referral to community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306591000000103,Diabetes structured education programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306861000000107,Did not attend diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306931000000106,Did not complete diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,334711000000100,Referral to diabetes special interest general practitioner,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,335621000000101,Maternally inherited diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,344061000000104,Referral to children's diabetes nurse specialist,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,385041000000108,Diabetes mellitus with multiple complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,385051000000106,Pre-existing diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,494961000000102,Discharged from diabetes shared care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,512561000000108,Unsuitable for diabetes year of care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,512581000000104,Declined consent for diabetes year of care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713671000000109,Diabetes monitoring administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713691000000108,Diabetes clinic administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,715111000000105,Diabetes screening administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,716911000000104,Exception reporting - diabetes quality indicators,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,754461000000105,Referral to type I diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,755491000000100,Diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,764921000000102,Gestational diabetes information leaflet given,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,771571000000102,H/O: secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,787061000000100,Diabetes care plan declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,810961000000103,Diabetes self-management plan review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,811391000000104,Referral to community diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,811981000000102,Diabetes self-management plan agreed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816711000000104,Gestational diabetes mellitus annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,819301000000105,Diabetes monitoring injection site check declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,819331000000104,Diabetes monitoring injection site not checked,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,828901000000109,Endocrinology and diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,829521000000104,Provision of diabetes clinical summary,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,837491000000107,High risk of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,841221000000102,Referral to community diabetes clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,850581000000106,High risk of diabetes mellitus annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,851501000000106,Diabetes clinical pathway,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,851991000000108,Diabetes quality of life questionnaire score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,857921000000103,Provision of written information about diabetes and driving,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,858301000000107,Pre-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,863501000000102,QDiabetes risk calculator,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,863521000000106,QDiabetes risk calculator score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,885931000000100,Diabetes structured education programme not available,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,887861000000105,Diabetes Year of Care annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,923461000000103,Lifestyle education for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,927821000000100,Discharge from secondary care diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,961931000000109,Diabetes education care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1024941000000100,NHS Diabetes Prevention Programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025601000000108,Leicester Diabetes Risk Score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1083111000000108,Diabetes monitoring invitation email,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1092721000000109,Signposting to Diabetes UK,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1103691000000102,Diabetes structured education programme offered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1108731000000100,Referral to online diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1362341000000103,Diabetes care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY +RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,12275391000119108,Diabetes screening declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY diff --git a/pathways_app/__init__.py b/pathways_app/__init__.py index d165788..75a8315 100644 --- a/pathways_app/__init__.py +++ b/pathways_app/__init__.py @@ -1,4 +1,4 @@ -# Re-export app from app_v2 for the new UI redesign -from pathways_app.app_v2 import app +# Re-export app from pathways_app +from pathways_app.pathways_app import app __all__ = ["app"] diff --git a/pathways_app/app_v2.py b/pathways_app/app_v2.py deleted file mode 100644 index d6fa085..0000000 --- a/pathways_app/app_v2.py +++ /dev/null @@ -1,1988 +0,0 @@ -""" -HCD Analysis v2 - Redesigned Reflex Application. - -Single-page dashboard with reactive filtering and real-time chart updates. -Design reference: DESIGN_SYSTEM.md -""" - -from datetime import datetime, timedelta -from pathlib import Path -from typing import Any - -import plotly.graph_objects as go -import reflex as rx - -from pathways_app.styles import ( - Colors, - Typography, - Spacing, - Radii, - Shadows, - Transitions, - TOP_BAR_HEIGHT, - PAGE_MAX_WIDTH, - PAGE_PADDING, - card_style, - input_style, - text_h1, - text_h3, - text_caption, - button_ghost_style, - kpi_card_style, - kpi_value_style, - kpi_label_style, -) - - -# ============================================================================= -# State -# ============================================================================= - -class AppState(rx.State): - """ - Application state for HCD Analysis v2. - - This is a minimal placeholder state for the app skeleton. - Will be expanded in Phase 3 with full filter state and data management. - """ - - # ========================================================================= - # Data State Variables - # ========================================================================= - - # Data loading status - data_loaded: bool = False - total_records: int = 0 - chart_loading: bool = False - error_message: str = "" - - # Data freshness tracking - last_updated: str = "" # ISO format timestamp of last data load - - # Raw data storage - list of dicts (Reflex-friendly) - # Each dict represents a patient record with keys like: - # UPID, Drug Name, Intervention Date, Price Actual, Directory, etc. - raw_data: list[dict[str, Any]] = [] - - # Latest date in dataset (detected on load, used for "to" date defaults) - latest_date_in_data: str = "" - - # ========================================================================= - # UI State Variables - # ========================================================================= - - # Placeholder for current chart type (for top bar tabs) - current_chart: str = "icicle" - - # ========================================================================= - # Filter State Variables - # ========================================================================= - - # Filter toggle state - initiated_filter_enabled: bool = False - last_seen_filter_enabled: bool = True - - # Date filter values (ISO format strings YYYY-MM-DD) - # Initiated filter: Defaults empty (filter is OFF by default) - initiated_from_date: str = "" - initiated_to_date: str = "" - - # Last Seen filter: Defaults to last 6 months (filter is ON by default) - # These will be updated on data load to use actual latest date - last_seen_from_date: str = (datetime.now() - timedelta(days=180)).strftime("%Y-%m-%d") - last_seen_to_date: str = datetime.now().strftime("%Y-%m-%d") - - # Available options for dropdowns (populated from data in Phase 3) - available_drugs: list[str] = ["Drug A", "Drug B", "Drug C", "Drug D", "Drug E"] - available_indications: list[str] = ["Indication 1", "Indication 2", "Indication 3"] - available_directorates: list[str] = ["Medical", "Surgical", "Oncology", "Rheumatology"] - - # Selected items (empty = all) - selected_drugs: list[str] = [] - selected_indications: list[str] = [] - selected_directorates: list[str] = [] - - # Search text for dropdowns - drug_search: str = "" - indication_search: str = "" - directorate_search: str = "" - - # Dropdown visibility state - drug_dropdown_open: bool = False - indication_dropdown_open: bool = False - directorate_dropdown_open: bool = False - - # Event handlers for filter toggles - def toggle_initiated_filter(self): - """Toggle initiated date filter on/off.""" - self.initiated_filter_enabled = not self.initiated_filter_enabled - if self.data_loaded: - self.apply_filters() - - def toggle_last_seen_filter(self): - """Toggle last seen date filter on/off.""" - self.last_seen_filter_enabled = not self.last_seen_filter_enabled - if self.data_loaded: - self.apply_filters() - - # Event handlers for date changes - def set_initiated_from(self, value: str): - """Set initiated from date.""" - self.initiated_from_date = value - if self.data_loaded: - self.apply_filters() - - def set_initiated_to(self, value: str): - """Set initiated to date.""" - self.initiated_to_date = value - if self.data_loaded: - self.apply_filters() - - def set_last_seen_from(self, value: str): - """Set last seen from date.""" - self.last_seen_from_date = value - if self.data_loaded: - self.apply_filters() - - def set_last_seen_to(self, value: str): - """Set last seen to date.""" - self.last_seen_to_date = value - if self.data_loaded: - self.apply_filters() - - # Event handlers for search - def set_drug_search(self, value: str): - """Update drug search text.""" - self.drug_search = value - - def set_indication_search(self, value: str): - """Update indication search text.""" - self.indication_search = value - - def set_directorate_search(self, value: str): - """Update directorate search text.""" - self.directorate_search = value - - # Event handlers for dropdown visibility - def toggle_drug_dropdown(self): - """Toggle drug dropdown visibility.""" - self.drug_dropdown_open = not self.drug_dropdown_open - # Close other dropdowns - self.indication_dropdown_open = False - self.directorate_dropdown_open = False - - def toggle_indication_dropdown(self): - """Toggle indication dropdown visibility.""" - self.indication_dropdown_open = not self.indication_dropdown_open - # Close other dropdowns - self.drug_dropdown_open = False - self.directorate_dropdown_open = False - - def toggle_directorate_dropdown(self): - """Toggle directorate dropdown visibility.""" - self.directorate_dropdown_open = not self.directorate_dropdown_open - # Close other dropdowns - self.drug_dropdown_open = False - self.indication_dropdown_open = False - - def close_all_dropdowns(self): - """Close all dropdowns.""" - self.drug_dropdown_open = False - self.indication_dropdown_open = False - self.directorate_dropdown_open = False - - # Event handlers for item selection - def toggle_drug(self, drug: str): - """Toggle a drug selection.""" - if drug in self.selected_drugs: - self.selected_drugs = [d for d in self.selected_drugs if d != drug] - else: - self.selected_drugs = self.selected_drugs + [drug] - if self.data_loaded: - self.apply_filters() - - def toggle_indication(self, indication: str): - """Toggle an indication selection.""" - if indication in self.selected_indications: - self.selected_indications = [i for i in self.selected_indications if i != indication] - else: - self.selected_indications = self.selected_indications + [indication] - # Note: Indication filter not yet implemented at database level - # Will be added when indication-based filtering is required - - def toggle_directorate(self, directorate: str): - """Toggle a directorate selection.""" - if directorate in self.selected_directorates: - self.selected_directorates = [d for d in self.selected_directorates if d != directorate] - else: - self.selected_directorates = self.selected_directorates + [directorate] - if self.data_loaded: - self.apply_filters() - - # Select/clear all handlers - def select_all_drugs(self): - """Select all available drugs.""" - self.selected_drugs = self.available_drugs.copy() - if self.data_loaded: - self.apply_filters() - - def clear_all_drugs(self): - """Clear all drug selections.""" - self.selected_drugs = [] - if self.data_loaded: - self.apply_filters() - - def select_all_indications(self): - """Select all available indications.""" - self.selected_indications = self.available_indications.copy() - # Note: Indication filter not yet implemented at database level - - def clear_all_indications(self): - """Clear all indication selections.""" - self.selected_indications = [] - # Note: Indication filter not yet implemented at database level - - def select_all_directorates(self): - """Select all available directorates.""" - self.selected_directorates = self.available_directorates.copy() - if self.data_loaded: - self.apply_filters() - - def clear_all_directorates(self): - """Clear all directorate selections.""" - self.selected_directorates = [] - if self.data_loaded: - self.apply_filters() - - # Computed vars for filtered options based on search - @rx.var - def filtered_drugs(self) -> list[str]: - """Return drugs filtered by search text.""" - if not self.drug_search: - return self.available_drugs - search_lower = self.drug_search.lower() - return [d for d in self.available_drugs if search_lower in d.lower()] - - @rx.var - def filtered_indications(self) -> list[str]: - """Return indications filtered by search text.""" - if not self.indication_search: - return self.available_indications - search_lower = self.indication_search.lower() - return [i for i in self.available_indications if search_lower in i.lower()] - - @rx.var - def filtered_directorates(self) -> list[str]: - """Return directorates filtered by search text.""" - if not self.directorate_search: - return self.available_directorates - search_lower = self.directorate_search.lower() - return [d for d in self.available_directorates if search_lower in d.lower()] - - # Computed vars for selection counts - @rx.var - def drug_selection_text(self) -> str: - """Display text for drug selection count.""" - count = len(self.selected_drugs) - total = len(self.available_drugs) - if count == 0: - return f"All {total} drugs" - return f"{count} of {total} selected" - - @rx.var - def indication_selection_text(self) -> str: - """Display text for indication selection count.""" - count = len(self.selected_indications) - total = len(self.available_indications) - if count == 0: - return f"All {total} indications" - return f"{count} of {total} selected" - - @rx.var - def directorate_selection_text(self) -> str: - """Display text for directorate selection count.""" - count = len(self.selected_directorates) - total = len(self.available_directorates) - if count == 0: - return f"All {total} directorates" - return f"{count} of {total} selected" - - # ========================================================================= - # KPI State Variables - # ========================================================================= - - # Placeholder KPI values (will be computed from filtered data in Phase 3) - # For now, these are static placeholders that demonstrate reactivity - unique_patients: int = 0 - total_drugs: int = 0 - total_cost: float = 0.0 - indication_match_rate: float = 0.0 - - # Computed KPI display values - @rx.var - def unique_patients_display(self) -> str: - """Format unique patients count for display.""" - if self.unique_patients == 0: - return "—" - return f"{self.unique_patients:,}" - - @rx.var - def total_drugs_display(self) -> str: - """Format total drugs count for display.""" - if self.total_drugs == 0: - return "—" - return f"{self.total_drugs:,}" - - @rx.var - def total_cost_display(self) -> str: - """Format total cost for display.""" - if self.total_cost == 0.0: - return "—" - # Format as £X.XM or £X.XK depending on magnitude - if self.total_cost >= 1_000_000: - return f"£{self.total_cost / 1_000_000:.1f}M" - if self.total_cost >= 1_000: - return f"£{self.total_cost / 1_000:.1f}K" - return f"£{self.total_cost:,.0f}" - - @rx.var - def match_rate_display(self) -> str: - """Format indication match rate for display.""" - if self.indication_match_rate == 0.0: - return "—" - return f"{self.indication_match_rate:.0f}%" - - @rx.var - def last_updated_display(self) -> str: - """Format last updated timestamp for display in top bar.""" - if not self.last_updated: - return "Never" - try: - # Parse ISO format timestamp - dt = datetime.fromisoformat(self.last_updated) - now = datetime.now() - diff = now - dt - - if diff.days == 0: - if diff.seconds < 60: - return "Just now" - if diff.seconds < 3600: - mins = diff.seconds // 60 - return f"{mins}m ago" - hours = diff.seconds // 3600 - return f"{hours}h ago" - if diff.days == 1: - return "Yesterday" - if diff.days < 7: - return f"{diff.days}d ago" - return dt.strftime("%d %b %Y") - except (ValueError, TypeError): - return "Unknown" - - # ========================================================================= - # Filter Logic Methods - # ========================================================================= - - def apply_filters(self): - """ - Apply current filter state to data and update KPI values. - - This method queries the SQLite database with the current filter settings: - - Initiated date filter: filters patients whose FIRST intervention date is within range - - Last Seen date filter: filters patients whose LAST intervention date is within range - - Drug filter: filters by selected drugs (empty = all) - - Directorate filter: filters by selected directorates (empty = all) - - Note: Indication filter is not implemented at the database level since indications - are derived from drug mappings, not stored directly in fact_interventions. - - Updates: unique_patients, total_drugs, total_cost, and filtered_record_count - """ - import sqlite3 - - db_path = Path("data/pathways.db") - - if not db_path.exists(): - self.error_message = "Unable to connect to database. Please ensure data has been loaded." - return - - try: - conn = sqlite3.connect(str(db_path)) - cursor = conn.cursor() - - # Build the filter query dynamically - # We use a CTE to compute first_seen and last_seen dates per patient, - # then filter based on those dates if date filters are enabled - - where_clauses = [] - params = [] - - # Drug filter (if any drugs selected) - if self.selected_drugs: - placeholders = ",".join("?" * len(self.selected_drugs)) - where_clauses.append(f"drug_name_std IN ({placeholders})") - params.extend(self.selected_drugs) - - # Directorate filter (if any directorates selected) - if self.selected_directorates: - placeholders = ",".join("?" * len(self.selected_directorates)) - where_clauses.append(f"directory IN ({placeholders})") - params.extend(self.selected_directorates) - - # Build WHERE clause for base data filtering - base_where = "" - if where_clauses: - base_where = "WHERE " + " AND ".join(where_clauses) - - # Date filter logic: - # - "Initiated" filters patients whose FIRST intervention is within the date range - # - "Last Seen" filters patients whose LAST intervention is within the date range - # We need to use a subquery to compute patient-level date ranges - - having_clauses = [] - having_params = [] - - # Initiated filter (when enabled) - if self.initiated_filter_enabled and self.initiated_from_date: - having_clauses.append("first_seen_date >= ?") - having_params.append(self.initiated_from_date) - if self.initiated_filter_enabled and self.initiated_to_date: - having_clauses.append("first_seen_date <= ?") - having_params.append(self.initiated_to_date) - - # Last Seen filter (when enabled) - if self.last_seen_filter_enabled and self.last_seen_from_date: - having_clauses.append("last_seen_date >= ?") - having_params.append(self.last_seen_from_date) - if self.last_seen_filter_enabled and self.last_seen_to_date: - having_clauses.append("last_seen_date <= ?") - having_params.append(self.last_seen_to_date) - - having_clause = "" - if having_clauses: - having_clause = "HAVING " + " AND ".join(having_clauses) - - # Query to get filtered patient UPIDs - # This computes per-patient first/last seen dates and filters accordingly - patient_filter_query = f""" - WITH patient_dates AS ( - SELECT - upid, - MIN(intervention_date) as first_seen_date, - MAX(intervention_date) as last_seen_date - FROM fact_interventions - {base_where} - GROUP BY upid - {having_clause} - ) - SELECT upid FROM patient_dates - """ - - # Now get KPI values for filtered patients - kpi_query = f""" - WITH filtered_patients AS ( - {patient_filter_query} - ) - SELECT - COUNT(DISTINCT f.upid) as unique_patients, - COUNT(DISTINCT f.drug_name_std) as unique_drugs, - COALESCE(SUM(f.price_actual), 0) as total_cost, - COUNT(*) as record_count - FROM fact_interventions f - INNER JOIN filtered_patients fp ON f.upid = fp.upid - {base_where.replace('WHERE', 'AND') if base_where else ''} - """ - - # Combine all params: base params for CTE, having params, then base params again for final join - all_params = params + having_params - if where_clauses: - all_params.extend(params) # For the AND conditions in the final query - - cursor.execute(kpi_query, all_params) - result = cursor.fetchone() - - if result: - self.unique_patients = result[0] or 0 - self.total_drugs = result[1] or 0 - self.total_cost = float(result[2]) if result[2] else 0.0 - # Note: filtered_record_count could be stored if needed - - conn.close() - self.error_message = "" - - # Update chart data with new filtered results - self.prepare_chart_data() - - except sqlite3.Error as e: - self.error_message = f"Unable to filter data. Database error: {str(e)}" - except Exception as e: - self.error_message = f"An unexpected error occurred while filtering. Details: {str(e)}" - - # ========================================================================= - # Data Loading Methods - # ========================================================================= - - def load_data(self): - """ - Load data from SQLite database on app initialization. - - This method: - 1. Connects to the SQLite database (data/pathways.db) - 2. Loads available drugs, indications, directorates from actual data - 3. Detects the latest date in the dataset for "to" date defaults - 4. Updates total_records, last_updated, and data_loaded state - """ - import sqlite3 - - db_path = Path("data/pathways.db") - - if not db_path.exists(): - self.error_message = "Database not found. Please ensure the data has been loaded (data/pathways.db)." - return - - try: - conn = sqlite3.connect(str(db_path)) - cursor = conn.cursor() - - # Get total records - cursor.execute("SELECT COUNT(*) FROM fact_interventions") - self.total_records = cursor.fetchone()[0] - - if self.total_records == 0: - self.error_message = "The database is empty. No patient records found." - conn.close() - return - - # Get available drugs (distinct, sorted) - cursor.execute(""" - SELECT DISTINCT drug_name_std - FROM fact_interventions - WHERE drug_name_std IS NOT NULL AND drug_name_std != '' - ORDER BY drug_name_std - """) - self.available_drugs = [row[0] for row in cursor.fetchall()] - - # Get available directories (distinct, sorted) - cursor.execute(""" - SELECT DISTINCT directory - FROM fact_interventions - WHERE directory IS NOT NULL AND directory != '' - ORDER BY directory - """) - self.available_directorates = [row[0] for row in cursor.fetchall()] - - # Get available indications from ref_drug_indication_clusters - cursor.execute(""" - SELECT DISTINCT indication - FROM ref_drug_indication_clusters - WHERE indication IS NOT NULL AND indication != '' - ORDER BY indication - """) - self.available_indications = [row[0] for row in cursor.fetchall()] - - # If no indications in reference table, use placeholder - if not self.available_indications: - self.available_indications = ["(No indications available)"] - - # Get date range from data - cursor.execute(""" - SELECT MIN(intervention_date), MAX(intervention_date) - FROM fact_interventions - """) - date_range = cursor.fetchone() - min_date, max_date = date_range - - # Update latest_date_in_data and set "to" date defaults - if max_date: - self.latest_date_in_data = max_date - self.last_seen_to_date = max_date - self.initiated_to_date = max_date - - # Set "from" date for last_seen filter (6 months before max_date) - max_dt = datetime.strptime(max_date, "%Y-%m-%d") - six_months_ago = max_dt - timedelta(days=180) - self.last_seen_from_date = six_months_ago.strftime("%Y-%m-%d") - - # Get unique patient count for KPIs - cursor.execute("SELECT COUNT(DISTINCT upid) FROM fact_interventions") - self.unique_patients = cursor.fetchone()[0] - - # Get unique drug count - self.total_drugs = len(self.available_drugs) - - # Get total cost - cursor.execute("SELECT SUM(price_actual) FROM fact_interventions") - total_cost_result = cursor.fetchone()[0] - self.total_cost = float(total_cost_result) if total_cost_result else 0.0 - - conn.close() - - # Set data_loaded and last_updated - self.data_loaded = True - self.last_updated = datetime.now().isoformat() - self.error_message = "" - - # Apply initial filters to compute KPI values - self.apply_filters() - - except sqlite3.Error as e: - self.error_message = f"Unable to load data. Database error: {str(e)}" - self.data_loaded = False - except Exception as e: - self.error_message = f"Failed to load data. Please check the database file. Details: {str(e)}" - self.data_loaded = False - - # ========================================================================= - # Chart Data Preparation Methods - # ========================================================================= - - # Chart data stored as list of dicts for Reflex serialization - # Structure: [{"parents": str, "ids": str, "labels": str, "value": int, "cost": float, "colour": float}, ...] - chart_data: list[dict[str, Any]] = [] - chart_title: str = "" - - def prepare_chart_data(self): - """ - Prepare hierarchical data for Plotly icicle chart. - - This method queries the filtered patient data and transforms it into - a hierarchical structure: Root → Trust → Directory → Drug - - The chart data is stored in self.chart_data as a list of dicts with: - - parents: Parent node identifier - - ids: Unique node identifier (hierarchical path) - - labels: Display label - - value: Patient count - - cost: Total cost - - colour: Color value (proportion of parent) - - Updates: chart_data, chart_title, chart_loading - """ - import sqlite3 - - db_path = Path("data/pathways.db") - - if not db_path.exists(): - self.error_message = "Unable to generate chart. Database not found." - self.chart_data = [] - return - - self.chart_loading = True - - try: - conn = sqlite3.connect(str(db_path)) - cursor = conn.cursor() - - # Build WHERE clause for filters - where_clauses = [] - params = [] - - # Drug filter (if any drugs selected) - if self.selected_drugs: - placeholders = ",".join("?" * len(self.selected_drugs)) - where_clauses.append(f"drug_name_std IN ({placeholders})") - params.extend(self.selected_drugs) - - # Directorate filter (if any directorates selected) - if self.selected_directorates: - placeholders = ",".join("?" * len(self.selected_directorates)) - where_clauses.append(f"directory IN ({placeholders})") - params.extend(self.selected_directorates) - - base_where = "" - if where_clauses: - base_where = "WHERE " + " AND ".join(where_clauses) - - # Build date filter HAVING clauses for patient-level filtering - having_clauses = [] - having_params = [] - - if self.initiated_filter_enabled and self.initiated_from_date: - having_clauses.append("first_seen >= ?") - having_params.append(self.initiated_from_date) - if self.initiated_filter_enabled and self.initiated_to_date: - having_clauses.append("first_seen <= ?") - having_params.append(self.initiated_to_date) - - if self.last_seen_filter_enabled and self.last_seen_from_date: - having_clauses.append("last_seen >= ?") - having_params.append(self.last_seen_from_date) - if self.last_seen_filter_enabled and self.last_seen_to_date: - having_clauses.append("last_seen <= ?") - having_params.append(self.last_seen_to_date) - - having_clause = "" - if having_clauses: - having_clause = "HAVING " + " AND ".join(having_clauses) - - # Query to get aggregated data by Trust -> Directory -> Drug - # fact_interventions already has org_name, use it directly - chart_query = f""" - WITH filtered_patients AS ( - SELECT upid - FROM ( - SELECT - upid, - MIN(intervention_date) as first_seen, - MAX(intervention_date) as last_seen - FROM fact_interventions - {base_where} - GROUP BY upid - {having_clause} - ) - ), - patient_records AS ( - SELECT - f.upid, - COALESCE(f.org_name, f.provider_code) as trust_name, - f.directory, - f.drug_name_std, - f.price_actual - FROM fact_interventions f - INNER JOIN filtered_patients fp ON f.upid = fp.upid - {base_where.replace('WHERE', 'AND') if base_where else ''} - ) - SELECT - trust_name, - directory, - drug_name_std, - COUNT(DISTINCT upid) as patient_count, - COALESCE(SUM(price_actual), 0) as total_cost - FROM patient_records - GROUP BY trust_name, directory, drug_name_std - ORDER BY trust_name, directory, drug_name_std - """ - - all_params = params + having_params - if where_clauses: - all_params.extend(params) - - cursor.execute(chart_query, all_params) - rows = cursor.fetchall() - - conn.close() - - # Build hierarchical chart data - chart_data = [] - hierarchy_totals = {} # Track totals for calculating color values - - # Root node - root_id = "N&WICS" - chart_data.append({ - "parents": "", - "ids": root_id, - "labels": "Norfolk & Waveney ICS", - "value": 0, - "cost": 0.0, - "colour": 1.0, - }) - - # Process rows to build hierarchy - trust_totals = {} - directory_totals = {} - drug_data = [] - - for row in rows: - trust_name, directory, drug_name, patient_count, cost = row - - if not trust_name or not directory or not drug_name: - continue - - # Trust level - trust_id = f"{root_id} - {trust_name}" - if trust_id not in trust_totals: - trust_totals[trust_id] = {"value": 0, "cost": 0.0, "label": trust_name} - trust_totals[trust_id]["value"] += patient_count - trust_totals[trust_id]["cost"] += cost - - # Directory level - dir_id = f"{trust_id} - {directory}" - if dir_id not in directory_totals: - directory_totals[dir_id] = { - "value": 0, - "cost": 0.0, - "label": directory, - "parent": trust_id, - } - directory_totals[dir_id]["value"] += patient_count - directory_totals[dir_id]["cost"] += cost - - # Drug level (leaf) - drug_id = f"{dir_id} - {drug_name}" - drug_data.append({ - "ids": drug_id, - "labels": drug_name, - "parent": dir_id, - "value": patient_count, - "cost": float(cost), - }) - - # Calculate root total - root_total = sum(t["value"] for t in trust_totals.values()) - root_cost = sum(t["cost"] for t in trust_totals.values()) - chart_data[0]["value"] = root_total - chart_data[0]["cost"] = root_cost - - # Add trust nodes with color proportions - for trust_id, data in trust_totals.items(): - colour = data["value"] / root_total if root_total > 0 else 0 - chart_data.append({ - "parents": root_id, - "ids": trust_id, - "labels": data["label"], - "value": data["value"], - "cost": data["cost"], - "colour": colour, - }) - - # Add directory nodes with color proportions - for dir_id, data in directory_totals.items(): - parent_total = trust_totals[data["parent"]]["value"] - colour = data["value"] / parent_total if parent_total > 0 else 0 - chart_data.append({ - "parents": data["parent"], - "ids": dir_id, - "labels": data["label"], - "value": data["value"], - "cost": data["cost"], - "colour": colour, - }) - - # Add drug nodes with color proportions - for drug in drug_data: - parent_dir = drug["parent"] - parent_total = directory_totals[parent_dir]["value"] - colour = drug["value"] / parent_total if parent_total > 0 else 0 - chart_data.append({ - "parents": parent_dir, - "ids": drug["ids"], - "labels": drug["labels"], - "value": drug["value"], - "cost": drug["cost"], - "colour": colour, - }) - - self.chart_data = chart_data - self.chart_title = self._generate_chart_title() - self.chart_loading = False - self.error_message = "" - - except sqlite3.Error as e: - self.error_message = f"Unable to generate chart. Database error: {str(e)}" - self.chart_data = [] - self.chart_loading = False - except Exception as e: - self.error_message = f"Unable to generate chart. Details: {str(e)}" - self.chart_data = [] - self.chart_loading = False - - def _generate_chart_title(self) -> str: - """Generate chart title based on current filter state.""" - parts = [] - - # Date range info - if self.last_seen_filter_enabled: - parts.append(f"Last seen: {self.last_seen_from_date} to {self.last_seen_to_date}") - elif self.initiated_filter_enabled: - parts.append(f"Initiated: {self.initiated_from_date} to {self.initiated_to_date}") - - # Drug selection info - if self.selected_drugs: - if len(self.selected_drugs) <= 3: - parts.append(", ".join(self.selected_drugs)) - else: - parts.append(f"{len(self.selected_drugs)} drugs selected") - - # Directorate selection info - if self.selected_directorates: - if len(self.selected_directorates) <= 2: - parts.append(", ".join(self.selected_directorates)) - else: - parts.append(f"{len(self.selected_directorates)} directorates") - - if parts: - return " | ".join(parts) - return "All Patients" - - # ========================================================================= - # Plotly Chart Generation - # ========================================================================= - - @rx.var - def icicle_figure(self) -> go.Figure: - """ - Generate Plotly icicle chart from chart_data. - - This computed property creates a go.Figure with the hierarchical icicle chart - using data from prepare_chart_data(). The chart displays patient pathways: - Root → Trust → Directory → Drug - - Colors use a custom NHS-inspired blue gradient colorscale. - Hover displays patient count, cost, and percentage of parent. - - Returns: - Plotly Figure object ready for rx.plotly() component - """ - # Return empty figure if no data - if not self.chart_data: - return go.Figure() - - # Extract lists from chart_data - parents = [d.get("parents", "") for d in self.chart_data] - ids = [d.get("ids", "") for d in self.chart_data] - labels = [d.get("labels", "") for d in self.chart_data] - values = [d.get("value", 0) for d in self.chart_data] - costs = [d.get("cost", 0.0) for d in self.chart_data] - colours = [d.get("colour", 0.0) for d in self.chart_data] - - # NHS-inspired blue gradient colorscale (from design system) - # Heritage Blue → Primary Blue → Vibrant Blue → Sky Blue → Pale Blue - colorscale = [ - [0.0, "#003087"], # Heritage Blue - [0.25, "#0066CC"], # Primary Blue - [0.5, "#1E88E5"], # Vibrant Blue - [0.75, "#4FC3F7"], # Sky Blue - [1.0, "#E3F2FD"], # Pale Blue - ] - - # Create the icicle chart - fig = go.Figure( - go.Icicle( - labels=labels, - ids=ids, - parents=parents, - values=values, - branchvalues="total", - marker=dict( - colors=colours, - colorscale=colorscale, - line=dict(width=1, color="#FFFFFF"), - ), - maxdepth=3, - # Custom data for hover template - customdata=list(zip(values, colours, costs)), - # Text shown on chart segments - texttemplate="%{label}
%{value:,} patients", - # Hover text with full details - hovertemplate=( - "%{label}
" - "Patients: %{customdata[0]:,} (%{customdata[1]:.1%} of parent)
" - "Total Cost: £%{customdata[2]:,.0f}" - "" - ), - textfont=dict( - family="Inter, system-ui, sans-serif", - size=12, - ), - ) - ) - - # Configure layout - fig.update_layout( - title=dict( - text=f"Patient Pathways — {self.chart_title}", - font=dict( - family="Inter, system-ui, sans-serif", - size=18, - color="#1E293B", # Slate 900 - ), - x=0.5, - xanchor="center", - ), - margin=dict(t=60, l=10, r=10, b=30), - hoverlabel=dict( - bgcolor="#FFFFFF", - bordercolor="#CBD5E1", # Slate 300 - font=dict( - family="Inter, system-ui, sans-serif", - size=13, - color="#1E293B", # Slate 900 - ), - ), - paper_bgcolor="rgba(0,0,0,0)", # Transparent background - plot_bgcolor="rgba(0,0,0,0)", - # Responsive sizing - height set but width auto - height=600, - # Enable interactivity - clickmode="event+select", - ) - - # Disable sort to maintain hierarchy order - fig.update_traces(sort=False) - - return fig - - -# ============================================================================= -# Layout Components -# ============================================================================= - -def date_range_picker( - label: str, - enabled: rx.Var[bool], - toggle_handler, - from_value: rx.Var[str], - to_value: rx.Var[str], - on_from_change, - on_to_change, -) -> rx.Component: - """ - Date range picker with enable/disable checkbox. - - Uses debounced inputs (300ms) to prevent excessive filter updates. - - Args: - label: Label for the date range (e.g., "Initiated", "Last Seen") - enabled: Whether the filter is active - toggle_handler: Event handler to toggle enabled state - from_value: Current "from" date value - to_value: Current "to" date value - on_from_change: Handler for from date change - on_to_change: Handler for to date change - """ - return rx.vstack( - # Header with checkbox - rx.hstack( - rx.checkbox( - checked=enabled, - on_change=toggle_handler, - size="2", - ), - rx.text( - label, - font_size=Typography.H3_SIZE, - font_weight=Typography.H3_WEIGHT, - color=Colors.SLATE_900, - font_family=Typography.FONT_FAMILY, - ), - align="center", - spacing="2", - ), - # Date inputs (debounced 300ms) - rx.hstack( - rx.vstack( - rx.text( - "From", - **text_caption(), - ), - rx.debounce_input( - rx.input( - type="date", - value=from_value, - on_change=on_from_change, - disabled=~enabled, - **input_style(), - width="140px", - opacity=rx.cond(enabled, "1", "0.5"), - ), - debounce_timeout=300, - ), - spacing="1", - align="start", - ), - rx.vstack( - rx.text( - "To", - **text_caption(), - ), - rx.debounce_input( - rx.input( - type="date", - value=to_value, - on_change=on_to_change, - disabled=~enabled, - **input_style(), - width="140px", - opacity=rx.cond(enabled, "1", "0.5"), - ), - debounce_timeout=300, - ), - spacing="1", - align="start", - ), - spacing="3", - align="end", - ), - spacing="2", - align="start", - ) - - -def searchable_dropdown( - label: str, - selection_text: rx.Var[str], - is_open: rx.Var[bool], - toggle_handler, - search_value: rx.Var[str], - on_search_change, - filtered_items: rx.Var[list[str]], - selected_items: rx.Var[list[str]], - toggle_item_handler, - select_all_handler, - clear_all_handler, -) -> rx.Component: - """ - Searchable multi-select dropdown component. - - Uses debounced search input (300ms) for smooth filtering. - - Args: - label: Label for the dropdown - selection_text: Text showing selection count - is_open: Whether dropdown is expanded - toggle_handler: Handler to toggle dropdown open/close - search_value: Current search text - on_search_change: Handler for search input change - filtered_items: Items filtered by search - selected_items: Currently selected items - toggle_item_handler: Handler to toggle item selection - select_all_handler: Handler to select all - clear_all_handler: Handler to clear selection - """ - return rx.box( - rx.vstack( - # Label - rx.text( - label, - font_size=Typography.CAPTION_SIZE, - font_weight=Typography.CAPTION_WEIGHT, - color=Colors.SLATE_700, - font_family=Typography.FONT_FAMILY, - ), - # Dropdown trigger button - rx.box( - rx.hstack( - rx.text( - selection_text, - font_size=Typography.BODY_SIZE, - color=Colors.SLATE_900, - font_family=Typography.FONT_FAMILY, - flex="1", - ), - rx.icon( - rx.cond(is_open, "chevron-up", "chevron-down"), - size=16, - color=Colors.SLATE_500, - ), - justify="between", - align="center", - width="100%", - ), - **input_style(), - display="flex", - align_items="center", - cursor="pointer", - on_click=toggle_handler, - width="100%", - ), - # Dropdown panel - rx.cond( - is_open, - rx.box( - rx.vstack( - # Search input (debounced 300ms) - rx.hstack( - rx.icon("search", size=14, color=Colors.SLATE_500), - rx.debounce_input( - rx.input( - placeholder="Search...", - value=search_value, - on_change=on_search_change, - variant="soft", - size="2", - width="100%", - ), - debounce_timeout=300, - ), - spacing="2", - align="center", - width="100%", - padding=Spacing.SM, - background_color=Colors.SLATE_100, - border_radius=Radii.SM, - ), - # Action buttons - rx.hstack( - rx.button( - "Select All", - on_click=select_all_handler, - variant="ghost", - size="1", - color_scheme="blue", - ), - rx.button( - "Clear", - on_click=clear_all_handler, - variant="ghost", - size="1", - color_scheme="gray", - ), - spacing="2", - ), - # Items list - rx.box( - rx.foreach( - filtered_items, - lambda item: rx.box( - rx.checkbox( - item, - checked=selected_items.contains(item), - on_change=lambda: toggle_item_handler(item), - size="2", - ), - padding_y=Spacing.XS, - padding_x=Spacing.SM, - border_radius=Radii.SM, - background_color=rx.cond( - selected_items.contains(item), - Colors.PALE, - "transparent", - ), - _hover={ - "background_color": Colors.SLATE_100, - }, - width="100%", - ), - ), - max_height="200px", - overflow_y="auto", - width="100%", - ), - spacing="2", - align="start", - width="100%", - padding=Spacing.SM, - ), - position="absolute", - top="100%", - left="0", - right="0", - background_color=Colors.WHITE, - border=f"1px solid {Colors.SLATE_300}", - border_radius=Radii.MD, - box_shadow=Shadows.LG, - z_index="50", - margin_top=Spacing.XS, - ), - ), - spacing="1", - align="start", - width="100%", - ), - position="relative", - width="100%", - ) - - -def chart_tab(label: str, chart_type: str, is_active: bool = False) -> rx.Component: - """ - Individual chart type tab/pill for top bar navigation. - - Active state: White background with Heritage Blue text - Inactive state: Transparent with white text, hover shows Vibrant Blue background - """ - return rx.box( - rx.text( - label, - font_size=Typography.BODY_SMALL_SIZE, - font_weight="500", - color=Colors.HERITAGE_BLUE if is_active else Colors.WHITE, - font_family=Typography.FONT_FAMILY, - ), - background_color=Colors.WHITE if is_active else "transparent", - padding_x=Spacing.LG, - padding_y=Spacing.SM, - border_radius=Radii.FULL, - cursor="pointer", - transition=f"background-color {Transitions.COLOR}", - _hover={ - "background_color": Colors.WHITE if is_active else "rgba(255,255,255,0.15)", - }, - # Future: on_click handler to switch chart type - ) - - -def top_bar() -> rx.Component: - """ - Top navigation bar component. - - Contains: Logo + App Name | Chart Type Tabs | Data Freshness Indicator - Fixed height: 64px (from design system) - Heritage Blue background with white text. - """ - return rx.box( - rx.hstack( - # Left: Logo and App Title - rx.hstack( - rx.image( - src="/logo.png", - height="36px", - alt="NHS Logo", - ), - rx.text( - "HCD Analysis", - font_size=Typography.H2_SIZE, - font_weight=Typography.H2_WEIGHT, - color=Colors.WHITE, - font_family=Typography.FONT_FAMILY, - letter_spacing="-0.01em", - ), - align="center", - spacing="3", - ), - # Center: Chart Type Tabs - rx.hstack( - chart_tab("Icicle", "icicle", is_active=True), - chart_tab("Sankey", "sankey", is_active=False), - chart_tab("Timeline", "timeline", is_active=False), - spacing="2", - align="center", - background_color="rgba(255,255,255,0.1)", - padding=Spacing.XS, - border_radius=Radii.FULL, - ), - # Right: Data Freshness Indicator - rx.hstack( - rx.icon( - "database", - size=16, - color=Colors.SKY, - ), - rx.vstack( - rx.text( - rx.cond( - AppState.data_loaded, - AppState.total_records.to_string() + " records", - "Loading data...", - ), - font_size=Typography.CAPTION_SIZE, - font_weight="500", - color=Colors.WHITE, - font_family=Typography.FONT_FAMILY, - ), - rx.text( - rx.cond( - AppState.data_loaded, - "Refreshed: " + AppState.last_updated_display, - "Connecting...", - ), - font_size="11px", - color=Colors.WHITE, - opacity="0.7", - font_family=Typography.FONT_FAMILY, - ), - spacing="0", - align="end", - ), - spacing="2", - align="center", - ), - justify="between", - align="center", - width="100%", - max_width=PAGE_MAX_WIDTH, - margin_x="auto", - padding_x=Spacing.XL, - ), - background_color=Colors.HERITAGE_BLUE, - height=TOP_BAR_HEIGHT, - width="100%", - display="flex", - align_items="center", - position="sticky", - top="0", - z_index="100", - box_shadow=Shadows.MD, - ) - - -def filter_section() -> rx.Component: - """ - Filter section component. - - Contains: - - Two date range pickers: Initiated (default OFF), Last Seen (default ON) - - Three searchable multi-select dropdowns: Drugs, Indications, Directorates - - Layout: Two rows - - Row 1: Date pickers side by side - - Row 2: Three dropdowns in a grid - """ - return rx.box( - rx.vstack( - # Header - rx.text( - "Filters", - **text_h1(), - ), - # Row 1: Date range pickers - rx.hstack( - date_range_picker( - label="Initiated", - enabled=AppState.initiated_filter_enabled, - toggle_handler=AppState.toggle_initiated_filter, - from_value=AppState.initiated_from_date, - to_value=AppState.initiated_to_date, - on_from_change=AppState.set_initiated_from, - on_to_change=AppState.set_initiated_to, - ), - rx.divider(orientation="vertical", size="3"), - date_range_picker( - label="Last Seen", - enabled=AppState.last_seen_filter_enabled, - toggle_handler=AppState.toggle_last_seen_filter, - from_value=AppState.last_seen_from_date, - to_value=AppState.last_seen_to_date, - on_from_change=AppState.set_last_seen_from, - on_to_change=AppState.set_last_seen_to, - ), - spacing="5", - align="start", - flex_wrap="wrap", - ), - # Divider - rx.divider(size="4"), - # Row 2: Searchable dropdowns - rx.hstack( - rx.box( - searchable_dropdown( - label="Drugs", - selection_text=AppState.drug_selection_text, - is_open=AppState.drug_dropdown_open, - toggle_handler=AppState.toggle_drug_dropdown, - search_value=AppState.drug_search, - on_search_change=AppState.set_drug_search, - filtered_items=AppState.filtered_drugs, - selected_items=AppState.selected_drugs, - toggle_item_handler=AppState.toggle_drug, - select_all_handler=AppState.select_all_drugs, - clear_all_handler=AppState.clear_all_drugs, - ), - flex="1", - min_width="200px", - ), - rx.box( - searchable_dropdown( - label="Indications", - selection_text=AppState.indication_selection_text, - is_open=AppState.indication_dropdown_open, - toggle_handler=AppState.toggle_indication_dropdown, - search_value=AppState.indication_search, - on_search_change=AppState.set_indication_search, - filtered_items=AppState.filtered_indications, - selected_items=AppState.selected_indications, - toggle_item_handler=AppState.toggle_indication, - select_all_handler=AppState.select_all_indications, - clear_all_handler=AppState.clear_all_indications, - ), - flex="1", - min_width="200px", - ), - rx.box( - searchable_dropdown( - label="Directorates", - selection_text=AppState.directorate_selection_text, - is_open=AppState.directorate_dropdown_open, - toggle_handler=AppState.toggle_directorate_dropdown, - search_value=AppState.directorate_search, - on_search_change=AppState.set_directorate_search, - filtered_items=AppState.filtered_directorates, - selected_items=AppState.selected_directorates, - toggle_item_handler=AppState.toggle_directorate, - select_all_handler=AppState.select_all_directorates, - clear_all_handler=AppState.clear_all_directorates, - ), - flex="1", - min_width="200px", - ), - spacing="4", - width="100%", - flex_wrap="wrap", - ), - spacing="4", - width="100%", - align="start", - ), - **card_style(), - width="100%", - ) - - -def kpi_card( - value: rx.Var[str], - label: str, - icon_name: str = None, - highlight: bool = False, -) -> rx.Component: - """ - KPI card component displaying a metric value with label. - - Args: - value: The display value (should be a formatted string from computed var) - label: Label describing the metric - icon_name: Optional Lucide icon name to display - highlight: If True, uses Pale Blue background tint - - Design specs from DESIGN_SYSTEM.md: - - Large mono number: 32-48px, Slate 900 - - Label: Caption size, Slate 500 - - Background: White or Pale Blue tint - """ - # Build content - icon only if provided - content_items = [] - if icon_name: - content_items.append( - rx.icon( - icon_name, - size=20, - color=Colors.PRIMARY, - ) - ) - - return rx.box( - rx.vstack( - # Optional icon - rx.icon( - icon_name if icon_name else "activity", - size=20, - color=Colors.PRIMARY, - ) if icon_name else rx.fragment(), - # Value - rx.text( - value, - **kpi_value_style(), - ), - # Label - rx.text( - label, - **kpi_label_style(), - ), - spacing="1", - align="center", - ), - # Apply card styling manually to allow background_color override - background_color=Colors.PALE if highlight else Colors.WHITE, - border=f"1px solid {Colors.SLATE_300}", - border_radius=Radii.LG, - padding=Spacing.XL, - box_shadow=Shadows.SM, - text_align="center", - min_width="180px", - flex="1", - transition=f"box-shadow {Transitions.SHADOW}, transform {Transitions.TRANSFORM}", - _hover={ - "box_shadow": Shadows.MD, - "transform": "translateY(-2px)", - }, - ) - - -def kpi_row() -> rx.Component: - """ - KPI metrics row component with responsive grid layout. - - Contains: - - Unique Patients: COUNT(DISTINCT patient_id) - - Total Drugs: Count of selected/filtered drugs - - Total Cost: Sum of costs in filtered data - - Match Rate: Indication match percentage - - Layout: Responsive flex row that wraps on smaller screens. - KPIs update reactively when filters change (Phase 3). - """ - return rx.hstack( - # Unique Patients KPI - highlighted as primary metric - kpi_card( - value=AppState.unique_patients_display, - label="Unique Patients", - icon_name="users", - highlight=True, - ), - # Total Drugs KPI - kpi_card( - value=AppState.total_drugs_display, - label="Drug Types", - icon_name="pill", - highlight=False, - ), - # Total Cost KPI - kpi_card( - value=AppState.total_cost_display, - label="Total Cost", - icon_name="pound-sterling", - highlight=False, - ), - # Indication Match Rate KPI - kpi_card( - value=AppState.match_rate_display, - label="Indication Match", - icon_name="circle-check", - highlight=False, - ), - spacing="4", - width="100%", - flex_wrap="wrap", - align="stretch", - ) - - -def chart_loading_skeleton() -> rx.Component: - """ - Loading skeleton for the chart area. - - Displays animated pulsing bars to indicate loading state. - Uses design system colors and spacing. - """ - return rx.box( - rx.vstack( - # Simulated chart bars at different heights - rx.hstack( - rx.box( - background_color=Colors.SLATE_300, - width="12%", - height="60%", - border_radius=Radii.SM, - animation="pulse 1.5s ease-in-out infinite", - ), - rx.box( - background_color=Colors.SLATE_300, - width="12%", - height="80%", - border_radius=Radii.SM, - animation="pulse 1.5s ease-in-out infinite", - animation_delay="0.1s", - ), - rx.box( - background_color=Colors.SLATE_300, - width="12%", - height="45%", - border_radius=Radii.SM, - animation="pulse 1.5s ease-in-out infinite", - animation_delay="0.2s", - ), - rx.box( - background_color=Colors.SLATE_300, - width="12%", - height="70%", - border_radius=Radii.SM, - animation="pulse 1.5s ease-in-out infinite", - animation_delay="0.3s", - ), - rx.box( - background_color=Colors.SLATE_300, - width="12%", - height="55%", - border_radius=Radii.SM, - animation="pulse 1.5s ease-in-out infinite", - animation_delay="0.4s", - ), - rx.box( - background_color=Colors.SLATE_300, - width="12%", - height="90%", - border_radius=Radii.SM, - animation="pulse 1.5s ease-in-out infinite", - animation_delay="0.5s", - ), - spacing="3", - align="end", - justify="center", - height="100%", - width="100%", - ), - # Loading text - rx.hstack( - rx.spinner(size="2"), - rx.text( - "Generating chart...", - font_size=Typography.BODY_SIZE, - font_weight=Typography.BODY_WEIGHT, - color=Colors.SLATE_500, - font_family=Typography.FONT_FAMILY, - ), - spacing="2", - align="center", - ), - spacing="4", - align="center", - justify="center", - height="100%", - width="100%", - ), - background_color=Colors.SLATE_100, - border_radius=Radii.MD, - width="100%", - height="500px", - padding=Spacing.XL, - ) - - -def chart_error_state(error_message: rx.Var[str]) -> rx.Component: - """ - Error state for the chart area. - - Displays a friendly error message with an icon and the error details. - Provides guidance on how to resolve the issue. - """ - return rx.box( - rx.center( - rx.vstack( - rx.icon( - "triangle-alert", - size=48, - color=Colors.WARNING, - ), - rx.text( - "Unable to Generate Chart", - font_size=Typography.H2_SIZE, - font_weight=Typography.H2_WEIGHT, - color=Colors.SLATE_900, - font_family=Typography.FONT_FAMILY, - ), - rx.text( - error_message, - font_size=Typography.BODY_SIZE, - font_weight=Typography.BODY_WEIGHT, - color=Colors.SLATE_700, - font_family=Typography.FONT_FAMILY, - text_align="center", - max_width="400px", - ), - rx.text( - "Try adjusting the filters or check the data source.", - font_size=Typography.CAPTION_SIZE, - font_weight=Typography.CAPTION_WEIGHT, - color=Colors.SLATE_500, - font_family=Typography.FONT_FAMILY, - ), - spacing="3", - align="center", - ), - width="100%", - height="100%", - ), - background_color=Colors.SLATE_100, - border_radius=Radii.MD, - width="100%", - height="500px", - padding=Spacing.XL, - ) - - -def chart_empty_state() -> rx.Component: - """ - Empty state for when no data matches the filters. - - Displays a friendly message encouraging filter adjustment. - """ - return rx.box( - rx.center( - rx.vstack( - rx.icon( - "search-x", - size=48, - color=Colors.SLATE_500, - ), - rx.text( - "No Data to Display", - font_size=Typography.H2_SIZE, - font_weight=Typography.H2_WEIGHT, - color=Colors.SLATE_900, - font_family=Typography.FONT_FAMILY, - ), - rx.text( - "No patient records match your current filter criteria.", - font_size=Typography.BODY_SIZE, - font_weight=Typography.BODY_WEIGHT, - color=Colors.SLATE_700, - font_family=Typography.FONT_FAMILY, - text_align="center", - ), - rx.text( - "Try widening your date range or selecting more drugs/indications.", - font_size=Typography.CAPTION_SIZE, - font_weight=Typography.CAPTION_WEIGHT, - color=Colors.SLATE_500, - font_family=Typography.FONT_FAMILY, - ), - spacing="3", - align="center", - ), - width="100%", - height="100%", - ), - background_color=Colors.SLATE_100, - border_radius=Radii.MD, - width="100%", - height="500px", - padding=Spacing.XL, - ) - - -def chart_display() -> rx.Component: - """ - Plotly icicle chart display component. - - Renders the interactive icicle chart from AppState.icicle_figure. - The figure is a computed property that updates reactively when - chart_data changes (which happens when filters change). - - Uses rx.plotly() to render the Plotly figure object. - """ - return rx.box( - rx.plotly( - data=AppState.icicle_figure, - width="100%", - height="600px", - ), - width="100%", - min_height="600px", - ) - - -def chart_section() -> rx.Component: - """ - Main chart section component. - - Contains: Plotly icicle chart with loading, error, empty, and ready states. - - State handling: - - Loading: Shows skeleton animation when chart_loading is True - - Error: Shows error message when error_message is not empty - - Empty: Shows empty state when data_loaded but unique_patients is 0 - - Ready: Shows interactive Plotly icicle chart - - The chart updates reactively when filters change via the icicle_figure computed property. - """ - return rx.box( - rx.vstack( - # Header row with title and chart type info - rx.hstack( - rx.text( - "Patient Pathway Visualization", - **text_h1(), - ), - rx.hstack( - rx.icon( - "info", - size=14, - color=Colors.SLATE_500, - ), - rx.text( - "Hierarchical view: Trust → Directorate → Drug → Patient Pathway", - font_size=Typography.CAPTION_SIZE, - font_weight=Typography.CAPTION_WEIGHT, - color=Colors.SLATE_500, - font_family=Typography.FONT_FAMILY, - ), - spacing="1", - align="center", - ), - justify="between", - align="center", - width="100%", - flex_wrap="wrap", - ), - # Chart container with state-based rendering - rx.cond( - # Priority 1: Loading state - AppState.chart_loading, - chart_loading_skeleton(), - # Not loading - check for error - rx.cond( - # Priority 2: Error state - AppState.error_message != "", - chart_error_state(AppState.error_message), - # No error - check if data loaded - rx.cond( - # Priority 3: Data loaded but empty - AppState.data_loaded & (AppState.unique_patients == 0), - chart_empty_state(), - # Priority 4: Ready state - show interactive Plotly chart - chart_display(), - ), - ), - ), - spacing="4", - width="100%", - align="start", - ), - **card_style(), - width="100%", - ) - - -def main_content() -> rx.Component: - """ - Main content area below the top bar. - - Layout: Filter Section → KPI Row → Chart Section - Max width constrained to PAGE_MAX_WIDTH, centered. - """ - return rx.box( - rx.vstack( - filter_section(), - kpi_row(), - chart_section(), - spacing="5", - width="100%", - align="stretch", - ), - width="100%", - max_width=PAGE_MAX_WIDTH, - margin_x="auto", - padding=PAGE_PADDING, - padding_top=Spacing.XL, - ) - - -def page_layout() -> rx.Component: - """ - Full page layout combining top bar and main content. - - Structure: - - Sticky top bar (64px) - - Scrollable main content area - - White background - """ - return rx.box( - rx.vstack( - top_bar(), - main_content(), - spacing="0", - width="100%", - min_height="100vh", - ), - background_color=Colors.WHITE, - font_family=Typography.FONT_FAMILY, - width="100%", - ) - - -# ============================================================================= -# Page Definition -# ============================================================================= - -def index() -> rx.Component: - """Main page for HCD Analysis v2.""" - return page_layout() - - -# ============================================================================= -# App Configuration -# ============================================================================= - -app = rx.App( - theme=rx.theme( - accent_color="blue", - gray_color="slate", - radius="medium", - ), - stylesheets=[ - # Google Fonts - Inter (primary) and JetBrains Mono (monospace) - "https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=JetBrains+Mono:wght@400;500&display=swap", - ], -) - -# Register page with on_load handler to load data on app initialization -app.add_page(index, route="/", title="HCD Analysis | Patient Pathways", on_load=AppState.load_data) diff --git a/ralph.ps1 b/ralph.ps1 index 78b1c4d..ced32f5 100644 --- a/ralph.ps1 +++ b/ralph.ps1 @@ -6,15 +6,13 @@ Outer loop for iterative Reflex frontend development. Each iteration spawns a fresh `claude --print` invocation. Memory persists via filesystem only: git commits, progress.txt, IMPLEMENTATION_PLAN.md, guardrails.md. - Completion detected via COMPLETE in output. + + Runs until completion (COMPLETE) or circuit breaker trips. + No arbitrary iteration limit — the loop continues until done. Circuit breakers prevent runaway costs: - No git changes for N consecutive iterations (stalled) - Same error repeated N consecutive iterations (stuck) - - Maximum iteration count reached - -.PARAMETER MaxIterations - Maximum number of loop iterations before stopping. Default: 15. .PARAMETER Model Claude model to use. Default: "sonnet". @@ -29,15 +27,14 @@ Number of consecutive iterations with the same error before circuit breaker trips. Default: 3. .EXAMPLE - .\ralph.ps1 -MaxIterations 15 -Model "sonnet" -BranchName "feature/ui-redesign" + .\ralph.ps1 -Model "sonnet" -BranchName "feature/ui-redesign" .EXAMPLE .\ralph.ps1 -Model "opus" -MaxNoProgress 2 #> param( - [int]$MaxIterations = 15, - [string]$Model = "sonnet", + [string]$Model = "opus", [string]$BranchName, [int]$MaxNoProgress = 3, [int]$MaxSameError = 3 @@ -151,17 +148,19 @@ if (Test-Path $progressFile) { Write-Host "" Write-Host "===== Ralph Wiggum Loop (Reflex UI) =====" -ForegroundColor Cyan -Write-Host "Model: $Model | Max iterations: $MaxIterations" -ForegroundColor Cyan +Write-Host "Model: $Model | Runs until COMPLETE" -ForegroundColor Cyan Write-Host "Circuit breakers: no-progress=$MaxNoProgress, same-error=$MaxSameError" -ForegroundColor Cyan if ($BranchName) { Write-Host "Branch: $BranchName" -ForegroundColor Cyan } if ($existingIterations -gt 0) { Write-Host "Previous iterations: $existingIterations" -ForegroundColor Cyan } Write-Host "===========================================" -ForegroundColor Cyan Write-Host "" -for ($i = 1; $i -le $MaxIterations; $i++) { +$i = 0 +while ($true) { + $i++ $totalIteration = $existingIterations + $i Write-Host "" - Write-Host "--- Iteration $i of $MaxIterations (Total: $totalIteration) ---" -ForegroundColor Yellow + Write-Host "--- Iteration $i (Total: $totalIteration) ---" -ForegroundColor Yellow # Record HEAD before this iteration $headBefore = git rev-parse HEAD 2>$null @@ -199,41 +198,41 @@ for ($i = 1; $i -le $MaxIterations; $i++) { $line = $_.ToString().Trim() if (-not $line) { return } - # Save raw event for debugging - Add-Content -Path $rawLogFile -Value $line -Encoding UTF8 + # Save raw event for debugging (with error handling for stream closure) + try { + Add-Content -Path $rawLogFile -Value $line -Encoding UTF8 -ErrorAction SilentlyContinue + } catch { + # Stream closed or file locked - ignore and continue + } try { $evt = $line | ConvertFrom-Json -ErrorAction Stop - # --- Tool use detection --- + # --- Tool use start (show tool name) --- if ($evt.type -eq 'content_block_start' -and $evt.content_block.type -eq 'tool_use') { $toolCount++ $toolName = $evt.content_block.name Write-Host " [$toolName]" -ForegroundColor DarkCyan } - elseif ($evt.tool_name) { - $toolCount++ - Write-Host " [$($evt.tool_name)]" -ForegroundColor DarkCyan - } - - # --- Text content --- + # --- Assistant text content (streaming deltas) --- elseif ($evt.type -eq 'content_block_delta' -and $evt.delta.type -eq 'text_delta' -and $evt.delta.text) { Write-Host -NoNewline $evt.delta.text [void]$textBuilder.Append($evt.delta.text) } - + # --- Result event (error display + text capture for circuit breakers) --- elseif ($evt.type -eq 'result') { - if ($evt.result) { - Write-Host $evt.result - [void]$textBuilder.AppendLine($evt.result) - } if ($evt.subtype -eq 'error_result' -and $evt.error) { Write-Host " [ERROR] $($evt.error)" -ForegroundColor Red [void]$textBuilder.AppendLine("ERROR: $($evt.error)") } + elseif ($evt.result) { + # Capture for circuit breaker detection; don't print + # (text already displayed via streaming deltas above) + [void]$textBuilder.AppendLine($evt.result) + } } - - elseif ($evt.message.content) { + # --- Message-level content (final message summary) --- + elseif ($evt.message -and $evt.message.content) { foreach ($block in $evt.message.content) { if ($block.type -eq 'text' -and $block.text) { Write-Host $block.text @@ -243,12 +242,16 @@ for ($i = 1; $i -le $MaxIterations; $i++) { $toolCount++ Write-Host " [$($block.name)]" -ForegroundColor DarkCyan } + # Silently ignore tool_result and other block types } } + # All other JSON events (input_json_delta, content_block_stop, + # message_start, message_stop, ping, etc.) are silently ignored } catch { - # Not valid JSON — likely stderr output - if ($line) { + # Not valid JSON — only print if it looks like meaningful stderr + # (filter out JSON fragments from multi-line events) + if ($line -and $line -notmatch '^\s*[\{\[\}\]"]') { Write-Host $line -ForegroundColor DarkYellow [void]$textBuilder.AppendLine($line) } @@ -338,9 +341,3 @@ for ($i = 1; $i -le $MaxIterations; $i++) { # Brief pause between iterations Start-Sleep -Seconds 2 } - -Write-Host "" -Write-Host "===== MAX ITERATIONS REACHED =====" -ForegroundColor Red -Write-Host "Completed $MaxIterations iterations without finishing all tasks." -ForegroundColor Red -Write-Host "Check progress.txt for current state and what remains." -ForegroundColor Red -exit 1 diff --git a/snomed_indication_mapping_query.sql b/snomed_indication_mapping_query.sql new file mode 100644 index 0000000..83e0eb0 --- /dev/null +++ b/snomed_indication_mapping_query.sql @@ -0,0 +1,186 @@ +-- NICE TA Indication SNOMED Mapping Query (v2 - optimized clusters) +-- Excludes overly broad clusters (GDPPR_COD, GDPPR2YR_COD) + +WITH SearchTermClusters AS ( + SELECT Search_Term, Cluster_ID FROM (VALUES + ('acute lymphoblastic leukaemia', 'HAEMCANMORPH_COD'), + ('acute myeloid leukaemia', 'C19HAEMCAN_COD'), + ('acute promyelocytic leukaemia', 'HAEMCANMORPH_COD'), + ('allergic asthma', 'AST_COD'), + ('allergic rhinitis', 'MILDINTAST_COD'), + ('alzheimer''s disease', 'DEMALZ_COD'), + ('amyloidosis', 'AMYLOID_COD'), + ('anaemia', 'eFI2_AnaemiaTimeSensitive'), + ('anaplastic large cell lymphoma', 'C19HAEMCAN_COD'), + ('apixaban', 'DOACCON_COD'), + ('aplastic anaemia', 'eFI2_AnaemiaEver'), + ('arthritis', 'eFI2_InflammatoryArthritis'), + ('asthma', 'eFI2_Asthma'), + ('atopic dermatitis', 'ATOPDERM_COD'), + ('atrial fibrillation', 'eFI2_AtrialFibrillation'), + ('attention deficit hyperactivity disorder', 'ADHD_COD'), + ('bipolar disorder', 'MH_COD'), + ('bladder', 'eFI2_UrinaryIncontinence'), + ('breast cancer', 'BRCANSCR_COD'), + ('cardiomyopathy', 'eFI2_HarmfulDrinking'), + ('cardiovascular disease', 'CVDRISKASS_COD'), + ('cervical cancer', 'CSDEC_COD'), + ('cholangiocarcinoma', 'eFI2_Cancer'), + ('chronic kidney disease', 'CKD_COD'), + ('chronic liver disease', 'eFI2_LiverProblems'), + ('chronic lymphocytic leukaemia', 'EPPHAEMCAN_COD'), + ('chronic myeloid leukaemia', 'EPPHAEMCAN_COD'), + ('chronic obstructive pulmonary disease', 'eFI2_COPD'), + ('colon cancer', 'eFI2_Cancer'), + ('colorectal cancer', 'GICANREF_COD'), + ('constipation', 'CHRONCONSTIP_COD'), + ('covid-19', 'POSSPOSTCOVID_COD'), + ('crohn''s disease', 'eFI2_InflammatoryBowelDisease'), + ('cutaneous t-cell lymphoma', 'C19HAEMCAN_COD'), + ('cystic fibrosis', 'CUST_ICB_CYSTIC_FIBROSIS'), + ('deep vein thrombosis', 'VTE_COD'), + ('depression', 'eFI2_Depression'), + ('diabetes', 'eFI2_DiabetesEver'), + ('diabetic retinopathy', 'DRSELIGIBILITY_COD'), + ('diffuse large b-cell lymphoma', 'C19HAEMCAN_COD'), + ('dravet syndrome', 'EPIL_COD'), + ('drug misuse', 'ILLSUBINT_COD'), + ('dyspepsia', 'eFI2_AbdominalPain'), + ('epilepsy', 'eFI2_Seizures'), + ('fallopian tube', 'STERIL_COD'), + ('follicular lymphoma', 'C19HAEMCAN_COD'), + ('gastric cancer', 'eFI2_Cancer'), + ('giant cell arteritis', 'GCA_COD'), + ('glioma', 'NHAEMCANMORPH_COD'), + ('gout', 'eFI2_InflammatoryArthritis'), + ('graft versus host disease', 'GVHD_COD'), + ('granulomatosis with polyangiitis', 'WEGENERVASC_COD'), + ('growth hormone deficiency', 'HYPOPITUITARY_COD'), + ('hand eczema', 'ECZEMA_COD'), + ('heart failure', 'eFI2_HeartFailure'), + ('hepatitis b', 'HEPBCVAC_COD'), + ('hepatocellular carcinoma', 'eFI2_Cancer'), + ('hiv', 'PREFLANG_COD'), + ('hodgkin lymphoma', 'HAEMCANMORPH_COD'), + ('hormone receptor', 'eFI2_ThyroidProblems'), + ('hypercholesterolaemia', 'CLASSFH_COD'), + ('immune thrombocytopenia', 'ITP_COD'), + ('influenza', 'FLUINVITE_COD'), + ('insomnia', 'eFI2_SleepProblems'), + ('irritable bowel syndrome', 'IBS_COD'), + ('ischaemic stroke', 'OSTR_COD'), + ('juvenile idiopathic arthritis', 'RARTHAD_COD'), + ('kidney transplant', 'RENALTRANSP_COD'), + ('leukaemia', 'eFI2_Cancer'), + ('lung cancer', 'FTCANREF_COD'), + ('lymphoma', 'C19HAEMCAN_COD'), + ('macular degeneration', 'CUST_ICB_VISUAL_IMPAIRMENT'), + ('macular oedema', 'CUST_ICB_VISUAL_IMPAIRMENT'), + ('major depressive episodes', 'eFI2_Depression'), + ('malignant melanoma', 'eFI2_Cancer'), + ('malignant pleural mesothelioma', 'LUNGCAN_COD'), + ('manic episode', 'MH_COD'), + ('mantle cell lymphoma', 'HAEMCANMORPH_COD'), + ('melanoma', 'eFI2_Cancer'), + ('merkel cell carcinoma', 'C19CAN_COD'), + ('migraine', 'eFI2_Headache'), + ('motor neurone disease', 'MND_COD'), + ('multiple myeloma', 'C19HAEMCAN_COD'), + ('multiple sclerosis', 'MS_COD'), + ('myelodysplastic', 'eFI2_AnaemiaEver'), + ('myelofibrosis', 'MDS_COD'), + ('myocardial infarction', 'eFI2_IschaemicHeartDisease'), + ('myotonia', 'CNDATRISK2_COD'), + ('narcolepsy', 'LD_COD'), + ('neuroendocrine tumour', 'LUNGCAN_COD'), + ('non-small cell lung cancer', 'LUNGCAN_COD'), + ('non-small-cell lung cancer', 'FTCANREF_COD'), + ('obesity', 'BMI30_COD'), + ('osteoarthritis', 'CUST_ICB_OSTEOARTHRITIS'), + ('osteoporosis', 'eFI2_Osteoporosis'), + ('osteosarcoma', 'NHAEMCANMORPH_COD'), + ('ovarian cancer', 'C19CAN_COD'), + ('peripheral arterial disease', 'PADEXC_COD'), + ('plaque psoriasis', 'PSORIASIS_COD'), + ('polycystic kidney disease', 'EPPCONGMALF_COD'), + ('polycythaemia vera', 'C19HAEMCAN_COD'), + ('pregnancy', 'C19PREG_COD'), + ('primary biliary cholangitis', 'eFI2_LiverProblems'), + ('primary hypercholesterolaemia', 'FNFHYP_COD'), + ('prostate cancer', 'EPPSOLIDCAN_COD'), + ('psoriasis', 'PSORIASIS_COD'), + ('psoriatic arthritis', 'RARTHAD_COD'), + ('pulmonary embolism', 'eFI2_RespiratoryDiseaseTimeSensitive'), + ('pulmonary fibrosis', 'ILD_COD'), + ('relapsing multiple sclerosis', 'MS_COD'), + ('renal cell carcinoma', 'C19CAN_COD'), + ('renal transplantation', 'RENALTRANSP_COD'), + ('retinal vein occlusion', 'CUST_ICB_VISUAL_IMPAIRMENT'), + ('rheumatoid arthritis', 'eFI2_InflammatoryArthritis'), + ('rivaroxaban', 'DOACCON_COD'), + ('schizophrenia', 'MH_COD'), + ('seizures', 'LSZFREQ_COD'), + ('sepsis', 'C19ACTIVITY_COD'), + ('severe persistent allergic asthma', 'SEVAST_COD'), + ('sickle cell disease', 'SICKLE_COD'), + ('sleep apnoea', 'CUST_ICB_NON_SEVERE_LDA'), + ('smoking cessation', 'SMOKINGINT_COD'), + ('soft tissue sarcoma', 'NHAEMCANMORPH_COD'), + ('spinal muscular atrophy', 'MND_COD'), + ('squamous cell', 'C19CAN_COD'), + ('squamous cell carcinoma', 'C19CAN_COD'), + ('stem cell transplant', 'ALLOTRANSP_COD'), + ('stroke', 'eFI2_Stroke'), + ('systemic lupus erythematosus', 'SLUPUS_COD'), + ('systemic mastocytosis', 'HAEMCANMORPH_COD'), + ('thrombocytopenic purpura', 'TTP_COD'), + ('thrombotic thrombocytopenic purpura', 'TTP_COD'), + ('thyroid cancer', 'C19CAN_COD'), + ('tophaceous gout', 'CUST_ICB_OSTEOARTHRITIS'), + ('transitional cell carcinoma', 'C19CAN_COD'), + ('type 1 diabetes', 'DMTYPE1_COD'), + ('type 2 diabetes', 'DMTYPE2_COD'), + ('ulcerative colitis', 'eFI2_InflammatoryBowelDisease'), + ('urothelial carcinoma', 'NHAEMCANMORPH_COD'), + ('urticaria', 'XSAL_COD'), + ('uveitis', 'CUST_ICB_VISUAL_IMPAIRMENT'), + ('vascular disease', 'CVDINVITE_COD'), + ('vasculitis', 'CRYOGLOBVASC_COD') + ) AS t(Search_Term, Cluster_ID) +), + +ClusterCodes AS ( + SELECT + stc.Search_Term, + c."SNOMEDCode", + c."SNOMEDDescription" + FROM SearchTermClusters stc + JOIN DATA_HUB.PHM."ClinicalCodingClusterSnomedCodes" c + ON stc.Cluster_ID = c."Cluster_ID" + WHERE c."SNOMEDCode" IS NOT NULL +), + +ExplicitCodes AS ( + SELECT Search_Term, SNOMEDCode, SNOMEDDescription FROM (VALUES + ('acute coronary syndrome', '837091000000100', 'Manual mapping'), + ('ankylosing spondylitis', '162930007', 'Manual mapping'), + ('ankylosing spondylitis', '239805001', 'Manual mapping'), + ('ankylosing spondylitis', '239810002', 'Manual mapping'), + ('ankylosing spondylitis', '239811003', 'Manual mapping'), + ('ankylosing spondylitis', '394990003', 'Manual mapping'), + ('ankylosing spondylitis', '429712009', 'Manual mapping'), + ('ankylosing spondylitis', '441562009', 'Manual mapping'), + ('ankylosing spondylitis', '441680005', 'Manual mapping'), + ('ankylosing spondylitis', '441930001', 'Manual mapping'), + ('axial spondyloarthritis', '723116002', 'Manual mapping'), + ('choroidal neovascularisation', '380621000000102', 'Manual mapping'), + ('choroidal neovascularisation', '733124000', 'Manual mapping') + ) AS t(Search_Term, SNOMEDCode, SNOMEDDescription) +) + +SELECT Search_Term, "SNOMEDCode" AS SNOMEDCode, "SNOMEDDescription" AS SNOMEDDescription +FROM ClusterCodes +UNION ALL +SELECT Search_Term, SNOMEDCode, SNOMEDDescription +FROM ExplicitCodes +ORDER BY Search_Term, SNOMEDCode; diff --git a/uv.lock b/uv.lock index f8a5c2d..cd9c9ee 100644 --- a/uv.lock +++ b/uv.lock @@ -6,21 +6,291 @@ resolution-markers = [ ] [[package]] -name = "altgraph" -version = "0.17.4" +name = "alembic" +version = "1.18.3" source = { registry = "https://pypi.org/simple" } -sdist = { url = "https://files.pythonhosted.org/packages/de/a8/7145824cf0b9e3c28046520480f207df47e927df83aa9555fb47f8505922/altgraph-0.17.4.tar.gz", hash = "sha256:1b5afbb98f6c4dcadb2e2ae6ab9fa994bbb8c1d75f4fa96d340f9437ae454406", size = 48418 } +dependencies = [ + { name = "mako" }, + { name = "sqlalchemy" }, + { name = "tomli", marker = "python_full_version < '3.11'" }, + { name = "typing-extensions" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/79/41/ab8f624929847b49f84955c594b165855efd829b0c271e1a8cac694138e5/alembic-1.18.3.tar.gz", hash = "sha256:1212aa3778626f2b0f0aa6dd4e99a5f99b94bd25a0c1ac0bba3be65e081e50b0", size = 2052564 } wheels = [ - { url = "https://files.pythonhosted.org/packages/4d/3f/3bc3f1d83f6e4a7fcb834d3720544ca597590425be5ba9db032b2bf322a2/altgraph-0.17.4-py2.py3-none-any.whl", hash = "sha256:642743b4750de17e655e6711601b077bc6598dbfa3ba5fa2b2a35ce12b508dff", size = 21212 }, + { url = "https://files.pythonhosted.org/packages/45/8e/d79281f323e7469b060f15bd229e48d7cdd219559e67e71c013720a88340/alembic-1.18.3-py3-none-any.whl", hash = "sha256:12a0359bfc068a4ecbb9b3b02cf77856033abfdb59e4a5aca08b7eacd7b74ddd", size = 262282 }, ] [[package]] -name = "babel" -version = "2.12.1" +name = "annotated-doc" +version = "0.0.4" source = { registry = "https://pypi.org/simple" } -sdist = { url = "https://files.pythonhosted.org/packages/ba/42/54426ba5d7aeebde9f4aaba9884596eb2fe02b413ad77d62ef0b0422e205/Babel-2.12.1.tar.gz", hash = "sha256:cc2d99999cd01d44420ae725a21c9e3711b3aadc7976d6147f622d8581963455", size = 9906735 } +sdist = { url = "https://files.pythonhosted.org/packages/57/ba/046ceea27344560984e26a590f90bc7f4a75b06701f653222458922b558c/annotated_doc-0.0.4.tar.gz", hash = "sha256:fbcda96e87e9c92ad167c2e53839e57503ecfda18804ea28102353485033faa4", size = 7288 } wheels = [ - { url = "https://files.pythonhosted.org/packages/df/c4/1088865e0246d7ecf56d819a233ab2b72f7d6ab043965ef327d0731b5434/Babel-2.12.1-py3-none-any.whl", hash = "sha256:b4246fb7677d3b98f501a39d43396d3cafdc8eadb045f4a31be01863f655c610", size = 10071794 }, + { url = "https://files.pythonhosted.org/packages/1e/d3/26bf1008eb3d2daa8ef4cacc7f3bfdc11818d111f7e2d0201bc6e3b49d45/annotated_doc-0.0.4-py3-none-any.whl", hash = "sha256:571ac1dc6991c450b25a9c2d84a3705e2ae7a53467b5d111c24fa8baabbed320", size = 5303 }, +] + +[[package]] +name = "annotated-types" +version = "0.7.0" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/ee/67/531ea369ba64dcff5ec9c3402f9f51bf748cec26dde048a2f973a4eea7f5/annotated_types-0.7.0.tar.gz", hash = "sha256:aff07c09a53a08bc8cfccb9c85b05f1aa9a2a6f23728d790723543408344ce89", size = 16081 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/78/b6/6307fbef88d9b5ee7421e68d78a9f162e0da4900bc5f5793f6d3d0e34fb8/annotated_types-0.7.0-py3-none-any.whl", hash = "sha256:1f02e8b43a8fbbc3f3e0d4f0f4bfc8131bcb4eebe8849b8e5c773f3a1c582a53", size = 13643 }, +] + +[[package]] +name = "anyio" +version = "4.12.1" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "exceptiongroup", marker = "python_full_version < '3.11'" }, + { name = "idna" }, + { name = "typing-extensions", marker = "python_full_version < '3.13'" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/96/f0/5eb65b2bb0d09ac6776f2eb54adee6abe8228ea05b20a5ad0e4945de8aac/anyio-4.12.1.tar.gz", hash = "sha256:41cfcc3a4c85d3f05c932da7c26d0201ac36f72abd4435ba90d0464a3ffed703", size = 228685 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/38/0e/27be9fdef66e72d64c0cdc3cc2823101b80585f8119b5c112c2e8f5f7dab/anyio-4.12.1-py3-none-any.whl", hash = "sha256:d405828884fc140aa80a3c667b8beed277f1dfedec42ba031bd6ac3db606ab6c", size = 113592 }, +] + +[[package]] +name = "async-timeout" +version = "5.0.1" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/a5/ae/136395dfbfe00dfc94da3f3e136d0b13f394cba8f4841120e34226265780/async_timeout-5.0.1.tar.gz", hash = "sha256:d9321a7a3d5a6a5e187e824d2fa0793ce379a202935782d555d6e9d2735677d3", size = 9274 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/fe/ba/e2081de779ca30d473f21f5b30e0e737c438205440784c7dfc81efc2b029/async_timeout-5.0.1-py3-none-any.whl", hash = "sha256:39e3809566ff85354557ec2398b55e096c8364bacac9405a7a1fa429e77fe76c", size = 6233 }, +] + +[[package]] +name = "bidict" +version = "0.23.1" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/9a/6e/026678aa5a830e07cd9498a05d3e7e650a4f56a42f267a53d22bcda1bdc9/bidict-0.23.1.tar.gz", hash = "sha256:03069d763bc387bbd20e7d49914e75fc4132a41937fa3405417e1a5a2d006d71", size = 29093 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/99/37/e8730c3587a65eb5645d4aba2d27aae48e8003614d6aaf15dda67f702f1f/bidict-0.23.1-py3-none-any.whl", hash = "sha256:5dae8d4d79b552a71cbabc7deb25dfe8ce710b17ff41711e13010ead2abfc3e5", size = 32764 }, +] + +[[package]] +name = "certifi" +version = "2026.1.4" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/e0/2d/a891ca51311197f6ad14a7ef42e2399f36cf2f9bd44752b3dc4eab60fdc5/certifi-2026.1.4.tar.gz", hash = "sha256:ac726dd470482006e014ad384921ed6438c457018f4b3d204aea4281258b2120", size = 154268 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/e6/ad/3cc14f097111b4de0040c83a525973216457bbeeb63739ef1ed275c1c021/certifi-2026.1.4-py3-none-any.whl", hash = "sha256:9943707519e4add1115f44c2bc244f782c0249876bf51b6599fee1ffbedd685c", size = 152900 }, +] + +[[package]] +name = "charset-normalizer" +version = "3.4.4" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/13/69/33ddede1939fdd074bce5434295f38fae7136463422fe4fd3e0e89b98062/charset_normalizer-3.4.4.tar.gz", hash = "sha256:94537985111c35f28720e43603b8e7b43a6ecfb2ce1d3058bbe955b73404e21a", size = 129418 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/1f/b8/6d51fc1d52cbd52cd4ccedd5b5b2f0f6a11bbf6765c782298b0f3e808541/charset_normalizer-3.4.4-cp310-cp310-macosx_10_9_universal2.whl", hash = "sha256:e824f1492727fa856dd6eda4f7cee25f8518a12f3c4a56a74e8095695089cf6d", size = 209709 }, + { url = "https://files.pythonhosted.org/packages/5c/af/1f9d7f7faafe2ddfb6f72a2e07a548a629c61ad510fe60f9630309908fef/charset_normalizer-3.4.4-cp310-cp310-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:4bd5d4137d500351a30687c2d3971758aac9a19208fc110ccb9d7188fbe709e8", size = 148814 }, + { url = "https://files.pythonhosted.org/packages/79/3d/f2e3ac2bbc056ca0c204298ea4e3d9db9b4afe437812638759db2c976b5f/charset_normalizer-3.4.4-cp310-cp310-manylinux2014_armv7l.manylinux_2_17_armv7l.manylinux_2_31_armv7l.whl", hash = "sha256:027f6de494925c0ab2a55eab46ae5129951638a49a34d87f4c3eda90f696b4ad", size = 144467 }, + { url = "https://files.pythonhosted.org/packages/ec/85/1bf997003815e60d57de7bd972c57dc6950446a3e4ccac43bc3070721856/charset_normalizer-3.4.4-cp310-cp310-manylinux2014_ppc64le.manylinux_2_17_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:f820802628d2694cb7e56db99213f930856014862f3fd943d290ea8438d07ca8", size = 162280 }, + { url = "https://files.pythonhosted.org/packages/3e/8e/6aa1952f56b192f54921c436b87f2aaf7c7a7c3d0d1a765547d64fd83c13/charset_normalizer-3.4.4-cp310-cp310-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:798d75d81754988d2565bff1b97ba5a44411867c0cf32b77a7e8f8d84796b10d", size = 159454 }, + { url = "https://files.pythonhosted.org/packages/36/3b/60cbd1f8e93aa25d1c669c649b7a655b0b5fb4c571858910ea9332678558/charset_normalizer-3.4.4-cp310-cp310-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:9d1bb833febdff5c8927f922386db610b49db6e0d4f4ee29601d71e7c2694313", size = 153609 }, + { url = "https://files.pythonhosted.org/packages/64/91/6a13396948b8fd3c4b4fd5bc74d045f5637d78c9675585e8e9fbe5636554/charset_normalizer-3.4.4-cp310-cp310-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:9cd98cdc06614a2f768d2b7286d66805f94c48cde050acdbbb7db2600ab3197e", size = 151849 }, + { url = "https://files.pythonhosted.org/packages/b7/7a/59482e28b9981d105691e968c544cc0df3b7d6133152fb3dcdc8f135da7a/charset_normalizer-3.4.4-cp310-cp310-musllinux_1_2_aarch64.whl", hash = "sha256:077fbb858e903c73f6c9db43374fd213b0b6a778106bc7032446a8e8b5b38b93", size = 151586 }, + { url = "https://files.pythonhosted.org/packages/92/59/f64ef6a1c4bdd2baf892b04cd78792ed8684fbc48d4c2afe467d96b4df57/charset_normalizer-3.4.4-cp310-cp310-musllinux_1_2_armv7l.whl", hash = "sha256:244bfb999c71b35de57821b8ea746b24e863398194a4014e4c76adc2bbdfeff0", size = 145290 }, + { url = "https://files.pythonhosted.org/packages/6b/63/3bf9f279ddfa641ffa1962b0db6a57a9c294361cc2f5fcac997049a00e9c/charset_normalizer-3.4.4-cp310-cp310-musllinux_1_2_ppc64le.whl", hash = "sha256:64b55f9dce520635f018f907ff1b0df1fdc31f2795a922fb49dd14fbcdf48c84", size = 163663 }, + { url = "https://files.pythonhosted.org/packages/ed/09/c9e38fc8fa9e0849b172b581fd9803bdf6e694041127933934184e19f8c3/charset_normalizer-3.4.4-cp310-cp310-musllinux_1_2_riscv64.whl", hash = "sha256:faa3a41b2b66b6e50f84ae4a68c64fcd0c44355741c6374813a800cd6695db9e", size = 151964 }, + { url = "https://files.pythonhosted.org/packages/d2/d1/d28b747e512d0da79d8b6a1ac18b7ab2ecfd81b2944c4c710e166d8dd09c/charset_normalizer-3.4.4-cp310-cp310-musllinux_1_2_s390x.whl", hash = "sha256:6515f3182dbe4ea06ced2d9e8666d97b46ef4c75e326b79bb624110f122551db", size = 161064 }, + { url = "https://files.pythonhosted.org/packages/bb/9a/31d62b611d901c3b9e5500c36aab0ff5eb442043fb3a1c254200d3d397d9/charset_normalizer-3.4.4-cp310-cp310-musllinux_1_2_x86_64.whl", hash = "sha256:cc00f04ed596e9dc0da42ed17ac5e596c6ccba999ba6bd92b0e0aef2f170f2d6", size = 155015 }, + { url = "https://files.pythonhosted.org/packages/1f/f3/107e008fa2bff0c8b9319584174418e5e5285fef32f79d8ee6a430d0039c/charset_normalizer-3.4.4-cp310-cp310-win32.whl", hash = "sha256:f34be2938726fc13801220747472850852fe6b1ea75869a048d6f896838c896f", size = 99792 }, + { url = "https://files.pythonhosted.org/packages/eb/66/e396e8a408843337d7315bab30dbf106c38966f1819f123257f5520f8a96/charset_normalizer-3.4.4-cp310-cp310-win_amd64.whl", hash = "sha256:a61900df84c667873b292c3de315a786dd8dac506704dea57bc957bd31e22c7d", size = 107198 }, + { url = "https://files.pythonhosted.org/packages/b5/58/01b4f815bf0312704c267f2ccb6e5d42bcc7752340cd487bc9f8c3710597/charset_normalizer-3.4.4-cp310-cp310-win_arm64.whl", hash = "sha256:cead0978fc57397645f12578bfd2d5ea9138ea0fac82b2f63f7f7c6877986a69", size = 100262 }, + { url = "https://files.pythonhosted.org/packages/ed/27/c6491ff4954e58a10f69ad90aca8a1b6fe9c5d3c6f380907af3c37435b59/charset_normalizer-3.4.4-cp311-cp311-macosx_10_9_universal2.whl", hash = "sha256:6e1fcf0720908f200cd21aa4e6750a48ff6ce4afe7ff5a79a90d5ed8a08296f8", size = 206988 }, + { url = "https://files.pythonhosted.org/packages/94/59/2e87300fe67ab820b5428580a53cad894272dbb97f38a7a814a2a1ac1011/charset_normalizer-3.4.4-cp311-cp311-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:5f819d5fe9234f9f82d75bdfa9aef3a3d72c4d24a6e57aeaebba32a704553aa0", size = 147324 }, + { url = "https://files.pythonhosted.org/packages/07/fb/0cf61dc84b2b088391830f6274cb57c82e4da8bbc2efeac8c025edb88772/charset_normalizer-3.4.4-cp311-cp311-manylinux2014_armv7l.manylinux_2_17_armv7l.manylinux_2_31_armv7l.whl", hash = "sha256:a59cb51917aa591b1c4e6a43c132f0cdc3c76dbad6155df4e28ee626cc77a0a3", size = 142742 }, + { url = "https://files.pythonhosted.org/packages/62/8b/171935adf2312cd745d290ed93cf16cf0dfe320863ab7cbeeae1dcd6535f/charset_normalizer-3.4.4-cp311-cp311-manylinux2014_ppc64le.manylinux_2_17_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:8ef3c867360f88ac904fd3f5e1f902f13307af9052646963ee08ff4f131adafc", size = 160863 }, + { url = "https://files.pythonhosted.org/packages/09/73/ad875b192bda14f2173bfc1bc9a55e009808484a4b256748d931b6948442/charset_normalizer-3.4.4-cp311-cp311-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:d9e45d7faa48ee908174d8fe84854479ef838fc6a705c9315372eacbc2f02897", size = 157837 }, + { url = "https://files.pythonhosted.org/packages/6d/fc/de9cce525b2c5b94b47c70a4b4fb19f871b24995c728e957ee68ab1671ea/charset_normalizer-3.4.4-cp311-cp311-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:840c25fb618a231545cbab0564a799f101b63b9901f2569faecd6b222ac72381", size = 151550 }, + { url = "https://files.pythonhosted.org/packages/55/c2/43edd615fdfba8c6f2dfbd459b25a6b3b551f24ea21981e23fb768503ce1/charset_normalizer-3.4.4-cp311-cp311-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:ca5862d5b3928c4940729dacc329aa9102900382fea192fc5e52eb69d6093815", size = 149162 }, + { url = "https://files.pythonhosted.org/packages/03/86/bde4ad8b4d0e9429a4e82c1e8f5c659993a9a863ad62c7df05cf7b678d75/charset_normalizer-3.4.4-cp311-cp311-musllinux_1_2_aarch64.whl", hash = "sha256:d9c7f57c3d666a53421049053eaacdd14bbd0a528e2186fcb2e672effd053bb0", size = 150019 }, + { url = "https://files.pythonhosted.org/packages/1f/86/a151eb2af293a7e7bac3a739b81072585ce36ccfb4493039f49f1d3cae8c/charset_normalizer-3.4.4-cp311-cp311-musllinux_1_2_armv7l.whl", hash = "sha256:277e970e750505ed74c832b4bf75dac7476262ee2a013f5574dd49075879e161", size = 143310 }, + { url = "https://files.pythonhosted.org/packages/b5/fe/43dae6144a7e07b87478fdfc4dbe9efd5defb0e7ec29f5f58a55aeef7bf7/charset_normalizer-3.4.4-cp311-cp311-musllinux_1_2_ppc64le.whl", hash = "sha256:31fd66405eaf47bb62e8cd575dc621c56c668f27d46a61d975a249930dd5e2a4", size = 162022 }, + { url = "https://files.pythonhosted.org/packages/80/e6/7aab83774f5d2bca81f42ac58d04caf44f0cc2b65fc6db2b3b2e8a05f3b3/charset_normalizer-3.4.4-cp311-cp311-musllinux_1_2_riscv64.whl", hash = "sha256:0d3d8f15c07f86e9ff82319b3d9ef6f4bf907608f53fe9d92b28ea9ae3d1fd89", size = 149383 }, + { url = "https://files.pythonhosted.org/packages/4f/e8/b289173b4edae05c0dde07f69f8db476a0b511eac556dfe0d6bda3c43384/charset_normalizer-3.4.4-cp311-cp311-musllinux_1_2_s390x.whl", hash = "sha256:9f7fcd74d410a36883701fafa2482a6af2ff5ba96b9a620e9e0721e28ead5569", size = 159098 }, + { url = "https://files.pythonhosted.org/packages/d8/df/fe699727754cae3f8478493c7f45f777b17c3ef0600e28abfec8619eb49c/charset_normalizer-3.4.4-cp311-cp311-musllinux_1_2_x86_64.whl", hash = "sha256:ebf3e58c7ec8a8bed6d66a75d7fb37b55e5015b03ceae72a8e7c74495551e224", size = 152991 }, + { url = "https://files.pythonhosted.org/packages/1a/86/584869fe4ddb6ffa3bd9f491b87a01568797fb9bd8933f557dba9771beaf/charset_normalizer-3.4.4-cp311-cp311-win32.whl", hash = "sha256:eecbc200c7fd5ddb9a7f16c7decb07b566c29fa2161a16cf67b8d068bd21690a", size = 99456 }, + { url = "https://files.pythonhosted.org/packages/65/f6/62fdd5feb60530f50f7e38b4f6a1d5203f4d16ff4f9f0952962c044e919a/charset_normalizer-3.4.4-cp311-cp311-win_amd64.whl", hash = "sha256:5ae497466c7901d54b639cf42d5b8c1b6a4fead55215500d2f486d34db48d016", size = 106978 }, + { url = "https://files.pythonhosted.org/packages/7a/9d/0710916e6c82948b3be62d9d398cb4fcf4e97b56d6a6aeccd66c4b2f2bd5/charset_normalizer-3.4.4-cp311-cp311-win_arm64.whl", hash = "sha256:65e2befcd84bc6f37095f5961e68a6f077bf44946771354a28ad434c2cce0ae1", size = 99969 }, + { url = "https://files.pythonhosted.org/packages/f3/85/1637cd4af66fa687396e757dec650f28025f2a2f5a5531a3208dc0ec43f2/charset_normalizer-3.4.4-cp312-cp312-macosx_10_13_universal2.whl", hash = "sha256:0a98e6759f854bd25a58a73fa88833fba3b7c491169f86ce1180c948ab3fd394", size = 208425 }, + { url = "https://files.pythonhosted.org/packages/9d/6a/04130023fef2a0d9c62d0bae2649b69f7b7d8d24ea5536feef50551029df/charset_normalizer-3.4.4-cp312-cp312-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:b5b290ccc2a263e8d185130284f8501e3e36c5e02750fc6b6bdeb2e9e96f1e25", size = 148162 }, + { url = "https://files.pythonhosted.org/packages/78/29/62328d79aa60da22c9e0b9a66539feae06ca0f5a4171ac4f7dc285b83688/charset_normalizer-3.4.4-cp312-cp312-manylinux2014_armv7l.manylinux_2_17_armv7l.manylinux_2_31_armv7l.whl", hash = "sha256:74bb723680f9f7a6234dcf67aea57e708ec1fbdf5699fb91dfd6f511b0a320ef", size = 144558 }, + { url = "https://files.pythonhosted.org/packages/86/bb/b32194a4bf15b88403537c2e120b817c61cd4ecffa9b6876e941c3ee38fe/charset_normalizer-3.4.4-cp312-cp312-manylinux2014_ppc64le.manylinux_2_17_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:f1e34719c6ed0b92f418c7c780480b26b5d9c50349e9a9af7d76bf757530350d", size = 161497 }, + { url = "https://files.pythonhosted.org/packages/19/89/a54c82b253d5b9b111dc74aca196ba5ccfcca8242d0fb64146d4d3183ff1/charset_normalizer-3.4.4-cp312-cp312-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:2437418e20515acec67d86e12bf70056a33abdacb5cb1655042f6538d6b085a8", size = 159240 }, + { url = "https://files.pythonhosted.org/packages/c0/10/d20b513afe03acc89ec33948320a5544d31f21b05368436d580dec4e234d/charset_normalizer-3.4.4-cp312-cp312-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:11d694519d7f29d6cd09f6ac70028dba10f92f6cdd059096db198c283794ac86", size = 153471 }, + { url = "https://files.pythonhosted.org/packages/61/fa/fbf177b55bdd727010f9c0a3c49eefa1d10f960e5f09d1d887bf93c2e698/charset_normalizer-3.4.4-cp312-cp312-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:ac1c4a689edcc530fc9d9aa11f5774b9e2f33f9a0c6a57864e90908f5208d30a", size = 150864 }, + { url = "https://files.pythonhosted.org/packages/05/12/9fbc6a4d39c0198adeebbde20b619790e9236557ca59fc40e0e3cebe6f40/charset_normalizer-3.4.4-cp312-cp312-musllinux_1_2_aarch64.whl", hash = "sha256:21d142cc6c0ec30d2efee5068ca36c128a30b0f2c53c1c07bd78cb6bc1d3be5f", size = 150647 }, + { url = "https://files.pythonhosted.org/packages/ad/1f/6a9a593d52e3e8c5d2b167daf8c6b968808efb57ef4c210acb907c365bc4/charset_normalizer-3.4.4-cp312-cp312-musllinux_1_2_armv7l.whl", hash = "sha256:5dbe56a36425d26d6cfb40ce79c314a2e4dd6211d51d6d2191c00bed34f354cc", size = 145110 }, + { url = "https://files.pythonhosted.org/packages/30/42/9a52c609e72471b0fc54386dc63c3781a387bb4fe61c20231a4ebcd58bdd/charset_normalizer-3.4.4-cp312-cp312-musllinux_1_2_ppc64le.whl", hash = "sha256:5bfbb1b9acf3334612667b61bd3002196fe2a1eb4dd74d247e0f2a4d50ec9bbf", size = 162839 }, + { url = "https://files.pythonhosted.org/packages/c4/5b/c0682bbf9f11597073052628ddd38344a3d673fda35a36773f7d19344b23/charset_normalizer-3.4.4-cp312-cp312-musllinux_1_2_riscv64.whl", hash = "sha256:d055ec1e26e441f6187acf818b73564e6e6282709e9bcb5b63f5b23068356a15", size = 150667 }, + { url = "https://files.pythonhosted.org/packages/e4/24/a41afeab6f990cf2daf6cb8c67419b63b48cf518e4f56022230840c9bfb2/charset_normalizer-3.4.4-cp312-cp312-musllinux_1_2_s390x.whl", hash = "sha256:af2d8c67d8e573d6de5bc30cdb27e9b95e49115cd9baad5ddbd1a6207aaa82a9", size = 160535 }, + { url = "https://files.pythonhosted.org/packages/2a/e5/6a4ce77ed243c4a50a1fecca6aaaab419628c818a49434be428fe24c9957/charset_normalizer-3.4.4-cp312-cp312-musllinux_1_2_x86_64.whl", hash = "sha256:780236ac706e66881f3b7f2f32dfe90507a09e67d1d454c762cf642e6e1586e0", size = 154816 }, + { url = "https://files.pythonhosted.org/packages/a8/ef/89297262b8092b312d29cdb2517cb1237e51db8ecef2e9af5edbe7b683b1/charset_normalizer-3.4.4-cp312-cp312-win32.whl", hash = "sha256:5833d2c39d8896e4e19b689ffc198f08ea58116bee26dea51e362ecc7cd3ed26", size = 99694 }, + { url = "https://files.pythonhosted.org/packages/3d/2d/1e5ed9dd3b3803994c155cd9aacb60c82c331bad84daf75bcb9c91b3295e/charset_normalizer-3.4.4-cp312-cp312-win_amd64.whl", hash = "sha256:a79cfe37875f822425b89a82333404539ae63dbdddf97f84dcbc3d339aae9525", size = 107131 }, + { url = "https://files.pythonhosted.org/packages/d0/d9/0ed4c7098a861482a7b6a95603edce4c0d9db2311af23da1fb2b75ec26fc/charset_normalizer-3.4.4-cp312-cp312-win_arm64.whl", hash = "sha256:376bec83a63b8021bb5c8ea75e21c4ccb86e7e45ca4eb81146091b56599b80c3", size = 100390 }, + { url = "https://files.pythonhosted.org/packages/97/45/4b3a1239bbacd321068ea6e7ac28875b03ab8bc0aa0966452db17cd36714/charset_normalizer-3.4.4-cp313-cp313-macosx_10_13_universal2.whl", hash = "sha256:e1f185f86a6f3403aa2420e815904c67b2f9ebc443f045edd0de921108345794", size = 208091 }, + { url = "https://files.pythonhosted.org/packages/7d/62/73a6d7450829655a35bb88a88fca7d736f9882a27eacdca2c6d505b57e2e/charset_normalizer-3.4.4-cp313-cp313-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:6b39f987ae8ccdf0d2642338faf2abb1862340facc796048b604ef14919e55ed", size = 147936 }, + { url = "https://files.pythonhosted.org/packages/89/c5/adb8c8b3d6625bef6d88b251bbb0d95f8205831b987631ab0c8bb5d937c2/charset_normalizer-3.4.4-cp313-cp313-manylinux2014_armv7l.manylinux_2_17_armv7l.manylinux_2_31_armv7l.whl", hash = "sha256:3162d5d8ce1bb98dd51af660f2121c55d0fa541b46dff7bb9b9f86ea1d87de72", size = 144180 }, + { url = "https://files.pythonhosted.org/packages/91/ed/9706e4070682d1cc219050b6048bfd293ccf67b3d4f5a4f39207453d4b99/charset_normalizer-3.4.4-cp313-cp313-manylinux2014_ppc64le.manylinux_2_17_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:81d5eb2a312700f4ecaa977a8235b634ce853200e828fbadf3a9c50bab278328", size = 161346 }, + { url = "https://files.pythonhosted.org/packages/d5/0d/031f0d95e4972901a2f6f09ef055751805ff541511dc1252ba3ca1f80cf5/charset_normalizer-3.4.4-cp313-cp313-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:5bd2293095d766545ec1a8f612559f6b40abc0eb18bb2f5d1171872d34036ede", size = 158874 }, + { url = "https://files.pythonhosted.org/packages/f5/83/6ab5883f57c9c801ce5e5677242328aa45592be8a00644310a008d04f922/charset_normalizer-3.4.4-cp313-cp313-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:a8a8b89589086a25749f471e6a900d3f662d1d3b6e2e59dcecf787b1cc3a1894", size = 153076 }, + { url = "https://files.pythonhosted.org/packages/75/1e/5ff781ddf5260e387d6419959ee89ef13878229732732ee73cdae01800f2/charset_normalizer-3.4.4-cp313-cp313-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:bc7637e2f80d8530ee4a78e878bce464f70087ce73cf7c1caf142416923b98f1", size = 150601 }, + { url = "https://files.pythonhosted.org/packages/d7/57/71be810965493d3510a6ca79b90c19e48696fb1ff964da319334b12677f0/charset_normalizer-3.4.4-cp313-cp313-musllinux_1_2_aarch64.whl", hash = "sha256:f8bf04158c6b607d747e93949aa60618b61312fe647a6369f88ce2ff16043490", size = 150376 }, + { url = "https://files.pythonhosted.org/packages/e5/d5/c3d057a78c181d007014feb7e9f2e65905a6c4ef182c0ddf0de2924edd65/charset_normalizer-3.4.4-cp313-cp313-musllinux_1_2_armv7l.whl", hash = "sha256:554af85e960429cf30784dd47447d5125aaa3b99a6f0683589dbd27e2f45da44", size = 144825 }, + { url = "https://files.pythonhosted.org/packages/e6/8c/d0406294828d4976f275ffbe66f00266c4b3136b7506941d87c00cab5272/charset_normalizer-3.4.4-cp313-cp313-musllinux_1_2_ppc64le.whl", hash = "sha256:74018750915ee7ad843a774364e13a3db91682f26142baddf775342c3f5b1133", size = 162583 }, + { url = "https://files.pythonhosted.org/packages/d7/24/e2aa1f18c8f15c4c0e932d9287b8609dd30ad56dbe41d926bd846e22fb8d/charset_normalizer-3.4.4-cp313-cp313-musllinux_1_2_riscv64.whl", hash = "sha256:c0463276121fdee9c49b98908b3a89c39be45d86d1dbaa22957e38f6321d4ce3", size = 150366 }, + { url = "https://files.pythonhosted.org/packages/e4/5b/1e6160c7739aad1e2df054300cc618b06bf784a7a164b0f238360721ab86/charset_normalizer-3.4.4-cp313-cp313-musllinux_1_2_s390x.whl", hash = "sha256:362d61fd13843997c1c446760ef36f240cf81d3ebf74ac62652aebaf7838561e", size = 160300 }, + { url = "https://files.pythonhosted.org/packages/7a/10/f882167cd207fbdd743e55534d5d9620e095089d176d55cb22d5322f2afd/charset_normalizer-3.4.4-cp313-cp313-musllinux_1_2_x86_64.whl", hash = "sha256:9a26f18905b8dd5d685d6d07b0cdf98a79f3c7a918906af7cc143ea2e164c8bc", size = 154465 }, + { url = "https://files.pythonhosted.org/packages/89/66/c7a9e1b7429be72123441bfdbaf2bc13faab3f90b933f664db506dea5915/charset_normalizer-3.4.4-cp313-cp313-win32.whl", hash = "sha256:9b35f4c90079ff2e2edc5b26c0c77925e5d2d255c42c74fdb70fb49b172726ac", size = 99404 }, + { url = "https://files.pythonhosted.org/packages/c4/26/b9924fa27db384bdcd97ab83b4f0a8058d96ad9626ead570674d5e737d90/charset_normalizer-3.4.4-cp313-cp313-win_amd64.whl", hash = "sha256:b435cba5f4f750aa6c0a0d92c541fb79f69a387c91e61f1795227e4ed9cece14", size = 107092 }, + { url = "https://files.pythonhosted.org/packages/af/8f/3ed4bfa0c0c72a7ca17f0380cd9e4dd842b09f664e780c13cff1dcf2ef1b/charset_normalizer-3.4.4-cp313-cp313-win_arm64.whl", hash = "sha256:542d2cee80be6f80247095cc36c418f7bddd14f4a6de45af91dfad36d817bba2", size = 100408 }, + { url = "https://files.pythonhosted.org/packages/2a/35/7051599bd493e62411d6ede36fd5af83a38f37c4767b92884df7301db25d/charset_normalizer-3.4.4-cp314-cp314-macosx_10_13_universal2.whl", hash = "sha256:da3326d9e65ef63a817ecbcc0df6e94463713b754fe293eaa03da99befb9a5bd", size = 207746 }, + { url = "https://files.pythonhosted.org/packages/10/9a/97c8d48ef10d6cd4fcead2415523221624bf58bcf68a802721a6bc807c8f/charset_normalizer-3.4.4-cp314-cp314-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:8af65f14dc14a79b924524b1e7fffe304517b2bff5a58bf64f30b98bbc5079eb", size = 147889 }, + { url = "https://files.pythonhosted.org/packages/10/bf/979224a919a1b606c82bd2c5fa49b5c6d5727aa47b4312bb27b1734f53cd/charset_normalizer-3.4.4-cp314-cp314-manylinux2014_armv7l.manylinux_2_17_armv7l.manylinux_2_31_armv7l.whl", hash = "sha256:74664978bb272435107de04e36db5a9735e78232b85b77d45cfb38f758efd33e", size = 143641 }, + { url = "https://files.pythonhosted.org/packages/ba/33/0ad65587441fc730dc7bd90e9716b30b4702dc7b617e6ba4997dc8651495/charset_normalizer-3.4.4-cp314-cp314-manylinux2014_ppc64le.manylinux_2_17_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:752944c7ffbfdd10c074dc58ec2d5a8a4cd9493b314d367c14d24c17684ddd14", size = 160779 }, + { url = "https://files.pythonhosted.org/packages/67/ed/331d6b249259ee71ddea93f6f2f0a56cfebd46938bde6fcc6f7b9a3d0e09/charset_normalizer-3.4.4-cp314-cp314-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:d1f13550535ad8cff21b8d757a3257963e951d96e20ec82ab44bc64aeb62a191", size = 159035 }, + { url = "https://files.pythonhosted.org/packages/67/ff/f6b948ca32e4f2a4576aa129d8bed61f2e0543bf9f5f2b7fc3758ed005c9/charset_normalizer-3.4.4-cp314-cp314-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:ecaae4149d99b1c9e7b88bb03e3221956f68fd6d50be2ef061b2381b61d20838", size = 152542 }, + { url = "https://files.pythonhosted.org/packages/16/85/276033dcbcc369eb176594de22728541a925b2632f9716428c851b149e83/charset_normalizer-3.4.4-cp314-cp314-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:cb6254dc36b47a990e59e1068afacdcd02958bdcce30bb50cc1700a8b9d624a6", size = 149524 }, + { url = "https://files.pythonhosted.org/packages/9e/f2/6a2a1f722b6aba37050e626530a46a68f74e63683947a8acff92569f979a/charset_normalizer-3.4.4-cp314-cp314-musllinux_1_2_aarch64.whl", hash = "sha256:c8ae8a0f02f57a6e61203a31428fa1d677cbe50c93622b4149d5c0f319c1d19e", size = 150395 }, + { url = "https://files.pythonhosted.org/packages/60/bb/2186cb2f2bbaea6338cad15ce23a67f9b0672929744381e28b0592676824/charset_normalizer-3.4.4-cp314-cp314-musllinux_1_2_armv7l.whl", hash = "sha256:47cc91b2f4dd2833fddaedd2893006b0106129d4b94fdb6af1f4ce5a9965577c", size = 143680 }, + { url = "https://files.pythonhosted.org/packages/7d/a5/bf6f13b772fbb2a90360eb620d52ed8f796f3c5caee8398c3b2eb7b1c60d/charset_normalizer-3.4.4-cp314-cp314-musllinux_1_2_ppc64le.whl", hash = "sha256:82004af6c302b5d3ab2cfc4cc5f29db16123b1a8417f2e25f9066f91d4411090", size = 162045 }, + { url = "https://files.pythonhosted.org/packages/df/c5/d1be898bf0dc3ef9030c3825e5d3b83f2c528d207d246cbabe245966808d/charset_normalizer-3.4.4-cp314-cp314-musllinux_1_2_riscv64.whl", hash = "sha256:2b7d8f6c26245217bd2ad053761201e9f9680f8ce52f0fcd8d0755aeae5b2152", size = 149687 }, + { url = "https://files.pythonhosted.org/packages/a5/42/90c1f7b9341eef50c8a1cb3f098ac43b0508413f33affd762855f67a410e/charset_normalizer-3.4.4-cp314-cp314-musllinux_1_2_s390x.whl", hash = "sha256:799a7a5e4fb2d5898c60b640fd4981d6a25f1c11790935a44ce38c54e985f828", size = 160014 }, + { url = "https://files.pythonhosted.org/packages/76/be/4d3ee471e8145d12795ab655ece37baed0929462a86e72372fd25859047c/charset_normalizer-3.4.4-cp314-cp314-musllinux_1_2_x86_64.whl", hash = "sha256:99ae2cffebb06e6c22bdc25801d7b30f503cc87dbd283479e7b606f70aff57ec", size = 154044 }, + { url = "https://files.pythonhosted.org/packages/b0/6f/8f7af07237c34a1defe7defc565a9bc1807762f672c0fde711a4b22bf9c0/charset_normalizer-3.4.4-cp314-cp314-win32.whl", hash = "sha256:f9d332f8c2a2fcbffe1378594431458ddbef721c1769d78e2cbc06280d8155f9", size = 99940 }, + { url = "https://files.pythonhosted.org/packages/4b/51/8ade005e5ca5b0d80fb4aff72a3775b325bdc3d27408c8113811a7cbe640/charset_normalizer-3.4.4-cp314-cp314-win_amd64.whl", hash = "sha256:8a6562c3700cce886c5be75ade4a5db4214fda19fede41d9792d100288d8f94c", size = 107104 }, + { url = "https://files.pythonhosted.org/packages/da/5f/6b8f83a55bb8278772c5ae54a577f3099025f9ade59d0136ac24a0df4bde/charset_normalizer-3.4.4-cp314-cp314-win_arm64.whl", hash = "sha256:de00632ca48df9daf77a2c65a484531649261ec9f25489917f09e455cb09ddb2", size = 100743 }, + { url = "https://files.pythonhosted.org/packages/0a/4c/925909008ed5a988ccbb72dcc897407e5d6d3bd72410d69e051fc0c14647/charset_normalizer-3.4.4-py3-none-any.whl", hash = "sha256:7a32c560861a02ff789ad905a2fe94e3f840803362c84fecf1851cb4cf3dc37f", size = 53402 }, +] + +[[package]] +name = "click" +version = "8.3.1" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "colorama", marker = "sys_platform == 'win32'" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/3d/fa/656b739db8587d7b5dfa22e22ed02566950fbfbcdc20311993483657a5c0/click-8.3.1.tar.gz", hash = "sha256:12ff4785d337a1bb490bb7e9c2b1ee5da3112e94a8622f26a6c77f5d2fc6842a", size = 295065 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/98/78/01c019cdb5d6498122777c1a43056ebb3ebfeef2076d9d026bfe15583b2b/click-8.3.1-py3-none-any.whl", hash = "sha256:981153a64e25f12d547d3426c367a4857371575ee7ad18df2a6183ab0545b2a6", size = 108274 }, +] + +[[package]] +name = "colorama" +version = "0.4.6" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/d8/53/6f443c9a4a8358a93a6792e2acffb9d9d5cb0a5cfd8802644b7b1c9a02e4/colorama-0.4.6.tar.gz", hash = "sha256:08695f5cb7ed6e0531a20572697297273c47b8cae5a63ffc6d6ed5c201be6e44", size = 27697 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/d1/d6/3965ed04c63042e047cb6a3e6ed1a63a35087b6a609aa3a15ed8ac56c221/colorama-0.4.6-py2.py3-none-any.whl", hash = "sha256:4f1d9991f5acc0ca119f9d443620b77f9d6b33703e51011c16baf57afb285fc6", size = 25335 }, +] + +[[package]] +name = "coverage" +version = "7.13.3" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/11/43/3e4ac666cc35f231fa70c94e9f38459299de1a152813f9d2f60fc5f3ecaf/coverage-7.13.3.tar.gz", hash = "sha256:f7f6182d3dfb8802c1747eacbfe611b669455b69b7c037484bb1efbbb56711ac", size = 826832 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/ab/07/1c8099563a8a6c389a31c2d0aa1497cee86d6248bb4b9ba5e779215db9f9/coverage-7.13.3-cp310-cp310-macosx_10_9_x86_64.whl", hash = "sha256:0b4f345f7265cdbdb5ec2521ffff15fa49de6d6c39abf89fc7ad68aa9e3a55f0", size = 219143 }, + { url = "https://files.pythonhosted.org/packages/69/39/a892d44af7aa092cab70e0cc5cdbba18eeccfe1d6930695dab1742eef9e9/coverage-7.13.3-cp310-cp310-macosx_11_0_arm64.whl", hash = "sha256:96c3be8bae9d0333e403cc1a8eb078a7f928b5650bae94a18fb4820cc993fb9b", size = 219663 }, + { url = "https://files.pythonhosted.org/packages/9a/25/9669dcf4c2bb4c3861469e6db20e52e8c11908cf53c14ec9b12e9fd4d602/coverage-7.13.3-cp310-cp310-manylinux1_i686.manylinux_2_28_i686.manylinux_2_5_i686.whl", hash = "sha256:d6f4a21328ea49d38565b55599e1c02834e76583a6953e5586d65cb1efebd8f8", size = 246424 }, + { url = "https://files.pythonhosted.org/packages/f3/68/d9766c4e298aca62ea5d9543e1dd1e4e1439d7284815244d8b7db1840bfb/coverage-7.13.3-cp310-cp310-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:fc970575799a9d17d5c3fafd83a0f6ccf5d5117cdc9ad6fbd791e9ead82418b0", size = 248228 }, + { url = "https://files.pythonhosted.org/packages/f0/e2/eea6cb4a4bd443741adf008d4cccec83a1f75401df59b6559aca2bdd9710/coverage-7.13.3-cp310-cp310-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:87ff33b652b3556b05e204ae20793d1f872161b0fa5ec8a9ac76f8430e152ed6", size = 250103 }, + { url = "https://files.pythonhosted.org/packages/db/77/664280ecd666c2191610842177e2fab9e5dbdeef97178e2078fed46a3d2c/coverage-7.13.3-cp310-cp310-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:7df8759ee57b9f3f7b66799b7660c282f4375bef620ade1686d6a7b03699e75f", size = 247107 }, + { url = "https://files.pythonhosted.org/packages/2b/df/2a672eab99e0d0eba52d8a63e47dc92245eee26954d1b2d3c8f7d372151f/coverage-7.13.3-cp310-cp310-musllinux_1_2_aarch64.whl", hash = "sha256:f45c9bcb16bee25a798ccba8a2f6a1251b19de6a0d617bb365d7d2f386c4e20e", size = 248143 }, + { url = "https://files.pythonhosted.org/packages/a5/dc/a104e7a87c13e57a358b8b9199a8955676e1703bb372d79722b54978ae45/coverage-7.13.3-cp310-cp310-musllinux_1_2_i686.whl", hash = "sha256:318b2e4753cbf611061e01b6cc81477e1cdfeb69c36c4a14e6595e674caadb56", size = 246148 }, + { url = "https://files.pythonhosted.org/packages/2b/89/e113d3a58dc20b03b7e59aed1e53ebc9ca6167f961876443e002b10e3ae9/coverage-7.13.3-cp310-cp310-musllinux_1_2_riscv64.whl", hash = "sha256:24db3959de8ee394eeeca89ccb8ba25305c2da9a668dd44173394cbd5aa0777f", size = 246414 }, + { url = "https://files.pythonhosted.org/packages/3f/60/a3fd0a6e8d89b488396019a2268b6a1f25ab56d6d18f3be50f35d77b47dc/coverage-7.13.3-cp310-cp310-musllinux_1_2_x86_64.whl", hash = "sha256:be14d0622125edef21b3a4d8cd2d138c4872bf6e38adc90fd92385e3312f406a", size = 247023 }, + { url = "https://files.pythonhosted.org/packages/19/fa/de4840bb939dbb22ba0648a6d8069fa91c9cf3b3fca8b0d1df461e885b3d/coverage-7.13.3-cp310-cp310-win32.whl", hash = "sha256:53be4aab8ddef18beb6188f3a3fdbf4d1af2277d098d4e618be3a8e6c88e74be", size = 221751 }, + { url = "https://files.pythonhosted.org/packages/de/87/233ff8b7ef62fb63f58c78623b50bef69681111e0c4d43504f422d88cda4/coverage-7.13.3-cp310-cp310-win_amd64.whl", hash = "sha256:bfeee64ad8b4aae3233abb77eb6b52b51b05fa89da9645518671b9939a78732b", size = 222686 }, + { url = "https://files.pythonhosted.org/packages/ec/09/1ac74e37cf45f17eb41e11a21854f7f92a4c2d6c6098ef4a1becb0c6d8d3/coverage-7.13.3-cp311-cp311-macosx_10_9_x86_64.whl", hash = "sha256:5907605ee20e126eeee2abe14aae137043c2c8af2fa9b38d2ab3b7a6b8137f73", size = 219276 }, + { url = "https://files.pythonhosted.org/packages/2e/cb/71908b08b21beb2c437d0d5870c4ec129c570ca1b386a8427fcdb11cf89c/coverage-7.13.3-cp311-cp311-macosx_11_0_arm64.whl", hash = "sha256:a88705500988c8acad8b8fd86c2a933d3aa96bec1ddc4bc5cb256360db7bbd00", size = 219776 }, + { url = "https://files.pythonhosted.org/packages/09/85/c4f3dd69232887666a2c0394d4be21c60ea934d404db068e6c96aa59cd87/coverage-7.13.3-cp311-cp311-manylinux1_i686.manylinux_2_28_i686.manylinux_2_5_i686.whl", hash = "sha256:7bbb5aa9016c4c29e3432e087aa29ebee3f8fda089cfbfb4e6d64bd292dcd1c2", size = 250196 }, + { url = "https://files.pythonhosted.org/packages/9c/cc/560ad6f12010344d0778e268df5ba9aa990aacccc310d478bf82bf3d302c/coverage-7.13.3-cp311-cp311-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:0c2be202a83dde768937a61cdc5d06bf9fb204048ca199d93479488e6247656c", size = 252111 }, + { url = "https://files.pythonhosted.org/packages/f0/66/3193985fb2c58e91f94cfbe9e21a6fdf941e9301fe2be9e92c072e9c8f8c/coverage-7.13.3-cp311-cp311-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:0f45e32ef383ce56e0ca099b2e02fcdf7950be4b1b56afaab27b4ad790befe5b", size = 254217 }, + { url = "https://files.pythonhosted.org/packages/c5/78/f0f91556bf1faa416792e537c523c5ef9db9b1d32a50572c102b3d7c45b3/coverage-7.13.3-cp311-cp311-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:6ed2e787249b922a93cd95c671cc9f4c9797a106e81b455c83a9ddb9d34590c0", size = 250318 }, + { url = "https://files.pythonhosted.org/packages/6f/aa/fc654e45e837d137b2c1f3a2cc09b4aea1e8b015acd2f774fa0f3d2ddeba/coverage-7.13.3-cp311-cp311-musllinux_1_2_aarch64.whl", hash = "sha256:05dd25b21afffe545e808265897c35f32d3e4437663923e0d256d9ab5031fb14", size = 251909 }, + { url = "https://files.pythonhosted.org/packages/73/4d/ab53063992add8a9ca0463c9d92cce5994a29e17affd1c2daa091b922a93/coverage-7.13.3-cp311-cp311-musllinux_1_2_i686.whl", hash = "sha256:46d29926349b5c4f1ea4fca95e8c892835515f3600995a383fa9a923b5739ea4", size = 249971 }, + { url = "https://files.pythonhosted.org/packages/29/25/83694b81e46fcff9899694a1b6f57573429cdd82b57932f09a698f03eea5/coverage-7.13.3-cp311-cp311-musllinux_1_2_riscv64.whl", hash = "sha256:fae6a21537519c2af00245e834e5bf2884699cc7c1055738fd0f9dc37a3644ad", size = 249692 }, + { url = "https://files.pythonhosted.org/packages/d4/ef/d68fc304301f4cb4bf6aefa0045310520789ca38dabdfba9dbecd3f37919/coverage-7.13.3-cp311-cp311-musllinux_1_2_x86_64.whl", hash = "sha256:c672d4e2f0575a4ca2bf2aa0c5ced5188220ab806c1bb6d7179f70a11a017222", size = 250597 }, + { url = "https://files.pythonhosted.org/packages/8d/85/240ad396f914df361d0f71e912ddcedb48130c71b88dc4193fe3c0306f00/coverage-7.13.3-cp311-cp311-win32.whl", hash = "sha256:fcda51c918c7a13ad93b5f89a58d56e3a072c9e0ba5c231b0ed81404bf2648fb", size = 221773 }, + { url = "https://files.pythonhosted.org/packages/2f/71/165b3a6d3d052704a9ab52d11ea64ef3426745de517dda44d872716213a7/coverage-7.13.3-cp311-cp311-win_amd64.whl", hash = "sha256:d1a049b5c51b3b679928dd35e47c4a2235e0b6128b479a7596d0ef5b42fa6301", size = 222711 }, + { url = "https://files.pythonhosted.org/packages/51/d0/0ddc9c5934cdd52639c5df1f1eb0fdab51bb52348f3a8d1c7db9c600d93a/coverage-7.13.3-cp311-cp311-win_arm64.whl", hash = "sha256:79f2670c7e772f4917895c3d89aad59e01f3dbe68a4ed2d0373b431fad1dcfba", size = 221377 }, + { url = "https://files.pythonhosted.org/packages/94/44/330f8e83b143f6668778ed61d17ece9dc48459e9e74669177de02f45fec5/coverage-7.13.3-cp312-cp312-macosx_10_13_x86_64.whl", hash = "sha256:ed48b4170caa2c4420e0cd27dc977caaffc7eecc317355751df8373dddcef595", size = 219441 }, + { url = "https://files.pythonhosted.org/packages/08/e7/29db05693562c2e65bdf6910c0af2fd6f9325b8f43caf7a258413f369e30/coverage-7.13.3-cp312-cp312-macosx_11_0_arm64.whl", hash = "sha256:8f2adf4bcffbbec41f366f2e6dffb9d24e8172d16e91da5799c9b7ed6b5716e6", size = 219801 }, + { url = "https://files.pythonhosted.org/packages/90/ae/7f8a78249b02b0818db46220795f8ac8312ea4abd1d37d79ea81db5cae81/coverage-7.13.3-cp312-cp312-manylinux1_i686.manylinux_2_28_i686.manylinux_2_5_i686.whl", hash = "sha256:01119735c690786b6966a1e9f098da4cd7ca9174c4cfe076d04e653105488395", size = 251306 }, + { url = "https://files.pythonhosted.org/packages/62/71/a18a53d1808e09b2e9ebd6b47dad5e92daf4c38b0686b4c4d1b2f3e42b7f/coverage-7.13.3-cp312-cp312-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:8bb09e83c603f152d855f666d70a71765ca8e67332e5829e62cb9466c176af23", size = 254051 }, + { url = "https://files.pythonhosted.org/packages/4a/0a/eb30f6455d04c5a3396d0696cad2df0269ae7444bb322f86ffe3376f7bf9/coverage-7.13.3-cp312-cp312-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:b607a40cba795cfac6d130220d25962931ce101f2f478a29822b19755377fb34", size = 255160 }, + { url = "https://files.pythonhosted.org/packages/7b/7e/a45baac86274ce3ed842dbb84f14560c673ad30535f397d89164ec56c5df/coverage-7.13.3-cp312-cp312-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:44f14a62f5da2e9aedf9080e01d2cda61df39197d48e323538ec037336d68da8", size = 251709 }, + { url = "https://files.pythonhosted.org/packages/c0/df/dd0dc12f30da11349993f3e218901fdf82f45ee44773596050c8f5a1fb25/coverage-7.13.3-cp312-cp312-musllinux_1_2_aarch64.whl", hash = "sha256:debf29e0b157769843dff0981cc76f79e0ed04e36bb773c6cac5f6029054bd8a", size = 253083 }, + { url = "https://files.pythonhosted.org/packages/ab/32/fc764c8389a8ce95cb90eb97af4c32f392ab0ac23ec57cadeefb887188d3/coverage-7.13.3-cp312-cp312-musllinux_1_2_i686.whl", hash = "sha256:824bb95cd71604031ae9a48edb91fd6effde669522f960375668ed21b36e3ec4", size = 251227 }, + { url = "https://files.pythonhosted.org/packages/dd/ca/d025e9da8f06f24c34d2da9873957cfc5f7e0d67802c3e34d0caa8452130/coverage-7.13.3-cp312-cp312-musllinux_1_2_riscv64.whl", hash = "sha256:8f1010029a5b52dc427c8e2a8dbddb2303ddd180b806687d1acd1bb1d06649e7", size = 250794 }, + { url = "https://files.pythonhosted.org/packages/45/c7/76bf35d5d488ec8f68682eb8e7671acc50a6d2d1c1182de1d2b6d4ffad3b/coverage-7.13.3-cp312-cp312-musllinux_1_2_x86_64.whl", hash = "sha256:cd5dee4fd7659d8306ffa79eeaaafd91fa30a302dac3af723b9b469e549247e0", size = 252671 }, + { url = "https://files.pythonhosted.org/packages/bf/10/1921f1a03a7c209e1cb374f81a6b9b68b03cdb3ecc3433c189bc90e2a3d5/coverage-7.13.3-cp312-cp312-win32.whl", hash = "sha256:f7f153d0184d45f3873b3ad3ad22694fd73aadcb8cdbc4337ab4b41ea6b4dff1", size = 221986 }, + { url = "https://files.pythonhosted.org/packages/3c/7c/f5d93297f8e125a80c15545edc754d93e0ed8ba255b65e609b185296af01/coverage-7.13.3-cp312-cp312-win_amd64.whl", hash = "sha256:03a6e5e1e50819d6d7436f5bc40c92ded7e484e400716886ac921e35c133149d", size = 222793 }, + { url = "https://files.pythonhosted.org/packages/43/59/c86b84170015b4555ebabca8649bdf9f4a1f737a73168088385ed0f947c4/coverage-7.13.3-cp312-cp312-win_arm64.whl", hash = "sha256:51c4c42c0e7d09a822b08b6cf79b3c4db8333fffde7450da946719ba0d45730f", size = 221410 }, + { url = "https://files.pythonhosted.org/packages/81/f3/4c333da7b373e8c8bfb62517e8174a01dcc373d7a9083698e3b39d50d59c/coverage-7.13.3-cp313-cp313-macosx_10_13_x86_64.whl", hash = "sha256:853c3d3c79ff0db65797aad79dee6be020efd218ac4510f15a205f1e8d13ce25", size = 219468 }, + { url = "https://files.pythonhosted.org/packages/d6/31/0714337b7d23630c8de2f4d56acf43c65f8728a45ed529b34410683f7217/coverage-7.13.3-cp313-cp313-macosx_11_0_arm64.whl", hash = "sha256:f75695e157c83d374f88dcc646a60cb94173304a9258b2e74ba5a66b7614a51a", size = 219839 }, + { url = "https://files.pythonhosted.org/packages/12/99/bd6f2a2738144c98945666f90cae446ed870cecf0421c767475fcf42cdbe/coverage-7.13.3-cp313-cp313-manylinux1_i686.manylinux_2_28_i686.manylinux_2_5_i686.whl", hash = "sha256:2d098709621d0819039f3f1e471ee554f55a0b2ac0d816883c765b14129b5627", size = 250828 }, + { url = "https://files.pythonhosted.org/packages/6f/99/97b600225fbf631e6f5bfd3ad5bcaf87fbb9e34ff87492e5a572ff01bbe2/coverage-7.13.3-cp313-cp313-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:16d23d6579cf80a474ad160ca14d8b319abaa6db62759d6eef53b2fc979b58c8", size = 253432 }, + { url = "https://files.pythonhosted.org/packages/5f/5c/abe2b3490bda26bd4f5e3e799be0bdf00bd81edebedc2c9da8d3ef288fa8/coverage-7.13.3-cp313-cp313-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:00d34b29a59d2076e6f318b30a00a69bf63687e30cd882984ed444e753990cc1", size = 254672 }, + { url = "https://files.pythonhosted.org/packages/31/ba/5d1957c76b40daff53971fe0adb84d9c2162b614280031d1d0653dd010c1/coverage-7.13.3-cp313-cp313-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:ab6d72bffac9deb6e6cb0f61042e748de3f9f8e98afb0375a8e64b0b6e11746b", size = 251050 }, + { url = "https://files.pythonhosted.org/packages/69/dc/dffdf3bfe9d32090f047d3c3085378558cb4eb6778cda7de414ad74581ed/coverage-7.13.3-cp313-cp313-musllinux_1_2_aarch64.whl", hash = "sha256:e129328ad1258e49cae0123a3b5fcb93d6c2fa90d540f0b4c7cdcdc019aaa3dc", size = 252801 }, + { url = "https://files.pythonhosted.org/packages/87/51/cdf6198b0f2746e04511a30dc9185d7b8cdd895276c07bdb538e37f1cd50/coverage-7.13.3-cp313-cp313-musllinux_1_2_i686.whl", hash = "sha256:2213a8d88ed35459bda71597599d4eec7c2ebad201c88f0bfc2c26fd9b0dd2ea", size = 250763 }, + { url = "https://files.pythonhosted.org/packages/d7/1a/596b7d62218c1d69f2475b69cc6b211e33c83c902f38ee6ae9766dd422da/coverage-7.13.3-cp313-cp313-musllinux_1_2_riscv64.whl", hash = "sha256:00dd3f02de6d5f5c9c3d95e3e036c3c2e2a669f8bf2d3ceb92505c4ce7838f67", size = 250587 }, + { url = "https://files.pythonhosted.org/packages/f7/46/52330d5841ff660f22c130b75f5e1dd3e352c8e7baef5e5fef6b14e3e991/coverage-7.13.3-cp313-cp313-musllinux_1_2_x86_64.whl", hash = "sha256:f9bada7bc660d20b23d7d312ebe29e927b655cf414dadcdb6335a2075695bd86", size = 252358 }, + { url = "https://files.pythonhosted.org/packages/36/8a/e69a5be51923097ba7d5cff9724466e74fe486e9232020ba97c809a8b42b/coverage-7.13.3-cp313-cp313-win32.whl", hash = "sha256:75b3c0300f3fa15809bd62d9ca8b170eb21fcf0100eb4b4154d6dc8b3a5bbd43", size = 222007 }, + { url = "https://files.pythonhosted.org/packages/0a/09/a5a069bcee0d613bdd48ee7637fa73bc09e7ed4342b26890f2df97cc9682/coverage-7.13.3-cp313-cp313-win_amd64.whl", hash = "sha256:a2f7589c6132c44c53f6e705e1a6677e2b7821378c22f7703b2cf5388d0d4587", size = 222812 }, + { url = "https://files.pythonhosted.org/packages/3d/4f/d62ad7dfe32f9e3d4a10c178bb6f98b10b083d6e0530ca202b399371f6c1/coverage-7.13.3-cp313-cp313-win_arm64.whl", hash = "sha256:123ceaf2b9d8c614f01110f908a341e05b1b305d6b2ada98763b9a5a59756051", size = 221433 }, + { url = "https://files.pythonhosted.org/packages/04/b2/4876c46d723d80b9c5b695f1a11bf5f7c3dabf540ec00d6edc076ff025e6/coverage-7.13.3-cp313-cp313t-macosx_10_13_x86_64.whl", hash = "sha256:cc7fd0f726795420f3678ac82ff882c7fc33770bd0074463b5aef7293285ace9", size = 220162 }, + { url = "https://files.pythonhosted.org/packages/fc/04/9942b64a0e0bdda2c109f56bda42b2a59d9d3df4c94b85a323c1cae9fc77/coverage-7.13.3-cp313-cp313t-macosx_11_0_arm64.whl", hash = "sha256:d358dc408edc28730aed5477a69338e444e62fba0b7e9e4a131c505fadad691e", size = 220510 }, + { url = "https://files.pythonhosted.org/packages/5a/82/5cfe1e81eae525b74669f9795f37eb3edd4679b873d79d1e6c1c14ee6c1c/coverage-7.13.3-cp313-cp313t-manylinux1_i686.manylinux_2_28_i686.manylinux_2_5_i686.whl", hash = "sha256:5d67b9ed6f7b5527b209b24b3df9f2e5bf0198c1bbf99c6971b0e2dcb7e2a107", size = 261801 }, + { url = "https://files.pythonhosted.org/packages/0b/ec/a553d7f742fd2cd12e36a16a7b4b3582d5934b496ef2b5ea8abeb10903d4/coverage-7.13.3-cp313-cp313t-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:59224bfb2e9b37c1335ae35d00daa3a5b4e0b1a20f530be208fff1ecfa436f43", size = 263882 }, + { url = "https://files.pythonhosted.org/packages/e1/58/8f54a2a93e3d675635bc406de1c9ac8d551312142ff52c9d71b5e533ad45/coverage-7.13.3-cp313-cp313t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:ae9306b5299e31e31e0d3b908c66bcb6e7e3ddca143dea0266e9ce6c667346d3", size = 266306 }, + { url = "https://files.pythonhosted.org/packages/1a/be/e593399fd6ea1f00aee79ebd7cc401021f218d34e96682a92e1bae092ff6/coverage-7.13.3-cp313-cp313t-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:343aaeb5f8bb7bcd38620fd7bc56e6ee8207847d8c6103a1e7b72322d381ba4a", size = 261051 }, + { url = "https://files.pythonhosted.org/packages/5c/e5/e9e0f6138b21bcdebccac36fbfde9cf15eb1bbcea9f5b1f35cd1f465fb91/coverage-7.13.3-cp313-cp313t-musllinux_1_2_aarch64.whl", hash = "sha256:b2182129f4c101272ff5f2f18038d7b698db1bf8e7aa9e615cb48440899ad32e", size = 263868 }, + { url = "https://files.pythonhosted.org/packages/9a/bf/de72cfebb69756f2d4a2dde35efcc33c47d85cd3ebdf844b3914aac2ef28/coverage-7.13.3-cp313-cp313t-musllinux_1_2_i686.whl", hash = "sha256:94d2ac94bd0cc57c5626f52f8c2fffed1444b5ae8c9fc68320306cc2b255e155", size = 261498 }, + { url = "https://files.pythonhosted.org/packages/f2/91/4a2d313a70fc2e98ca53afd1c8ce67a89b1944cd996589a5b1fe7fbb3e5c/coverage-7.13.3-cp313-cp313t-musllinux_1_2_riscv64.whl", hash = "sha256:65436cde5ecabe26fb2f0bf598962f0a054d3f23ad529361326ac002c61a2a1e", size = 260394 }, + { url = "https://files.pythonhosted.org/packages/40/83/25113af7cf6941e779eb7ed8de2a677865b859a07ccee9146d4cc06a03e3/coverage-7.13.3-cp313-cp313t-musllinux_1_2_x86_64.whl", hash = "sha256:db83b77f97129813dbd463a67e5335adc6a6a91db652cc085d60c2d512746f96", size = 262579 }, + { url = "https://files.pythonhosted.org/packages/1e/19/a5f2b96262977e82fb9aabbe19b4d83561f5d063f18dde3e72f34ffc3b2f/coverage-7.13.3-cp313-cp313t-win32.whl", hash = "sha256:dfb428e41377e6b9ba1b0a32df6db5409cb089a0ed1d0a672dc4953ec110d84f", size = 222679 }, + { url = "https://files.pythonhosted.org/packages/81/82/ef1747b88c87a5c7d7edc3704799ebd650189a9158e680a063308b6125ef/coverage-7.13.3-cp313-cp313t-win_amd64.whl", hash = "sha256:5badd7e596e6b0c89aa8ec6d37f4473e4357f982ce57f9a2942b0221cd9cf60c", size = 223740 }, + { url = "https://files.pythonhosted.org/packages/1c/4c/a67c7bb5b560241c22736a9cb2f14c5034149ffae18630323fde787339e4/coverage-7.13.3-cp313-cp313t-win_arm64.whl", hash = "sha256:989aa158c0eb19d83c76c26f4ba00dbb272485c56e452010a3450bdbc9daafd9", size = 221996 }, + { url = "https://files.pythonhosted.org/packages/5e/b3/677bb43427fed9298905106f39c6520ac75f746f81b8f01104526a8026e4/coverage-7.13.3-cp314-cp314-macosx_10_15_x86_64.whl", hash = "sha256:c6f6169bbdbdb85aab8ac0392d776948907267fcc91deeacf6f9d55f7a83ae3b", size = 219513 }, + { url = "https://files.pythonhosted.org/packages/42/53/290046e3bbf8986cdb7366a42dab3440b9983711eaff044a51b11006c67b/coverage-7.13.3-cp314-cp314-macosx_11_0_arm64.whl", hash = "sha256:2f5e731627a3d5ef11a2a35aa0c6f7c435867c7ccbc391268eb4f2ca5dbdcc10", size = 219850 }, + { url = "https://files.pythonhosted.org/packages/ea/2b/ab41f10345ba2e49d5e299be8663be2b7db33e77ac1b85cd0af985ea6406/coverage-7.13.3-cp314-cp314-manylinux1_i686.manylinux_2_28_i686.manylinux_2_5_i686.whl", hash = "sha256:9db3a3285d91c0b70fab9f39f0a4aa37d375873677efe4e71e58d8321e8c5d39", size = 250886 }, + { url = "https://files.pythonhosted.org/packages/72/2d/b3f6913ee5a1d5cdd04106f257e5fac5d048992ffc2d9995d07b0f17739f/coverage-7.13.3-cp314-cp314-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:06e49c5897cb12e3f7ecdc111d44e97c4f6d0557b81a7a0204ed70a8b038f86f", size = 253393 }, + { url = "https://files.pythonhosted.org/packages/f0/f6/b1f48810ffc6accf49a35b9943636560768f0812330f7456aa87dc39aff5/coverage-7.13.3-cp314-cp314-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:fb25061a66802df9fc13a9ba1967d25faa4dae0418db469264fd9860a921dde4", size = 254740 }, + { url = "https://files.pythonhosted.org/packages/57/d0/e59c54f9be0b61808f6bc4c8c4346bd79f02dd6bbc3f476ef26124661f20/coverage-7.13.3-cp314-cp314-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:99fee45adbb1caeb914da16f70e557fb7ff6ddc9e4b14de665bd41af631367ef", size = 250905 }, + { url = "https://files.pythonhosted.org/packages/d5/f7/5291bcdf498bafbee3796bb32ef6966e9915aebd4d0954123c8eae921c32/coverage-7.13.3-cp314-cp314-musllinux_1_2_aarch64.whl", hash = "sha256:318002f1fd819bdc1651c619268aa5bc853c35fa5cc6d1e8c96bd9cd6c828b75", size = 252753 }, + { url = "https://files.pythonhosted.org/packages/a0/a9/1dcafa918c281554dae6e10ece88c1add82db685be123e1b05c2056ff3fb/coverage-7.13.3-cp314-cp314-musllinux_1_2_i686.whl", hash = "sha256:71295f2d1d170b9977dc386d46a7a1b7cbb30e5405492529b4c930113a33f895", size = 250716 }, + { url = "https://files.pythonhosted.org/packages/44/bb/4ea4eabcce8c4f6235df6e059fbc5db49107b24c4bdffc44aee81aeca5a8/coverage-7.13.3-cp314-cp314-musllinux_1_2_riscv64.whl", hash = "sha256:5b1ad2e0dc672625c44bc4fe34514602a9fd8b10d52ddc414dc585f74453516c", size = 250530 }, + { url = "https://files.pythonhosted.org/packages/6d/31/4a6c9e6a71367e6f923b27b528448c37f4e959b7e4029330523014691007/coverage-7.13.3-cp314-cp314-musllinux_1_2_x86_64.whl", hash = "sha256:b2beb64c145593a50d90db5c7178f55daeae129123b0d265bdb3cbec83e5194a", size = 252186 }, + { url = "https://files.pythonhosted.org/packages/27/92/e1451ef6390a4f655dc42da35d9971212f7abbbcad0bdb7af4407897eb76/coverage-7.13.3-cp314-cp314-win32.whl", hash = "sha256:3d1aed4f4e837a832df2f3b4f68a690eede0de4560a2dbc214ea0bc55aabcdb4", size = 222253 }, + { url = "https://files.pythonhosted.org/packages/8a/98/78885a861a88de020c32a2693487c37d15a9873372953f0c3c159d575a43/coverage-7.13.3-cp314-cp314-win_amd64.whl", hash = "sha256:9f9efbbaf79f935d5fbe3ad814825cbce4f6cdb3054384cb49f0c0f496125fa0", size = 223069 }, + { url = "https://files.pythonhosted.org/packages/eb/fb/3784753a48da58a5337972abf7ca58b1fb0f1bda21bc7b4fae992fd28e47/coverage-7.13.3-cp314-cp314-win_arm64.whl", hash = "sha256:31b6e889c53d4e6687ca63706148049494aace140cffece1c4dc6acadb70a7b3", size = 221633 }, + { url = "https://files.pythonhosted.org/packages/40/f9/75b732d9674d32cdbffe801ed5f770786dd1c97eecedef2125b0d25102dc/coverage-7.13.3-cp314-cp314t-macosx_10_15_x86_64.whl", hash = "sha256:c5e9787cec750793a19a28df7edd85ac4e49d3fb91721afcdc3b86f6c08d9aa8", size = 220243 }, + { url = "https://files.pythonhosted.org/packages/cf/7e/2868ec95de5a65703e6f0c87407ea822d1feb3619600fbc3c1c4fa986090/coverage-7.13.3-cp314-cp314t-macosx_11_0_arm64.whl", hash = "sha256:e5b86db331c682fd0e4be7098e6acee5e8a293f824d41487c667a93705d415ca", size = 220515 }, + { url = "https://files.pythonhosted.org/packages/7d/eb/9f0d349652fced20bcaea0f67fc5777bd097c92369f267975732f3dc5f45/coverage-7.13.3-cp314-cp314t-manylinux1_i686.manylinux_2_28_i686.manylinux_2_5_i686.whl", hash = "sha256:edc7754932682d52cf6e7a71806e529ecd5ce660e630e8bd1d37109a2e5f63ba", size = 261874 }, + { url = "https://files.pythonhosted.org/packages/ee/a5/6619bc4a6c7b139b16818149a3e74ab2e21599ff9a7b6811b6afde99f8ec/coverage-7.13.3-cp314-cp314t-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:d3a16d6398666510a6886f67f43d9537bfd0e13aca299688a19daa84f543122f", size = 264004 }, + { url = "https://files.pythonhosted.org/packages/29/b7/90aa3fc645a50c6f07881fca4fd0ba21e3bfb6ce3a7078424ea3a35c74c9/coverage-7.13.3-cp314-cp314t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:303d38b19626c1981e1bb067a9928236d88eb0e4479b18a74812f05a82071508", size = 266408 }, + { url = "https://files.pythonhosted.org/packages/62/55/08bb2a1e4dcbae384e638f0effef486ba5987b06700e481691891427d879/coverage-7.13.3-cp314-cp314t-manylinux_2_31_riscv64.manylinux_2_39_riscv64.whl", hash = "sha256:284e06eadfe15ddfee2f4ee56631f164ef897a7d7d5a15bca5f0bb88889fc5ba", size = 260977 }, + { url = "https://files.pythonhosted.org/packages/9b/76/8bd4ae055a42d8fb5dd2230e5cf36ff2e05f85f2427e91b11a27fea52ed7/coverage-7.13.3-cp314-cp314t-musllinux_1_2_aarch64.whl", hash = "sha256:d401f0864a1d3198422816878e4e84ca89ec1c1bf166ecc0ae01380a39b888cd", size = 263868 }, + { url = "https://files.pythonhosted.org/packages/e3/f9/ba000560f11e9e32ec03df5aa8477242c2d95b379c99ac9a7b2e7fbacb1a/coverage-7.13.3-cp314-cp314t-musllinux_1_2_i686.whl", hash = "sha256:3f379b02c18a64de78c4ccdddf1c81c2c5ae1956c72dacb9133d7dd7809794ab", size = 261474 }, + { url = "https://files.pythonhosted.org/packages/90/4b/4de4de8f9ca7af4733bfcf4baa440121b7dbb3856daf8428ce91481ff63b/coverage-7.13.3-cp314-cp314t-musllinux_1_2_riscv64.whl", hash = "sha256:7a482f2da9086971efb12daca1d6547007ede3674ea06e16d7663414445c683e", size = 260317 }, + { url = "https://files.pythonhosted.org/packages/05/71/5cd8436e2c21410ff70be81f738c0dddea91bcc3189b1517d26e0102ccb3/coverage-7.13.3-cp314-cp314t-musllinux_1_2_x86_64.whl", hash = "sha256:562136b0d401992118d9b49fbee5454e16f95f85b120a4226a04d816e33fe024", size = 262635 }, + { url = "https://files.pythonhosted.org/packages/e7/f8/2834bb45bdd70b55a33ec354b8b5f6062fc90e5bb787e14385903a979503/coverage-7.13.3-cp314-cp314t-win32.whl", hash = "sha256:ca46e5c3be3b195098dd88711890b8011a9fa4feca942292bb84714ce5eab5d3", size = 223035 }, + { url = "https://files.pythonhosted.org/packages/26/75/f8290f0073c00d9ae14056d2b84ab92dff21d5370e464cb6cb06f52bf580/coverage-7.13.3-cp314-cp314t-win_amd64.whl", hash = "sha256:06d316dbb3d9fd44cca05b2dbcfbef22948493d63a1f28e828d43e6cc505fed8", size = 224142 }, + { url = "https://files.pythonhosted.org/packages/03/01/43ac78dfea8946c4a9161bbc034b5549115cb2b56781a4b574927f0d141a/coverage-7.13.3-cp314-cp314t-win_arm64.whl", hash = "sha256:299d66e9218193f9dc6e4880629ed7c4cd23486005166247c283fb98531656c3", size = 222166 }, + { url = "https://files.pythonhosted.org/packages/7d/fb/70af542d2d938c778c9373ce253aa4116dbe7c0a5672f78b2b2ae0e1b94b/coverage-7.13.3-py3-none-any.whl", hash = "sha256:90a8af9dba6429b2573199622d72e0ebf024d6276f16abce394ad4d181bb0910", size = 211237 }, +] + +[package.optional-dependencies] +toml = [ + { name = "tomli", marker = "python_full_version <= '3.11'" }, ] [[package]] @@ -103,18 +373,6 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/50/58/da5ada423f010318958db6de98c188afa915e31f5ad4ac072c2e73563a53/cramjam-2.10.0-pp311-pypy311_pp73-win_amd64.whl", hash = "sha256:2c1eb6e6c3d5c1cc3f7c7f8a52e034340a3c454641f019687fa94077c05da5c2", size = 1707057 }, ] -[[package]] -name = "customtkinter" -version = "5.2.0" -source = { registry = "https://pypi.org/simple" } -dependencies = [ - { name = "darkdetect" }, -] -sdist = { url = "https://files.pythonhosted.org/packages/e3/85/2aea0f61e68c4896e0522bb1ff01badb7f40c83a550099156856037893ed/customtkinter-5.2.0.tar.gz", hash = "sha256:e93448a8d22121e20ec16e95960a8306e17cf7e0079766f5804b2e855e614937", size = 261634 } -wheels = [ - { url = "https://files.pythonhosted.org/packages/82/23/00394404c38db474d31471e618abbbc0034483c0d4178ba6328647da1a32/customtkinter-5.2.0-py3-none-any.whl", hash = "sha256:f8b2db189959033539884d7faff99ebbb654c18097d761ed844180e32f0b5929", size = 295625 }, -] - [[package]] name = "darkdetect" version = "0.8.0" @@ -133,6 +391,15 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/d5/50/83c593b07763e1161326b3b8c6686f0f4b0f24d5526546bee538c89837d6/decorator-5.1.1-py3-none-any.whl", hash = "sha256:b8c3f85900b9dc423225913c5aace94729fe1fa9763b38939a95226f02d37186", size = 9073 }, ] +[[package]] +name = "distro" +version = "1.9.0" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/fc/f8/98eea607f65de6527f8a2e8885fc8015d3e6f5775df186e443e0964a11c3/distro-1.9.0.tar.gz", hash = "sha256:2fa77c6fd8940f116ee1d6b94a2f90b13b5ea8d019b98bc8bafdcabcdd9bdbed", size = 60722 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/12/b3/231ffd4ab1fc9d679809f356cebee130ac7daa00d6d6f3206dd4fd137e9e/distro-1.9.0-py3-none-any.whl", hash = "sha256:7bffd925d65168f85027d8da9af6bddab658135b840670a223589bc0c8ef02b2", size = 20277 }, +] + [[package]] name = "et-xmlfile" version = "1.1.0" @@ -142,6 +409,18 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/96/c2/3dd434b0108730014f1b96fd286040dc3bcb70066346f7e01ec2ac95865f/et_xmlfile-1.1.0-py3-none-any.whl", hash = "sha256:a2ba85d1d6a74ef63837eed693bcb89c3f752169b0e3e7ae5b16ca5e1b3deada", size = 4688 }, ] +[[package]] +name = "exceptiongroup" +version = "1.3.1" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "typing-extensions", marker = "python_full_version < '3.11'" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/50/79/66800aadf48771f6b62f7eb014e352e5d06856655206165d775e675a02c9/exceptiongroup-1.3.1.tar.gz", hash = "sha256:8b412432c6055b0b7d14c310000ae93352ed6754f70fa8f7c34141f91c4e3219", size = 30371 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/8a/0e/97c33bf5009bdbac74fd2beace167cab3f978feb69cc36f1ef79360d6c4e/exceptiongroup-1.3.1-py3-none-any.whl", hash = "sha256:a7a39a3bd276781e98394987d3a5701d0c4edffb633bb7a5144577f82c773598", size = 16740 }, +] + [[package]] name = "executing" version = "1.2.0" @@ -151,6 +430,21 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/28/3c/bc3819dd8b1a1588c9215a87271b6178cc5498acaa83885211f5d4d9e693/executing-1.2.0-py2.py3-none-any.whl", hash = "sha256:0314a69e37426e3608aada02473b4161d4caf5a4b244d1d0c48072b8fee7bacc", size = 24360 }, ] +[[package]] +name = "fastapi" +version = "0.128.1" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "annotated-doc" }, + { name = "pydantic" }, + { name = "starlette" }, + { name = "typing-extensions" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/f6/59/28bde150415783ff084334e3de106eb7461a57864cf69f343950ad5a5ddd/fastapi-0.128.1.tar.gz", hash = "sha256:ce5be4fa26d4ce6f54debcc873d1fb8e0e248f5c48d7502ba6c61457ab2dc766", size = 374260 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/1a/08/3953db1979ea131c68279b997c6465080118b407f0800445b843f8e164b3/fastapi-0.128.1-py3-none-any.whl", hash = "sha256:ee82146bbf91ea5bbf2bb8629e4c6e056c4fbd997ea6068501b11b15260b50fb", size = 103810 }, +] + [[package]] name = "fastparquet" version = "2024.11.0" @@ -207,6 +501,209 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/44/4b/e0cfc1a6f17e990f3e64b7d941ddc4acdc7b19d6edd51abf495f32b1a9e4/fsspec-2025.3.2-py3-none-any.whl", hash = "sha256:2daf8dc3d1dfa65b6aa37748d112773a7a08416f6c70d96b264c96476ecaf711", size = 194435 }, ] +[[package]] +name = "granian" +version = "2.7.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "click" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/43/75/bdea4ab49a02772a3007e667284764081d401169e96d0270d95509e3e240/granian-2.7.0.tar.gz", hash = "sha256:bee8e8a81a259e6f08613c973062df9db5f8451b521bb0259ed8f27d3e2bab23", size = 127963 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/f2/c5/0c4469c7eb6d42e8ad3706e8f918fdbed1e79f4b2061749ed89568b84746/granian-2.7.0-cp310-cp310-macosx_10_12_x86_64.whl", hash = "sha256:442ced696212b1964579a89bb40bd504822ad87326f95488d8117fff0c21cba9", size = 4581109 }, + { url = "https://files.pythonhosted.org/packages/4f/dd/7954ec98c82e0b3e954a9b5263fcd77258b502bf0e021f2c5e8a84da87b6/granian-2.7.0-cp310-cp310-macosx_11_0_arm64.whl", hash = "sha256:4c07ebe3f8b7284264475ac4ee58839c0f3f1d3f292b40f8ea50363bf8277ef5", size = 4210308 }, + { url = "https://files.pythonhosted.org/packages/70/e8/62a48b7f0092f465cd24c71e7c990c55554095c6cad5c97975009e5ef223/granian-2.7.0-cp310-cp310-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:c7817854489e944e8d0cdfe4695b5605a3b042ae169fc43505c6f6c5b05d8c3a", size = 5129886 }, + { url = "https://files.pythonhosted.org/packages/09/28/43d8fcfad80ddb38a9311538de93f5225a5e28db8b7fc31146199f6d8cdd/granian-2.7.0-cp310-cp310-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:0d9f4dc1e575d15ea8c0f433dc4190efa69d259bf59a136f009b28de223ef177", size = 4576645 }, + { url = "https://files.pythonhosted.org/packages/a4/66/5409d0049b0878775e50b8f4e1bc71cb1780f895632e5c7d08c558b3fec2/granian-2.7.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:960908d8a2fb3cc5472fdd3de52a342d6fd76a12146e2447b38706bb01c31f76", size = 4975287 }, + { url = "https://files.pythonhosted.org/packages/58/eb/a6c1992d2902db13cca3637758b5e1064e70ee2342f6d8b66b80ba805f1f/granian-2.7.0-cp310-cp310-manylinux_2_28_aarch64.whl", hash = "sha256:b974e28265e2001539446f456973e6dc8aaeee8c61d31233d0a55d34c2f5482c", size = 4827993 }, + { url = "https://files.pythonhosted.org/packages/0a/8a/0dbafb77124c3534048879fd7466f880fcff3606e63ebdac94633a3694c3/granian-2.7.0-cp310-cp310-musllinux_1_1_aarch64.whl", hash = "sha256:a83a107ce9bcb9609fa3e808f39e3d940cd3933f6c54d7b6c37053767a862b9a", size = 4939190 }, + { url = "https://files.pythonhosted.org/packages/8c/c5/ec1910ca216429e091dd39d07d9053592a38a0e75d25bdcf79cf77fc8d79/granian-2.7.0-cp310-cp310-musllinux_1_1_armv7l.whl", hash = "sha256:aa4876903c4c80b26c23231ff71437b1c7489504c4e1c18642ab6898926e2e38", size = 5292735 }, + { url = "https://files.pythonhosted.org/packages/a0/0f/778a5cb91502f1d813d135b0a0c99a6b7d46cdb00af0b9d7e3b8c1b557c5/granian-2.7.0-cp310-cp310-musllinux_1_1_x86_64.whl", hash = "sha256:be9638b47c9554104eebc99ef9313d016f37ee6e37e03d1d65f1fa495880856d", size = 5087382 }, + { url = "https://files.pythonhosted.org/packages/68/63/5b420ba3c60eaff7c41729cdadeb9e42ce99be3cbab5e6724c6b2844cad1/granian-2.7.0-cp310-cp310-win_amd64.whl", hash = "sha256:4ab66aaf9a7a8fb47d54e6a8eb167d3dd4cdceb4842e57d7a019a2d303bcefd8", size = 3221039 }, + { url = "https://files.pythonhosted.org/packages/8a/28/a3ee3f2220c0b9045f8caa2a2cb7484618961b7500f88594349a7889d391/granian-2.7.0-cp311-cp311-macosx_10_12_x86_64.whl", hash = "sha256:e76afb483d7f42a0b911bdb447d282f70ad7a96caabd4c99cdc300117c5f8977", size = 4580966 }, + { url = "https://files.pythonhosted.org/packages/1b/60/b53da9c255f6853a5516d0f8a3e7325c24123f0f7e77856558c49810f4ce/granian-2.7.0-cp311-cp311-macosx_11_0_arm64.whl", hash = "sha256:628523302274f95ca967f295a9aa7bc4ade5e1eced42afc60d06dfe20f2da07a", size = 4210344 }, + { url = "https://files.pythonhosted.org/packages/a2/bb/c3380106565bc99edfb90baafa1a8081a4334709ce0200d207ddda36275e/granian-2.7.0-cp311-cp311-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:a62560b64a17e1cbae61038285d5fa8a32613ada9a46f05047dc607ea7d38f23", size = 5130258 }, + { url = "https://files.pythonhosted.org/packages/a2/8f/2c3348d6d33807e3b818ac07366b5251e811ce2548fbe82e0b55982d8a13/granian-2.7.0-cp311-cp311-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:47b8e0e9497d24466d6511443cc18f22f18405aab5a7e2fece1dd38206af88c4", size = 4576496 }, + { url = "https://files.pythonhosted.org/packages/f6/71/d1d146170a23f3523d8629b47f849b30ba0d513eb519188ce5d7bfd1b916/granian-2.7.0-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:cc6039c61a07b2d36462c487b66b131ae3fd862bdc8fb81d6e5c206c1a2b683c", size = 4975062 }, + { url = "https://files.pythonhosted.org/packages/16/f9/f3acbf8c41cd10ff81109bd9078d3228f23e52bab8673763c65739a87e30/granian-2.7.0-cp311-cp311-manylinux_2_28_aarch64.whl", hash = "sha256:f3b0442beb11b035ee09959726f44b3730d0b55688110defd1d9a9a6c7486955", size = 4827755 }, + { url = "https://files.pythonhosted.org/packages/9f/f8/503135b89539feea2be495b47858c22409ba77ffcb71920ae0727c674189/granian-2.7.0-cp311-cp311-musllinux_1_1_aarch64.whl", hash = "sha256:741d0b58a5133cc5902b3129a8a4c55143f0f8769a80e7aa80caadc64c9f1d8b", size = 4939033 }, + { url = "https://files.pythonhosted.org/packages/99/90/aaabe2c1162d07a6af55532b6f616199aa237805ef1d732fa78d9883d217/granian-2.7.0-cp311-cp311-musllinux_1_1_armv7l.whl", hash = "sha256:02a6fe6a19f290b70bc23feeb3809511becdaff2263b0469f02c28772af97652", size = 5292980 }, + { url = "https://files.pythonhosted.org/packages/eb/aa/d1eb7342676893ab0ec1e66cceca4450bec3f29c488db2a92af5b4211d4d/granian-2.7.0-cp311-cp311-musllinux_1_1_x86_64.whl", hash = "sha256:8239b1a661271428c3e358e4bdcaaaf877a432cc593e93fc6b5a612ae521b06a", size = 5087230 }, + { url = "https://files.pythonhosted.org/packages/b8/93/5e907400c378b666b0b859a64719417a15e21173c15a89785270a2f9f5f2/granian-2.7.0-cp311-cp311-win_amd64.whl", hash = "sha256:bbc3da561f28c8ff28d1d40375585be350663955fc996a41acd911fc246d5e4b", size = 3220857 }, + { url = "https://files.pythonhosted.org/packages/97/1a/b6d7840bfd9cd9bed627b138e6e8e49d1961997adba30ee39ad75d07ed58/granian-2.7.0-cp312-cp312-macosx_10_12_x86_64.whl", hash = "sha256:d9c42562dcbf52848d0a9d0db58f8f2e790586eb0c363b8ad1b30fe0bd362117", size = 4572728 }, + { url = "https://files.pythonhosted.org/packages/15/93/f8f7224d9eaaaf4dbf493035a85287fa2e27c17e5f7aacc01821d8aa66b4/granian-2.7.0-cp312-cp312-macosx_11_0_arm64.whl", hash = "sha256:a3421bd5c90430073e1f3f88fc63bc8d0a8ee547a9a5c06d577a281f384160bd", size = 4195034 }, + { url = "https://files.pythonhosted.org/packages/4b/db/66843a35e1b6345da2a1c71839fb9aa7eb0f17d380fbf4cb5c7e06eb6f85/granian-2.7.0-cp312-cp312-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:8b8057dc81772932e208f2327b5e347459eb78896118e27af9845801e267cec5", size = 5123768 }, + { url = "https://files.pythonhosted.org/packages/10/ce/631c5c1f7a4e6b8c98ec857b3e6795fe64e474b6f48df388ac701a21f3fe/granian-2.7.0-cp312-cp312-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:1e5e70f438b1a4787d76566770e98bf7732407efa02802f38f10c960247107d7", size = 4562424 }, + { url = "https://files.pythonhosted.org/packages/28/41/19bdfa3719e22c4dcf6fa1a53323551a37aa58a4ca7a768db6a0ba714ab0/granian-2.7.0-cp312-cp312-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:213dd224a47c7bfcbb91718c7eeb56d6067825a28dcae50f537964e2dafb729a", size = 5006002 }, + { url = "https://files.pythonhosted.org/packages/3c/5b/3b40f489e2449eb58df93ad38f42d1a6c2910502a4bc8017c047e16d637c/granian-2.7.0-cp312-cp312-manylinux_2_28_aarch64.whl", hash = "sha256:bb5be27c0265268d43bab9a878ac27a20b4288843ffc9fda1009b8226673f629", size = 4825073 }, + { url = "https://files.pythonhosted.org/packages/04/92/b6de6f8c4146409efb58aee75277b810d54de03a1687d33f1f3f1feb3395/granian-2.7.0-cp312-cp312-musllinux_1_1_aarch64.whl", hash = "sha256:a6ff95aede82903c06eb560a32b10e9235fdafc4568c8fe7dcac28d62be5ffa2", size = 4928628 }, + { url = "https://files.pythonhosted.org/packages/39/21/d8a191dcfbf8422b868ab847829670075ba3e4325611e0a9fd2dc909a142/granian-2.7.0-cp312-cp312-musllinux_1_1_armv7l.whl", hash = "sha256:e44f0c1676b27582df26d47cf466fedebd72f520edc2025f125c83ff58af77f9", size = 5282898 }, + { url = "https://files.pythonhosted.org/packages/d0/46/2746f1a4f0f093576fb64b63c3f022f254c6d2c4cc66d37dd881608397ce/granian-2.7.0-cp312-cp312-musllinux_1_1_x86_64.whl", hash = "sha256:9241b72f95ceb57e2bbce55e0f61c250c1c02e9d2f8531b027dd3dc204209fdd", size = 5118453 }, + { url = "https://files.pythonhosted.org/packages/5d/ae/5eed3948ecb11a10cb3ec61526d294472e714dd9c6702971c9675c0567f3/granian-2.7.0-cp312-cp312-win_amd64.whl", hash = "sha256:890b7d4fdf8e9cefe16bcde4c6395f14f5ee3b5b73df7fda7dd2799fc7660815", size = 3232918 }, + { url = "https://files.pythonhosted.org/packages/f8/df/b68626242fb4913df0968ee5662f5a394857b3d6fc4ee17c94be69664491/granian-2.7.0-cp313-cp313-macosx_10_12_x86_64.whl", hash = "sha256:bc61451791c8963232e4921c6805e7c2e366635e1e658267b1854889116ff6d7", size = 4572200 }, + { url = "https://files.pythonhosted.org/packages/c0/15/2fe28bca0751d9dc46e5c7e9e4b0c4fd1a55e3e8ba062f28292322ee160b/granian-2.7.0-cp313-cp313-macosx_11_0_arm64.whl", hash = "sha256:e274a0d6a01c475b9135212106ca5b69f5ec2f67f4ca6ce812d185d80255cdf5", size = 4195415 }, + { url = "https://files.pythonhosted.org/packages/07/2a/d4dc40e58a55835cac5296f5090cc3ce2d43332ad486bbf78b3a00e46199/granian-2.7.0-cp313-cp313-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:34bd28075adae3453c596ee20089e0288379e3fdf1cec8bafff89bb175ea0eb4", size = 5122981 }, + { url = "https://files.pythonhosted.org/packages/bd/fe/8c79837df620dc0eca6a8b799505910cbba2d85d92ccc58d1c549f7027be/granian-2.7.0-cp313-cp313-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:f526583b72cf9e6ca9a4849c781ed546f44005f0ad4b5c7eb1090e1ebec209bf", size = 4561440 }, + { url = "https://files.pythonhosted.org/packages/4f/e7/d7abfaa9829ff50cddc27919bd3ce5a335402ebbbaa650e96fe579136674/granian-2.7.0-cp313-cp313-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:95ac07d5314e03e667210349dfc76124d69726731007c24716e21a2554cc15ca", size = 5005076 }, + { url = "https://files.pythonhosted.org/packages/1a/45/108afaa0636c93b6a8ff12810787e4a1ea27fffe59f12ca0de7c784b119a/granian-2.7.0-cp313-cp313-manylinux_2_28_aarch64.whl", hash = "sha256:f6812e342c41ca80e1b34fb6c9a7e51a4bbd14f59025bd1bb59d45a39e02b8d5", size = 4825142 }, + { url = "https://files.pythonhosted.org/packages/4b/eb/cedf4675b1047490f819ce8bd1ee1ea74b6c772ae9d9dd1c117ae690a3eb/granian-2.7.0-cp313-cp313-musllinux_1_1_aarch64.whl", hash = "sha256:7a4099ba59885123405699a5313757556ff106f90336dccdf4ceda76f32657d0", size = 4927830 }, + { url = "https://files.pythonhosted.org/packages/f9/b5/2d7a2e03ba29a6915ad41502e2870899b9eb54861e3d06ad8470c5e70b41/granian-2.7.0-cp313-cp313-musllinux_1_1_armv7l.whl", hash = "sha256:c487731fbae86808410e88c587eb4071213812c5f52570b7981bf07a1b84be25", size = 5282142 }, + { url = "https://files.pythonhosted.org/packages/a9/e7/c851b2e2351727186b4bc4a35df832e2e97e4f77b8a93dfdb6daa098cf9e/granian-2.7.0-cp313-cp313-musllinux_1_1_x86_64.whl", hash = "sha256:ca4877ebf8873488ba72a299206621bd0c6febb8f091f3da62117c1fe344501f", size = 5117907 }, + { url = "https://files.pythonhosted.org/packages/48/ca/87b47f9d63a33a7a16d0fd80217368361d68767fc3adffa5d22342bc1b23/granian-2.7.0-cp313-cp313-win_amd64.whl", hash = "sha256:92004cbb18c1a5b8712260677312fe517807ad39fbc3ad6ff9769c274c11b4ec", size = 3232425 }, + { url = "https://files.pythonhosted.org/packages/e1/2f/c9bcd4aa36d3092fe88a623e60aa89bd4ff16836803a633b8b454946a845/granian-2.7.0-cp313-cp313t-macosx_10_12_x86_64.whl", hash = "sha256:e1df8e4669b4fb69b373b2ab40a10a8c511eeb41838d65adb375d1c0e4e7454c", size = 4493110 }, + { url = "https://files.pythonhosted.org/packages/6a/b4/02d11870255920d35f8eab390e509d3688fe0018011bb606aa00057b778f/granian-2.7.0-cp313-cp313t-macosx_11_0_arm64.whl", hash = "sha256:6331ed9d3eb06cfba737dfb8efa3f0a8b4d4312a5af91c0a67bfbaa078b62eb4", size = 4122388 }, + { url = "https://files.pythonhosted.org/packages/98/50/dfad5a414a2e3e14c30cd0d54cef1dab4874a67c1e6f8b1124d9998ed8b2/granian-2.7.0-cp313-cp313t-manylinux_2_12_i686.manylinux2010_i686.whl", hash = "sha256:093e1c277eddba00eaa94ca82ff7a9ab57b0554cd7013e5b2f3468635dbe520d", size = 4379344 }, + { url = "https://files.pythonhosted.org/packages/6e/53/ef086af03ef31aa3c1dbff2da5928a9b5dd1f48d8ebee18dd6628951ae9e/granian-2.7.0-cp313-cp313t-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:8e8e317bdc9ca9905d0b20f665f8fe31080c7f13d90675439113932bb3272c24", size = 5069172 }, + { url = "https://files.pythonhosted.org/packages/c3/57/117864ea46c6cbcbeff733a4da736e814b06d6634beeb201b9db176bd6be/granian-2.7.0-cp313-cp313t-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:391e8589265178fd7f444b6711b6dda157a6b66059a15bf1033ffceeaf26918c", size = 4848246 }, + { url = "https://files.pythonhosted.org/packages/60/da/2d45b7b6638a77362228d6770a61fa2bc3feae6c52a80993c230f344b197/granian-2.7.0-cp313-cp313t-manylinux_2_28_aarch64.whl", hash = "sha256:49b6873f4a8ee7a1ea627ff98d67ecdd644cfc18aab475b2e15f651dbcbe4140", size = 4669023 }, + { url = "https://files.pythonhosted.org/packages/22/69/49e54eb6ed67ccf471c19d4c65f64197dd5a416d501620519e28ea92c82e/granian-2.7.0-cp313-cp313t-musllinux_1_1_aarch64.whl", hash = "sha256:39778147c7527de0bcda12cd9c38863d4e6a80d3a8a96ddeb6fe2d1342f337db", size = 4896002 }, + { url = "https://files.pythonhosted.org/packages/c5/f1/a864a78029265d06a6fd61c760c8facf032be0d345deca5081718cbb006f/granian-2.7.0-cp313-cp313t-musllinux_1_1_armv7l.whl", hash = "sha256:8135d0a4574dc5a0acf3a815fc6cad5bbe9075ef86df2c091ec34fbd21639c1c", size = 5239945 }, + { url = "https://files.pythonhosted.org/packages/26/33/feef40e4570b771d815c1ddd1008ccc9c0e81ce5a015deded6788e919f18/granian-2.7.0-cp313-cp313t-musllinux_1_1_x86_64.whl", hash = "sha256:47df2d9e50f22fa820b34fd38ceeeedc0b97994fa164425fa30e746759db8a44", size = 5078968 }, + { url = "https://files.pythonhosted.org/packages/ca/20/992f1b02eb444d81efbffb174d9bb97479f50a084e8f22a554bcea0074f3/granian-2.7.0-cp313-cp313t-win_amd64.whl", hash = "sha256:ec1701fdfac2372f1719c593e2c654929c5ecf4ebaecc8e9770e7366b97b024a", size = 3188468 }, + { url = "https://files.pythonhosted.org/packages/b9/6a/b8d58474bbcbca450f030fd41b65c94ae0afb5e8f58c39fbea2df4efee2b/granian-2.7.0-cp314-cp314-macosx_10_12_x86_64.whl", hash = "sha256:23c6531b75c94c7b533812aed4f40dc93008c406cfa5629ec93397cd0f6770cb", size = 4569780 }, + { url = "https://files.pythonhosted.org/packages/c2/dc/a8b11425ebdf6cb58e1084fdb7759d853ca7f0b00376e4bb66300322f5d3/granian-2.7.0-cp314-cp314-macosx_11_0_arm64.whl", hash = "sha256:e4939b86f2b7918202ce56cb01c2efe20a393c742d41640b444e82c8b444b614", size = 4195285 }, + { url = "https://files.pythonhosted.org/packages/7e/b5/6cc0b94f997d93f4b1510b2d953f07a7f1d16a143d60b53e0e50b887fa12/granian-2.7.0-cp314-cp314-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:38fa10adf3c4d50e31a08401e6701ee2488613d905bb316cad456e5ebad5aa81", size = 5121311 }, + { url = "https://files.pythonhosted.org/packages/f4/f9/df3d862874cf4b233f97253bb78991ae4f31179a5581beaa41a2100e3bce/granian-2.7.0-cp314-cp314-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:9b366a9fd713a20321e668768b122b7b0140bfaeb3cb0557b6cb11dce827a4fb", size = 4557737 }, + { url = "https://files.pythonhosted.org/packages/c7/7f/e3063368345f39188afe5baa1ab62fdd951097656cd83bec3964f91f6e66/granian-2.7.0-cp314-cp314-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:a916413e0dcd5c6eaf7f7413a6d899f7ba53a988d08e3b3c7ab2e0b5fa687559", size = 5004108 }, + { url = "https://files.pythonhosted.org/packages/bc/eb/892bcc0cfc44ed791795bab251e0b6ed767397182bac134d9f0fcecc552e/granian-2.7.0-cp314-cp314-manylinux_2_28_aarch64.whl", hash = "sha256:e315adf24162294d35ca4bed66c8f66ac15a0696f2cb462e729122d148f6d958", size = 4823143 }, + { url = "https://files.pythonhosted.org/packages/b3/e0/ff8528bf620b6da7833171f6d30bfe4b4b1d6e7d155b634bd17590e0c4b4/granian-2.7.0-cp314-cp314-musllinux_1_1_aarch64.whl", hash = "sha256:486f8785e716f76f96534aaba25acd5dee1a8398725ffd2a55f0833689c75933", size = 4926328 }, + { url = "https://files.pythonhosted.org/packages/02/f7/fb0a761d39245295660703a42e9448f3c04ce1f26b2f62e044d179167880/granian-2.7.0-cp314-cp314-musllinux_1_1_armv7l.whl", hash = "sha256:0e5e2c1c6ff1501e3675e5237096b90b767f506bb0ef88594310b7b9eaa95532", size = 5281190 }, + { url = "https://files.pythonhosted.org/packages/d6/d8/860e7e96ea109c6db431c8284040d265758bded35f9ce2de05f3969d7c0c/granian-2.7.0-cp314-cp314-musllinux_1_1_x86_64.whl", hash = "sha256:d4418b417f9c2162b4fa9ec41ec34ed3e8ed891463bb058873034222be53542f", size = 5117989 }, + { url = "https://files.pythonhosted.org/packages/c6/27/6e4401bb6ad0d644b3f14ed634d787949943e422f59f45e30c9c761e3167/granian-2.7.0-cp314-cp314-win_amd64.whl", hash = "sha256:648d406dc9cb1d703034611f04d726c1e3fda475c9047b3338a783e9780a3540", size = 3232672 }, + { url = "https://files.pythonhosted.org/packages/fb/9a/500ab01ae273870e8fc056956cc49716707b4a0e76fb2b5993258e1494f7/granian-2.7.0-cp314-cp314t-macosx_10_12_x86_64.whl", hash = "sha256:b4367c088c00bdc38a8a495282070010914931edb4c488499f290c91018d9e80", size = 4492656 }, + { url = "https://files.pythonhosted.org/packages/d0/26/86dc5a6fff60ee0cc38c2fcd1a0d4cebd52e6764a9f752a20458001ca57e/granian-2.7.0-cp314-cp314t-macosx_11_0_arm64.whl", hash = "sha256:c8f3df224284ed1ff673f61de652337d7721100bf4cfc336b2047005b0edb2e0", size = 4122201 }, + { url = "https://files.pythonhosted.org/packages/0f/60/887dc5a099135ff449adcdea9a2aa38f39673baf99de9acb78077b701432/granian-2.7.0-cp314-cp314t-manylinux_2_12_i686.manylinux2010_i686.whl", hash = "sha256:6682c08b0d82ad75f8e9d1571254630133e1563c49f0600c2e2dc26cec743ae7", size = 4377489 }, + { url = "https://files.pythonhosted.org/packages/5a/6b/68c12f8c4c1f1c109bf55d66beeb37a817fd908af5d5d9b48afcbdc3e623/granian-2.7.0-cp314-cp314t-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:d6ccc3bdc2248775b6bd292d7d37a1bff79eb1aaf931f3a217ea9fb9a6fe7ca4", size = 5067294 }, + { url = "https://files.pythonhosted.org/packages/ff/4f/be4f9c129f5f80f52654f257abe91f647defec020fa134b3600013b7219d/granian-2.7.0-cp314-cp314t-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:5431272a4d6f49a200aeb7b01010a3785b93b9bd8cd813d98ed29c8e9ba1c476", size = 4848356 }, + { url = "https://files.pythonhosted.org/packages/d7/aa/f6efcfb435f370a6f3626bd5837465bfb71950f6b3cb3c74e54b176c72e2/granian-2.7.0-cp314-cp314t-manylinux_2_28_aarch64.whl", hash = "sha256:790b150255576775672f26dbcbd6eb05f70260dd661b91ce462f6f3846db9501", size = 4669022 }, + { url = "https://files.pythonhosted.org/packages/1d/36/e86050c476046ef1f0aae0eb86d098fa787abfc8887a131c82baccc7565e/granian-2.7.0-cp314-cp314t-musllinux_1_1_aarch64.whl", hash = "sha256:ce9be999273c181e4b65efbbd82a5bc6f223f1db3463660514d1dc229c8ba760", size = 4895567 }, + { url = "https://files.pythonhosted.org/packages/2b/5e/25283ff7fc12fcf42ae8a5687243119739cf4b0bf5ccb1c32d11d37987b1/granian-2.7.0-cp314-cp314t-musllinux_1_1_armv7l.whl", hash = "sha256:319b34f18ed3162354513acb5a9e8cee720ac166cd88fe05f0f057703eb47e4f", size = 5238652 }, + { url = "https://files.pythonhosted.org/packages/5f/60/06148781120e086c7437aa9513198025ea1eb847cb2e244d5e2b9801782e/granian-2.7.0-cp314-cp314t-musllinux_1_1_x86_64.whl", hash = "sha256:b01bed8ad748840e7ab49373f642076f3bc459e39937a4ce11c5be03e67cdfd9", size = 5079018 }, + { url = "https://files.pythonhosted.org/packages/27/a0/939f10f097000f263310d7fd10ed8a377d0346e2344ac8ffae516767f7b4/granian-2.7.0-cp314-cp314t-win_amd64.whl", hash = "sha256:97c3a714e5716e58f413d186f33d5dedd5853bd40fa6a58a52e14b48a8e009f4", size = 3188857 }, + { url = "https://files.pythonhosted.org/packages/0f/0b/39ebf1b791bbd4049239ecfee8f072321211879e5617a023921961be1d55/granian-2.7.0-pp311-pypy311_pp73-macosx_10_12_x86_64.whl", hash = "sha256:24a1f6a894bea95ef0e603bebacbccd19c319c0da493bb4fde8b94b8629f3dc8", size = 4581648 }, + { url = "https://files.pythonhosted.org/packages/2f/cd/4642192520478bba4cd547124d92607c958a0786864ebe378f3008b40048/granian-2.7.0-pp311-pypy311_pp73-macosx_11_0_arm64.whl", hash = "sha256:c2799497ac896cffea85512983c5d9eb4ae51ebacd7a9a5fd3d2ac81f1755fac", size = 4214257 }, + { url = "https://files.pythonhosted.org/packages/e2/3f/615f93753c3b682219fe546196fc9eb3a045d846e57883312c97de4d785a/granian-2.7.0-pp311-pypy311_pp73-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:b66a15d004136e641706e0e5522b3509151e2027a0677cf4fa97d049d9ddfa41", size = 4979656 }, + { url = "https://files.pythonhosted.org/packages/6e/68/1f2c36a964f93bfe8d6189431b8425acc591b735e47d8898b2e70c478398/granian-2.7.0-pp311-pypy311_pp73-manylinux_2_28_aarch64.whl", hash = "sha256:de5a6fa93d2138ba2372d20d97b87c1af75fa16a59a93841745326825c3ddf83", size = 4844448 }, + { url = "https://files.pythonhosted.org/packages/df/23/d8c83fe6a6656026c734c2ea771cbcdec6f0010e749f8ab0db1bfc8a3dfe/granian-2.7.0-pp311-pypy311_pp73-musllinux_1_1_aarch64.whl", hash = "sha256:aacda2ad46724490c4cd811b8dcadff2260603a3e95ca0d8c33552d791a3c6ac", size = 4930755 }, + { url = "https://files.pythonhosted.org/packages/20/e5/2a86ee18544185e72fc50b50985b6bfb4504f7835875d2636f573e100071/granian-2.7.0-pp311-pypy311_pp73-musllinux_1_1_armv7l.whl", hash = "sha256:7efb5ebdb308ed1685a80cded6ea51447753e8afe92c21fc3abf9a06a9eb5d2e", size = 5295728 }, + { url = "https://files.pythonhosted.org/packages/7e/bd/0d47d17769601c56d876b289456f27799611571227b99ad300e221600bbd/granian-2.7.0-pp311-pypy311_pp73-musllinux_1_1_x86_64.whl", hash = "sha256:ae96b75420d01d9a7dbe1bd84f1898b2b0ade6883db59bfe2b233d7c28c6b0df", size = 5095149 }, + { url = "https://files.pythonhosted.org/packages/a9/36/450aeb7188bdc8efa9827b3ac271c13f738ada4acf3e835324daab744f61/granian-2.7.0-pp311-pypy311_pp73-win_amd64.whl", hash = "sha256:3ec9f1a10f530598d2e23711bebf961fd9b1c1c5d1d5e2491884c5ca8939b4fe", size = 3226981 }, +] + +[package.optional-dependencies] +reload = [ + { name = "watchfiles" }, +] + +[[package]] +name = "greenlet" +version = "3.3.1" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/8a/99/1cd3411c56a410994669062bd73dd58270c00cc074cac15f385a1fd91f8a/greenlet-3.3.1.tar.gz", hash = "sha256:41848f3230b58c08bb43dee542e74a2a2e34d3c59dc3076cec9151aeeedcae98", size = 184690 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/fe/65/5b235b40581ad75ab97dcd8b4218022ae8e3ab77c13c919f1a1dfe9171fd/greenlet-3.3.1-cp310-cp310-macosx_11_0_universal2.whl", hash = "sha256:04bee4775f40ecefcdaa9d115ab44736cd4b9c5fba733575bfe9379419582e13", size = 273723 }, + { url = "https://files.pythonhosted.org/packages/ce/ad/eb4729b85cba2d29499e0a04ca6fbdd8f540afd7be142fd571eea43d712f/greenlet-3.3.1-cp310-cp310-manylinux_2_24_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:50e1457f4fed12a50e427988a07f0f9df53cf0ee8da23fab16e6732c2ec909d4", size = 574874 }, + { url = "https://files.pythonhosted.org/packages/87/32/57cad7fe4c8b82fdaa098c89498ef85ad92dfbb09d5eb713adedfc2ae1f5/greenlet-3.3.1-cp310-cp310-manylinux_2_24_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:070472cd156f0656f86f92e954591644e158fd65aa415ffbe2d44ca77656a8f5", size = 586309 }, + { url = "https://files.pythonhosted.org/packages/66/66/f041005cb87055e62b0d68680e88ec1a57f4688523d5e2fb305841bc8307/greenlet-3.3.1-cp310-cp310-manylinux_2_24_s390x.manylinux_2_28_s390x.whl", hash = "sha256:1108b61b06b5224656121c3c8ee8876161c491cbe74e5c519e0634c837cf93d5", size = 597461 }, + { url = "https://files.pythonhosted.org/packages/87/eb/8a1ec2da4d55824f160594a75a9d8354a5fe0a300fb1c48e7944265217e1/greenlet-3.3.1-cp310-cp310-manylinux_2_24_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:3a300354f27dd86bae5fbf7002e6dd2b3255cd372e9242c933faf5e859b703fe", size = 586985 }, + { url = "https://files.pythonhosted.org/packages/15/1c/0621dd4321dd8c351372ee8f9308136acb628600658a49be1b7504208738/greenlet-3.3.1-cp310-cp310-musllinux_1_2_aarch64.whl", hash = "sha256:e84b51cbebf9ae573b5fbd15df88887815e3253fc000a7d0ff95170e8f7e9729", size = 1547271 }, + { url = "https://files.pythonhosted.org/packages/9d/53/24047f8924c83bea7a59c8678d9571209c6bfe5f4c17c94a78c06024e9f2/greenlet-3.3.1-cp310-cp310-musllinux_1_2_x86_64.whl", hash = "sha256:e0093bd1a06d899892427217f0ff2a3c8f306182b8c754336d32e2d587c131b4", size = 1613427 }, + { url = "https://files.pythonhosted.org/packages/ff/07/ac9bf1ec008916d1a3373cae212884c1dcff4a4ba0d41127ce81a8deb4e9/greenlet-3.3.1-cp310-cp310-win_amd64.whl", hash = "sha256:7932f5f57609b6a3b82cc11877709aa7a98e3308983ed93552a1c377069b20c8", size = 226100 }, + { url = "https://files.pythonhosted.org/packages/ec/e8/2e1462c8fdbe0f210feb5ac7ad2d9029af8be3bf45bd9fa39765f821642f/greenlet-3.3.1-cp311-cp311-macosx_11_0_universal2.whl", hash = "sha256:5fd23b9bc6d37b563211c6abbb1b3cab27db385a4449af5c32e932f93017080c", size = 274974 }, + { url = "https://files.pythonhosted.org/packages/7e/a8/530a401419a6b302af59f67aaf0b9ba1015855ea7e56c036b5928793c5bd/greenlet-3.3.1-cp311-cp311-manylinux_2_24_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:09f51496a0bfbaa9d74d36a52d2580d1ef5ed4fdfcff0a73730abfbbbe1403dd", size = 577175 }, + { url = "https://files.pythonhosted.org/packages/8e/89/7e812bb9c05e1aaef9b597ac1d0962b9021d2c6269354966451e885c4e6b/greenlet-3.3.1-cp311-cp311-manylinux_2_24_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:cb0feb07fe6e6a74615ee62a880007d976cf739b6669cce95daa7373d4fc69c5", size = 590401 }, + { url = "https://files.pythonhosted.org/packages/70/ae/e2d5f0e59b94a2269b68a629173263fa40b63da32f5c231307c349315871/greenlet-3.3.1-cp311-cp311-manylinux_2_24_s390x.manylinux_2_28_s390x.whl", hash = "sha256:67ea3fc73c8cd92f42467a72b75e8f05ed51a0e9b1d15398c913416f2dafd49f", size = 601161 }, + { url = "https://files.pythonhosted.org/packages/5c/ae/8d472e1f5ac5efe55c563f3eabb38c98a44b832602e12910750a7c025802/greenlet-3.3.1-cp311-cp311-manylinux_2_24_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:39eda9ba259cc9801da05351eaa8576e9aa83eb9411e8f0c299e05d712a210f2", size = 590272 }, + { url = "https://files.pythonhosted.org/packages/a8/51/0fde34bebfcadc833550717eade64e35ec8738e6b097d5d248274a01258b/greenlet-3.3.1-cp311-cp311-musllinux_1_2_aarch64.whl", hash = "sha256:e2e7e882f83149f0a71ac822ebf156d902e7a5d22c9045e3e0d1daf59cee2cc9", size = 1550729 }, + { url = "https://files.pythonhosted.org/packages/16/c9/2fb47bee83b25b119d5a35d580807bb8b92480a54b68fef009a02945629f/greenlet-3.3.1-cp311-cp311-musllinux_1_2_x86_64.whl", hash = "sha256:80aa4d79eb5564f2e0a6144fcc744b5a37c56c4a92d60920720e99210d88db0f", size = 1615552 }, + { url = "https://files.pythonhosted.org/packages/1f/54/dcf9f737b96606f82f8dd05becfb8d238db0633dd7397d542a296fe9cad3/greenlet-3.3.1-cp311-cp311-win_amd64.whl", hash = "sha256:32e4ca9777c5addcbf42ff3915d99030d8e00173a56f80001fb3875998fe410b", size = 226462 }, + { url = "https://files.pythonhosted.org/packages/91/37/61e1015cf944ddd2337447d8e97fb423ac9bc21f9963fb5f206b53d65649/greenlet-3.3.1-cp311-cp311-win_arm64.whl", hash = "sha256:da19609432f353fed186cc1b85e9440db93d489f198b4bdf42ae19cc9d9ac9b4", size = 225715 }, + { url = "https://files.pythonhosted.org/packages/f9/c8/9d76a66421d1ae24340dfae7e79c313957f6e3195c144d2c73333b5bfe34/greenlet-3.3.1-cp312-cp312-macosx_11_0_universal2.whl", hash = "sha256:7e806ca53acf6d15a888405880766ec84721aa4181261cd11a457dfe9a7a4975", size = 276443 }, + { url = "https://files.pythonhosted.org/packages/81/99/401ff34bb3c032d1f10477d199724f5e5f6fbfb59816ad1455c79c1eb8e7/greenlet-3.3.1-cp312-cp312-manylinux_2_24_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:d842c94b9155f1c9b3058036c24ffb8ff78b428414a19792b2380be9cecf4f36", size = 597359 }, + { url = "https://files.pythonhosted.org/packages/2b/bc/4dcc0871ed557792d304f50be0f7487a14e017952ec689effe2180a6ff35/greenlet-3.3.1-cp312-cp312-manylinux_2_24_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:20fedaadd422fa02695f82093f9a98bad3dab5fcda793c658b945fcde2ab27ba", size = 607805 }, + { url = "https://files.pythonhosted.org/packages/3b/cd/7a7ca57588dac3389e97f7c9521cb6641fd8b6602faf1eaa4188384757df/greenlet-3.3.1-cp312-cp312-manylinux_2_24_s390x.manylinux_2_28_s390x.whl", hash = "sha256:c620051669fd04ac6b60ebc70478210119c56e2d5d5df848baec4312e260e4ca", size = 622363 }, + { url = "https://files.pythonhosted.org/packages/cf/05/821587cf19e2ce1f2b24945d890b164401e5085f9d09cbd969b0c193cd20/greenlet-3.3.1-cp312-cp312-manylinux_2_24_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:14194f5f4305800ff329cbf02c5fcc88f01886cadd29941b807668a45f0d2336", size = 609947 }, + { url = "https://files.pythonhosted.org/packages/a4/52/ee8c46ed9f8babaa93a19e577f26e3d28a519feac6350ed6f25f1afee7e9/greenlet-3.3.1-cp312-cp312-musllinux_1_2_aarch64.whl", hash = "sha256:7b2fe4150a0cf59f847a67db8c155ac36aed89080a6a639e9f16df5d6c6096f1", size = 1567487 }, + { url = "https://files.pythonhosted.org/packages/8f/7c/456a74f07029597626f3a6db71b273a3632aecb9afafeeca452cfa633197/greenlet-3.3.1-cp312-cp312-musllinux_1_2_x86_64.whl", hash = "sha256:49f4ad195d45f4a66a0eb9c1ba4832bb380570d361912fa3554746830d332149", size = 1636087 }, + { url = "https://files.pythonhosted.org/packages/34/2f/5e0e41f33c69655300a5e54aeb637cf8ff57f1786a3aba374eacc0228c1d/greenlet-3.3.1-cp312-cp312-win_amd64.whl", hash = "sha256:cc98b9c4e4870fa983436afa999d4eb16b12872fab7071423d5262fa7120d57a", size = 227156 }, + { url = "https://files.pythonhosted.org/packages/c8/ab/717c58343cf02c5265b531384b248787e04d8160b8afe53d9eec053d7b44/greenlet-3.3.1-cp312-cp312-win_arm64.whl", hash = "sha256:bfb2d1763d777de5ee495c85309460f6fd8146e50ec9d0ae0183dbf6f0a829d1", size = 226403 }, + { url = "https://files.pythonhosted.org/packages/ec/ab/d26750f2b7242c2b90ea2ad71de70cfcd73a948a49513188a0fc0d6fc15a/greenlet-3.3.1-cp313-cp313-macosx_11_0_universal2.whl", hash = "sha256:7ab327905cabb0622adca5971e488064e35115430cec2c35a50fd36e72a315b3", size = 275205 }, + { url = "https://files.pythonhosted.org/packages/10/d3/be7d19e8fad7c5a78eeefb2d896a08cd4643e1e90c605c4be3b46264998f/greenlet-3.3.1-cp313-cp313-manylinux_2_24_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:65be2f026ca6a176f88fb935ee23c18333ccea97048076aef4db1ef5bc0713ac", size = 599284 }, + { url = "https://files.pythonhosted.org/packages/ae/21/fe703aaa056fdb0f17e5afd4b5c80195bbdab701208918938bd15b00d39b/greenlet-3.3.1-cp313-cp313-manylinux_2_24_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:7a3ae05b3d225b4155bda56b072ceb09d05e974bc74be6c3fc15463cf69f33fd", size = 610274 }, + { url = "https://files.pythonhosted.org/packages/06/00/95df0b6a935103c0452dad2203f5be8377e551b8466a29650c4c5a5af6cc/greenlet-3.3.1-cp313-cp313-manylinux_2_24_s390x.manylinux_2_28_s390x.whl", hash = "sha256:12184c61e5d64268a160226fb4818af4df02cfead8379d7f8b99a56c3a54ff3e", size = 624375 }, + { url = "https://files.pythonhosted.org/packages/cb/86/5c6ab23bb3c28c21ed6bebad006515cfe08b04613eb105ca0041fecca852/greenlet-3.3.1-cp313-cp313-manylinux_2_24_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:6423481193bbbe871313de5fd06a082f2649e7ce6e08015d2a76c1e9186ca5b3", size = 612904 }, + { url = "https://files.pythonhosted.org/packages/c2/f3/7949994264e22639e40718c2daf6f6df5169bf48fb038c008a489ec53a50/greenlet-3.3.1-cp313-cp313-musllinux_1_2_aarch64.whl", hash = "sha256:33a956fe78bbbda82bfc95e128d61129b32d66bcf0a20a1f0c08aa4839ffa951", size = 1567316 }, + { url = "https://files.pythonhosted.org/packages/8d/6e/d73c94d13b6465e9f7cd6231c68abde838bb22408596c05d9059830b7872/greenlet-3.3.1-cp313-cp313-musllinux_1_2_x86_64.whl", hash = "sha256:4b065d3284be43728dd280f6f9a13990b56470b81be20375a207cdc814a983f2", size = 1636549 }, + { url = "https://files.pythonhosted.org/packages/5e/b3/c9c23a6478b3bcc91f979ce4ca50879e4d0b2bd7b9a53d8ecded719b92e2/greenlet-3.3.1-cp313-cp313-win_amd64.whl", hash = "sha256:27289986f4e5b0edec7b5a91063c109f0276abb09a7e9bdab08437525977c946", size = 227042 }, + { url = "https://files.pythonhosted.org/packages/90/e7/824beda656097edee36ab15809fd063447b200cc03a7f6a24c34d520bc88/greenlet-3.3.1-cp313-cp313-win_arm64.whl", hash = "sha256:2f080e028001c5273e0b42690eaf359aeef9cb1389da0f171ea51a5dc3c7608d", size = 226294 }, + { url = "https://files.pythonhosted.org/packages/ae/fb/011c7c717213182caf78084a9bea51c8590b0afda98001f69d9f853a495b/greenlet-3.3.1-cp314-cp314-macosx_11_0_universal2.whl", hash = "sha256:bd59acd8529b372775cd0fcbc5f420ae20681c5b045ce25bd453ed8455ab99b5", size = 275737 }, + { url = "https://files.pythonhosted.org/packages/41/2e/a3a417d620363fdbb08a48b1dd582956a46a61bf8fd27ee8164f9dfe87c2/greenlet-3.3.1-cp314-cp314-manylinux_2_24_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:b31c05dd84ef6871dd47120386aed35323c944d86c3d91a17c4b8d23df62f15b", size = 646422 }, + { url = "https://files.pythonhosted.org/packages/b4/09/c6c4a0db47defafd2d6bab8ddfe47ad19963b4e30f5bed84d75328059f8c/greenlet-3.3.1-cp314-cp314-manylinux_2_24_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:02925a0bfffc41e542c70aa14c7eda3593e4d7e274bfcccca1827e6c0875902e", size = 658219 }, + { url = "https://files.pythonhosted.org/packages/e2/89/b95f2ddcc5f3c2bc09c8ee8d77be312df7f9e7175703ab780f2014a0e781/greenlet-3.3.1-cp314-cp314-manylinux_2_24_s390x.manylinux_2_28_s390x.whl", hash = "sha256:3e0f3878ca3a3ff63ab4ea478585942b53df66ddde327b59ecb191b19dbbd62d", size = 671455 }, + { url = "https://files.pythonhosted.org/packages/80/38/9d42d60dffb04b45f03dbab9430898352dba277758640751dc5cc316c521/greenlet-3.3.1-cp314-cp314-manylinux_2_24_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:34a729e2e4e4ffe9ae2408d5ecaf12f944853f40ad724929b7585bca808a9d6f", size = 660237 }, + { url = "https://files.pythonhosted.org/packages/96/61/373c30b7197f9e756e4c81ae90a8d55dc3598c17673f91f4d31c3c689c3f/greenlet-3.3.1-cp314-cp314-musllinux_1_2_aarch64.whl", hash = "sha256:aec9ab04e82918e623415947921dea15851b152b822661cce3f8e4393c3df683", size = 1615261 }, + { url = "https://files.pythonhosted.org/packages/fd/d3/ca534310343f5945316f9451e953dcd89b36fe7a19de652a1dc5a0eeef3f/greenlet-3.3.1-cp314-cp314-musllinux_1_2_x86_64.whl", hash = "sha256:71c767cf281a80d02b6c1bdc41c9468e1f5a494fb11bc8688c360524e273d7b1", size = 1683719 }, + { url = "https://files.pythonhosted.org/packages/52/cb/c21a3fd5d2c9c8b622e7bede6d6d00e00551a5ee474ea6d831b5f567a8b4/greenlet-3.3.1-cp314-cp314-win_amd64.whl", hash = "sha256:96aff77af063b607f2489473484e39a0bbae730f2ea90c9e5606c9b73c44174a", size = 228125 }, + { url = "https://files.pythonhosted.org/packages/6a/8e/8a2db6d11491837af1de64b8aff23707c6e85241be13c60ed399a72e2ef8/greenlet-3.3.1-cp314-cp314-win_arm64.whl", hash = "sha256:b066e8b50e28b503f604fa538adc764a638b38cf8e81e025011d26e8a627fa79", size = 227519 }, + { url = "https://files.pythonhosted.org/packages/28/24/cbbec49bacdcc9ec652a81d3efef7b59f326697e7edf6ed775a5e08e54c2/greenlet-3.3.1-cp314-cp314t-macosx_11_0_universal2.whl", hash = "sha256:3e63252943c921b90abb035ebe9de832c436401d9c45f262d80e2d06cc659242", size = 282706 }, + { url = "https://files.pythonhosted.org/packages/86/2e/4f2b9323c144c4fe8842a4e0d92121465485c3c2c5b9e9b30a52e80f523f/greenlet-3.3.1-cp314-cp314t-manylinux_2_24_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:76e39058e68eb125de10c92524573924e827927df5d3891fbc97bd55764a8774", size = 651209 }, + { url = "https://files.pythonhosted.org/packages/d9/87/50ca60e515f5bb55a2fbc5f0c9b5b156de7d2fc51a0a69abc9d23914a237/greenlet-3.3.1-cp314-cp314t-manylinux_2_24_ppc64le.manylinux_2_28_ppc64le.whl", hash = "sha256:c9f9d5e7a9310b7a2f416dd13d2e3fd8b42d803968ea580b7c0f322ccb389b97", size = 654300 }, + { url = "https://files.pythonhosted.org/packages/7c/25/c51a63f3f463171e09cb586eb64db0861eb06667ab01a7968371a24c4f3b/greenlet-3.3.1-cp314-cp314t-manylinux_2_24_s390x.manylinux_2_28_s390x.whl", hash = "sha256:4b9721549a95db96689458a1e0ae32412ca18776ed004463df3a9299c1b257ab", size = 662574 }, + { url = "https://files.pythonhosted.org/packages/1d/94/74310866dfa2b73dd08659a3d18762f83985ad3281901ba0ee9a815194fb/greenlet-3.3.1-cp314-cp314t-manylinux_2_24_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:92497c78adf3ac703b57f1e3813c2d874f27f71a178f9ea5887855da413cd6d2", size = 653842 }, + { url = "https://files.pythonhosted.org/packages/97/43/8bf0ffa3d498eeee4c58c212a3905dd6146c01c8dc0b0a046481ca29b18c/greenlet-3.3.1-cp314-cp314t-musllinux_1_2_aarch64.whl", hash = "sha256:ed6b402bc74d6557a705e197d47f9063733091ed6357b3de33619d8a8d93ac53", size = 1614917 }, + { url = "https://files.pythonhosted.org/packages/89/90/a3be7a5f378fc6e84abe4dcfb2ba32b07786861172e502388b4c90000d1b/greenlet-3.3.1-cp314-cp314t-musllinux_1_2_x86_64.whl", hash = "sha256:59913f1e5ada20fde795ba906916aea25d442abcc0593fba7e26c92b7ad76249", size = 1676092 }, + { url = "https://files.pythonhosted.org/packages/e1/2b/98c7f93e6db9977aaee07eb1e51ca63bd5f779b900d362791d3252e60558/greenlet-3.3.1-cp314-cp314t-win_amd64.whl", hash = "sha256:301860987846c24cb8964bdec0e31a96ad4a2a801b41b4ef40963c1b44f33451", size = 233181 }, +] + +[[package]] +name = "gunicorn" +version = "23.0.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "packaging" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/34/72/9614c465dc206155d93eff0ca20d42e1e35afc533971379482de953521a4/gunicorn-23.0.0.tar.gz", hash = "sha256:f014447a0101dc57e294f6c18ca6b40227a4c90e9bdb586042628030cba004ec", size = 375031 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/cb/7d/6dac2a6e1eba33ee43f318edbed4ff29151a49b5d37f080aad1e6469bca4/gunicorn-23.0.0-py3-none-any.whl", hash = "sha256:ec400d38950de4dfd418cff8328b2c8faed0edb0d517d3394e457c317908ca4d", size = 85029 }, +] + +[[package]] +name = "h11" +version = "0.16.0" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/01/ee/02a2c011bdab74c6fb3c75474d40b3052059d95df7e73351460c8588d963/h11-0.16.0.tar.gz", hash = "sha256:4e35b956cf45792e4caa5885e69fba00bdbc6ffafbfa020300e549b208ee5ff1", size = 101250 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/04/4b/29cac41a4d98d144bf5f6d33995617b185d14b22401f75ca86f384e87ff1/h11-0.16.0-py3-none-any.whl", hash = "sha256:63cf8bbe7522de3bf65932fda1d9c2772064ffb3dae62d55932da54b31cb6c86", size = 37515 }, +] + +[[package]] +name = "httpcore" +version = "1.0.9" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "certifi" }, + { name = "h11" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/06/94/82699a10bca87a5556c9c59b5963f2d039dbd239f25bc2a63907a05a14cb/httpcore-1.0.9.tar.gz", hash = "sha256:6e34463af53fd2ab5d807f399a9b45ea31c3dfa2276f15a2c3f00afff6e176e8", size = 85484 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/7e/f5/f66802a942d491edb555dd61e3a9961140fd64c90bce1eafd741609d334d/httpcore-1.0.9-py3-none-any.whl", hash = "sha256:2d400746a40668fc9dec9810239072b40b4484b640a8c38fd654a024c7a1bf55", size = 78784 }, +] + +[[package]] +name = "httpx" +version = "0.28.1" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "anyio" }, + { name = "certifi" }, + { name = "httpcore" }, + { name = "idna" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/b1/df/48c586a5fe32a0f01324ee087459e112ebb7224f646c0b5023f5e79e9956/httpx-0.28.1.tar.gz", hash = "sha256:75e98c5f16b0f35b567856f597f06ff2270a374470a5c2392242528e3e3e42fc", size = 141406 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/2a/39/e50c7c3a983047577ee07d2a9e53faf5a69493943ec3f6a384bdc792deb2/httpx-0.28.1-py3-none-any.whl", hash = "sha256:d909fcccc110f8c7faf814ca82a9a4d816bc5a6dbfea25d6591d6985b8ba59ad", size = 73517 }, +] + [[package]] name = "idna" version = "3.4" @@ -216,6 +713,15 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/fc/34/3030de6f1370931b9dbb4dad48f6ab1015ab1d32447850b9fc94e60097be/idna-3.4-py3-none-any.whl", hash = "sha256:90b77e79eaa3eba6de819a0c442c0b4ceefc341a7a2ab77d7562bf49f425c5c2", size = 61538 }, ] +[[package]] +name = "iniconfig" +version = "2.3.0" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/72/34/14ca021ce8e5dfedc35312d08ba8bf51fdd999c576889fc2c24cb97f4f10/iniconfig-2.3.0.tar.gz", hash = "sha256:c76315c77db068650d49c5b56314774a7804df16fee4402c1f19d6d15d8c4730", size = 20503 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/cb/b1/3846dd7f199d53cb17f49cba7e651e9ce294d8497c8c150530ed11865bb8/iniconfig-2.3.0-py3-none-any.whl", hash = "sha256:f631c04d2c48c52b84d0d0549c99ff3859c98df65b3101406327ecc7d53fbf12", size = 7484 }, +] + [[package]] name = "itsdangerous" version = "2.1.2" @@ -264,15 +770,27 @@ wheels = [ ] [[package]] -name = "macholib" -version = "1.16.3" +name = "mako" +version = "1.3.10" source = { registry = "https://pypi.org/simple" } dependencies = [ - { name = "altgraph" }, + { name = "markupsafe" }, ] -sdist = { url = "https://files.pythonhosted.org/packages/95/ee/af1a3842bdd5902ce133bd246eb7ffd4375c38642aeb5dc0ae3a0329dfa2/macholib-1.16.3.tar.gz", hash = "sha256:07ae9e15e8e4cd9a788013d81f5908b3609aa76f9b1421bae9c4d7606ec86a30", size = 59309 } +sdist = { url = "https://files.pythonhosted.org/packages/9e/38/bd5b78a920a64d708fe6bc8e0a2c075e1389d53bef8413725c63ba041535/mako-1.3.10.tar.gz", hash = "sha256:99579a6f39583fa7e5630a28c3c1f440e4e97a414b80372649c0ce338da2ea28", size = 392474 } wheels = [ - { url = "https://files.pythonhosted.org/packages/d1/5d/c059c180c84f7962db0aeae7c3b9303ed1d73d76f2bfbc32bc231c8be314/macholib-1.16.3-py2.py3-none-any.whl", hash = "sha256:0e315d7583d38b8c77e815b1ecbdbf504a8258d8b3e17b61165c6feb60d18f2c", size = 38094 }, + { url = "https://files.pythonhosted.org/packages/87/fb/99f81ac72ae23375f22b7afdb7642aba97c00a713c217124420147681a2f/mako-1.3.10-py3-none-any.whl", hash = "sha256:baef24a52fc4fc514a0887ac600f9f1cff3d82c61d4d700a1fa84d597b88db59", size = 78509 }, +] + +[[package]] +name = "markdown-it-py" +version = "4.0.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "mdurl" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/5b/f5/4ec618ed16cc4f8fb3b701563655a69816155e79e24a17b651541804721d/markdown_it_py-4.0.0.tar.gz", hash = "sha256:cb0a2b4aa34f932c007117b194e945bd74e0ec24133ceb5bac59009cda1cb9f3", size = 73070 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/94/54/e7d793b573f298e1c9013b8c4dade17d481164aa517d1d7148619c2cedbf/markdown_it_py-4.0.0-py3-none-any.whl", hash = "sha256:87327c59b172c5011896038353a81343b6754500a08cd7a4973bb48c6d578147", size = 87321 }, ] [[package]] @@ -313,6 +831,15 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/44/44/dbaf65876e258facd65f586dde158387ab89963e7f2235551afc9c2e24c2/MarkupSafe-2.1.3-cp312-cp312-win_amd64.whl", hash = "sha256:1b8dd8c3fd14349433c79fa8abeb573a55fc0fdd769133baac1f5e07abf54aeb", size = 16979 }, ] +[[package]] +name = "mdurl" +version = "0.1.2" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/d6/54/cfe61301667036ec958cb99bd3efefba235e65cdeb9c84d24a8293ba1d90/mdurl-0.1.2.tar.gz", hash = "sha256:bb413d29f5eea38f31dd4754dd7377d4465116fb207585f97bf925588687c1ba", size = 8729 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/b3/38/89ba8ad64ae25be8de66a6d463314cf1eb366222074cfda9ee839c56a4b4/mdurl-0.1.2-py3-none-any.whl", hash = "sha256:84008a41e51615a49fc9966191ff91509e3c40b939176e643fd50a5c2196b8f8", size = 9979 }, +] + [[package]] name = "numpy" version = "1.25.0" @@ -384,7 +911,6 @@ name = "patient-pathway-analysis" version = "0.1.0" source = { virtual = "." } dependencies = [ - { name = "customtkinter" }, { name = "darkdetect" }, { name = "decorator" }, { name = "et-xmlfile" }, @@ -401,16 +927,19 @@ dependencies = [ { name = "pillow" }, { name = "plotly" }, { name = "pyarrow" }, - { name = "pyglet" }, - { name = "pyinstaller" }, { name = "python-dateutil" }, + { name = "reflex" }, { name = "tenacity" }, - { name = "tkcalendar" }, +] + +[package.optional-dependencies] +test = [ + { name = "pytest" }, + { name = "pytest-cov" }, ] [package.metadata] requires-dist = [ - { name = "customtkinter", specifier = "==5.2.0" }, { name = "darkdetect", specifier = "==0.8.0" }, { name = "decorator", specifier = "==5.1.1" }, { name = "et-xmlfile", specifier = "==1.1.0" }, @@ -427,20 +956,11 @@ requires-dist = [ { name = "pillow", specifier = "==10.0.0" }, { name = "plotly", specifier = "==5.15.0" }, { name = "pyarrow", specifier = ">=20.0.0" }, - { name = "pyglet", specifier = "==2.0.9" }, - { name = "pyinstaller", specifier = ">=6.13.0" }, + { name = "pytest", marker = "extra == 'test'", specifier = ">=8.0.0" }, + { name = "pytest-cov", marker = "extra == 'test'", specifier = ">=4.0.0" }, { name = "python-dateutil", specifier = "==2.8.2" }, + { name = "reflex", specifier = "==0.8.26" }, { name = "tenacity", specifier = "==8.2.2" }, - { name = "tkcalendar", specifier = "==1.6.1" }, -] - -[[package]] -name = "pefile" -version = "2023.2.7" -source = { registry = "https://pypi.org/simple" } -sdist = { url = "https://files.pythonhosted.org/packages/78/c5/3b3c62223f72e2360737fd2a57c30e5b2adecd85e70276879609a7403334/pefile-2023.2.7.tar.gz", hash = "sha256:82e6114004b3d6911c77c3953e3838654b04511b8b66e8583db70c65998017dc", size = 74854 } -wheels = [ - { url = "https://files.pythonhosted.org/packages/55/26/d0ad8b448476d0a1e8d3ea5622dc77b916db84c6aa3cb1e1c0965af948fc/pefile-2023.2.7-py3-none-any.whl", hash = "sha256:da185cd2af68c08a6cd4481f7325ed600a88f6a813bad9dea07ab3ef73d8d8d6", size = 71791 }, ] [[package]] @@ -486,11 +1006,11 @@ wheels = [ [[package]] name = "platformdirs" -version = "3.8.1" +version = "4.5.1" source = { registry = "https://pypi.org/simple" } -sdist = { url = "https://files.pythonhosted.org/packages/92/38/3dd18a282991c004851ea1f0953105a186cfc691eee2792778ac2ca060f8/platformdirs-3.8.1.tar.gz", hash = "sha256:f87ca4fcff7d2b0f81c6a748a77973d7af0f4d526f98f308477c3c436c74d528", size = 18533 } +sdist = { url = "https://files.pythonhosted.org/packages/cf/86/0248f086a84f01b37aaec0fa567b397df1a119f73c16f6c7a9aac73ea309/platformdirs-4.5.1.tar.gz", hash = "sha256:61d5cdcc6065745cdd94f0f878977f8de9437be93de97c1c12f853c9c0cdcbda", size = 21715 } wheels = [ - { url = "https://files.pythonhosted.org/packages/9e/d8/563a9fc17153c588c8c2042d2f0f84a89057cdb1c30270f589c88b42d62c/platformdirs-3.8.1-py3-none-any.whl", hash = "sha256:cec7b889196b9144d088e4c57d9ceef7374f6c39694ad1577a0aab50d27ea28c", size = 16629 }, + { url = "https://files.pythonhosted.org/packages/cb/28/3bfe2fa5a7b9c46fe7e13c97bda14c895fb10fa2ebf1d0abb90e0cea7ee1/platformdirs-4.5.1-py3-none-any.whl", hash = "sha256:d03afa3963c806a9bed9d5125c8f4cb2fdaf74a55ab60e5d59b3fde758104d31", size = 18731 }, ] [[package]] @@ -506,6 +1026,43 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/a5/07/5bef9376c975ce23306d9217ab69ca94c07f2a3c90b17c03e3ae4db87170/plotly-5.15.0-py2.py3-none-any.whl", hash = "sha256:3508876bbd6aefb8a692c21a7128ca87ce42498dd041efa5c933ee44b55aab24", size = 15519872 }, ] +[[package]] +name = "pluggy" +version = "1.6.0" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/f9/e2/3e91f31a7d2b083fe6ef3fa267035b518369d9511ffab804f839851d2779/pluggy-1.6.0.tar.gz", hash = "sha256:7dcc130b76258d33b90f61b658791dede3486c3e6bfb003ee5c9bfb396dd22f3", size = 69412 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/54/20/4d324d65cc6d9205fabedc306948156824eb9f0ee1633355a8f7ec5c66bf/pluggy-1.6.0-py3-none-any.whl", hash = "sha256:e920276dd6813095e9377c0bc5566d94c932c33b27a3e3945d8389c374dd4746", size = 20538 }, +] + +[[package]] +name = "psutil" +version = "7.2.2" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/aa/c6/d1ddf4abb55e93cebc4f2ed8b5d6dbad109ecb8d63748dd2b20ab5e57ebe/psutil-7.2.2.tar.gz", hash = "sha256:0746f5f8d406af344fd547f1c8daa5f5c33dbc293bb8d6a16d80b4bb88f59372", size = 493740 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/51/08/510cbdb69c25a96f4ae523f733cdc963ae654904e8db864c07585ef99875/psutil-7.2.2-cp313-cp313t-macosx_10_13_x86_64.whl", hash = "sha256:2edccc433cbfa046b980b0df0171cd25bcaeb3a68fe9022db0979e7aa74a826b", size = 130595 }, + { url = "https://files.pythonhosted.org/packages/d6/f5/97baea3fe7a5a9af7436301f85490905379b1c6f2dd51fe3ecf24b4c5fbf/psutil-7.2.2-cp313-cp313t-macosx_11_0_arm64.whl", hash = "sha256:e78c8603dcd9a04c7364f1a3e670cea95d51ee865e4efb3556a3a63adef958ea", size = 131082 }, + { url = "https://files.pythonhosted.org/packages/37/d6/246513fbf9fa174af531f28412297dd05241d97a75911ac8febefa1a53c6/psutil-7.2.2-cp313-cp313t-manylinux2010_x86_64.manylinux_2_12_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:1a571f2330c966c62aeda00dd24620425d4b0cc86881c89861fbc04549e5dc63", size = 181476 }, + { url = "https://files.pythonhosted.org/packages/b8/b5/9182c9af3836cca61696dabe4fd1304e17bc56cb62f17439e1154f225dd3/psutil-7.2.2-cp313-cp313t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:917e891983ca3c1887b4ef36447b1e0873e70c933afc831c6b6da078ba474312", size = 184062 }, + { url = "https://files.pythonhosted.org/packages/16/ba/0756dca669f5a9300d0cbcbfae9a4c30e446dfc7440ffe43ded5724bfd93/psutil-7.2.2-cp313-cp313t-win_amd64.whl", hash = "sha256:ab486563df44c17f5173621c7b198955bd6b613fb87c71c161f827d3fb149a9b", size = 139893 }, + { url = "https://files.pythonhosted.org/packages/1c/61/8fa0e26f33623b49949346de05ec1ddaad02ed8ba64af45f40a147dbfa97/psutil-7.2.2-cp313-cp313t-win_arm64.whl", hash = "sha256:ae0aefdd8796a7737eccea863f80f81e468a1e4cf14d926bd9b6f5f2d5f90ca9", size = 135589 }, + { url = "https://files.pythonhosted.org/packages/81/69/ef179ab5ca24f32acc1dac0c247fd6a13b501fd5534dbae0e05a1c48b66d/psutil-7.2.2-cp314-cp314t-macosx_10_15_x86_64.whl", hash = "sha256:eed63d3b4d62449571547b60578c5b2c4bcccc5387148db46e0c2313dad0ee00", size = 130664 }, + { url = "https://files.pythonhosted.org/packages/7b/64/665248b557a236d3fa9efc378d60d95ef56dd0a490c2cd37dafc7660d4a9/psutil-7.2.2-cp314-cp314t-macosx_11_0_arm64.whl", hash = "sha256:7b6d09433a10592ce39b13d7be5a54fbac1d1228ed29abc880fb23df7cb694c9", size = 131087 }, + { url = "https://files.pythonhosted.org/packages/d5/2e/e6782744700d6759ebce3043dcfa661fb61e2fb752b91cdeae9af12c2178/psutil-7.2.2-cp314-cp314t-manylinux2010_x86_64.manylinux_2_12_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:1fa4ecf83bcdf6e6c8f4449aff98eefb5d0604bf88cb883d7da3d8d2d909546a", size = 182383 }, + { url = "https://files.pythonhosted.org/packages/57/49/0a41cefd10cb7505cdc04dab3eacf24c0c2cb158a998b8c7b1d27ee2c1f5/psutil-7.2.2-cp314-cp314t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:e452c464a02e7dc7822a05d25db4cde564444a67e58539a00f929c51eddda0cf", size = 185210 }, + { url = "https://files.pythonhosted.org/packages/dd/2c/ff9bfb544f283ba5f83ba725a3c5fec6d6b10b8f27ac1dc641c473dc390d/psutil-7.2.2-cp314-cp314t-win_amd64.whl", hash = "sha256:c7663d4e37f13e884d13994247449e9f8f574bc4655d509c3b95e9ec9e2b9dc1", size = 141228 }, + { url = "https://files.pythonhosted.org/packages/f2/fc/f8d9c31db14fcec13748d373e668bc3bed94d9077dbc17fb0eebc073233c/psutil-7.2.2-cp314-cp314t-win_arm64.whl", hash = "sha256:11fe5a4f613759764e79c65cf11ebdf26e33d6dd34336f8a337aa2996d71c841", size = 136284 }, + { url = "https://files.pythonhosted.org/packages/e7/36/5ee6e05c9bd427237b11b3937ad82bb8ad2752d72c6969314590dd0c2f6e/psutil-7.2.2-cp36-abi3-macosx_10_9_x86_64.whl", hash = "sha256:ed0cace939114f62738d808fdcecd4c869222507e266e574799e9c0faa17d486", size = 129090 }, + { url = "https://files.pythonhosted.org/packages/80/c4/f5af4c1ca8c1eeb2e92ccca14ce8effdeec651d5ab6053c589b074eda6e1/psutil-7.2.2-cp36-abi3-macosx_11_0_arm64.whl", hash = "sha256:1a7b04c10f32cc88ab39cbf606e117fd74721c831c98a27dc04578deb0c16979", size = 129859 }, + { url = "https://files.pythonhosted.org/packages/b5/70/5d8df3b09e25bce090399cf48e452d25c935ab72dad19406c77f4e828045/psutil-7.2.2-cp36-abi3-manylinux2010_x86_64.manylinux_2_12_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:076a2d2f923fd4821644f5ba89f059523da90dc9014e85f8e45a5774ca5bc6f9", size = 155560 }, + { url = "https://files.pythonhosted.org/packages/63/65/37648c0c158dc222aba51c089eb3bdfa238e621674dc42d48706e639204f/psutil-7.2.2-cp36-abi3-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:b0726cecd84f9474419d67252add4ac0cd9811b04d61123054b9fb6f57df6e9e", size = 156997 }, + { url = "https://files.pythonhosted.org/packages/8e/13/125093eadae863ce03c6ffdbae9929430d116a246ef69866dad94da3bfbc/psutil-7.2.2-cp36-abi3-musllinux_1_2_aarch64.whl", hash = "sha256:fd04ef36b4a6d599bbdb225dd1d3f51e00105f6d48a28f006da7f9822f2606d8", size = 148972 }, + { url = "https://files.pythonhosted.org/packages/04/78/0acd37ca84ce3ddffaa92ef0f571e073faa6d8ff1f0559ab1272188ea2be/psutil-7.2.2-cp36-abi3-musllinux_1_2_x86_64.whl", hash = "sha256:b58fabe35e80b264a4e3bb23e6b96f9e45a3df7fb7eed419ac0e5947c61e47cc", size = 148266 }, + { url = "https://files.pythonhosted.org/packages/b4/90/e2159492b5426be0c1fef7acba807a03511f97c5f86b3caeda6ad92351a7/psutil-7.2.2-cp37-abi3-win_amd64.whl", hash = "sha256:eb7e81434c8d223ec4a219b5fc1c47d0417b12be7ea866e24fb5ad6e84b3d988", size = 137737 }, + { url = "https://files.pythonhosted.org/packages/8c/c7/7bb2e321574b10df20cbde462a94e2b71d05f9bbda251ef27d104668306a/psutil-7.2.2-cp37-abi3-win_arm64.whl", hash = "sha256:8c233660f575a5a89e6d4cb65d9f938126312bca76d8fe087b947b3a1aaac9ee", size = 134617 }, +] + [[package]] name = "pyarrow" version = "20.0.0" @@ -560,53 +1117,178 @@ wheels = [ ] [[package]] -name = "pyglet" -version = "2.0.9" +name = "pydantic" +version = "2.12.5" source = { registry = "https://pypi.org/simple" } -sdist = { url = "https://files.pythonhosted.org/packages/c8/6d/6f21100a8a60d16049dd4d187b36e643619f694c9803ae3d92fcbac366a8/pyglet-2.0.9.zip", hash = "sha256:a0922e42f2d258505678e2f4a355c5476c1a6352c3f3a37754042ddb7e7cf72f", size = 6525060 } +dependencies = [ + { name = "annotated-types" }, + { name = "pydantic-core" }, + { name = "typing-extensions" }, + { name = "typing-inspection" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/69/44/36f1a6e523abc58ae5f928898e4aca2e0ea509b5aa6f6f392a5d882be928/pydantic-2.12.5.tar.gz", hash = "sha256:4d351024c75c0f085a9febbb665ce8c0c6ec5d30e903bdb6394b7ede26aebb49", size = 821591 } wheels = [ - { url = "https://files.pythonhosted.org/packages/94/a1/475458ccf34d2996abdb6ef29fa8d3fed2e62f72df5f2a7f4b4b076915c7/pyglet-2.0.9-py3-none-any.whl", hash = "sha256:8520b22dde75f47167e1fedeed58ac0bb0c890c0dca17d8528427d6b318cd9cc", size = 854706 }, + { url = "https://files.pythonhosted.org/packages/5a/87/b70ad306ebb6f9b585f114d0ac2137d792b48be34d732d60e597c2f8465a/pydantic-2.12.5-py3-none-any.whl", hash = "sha256:e561593fccf61e8a20fc46dfc2dfe075b8be7d0188df33f221ad1f0139180f9d", size = 463580 }, ] [[package]] -name = "pyinstaller" -version = "6.13.0" +name = "pydantic-core" +version = "2.41.5" source = { registry = "https://pypi.org/simple" } dependencies = [ - { name = "altgraph" }, - { name = "macholib", marker = "sys_platform == 'darwin'" }, - { name = "packaging" }, - { name = "pefile", marker = "sys_platform == 'win32'" }, - { name = "pyinstaller-hooks-contrib" }, - { name = "pywin32-ctypes", marker = "sys_platform == 'win32'" }, - { name = "setuptools" }, + { name = "typing-extensions" }, ] -sdist = { url = "https://files.pythonhosted.org/packages/a8/b1/2949fe6d3874e961898ca5cfc1bf2cf13bdeea488b302e74a745bc28c8ba/pyinstaller-6.13.0.tar.gz", hash = "sha256:38911feec2c5e215e5159a7e66fdb12400168bd116143b54a8a7a37f08733456", size = 4276427 } +sdist = { url = "https://files.pythonhosted.org/packages/71/70/23b021c950c2addd24ec408e9ab05d59b035b39d97cdc1130e1bce647bb6/pydantic_core-2.41.5.tar.gz", hash = "sha256:08daa51ea16ad373ffd5e7606252cc32f07bc72b28284b6bc9c6df804816476e", size = 460952 } wheels = [ - { url = "https://files.pythonhosted.org/packages/b4/02/d1a347d35b1b627da1e148159e617576555619ac3bb8bbd5fed661fc7bb5/pyinstaller-6.13.0-py3-none-macosx_10_13_universal2.whl", hash = "sha256:aa404f0b02cd57948098055e76ee190b8e65ccf7a2a3f048e5000f668317069f", size = 1001923 }, - { url = "https://files.pythonhosted.org/packages/6b/80/6da39f7aeac65c9ca5afad0fac37887d75fdfd480178a7077c9d30b0704c/pyinstaller-6.13.0-py3-none-manylinux2014_aarch64.whl", hash = "sha256:92efcf2f09e78f07b568c5cb7ed48c9940f5dad627af4b49bede6320fab2a06e", size = 718135 }, - { url = "https://files.pythonhosted.org/packages/05/2c/d21d31f780a489609e7bf6385c0f7635238dc98b37cba8645b53322b7450/pyinstaller-6.13.0-py3-none-manylinux2014_i686.whl", hash = "sha256:9f82f113c463f012faa0e323d952ca30a6f922685d9636e754bd3a256c7ed200", size = 728543 }, - { url = "https://files.pythonhosted.org/packages/e1/20/e6ca87bbed6c0163533195707f820f05e10b8da1223fc6972cfe3c3c50c7/pyinstaller-6.13.0-py3-none-manylinux2014_ppc64le.whl", hash = "sha256:db0e7945ebe276f604eb7c36e536479556ab32853412095e19172a5ec8fca1c5", size = 726868 }, - { url = "https://files.pythonhosted.org/packages/20/d5/53b19285f8817ab6c4b07c570208d62606bab0e5a049d50c93710a1d9dc6/pyinstaller-6.13.0-py3-none-manylinux2014_s390x.whl", hash = "sha256:92fe7337c5aa08d42b38d7a79614492cb571489f2cb0a8f91dc9ef9ccbe01ed3", size = 725037 }, - { url = "https://files.pythonhosted.org/packages/84/5b/08e0b305ba71e6d7cb247e27d714da7536895b0283132d74d249bf662366/pyinstaller-6.13.0-py3-none-manylinux2014_x86_64.whl", hash = "sha256:bc09795f5954135dd4486c1535650958c8218acb954f43860e4b05fb515a21c0", size = 721027 }, - { url = "https://files.pythonhosted.org/packages/1f/9c/d8d0a7120103471be8dbe1c5419542aa794b9b9ec2ef628b542f9e6f9ef0/pyinstaller-6.13.0-py3-none-musllinux_1_1_aarch64.whl", hash = "sha256:589937548d34978c568cfdc39f31cf386f45202bc27fdb8facb989c79dfb4c02", size = 723443 }, - { url = "https://files.pythonhosted.org/packages/52/c7/8a9d81569dda2352068ecc6ee779d5feff6729569dd1b4ffd1236ecd38fe/pyinstaller-6.13.0-py3-none-musllinux_1_1_x86_64.whl", hash = "sha256:b7260832f7501ba1d2ce1834d4cddc0f2b94315282bc89c59333433715015447", size = 719915 }, - { url = "https://files.pythonhosted.org/packages/d5/e6/cccadb02b90198c7ed4ffb8bc34d420efb72b996f47cbd4738067a602d65/pyinstaller-6.13.0-py3-none-win32.whl", hash = "sha256:80c568848529635aa7ca46d8d525f68486d53e03f68b7bb5eba2c88d742e302c", size = 1294997 }, - { url = "https://files.pythonhosted.org/packages/1a/06/15cbe0e25d1e73d5b981fa41ff0bb02b15e924e30b8c61256f4a28c4c837/pyinstaller-6.13.0-py3-none-win_amd64.whl", hash = "sha256:8d4296236b85aae570379488c2da833b28828b17c57c2cc21fccd7e3811fe372", size = 1352714 }, - { url = "https://files.pythonhosted.org/packages/83/ef/74379298d46e7caa6aa7ceccc865106d3d4b15ac487ffdda2a35bfb6fe79/pyinstaller-6.13.0-py3-none-win_arm64.whl", hash = "sha256:d9f21d56ca2443aa6a1e255e7ad285c76453893a454105abe1b4d45e92bb9a20", size = 1293589 }, + { url = "https://files.pythonhosted.org/packages/c6/90/32c9941e728d564b411d574d8ee0cf09b12ec978cb22b294995bae5549a5/pydantic_core-2.41.5-cp310-cp310-macosx_10_12_x86_64.whl", hash = "sha256:77b63866ca88d804225eaa4af3e664c5faf3568cea95360d21f4725ab6e07146", size = 2107298 }, + { url = "https://files.pythonhosted.org/packages/fb/a8/61c96a77fe28993d9a6fb0f4127e05430a267b235a124545d79fea46dd65/pydantic_core-2.41.5-cp310-cp310-macosx_11_0_arm64.whl", hash = "sha256:dfa8a0c812ac681395907e71e1274819dec685fec28273a28905df579ef137e2", size = 1901475 }, + { url = "https://files.pythonhosted.org/packages/5d/b6/338abf60225acc18cdc08b4faef592d0310923d19a87fba1faf05af5346e/pydantic_core-2.41.5-cp310-cp310-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:5921a4d3ca3aee735d9fd163808f5e8dd6c6972101e4adbda9a4667908849b97", size = 1918815 }, + { url = "https://files.pythonhosted.org/packages/d1/1c/2ed0433e682983d8e8cba9c8d8ef274d4791ec6a6f24c58935b90e780e0a/pydantic_core-2.41.5-cp310-cp310-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:e25c479382d26a2a41b7ebea1043564a937db462816ea07afa8a44c0866d52f9", size = 2065567 }, + { url = "https://files.pythonhosted.org/packages/b3/24/cf84974ee7d6eae06b9e63289b7b8f6549d416b5c199ca2d7ce13bbcf619/pydantic_core-2.41.5-cp310-cp310-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:f547144f2966e1e16ae626d8ce72b4cfa0caedc7fa28052001c94fb2fcaa1c52", size = 2230442 }, + { url = "https://files.pythonhosted.org/packages/fd/21/4e287865504b3edc0136c89c9c09431be326168b1eb7841911cbc877a995/pydantic_core-2.41.5-cp310-cp310-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:6f52298fbd394f9ed112d56f3d11aabd0d5bd27beb3084cc3d8ad069483b8941", size = 2350956 }, + { url = "https://files.pythonhosted.org/packages/a8/76/7727ef2ffa4b62fcab916686a68a0426b9b790139720e1934e8ba797e238/pydantic_core-2.41.5-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:100baa204bb412b74fe285fb0f3a385256dad1d1879f0a5cb1499ed2e83d132a", size = 2068253 }, + { url = "https://files.pythonhosted.org/packages/d5/8c/a4abfc79604bcb4c748e18975c44f94f756f08fb04218d5cb87eb0d3a63e/pydantic_core-2.41.5-cp310-cp310-manylinux_2_5_i686.manylinux1_i686.whl", hash = "sha256:05a2c8852530ad2812cb7914dc61a1125dc4e06252ee98e5638a12da6cc6fb6c", size = 2177050 }, + { url = "https://files.pythonhosted.org/packages/67/b1/de2e9a9a79b480f9cb0b6e8b6ba4c50b18d4e89852426364c66aa82bb7b3/pydantic_core-2.41.5-cp310-cp310-musllinux_1_1_aarch64.whl", hash = "sha256:29452c56df2ed968d18d7e21f4ab0ac55e71dc59524872f6fc57dcf4a3249ed2", size = 2147178 }, + { url = "https://files.pythonhosted.org/packages/16/c1/dfb33f837a47b20417500efaa0378adc6635b3c79e8369ff7a03c494b4ac/pydantic_core-2.41.5-cp310-cp310-musllinux_1_1_armv7l.whl", hash = "sha256:d5160812ea7a8a2ffbe233d8da666880cad0cbaf5d4de74ae15c313213d62556", size = 2341833 }, + { url = "https://files.pythonhosted.org/packages/47/36/00f398642a0f4b815a9a558c4f1dca1b4020a7d49562807d7bc9ff279a6c/pydantic_core-2.41.5-cp310-cp310-musllinux_1_1_x86_64.whl", hash = "sha256:df3959765b553b9440adfd3c795617c352154e497a4eaf3752555cfb5da8fc49", size = 2321156 }, + { url = "https://files.pythonhosted.org/packages/7e/70/cad3acd89fde2010807354d978725ae111ddf6d0ea46d1ea1775b5c1bd0c/pydantic_core-2.41.5-cp310-cp310-win32.whl", hash = "sha256:1f8d33a7f4d5a7889e60dc39856d76d09333d8a6ed0f5f1190635cbec70ec4ba", size = 1989378 }, + { url = "https://files.pythonhosted.org/packages/76/92/d338652464c6c367e5608e4488201702cd1cbb0f33f7b6a85a60fe5f3720/pydantic_core-2.41.5-cp310-cp310-win_amd64.whl", hash = "sha256:62de39db01b8d593e45871af2af9e497295db8d73b085f6bfd0b18c83c70a8f9", size = 2013622 }, + { url = "https://files.pythonhosted.org/packages/e8/72/74a989dd9f2084b3d9530b0915fdda64ac48831c30dbf7c72a41a5232db8/pydantic_core-2.41.5-cp311-cp311-macosx_10_12_x86_64.whl", hash = "sha256:a3a52f6156e73e7ccb0f8cced536adccb7042be67cb45f9562e12b319c119da6", size = 2105873 }, + { url = "https://files.pythonhosted.org/packages/12/44/37e403fd9455708b3b942949e1d7febc02167662bf1a7da5b78ee1ea2842/pydantic_core-2.41.5-cp311-cp311-macosx_11_0_arm64.whl", hash = "sha256:7f3bf998340c6d4b0c9a2f02d6a400e51f123b59565d74dc60d252ce888c260b", size = 1899826 }, + { url = "https://files.pythonhosted.org/packages/33/7f/1d5cab3ccf44c1935a359d51a8a2a9e1a654b744b5e7f80d41b88d501eec/pydantic_core-2.41.5-cp311-cp311-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:378bec5c66998815d224c9ca994f1e14c0c21cb95d2f52b6021cc0b2a58f2a5a", size = 1917869 }, + { url = "https://files.pythonhosted.org/packages/6e/6a/30d94a9674a7fe4f4744052ed6c5e083424510be1e93da5bc47569d11810/pydantic_core-2.41.5-cp311-cp311-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:e7b576130c69225432866fe2f4a469a85a54ade141d96fd396dffcf607b558f8", size = 2063890 }, + { url = "https://files.pythonhosted.org/packages/50/be/76e5d46203fcb2750e542f32e6c371ffa9b8ad17364cf94bb0818dbfb50c/pydantic_core-2.41.5-cp311-cp311-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:6cb58b9c66f7e4179a2d5e0f849c48eff5c1fca560994d6eb6543abf955a149e", size = 2229740 }, + { url = "https://files.pythonhosted.org/packages/d3/ee/fed784df0144793489f87db310a6bbf8118d7b630ed07aa180d6067e653a/pydantic_core-2.41.5-cp311-cp311-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:88942d3a3dff3afc8288c21e565e476fc278902ae4d6d134f1eeda118cc830b1", size = 2350021 }, + { url = "https://files.pythonhosted.org/packages/c8/be/8fed28dd0a180dca19e72c233cbf58efa36df055e5b9d90d64fd1740b828/pydantic_core-2.41.5-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:f31d95a179f8d64d90f6831d71fa93290893a33148d890ba15de25642c5d075b", size = 2066378 }, + { url = "https://files.pythonhosted.org/packages/b0/3b/698cf8ae1d536a010e05121b4958b1257f0b5522085e335360e53a6b1c8b/pydantic_core-2.41.5-cp311-cp311-manylinux_2_5_i686.manylinux1_i686.whl", hash = "sha256:c1df3d34aced70add6f867a8cf413e299177e0c22660cc767218373d0779487b", size = 2175761 }, + { url = "https://files.pythonhosted.org/packages/b8/ba/15d537423939553116dea94ce02f9c31be0fa9d0b806d427e0308ec17145/pydantic_core-2.41.5-cp311-cp311-musllinux_1_1_aarch64.whl", hash = "sha256:4009935984bd36bd2c774e13f9a09563ce8de4abaa7226f5108262fa3e637284", size = 2146303 }, + { url = "https://files.pythonhosted.org/packages/58/7f/0de669bf37d206723795f9c90c82966726a2ab06c336deba4735b55af431/pydantic_core-2.41.5-cp311-cp311-musllinux_1_1_armv7l.whl", hash = "sha256:34a64bc3441dc1213096a20fe27e8e128bd3ff89921706e83c0b1ac971276594", size = 2340355 }, + { url = "https://files.pythonhosted.org/packages/e5/de/e7482c435b83d7e3c3ee5ee4451f6e8973cff0eb6007d2872ce6383f6398/pydantic_core-2.41.5-cp311-cp311-musllinux_1_1_x86_64.whl", hash = "sha256:c9e19dd6e28fdcaa5a1de679aec4141f691023916427ef9bae8584f9c2fb3b0e", size = 2319875 }, + { url = "https://files.pythonhosted.org/packages/fe/e6/8c9e81bb6dd7560e33b9053351c29f30c8194b72f2d6932888581f503482/pydantic_core-2.41.5-cp311-cp311-win32.whl", hash = "sha256:2c010c6ded393148374c0f6f0bf89d206bf3217f201faa0635dcd56bd1520f6b", size = 1987549 }, + { url = "https://files.pythonhosted.org/packages/11/66/f14d1d978ea94d1bc21fc98fcf570f9542fe55bfcc40269d4e1a21c19bf7/pydantic_core-2.41.5-cp311-cp311-win_amd64.whl", hash = "sha256:76ee27c6e9c7f16f47db7a94157112a2f3a00e958bc626e2f4ee8bec5c328fbe", size = 2011305 }, + { url = "https://files.pythonhosted.org/packages/56/d8/0e271434e8efd03186c5386671328154ee349ff0354d83c74f5caaf096ed/pydantic_core-2.41.5-cp311-cp311-win_arm64.whl", hash = "sha256:4bc36bbc0b7584de96561184ad7f012478987882ebf9f9c389b23f432ea3d90f", size = 1972902 }, + { url = "https://files.pythonhosted.org/packages/5f/5d/5f6c63eebb5afee93bcaae4ce9a898f3373ca23df3ccaef086d0233a35a7/pydantic_core-2.41.5-cp312-cp312-macosx_10_12_x86_64.whl", hash = "sha256:f41a7489d32336dbf2199c8c0a215390a751c5b014c2c1c5366e817202e9cdf7", size = 2110990 }, + { url = "https://files.pythonhosted.org/packages/aa/32/9c2e8ccb57c01111e0fd091f236c7b371c1bccea0fa85247ac55b1e2b6b6/pydantic_core-2.41.5-cp312-cp312-macosx_11_0_arm64.whl", hash = "sha256:070259a8818988b9a84a449a2a7337c7f430a22acc0859c6b110aa7212a6d9c0", size = 1896003 }, + { url = "https://files.pythonhosted.org/packages/68/b8/a01b53cb0e59139fbc9e4fda3e9724ede8de279097179be4ff31f1abb65a/pydantic_core-2.41.5-cp312-cp312-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:e96cea19e34778f8d59fe40775a7a574d95816eb150850a85a7a4c8f4b94ac69", size = 1919200 }, + { url = "https://files.pythonhosted.org/packages/38/de/8c36b5198a29bdaade07b5985e80a233a5ac27137846f3bc2d3b40a47360/pydantic_core-2.41.5-cp312-cp312-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:ed2e99c456e3fadd05c991f8f437ef902e00eedf34320ba2b0842bd1c3ca3a75", size = 2052578 }, + { url = "https://files.pythonhosted.org/packages/00/b5/0e8e4b5b081eac6cb3dbb7e60a65907549a1ce035a724368c330112adfdd/pydantic_core-2.41.5-cp312-cp312-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:65840751b72fbfd82c3c640cff9284545342a4f1eb1586ad0636955b261b0b05", size = 2208504 }, + { url = "https://files.pythonhosted.org/packages/77/56/87a61aad59c7c5b9dc8caad5a41a5545cba3810c3e828708b3d7404f6cef/pydantic_core-2.41.5-cp312-cp312-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:e536c98a7626a98feb2d3eaf75944ef6f3dbee447e1f841eae16f2f0a72d8ddc", size = 2335816 }, + { url = "https://files.pythonhosted.org/packages/0d/76/941cc9f73529988688a665a5c0ecff1112b3d95ab48f81db5f7606f522d3/pydantic_core-2.41.5-cp312-cp312-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:eceb81a8d74f9267ef4081e246ffd6d129da5d87e37a77c9bde550cb04870c1c", size = 2075366 }, + { url = "https://files.pythonhosted.org/packages/d3/43/ebef01f69baa07a482844faaa0a591bad1ef129253ffd0cdaa9d8a7f72d3/pydantic_core-2.41.5-cp312-cp312-manylinux_2_5_i686.manylinux1_i686.whl", hash = "sha256:d38548150c39b74aeeb0ce8ee1d8e82696f4a4e16ddc6de7b1d8823f7de4b9b5", size = 2171698 }, + { url = "https://files.pythonhosted.org/packages/b1/87/41f3202e4193e3bacfc2c065fab7706ebe81af46a83d3e27605029c1f5a6/pydantic_core-2.41.5-cp312-cp312-musllinux_1_1_aarch64.whl", hash = "sha256:c23e27686783f60290e36827f9c626e63154b82b116d7fe9adba1fda36da706c", size = 2132603 }, + { url = "https://files.pythonhosted.org/packages/49/7d/4c00df99cb12070b6bccdef4a195255e6020a550d572768d92cc54dba91a/pydantic_core-2.41.5-cp312-cp312-musllinux_1_1_armv7l.whl", hash = "sha256:482c982f814460eabe1d3bb0adfdc583387bd4691ef00b90575ca0d2b6fe2294", size = 2329591 }, + { url = "https://files.pythonhosted.org/packages/cc/6a/ebf4b1d65d458f3cda6a7335d141305dfa19bdc61140a884d165a8a1bbc7/pydantic_core-2.41.5-cp312-cp312-musllinux_1_1_x86_64.whl", hash = "sha256:bfea2a5f0b4d8d43adf9d7b8bf019fb46fdd10a2e5cde477fbcb9d1fa08c68e1", size = 2319068 }, + { url = "https://files.pythonhosted.org/packages/49/3b/774f2b5cd4192d5ab75870ce4381fd89cf218af999515baf07e7206753f0/pydantic_core-2.41.5-cp312-cp312-win32.whl", hash = "sha256:b74557b16e390ec12dca509bce9264c3bbd128f8a2c376eaa68003d7f327276d", size = 1985908 }, + { url = "https://files.pythonhosted.org/packages/86/45/00173a033c801cacf67c190fef088789394feaf88a98a7035b0e40d53dc9/pydantic_core-2.41.5-cp312-cp312-win_amd64.whl", hash = "sha256:1962293292865bca8e54702b08a4f26da73adc83dd1fcf26fbc875b35d81c815", size = 2020145 }, + { url = "https://files.pythonhosted.org/packages/f9/22/91fbc821fa6d261b376a3f73809f907cec5ca6025642c463d3488aad22fb/pydantic_core-2.41.5-cp312-cp312-win_arm64.whl", hash = "sha256:1746d4a3d9a794cacae06a5eaaccb4b8643a131d45fbc9af23e353dc0a5ba5c3", size = 1976179 }, + { url = "https://files.pythonhosted.org/packages/87/06/8806241ff1f70d9939f9af039c6c35f2360cf16e93c2ca76f184e76b1564/pydantic_core-2.41.5-cp313-cp313-macosx_10_12_x86_64.whl", hash = "sha256:941103c9be18ac8daf7b7adca8228f8ed6bb7a1849020f643b3a14d15b1924d9", size = 2120403 }, + { url = "https://files.pythonhosted.org/packages/94/02/abfa0e0bda67faa65fef1c84971c7e45928e108fe24333c81f3bfe35d5f5/pydantic_core-2.41.5-cp313-cp313-macosx_11_0_arm64.whl", hash = "sha256:112e305c3314f40c93998e567879e887a3160bb8689ef3d2c04b6cc62c33ac34", size = 1896206 }, + { url = "https://files.pythonhosted.org/packages/15/df/a4c740c0943e93e6500f9eb23f4ca7ec9bf71b19e608ae5b579678c8d02f/pydantic_core-2.41.5-cp313-cp313-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:0cbaad15cb0c90aa221d43c00e77bb33c93e8d36e0bf74760cd00e732d10a6a0", size = 1919307 }, + { url = "https://files.pythonhosted.org/packages/9a/e3/6324802931ae1d123528988e0e86587c2072ac2e5394b4bc2bc34b61ff6e/pydantic_core-2.41.5-cp313-cp313-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:03ca43e12fab6023fc79d28ca6b39b05f794ad08ec2feccc59a339b02f2b3d33", size = 2063258 }, + { url = "https://files.pythonhosted.org/packages/c9/d4/2230d7151d4957dd79c3044ea26346c148c98fbf0ee6ebd41056f2d62ab5/pydantic_core-2.41.5-cp313-cp313-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:dc799088c08fa04e43144b164feb0c13f9a0bc40503f8df3e9fde58a3c0c101e", size = 2214917 }, + { url = "https://files.pythonhosted.org/packages/e6/9f/eaac5df17a3672fef0081b6c1bb0b82b33ee89aa5cec0d7b05f52fd4a1fa/pydantic_core-2.41.5-cp313-cp313-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:97aeba56665b4c3235a0e52b2c2f5ae9cd071b8a8310ad27bddb3f7fb30e9aa2", size = 2332186 }, + { url = "https://files.pythonhosted.org/packages/cf/4e/35a80cae583a37cf15604b44240e45c05e04e86f9cfd766623149297e971/pydantic_core-2.41.5-cp313-cp313-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:406bf18d345822d6c21366031003612b9c77b3e29ffdb0f612367352aab7d586", size = 2073164 }, + { url = "https://files.pythonhosted.org/packages/bf/e3/f6e262673c6140dd3305d144d032f7bd5f7497d3871c1428521f19f9efa2/pydantic_core-2.41.5-cp313-cp313-manylinux_2_5_i686.manylinux1_i686.whl", hash = "sha256:b93590ae81f7010dbe380cdeab6f515902ebcbefe0b9327cc4804d74e93ae69d", size = 2179146 }, + { url = "https://files.pythonhosted.org/packages/75/c7/20bd7fc05f0c6ea2056a4565c6f36f8968c0924f19b7d97bbfea55780e73/pydantic_core-2.41.5-cp313-cp313-musllinux_1_1_aarch64.whl", hash = "sha256:01a3d0ab748ee531f4ea6c3e48ad9dac84ddba4b0d82291f87248f2f9de8d740", size = 2137788 }, + { url = "https://files.pythonhosted.org/packages/3a/8d/34318ef985c45196e004bc46c6eab2eda437e744c124ef0dbe1ff2c9d06b/pydantic_core-2.41.5-cp313-cp313-musllinux_1_1_armv7l.whl", hash = "sha256:6561e94ba9dacc9c61bce40e2d6bdc3bfaa0259d3ff36ace3b1e6901936d2e3e", size = 2340133 }, + { url = "https://files.pythonhosted.org/packages/9c/59/013626bf8c78a5a5d9350d12e7697d3d4de951a75565496abd40ccd46bee/pydantic_core-2.41.5-cp313-cp313-musllinux_1_1_x86_64.whl", hash = "sha256:915c3d10f81bec3a74fbd4faebe8391013ba61e5a1a8d48c4455b923bdda7858", size = 2324852 }, + { url = "https://files.pythonhosted.org/packages/1a/d9/c248c103856f807ef70c18a4f986693a46a8ffe1602e5d361485da502d20/pydantic_core-2.41.5-cp313-cp313-win32.whl", hash = "sha256:650ae77860b45cfa6e2cdafc42618ceafab3a2d9a3811fcfbd3bbf8ac3c40d36", size = 1994679 }, + { url = "https://files.pythonhosted.org/packages/9e/8b/341991b158ddab181cff136acd2552c9f35bd30380422a639c0671e99a91/pydantic_core-2.41.5-cp313-cp313-win_amd64.whl", hash = "sha256:79ec52ec461e99e13791ec6508c722742ad745571f234ea6255bed38c6480f11", size = 2019766 }, + { url = "https://files.pythonhosted.org/packages/73/7d/f2f9db34af103bea3e09735bb40b021788a5e834c81eedb541991badf8f5/pydantic_core-2.41.5-cp313-cp313-win_arm64.whl", hash = "sha256:3f84d5c1b4ab906093bdc1ff10484838aca54ef08de4afa9de0f5f14d69639cd", size = 1981005 }, + { url = "https://files.pythonhosted.org/packages/ea/28/46b7c5c9635ae96ea0fbb779e271a38129df2550f763937659ee6c5dbc65/pydantic_core-2.41.5-cp314-cp314-macosx_10_12_x86_64.whl", hash = "sha256:3f37a19d7ebcdd20b96485056ba9e8b304e27d9904d233d7b1015db320e51f0a", size = 2119622 }, + { url = "https://files.pythonhosted.org/packages/74/1a/145646e5687e8d9a1e8d09acb278c8535ebe9e972e1f162ed338a622f193/pydantic_core-2.41.5-cp314-cp314-macosx_11_0_arm64.whl", hash = "sha256:1d1d9764366c73f996edd17abb6d9d7649a7eb690006ab6adbda117717099b14", size = 1891725 }, + { url = "https://files.pythonhosted.org/packages/23/04/e89c29e267b8060b40dca97bfc64a19b2a3cf99018167ea1677d96368273/pydantic_core-2.41.5-cp314-cp314-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:25e1c2af0fce638d5f1988b686f3b3ea8cd7de5f244ca147c777769e798a9cd1", size = 1915040 }, + { url = "https://files.pythonhosted.org/packages/84/a3/15a82ac7bd97992a82257f777b3583d3e84bdb06ba6858f745daa2ec8a85/pydantic_core-2.41.5-cp314-cp314-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:506d766a8727beef16b7adaeb8ee6217c64fc813646b424d0804d67c16eddb66", size = 2063691 }, + { url = "https://files.pythonhosted.org/packages/74/9b/0046701313c6ef08c0c1cf0e028c67c770a4e1275ca73131563c5f2a310a/pydantic_core-2.41.5-cp314-cp314-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:4819fa52133c9aa3c387b3328f25c1facc356491e6135b459f1de698ff64d869", size = 2213897 }, + { url = "https://files.pythonhosted.org/packages/8a/cd/6bac76ecd1b27e75a95ca3a9a559c643b3afcd2dd62086d4b7a32a18b169/pydantic_core-2.41.5-cp314-cp314-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:2b761d210c9ea91feda40d25b4efe82a1707da2ef62901466a42492c028553a2", size = 2333302 }, + { url = "https://files.pythonhosted.org/packages/4c/d2/ef2074dc020dd6e109611a8be4449b98cd25e1b9b8a303c2f0fca2f2bcf7/pydantic_core-2.41.5-cp314-cp314-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:22f0fb8c1c583a3b6f24df2470833b40207e907b90c928cc8d3594b76f874375", size = 2064877 }, + { url = "https://files.pythonhosted.org/packages/18/66/e9db17a9a763d72f03de903883c057b2592c09509ccfe468187f2a2eef29/pydantic_core-2.41.5-cp314-cp314-manylinux_2_5_i686.manylinux1_i686.whl", hash = "sha256:2782c870e99878c634505236d81e5443092fba820f0373997ff75f90f68cd553", size = 2180680 }, + { url = "https://files.pythonhosted.org/packages/d3/9e/3ce66cebb929f3ced22be85d4c2399b8e85b622db77dad36b73c5387f8f8/pydantic_core-2.41.5-cp314-cp314-musllinux_1_1_aarch64.whl", hash = "sha256:0177272f88ab8312479336e1d777f6b124537d47f2123f89cb37e0accea97f90", size = 2138960 }, + { url = "https://files.pythonhosted.org/packages/a6/62/205a998f4327d2079326b01abee48e502ea739d174f0a89295c481a2272e/pydantic_core-2.41.5-cp314-cp314-musllinux_1_1_armv7l.whl", hash = "sha256:63510af5e38f8955b8ee5687740d6ebf7c2a0886d15a6d65c32814613681bc07", size = 2339102 }, + { url = "https://files.pythonhosted.org/packages/3c/0d/f05e79471e889d74d3d88f5bd20d0ed189ad94c2423d81ff8d0000aab4ff/pydantic_core-2.41.5-cp314-cp314-musllinux_1_1_x86_64.whl", hash = "sha256:e56ba91f47764cc14f1daacd723e3e82d1a89d783f0f5afe9c364b8bb491ccdb", size = 2326039 }, + { url = "https://files.pythonhosted.org/packages/ec/e1/e08a6208bb100da7e0c4b288eed624a703f4d129bde2da475721a80cab32/pydantic_core-2.41.5-cp314-cp314-win32.whl", hash = "sha256:aec5cf2fd867b4ff45b9959f8b20ea3993fc93e63c7363fe6851424c8a7e7c23", size = 1995126 }, + { url = "https://files.pythonhosted.org/packages/48/5d/56ba7b24e9557f99c9237e29f5c09913c81eeb2f3217e40e922353668092/pydantic_core-2.41.5-cp314-cp314-win_amd64.whl", hash = "sha256:8e7c86f27c585ef37c35e56a96363ab8de4e549a95512445b85c96d3e2f7c1bf", size = 2015489 }, + { url = "https://files.pythonhosted.org/packages/4e/bb/f7a190991ec9e3e0ba22e4993d8755bbc4a32925c0b5b42775c03e8148f9/pydantic_core-2.41.5-cp314-cp314-win_arm64.whl", hash = "sha256:e672ba74fbc2dc8eea59fb6d4aed6845e6905fc2a8afe93175d94a83ba2a01a0", size = 1977288 }, + { url = "https://files.pythonhosted.org/packages/92/ed/77542d0c51538e32e15afe7899d79efce4b81eee631d99850edc2f5e9349/pydantic_core-2.41.5-cp314-cp314t-macosx_10_12_x86_64.whl", hash = "sha256:8566def80554c3faa0e65ac30ab0932b9e3a5cd7f8323764303d468e5c37595a", size = 2120255 }, + { url = "https://files.pythonhosted.org/packages/bb/3d/6913dde84d5be21e284439676168b28d8bbba5600d838b9dca99de0fad71/pydantic_core-2.41.5-cp314-cp314t-macosx_11_0_arm64.whl", hash = "sha256:b80aa5095cd3109962a298ce14110ae16b8c1aece8b72f9dafe81cf597ad80b3", size = 1863760 }, + { url = "https://files.pythonhosted.org/packages/5a/f0/e5e6b99d4191da102f2b0eb9687aaa7f5bea5d9964071a84effc3e40f997/pydantic_core-2.41.5-cp314-cp314t-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:3006c3dd9ba34b0c094c544c6006cc79e87d8612999f1a5d43b769b89181f23c", size = 1878092 }, + { url = "https://files.pythonhosted.org/packages/71/48/36fb760642d568925953bcc8116455513d6e34c4beaa37544118c36aba6d/pydantic_core-2.41.5-cp314-cp314t-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:72f6c8b11857a856bcfa48c86f5368439f74453563f951e473514579d44aa612", size = 2053385 }, + { url = "https://files.pythonhosted.org/packages/20/25/92dc684dd8eb75a234bc1c764b4210cf2646479d54b47bf46061657292a8/pydantic_core-2.41.5-cp314-cp314t-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:5cb1b2f9742240e4bb26b652a5aeb840aa4b417c7748b6f8387927bc6e45e40d", size = 2218832 }, + { url = "https://files.pythonhosted.org/packages/e2/09/f53e0b05023d3e30357d82eb35835d0f6340ca344720a4599cd663dca599/pydantic_core-2.41.5-cp314-cp314t-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:bd3d54f38609ff308209bd43acea66061494157703364ae40c951f83ba99a1a9", size = 2327585 }, + { url = "https://files.pythonhosted.org/packages/aa/4e/2ae1aa85d6af35a39b236b1b1641de73f5a6ac4d5a7509f77b814885760c/pydantic_core-2.41.5-cp314-cp314t-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:2ff4321e56e879ee8d2a879501c8e469414d948f4aba74a2d4593184eb326660", size = 2041078 }, + { url = "https://files.pythonhosted.org/packages/cd/13/2e215f17f0ef326fc72afe94776edb77525142c693767fc347ed6288728d/pydantic_core-2.41.5-cp314-cp314t-manylinux_2_5_i686.manylinux1_i686.whl", hash = "sha256:d0d2568a8c11bf8225044aa94409e21da0cb09dcdafe9ecd10250b2baad531a9", size = 2173914 }, + { url = "https://files.pythonhosted.org/packages/02/7a/f999a6dcbcd0e5660bc348a3991c8915ce6599f4f2c6ac22f01d7a10816c/pydantic_core-2.41.5-cp314-cp314t-musllinux_1_1_aarch64.whl", hash = "sha256:a39455728aabd58ceabb03c90e12f71fd30fa69615760a075b9fec596456ccc3", size = 2129560 }, + { url = "https://files.pythonhosted.org/packages/3a/b1/6c990ac65e3b4c079a4fb9f5b05f5b013afa0f4ed6780a3dd236d2cbdc64/pydantic_core-2.41.5-cp314-cp314t-musllinux_1_1_armv7l.whl", hash = "sha256:239edca560d05757817c13dc17c50766136d21f7cd0fac50295499ae24f90fdf", size = 2329244 }, + { url = "https://files.pythonhosted.org/packages/d9/02/3c562f3a51afd4d88fff8dffb1771b30cfdfd79befd9883ee094f5b6c0d8/pydantic_core-2.41.5-cp314-cp314t-musllinux_1_1_x86_64.whl", hash = "sha256:2a5e06546e19f24c6a96a129142a75cee553cc018ffee48a460059b1185f4470", size = 2331955 }, + { url = "https://files.pythonhosted.org/packages/5c/96/5fb7d8c3c17bc8c62fdb031c47d77a1af698f1d7a406b0f79aaa1338f9ad/pydantic_core-2.41.5-cp314-cp314t-win32.whl", hash = "sha256:b4ececa40ac28afa90871c2cc2b9ffd2ff0bf749380fbdf57d165fd23da353aa", size = 1988906 }, + { url = "https://files.pythonhosted.org/packages/22/ed/182129d83032702912c2e2d8bbe33c036f342cc735737064668585dac28f/pydantic_core-2.41.5-cp314-cp314t-win_amd64.whl", hash = "sha256:80aa89cad80b32a912a65332f64a4450ed00966111b6615ca6816153d3585a8c", size = 1981607 }, + { url = "https://files.pythonhosted.org/packages/9f/ed/068e41660b832bb0b1aa5b58011dea2a3fe0ba7861ff38c4d4904c1c1a99/pydantic_core-2.41.5-cp314-cp314t-win_arm64.whl", hash = "sha256:35b44f37a3199f771c3eaa53051bc8a70cd7b54f333531c59e29fd4db5d15008", size = 1974769 }, + { url = "https://files.pythonhosted.org/packages/e6/b0/1a2aa41e3b5a4ba11420aba2d091b2d17959c8d1519ece3627c371951e73/pydantic_core-2.41.5-pp310-pypy310_pp73-macosx_10_12_x86_64.whl", hash = "sha256:b5819cd790dbf0c5eb9f82c73c16b39a65dd6dd4d1439dcdea7816ec9adddab8", size = 2103351 }, + { url = "https://files.pythonhosted.org/packages/a4/ee/31b1f0020baaf6d091c87900ae05c6aeae101fa4e188e1613c80e4f1ea31/pydantic_core-2.41.5-pp310-pypy310_pp73-macosx_11_0_arm64.whl", hash = "sha256:5a4e67afbc95fa5c34cf27d9089bca7fcab4e51e57278d710320a70b956d1b9a", size = 1925363 }, + { url = "https://files.pythonhosted.org/packages/e1/89/ab8e86208467e467a80deaca4e434adac37b10a9d134cd2f99b28a01e483/pydantic_core-2.41.5-pp310-pypy310_pp73-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:ece5c59f0ce7d001e017643d8d24da587ea1f74f6993467d85ae8a5ef9d4f42b", size = 2135615 }, + { url = "https://files.pythonhosted.org/packages/99/0a/99a53d06dd0348b2008f2f30884b34719c323f16c3be4e6cc1203b74a91d/pydantic_core-2.41.5-pp310-pypy310_pp73-manylinux_2_5_i686.manylinux1_i686.whl", hash = "sha256:16f80f7abe3351f8ea6858914ddc8c77e02578544a0ebc15b4c2e1a0e813b0b2", size = 2175369 }, + { url = "https://files.pythonhosted.org/packages/6d/94/30ca3b73c6d485b9bb0bc66e611cff4a7138ff9736b7e66bcf0852151636/pydantic_core-2.41.5-pp310-pypy310_pp73-musllinux_1_1_aarch64.whl", hash = "sha256:33cb885e759a705b426baada1fe68cbb0a2e68e34c5d0d0289a364cf01709093", size = 2144218 }, + { url = "https://files.pythonhosted.org/packages/87/57/31b4f8e12680b739a91f472b5671294236b82586889ef764b5fbc6669238/pydantic_core-2.41.5-pp310-pypy310_pp73-musllinux_1_1_armv7l.whl", hash = "sha256:c8d8b4eb992936023be7dee581270af5c6e0697a8559895f527f5b7105ecd36a", size = 2329951 }, + { url = "https://files.pythonhosted.org/packages/7d/73/3c2c8edef77b8f7310e6fb012dbc4b8551386ed575b9eb6fb2506e28a7eb/pydantic_core-2.41.5-pp310-pypy310_pp73-musllinux_1_1_x86_64.whl", hash = "sha256:242a206cd0318f95cd21bdacff3fcc3aab23e79bba5cac3db5a841c9ef9c6963", size = 2318428 }, + { url = "https://files.pythonhosted.org/packages/2f/02/8559b1f26ee0d502c74f9cca5c0d2fd97e967e083e006bbbb4e97f3a043a/pydantic_core-2.41.5-pp310-pypy310_pp73-win_amd64.whl", hash = "sha256:d3a978c4f57a597908b7e697229d996d77a6d3c94901e9edee593adada95ce1a", size = 2147009 }, + { url = "https://files.pythonhosted.org/packages/5f/9b/1b3f0e9f9305839d7e84912f9e8bfbd191ed1b1ef48083609f0dabde978c/pydantic_core-2.41.5-pp311-pypy311_pp73-macosx_10_12_x86_64.whl", hash = "sha256:b2379fa7ed44ddecb5bfe4e48577d752db9fc10be00a6b7446e9663ba143de26", size = 2101980 }, + { url = "https://files.pythonhosted.org/packages/a4/ed/d71fefcb4263df0da6a85b5d8a7508360f2f2e9b3bf5814be9c8bccdccc1/pydantic_core-2.41.5-pp311-pypy311_pp73-macosx_11_0_arm64.whl", hash = "sha256:266fb4cbf5e3cbd0b53669a6d1b039c45e3ce651fd5442eff4d07c2cc8d66808", size = 1923865 }, + { url = "https://files.pythonhosted.org/packages/ce/3a/626b38db460d675f873e4444b4bb030453bbe7b4ba55df821d026a0493c4/pydantic_core-2.41.5-pp311-pypy311_pp73-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:58133647260ea01e4d0500089a8c4f07bd7aa6ce109682b1426394988d8aaacc", size = 2134256 }, + { url = "https://files.pythonhosted.org/packages/83/d9/8412d7f06f616bbc053d30cb4e5f76786af3221462ad5eee1f202021eb4e/pydantic_core-2.41.5-pp311-pypy311_pp73-manylinux_2_5_i686.manylinux1_i686.whl", hash = "sha256:287dad91cfb551c363dc62899a80e9e14da1f0e2b6ebde82c806612ca2a13ef1", size = 2174762 }, + { url = "https://files.pythonhosted.org/packages/55/4c/162d906b8e3ba3a99354e20faa1b49a85206c47de97a639510a0e673f5da/pydantic_core-2.41.5-pp311-pypy311_pp73-musllinux_1_1_aarch64.whl", hash = "sha256:03b77d184b9eb40240ae9fd676ca364ce1085f203e1b1256f8ab9984dca80a84", size = 2143141 }, + { url = "https://files.pythonhosted.org/packages/1f/f2/f11dd73284122713f5f89fc940f370d035fa8e1e078d446b3313955157fe/pydantic_core-2.41.5-pp311-pypy311_pp73-musllinux_1_1_armv7l.whl", hash = "sha256:a668ce24de96165bb239160b3d854943128f4334822900534f2fe947930e5770", size = 2330317 }, + { url = "https://files.pythonhosted.org/packages/88/9d/b06ca6acfe4abb296110fb1273a4d848a0bfb2ff65f3ee92127b3244e16b/pydantic_core-2.41.5-pp311-pypy311_pp73-musllinux_1_1_x86_64.whl", hash = "sha256:f14f8f046c14563f8eb3f45f499cc658ab8d10072961e07225e507adb700e93f", size = 2316992 }, + { url = "https://files.pythonhosted.org/packages/36/c7/cfc8e811f061c841d7990b0201912c3556bfeb99cdcb7ed24adc8d6f8704/pydantic_core-2.41.5-pp311-pypy311_pp73-win_amd64.whl", hash = "sha256:56121965f7a4dc965bff783d70b907ddf3d57f6eba29b6d2e5dabfaf07799c51", size = 2145302 }, ] [[package]] -name = "pyinstaller-hooks-contrib" -version = "2025.3" +name = "pygments" +version = "2.19.2" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/b0/77/a5b8c569bf593b0140bde72ea885a803b82086995367bf2037de0159d924/pygments-2.19.2.tar.gz", hash = "sha256:636cb2477cec7f8952536970bc533bc43743542f70392ae026374600add5b887", size = 4968631 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/c7/21/705964c7812476f378728bdf590ca4b771ec72385c533964653c68e86bdc/pygments-2.19.2-py3-none-any.whl", hash = "sha256:86540386c03d588bb81d44bc3928634ff26449851e99741617ecb9037ee5ec0b", size = 1225217 }, +] + +[[package]] +name = "pyjwt" +version = "2.11.0" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/5c/5a/b46fa56bf322901eee5b0454a34343cdbdae202cd421775a8ee4e42fd519/pyjwt-2.11.0.tar.gz", hash = "sha256:35f95c1f0fbe5d5ba6e43f00271c275f7a1a4db1dab27bf708073b75318ea623", size = 98019 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/6f/01/c26ce75ba460d5cd503da9e13b21a33804d38c2165dec7b716d06b13010c/pyjwt-2.11.0-py3-none-any.whl", hash = "sha256:94a6bde30eb5c8e04fee991062b534071fd1439ef58d2adc9ccb823e7bcd0469", size = 28224 }, +] + +[[package]] +name = "pytest" +version = "9.0.2" source = { registry = "https://pypi.org/simple" } dependencies = [ + { name = "colorama", marker = "sys_platform == 'win32'" }, + { name = "exceptiongroup", marker = "python_full_version < '3.11'" }, + { name = "iniconfig" }, { name = "packaging" }, - { name = "setuptools" }, + { name = "pluggy" }, + { name = "pygments" }, + { name = "tomli", marker = "python_full_version < '3.11'" }, ] -sdist = { url = "https://files.pythonhosted.org/packages/18/46/195324574e44e52c1ba7f7b0607bc9d488b057d93e253918f1a2759d6a98/pyinstaller_hooks_contrib-2025.3.tar.gz", hash = "sha256:af129da5cd6219669fbda360e295cc822abac55b7647d03fec63a8fcf0a608cf", size = 162501 } +sdist = { url = "https://files.pythonhosted.org/packages/d1/db/7ef3487e0fb0049ddb5ce41d3a49c235bf9ad299b6a25d5780a89f19230f/pytest-9.0.2.tar.gz", hash = "sha256:75186651a92bd89611d1d9fc20f0b4345fd827c41ccd5c299a868a05d70edf11", size = 1568901 } wheels = [ - { url = "https://files.pythonhosted.org/packages/9a/98/0273ffc4f85a4038c8d316a75ef5ac1f10f1bbe5ba50c27871b73da2e3d2/pyinstaller_hooks_contrib-2025.3-py3-none-any.whl", hash = "sha256:70cba46b1a6b82ae9104f074c25926e31f3dde50ff217434d1d660355b949683", size = 434307 }, + { url = "https://files.pythonhosted.org/packages/3b/ab/b3226f0bd7cdcf710fbede2b3548584366da3b19b5021e74f5bde2a8fa3f/pytest-9.0.2-py3-none-any.whl", hash = "sha256:711ffd45bf766d5264d487b917733b453d917afd2b0ad65223959f59089f875b", size = 374801 }, +] + +[[package]] +name = "pytest-cov" +version = "7.0.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "coverage", extra = ["toml"] }, + { name = "pluggy" }, + { name = "pytest" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/5e/f7/c933acc76f5208b3b00089573cf6a2bc26dc80a8aece8f52bb7d6b1855ca/pytest_cov-7.0.0.tar.gz", hash = "sha256:33c97eda2e049a0c5298e91f519302a1334c26ac65c1a483d6206fd458361af1", size = 54328 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/ee/49/1377b49de7d0c1ce41292161ea0f721913fa8722c19fb9c1e3aa0367eecb/pytest_cov-7.0.0-py3-none-any.whl", hash = "sha256:3b8e9558b16cc1479da72058bdecf8073661c7f57f7d3c5f22a1c23507f2d861", size = 22424 }, ] [[package]] @@ -621,6 +1303,40 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/36/7a/87837f39d0296e723bb9b62bbb257d0355c7f6128853c78955f57342a56d/python_dateutil-2.8.2-py2.py3-none-any.whl", hash = "sha256:961d03dc3453ebbc59dbdea9e4e11c5651520a876d0f4db161e8674aae935da9", size = 247702 }, ] +[[package]] +name = "python-engineio" +version = "4.13.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "simple-websocket" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/42/5a/349caac055e03ef9e56ed29fa304846063b1771ee54ab8132bf98b29491e/python_engineio-4.13.0.tar.gz", hash = "sha256:f9c51a8754d2742ba832c24b46ed425fdd3064356914edd5a1e8ffde76ab7709", size = 92194 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/50/74/c655a6eda0fd188d490c14142a0f0380655ac7099604e1fbf8fa1a97f0a1/python_engineio-4.13.0-py3-none-any.whl", hash = "sha256:57b94eac094fa07b050c6da59f48b12250ab1cd920765f4849963e3d89ad9de3", size = 59676 }, +] + +[[package]] +name = "python-multipart" +version = "0.0.22" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/94/01/979e98d542a70714b0cb2b6728ed0b7c46792b695e3eaec3e20711271ca3/python_multipart-0.0.22.tar.gz", hash = "sha256:7340bef99a7e0032613f56dc36027b959fd3b30a787ed62d310e951f7c3a3a58", size = 37612 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/1b/d0/397f9626e711ff749a95d96b7af99b9c566a9bb5129b8e4c10fc4d100304/python_multipart-0.0.22-py3-none-any.whl", hash = "sha256:2b2cd894c83d21bf49d702499531c7bafd057d730c201782048f7945d82de155", size = 24579 }, +] + +[[package]] +name = "python-socketio" +version = "5.16.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "bidict" }, + { name = "python-engineio" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/b8/55/5d8af5884283b58e4405580bcd84af1d898c457173c708736e065f10ca4a/python_socketio-5.16.0.tar.gz", hash = "sha256:f79403c7f1ba8b84460aa8fe4c671414c8145b21a501b46b676f3740286356fd", size = 127120 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/28/d2/2ccc2b69a187b80fda3152745670cfba936704f296a9fa54c6c8ac694d12/python_socketio-5.16.0-py3-none-any.whl", hash = "sha256:d95802961e15c7bd54ecf884c6e7644f81be8460f0a02ee66b473df58088ee8a", size = 79607 }, +] + [[package]] name = "pytz" version = "2023.3" @@ -646,21 +1362,166 @@ wheels = [ ] [[package]] -name = "pywin32-ctypes" -version = "0.2.3" +name = "pyyaml" +version = "6.0.3" source = { registry = "https://pypi.org/simple" } -sdist = { url = "https://files.pythonhosted.org/packages/85/9f/01a1a99704853cb63f253eea009390c88e7131c67e66a0a02099a8c917cb/pywin32-ctypes-0.2.3.tar.gz", hash = "sha256:d162dc04946d704503b2edc4d55f3dba5c1d539ead017afa00142c38b9885755", size = 29471 } +sdist = { url = "https://files.pythonhosted.org/packages/05/8e/961c0007c59b8dd7729d542c61a4d537767a59645b82a0b521206e1e25c2/pyyaml-6.0.3.tar.gz", hash = "sha256:d76623373421df22fb4cf8817020cbb7ef15c725b9d5e45f17e189bfc384190f", size = 130960 } wheels = [ - { url = "https://files.pythonhosted.org/packages/de/3d/8161f7711c017e01ac9f008dfddd9410dff3674334c233bde66e7ba65bbf/pywin32_ctypes-0.2.3-py3-none-any.whl", hash = "sha256:8a1513379d709975552d202d942d9837758905c8d01eb82b8bcc30918929e7b8", size = 30756 }, + { url = "https://files.pythonhosted.org/packages/f4/a0/39350dd17dd6d6c6507025c0e53aef67a9293a6d37d3511f23ea510d5800/pyyaml-6.0.3-cp310-cp310-macosx_10_13_x86_64.whl", hash = "sha256:214ed4befebe12df36bcc8bc2b64b396ca31be9304b8f59e25c11cf94a4c033b", size = 184227 }, + { url = "https://files.pythonhosted.org/packages/05/14/52d505b5c59ce73244f59c7a50ecf47093ce4765f116cdb98286a71eeca2/pyyaml-6.0.3-cp310-cp310-macosx_11_0_arm64.whl", hash = "sha256:02ea2dfa234451bbb8772601d7b8e426c2bfa197136796224e50e35a78777956", size = 174019 }, + { url = "https://files.pythonhosted.org/packages/43/f7/0e6a5ae5599c838c696adb4e6330a59f463265bfa1e116cfd1fbb0abaaae/pyyaml-6.0.3-cp310-cp310-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:b30236e45cf30d2b8e7b3e85881719e98507abed1011bf463a8fa23e9c3e98a8", size = 740646 }, + { url = "https://files.pythonhosted.org/packages/2f/3a/61b9db1d28f00f8fd0ae760459a5c4bf1b941baf714e207b6eb0657d2578/pyyaml-6.0.3-cp310-cp310-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:66291b10affd76d76f54fad28e22e51719ef9ba22b29e1d7d03d6777a9174198", size = 840793 }, + { url = "https://files.pythonhosted.org/packages/7a/1e/7acc4f0e74c4b3d9531e24739e0ab832a5edf40e64fbae1a9c01941cabd7/pyyaml-6.0.3-cp310-cp310-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:9c7708761fccb9397fe64bbc0395abcae8c4bf7b0eac081e12b809bf47700d0b", size = 770293 }, + { url = "https://files.pythonhosted.org/packages/8b/ef/abd085f06853af0cd59fa5f913d61a8eab65d7639ff2a658d18a25d6a89d/pyyaml-6.0.3-cp310-cp310-musllinux_1_2_aarch64.whl", hash = "sha256:418cf3f2111bc80e0933b2cd8cd04f286338bb88bdc7bc8e6dd775ebde60b5e0", size = 732872 }, + { url = "https://files.pythonhosted.org/packages/1f/15/2bc9c8faf6450a8b3c9fc5448ed869c599c0a74ba2669772b1f3a0040180/pyyaml-6.0.3-cp310-cp310-musllinux_1_2_x86_64.whl", hash = "sha256:5e0b74767e5f8c593e8c9b5912019159ed0533c70051e9cce3e8b6aa699fcd69", size = 758828 }, + { url = "https://files.pythonhosted.org/packages/a3/00/531e92e88c00f4333ce359e50c19b8d1de9fe8d581b1534e35ccfbc5f393/pyyaml-6.0.3-cp310-cp310-win32.whl", hash = "sha256:28c8d926f98f432f88adc23edf2e6d4921ac26fb084b028c733d01868d19007e", size = 142415 }, + { url = "https://files.pythonhosted.org/packages/2a/fa/926c003379b19fca39dd4634818b00dec6c62d87faf628d1394e137354d4/pyyaml-6.0.3-cp310-cp310-win_amd64.whl", hash = "sha256:bdb2c67c6c1390b63c6ff89f210c8fd09d9a1217a465701eac7316313c915e4c", size = 158561 }, + { url = "https://files.pythonhosted.org/packages/6d/16/a95b6757765b7b031c9374925bb718d55e0a9ba8a1b6a12d25962ea44347/pyyaml-6.0.3-cp311-cp311-macosx_10_13_x86_64.whl", hash = "sha256:44edc647873928551a01e7a563d7452ccdebee747728c1080d881d68af7b997e", size = 185826 }, + { url = "https://files.pythonhosted.org/packages/16/19/13de8e4377ed53079ee996e1ab0a9c33ec2faf808a4647b7b4c0d46dd239/pyyaml-6.0.3-cp311-cp311-macosx_11_0_arm64.whl", hash = "sha256:652cb6edd41e718550aad172851962662ff2681490a8a711af6a4d288dd96824", size = 175577 }, + { url = "https://files.pythonhosted.org/packages/0c/62/d2eb46264d4b157dae1275b573017abec435397aa59cbcdab6fc978a8af4/pyyaml-6.0.3-cp311-cp311-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:10892704fc220243f5305762e276552a0395f7beb4dbf9b14ec8fd43b57f126c", size = 775556 }, + { url = "https://files.pythonhosted.org/packages/10/cb/16c3f2cf3266edd25aaa00d6c4350381c8b012ed6f5276675b9eba8d9ff4/pyyaml-6.0.3-cp311-cp311-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:850774a7879607d3a6f50d36d04f00ee69e7fc816450e5f7e58d7f17f1ae5c00", size = 882114 }, + { url = "https://files.pythonhosted.org/packages/71/60/917329f640924b18ff085ab889a11c763e0b573da888e8404ff486657602/pyyaml-6.0.3-cp311-cp311-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:b8bb0864c5a28024fac8a632c443c87c5aa6f215c0b126c449ae1a150412f31d", size = 806638 }, + { url = "https://files.pythonhosted.org/packages/dd/6f/529b0f316a9fd167281a6c3826b5583e6192dba792dd55e3203d3f8e655a/pyyaml-6.0.3-cp311-cp311-musllinux_1_2_aarch64.whl", hash = "sha256:1d37d57ad971609cf3c53ba6a7e365e40660e3be0e5175fa9f2365a379d6095a", size = 767463 }, + { url = "https://files.pythonhosted.org/packages/f2/6a/b627b4e0c1dd03718543519ffb2f1deea4a1e6d42fbab8021936a4d22589/pyyaml-6.0.3-cp311-cp311-musllinux_1_2_x86_64.whl", hash = "sha256:37503bfbfc9d2c40b344d06b2199cf0e96e97957ab1c1b546fd4f87e53e5d3e4", size = 794986 }, + { url = "https://files.pythonhosted.org/packages/45/91/47a6e1c42d9ee337c4839208f30d9f09caa9f720ec7582917b264defc875/pyyaml-6.0.3-cp311-cp311-win32.whl", hash = "sha256:8098f252adfa6c80ab48096053f512f2321f0b998f98150cea9bd23d83e1467b", size = 142543 }, + { url = "https://files.pythonhosted.org/packages/da/e3/ea007450a105ae919a72393cb06f122f288ef60bba2dc64b26e2646fa315/pyyaml-6.0.3-cp311-cp311-win_amd64.whl", hash = "sha256:9f3bfb4965eb874431221a3ff3fdcddc7e74e3b07799e0e84ca4a0f867d449bf", size = 158763 }, + { url = "https://files.pythonhosted.org/packages/d1/33/422b98d2195232ca1826284a76852ad5a86fe23e31b009c9886b2d0fb8b2/pyyaml-6.0.3-cp312-cp312-macosx_10_13_x86_64.whl", hash = "sha256:7f047e29dcae44602496db43be01ad42fc6f1cc0d8cd6c83d342306c32270196", size = 182063 }, + { url = "https://files.pythonhosted.org/packages/89/a0/6cf41a19a1f2f3feab0e9c0b74134aa2ce6849093d5517a0c550fe37a648/pyyaml-6.0.3-cp312-cp312-macosx_11_0_arm64.whl", hash = "sha256:fc09d0aa354569bc501d4e787133afc08552722d3ab34836a80547331bb5d4a0", size = 173973 }, + { url = "https://files.pythonhosted.org/packages/ed/23/7a778b6bd0b9a8039df8b1b1d80e2e2ad78aa04171592c8a5c43a56a6af4/pyyaml-6.0.3-cp312-cp312-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:9149cad251584d5fb4981be1ecde53a1ca46c891a79788c0df828d2f166bda28", size = 775116 }, + { url = "https://files.pythonhosted.org/packages/65/30/d7353c338e12baef4ecc1b09e877c1970bd3382789c159b4f89d6a70dc09/pyyaml-6.0.3-cp312-cp312-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:5fdec68f91a0c6739b380c83b951e2c72ac0197ace422360e6d5a959d8d97b2c", size = 844011 }, + { url = "https://files.pythonhosted.org/packages/8b/9d/b3589d3877982d4f2329302ef98a8026e7f4443c765c46cfecc8858c6b4b/pyyaml-6.0.3-cp312-cp312-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:ba1cc08a7ccde2d2ec775841541641e4548226580ab850948cbfda66a1befcdc", size = 807870 }, + { url = "https://files.pythonhosted.org/packages/05/c0/b3be26a015601b822b97d9149ff8cb5ead58c66f981e04fedf4e762f4bd4/pyyaml-6.0.3-cp312-cp312-musllinux_1_2_aarch64.whl", hash = "sha256:8dc52c23056b9ddd46818a57b78404882310fb473d63f17b07d5c40421e47f8e", size = 761089 }, + { url = "https://files.pythonhosted.org/packages/be/8e/98435a21d1d4b46590d5459a22d88128103f8da4c2d4cb8f14f2a96504e1/pyyaml-6.0.3-cp312-cp312-musllinux_1_2_x86_64.whl", hash = "sha256:41715c910c881bc081f1e8872880d3c650acf13dfa8214bad49ed4cede7c34ea", size = 790181 }, + { url = "https://files.pythonhosted.org/packages/74/93/7baea19427dcfbe1e5a372d81473250b379f04b1bd3c4c5ff825e2327202/pyyaml-6.0.3-cp312-cp312-win32.whl", hash = "sha256:96b533f0e99f6579b3d4d4995707cf36df9100d67e0c8303a0c55b27b5f99bc5", size = 137658 }, + { url = "https://files.pythonhosted.org/packages/86/bf/899e81e4cce32febab4fb42bb97dcdf66bc135272882d1987881a4b519e9/pyyaml-6.0.3-cp312-cp312-win_amd64.whl", hash = "sha256:5fcd34e47f6e0b794d17de1b4ff496c00986e1c83f7ab2fb8fcfe9616ff7477b", size = 154003 }, + { url = "https://files.pythonhosted.org/packages/1a/08/67bd04656199bbb51dbed1439b7f27601dfb576fb864099c7ef0c3e55531/pyyaml-6.0.3-cp312-cp312-win_arm64.whl", hash = "sha256:64386e5e707d03a7e172c0701abfb7e10f0fb753ee1d773128192742712a98fd", size = 140344 }, + { url = "https://files.pythonhosted.org/packages/d1/11/0fd08f8192109f7169db964b5707a2f1e8b745d4e239b784a5a1dd80d1db/pyyaml-6.0.3-cp313-cp313-macosx_10_13_x86_64.whl", hash = "sha256:8da9669d359f02c0b91ccc01cac4a67f16afec0dac22c2ad09f46bee0697eba8", size = 181669 }, + { url = "https://files.pythonhosted.org/packages/b1/16/95309993f1d3748cd644e02e38b75d50cbc0d9561d21f390a76242ce073f/pyyaml-6.0.3-cp313-cp313-macosx_11_0_arm64.whl", hash = "sha256:2283a07e2c21a2aa78d9c4442724ec1eb15f5e42a723b99cb3d822d48f5f7ad1", size = 173252 }, + { url = "https://files.pythonhosted.org/packages/50/31/b20f376d3f810b9b2371e72ef5adb33879b25edb7a6d072cb7ca0c486398/pyyaml-6.0.3-cp313-cp313-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:ee2922902c45ae8ccada2c5b501ab86c36525b883eff4255313a253a3160861c", size = 767081 }, + { url = "https://files.pythonhosted.org/packages/49/1e/a55ca81e949270d5d4432fbbd19dfea5321eda7c41a849d443dc92fd1ff7/pyyaml-6.0.3-cp313-cp313-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:a33284e20b78bd4a18c8c2282d549d10bc8408a2a7ff57653c0cf0b9be0afce5", size = 841159 }, + { url = "https://files.pythonhosted.org/packages/74/27/e5b8f34d02d9995b80abcef563ea1f8b56d20134d8f4e5e81733b1feceb2/pyyaml-6.0.3-cp313-cp313-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:0f29edc409a6392443abf94b9cf89ce99889a1dd5376d94316ae5145dfedd5d6", size = 801626 }, + { url = "https://files.pythonhosted.org/packages/f9/11/ba845c23988798f40e52ba45f34849aa8a1f2d4af4b798588010792ebad6/pyyaml-6.0.3-cp313-cp313-musllinux_1_2_aarch64.whl", hash = "sha256:f7057c9a337546edc7973c0d3ba84ddcdf0daa14533c2065749c9075001090e6", size = 753613 }, + { url = "https://files.pythonhosted.org/packages/3d/e0/7966e1a7bfc0a45bf0a7fb6b98ea03fc9b8d84fa7f2229e9659680b69ee3/pyyaml-6.0.3-cp313-cp313-musllinux_1_2_x86_64.whl", hash = "sha256:eda16858a3cab07b80edaf74336ece1f986ba330fdb8ee0d6c0d68fe82bc96be", size = 794115 }, + { url = "https://files.pythonhosted.org/packages/de/94/980b50a6531b3019e45ddeada0626d45fa85cbe22300844a7983285bed3b/pyyaml-6.0.3-cp313-cp313-win32.whl", hash = "sha256:d0eae10f8159e8fdad514efdc92d74fd8d682c933a6dd088030f3834bc8e6b26", size = 137427 }, + { url = "https://files.pythonhosted.org/packages/97/c9/39d5b874e8b28845e4ec2202b5da735d0199dbe5b8fb85f91398814a9a46/pyyaml-6.0.3-cp313-cp313-win_amd64.whl", hash = "sha256:79005a0d97d5ddabfeeea4cf676af11e647e41d81c9a7722a193022accdb6b7c", size = 154090 }, + { url = "https://files.pythonhosted.org/packages/73/e8/2bdf3ca2090f68bb3d75b44da7bbc71843b19c9f2b9cb9b0f4ab7a5a4329/pyyaml-6.0.3-cp313-cp313-win_arm64.whl", hash = "sha256:5498cd1645aa724a7c71c8f378eb29ebe23da2fc0d7a08071d89469bf1d2defb", size = 140246 }, + { url = "https://files.pythonhosted.org/packages/9d/8c/f4bd7f6465179953d3ac9bc44ac1a8a3e6122cf8ada906b4f96c60172d43/pyyaml-6.0.3-cp314-cp314-macosx_10_13_x86_64.whl", hash = "sha256:8d1fab6bb153a416f9aeb4b8763bc0f22a5586065f86f7664fc23339fc1c1fac", size = 181814 }, + { url = "https://files.pythonhosted.org/packages/bd/9c/4d95bb87eb2063d20db7b60faa3840c1b18025517ae857371c4dd55a6b3a/pyyaml-6.0.3-cp314-cp314-macosx_11_0_arm64.whl", hash = "sha256:34d5fcd24b8445fadc33f9cf348c1047101756fd760b4dacb5c3e99755703310", size = 173809 }, + { url = "https://files.pythonhosted.org/packages/92/b5/47e807c2623074914e29dabd16cbbdd4bf5e9b2db9f8090fa64411fc5382/pyyaml-6.0.3-cp314-cp314-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:501a031947e3a9025ed4405a168e6ef5ae3126c59f90ce0cd6f2bfc477be31b7", size = 766454 }, + { url = "https://files.pythonhosted.org/packages/02/9e/e5e9b168be58564121efb3de6859c452fccde0ab093d8438905899a3a483/pyyaml-6.0.3-cp314-cp314-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:b3bc83488de33889877a0f2543ade9f70c67d66d9ebb4ac959502e12de895788", size = 836355 }, + { url = "https://files.pythonhosted.org/packages/88/f9/16491d7ed2a919954993e48aa941b200f38040928474c9e85ea9e64222c3/pyyaml-6.0.3-cp314-cp314-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:c458b6d084f9b935061bc36216e8a69a7e293a2f1e68bf956dcd9e6cbcd143f5", size = 794175 }, + { url = "https://files.pythonhosted.org/packages/dd/3f/5989debef34dc6397317802b527dbbafb2b4760878a53d4166579111411e/pyyaml-6.0.3-cp314-cp314-musllinux_1_2_aarch64.whl", hash = "sha256:7c6610def4f163542a622a73fb39f534f8c101d690126992300bf3207eab9764", size = 755228 }, + { url = "https://files.pythonhosted.org/packages/d7/ce/af88a49043cd2e265be63d083fc75b27b6ed062f5f9fd6cdc223ad62f03e/pyyaml-6.0.3-cp314-cp314-musllinux_1_2_x86_64.whl", hash = "sha256:5190d403f121660ce8d1d2c1bb2ef1bd05b5f68533fc5c2ea899bd15f4399b35", size = 789194 }, + { url = "https://files.pythonhosted.org/packages/23/20/bb6982b26a40bb43951265ba29d4c246ef0ff59c9fdcdf0ed04e0687de4d/pyyaml-6.0.3-cp314-cp314-win_amd64.whl", hash = "sha256:4a2e8cebe2ff6ab7d1050ecd59c25d4c8bd7e6f400f5f82b96557ac0abafd0ac", size = 156429 }, + { url = "https://files.pythonhosted.org/packages/f4/f4/a4541072bb9422c8a883ab55255f918fa378ecf083f5b85e87fc2b4eda1b/pyyaml-6.0.3-cp314-cp314-win_arm64.whl", hash = "sha256:93dda82c9c22deb0a405ea4dc5f2d0cda384168e466364dec6255b293923b2f3", size = 143912 }, + { url = "https://files.pythonhosted.org/packages/7c/f9/07dd09ae774e4616edf6cda684ee78f97777bdd15847253637a6f052a62f/pyyaml-6.0.3-cp314-cp314t-macosx_10_13_x86_64.whl", hash = "sha256:02893d100e99e03eda1c8fd5c441d8c60103fd175728e23e431db1b589cf5ab3", size = 189108 }, + { url = "https://files.pythonhosted.org/packages/4e/78/8d08c9fb7ce09ad8c38ad533c1191cf27f7ae1effe5bb9400a46d9437fcf/pyyaml-6.0.3-cp314-cp314t-macosx_11_0_arm64.whl", hash = "sha256:c1ff362665ae507275af2853520967820d9124984e0f7466736aea23d8611fba", size = 183641 }, + { url = "https://files.pythonhosted.org/packages/7b/5b/3babb19104a46945cf816d047db2788bcaf8c94527a805610b0289a01c6b/pyyaml-6.0.3-cp314-cp314t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:6adc77889b628398debc7b65c073bcb99c4a0237b248cacaf3fe8a557563ef6c", size = 831901 }, + { url = "https://files.pythonhosted.org/packages/8b/cc/dff0684d8dc44da4d22a13f35f073d558c268780ce3c6ba1b87055bb0b87/pyyaml-6.0.3-cp314-cp314t-manylinux2014_s390x.manylinux_2_17_s390x.manylinux_2_28_s390x.whl", hash = "sha256:a80cb027f6b349846a3bf6d73b5e95e782175e52f22108cfa17876aaeff93702", size = 861132 }, + { url = "https://files.pythonhosted.org/packages/b1/5e/f77dc6b9036943e285ba76b49e118d9ea929885becb0a29ba8a7c75e29fe/pyyaml-6.0.3-cp314-cp314t-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:00c4bdeba853cc34e7dd471f16b4114f4162dc03e6b7afcc2128711f0eca823c", size = 839261 }, + { url = "https://files.pythonhosted.org/packages/ce/88/a9db1376aa2a228197c58b37302f284b5617f56a5d959fd1763fb1675ce6/pyyaml-6.0.3-cp314-cp314t-musllinux_1_2_aarch64.whl", hash = "sha256:66e1674c3ef6f541c35191caae2d429b967b99e02040f5ba928632d9a7f0f065", size = 805272 }, + { url = "https://files.pythonhosted.org/packages/da/92/1446574745d74df0c92e6aa4a7b0b3130706a4142b2d1a5869f2eaa423c6/pyyaml-6.0.3-cp314-cp314t-musllinux_1_2_x86_64.whl", hash = "sha256:16249ee61e95f858e83976573de0f5b2893b3677ba71c9dd36b9cf8be9ac6d65", size = 829923 }, + { url = "https://files.pythonhosted.org/packages/f0/7a/1c7270340330e575b92f397352af856a8c06f230aa3e76f86b39d01b416a/pyyaml-6.0.3-cp314-cp314t-win_amd64.whl", hash = "sha256:4ad1906908f2f5ae4e5a8ddfce73c320c2a1429ec52eafd27138b7f1cbe341c9", size = 174062 }, + { url = "https://files.pythonhosted.org/packages/f1/12/de94a39c2ef588c7e6455cfbe7343d3b2dc9d6b6b2f40c4c6565744c873d/pyyaml-6.0.3-cp314-cp314t-win_arm64.whl", hash = "sha256:ebc55a14a21cb14062aa4162f906cd962b28e2e9ea38f9b4391244cd8de4ae0b", size = 149341 }, ] [[package]] -name = "setuptools" -version = "80.0.1" +name = "redis" +version = "5.3.1" source = { registry = "https://pypi.org/simple" } -sdist = { url = "https://files.pythonhosted.org/packages/26/da/7a7021c150030617f90aa4a90a5b23f7b49af877f70ca46967e991645117/setuptools-80.0.1.tar.gz", hash = "sha256:20fe373a22ef9f3925512650d1db90b1b8de01cdb6df91ab1788263139cbf9a2", size = 1354165 } +dependencies = [ + { name = "async-timeout", marker = "python_full_version < '3.11.3'" }, + { name = "pyjwt" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/6a/cf/128b1b6d7086200c9f387bd4be9b2572a30b90745ef078bd8b235042dc9f/redis-5.3.1.tar.gz", hash = "sha256:ca49577a531ea64039b5a36db3d6cd1a0c7a60c34124d46924a45b956e8cf14c", size = 4626200 } wheels = [ - { url = "https://files.pythonhosted.org/packages/2a/8e/2ee81652472f3c11503d1780c41844a9a9656989b69c29811a4631e4aeb9/setuptools-80.0.1-py3-none-any.whl", hash = "sha256:f4b49d457765b3aae7cbbeb1c71f6633a61b729408c2d1a837dae064cca82ef2", size = 1240915 }, + { url = "https://files.pythonhosted.org/packages/7f/26/5c5fa0e83c3621db835cfc1f1d789b37e7fa99ed54423b5f519beb931aa7/redis-5.3.1-py3-none-any.whl", hash = "sha256:dc1909bd24669cc31b5f67a039700b16ec30571096c5f1f0d9d2324bff31af97", size = 272833 }, +] + +[[package]] +name = "reflex" +version = "0.7.6.post1" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "alembic" }, + { name = "distro", marker = "sys_platform == 'linux'" }, + { name = "fastapi" }, + { name = "granian", extra = ["reload"] }, + { name = "gunicorn" }, + { name = "httpx" }, + { name = "jinja2" }, + { name = "packaging" }, + { name = "platformdirs" }, + { name = "psutil" }, + { name = "pydantic" }, + { name = "python-multipart" }, + { name = "python-socketio" }, + { name = "redis" }, + { name = "reflex-hosting-cli" }, + { name = "rich" }, + { name = "sqlmodel" }, + { name = "typer" }, + { name = "typing-extensions" }, + { name = "uvicorn" }, + { name = "wrapt" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/85/58/577a191a71020d0109b22fc52b16403e6ed673d84df2d8f70bfea9c02312/reflex-0.7.6.post1.tar.gz", hash = "sha256:827954a11d56af17b5601cf19e4fe5aaa69708382704a0d1261d8f99fb44b54a", size = 558025 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/19/27/49b21793f248226c7f87b5ca355eadc9917af2dfcdfcf93043af2920e27c/reflex-0.7.6.post1-py3-none-any.whl", hash = "sha256:d2721cc48084c31644507fb981e6d2149917162ccf52551bdc133b8f06158276", size = 846970 }, +] + +[[package]] +name = "reflex-hosting-cli" +version = "0.1.42" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "charset-normalizer" }, + { name = "httpx" }, + { name = "platformdirs" }, + { name = "pydantic" }, + { name = "pyyaml" }, + { name = "rich" }, + { name = "tabulate" }, + { name = "typer" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/37/b7/c129f7398590c73ef74dd521942d31bbf512cecec777ce8c94929642c6db/reflex_hosting_cli-0.1.42.tar.gz", hash = "sha256:929d92df19dc94c92d122e9aa8c05a85055941e2eb8928a0abbee646efbb03d2", size = 30901 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/0a/4d/5526f5a21a01b6179e3ebe9abc46dce01d9692ef655e22002a08e10de8b7/reflex_hosting_cli-0.1.42-py3-none-any.whl", hash = "sha256:2742d9eb3576fa001ea2a4971cef1e1db56a08aad619aa035af3b6cc8f80de4c", size = 38668 }, +] + +[[package]] +name = "rich" +version = "13.9.4" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "markdown-it-py" }, + { name = "pygments" }, + { name = "typing-extensions", marker = "python_full_version < '3.11'" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/ab/3a/0316b28d0761c6734d6bc14e770d85506c986c85ffb239e688eeaab2c2bc/rich-13.9.4.tar.gz", hash = "sha256:439594978a49a09530cff7ebc4b5c7103ef57baf48d5ea3184f21d9a2befa098", size = 223149 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/19/71/39c7c0d87f8d4e6c020a393182060eaefeeae6c01dab6a84ec346f2567df/rich-13.9.4-py3-none-any.whl", hash = "sha256:6049d5e6ec054bf2779ab3358186963bac2ea89175919d699e378b99738c2a90", size = 242424 }, +] + +[[package]] +name = "shellingham" +version = "1.5.4" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/58/15/8b3609fd3830ef7b27b655beb4b4e9c62313a4e8da8c676e142cc210d58e/shellingham-1.5.4.tar.gz", hash = "sha256:8dbca0739d487e5bd35ab3ca4b36e11c4078f3a234bfce294b0a0291363404de", size = 10310 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/e0/f9/0595336914c5619e5f28a1fb793285925a8cd4b432c9da0a987836c7f822/shellingham-1.5.4-py2.py3-none-any.whl", hash = "sha256:7ecfff8f2fd72616f7481040475a65b2bf8af90a56c89140852d1120324e8686", size = 9755 }, +] + +[[package]] +name = "simple-websocket" +version = "1.1.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "wsproto" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/b0/d4/bfa032f961103eba93de583b161f0e6a5b63cebb8f2c7d0c6e6efe1e3d2e/simple_websocket-1.1.0.tar.gz", hash = "sha256:7939234e7aa067c534abdab3a9ed933ec9ce4691b0713c78acb195560aa52ae4", size = 17300 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/52/59/0782e51887ac6b07ffd1570e0364cf901ebc36345fea669969d2084baebb/simple_websocket-1.1.0-py3-none-any.whl", hash = "sha256:4af6069630a38ed6c561010f0e11a5bc0d4ca569b36306eb257cd9a192497c8c", size = 13842 }, ] [[package]] @@ -672,6 +1533,97 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/d9/5a/e7c31adbe875f2abbb91bd84cf2dc52d792b5a01506781dbcf25c91daf11/six-1.16.0-py2.py3-none-any.whl", hash = "sha256:8abb2f1d86890a2dfb989f9a77cfcfd3e47c2a354b01111771326f8aa26e0254", size = 11053 }, ] +[[package]] +name = "sqlalchemy" +version = "2.0.46" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "greenlet", marker = "platform_machine == 'AMD64' or platform_machine == 'WIN32' or platform_machine == 'aarch64' or platform_machine == 'amd64' or platform_machine == 'ppc64le' or platform_machine == 'win32' or platform_machine == 'x86_64'" }, + { name = "typing-extensions" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/06/aa/9ce0f3e7a9829ead5c8ce549392f33a12c4555a6c0609bb27d882e9c7ddf/sqlalchemy-2.0.46.tar.gz", hash = "sha256:cf36851ee7219c170bb0793dbc3da3e80c582e04a5437bc601bfe8c85c9216d7", size = 9865393 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/40/26/66ba59328dc25e523bfcb0f8db48bdebe2035e0159d600e1f01c0fc93967/sqlalchemy-2.0.46-cp310-cp310-macosx_11_0_arm64.whl", hash = "sha256:895296687ad06dc9b11a024cf68e8d9d3943aa0b4964278d2553b86f1b267735", size = 2155051 }, + { url = "https://files.pythonhosted.org/packages/21/cd/9336732941df972fbbfa394db9caa8bb0cf9fe03656ec728d12e9cbd6edc/sqlalchemy-2.0.46-cp310-cp310-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:ab65cb2885a9f80f979b85aa4e9c9165a31381ca322cbde7c638fe6eefd1ec39", size = 3234666 }, + { url = "https://files.pythonhosted.org/packages/38/62/865ae8b739930ec433cd4123760bee7f8dafdc10abefd725a025604fb0de/sqlalchemy-2.0.46-cp310-cp310-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:52fe29b3817bd191cc20bad564237c808967972c97fa683c04b28ec8979ae36f", size = 3232917 }, + { url = "https://files.pythonhosted.org/packages/24/38/805904b911857f2b5e00fdea44e9570df62110f834378706939825579296/sqlalchemy-2.0.46-cp310-cp310-musllinux_1_2_aarch64.whl", hash = "sha256:09168817d6c19954d3b7655da6ba87fcb3a62bb575fb396a81a8b6a9fadfe8b5", size = 3185790 }, + { url = "https://files.pythonhosted.org/packages/69/4f/3260bb53aabd2d274856337456ea52f6a7eccf6cce208e558f870cec766b/sqlalchemy-2.0.46-cp310-cp310-musllinux_1_2_x86_64.whl", hash = "sha256:be6c0466b4c25b44c5d82b0426b5501de3c424d7a3220e86cd32f319ba56798e", size = 3207206 }, + { url = "https://files.pythonhosted.org/packages/ce/b3/67c432d7f9d88bb1a61909b67e29f6354d59186c168fb5d381cf438d3b73/sqlalchemy-2.0.46-cp310-cp310-win32.whl", hash = "sha256:1bc3f601f0a818d27bfe139f6766487d9c88502062a2cd3a7ee6c342e81d5047", size = 2115296 }, + { url = "https://files.pythonhosted.org/packages/4a/8c/25fb284f570f9d48e6c240f0269a50cec9cf009a7e08be4c0aaaf0654972/sqlalchemy-2.0.46-cp310-cp310-win_amd64.whl", hash = "sha256:e0c05aff5c6b1bb5fb46a87e0f9d2f733f83ef6cbbbcd5c642b6c01678268061", size = 2138540 }, + { url = "https://files.pythonhosted.org/packages/69/ac/b42ad16800d0885105b59380ad69aad0cce5a65276e269ce2729a2343b6a/sqlalchemy-2.0.46-cp311-cp311-macosx_11_0_arm64.whl", hash = "sha256:261c4b1f101b4a411154f1da2b76497d73abbfc42740029205d4d01fa1052684", size = 2154851 }, + { url = "https://files.pythonhosted.org/packages/a0/60/d8710068cb79f64d002ebed62a7263c00c8fd95f4ebd4b5be8f7ca93f2bc/sqlalchemy-2.0.46-cp311-cp311-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:181903fe8c1b9082995325f1b2e84ac078b1189e2819380c2303a5f90e114a62", size = 3311241 }, + { url = "https://files.pythonhosted.org/packages/2b/0f/20c71487c7219ab3aa7421c7c62d93824c97c1460f2e8bb72404b0192d13/sqlalchemy-2.0.46-cp311-cp311-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:590be24e20e2424a4c3c1b0835e9405fa3d0af5823a1a9fc02e5dff56471515f", size = 3310741 }, + { url = "https://files.pythonhosted.org/packages/65/80/d26d00b3b249ae000eee4db206fcfc564bf6ca5030e4747adf451f4b5108/sqlalchemy-2.0.46-cp311-cp311-musllinux_1_2_aarch64.whl", hash = "sha256:7568fe771f974abadce52669ef3a03150ff03186d8eb82613bc8adc435a03f01", size = 3263116 }, + { url = "https://files.pythonhosted.org/packages/da/ee/74dda7506640923821340541e8e45bd3edd8df78664f1f2e0aae8077192b/sqlalchemy-2.0.46-cp311-cp311-musllinux_1_2_x86_64.whl", hash = "sha256:ebf7e1e78af38047e08836d33502c7a278915698b7c2145d045f780201679999", size = 3285327 }, + { url = "https://files.pythonhosted.org/packages/9f/25/6dcf8abafff1389a21c7185364de145107b7394ecdcb05233815b236330d/sqlalchemy-2.0.46-cp311-cp311-win32.whl", hash = "sha256:9d80ea2ac519c364a7286e8d765d6cd08648f5b21ca855a8017d9871f075542d", size = 2114564 }, + { url = "https://files.pythonhosted.org/packages/93/5f/e081490f8523adc0088f777e4ebad3cac21e498ec8a3d4067074e21447a1/sqlalchemy-2.0.46-cp311-cp311-win_amd64.whl", hash = "sha256:585af6afe518732d9ccd3aea33af2edaae4a7aa881af5d8f6f4fe3a368699597", size = 2139233 }, + { url = "https://files.pythonhosted.org/packages/b6/35/d16bfa235c8b7caba3730bba43e20b1e376d2224f407c178fbf59559f23e/sqlalchemy-2.0.46-cp312-cp312-macosx_11_0_arm64.whl", hash = "sha256:3a9a72b0da8387f15d5810f1facca8f879de9b85af8c645138cba61ea147968c", size = 2153405 }, + { url = "https://files.pythonhosted.org/packages/06/6c/3192e24486749862f495ddc6584ed730c0c994a67550ec395d872a2ad650/sqlalchemy-2.0.46-cp312-cp312-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:2347c3f0efc4de367ba00218e0ae5c4ba2306e47216ef80d6e31761ac97cb0b9", size = 3334702 }, + { url = "https://files.pythonhosted.org/packages/ea/a2/b9f33c8d68a3747d972a0bb758c6b63691f8fb8a49014bc3379ba15d4274/sqlalchemy-2.0.46-cp312-cp312-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:9094c8b3197db12aa6f05c51c05daaad0a92b8c9af5388569847b03b1007fb1b", size = 3347664 }, + { url = "https://files.pythonhosted.org/packages/aa/d2/3e59e2a91eaec9db7e8dc6b37b91489b5caeb054f670f32c95bcba98940f/sqlalchemy-2.0.46-cp312-cp312-musllinux_1_2_aarch64.whl", hash = "sha256:37fee2164cf21417478b6a906adc1a91d69ae9aba8f9533e67ce882f4bb1de53", size = 3277372 }, + { url = "https://files.pythonhosted.org/packages/dd/dd/67bc2e368b524e2192c3927b423798deda72c003e73a1e94c21e74b20a85/sqlalchemy-2.0.46-cp312-cp312-musllinux_1_2_x86_64.whl", hash = "sha256:b1e14b2f6965a685c7128bd315e27387205429c2e339eeec55cb75ca4ab0ea2e", size = 3312425 }, + { url = "https://files.pythonhosted.org/packages/43/82/0ecd68e172bfe62247e96cb47867c2d68752566811a4e8c9d8f6e7c38a65/sqlalchemy-2.0.46-cp312-cp312-win32.whl", hash = "sha256:412f26bb4ba942d52016edc8d12fb15d91d3cd46b0047ba46e424213ad407bcb", size = 2113155 }, + { url = "https://files.pythonhosted.org/packages/bc/2a/2821a45742073fc0331dc132552b30de68ba9563230853437cac54b2b53e/sqlalchemy-2.0.46-cp312-cp312-win_amd64.whl", hash = "sha256:ea3cd46b6713a10216323cda3333514944e510aa691c945334713fca6b5279ff", size = 2140078 }, + { url = "https://files.pythonhosted.org/packages/b3/4b/fa7838fe20bb752810feed60e45625a9a8b0102c0c09971e2d1d95362992/sqlalchemy-2.0.46-cp313-cp313-macosx_11_0_arm64.whl", hash = "sha256:93a12da97cca70cea10d4b4fc602589c4511f96c1f8f6c11817620c021d21d00", size = 2150268 }, + { url = "https://files.pythonhosted.org/packages/46/c1/b34dccd712e8ea846edf396e00973dda82d598cb93762e55e43e6835eba9/sqlalchemy-2.0.46-cp313-cp313-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:af865c18752d416798dae13f83f38927c52f085c52e2f32b8ab0fef46fdd02c2", size = 3276511 }, + { url = "https://files.pythonhosted.org/packages/96/48/a04d9c94753e5d5d096c628c82a98c4793b9c08ca0e7155c3eb7d7db9f24/sqlalchemy-2.0.46-cp313-cp313-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:8d679b5f318423eacb61f933a9a0f75535bfca7056daeadbf6bd5bcee6183aee", size = 3292881 }, + { url = "https://files.pythonhosted.org/packages/be/f4/06eda6e91476f90a7d8058f74311cb65a2fb68d988171aced81707189131/sqlalchemy-2.0.46-cp313-cp313-musllinux_1_2_aarch64.whl", hash = "sha256:64901e08c33462acc9ec3bad27fc7a5c2b6491665f2aa57564e57a4f5d7c52ad", size = 3224559 }, + { url = "https://files.pythonhosted.org/packages/ab/a2/d2af04095412ca6345ac22b33b89fe8d6f32a481e613ffcb2377d931d8d0/sqlalchemy-2.0.46-cp313-cp313-musllinux_1_2_x86_64.whl", hash = "sha256:e8ac45e8f4eaac0f9f8043ea0e224158855c6a4329fd4ee37c45c61e3beb518e", size = 3262728 }, + { url = "https://files.pythonhosted.org/packages/31/48/1980c7caa5978a3b8225b4d230e69a2a6538a3562b8b31cea679b6933c83/sqlalchemy-2.0.46-cp313-cp313-win32.whl", hash = "sha256:8d3b44b3d0ab2f1319d71d9863d76eeb46766f8cf9e921ac293511804d39813f", size = 2111295 }, + { url = "https://files.pythonhosted.org/packages/2d/54/f8d65bbde3d877617c4720f3c9f60e99bb7266df0d5d78b6e25e7c149f35/sqlalchemy-2.0.46-cp313-cp313-win_amd64.whl", hash = "sha256:77f8071d8fbcbb2dd11b7fd40dedd04e8ebe2eb80497916efedba844298065ef", size = 2137076 }, + { url = "https://files.pythonhosted.org/packages/56/ba/9be4f97c7eb2b9d5544f2624adfc2853e796ed51d2bb8aec90bc94b7137e/sqlalchemy-2.0.46-cp313-cp313t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:a1e8cc6cc01da346dc92d9509a63033b9b1bda4fed7a7a7807ed385c7dccdc10", size = 3556533 }, + { url = "https://files.pythonhosted.org/packages/20/a6/b1fc6634564dbb4415b7ed6419cdfeaadefd2c39cdab1e3aa07a5f2474c2/sqlalchemy-2.0.46-cp313-cp313t-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:96c7cca1a4babaaf3bfff3e4e606e38578856917e52f0384635a95b226c87764", size = 3523208 }, + { url = "https://files.pythonhosted.org/packages/a1/d8/41e0bdfc0f930ff236f86fccd12962d8fa03713f17ed57332d38af6a3782/sqlalchemy-2.0.46-cp313-cp313t-musllinux_1_2_aarch64.whl", hash = "sha256:b2a9f9aee38039cf4755891a1e50e1effcc42ea6ba053743f452c372c3152b1b", size = 3464292 }, + { url = "https://files.pythonhosted.org/packages/f0/8b/9dcbec62d95bea85f5ecad9b8d65b78cc30fb0ffceeb3597961f3712549b/sqlalchemy-2.0.46-cp313-cp313t-musllinux_1_2_x86_64.whl", hash = "sha256:db23b1bf8cfe1f7fda19018e7207b20cdb5168f83c437ff7e95d19e39289c447", size = 3473497 }, + { url = "https://files.pythonhosted.org/packages/e9/f8/5ecdfc73383ec496de038ed1614de9e740a82db9ad67e6e4514ebc0708a3/sqlalchemy-2.0.46-cp314-cp314-macosx_11_0_arm64.whl", hash = "sha256:56bdd261bfd0895452006d5316cbf35739c53b9bb71a170a331fa0ea560b2ada", size = 2152079 }, + { url = "https://files.pythonhosted.org/packages/e5/bf/eba3036be7663ce4d9c050bc3d63794dc29fbe01691f2bf5ccb64e048d20/sqlalchemy-2.0.46-cp314-cp314-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:33e462154edb9493f6c3ad2125931e273bbd0be8ae53f3ecd1c161ea9a1dd366", size = 3272216 }, + { url = "https://files.pythonhosted.org/packages/05/45/1256fb597bb83b58a01ddb600c59fe6fdf0e5afe333f0456ed75c0f8d7bd/sqlalchemy-2.0.46-cp314-cp314-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:9bcdce05f056622a632f1d44bb47dbdb677f58cad393612280406ce37530eb6d", size = 3277208 }, + { url = "https://files.pythonhosted.org/packages/d9/a0/2053b39e4e63b5d7ceb3372cface0859a067c1ddbd575ea7e9985716f771/sqlalchemy-2.0.46-cp314-cp314-musllinux_1_2_aarch64.whl", hash = "sha256:8e84b09a9b0f19accedcbeff5c2caf36e0dd537341a33aad8d680336152dc34e", size = 3221994 }, + { url = "https://files.pythonhosted.org/packages/1e/87/97713497d9502553c68f105a1cb62786ba1ee91dea3852ae4067ed956a50/sqlalchemy-2.0.46-cp314-cp314-musllinux_1_2_x86_64.whl", hash = "sha256:4f52f7291a92381e9b4de9050b0a65ce5d6a763333406861e33906b8aa4906bf", size = 3243990 }, + { url = "https://files.pythonhosted.org/packages/a8/87/5d1b23548f420ff823c236f8bea36b1a997250fd2f892e44a3838ca424f4/sqlalchemy-2.0.46-cp314-cp314-win32.whl", hash = "sha256:70ed2830b169a9960193f4d4322d22be5c0925357d82cbf485b3369893350908", size = 2114215 }, + { url = "https://files.pythonhosted.org/packages/3a/20/555f39cbcf0c10cf452988b6a93c2a12495035f68b3dbd1a408531049d31/sqlalchemy-2.0.46-cp314-cp314-win_amd64.whl", hash = "sha256:3c32e993bc57be6d177f7d5d31edb93f30726d798ad86ff9066d75d9bf2e0b6b", size = 2139867 }, + { url = "https://files.pythonhosted.org/packages/3e/f0/f96c8057c982d9d8a7a68f45d69c674bc6f78cad401099692fe16521640a/sqlalchemy-2.0.46-cp314-cp314t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:4dafb537740eef640c4d6a7c254611dca2df87eaf6d14d6a5fca9d1f4c3fc0fa", size = 3561202 }, + { url = "https://files.pythonhosted.org/packages/d7/53/3b37dda0a5b137f21ef608d8dfc77b08477bab0fe2ac9d3e0a66eaeab6fc/sqlalchemy-2.0.46-cp314-cp314t-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:42a1643dc5427b69aca967dae540a90b0fbf57eaf248f13a90ea5930e0966863", size = 3526296 }, + { url = "https://files.pythonhosted.org/packages/33/75/f28622ba6dde79cd545055ea7bd4062dc934e0621f7b3be2891f8563f8de/sqlalchemy-2.0.46-cp314-cp314t-musllinux_1_2_aarch64.whl", hash = "sha256:ff33c6e6ad006bbc0f34f5faf941cfc62c45841c64c0a058ac38c799f15b5ede", size = 3470008 }, + { url = "https://files.pythonhosted.org/packages/a9/42/4afecbbc38d5e99b18acef446453c76eec6fbd03db0a457a12a056836e22/sqlalchemy-2.0.46-cp314-cp314t-musllinux_1_2_x86_64.whl", hash = "sha256:82ec52100ec1e6ec671563bbd02d7c7c8d0b9e71a0723c72f22ecf52d1755330", size = 3476137 }, + { url = "https://files.pythonhosted.org/packages/fc/a1/9c4efa03300926601c19c18582531b45aededfb961ab3c3585f1e24f120b/sqlalchemy-2.0.46-py3-none-any.whl", hash = "sha256:f9c11766e7e7c0a2767dda5acb006a118640c9fc0a4104214b96269bfb78399e", size = 1937882 }, +] + +[[package]] +name = "sqlmodel" +version = "0.0.32" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "pydantic" }, + { name = "sqlalchemy" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/d1/89/67f8964f3b2ed073fa4e95201e708291935d00e3600f36f09c1be3e279fe/sqlmodel-0.0.32.tar.gz", hash = "sha256:48e8fe4c8c3d7d8bf8468db17fa92ca680421e86cfec8b352217ef40736767be", size = 94140 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/ed/de/d9b40ed2c570fd612c2abd57e4d9084a9d8eb1797447e2ce897b77b1c4b2/sqlmodel-0.0.32-py3-none-any.whl", hash = "sha256:d62f0702599592046c1a136d3512feab3d5a80e2988642ef0ed2c89b9b8b297b", size = 27416 }, +] + +[[package]] +name = "starlette" +version = "0.50.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "anyio" }, + { name = "typing-extensions", marker = "python_full_version < '3.13'" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/ba/b8/73a0e6a6e079a9d9cfa64113d771e421640b6f679a52eeb9b32f72d871a1/starlette-0.50.0.tar.gz", hash = "sha256:a2a17b22203254bcbc2e1f926d2d55f3f9497f769416b3190768befe598fa3ca", size = 2646985 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/d9/52/1064f510b141bd54025f9b55105e26d1fa970b9be67ad766380a3c9b74b0/starlette-0.50.0-py3-none-any.whl", hash = "sha256:9e5391843ec9b6e472eed1365a78c8098cfceb7a74bfd4d6b1c0c0095efb3bca", size = 74033 }, +] + +[[package]] +name = "tabulate" +version = "0.9.0" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/ec/fe/802052aecb21e3797b8f7902564ab6ea0d60ff8ca23952079064155d1ae1/tabulate-0.9.0.tar.gz", hash = "sha256:0095b12bf5966de529c0feb1fa08671671b3368eec77d7ef7ab114be2c068b3c", size = 81090 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/40/44/4a5f08c96eb108af5cb50b41f76142f0afa346dfa99d5296fe7202a11854/tabulate-0.9.0-py3-none-any.whl", hash = "sha256:024ca478df22e9340661486f85298cff5f6dcdba14f3813e8830015b9ed1948f", size = 35252 }, +] + [[package]] name = "tenacity" version = "8.2.2" @@ -682,15 +1634,57 @@ wheels = [ ] [[package]] -name = "tkcalendar" -version = "1.6.1" +name = "tomli" +version = "2.4.0" source = { registry = "https://pypi.org/simple" } -dependencies = [ - { name = "babel" }, -] -sdist = { url = "https://files.pythonhosted.org/packages/65/3d/3406cf7963661ed890082bff17ed4c5e26b5a564306639303d4fbb2a047f/tkcalendar-1.6.1.tar.gz", hash = "sha256:5edf958c0a59429e90309e9b805b2e229192bbcab952460247204d7030eea5cf", size = 32916 } +sdist = { url = "https://files.pythonhosted.org/packages/82/30/31573e9457673ab10aa432461bee537ce6cef177667deca369efb79df071/tomli-2.4.0.tar.gz", hash = "sha256:aa89c3f6c277dd275d8e243ad24f3b5e701491a860d5121f2cdd399fbb31fc9c", size = 17477 } wheels = [ - { url = "https://files.pythonhosted.org/packages/e9/d4/9528ea6ecb5d4394f425df651957da6f6a715b41c5b12d43d41888c14394/tkcalendar-1.6.1-py3-none-any.whl", hash = "sha256:9d3a80816a7b32d64fab696fa3d2a007fb23c87953267d5e343a38ff4cd7c15c", size = 40912 }, + { url = "https://files.pythonhosted.org/packages/3c/d9/3dc2289e1f3b32eb19b9785b6a006b28ee99acb37d1d47f78d4c10e28bf8/tomli-2.4.0-cp311-cp311-macosx_10_9_x86_64.whl", hash = "sha256:b5ef256a3fd497d4973c11bf142e9ed78b150d36f5773f1ca6088c230ffc5867", size = 153663 }, + { url = "https://files.pythonhosted.org/packages/51/32/ef9f6845e6b9ca392cd3f64f9ec185cc6f09f0a2df3db08cbe8809d1d435/tomli-2.4.0-cp311-cp311-macosx_11_0_arm64.whl", hash = "sha256:5572e41282d5268eb09a697c89a7bee84fae66511f87533a6f88bd2f7b652da9", size = 148469 }, + { url = "https://files.pythonhosted.org/packages/d6/c2/506e44cce89a8b1b1e047d64bd495c22c9f71f21e05f380f1a950dd9c217/tomli-2.4.0-cp311-cp311-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:551e321c6ba03b55676970b47cb1b73f14a0a4dce6a3e1a9458fd6d921d72e95", size = 236039 }, + { url = "https://files.pythonhosted.org/packages/b3/40/e1b65986dbc861b7e986e8ec394598187fa8aee85b1650b01dd925ca0be8/tomli-2.4.0-cp311-cp311-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:5e3f639a7a8f10069d0e15408c0b96a2a828cfdec6fca05296ebcdcc28ca7c76", size = 243007 }, + { url = "https://files.pythonhosted.org/packages/9c/6f/6e39ce66b58a5b7ae572a0f4352ff40c71e8573633deda43f6a379d56b3e/tomli-2.4.0-cp311-cp311-musllinux_1_2_aarch64.whl", hash = "sha256:1b168f2731796b045128c45982d3a4874057626da0e2ef1fdd722848b741361d", size = 240875 }, + { url = "https://files.pythonhosted.org/packages/aa/ad/cb089cb190487caa80204d503c7fd0f4d443f90b95cf4ef5cf5aa0f439b0/tomli-2.4.0-cp311-cp311-musllinux_1_2_x86_64.whl", hash = "sha256:133e93646ec4300d651839d382d63edff11d8978be23da4cc106f5a18b7d0576", size = 246271 }, + { url = "https://files.pythonhosted.org/packages/0b/63/69125220e47fd7a3a27fd0de0c6398c89432fec41bc739823bcc66506af6/tomli-2.4.0-cp311-cp311-win32.whl", hash = "sha256:b6c78bdf37764092d369722d9946cb65b8767bfa4110f902a1b2542d8d173c8a", size = 96770 }, + { url = "https://files.pythonhosted.org/packages/1e/0d/a22bb6c83f83386b0008425a6cd1fa1c14b5f3dd4bad05e98cf3dbbf4a64/tomli-2.4.0-cp311-cp311-win_amd64.whl", hash = "sha256:d3d1654e11d724760cdb37a3d7691f0be9db5fbdaef59c9f532aabf87006dbaa", size = 107626 }, + { url = "https://files.pythonhosted.org/packages/2f/6d/77be674a3485e75cacbf2ddba2b146911477bd887dda9d8c9dfb2f15e871/tomli-2.4.0-cp311-cp311-win_arm64.whl", hash = "sha256:cae9c19ed12d4e8f3ebf46d1a75090e4c0dc16271c5bce1c833ac168f08fb614", size = 94842 }, + { url = "https://files.pythonhosted.org/packages/3c/43/7389a1869f2f26dba52404e1ef13b4784b6b37dac93bac53457e3ff24ca3/tomli-2.4.0-cp312-cp312-macosx_10_13_x86_64.whl", hash = "sha256:920b1de295e72887bafa3ad9f7a792f811847d57ea6b1215154030cf131f16b1", size = 154894 }, + { url = "https://files.pythonhosted.org/packages/e9/05/2f9bf110b5294132b2edf13fe6ca6ae456204f3d749f623307cbb7a946f2/tomli-2.4.0-cp312-cp312-macosx_11_0_arm64.whl", hash = "sha256:7d6d9a4aee98fac3eab4952ad1d73aee87359452d1c086b5ceb43ed02ddb16b8", size = 149053 }, + { url = "https://files.pythonhosted.org/packages/e8/41/1eda3ca1abc6f6154a8db4d714a4d35c4ad90adc0bcf700657291593fbf3/tomli-2.4.0-cp312-cp312-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:36b9d05b51e65b254ea6c2585b59d2c4cb91c8a3d91d0ed0f17591a29aaea54a", size = 243481 }, + { url = "https://files.pythonhosted.org/packages/d2/6d/02ff5ab6c8868b41e7d4b987ce2b5f6a51d3335a70aa144edd999e055a01/tomli-2.4.0-cp312-cp312-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:1c8a885b370751837c029ef9bc014f27d80840e48bac415f3412e6593bbc18c1", size = 251720 }, + { url = "https://files.pythonhosted.org/packages/7b/57/0405c59a909c45d5b6f146107c6d997825aa87568b042042f7a9c0afed34/tomli-2.4.0-cp312-cp312-musllinux_1_2_aarch64.whl", hash = "sha256:8768715ffc41f0008abe25d808c20c3d990f42b6e2e58305d5da280ae7d1fa3b", size = 247014 }, + { url = "https://files.pythonhosted.org/packages/2c/0e/2e37568edd944b4165735687cbaf2fe3648129e440c26d02223672ee0630/tomli-2.4.0-cp312-cp312-musllinux_1_2_x86_64.whl", hash = "sha256:7b438885858efd5be02a9a133caf5812b8776ee0c969fea02c45e8e3f296ba51", size = 251820 }, + { url = "https://files.pythonhosted.org/packages/5a/1c/ee3b707fdac82aeeb92d1a113f803cf6d0f37bdca0849cb489553e1f417a/tomli-2.4.0-cp312-cp312-win32.whl", hash = "sha256:0408e3de5ec77cc7f81960c362543cbbd91ef883e3138e81b729fc3eea5b9729", size = 97712 }, + { url = "https://files.pythonhosted.org/packages/69/13/c07a9177d0b3bab7913299b9278845fc6eaaca14a02667c6be0b0a2270c8/tomli-2.4.0-cp312-cp312-win_amd64.whl", hash = "sha256:685306e2cc7da35be4ee914fd34ab801a6acacb061b6a7abca922aaf9ad368da", size = 108296 }, + { url = "https://files.pythonhosted.org/packages/18/27/e267a60bbeeee343bcc279bb9e8fbed0cbe224bc7b2a3dc2975f22809a09/tomli-2.4.0-cp312-cp312-win_arm64.whl", hash = "sha256:5aa48d7c2356055feef06a43611fc401a07337d5b006be13a30f6c58f869e3c3", size = 94553 }, + { url = "https://files.pythonhosted.org/packages/34/91/7f65f9809f2936e1f4ce6268ae1903074563603b2a2bd969ebbda802744f/tomli-2.4.0-cp313-cp313-macosx_10_13_x86_64.whl", hash = "sha256:84d081fbc252d1b6a982e1870660e7330fb8f90f676f6e78b052ad4e64714bf0", size = 154915 }, + { url = "https://files.pythonhosted.org/packages/20/aa/64dd73a5a849c2e8f216b755599c511badde80e91e9bc2271baa7b2cdbb1/tomli-2.4.0-cp313-cp313-macosx_11_0_arm64.whl", hash = "sha256:9a08144fa4cba33db5255f9b74f0b89888622109bd2776148f2597447f92a94e", size = 149038 }, + { url = "https://files.pythonhosted.org/packages/9e/8a/6d38870bd3d52c8d1505ce054469a73f73a0fe62c0eaf5dddf61447e32fa/tomli-2.4.0-cp313-cp313-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:c73add4bb52a206fd0c0723432db123c0c75c280cbd67174dd9d2db228ebb1b4", size = 242245 }, + { url = "https://files.pythonhosted.org/packages/59/bb/8002fadefb64ab2669e5b977df3f5e444febea60e717e755b38bb7c41029/tomli-2.4.0-cp313-cp313-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:1fb2945cbe303b1419e2706e711b7113da57b7db31ee378d08712d678a34e51e", size = 250335 }, + { url = "https://files.pythonhosted.org/packages/a5/3d/4cdb6f791682b2ea916af2de96121b3cb1284d7c203d97d92d6003e91c8d/tomli-2.4.0-cp313-cp313-musllinux_1_2_aarch64.whl", hash = "sha256:bbb1b10aa643d973366dc2cb1ad94f99c1726a02343d43cbc011edbfac579e7c", size = 245962 }, + { url = "https://files.pythonhosted.org/packages/f2/4a/5f25789f9a460bd858ba9756ff52d0830d825b458e13f754952dd15fb7bb/tomli-2.4.0-cp313-cp313-musllinux_1_2_x86_64.whl", hash = "sha256:4cbcb367d44a1f0c2be408758b43e1ffb5308abe0ea222897d6bfc8e8281ef2f", size = 250396 }, + { url = "https://files.pythonhosted.org/packages/aa/2f/b73a36fea58dfa08e8b3a268750e6853a6aac2a349241a905ebd86f3047a/tomli-2.4.0-cp313-cp313-win32.whl", hash = "sha256:7d49c66a7d5e56ac959cb6fc583aff0651094ec071ba9ad43df785abc2320d86", size = 97530 }, + { url = "https://files.pythonhosted.org/packages/3b/af/ca18c134b5d75de7e8dc551c5234eaba2e8e951f6b30139599b53de9c187/tomli-2.4.0-cp313-cp313-win_amd64.whl", hash = "sha256:3cf226acb51d8f1c394c1b310e0e0e61fecdd7adcb78d01e294ac297dd2e7f87", size = 108227 }, + { url = "https://files.pythonhosted.org/packages/22/c3/b386b832f209fee8073c8138ec50f27b4460db2fdae9ffe022df89a57f9b/tomli-2.4.0-cp313-cp313-win_arm64.whl", hash = "sha256:d20b797a5c1ad80c516e41bc1fb0443ddb5006e9aaa7bda2d71978346aeb9132", size = 94748 }, + { url = "https://files.pythonhosted.org/packages/f3/c4/84047a97eb1004418bc10bdbcfebda209fca6338002eba2dc27cc6d13563/tomli-2.4.0-cp314-cp314-macosx_10_15_x86_64.whl", hash = "sha256:26ab906a1eb794cd4e103691daa23d95c6919cc2fa9160000ac02370cc9dd3f6", size = 154725 }, + { url = "https://files.pythonhosted.org/packages/a8/5d/d39038e646060b9d76274078cddf146ced86dc2b9e8bbf737ad5983609a0/tomli-2.4.0-cp314-cp314-macosx_11_0_arm64.whl", hash = "sha256:20cedb4ee43278bc4f2fee6cb50daec836959aadaf948db5172e776dd3d993fc", size = 148901 }, + { url = "https://files.pythonhosted.org/packages/73/e5/383be1724cb30f4ce44983d249645684a48c435e1cd4f8b5cded8a816d3c/tomli-2.4.0-cp314-cp314-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:39b0b5d1b6dd03684b3fb276407ebed7090bbec989fa55838c98560c01113b66", size = 243375 }, + { url = "https://files.pythonhosted.org/packages/31/f0/bea80c17971c8d16d3cc109dc3585b0f2ce1036b5f4a8a183789023574f2/tomli-2.4.0-cp314-cp314-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:a26d7ff68dfdb9f87a016ecfd1e1c2bacbe3108f4e0f8bcd2228ef9a766c787d", size = 250639 }, + { url = "https://files.pythonhosted.org/packages/2c/8f/2853c36abbb7608e3f945d8a74e32ed3a74ee3a1f468f1ffc7d1cb3abba6/tomli-2.4.0-cp314-cp314-musllinux_1_2_aarch64.whl", hash = "sha256:20ffd184fb1df76a66e34bd1b36b4a4641bd2b82954befa32fe8163e79f1a702", size = 246897 }, + { url = "https://files.pythonhosted.org/packages/49/f0/6c05e3196ed5337b9fe7ea003e95fd3819a840b7a0f2bf5a408ef1dad8ed/tomli-2.4.0-cp314-cp314-musllinux_1_2_x86_64.whl", hash = "sha256:75c2f8bbddf170e8effc98f5e9084a8751f8174ea6ccf4fca5398436e0320bc8", size = 254697 }, + { url = "https://files.pythonhosted.org/packages/f3/f5/2922ef29c9f2951883525def7429967fc4d8208494e5ab524234f06b688b/tomli-2.4.0-cp314-cp314-win32.whl", hash = "sha256:31d556d079d72db7c584c0627ff3a24c5d3fb4f730221d3444f3efb1b2514776", size = 98567 }, + { url = "https://files.pythonhosted.org/packages/7b/31/22b52e2e06dd2a5fdbc3ee73226d763b184ff21fc24e20316a44ccc4d96b/tomli-2.4.0-cp314-cp314-win_amd64.whl", hash = "sha256:43e685b9b2341681907759cf3a04e14d7104b3580f808cfde1dfdb60ada85475", size = 108556 }, + { url = "https://files.pythonhosted.org/packages/48/3d/5058dff3255a3d01b705413f64f4306a141a8fd7a251e5a495e3f192a998/tomli-2.4.0-cp314-cp314-win_arm64.whl", hash = "sha256:3d895d56bd3f82ddd6faaff993c275efc2ff38e52322ea264122d72729dca2b2", size = 96014 }, + { url = "https://files.pythonhosted.org/packages/b8/4e/75dab8586e268424202d3a1997ef6014919c941b50642a1682df43204c22/tomli-2.4.0-cp314-cp314t-macosx_10_15_x86_64.whl", hash = "sha256:5b5807f3999fb66776dbce568cc9a828544244a8eb84b84b9bafc080c99597b9", size = 163339 }, + { url = "https://files.pythonhosted.org/packages/06/e3/b904d9ab1016829a776d97f163f183a48be6a4deb87304d1e0116a349519/tomli-2.4.0-cp314-cp314t-macosx_11_0_arm64.whl", hash = "sha256:c084ad935abe686bd9c898e62a02a19abfc9760b5a79bc29644463eaf2840cb0", size = 159490 }, + { url = "https://files.pythonhosted.org/packages/e3/5a/fc3622c8b1ad823e8ea98a35e3c632ee316d48f66f80f9708ceb4f2a0322/tomli-2.4.0-cp314-cp314t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:0f2e3955efea4d1cfbcb87bc321e00dc08d2bcb737fd1d5e398af111d86db5df", size = 269398 }, + { url = "https://files.pythonhosted.org/packages/fd/33/62bd6152c8bdd4c305ad9faca48f51d3acb2df1f8791b1477d46ff86e7f8/tomli-2.4.0-cp314-cp314t-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl", hash = "sha256:0e0fe8a0b8312acf3a88077a0802565cb09ee34107813bba1c7cd591fa6cfc8d", size = 276515 }, + { url = "https://files.pythonhosted.org/packages/4b/ff/ae53619499f5235ee4211e62a8d7982ba9e439a0fb4f2f351a93d67c1dd2/tomli-2.4.0-cp314-cp314t-musllinux_1_2_aarch64.whl", hash = "sha256:413540dce94673591859c4c6f794dfeaa845e98bf35d72ed59636f869ef9f86f", size = 273806 }, + { url = "https://files.pythonhosted.org/packages/47/71/cbca7787fa68d4d0a9f7072821980b39fbb1b6faeb5f5cf02f4a5559fa28/tomli-2.4.0-cp314-cp314t-musllinux_1_2_x86_64.whl", hash = "sha256:0dc56fef0e2c1c470aeac5b6ca8cc7b640bb93e92d9803ddaf9ea03e198f5b0b", size = 281340 }, + { url = "https://files.pythonhosted.org/packages/f5/00/d595c120963ad42474cf6ee7771ad0d0e8a49d0f01e29576ee9195d9ecdf/tomli-2.4.0-cp314-cp314t-win32.whl", hash = "sha256:d878f2a6707cc9d53a1be1414bbb419e629c3d6e67f69230217bb663e76b5087", size = 108106 }, + { url = "https://files.pythonhosted.org/packages/de/69/9aa0c6a505c2f80e519b43764f8b4ba93b5a0bbd2d9a9de6e2b24271b9a5/tomli-2.4.0-cp314-cp314t-win_amd64.whl", hash = "sha256:2add28aacc7425117ff6364fe9e06a183bb0251b03f986df0e78e974047571fd", size = 120504 }, + { url = "https://files.pythonhosted.org/packages/b3/9f/f1668c281c58cfae01482f7114a4b88d345e4c140386241a1a24dcc9e7bc/tomli-2.4.0-cp314-cp314t-win_arm64.whl", hash = "sha256:2b1e3b80e1d5e52e40e9b924ec43d81570f0e7d09d11081b797bc4692765a3d4", size = 99561 }, + { url = "https://files.pythonhosted.org/packages/23/d1/136eb2cb77520a31e1f64cbae9d33ec6df0d78bdf4160398e86eec8a8754/tomli-2.4.0-py3-none-any.whl", hash = "sha256:1f776e7d669ebceb01dee46484485f43a4048746235e683bcdffacdf1fb4785a", size = 14477 }, ] [[package]] @@ -702,6 +1696,42 @@ wheels = [ { url = "https://files.pythonhosted.org/packages/77/75/c28e9ef7abec2b7e9ff35aea3e0be6c1aceaf7873c26c95ae1f0d594de71/traitlets-5.9.0-py3-none-any.whl", hash = "sha256:9e6ec080259b9a5940c797d58b613b5e31441c2257b87c2e795c5228ae80d2d8", size = 117376 }, ] +[[package]] +name = "typer" +version = "0.21.1" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "click" }, + { name = "rich" }, + { name = "shellingham" }, + { name = "typing-extensions" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/36/bf/8825b5929afd84d0dabd606c67cd57b8388cb3ec385f7ef19c5cc2202069/typer-0.21.1.tar.gz", hash = "sha256:ea835607cd752343b6b2b7ce676893e5a0324082268b48f27aa058bdb7d2145d", size = 110371 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/a0/1d/d9257dd49ff2ca23ea5f132edf1281a0c4f9de8a762b9ae399b670a59235/typer-0.21.1-py3-none-any.whl", hash = "sha256:7985e89081c636b88d172c2ee0cfe33c253160994d47bdfdc302defd7d1f1d01", size = 47381 }, +] + +[[package]] +name = "typing-extensions" +version = "4.15.0" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/72/94/1a15dd82efb362ac84269196e94cf00f187f7ed21c242792a923cdb1c61f/typing_extensions-4.15.0.tar.gz", hash = "sha256:0cea48d173cc12fa28ecabc3b837ea3cf6f38c6d1136f85cbaaf598984861466", size = 109391 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/18/67/36e9267722cc04a6b9f15c7f3441c2363321a3ea07da7ae0c0707beb2a9c/typing_extensions-4.15.0-py3-none-any.whl", hash = "sha256:f0fa19c6845758ab08074a0cfa8b7aecb71c999ca73d62883bc25cc018c4e548", size = 44614 }, +] + +[[package]] +name = "typing-inspection" +version = "0.4.2" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "typing-extensions" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/55/e3/70399cb7dd41c10ac53367ae42139cf4b1ca5f36bb3dc6c9d33acdb43655/typing_inspection-0.4.2.tar.gz", hash = "sha256:ba561c48a67c5958007083d386c3295464928b01faa735ab8547c5692e87f464", size = 75949 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/dc/9b/47798a6c91d8bdb567fe2698fe81e0c6b7cb7ef4d13da4114b41d239f65d/typing_inspection-0.4.2-py3-none-any.whl", hash = "sha256:4ed1cacbdc298c220f1bd249ed5287caa16f34d44ef4e9c3d0cbad5b521545e7", size = 14611 }, +] + [[package]] name = "tzdata" version = "2023.3" @@ -710,3 +1740,201 @@ sdist = { url = "https://files.pythonhosted.org/packages/70/e5/81f99b9fced596245 wheels = [ { url = "https://files.pythonhosted.org/packages/d5/fb/a79efcab32b8a1f1ddca7f35109a50e4a80d42ac1c9187ab46522b2407d7/tzdata-2023.3-py2.py3-none-any.whl", hash = "sha256:7e65763eef3120314099b6939b5546db7adce1e7d6f2e179e3df563c70511eda", size = 341835 }, ] + +[[package]] +name = "uvicorn" +version = "0.40.0" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "click" }, + { name = "h11" }, + { name = "typing-extensions", marker = "python_full_version < '3.11'" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/c3/d1/8f3c683c9561a4e6689dd3b1d345c815f10f86acd044ee1fb9a4dcd0b8c5/uvicorn-0.40.0.tar.gz", hash = "sha256:839676675e87e73694518b5574fd0f24c9d97b46bea16df7b8c05ea1a51071ea", size = 81761 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/3d/d8/2083a1daa7439a66f3a48589a57d576aa117726762618f6bb09fe3798796/uvicorn-0.40.0-py3-none-any.whl", hash = "sha256:c6c8f55bc8bf13eb6fa9ff87ad62308bbbc33d0b67f84293151efe87e0d5f2ee", size = 68502 }, +] + +[[package]] +name = "watchfiles" +version = "1.1.1" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "anyio" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/c2/c9/8869df9b2a2d6c59d79220a4db37679e74f807c559ffe5265e08b227a210/watchfiles-1.1.1.tar.gz", hash = "sha256:a173cb5c16c4f40ab19cecf48a534c409f7ea983ab8fed0741304a1c0a31b3f2", size = 94440 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/a7/1a/206e8cf2dd86fddf939165a57b4df61607a1e0add2785f170a3f616b7d9f/watchfiles-1.1.1-cp310-cp310-macosx_10_12_x86_64.whl", hash = "sha256:eef58232d32daf2ac67f42dea51a2c80f0d03379075d44a587051e63cc2e368c", size = 407318 }, + { url = "https://files.pythonhosted.org/packages/b3/0f/abaf5262b9c496b5dad4ed3c0e799cbecb1f8ea512ecb6ddd46646a9fca3/watchfiles-1.1.1-cp310-cp310-macosx_11_0_arm64.whl", hash = "sha256:03fa0f5237118a0c5e496185cafa92878568b652a2e9a9382a5151b1a0380a43", size = 394478 }, + { url = "https://files.pythonhosted.org/packages/b1/04/9cc0ba88697b34b755371f5ace8d3a4d9a15719c07bdc7bd13d7d8c6a341/watchfiles-1.1.1-cp310-cp310-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:8ca65483439f9c791897f7db49202301deb6e15fe9f8fe2fed555bf986d10c31", size = 449894 }, + { url = "https://files.pythonhosted.org/packages/d2/9c/eda4615863cd8621e89aed4df680d8c3ec3da6a4cf1da113c17decd87c7f/watchfiles-1.1.1-cp310-cp310-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:f0ab1c1af0cb38e3f598244c17919fb1a84d1629cc08355b0074b6d7f53138ac", size = 459065 }, + { url = "https://files.pythonhosted.org/packages/84/13/f28b3f340157d03cbc8197629bc109d1098764abe1e60874622a0be5c112/watchfiles-1.1.1-cp310-cp310-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:3bc570d6c01c206c46deb6e935a260be44f186a2f05179f52f7fcd2be086a94d", size = 488377 }, + { url = "https://files.pythonhosted.org/packages/86/93/cfa597fa9389e122488f7ffdbd6db505b3b915ca7435ecd7542e855898c2/watchfiles-1.1.1-cp310-cp310-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:e84087b432b6ac94778de547e08611266f1f8ffad28c0ee4c82e028b0fc5966d", size = 595837 }, + { url = "https://files.pythonhosted.org/packages/57/1e/68c1ed5652b48d89fc24d6af905d88ee4f82fa8bc491e2666004e307ded1/watchfiles-1.1.1-cp310-cp310-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:620bae625f4cb18427b1bb1a2d9426dc0dd5a5ba74c7c2cdb9de405f7b129863", size = 473456 }, + { url = "https://files.pythonhosted.org/packages/d5/dc/1a680b7458ffa3b14bb64878112aefc8f2e4f73c5af763cbf0bd43100658/watchfiles-1.1.1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:544364b2b51a9b0c7000a4b4b02f90e9423d97fbbf7e06689236443ebcad81ab", size = 455614 }, + { url = "https://files.pythonhosted.org/packages/61/a5/3d782a666512e01eaa6541a72ebac1d3aae191ff4a31274a66b8dd85760c/watchfiles-1.1.1-cp310-cp310-musllinux_1_1_aarch64.whl", hash = "sha256:bbe1ef33d45bc71cf21364df962af171f96ecaeca06bd9e3d0b583efb12aec82", size = 630690 }, + { url = "https://files.pythonhosted.org/packages/9b/73/bb5f38590e34687b2a9c47a244aa4dd50c56a825969c92c9c5fc7387cea1/watchfiles-1.1.1-cp310-cp310-musllinux_1_1_x86_64.whl", hash = "sha256:1a0bb430adb19ef49389e1ad368450193a90038b5b752f4ac089ec6942c4dff4", size = 622459 }, + { url = "https://files.pythonhosted.org/packages/f1/ac/c9bb0ec696e07a20bd58af5399aeadaef195fb2c73d26baf55180fe4a942/watchfiles-1.1.1-cp310-cp310-win32.whl", hash = "sha256:3f6d37644155fb5beca5378feb8c1708d5783145f2a0f1c4d5a061a210254844", size = 272663 }, + { url = "https://files.pythonhosted.org/packages/11/a0/a60c5a7c2ec59fa062d9a9c61d02e3b6abd94d32aac2d8344c4bdd033326/watchfiles-1.1.1-cp310-cp310-win_amd64.whl", hash = "sha256:a36d8efe0f290835fd0f33da35042a1bb5dc0e83cbc092dcf69bce442579e88e", size = 287453 }, + { url = "https://files.pythonhosted.org/packages/1f/f8/2c5f479fb531ce2f0564eda479faecf253d886b1ab3630a39b7bf7362d46/watchfiles-1.1.1-cp311-cp311-macosx_10_12_x86_64.whl", hash = "sha256:f57b396167a2565a4e8b5e56a5a1c537571733992b226f4f1197d79e94cf0ae5", size = 406529 }, + { url = "https://files.pythonhosted.org/packages/fe/cd/f515660b1f32f65df671ddf6f85bfaca621aee177712874dc30a97397977/watchfiles-1.1.1-cp311-cp311-macosx_11_0_arm64.whl", hash = "sha256:421e29339983e1bebc281fab40d812742268ad057db4aee8c4d2bce0af43b741", size = 394384 }, + { url = "https://files.pythonhosted.org/packages/7b/c3/28b7dc99733eab43fca2d10f55c86e03bd6ab11ca31b802abac26b23d161/watchfiles-1.1.1-cp311-cp311-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:6e43d39a741e972bab5d8100b5cdacf69db64e34eb19b6e9af162bccf63c5cc6", size = 448789 }, + { url = "https://files.pythonhosted.org/packages/4a/24/33e71113b320030011c8e4316ccca04194bf0cbbaeee207f00cbc7d6b9f5/watchfiles-1.1.1-cp311-cp311-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:f537afb3276d12814082a2e9b242bdcf416c2e8fd9f799a737990a1dbe906e5b", size = 460521 }, + { url = "https://files.pythonhosted.org/packages/f4/c3/3c9a55f255aa57b91579ae9e98c88704955fa9dac3e5614fb378291155df/watchfiles-1.1.1-cp311-cp311-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:b2cd9e04277e756a2e2d2543d65d1e2166d6fd4c9b183f8808634fda23f17b14", size = 488722 }, + { url = "https://files.pythonhosted.org/packages/49/36/506447b73eb46c120169dc1717fe2eff07c234bb3232a7200b5f5bd816e9/watchfiles-1.1.1-cp311-cp311-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:5f3f58818dc0b07f7d9aa7fe9eb1037aecb9700e63e1f6acfed13e9fef648f5d", size = 596088 }, + { url = "https://files.pythonhosted.org/packages/82/ab/5f39e752a9838ec4d52e9b87c1e80f1ee3ccdbe92e183c15b6577ab9de16/watchfiles-1.1.1-cp311-cp311-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:9bb9f66367023ae783551042d31b1d7fd422e8289eedd91f26754a66f44d5cff", size = 472923 }, + { url = "https://files.pythonhosted.org/packages/af/b9/a419292f05e302dea372fa7e6fda5178a92998411f8581b9830d28fb9edb/watchfiles-1.1.1-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:aebfd0861a83e6c3d1110b78ad54704486555246e542be3e2bb94195eabb2606", size = 456080 }, + { url = "https://files.pythonhosted.org/packages/b0/c3/d5932fd62bde1a30c36e10c409dc5d54506726f08cb3e1d8d0ba5e2bc8db/watchfiles-1.1.1-cp311-cp311-musllinux_1_1_aarch64.whl", hash = "sha256:5fac835b4ab3c6487b5dbad78c4b3724e26bcc468e886f8ba8cc4306f68f6701", size = 629432 }, + { url = "https://files.pythonhosted.org/packages/f7/77/16bddd9779fafb795f1a94319dc965209c5641db5bf1edbbccace6d1b3c0/watchfiles-1.1.1-cp311-cp311-musllinux_1_1_x86_64.whl", hash = "sha256:399600947b170270e80134ac854e21b3ccdefa11a9529a3decc1327088180f10", size = 623046 }, + { url = "https://files.pythonhosted.org/packages/46/ef/f2ecb9a0f342b4bfad13a2787155c6ee7ce792140eac63a34676a2feeef2/watchfiles-1.1.1-cp311-cp311-win32.whl", hash = "sha256:de6da501c883f58ad50db3a32ad397b09ad29865b5f26f64c24d3e3281685849", size = 271473 }, + { url = "https://files.pythonhosted.org/packages/94/bc/f42d71125f19731ea435c3948cad148d31a64fccde3867e5ba4edee901f9/watchfiles-1.1.1-cp311-cp311-win_amd64.whl", hash = "sha256:35c53bd62a0b885bf653ebf6b700d1bf05debb78ad9292cf2a942b23513dc4c4", size = 287598 }, + { url = "https://files.pythonhosted.org/packages/57/c9/a30f897351f95bbbfb6abcadafbaca711ce1162f4db95fc908c98a9165f3/watchfiles-1.1.1-cp311-cp311-win_arm64.whl", hash = "sha256:57ca5281a8b5e27593cb7d82c2ac927ad88a96ed406aa446f6344e4328208e9e", size = 277210 }, + { url = "https://files.pythonhosted.org/packages/74/d5/f039e7e3c639d9b1d09b07ea412a6806d38123f0508e5f9b48a87b0a76cc/watchfiles-1.1.1-cp312-cp312-macosx_10_12_x86_64.whl", hash = "sha256:8c89f9f2f740a6b7dcc753140dd5e1ab9215966f7a3530d0c0705c83b401bd7d", size = 404745 }, + { url = "https://files.pythonhosted.org/packages/a5/96/a881a13aa1349827490dab2d363c8039527060cfcc2c92cc6d13d1b1049e/watchfiles-1.1.1-cp312-cp312-macosx_11_0_arm64.whl", hash = "sha256:bd404be08018c37350f0d6e34676bd1e2889990117a2b90070b3007f172d0610", size = 391769 }, + { url = "https://files.pythonhosted.org/packages/4b/5b/d3b460364aeb8da471c1989238ea0e56bec24b6042a68046adf3d9ddb01c/watchfiles-1.1.1-cp312-cp312-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:8526e8f916bb5b9a0a777c8317c23ce65de259422bba5b31325a6fa6029d33af", size = 449374 }, + { url = "https://files.pythonhosted.org/packages/b9/44/5769cb62d4ed055cb17417c0a109a92f007114a4e07f30812a73a4efdb11/watchfiles-1.1.1-cp312-cp312-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:2edc3553362b1c38d9f06242416a5d8e9fe235c204a4072e988ce2e5bb1f69f6", size = 459485 }, + { url = "https://files.pythonhosted.org/packages/19/0c/286b6301ded2eccd4ffd0041a1b726afda999926cf720aab63adb68a1e36/watchfiles-1.1.1-cp312-cp312-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:30f7da3fb3f2844259cba4720c3fc7138eb0f7b659c38f3bfa65084c7fc7abce", size = 488813 }, + { url = "https://files.pythonhosted.org/packages/c7/2b/8530ed41112dd4a22f4dcfdb5ccf6a1baad1ff6eed8dc5a5f09e7e8c41c7/watchfiles-1.1.1-cp312-cp312-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:f8979280bdafff686ba5e4d8f97840f929a87ed9cdf133cbbd42f7766774d2aa", size = 594816 }, + { url = "https://files.pythonhosted.org/packages/ce/d2/f5f9fb49489f184f18470d4f99f4e862a4b3e9ac2865688eb2099e3d837a/watchfiles-1.1.1-cp312-cp312-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:dcc5c24523771db3a294c77d94771abcfcb82a0e0ee8efd910c37c59ec1b31bb", size = 475186 }, + { url = "https://files.pythonhosted.org/packages/cf/68/5707da262a119fb06fbe214d82dd1fe4a6f4af32d2d14de368d0349eb52a/watchfiles-1.1.1-cp312-cp312-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:1db5d7ae38ff20153d542460752ff397fcf5c96090c1230803713cf3147a6803", size = 456812 }, + { url = "https://files.pythonhosted.org/packages/66/ab/3cbb8756323e8f9b6f9acb9ef4ec26d42b2109bce830cc1f3468df20511d/watchfiles-1.1.1-cp312-cp312-musllinux_1_1_aarch64.whl", hash = "sha256:28475ddbde92df1874b6c5c8aaeb24ad5be47a11f87cde5a28ef3835932e3e94", size = 630196 }, + { url = "https://files.pythonhosted.org/packages/78/46/7152ec29b8335f80167928944a94955015a345440f524d2dfe63fc2f437b/watchfiles-1.1.1-cp312-cp312-musllinux_1_1_x86_64.whl", hash = "sha256:36193ed342f5b9842edd3532729a2ad55c4160ffcfa3700e0d54be496b70dd43", size = 622657 }, + { url = "https://files.pythonhosted.org/packages/0a/bf/95895e78dd75efe9a7f31733607f384b42eb5feb54bd2eb6ed57cc2e94f4/watchfiles-1.1.1-cp312-cp312-win32.whl", hash = "sha256:859e43a1951717cc8de7f4c77674a6d389b106361585951d9e69572823f311d9", size = 272042 }, + { url = "https://files.pythonhosted.org/packages/87/0a/90eb755f568de2688cb220171c4191df932232c20946966c27a59c400850/watchfiles-1.1.1-cp312-cp312-win_amd64.whl", hash = "sha256:91d4c9a823a8c987cce8fa2690923b069966dabb196dd8d137ea2cede885fde9", size = 288410 }, + { url = "https://files.pythonhosted.org/packages/36/76/f322701530586922fbd6723c4f91ace21364924822a8772c549483abed13/watchfiles-1.1.1-cp312-cp312-win_arm64.whl", hash = "sha256:a625815d4a2bdca61953dbba5a39d60164451ef34c88d751f6c368c3ea73d404", size = 278209 }, + { url = "https://files.pythonhosted.org/packages/bb/f4/f750b29225fe77139f7ae5de89d4949f5a99f934c65a1f1c0b248f26f747/watchfiles-1.1.1-cp313-cp313-macosx_10_12_x86_64.whl", hash = "sha256:130e4876309e8686a5e37dba7d5e9bc77e6ed908266996ca26572437a5271e18", size = 404321 }, + { url = "https://files.pythonhosted.org/packages/2b/f9/f07a295cde762644aa4c4bb0f88921d2d141af45e735b965fb2e87858328/watchfiles-1.1.1-cp313-cp313-macosx_11_0_arm64.whl", hash = "sha256:5f3bde70f157f84ece3765b42b4a52c6ac1a50334903c6eaf765362f6ccca88a", size = 391783 }, + { url = "https://files.pythonhosted.org/packages/bc/11/fc2502457e0bea39a5c958d86d2cb69e407a4d00b85735ca724bfa6e0d1a/watchfiles-1.1.1-cp313-cp313-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:14e0b1fe858430fc0251737ef3824c54027bedb8c37c38114488b8e131cf8219", size = 449279 }, + { url = "https://files.pythonhosted.org/packages/e3/1f/d66bc15ea0b728df3ed96a539c777acfcad0eb78555ad9efcaa1274688f0/watchfiles-1.1.1-cp313-cp313-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:f27db948078f3823a6bb3b465180db8ebecf26dd5dae6f6180bd87383b6b4428", size = 459405 }, + { url = "https://files.pythonhosted.org/packages/be/90/9f4a65c0aec3ccf032703e6db02d89a157462fbb2cf20dd415128251cac0/watchfiles-1.1.1-cp313-cp313-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:059098c3a429f62fc98e8ec62b982230ef2c8df68c79e826e37b895bc359a9c0", size = 488976 }, + { url = "https://files.pythonhosted.org/packages/37/57/ee347af605d867f712be7029bb94c8c071732a4b44792e3176fa3c612d39/watchfiles-1.1.1-cp313-cp313-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:bfb5862016acc9b869bb57284e6cb35fdf8e22fe59f7548858e2f971d045f150", size = 595506 }, + { url = "https://files.pythonhosted.org/packages/a8/78/cc5ab0b86c122047f75e8fc471c67a04dee395daf847d3e59381996c8707/watchfiles-1.1.1-cp313-cp313-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:319b27255aacd9923b8a276bb14d21a5f7ff82564c744235fc5eae58d95422ae", size = 474936 }, + { url = "https://files.pythonhosted.org/packages/62/da/def65b170a3815af7bd40a3e7010bf6ab53089ef1b75d05dd5385b87cf08/watchfiles-1.1.1-cp313-cp313-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:c755367e51db90e75b19454b680903631d41f9e3607fbd941d296a020c2d752d", size = 456147 }, + { url = "https://files.pythonhosted.org/packages/57/99/da6573ba71166e82d288d4df0839128004c67d2778d3b566c138695f5c0b/watchfiles-1.1.1-cp313-cp313-musllinux_1_1_aarch64.whl", hash = "sha256:c22c776292a23bfc7237a98f791b9ad3144b02116ff10d820829ce62dff46d0b", size = 630007 }, + { url = "https://files.pythonhosted.org/packages/a8/51/7439c4dd39511368849eb1e53279cd3454b4a4dbace80bab88feeb83c6b5/watchfiles-1.1.1-cp313-cp313-musllinux_1_1_x86_64.whl", hash = "sha256:3a476189be23c3686bc2f4321dd501cb329c0a0469e77b7b534ee10129ae6374", size = 622280 }, + { url = "https://files.pythonhosted.org/packages/95/9c/8ed97d4bba5db6fdcdb2b298d3898f2dd5c20f6b73aee04eabe56c59677e/watchfiles-1.1.1-cp313-cp313-win32.whl", hash = "sha256:bf0a91bfb5574a2f7fc223cf95eeea79abfefa404bf1ea5e339c0c1560ae99a0", size = 272056 }, + { url = "https://files.pythonhosted.org/packages/1f/f3/c14e28429f744a260d8ceae18bf58c1d5fa56b50d006a7a9f80e1882cb0d/watchfiles-1.1.1-cp313-cp313-win_amd64.whl", hash = "sha256:52e06553899e11e8074503c8e716d574adeeb7e68913115c4b3653c53f9bae42", size = 288162 }, + { url = "https://files.pythonhosted.org/packages/dc/61/fe0e56c40d5cd29523e398d31153218718c5786b5e636d9ae8ae79453d27/watchfiles-1.1.1-cp313-cp313-win_arm64.whl", hash = "sha256:ac3cc5759570cd02662b15fbcd9d917f7ecd47efe0d6b40474eafd246f91ea18", size = 277909 }, + { url = "https://files.pythonhosted.org/packages/79/42/e0a7d749626f1e28c7108a99fb9bf524b501bbbeb9b261ceecde644d5a07/watchfiles-1.1.1-cp313-cp313t-macosx_10_12_x86_64.whl", hash = "sha256:563b116874a9a7ce6f96f87cd0b94f7faf92d08d0021e837796f0a14318ef8da", size = 403389 }, + { url = "https://files.pythonhosted.org/packages/15/49/08732f90ce0fbbc13913f9f215c689cfc9ced345fb1bcd8829a50007cc8d/watchfiles-1.1.1-cp313-cp313t-macosx_11_0_arm64.whl", hash = "sha256:3ad9fe1dae4ab4212d8c91e80b832425e24f421703b5a42ef2e4a1e215aff051", size = 389964 }, + { url = "https://files.pythonhosted.org/packages/27/0d/7c315d4bd5f2538910491a0393c56bf70d333d51bc5b34bee8e68e8cea19/watchfiles-1.1.1-cp313-cp313t-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:ce70f96a46b894b36eba678f153f052967a0d06d5b5a19b336ab0dbbd029f73e", size = 448114 }, + { url = "https://files.pythonhosted.org/packages/c3/24/9e096de47a4d11bc4df41e9d1e61776393eac4cb6eb11b3e23315b78b2cc/watchfiles-1.1.1-cp313-cp313t-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:cb467c999c2eff23a6417e58d75e5828716f42ed8289fe6b77a7e5a91036ca70", size = 460264 }, + { url = "https://files.pythonhosted.org/packages/cc/0f/e8dea6375f1d3ba5fcb0b3583e2b493e77379834c74fd5a22d66d85d6540/watchfiles-1.1.1-cp313-cp313t-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:836398932192dae4146c8f6f737d74baeac8b70ce14831a239bdb1ca882fc261", size = 487877 }, + { url = "https://files.pythonhosted.org/packages/ac/5b/df24cfc6424a12deb41503b64d42fbea6b8cb357ec62ca84a5a3476f654a/watchfiles-1.1.1-cp313-cp313t-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:743185e7372b7bc7c389e1badcc606931a827112fbbd37f14c537320fca08620", size = 595176 }, + { url = "https://files.pythonhosted.org/packages/8f/b5/853b6757f7347de4e9b37e8cc3289283fb983cba1ab4d2d7144694871d9c/watchfiles-1.1.1-cp313-cp313t-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:afaeff7696e0ad9f02cbb8f56365ff4686ab205fcf9c4c5b6fdfaaa16549dd04", size = 473577 }, + { url = "https://files.pythonhosted.org/packages/e1/f7/0a4467be0a56e80447c8529c9fce5b38eab4f513cb3d9bf82e7392a5696b/watchfiles-1.1.1-cp313-cp313t-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:3f7eb7da0eb23aa2ba036d4f616d46906013a68caf61b7fdbe42fc8b25132e77", size = 455425 }, + { url = "https://files.pythonhosted.org/packages/8e/e0/82583485ea00137ddf69bc84a2db88bd92ab4a6e3c405e5fb878ead8d0e7/watchfiles-1.1.1-cp313-cp313t-musllinux_1_1_aarch64.whl", hash = "sha256:831a62658609f0e5c64178211c942ace999517f5770fe9436be4c2faeba0c0ef", size = 628826 }, + { url = "https://files.pythonhosted.org/packages/28/9a/a785356fccf9fae84c0cc90570f11702ae9571036fb25932f1242c82191c/watchfiles-1.1.1-cp313-cp313t-musllinux_1_1_x86_64.whl", hash = "sha256:f9a2ae5c91cecc9edd47e041a930490c31c3afb1f5e6d71de3dc671bfaca02bf", size = 622208 }, + { url = "https://files.pythonhosted.org/packages/c3/f4/0872229324ef69b2c3edec35e84bd57a1289e7d3fe74588048ed8947a323/watchfiles-1.1.1-cp314-cp314-macosx_10_12_x86_64.whl", hash = "sha256:d1715143123baeeaeadec0528bb7441103979a1d5f6fd0e1f915383fea7ea6d5", size = 404315 }, + { url = "https://files.pythonhosted.org/packages/7b/22/16d5331eaed1cb107b873f6ae1b69e9ced582fcf0c59a50cd84f403b1c32/watchfiles-1.1.1-cp314-cp314-macosx_11_0_arm64.whl", hash = "sha256:39574d6370c4579d7f5d0ad940ce5b20db0e4117444e39b6d8f99db5676c52fd", size = 390869 }, + { url = "https://files.pythonhosted.org/packages/b2/7e/5643bfff5acb6539b18483128fdc0ef2cccc94a5b8fbda130c823e8ed636/watchfiles-1.1.1-cp314-cp314-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:7365b92c2e69ee952902e8f70f3ba6360d0d596d9299d55d7d386df84b6941fb", size = 449919 }, + { url = "https://files.pythonhosted.org/packages/51/2e/c410993ba5025a9f9357c376f48976ef0e1b1aefb73b97a5ae01a5972755/watchfiles-1.1.1-cp314-cp314-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:bfff9740c69c0e4ed32416f013f3c45e2ae42ccedd1167ef2d805c000b6c71a5", size = 460845 }, + { url = "https://files.pythonhosted.org/packages/8e/a4/2df3b404469122e8680f0fcd06079317e48db58a2da2950fb45020947734/watchfiles-1.1.1-cp314-cp314-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:b27cf2eb1dda37b2089e3907d8ea92922b673c0c427886d4edc6b94d8dfe5db3", size = 489027 }, + { url = "https://files.pythonhosted.org/packages/ea/84/4587ba5b1f267167ee715b7f66e6382cca6938e0a4b870adad93e44747e6/watchfiles-1.1.1-cp314-cp314-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:526e86aced14a65a5b0ec50827c745597c782ff46b571dbfe46192ab9e0b3c33", size = 595615 }, + { url = "https://files.pythonhosted.org/packages/6a/0f/c6988c91d06e93cd0bb3d4a808bcf32375ca1904609835c3031799e3ecae/watchfiles-1.1.1-cp314-cp314-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:04e78dd0b6352db95507fd8cb46f39d185cf8c74e4cf1e4fbad1d3df96faf510", size = 474836 }, + { url = "https://files.pythonhosted.org/packages/b4/36/ded8aebea91919485b7bbabbd14f5f359326cb5ec218cd67074d1e426d74/watchfiles-1.1.1-cp314-cp314-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:5c85794a4cfa094714fb9c08d4a218375b2b95b8ed1666e8677c349906246c05", size = 455099 }, + { url = "https://files.pythonhosted.org/packages/98/e0/8c9bdba88af756a2fce230dd365fab2baf927ba42cd47521ee7498fd5211/watchfiles-1.1.1-cp314-cp314-musllinux_1_1_aarch64.whl", hash = "sha256:74d5012b7630714b66be7b7b7a78855ef7ad58e8650c73afc4c076a1f480a8d6", size = 630626 }, + { url = "https://files.pythonhosted.org/packages/2a/84/a95db05354bf2d19e438520d92a8ca475e578c647f78f53197f5a2f17aaf/watchfiles-1.1.1-cp314-cp314-musllinux_1_1_x86_64.whl", hash = "sha256:8fbe85cb3201c7d380d3d0b90e63d520f15d6afe217165d7f98c9c649654db81", size = 622519 }, + { url = "https://files.pythonhosted.org/packages/1d/ce/d8acdc8de545de995c339be67711e474c77d643555a9bb74a9334252bd55/watchfiles-1.1.1-cp314-cp314-win32.whl", hash = "sha256:3fa0b59c92278b5a7800d3ee7733da9d096d4aabcfabb9a928918bd276ef9b9b", size = 272078 }, + { url = "https://files.pythonhosted.org/packages/c4/c9/a74487f72d0451524be827e8edec251da0cc1fcf111646a511ae752e1a3d/watchfiles-1.1.1-cp314-cp314-win_amd64.whl", hash = "sha256:c2047d0b6cea13b3316bdbafbfa0c4228ae593d995030fda39089d36e64fc03a", size = 287664 }, + { url = "https://files.pythonhosted.org/packages/df/b8/8ac000702cdd496cdce998c6f4ee0ca1f15977bba51bdf07d872ebdfc34c/watchfiles-1.1.1-cp314-cp314-win_arm64.whl", hash = "sha256:842178b126593addc05acf6fce960d28bc5fae7afbaa2c6c1b3a7b9460e5be02", size = 277154 }, + { url = "https://files.pythonhosted.org/packages/47/a8/e3af2184707c29f0f14b1963c0aace6529f9d1b8582d5b99f31bbf42f59e/watchfiles-1.1.1-cp314-cp314t-macosx_10_12_x86_64.whl", hash = "sha256:88863fbbc1a7312972f1c511f202eb30866370ebb8493aef2812b9ff28156a21", size = 403820 }, + { url = "https://files.pythonhosted.org/packages/c0/ec/e47e307c2f4bd75f9f9e8afbe3876679b18e1bcec449beca132a1c5ffb2d/watchfiles-1.1.1-cp314-cp314t-macosx_11_0_arm64.whl", hash = "sha256:55c7475190662e202c08c6c0f4d9e345a29367438cf8e8037f3155e10a88d5a5", size = 390510 }, + { url = "https://files.pythonhosted.org/packages/d5/a0/ad235642118090f66e7b2f18fd5c42082418404a79205cdfca50b6309c13/watchfiles-1.1.1-cp314-cp314t-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:3f53fa183d53a1d7a8852277c92b967ae99c2d4dcee2bfacff8868e6e30b15f7", size = 448408 }, + { url = "https://files.pythonhosted.org/packages/df/85/97fa10fd5ff3332ae17e7e40e20784e419e28521549780869f1413742e9d/watchfiles-1.1.1-cp314-cp314t-manylinux_2_17_armv7l.manylinux2014_armv7l.whl", hash = "sha256:6aae418a8b323732fa89721d86f39ec8f092fc2af67f4217a2b07fd3e93c6101", size = 458968 }, + { url = "https://files.pythonhosted.org/packages/47/c2/9059c2e8966ea5ce678166617a7f75ecba6164375f3b288e50a40dc6d489/watchfiles-1.1.1-cp314-cp314t-manylinux_2_17_i686.manylinux2014_i686.whl", hash = "sha256:f096076119da54a6080e8920cbdaac3dbee667eb91dcc5e5b78840b87415bd44", size = 488096 }, + { url = "https://files.pythonhosted.org/packages/94/44/d90a9ec8ac309bc26db808a13e7bfc0e4e78b6fc051078a554e132e80160/watchfiles-1.1.1-cp314-cp314t-manylinux_2_17_ppc64le.manylinux2014_ppc64le.whl", hash = "sha256:00485f441d183717038ed2e887a7c868154f216877653121068107b227a2f64c", size = 596040 }, + { url = "https://files.pythonhosted.org/packages/95/68/4e3479b20ca305cfc561db3ed207a8a1c745ee32bf24f2026a129d0ddb6e/watchfiles-1.1.1-cp314-cp314t-manylinux_2_17_s390x.manylinux2014_s390x.whl", hash = "sha256:a55f3e9e493158d7bfdb60a1165035f1cf7d320914e7b7ea83fe22c6023b58fc", size = 473847 }, + { url = "https://files.pythonhosted.org/packages/4f/55/2af26693fd15165c4ff7857e38330e1b61ab8c37d15dc79118cdba115b7a/watchfiles-1.1.1-cp314-cp314t-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:8c91ed27800188c2ae96d16e3149f199d62f86c7af5f5f4d2c61a3ed8cd3666c", size = 455072 }, + { url = "https://files.pythonhosted.org/packages/66/1d/d0d200b10c9311ec25d2273f8aad8c3ef7cc7ea11808022501811208a750/watchfiles-1.1.1-cp314-cp314t-musllinux_1_1_aarch64.whl", hash = "sha256:311ff15a0bae3714ffb603e6ba6dbfba4065ab60865d15a6ec544133bdb21099", size = 629104 }, + { url = "https://files.pythonhosted.org/packages/e3/bd/fa9bb053192491b3867ba07d2343d9f2252e00811567d30ae8d0f78136fe/watchfiles-1.1.1-cp314-cp314t-musllinux_1_1_x86_64.whl", hash = "sha256:a916a2932da8f8ab582f242c065f5c81bed3462849ca79ee357dd9551b0e9b01", size = 622112 }, + { url = "https://files.pythonhosted.org/packages/ba/4c/a888c91e2e326872fa4705095d64acd8aa2fb9c1f7b9bd0588f33850516c/watchfiles-1.1.1-pp310-pypy310_pp73-macosx_10_12_x86_64.whl", hash = "sha256:17ef139237dfced9da49fb7f2232c86ca9421f666d78c264c7ffca6601d154c3", size = 409611 }, + { url = "https://files.pythonhosted.org/packages/1e/c7/5420d1943c8e3ce1a21c0a9330bcf7edafb6aa65d26b21dbb3267c9e8112/watchfiles-1.1.1-pp310-pypy310_pp73-macosx_11_0_arm64.whl", hash = "sha256:672b8adf25b1a0d35c96b5888b7b18699d27d4194bac8beeae75be4b7a3fc9b2", size = 396889 }, + { url = "https://files.pythonhosted.org/packages/0c/e5/0072cef3804ce8d3aaddbfe7788aadff6b3d3f98a286fdbee9fd74ca59a7/watchfiles-1.1.1-pp310-pypy310_pp73-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:77a13aea58bc2b90173bc69f2a90de8e282648939a00a602e1dc4ee23e26b66d", size = 451616 }, + { url = "https://files.pythonhosted.org/packages/83/4e/b87b71cbdfad81ad7e83358b3e447fedd281b880a03d64a760fe0a11fc2e/watchfiles-1.1.1-pp310-pypy310_pp73-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:0b495de0bb386df6a12b18335a0285dda90260f51bdb505503c02bcd1ce27a8b", size = 458413 }, + { url = "https://files.pythonhosted.org/packages/d3/8e/e500f8b0b77be4ff753ac94dc06b33d8f0d839377fee1b78e8c8d8f031bf/watchfiles-1.1.1-pp311-pypy311_pp73-macosx_10_12_x86_64.whl", hash = "sha256:db476ab59b6765134de1d4fe96a1a9c96ddf091683599be0f26147ea1b2e4b88", size = 408250 }, + { url = "https://files.pythonhosted.org/packages/bd/95/615e72cd27b85b61eec764a5ca51bd94d40b5adea5ff47567d9ebc4d275a/watchfiles-1.1.1-pp311-pypy311_pp73-macosx_11_0_arm64.whl", hash = "sha256:89eef07eee5e9d1fda06e38822ad167a044153457e6fd997f8a858ab7564a336", size = 396117 }, + { url = "https://files.pythonhosted.org/packages/c9/81/e7fe958ce8a7fb5c73cc9fb07f5aeaf755e6aa72498c57d760af760c91f8/watchfiles-1.1.1-pp311-pypy311_pp73-manylinux_2_17_aarch64.manylinux2014_aarch64.whl", hash = "sha256:ce19e06cbda693e9e7686358af9cd6f5d61312ab8b00488bc36f5aabbaf77e24", size = 450493 }, + { url = "https://files.pythonhosted.org/packages/6e/d4/ed38dd3b1767193de971e694aa544356e63353c33a85d948166b5ff58b9e/watchfiles-1.1.1-pp311-pypy311_pp73-manylinux_2_17_x86_64.manylinux2014_x86_64.whl", hash = "sha256:3e6f39af2eab0118338902798b5aa6664f46ff66bc0280de76fca67a7f262a49", size = 457546 }, +] + +[[package]] +name = "wrapt" +version = "1.17.3" +source = { registry = "https://pypi.org/simple" } +sdist = { url = "https://files.pythonhosted.org/packages/95/8f/aeb76c5b46e273670962298c23e7ddde79916cb74db802131d49a85e4b7d/wrapt-1.17.3.tar.gz", hash = "sha256:f66eb08feaa410fe4eebd17f2a2c8e2e46d3476e9f8c783daa8e09e0faa666d0", size = 55547 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/3f/23/bb82321b86411eb51e5a5db3fb8f8032fd30bd7c2d74bfe936136b2fa1d6/wrapt-1.17.3-cp310-cp310-macosx_10_9_universal2.whl", hash = "sha256:88bbae4d40d5a46142e70d58bf664a89b6b4befaea7b2ecc14e03cedb8e06c04", size = 53482 }, + { url = "https://files.pythonhosted.org/packages/45/69/f3c47642b79485a30a59c63f6d739ed779fb4cc8323205d047d741d55220/wrapt-1.17.3-cp310-cp310-macosx_10_9_x86_64.whl", hash = "sha256:e6b13af258d6a9ad602d57d889f83b9d5543acd471eee12eb51f5b01f8eb1bc2", size = 38676 }, + { url = "https://files.pythonhosted.org/packages/d1/71/e7e7f5670c1eafd9e990438e69d8fb46fa91a50785332e06b560c869454f/wrapt-1.17.3-cp310-cp310-macosx_11_0_arm64.whl", hash = "sha256:fd341868a4b6714a5962c1af0bd44f7c404ef78720c7de4892901e540417111c", size = 38957 }, + { url = "https://files.pythonhosted.org/packages/de/17/9f8f86755c191d6779d7ddead1a53c7a8aa18bccb7cea8e7e72dfa6a8a09/wrapt-1.17.3-cp310-cp310-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:f9b2601381be482f70e5d1051a5965c25fb3625455a2bf520b5a077b22afb775", size = 81975 }, + { url = "https://files.pythonhosted.org/packages/f2/15/dd576273491f9f43dd09fce517f6c2ce6eb4fe21681726068db0d0467096/wrapt-1.17.3-cp310-cp310-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:343e44b2a8e60e06a7e0d29c1671a0d9951f59174f3709962b5143f60a2a98bd", size = 83149 }, + { url = "https://files.pythonhosted.org/packages/0c/c4/5eb4ce0d4814521fee7aa806264bf7a114e748ad05110441cd5b8a5c744b/wrapt-1.17.3-cp310-cp310-musllinux_1_2_aarch64.whl", hash = "sha256:33486899acd2d7d3066156b03465b949da3fd41a5da6e394ec49d271baefcf05", size = 82209 }, + { url = "https://files.pythonhosted.org/packages/31/4b/819e9e0eb5c8dc86f60dfc42aa4e2c0d6c3db8732bce93cc752e604bb5f5/wrapt-1.17.3-cp310-cp310-musllinux_1_2_x86_64.whl", hash = "sha256:e6f40a8aa5a92f150bdb3e1c44b7e98fb7113955b2e5394122fa5532fec4b418", size = 81551 }, + { url = "https://files.pythonhosted.org/packages/f8/83/ed6baf89ba3a56694700139698cf703aac9f0f9eb03dab92f57551bd5385/wrapt-1.17.3-cp310-cp310-win32.whl", hash = "sha256:a36692b8491d30a8c75f1dfee65bef119d6f39ea84ee04d9f9311f83c5ad9390", size = 36464 }, + { url = "https://files.pythonhosted.org/packages/2f/90/ee61d36862340ad7e9d15a02529df6b948676b9a5829fd5e16640156627d/wrapt-1.17.3-cp310-cp310-win_amd64.whl", hash = "sha256:afd964fd43b10c12213574db492cb8f73b2f0826c8df07a68288f8f19af2ebe6", size = 38748 }, + { url = "https://files.pythonhosted.org/packages/bd/c3/cefe0bd330d389c9983ced15d326f45373f4073c9f4a8c2f99b50bfea329/wrapt-1.17.3-cp310-cp310-win_arm64.whl", hash = "sha256:af338aa93554be859173c39c85243970dc6a289fa907402289eeae7543e1ae18", size = 36810 }, + { url = "https://files.pythonhosted.org/packages/52/db/00e2a219213856074a213503fdac0511203dceefff26e1daa15250cc01a0/wrapt-1.17.3-cp311-cp311-macosx_10_9_universal2.whl", hash = "sha256:273a736c4645e63ac582c60a56b0acb529ef07f78e08dc6bfadf6a46b19c0da7", size = 53482 }, + { url = "https://files.pythonhosted.org/packages/5e/30/ca3c4a5eba478408572096fe9ce36e6e915994dd26a4e9e98b4f729c06d9/wrapt-1.17.3-cp311-cp311-macosx_10_9_x86_64.whl", hash = "sha256:5531d911795e3f935a9c23eb1c8c03c211661a5060aab167065896bbf62a5f85", size = 38674 }, + { url = "https://files.pythonhosted.org/packages/31/25/3e8cc2c46b5329c5957cec959cb76a10718e1a513309c31399a4dad07eb3/wrapt-1.17.3-cp311-cp311-macosx_11_0_arm64.whl", hash = "sha256:0610b46293c59a3adbae3dee552b648b984176f8562ee0dba099a56cfbe4df1f", size = 38959 }, + { url = "https://files.pythonhosted.org/packages/5d/8f/a32a99fc03e4b37e31b57cb9cefc65050ea08147a8ce12f288616b05ef54/wrapt-1.17.3-cp311-cp311-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:b32888aad8b6e68f83a8fdccbf3165f5469702a7544472bdf41f582970ed3311", size = 82376 }, + { url = "https://files.pythonhosted.org/packages/31/57/4930cb8d9d70d59c27ee1332a318c20291749b4fba31f113c2f8ac49a72e/wrapt-1.17.3-cp311-cp311-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:8cccf4f81371f257440c88faed6b74f1053eef90807b77e31ca057b2db74edb1", size = 83604 }, + { url = "https://files.pythonhosted.org/packages/a8/f3/1afd48de81d63dd66e01b263a6fbb86e1b5053b419b9b33d13e1f6d0f7d0/wrapt-1.17.3-cp311-cp311-musllinux_1_2_aarch64.whl", hash = "sha256:d8a210b158a34164de8bb68b0e7780041a903d7b00c87e906fb69928bf7890d5", size = 82782 }, + { url = "https://files.pythonhosted.org/packages/1e/d7/4ad5327612173b144998232f98a85bb24b60c352afb73bc48e3e0d2bdc4e/wrapt-1.17.3-cp311-cp311-musllinux_1_2_x86_64.whl", hash = "sha256:79573c24a46ce11aab457b472efd8d125e5a51da2d1d24387666cd85f54c05b2", size = 82076 }, + { url = "https://files.pythonhosted.org/packages/bb/59/e0adfc831674a65694f18ea6dc821f9fcb9ec82c2ce7e3d73a88ba2e8718/wrapt-1.17.3-cp311-cp311-win32.whl", hash = "sha256:c31eebe420a9a5d2887b13000b043ff6ca27c452a9a22fa71f35f118e8d4bf89", size = 36457 }, + { url = "https://files.pythonhosted.org/packages/83/88/16b7231ba49861b6f75fc309b11012ede4d6b0a9c90969d9e0db8d991aeb/wrapt-1.17.3-cp311-cp311-win_amd64.whl", hash = "sha256:0b1831115c97f0663cb77aa27d381237e73ad4f721391a9bfb2fe8bc25fa6e77", size = 38745 }, + { url = "https://files.pythonhosted.org/packages/9a/1e/c4d4f3398ec073012c51d1c8d87f715f56765444e1a4b11e5180577b7e6e/wrapt-1.17.3-cp311-cp311-win_arm64.whl", hash = "sha256:5a7b3c1ee8265eb4c8f1b7d29943f195c00673f5ab60c192eba2d4a7eae5f46a", size = 36806 }, + { url = "https://files.pythonhosted.org/packages/9f/41/cad1aba93e752f1f9268c77270da3c469883d56e2798e7df6240dcb2287b/wrapt-1.17.3-cp312-cp312-macosx_10_13_universal2.whl", hash = "sha256:ab232e7fdb44cdfbf55fc3afa31bcdb0d8980b9b95c38b6405df2acb672af0e0", size = 53998 }, + { url = "https://files.pythonhosted.org/packages/60/f8/096a7cc13097a1869fe44efe68dace40d2a16ecb853141394047f0780b96/wrapt-1.17.3-cp312-cp312-macosx_10_13_x86_64.whl", hash = "sha256:9baa544e6acc91130e926e8c802a17f3b16fbea0fd441b5a60f5cf2cc5c3deba", size = 39020 }, + { url = "https://files.pythonhosted.org/packages/33/df/bdf864b8997aab4febb96a9ae5c124f700a5abd9b5e13d2a3214ec4be705/wrapt-1.17.3-cp312-cp312-macosx_11_0_arm64.whl", hash = "sha256:6b538e31eca1a7ea4605e44f81a48aa24c4632a277431a6ed3f328835901f4fd", size = 39098 }, + { url = "https://files.pythonhosted.org/packages/9f/81/5d931d78d0eb732b95dc3ddaeeb71c8bb572fb01356e9133916cd729ecdd/wrapt-1.17.3-cp312-cp312-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:042ec3bb8f319c147b1301f2393bc19dba6e176b7da446853406d041c36c7828", size = 88036 }, + { url = "https://files.pythonhosted.org/packages/ca/38/2e1785df03b3d72d34fc6252d91d9d12dc27a5c89caef3335a1bbb8908ca/wrapt-1.17.3-cp312-cp312-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:3af60380ba0b7b5aeb329bc4e402acd25bd877e98b3727b0135cb5c2efdaefe9", size = 88156 }, + { url = "https://files.pythonhosted.org/packages/b3/8b/48cdb60fe0603e34e05cffda0b2a4adab81fd43718e11111a4b0100fd7c1/wrapt-1.17.3-cp312-cp312-musllinux_1_2_aarch64.whl", hash = "sha256:0b02e424deef65c9f7326d8c19220a2c9040c51dc165cddb732f16198c168396", size = 87102 }, + { url = "https://files.pythonhosted.org/packages/3c/51/d81abca783b58f40a154f1b2c56db1d2d9e0d04fa2d4224e357529f57a57/wrapt-1.17.3-cp312-cp312-musllinux_1_2_x86_64.whl", hash = "sha256:74afa28374a3c3a11b3b5e5fca0ae03bef8450d6aa3ab3a1e2c30e3a75d023dc", size = 87732 }, + { url = "https://files.pythonhosted.org/packages/9e/b1/43b286ca1392a006d5336412d41663eeef1ad57485f3e52c767376ba7e5a/wrapt-1.17.3-cp312-cp312-win32.whl", hash = "sha256:4da9f45279fff3543c371d5ababc57a0384f70be244de7759c85a7f989cb4ebe", size = 36705 }, + { url = "https://files.pythonhosted.org/packages/28/de/49493f962bd3c586ab4b88066e967aa2e0703d6ef2c43aa28cb83bf7b507/wrapt-1.17.3-cp312-cp312-win_amd64.whl", hash = "sha256:e71d5c6ebac14875668a1e90baf2ea0ef5b7ac7918355850c0908ae82bcb297c", size = 38877 }, + { url = "https://files.pythonhosted.org/packages/f1/48/0f7102fe9cb1e8a5a77f80d4f0956d62d97034bbe88d33e94699f99d181d/wrapt-1.17.3-cp312-cp312-win_arm64.whl", hash = "sha256:604d076c55e2fdd4c1c03d06dc1a31b95130010517b5019db15365ec4a405fc6", size = 36885 }, + { url = "https://files.pythonhosted.org/packages/fc/f6/759ece88472157acb55fc195e5b116e06730f1b651b5b314c66291729193/wrapt-1.17.3-cp313-cp313-macosx_10_13_universal2.whl", hash = "sha256:a47681378a0439215912ef542c45a783484d4dd82bac412b71e59cf9c0e1cea0", size = 54003 }, + { url = "https://files.pythonhosted.org/packages/4f/a9/49940b9dc6d47027dc850c116d79b4155f15c08547d04db0f07121499347/wrapt-1.17.3-cp313-cp313-macosx_10_13_x86_64.whl", hash = "sha256:54a30837587c6ee3cd1a4d1c2ec5d24e77984d44e2f34547e2323ddb4e22eb77", size = 39025 }, + { url = "https://files.pythonhosted.org/packages/45/35/6a08de0f2c96dcdd7fe464d7420ddb9a7655a6561150e5fc4da9356aeaab/wrapt-1.17.3-cp313-cp313-macosx_11_0_arm64.whl", hash = "sha256:16ecf15d6af39246fe33e507105d67e4b81d8f8d2c6598ff7e3ca1b8a37213f7", size = 39108 }, + { url = "https://files.pythonhosted.org/packages/0c/37/6faf15cfa41bf1f3dba80cd3f5ccc6622dfccb660ab26ed79f0178c7497f/wrapt-1.17.3-cp313-cp313-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:6fd1ad24dc235e4ab88cda009e19bf347aabb975e44fd5c2fb22a3f6e4141277", size = 88072 }, + { url = "https://files.pythonhosted.org/packages/78/f2/efe19ada4a38e4e15b6dff39c3e3f3f73f5decf901f66e6f72fe79623a06/wrapt-1.17.3-cp313-cp313-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:0ed61b7c2d49cee3c027372df5809a59d60cf1b6c2f81ee980a091f3afed6a2d", size = 88214 }, + { url = "https://files.pythonhosted.org/packages/40/90/ca86701e9de1622b16e09689fc24b76f69b06bb0150990f6f4e8b0eeb576/wrapt-1.17.3-cp313-cp313-musllinux_1_2_aarch64.whl", hash = "sha256:423ed5420ad5f5529db9ce89eac09c8a2f97da18eb1c870237e84c5a5c2d60aa", size = 87105 }, + { url = "https://files.pythonhosted.org/packages/fd/e0/d10bd257c9a3e15cbf5523025252cc14d77468e8ed644aafb2d6f54cb95d/wrapt-1.17.3-cp313-cp313-musllinux_1_2_x86_64.whl", hash = "sha256:e01375f275f010fcbf7f643b4279896d04e571889b8a5b3f848423d91bf07050", size = 87766 }, + { url = "https://files.pythonhosted.org/packages/e8/cf/7d848740203c7b4b27eb55dbfede11aca974a51c3d894f6cc4b865f42f58/wrapt-1.17.3-cp313-cp313-win32.whl", hash = "sha256:53e5e39ff71b3fc484df8a522c933ea2b7cdd0d5d15ae82e5b23fde87d44cbd8", size = 36711 }, + { url = "https://files.pythonhosted.org/packages/57/54/35a84d0a4d23ea675994104e667ceff49227ce473ba6a59ba2c84f250b74/wrapt-1.17.3-cp313-cp313-win_amd64.whl", hash = "sha256:1f0b2f40cf341ee8cc1a97d51ff50dddb9fcc73241b9143ec74b30fc4f44f6cb", size = 38885 }, + { url = "https://files.pythonhosted.org/packages/01/77/66e54407c59d7b02a3c4e0af3783168fff8e5d61def52cda8728439d86bc/wrapt-1.17.3-cp313-cp313-win_arm64.whl", hash = "sha256:7425ac3c54430f5fc5e7b6f41d41e704db073309acfc09305816bc6a0b26bb16", size = 36896 }, + { url = "https://files.pythonhosted.org/packages/02/a2/cd864b2a14f20d14f4c496fab97802001560f9f41554eef6df201cd7f76c/wrapt-1.17.3-cp314-cp314-macosx_10_13_universal2.whl", hash = "sha256:cf30f6e3c077c8e6a9a7809c94551203c8843e74ba0c960f4a98cd80d4665d39", size = 54132 }, + { url = "https://files.pythonhosted.org/packages/d5/46/d011725b0c89e853dc44cceb738a307cde5d240d023d6d40a82d1b4e1182/wrapt-1.17.3-cp314-cp314-macosx_10_13_x86_64.whl", hash = "sha256:e228514a06843cae89621384cfe3a80418f3c04aadf8a3b14e46a7be704e4235", size = 39091 }, + { url = "https://files.pythonhosted.org/packages/2e/9e/3ad852d77c35aae7ddebdbc3b6d35ec8013af7d7dddad0ad911f3d891dae/wrapt-1.17.3-cp314-cp314-macosx_11_0_arm64.whl", hash = "sha256:5ea5eb3c0c071862997d6f3e02af1d055f381b1d25b286b9d6644b79db77657c", size = 39172 }, + { url = "https://files.pythonhosted.org/packages/c3/f7/c983d2762bcce2326c317c26a6a1e7016f7eb039c27cdf5c4e30f4160f31/wrapt-1.17.3-cp314-cp314-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:281262213373b6d5e4bb4353bc36d1ba4084e6d6b5d242863721ef2bf2c2930b", size = 87163 }, + { url = "https://files.pythonhosted.org/packages/e4/0f/f673f75d489c7f22d17fe0193e84b41540d962f75fce579cf6873167c29b/wrapt-1.17.3-cp314-cp314-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:dc4a8d2b25efb6681ecacad42fca8859f88092d8732b170de6a5dddd80a1c8fa", size = 87963 }, + { url = "https://files.pythonhosted.org/packages/df/61/515ad6caca68995da2fac7a6af97faab8f78ebe3bf4f761e1b77efbc47b5/wrapt-1.17.3-cp314-cp314-musllinux_1_2_aarch64.whl", hash = "sha256:373342dd05b1d07d752cecbec0c41817231f29f3a89aa8b8843f7b95992ed0c7", size = 86945 }, + { url = "https://files.pythonhosted.org/packages/d3/bd/4e70162ce398462a467bc09e768bee112f1412e563620adc353de9055d33/wrapt-1.17.3-cp314-cp314-musllinux_1_2_x86_64.whl", hash = "sha256:d40770d7c0fd5cbed9d84b2c3f2e156431a12c9a37dc6284060fb4bec0b7ffd4", size = 86857 }, + { url = "https://files.pythonhosted.org/packages/2b/b8/da8560695e9284810b8d3df8a19396a6e40e7518059584a1a394a2b35e0a/wrapt-1.17.3-cp314-cp314-win32.whl", hash = "sha256:fbd3c8319de8e1dc79d346929cd71d523622da527cca14e0c1d257e31c2b8b10", size = 37178 }, + { url = "https://files.pythonhosted.org/packages/db/c8/b71eeb192c440d67a5a0449aaee2310a1a1e8eca41676046f99ed2487e9f/wrapt-1.17.3-cp314-cp314-win_amd64.whl", hash = "sha256:e1a4120ae5705f673727d3253de3ed0e016f7cd78dc463db1b31e2463e1f3cf6", size = 39310 }, + { url = "https://files.pythonhosted.org/packages/45/20/2cda20fd4865fa40f86f6c46ed37a2a8356a7a2fde0773269311f2af56c7/wrapt-1.17.3-cp314-cp314-win_arm64.whl", hash = "sha256:507553480670cab08a800b9463bdb881b2edeed77dc677b0a5915e6106e91a58", size = 37266 }, + { url = "https://files.pythonhosted.org/packages/77/ed/dd5cf21aec36c80443c6f900449260b80e2a65cf963668eaef3b9accce36/wrapt-1.17.3-cp314-cp314t-macosx_10_13_universal2.whl", hash = "sha256:ed7c635ae45cfbc1a7371f708727bf74690daedc49b4dba310590ca0bd28aa8a", size = 56544 }, + { url = "https://files.pythonhosted.org/packages/8d/96/450c651cc753877ad100c7949ab4d2e2ecc4d97157e00fa8f45df682456a/wrapt-1.17.3-cp314-cp314t-macosx_10_13_x86_64.whl", hash = "sha256:249f88ed15503f6492a71f01442abddd73856a0032ae860de6d75ca62eed8067", size = 40283 }, + { url = "https://files.pythonhosted.org/packages/d1/86/2fcad95994d9b572db57632acb6f900695a648c3e063f2cd344b3f5c5a37/wrapt-1.17.3-cp314-cp314t-macosx_11_0_arm64.whl", hash = "sha256:5a03a38adec8066d5a37bea22f2ba6bbf39fcdefbe2d91419ab864c3fb515454", size = 40366 }, + { url = "https://files.pythonhosted.org/packages/64/0e/f4472f2fdde2d4617975144311f8800ef73677a159be7fe61fa50997d6c0/wrapt-1.17.3-cp314-cp314t-manylinux1_x86_64.manylinux_2_28_x86_64.manylinux_2_5_x86_64.whl", hash = "sha256:5d4478d72eb61c36e5b446e375bbc49ed002430d17cdec3cecb36993398e1a9e", size = 108571 }, + { url = "https://files.pythonhosted.org/packages/cc/01/9b85a99996b0a97c8a17484684f206cbb6ba73c1ce6890ac668bcf3838fb/wrapt-1.17.3-cp314-cp314t-manylinux2014_aarch64.manylinux_2_17_aarch64.manylinux_2_28_aarch64.whl", hash = "sha256:223db574bb38637e8230eb14b185565023ab624474df94d2af18f1cdb625216f", size = 113094 }, + { url = "https://files.pythonhosted.org/packages/25/02/78926c1efddcc7b3aa0bc3d6b33a822f7d898059f7cd9ace8c8318e559ef/wrapt-1.17.3-cp314-cp314t-musllinux_1_2_aarch64.whl", hash = "sha256:e405adefb53a435f01efa7ccdec012c016b5a1d3f35459990afc39b6be4d5056", size = 110659 }, + { url = "https://files.pythonhosted.org/packages/dc/ee/c414501ad518ac3e6fe184753632fe5e5ecacdcf0effc23f31c1e4f7bfcf/wrapt-1.17.3-cp314-cp314t-musllinux_1_2_x86_64.whl", hash = "sha256:88547535b787a6c9ce4086917b6e1d291aa8ed914fdd3a838b3539dc95c12804", size = 106946 }, + { url = "https://files.pythonhosted.org/packages/be/44/a1bd64b723d13bb151d6cc91b986146a1952385e0392a78567e12149c7b4/wrapt-1.17.3-cp314-cp314t-win32.whl", hash = "sha256:41b1d2bc74c2cac6f9074df52b2efbef2b30bdfe5f40cb78f8ca22963bc62977", size = 38717 }, + { url = "https://files.pythonhosted.org/packages/79/d9/7cfd5a312760ac4dd8bf0184a6ee9e43c33e47f3dadc303032ce012b8fa3/wrapt-1.17.3-cp314-cp314t-win_amd64.whl", hash = "sha256:73d496de46cd2cdbdbcce4ae4bcdb4afb6a11234a1df9c085249d55166b95116", size = 41334 }, + { url = "https://files.pythonhosted.org/packages/46/78/10ad9781128ed2f99dbc474f43283b13fea8ba58723e98844367531c18e9/wrapt-1.17.3-cp314-cp314t-win_arm64.whl", hash = "sha256:f38e60678850c42461d4202739f9bf1e3a737c7ad283638251e79cc49effb6b6", size = 38471 }, + { url = "https://files.pythonhosted.org/packages/1f/f6/a933bd70f98e9cf3e08167fc5cd7aaaca49147e48411c0bd5ae701bb2194/wrapt-1.17.3-py3-none-any.whl", hash = "sha256:7171ae35d2c33d326ac19dd8facb1e82e5fd04ef8c6c0e394d7af55a55051c22", size = 23591 }, +] + +[[package]] +name = "wsproto" +version = "1.3.2" +source = { registry = "https://pypi.org/simple" } +dependencies = [ + { name = "h11" }, +] +sdist = { url = "https://files.pythonhosted.org/packages/c7/79/12135bdf8b9c9367b8701c2c19a14c913c120b882d50b014ca0d38083c2c/wsproto-1.3.2.tar.gz", hash = "sha256:b86885dcf294e15204919950f666e06ffc6c7c114ca900b060d6e16293528294", size = 50116 } +wheels = [ + { url = "https://files.pythonhosted.org/packages/a4/f5/10b68b7b1544245097b2a1b8238f66f2fc6dcaeb24ba5d917f52bd2eed4f/wsproto-1.3.2-py3-none-any.whl", hash = "sha256:61eea322cdf56e8cc904bd3ad7573359a242ba65688716b0710a5eb12beab584", size = 24405 }, +]